
<html lang="en"     class="pb-page"  data-request-id="5e48dad4-fee1-43db-924d-947829bd96d3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.5b01781;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-18"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis" /></meta><meta name="dc.Creator" content="John-David  Aubert" /></meta><meta name="dc.Creator" content="Lucienne  Juillerat-Jeanneret" /></meta><meta name="dc.Description" content="The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases. Endothelin-receptor antagonists are in clinical use to t..." /></meta><meta name="Description" content="The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases. Endothelin-receptor antagonists are in clinical use to t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 15, 2016" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01781" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01781" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01781" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01781" /></link>
        
    
    

<title>Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01781" /></meta><meta property="og:title" content="Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0008.jpeg" /></meta><meta property="og:description" content="The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases. Endothelin-receptor antagonists are in clinical use to treat pulmonary arterial hypertension and have been under clinical investigation for the treatment of several other diseases, such as systemic hypertension, cancer, vasospasm, and fibrogenic diseases. In this Perspective, we review the molecules that have been evaluated in human clinical trials for the treatment of pulmonary arterial hypertension, as well as other cardiovascular diseases, cancer, and fibrosis. We will also discuss the therapeutic consequences of receptor selectivity with regard to ETA-selective, ETB-selective, or dual ETA/ETB antagonists. We will also consider which chemical characteristics are relevant to clinical use and the properties of molecules necessary for efficacy in treating diseases against which known molecules displayed suboptimal efficacy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01781"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01781">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01781&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01781&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01781&amp;href=/doi/10.1021/acs.jmedchem.5b01781" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8168-8188</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01770" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.6b00197" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.7b00121"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John-David++Aubert">John-David Aubert</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lucienne++Juillerat-Jeanneret">Lucienne Juillerat-Jeanneret</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Pneumology Division and Transplantation Center, Centre Hospitalier Universitaire Vaudois (CHUV), CH1011 Lausanne, Switzerland</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">University Institute of Pathology and Transplantation Center, Centre Hospitalier Universitaire Vaudois (CHUV), and University of Lausanne (UNIL), CH1011 Lausanne, Switzerland</span></div><div class="corresp-info"><strong>*</strong>J.-D.A.: phone, +41 21 314 1376; e-mail, <a href="/cdn-cgi/l/email-protection#4d2722252360292c3b2429632c382f283f390d2e25383b632e25"><span class="__cf_email__" data-cfemail="046e6b6c6a296065726d602a65716661767044676c71722a676c">[emailÂ protected]</span></a></div><div class="corresp-info"><strong>*</strong>L.J.-J.: phone, +41 21 314 7214/7117; e-mail, <a href="/cdn-cgi/l/email-protection#670b12040e02090902490d120e0b0b0215061327040f121149040f"><span class="__cf_email__" data-cfemail="8be7fee8e2eee5e5eea5e1fee2e7e7eef9eaffcbe8e3fefda5e8e3">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01781&amp;href=/doi/10.1021%2Facs.jmedchem.5b01781" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8168â8188</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 7, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 November 2015</li><li><span class="item_label"><b>Published</b> online</span>15 June 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 September 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01781" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01781</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8168%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJohn-David%2BAubert%252C%2BLucienne%2BJuillerat-Jeanneret%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D18%26contentID%3Dacs.jmedchem.5b01781%26title%3DEndothelin-Receptor%2BAntagonists%2Bbeyond%2BPulmonary%2BArterial%2BHypertension%253A%2BCancer%2Band%2BFibrosis%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8188%26publicationDate%3DSeptember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01781"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1605</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01781" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;John-David&quot;,&quot;last_name&quot;:&quot;Aubert&quot;},{&quot;first_name&quot;:&quot;Lucienne&quot;,&quot;last_name&quot;:&quot;Juillerat-Jeanneret&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;8168-8188&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01781&quot;},&quot;abstract&quot;:&quot;The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases. Endothelin-receptor antagonists are in clinical use to treat pulmonary arterial hypertension and have been under clinical investigation for the treatment of several other diseases, such as systemic hypertension, cancer, vasospasm, and fibrogenic diseases. In this Perspective, we review the molecules that have been evaluated in human clinical trials for the treatment of pulmonary arterial hypertension, as well as other cardiovascular diseases, cancer, and fibrosis. We will also discuss the therapeutic consequences of receptor selectivity with regard to ETA-selective, ETB-selective, or dual ETA/ETB antagonists. We will also consider which chemical characteristics are relevant to clinical use and the properties of molecules necessary for efficacy in treating diseases against which known molecules displayed suboptimal efficacy.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01781&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01781" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01781&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01781" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01781&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01781" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01781&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01781&amp;href=/doi/10.1021/acs.jmedchem.5b01781" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01781" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01781" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01781%26sid%3Dliteratum%253Aachs%26pmid%3D27266371%26genre%3Darticle%26aulast%3DAubert%26date%3D2016%26atitle%3DEndothelin-Receptor%2BAntagonists%2Bbeyond%2BPulmonary%2BArterial%2BHypertension%253A%2BCancer%2Band%2BFibrosis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D18%26spage%3D8168%26epage%3D8188%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/jmcmar.2016.59.issue-18/20160922/jmcmar.2016.59.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01781&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The endothelin axis and in particular the two endothelin receptors, ET<sub>A</sub> and ET<sub>B</sub>, are targets for therapeutic intervention in human diseases. Endothelin-receptor antagonists are in clinical use to treat pulmonary arterial hypertension and have been under clinical investigation for the treatment of several other diseases, such as systemic hypertension, cancer, vasospasm, and fibrogenic diseases. In this Perspective, we review the molecules that have been evaluated in human clinical trials for the treatment of pulmonary arterial hypertension, as well as other cardiovascular diseases, cancer, and fibrosis. We will also discuss the therapeutic consequences of receptor selectivity with regard to ET<sub>A</sub>-selective, ET<sub>B</sub>-selective, or dual ET<sub>A</sub>/ET<sub>B</sub> antagonists. We will also consider which chemical characteristics are relevant to clinical use and the properties of molecules necessary for efficacy in treating diseases against which known molecules displayed suboptimal efficacy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i2" class="anchor-spacer"></div><h3 class="article-section__title" id="_i2"> Endothelin Axis</h3><div class="NLM_p">The endothelin (ET) axis is mainly recognized for its action as a potent vasoconstrictor system involved in the regulation of vascular tone, but it has pleiotropic other functions able to mediate fundamental cellular processes such as cell proliferation and apoptosis. Thus, besides its normal functions, the endothelin axis has also been involved in human hypertensive and cardiovascular pathologies and in fibrogenic, inflammatory, and oncologic diseases and has putative roles in other pathologies including septic shock, atherosclerosis, heart failure, renal insufficiency, and cerebrovascular conditions associated with subarachnoid hemorrhage.</div><div class="NLM_p">The endothelins (ET-1, ET-2, and ET-3) constitute a family of 21 amino acid (aa) peptides synthesized as longer precursor polypeptides of 212 aa (ppETs). These peptides are further proteolytically cleaved by a signal peptidase to produce pro-ET-1 and further activated by a subtilisin-like convertase/furin-like protease that releases the 38 aa-long pro-ETs (big-ETs). Big ETs are then subsequently cleaved by the more specific membrane-bound endothelin converting enzyme 1 (ECE-1)<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> to yield the 21-aa active ET peptides. Following their proteolytic processing, the ET peptides either can be constitutively secreted or can be stored in intracellular granules, then secreted according to a regulated pathway in response to a stimulus.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Following activation and secretion, ET peptides act on two distinct high-affinity receptor subtypes, ET<sub>A</sub> and ET<sub>B</sub>, which are located on target cell membranes.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">The cell expression and tissue expression of the components of the endothelin axis are numerous. The vascular endothelium is an abundant source of the components of the endothelin axis; however, they may also be expressed by leukocytes, smooth muscle cells, mesangial cells, cardiac myocytes, or astrocytes. The most representative peptide of the axis, endothelin (ET) 1, can be induced in endothelial cells by many factors including mechanical stimulation, various hormones, and proinflammatory cytokines. Its production is inhibited by nitric oxide (NO), cyclic nucleotides, prostacyclin, and atrial natriuretic peptide (ANP). ET-1 also stimulates cardiac contraction and the growth of cardiac myocytes, regulates the release of vasoactive substances, and stimulates smooth muscle cell mitogenesis. ET-1 may control inflammatory responses by promoting the adhesion and migration of neutrophils and by stimulating the production of proinflammatory cytokines. It has also been implicated in cancer progression, regulating the proliferation and migration of tumor cells and acting as a proangiogenic factor and an inducer of stromal reaction.</div><div class="NLM_p last">In this Perspective, we will first describe the components of the endothelin axis, then we will discuss attempts made to therapeutically control the functions of the endothelin axis in diseases. We will also discuss and evaluate in more detail the therapeutic interest of endothelin-receptor antagonists in three pathological conditions of proliferative fibrogenic disorders: (1) pulmonary arterial hypertension (PAH), for which endothelin-receptor antagonists are in clinical use; (2) cancer, for which clinical trials have been launched but for which no antagonist has yet reached clinical use; (3) fibrogenic diseases of the kidney, for which such antagonists are being considered for therapy. Fibrogenic disorders involve the recruitment of inflammatory/immune cells, which ultimately drive the activation and proliferation of fibroblasts and the replacement of tissue cells by these activated (myo)fibroblasts. These three conditions imply an enhanced proliferative component involving different but complementary cells. Not surprisingly, as ET-1 and its associated components are cell-proliferation, antiapoptotic, prosurvival, and contractile factors, they have been evaluated as therapeutic targets for these potential therapeutic possibilities. Only drugs able to inhibit the binding of ETs to their cognate ET<sub>A</sub> and/or ET<sub>B</sub> receptors, the âsentanâ family of endothelin-receptor antagonists, have reached clinical evaluation and use and will be described in detail in this Perspective.</div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Components of the Endothelin Axis</h3><div id="sec1_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i4" class="anchor-spacer"></div><h4 class="article-section__title" id="_i4"> Endothelin Peptides: ET-1, ET-2, and ET-3</h4><div class="NLM_p last">The most-studied peptide from the ET family, endothelin 1 (ET-1), was discovered in 1988<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> as a potent and long-lasting vasoconstrictor peptide, much more potent than angiotensin II. The 21-aa active ET peptides are characterized by a single Î± helix, two essential disulfide bridges, Cys3-Cys11 and Cys1-Cys15, and six conserved amino acid residues at the C-terminus. ET-1 has been the most studied peptide of the family; however, the other peptides of the endothelin family, ET-2 and ET-3, may also be of therapeutic interest.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> A role for ET-2 is emerging in ovarian development, the cardiovascular system, immunology, and cancer. In human, ET-2 differs from ET-1 by only two amino acids and has the same affinity as ET-1 for ET<sub>A</sub> and ET<sub>B</sub> receptors, unlike ET-3. Until recently, it was assumed that ET-2 mimics the functions of ET-1; however, recent evidence has pointed to a specific ET-2 pathway as a key regulator of ovarian contractile physiology, with roles as well in heart failure, immunology, and cancer. ET-3 differs from ET-1 by six amino acids and has differential affinities for ET<sub>A</sub> and ET<sub>B</sub>, being highly selective for ET<sub>B</sub>. ET-3 is the main ET peptide in the central nervous system. In cancer, ET-2 and ET-3 may counteract the functions of ET-1 but are also frequently silenced. In human, the genes encoding for ET-1, ET-2, and ET-3 are located on chromosomes 6, 1, and 20, respectively. Epigenetic inactivation by hypermethylation of ET-2 and ET-3 promoters in colon cancer was postulated to favor ET-1-mediated tumor progression, suggesting that ET-2 and ET-3 are natural antagonists of ET-1 and that re-expression of ET-2 and ET-3 may be a complementary approach to receptor antagonists.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The activation of ET precursors by ECEs and chymase may also allow the selective activation of one of the pathways.</div></div><div id="sec1_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i5" class="anchor-spacer"></div><h4 class="article-section__title" id="_i5"> Endothelin Activating Enzymes: Furins and Endothelin-Converting Enzymes</h4><div class="NLM_p">Furins are a family of intracellular serine proteases belonging to the subtilisin-like proprotein convertase family. The members of this family process latent precursor proteins at paired basic amino acid sequences (Arg/Lys-Arg) into their biologically active products. These endoproteases can cleave many precursor proteins, including ppETs, and are involved in several human disorders.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Furins are mainly located within the Golgi/trans-Golgi secretory pathway. The catalytic mechanism in enzymes of the serine protease family involves a catalytic triad consisting of three essential amino acids: one histidine, one serine, and one aspartic acid. In the enzymatic mechanism, covalent intermediates are generated. Inhibitors of furins, which include Î±1-antitrypsin, polyarginine compounds, decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone, as well as a few synthetic molecules, are under consideration as therapeutic agents.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> However, to the best of our knowledge, no therapeutic attempts have been made to control the endothelin axis with furin inhibitors.</div><div class="NLM_p last">Two metalloprotease endothelin-converting enzymes (ECEs) have been described.<a onclick="showRef(event, 'ref1 ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref1 ref9 ref10 ref11 ref12">(1, 9-12)</a> ECE-1 (EC 3.4.24.71) hydrolyzes the Trp11-Val12 bond of human big-ET-1 at neutral pH and is expressed as four isoforms, ECE-1<sub>aâd</sub>, from one gene through the use of different promoters. ECE-2 is active at acidic pH, but as little information exists concerning its physiological importance in human diseases, it will not be discussed in this Perspective. The effect of inhibition of ECE-1 has been evaluated only in animal models of cardiovascular disorders and in vitro in cancer<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and will not be reviewed in detail here because no human trials for therapeutic purposes have been published with these inhibitors.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> However, some observations may be of interest. Depending on the particular ECE-1 isoform or on external factors, ECE-1 may be secreted or expressed at the cell surface (ECE-1<sub>a</sub> and ECE-1<sub>c</sub>) and thus may be directly accessible to inhibitors. Alternatively, ECE-1 may remain intracellular (ECE-1<sub>b</sub> and ECE-1<sub>d</sub>), thus necessitating that inhibitors traverse the cell membrane. NEP 24.11/neprilysin may also activate and degrade big-ET-1 but with a much lower efficiency than ECE-1.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Some information also suggests that mast-cell-derived chymase cleaves the Tyr<sup>31</sup>-Gly<sup>32</sup> bond of big-ET-1 to yield ET-1 (1â31). This peptide is further processed into the active ET- (1â21) by either ECE-1, the main activator of big-ET-1, or NEP24.11, as both thiorphan (a selective NEP 24.11 inhibitor) and phosphoramidon (a dual ECE-1/NEP24.11 inhibitor) abolish ET-1 (1â31) processing.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The enzymes of this latter pathway and their inhibitors have not been evaluated in much detail for therapeutic purposes, and this alternative pathway will not be discussed further here. However, while pure ECE-1 inhibitors have not been tested in the clinic, dual ECE-1/ACE inhibitors have been evaluated in clinical trials.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a></div></div><div id="sec1_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6"> Endothelin Receptors: ET<sub>A</sub> and ET<sub>B</sub></h4><div class="NLM_p">ET receptors belong to the family of seven transmembrane G-protein-coupled receptors (GPCR). Heterotrimeric guanine nucleotide-binding G proteins, composed of Î±-, Î²-, and Î³-subunits on the inner membrane surface of the cells, are key determinants of many signaling processes, including cell proliferation, apoptosis, survival, contraction, migration, and/or differentiation. GPCR ligands interact with many downstream effectors, including adenyl cyclases, phosphodiesterases, phospholipases, tyrosine kinases, and ion channels. The duration of the signal is modulated by the activity of the multiple GPCR-mediated signaling pathways, leading to diverse biological responses.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> At physiological concentrations, ET-1 and ET-2, but not ET-3, bind to ET<sub>A</sub> receptors with comparable affinity (<i>K</i><sub>D</sub>(ET-1) = <i>K</i><sub>D</sub>(ET-2) â 20â60 pM, <i>K</i><sub>D</sub>(ET-3) â 6500 pM), whereas all three ET ligands bind ET<sub>B</sub> receptors with similar affinity (<i>K</i><sub>D</sub>(ET-1) = <i>K</i><sub>D</sub>(ET-2) = <i>K</i><sub>D</sub>(ET-3) â 15 pM). In humans, ET<sub>A</sub> is located in the vasculature and is mostly expressed by cells of the vascular smooth muscle lineage. In these cells, binding of ET-1 to ET<sub>A</sub> mainly induces vasoconstriction and cell proliferation. ET<sub>B</sub> in the vasculature is mostly expressed by endothelial cells. In these cells, binding of ETs to ET<sub>B</sub> induces vasodilatation, bronchoconstriction, and cell proliferation. In the endothelium, ET-1 is mainly released abluminally rather than into the bloodstream, suggesting autocrine/paracrine-localized tissue functions rather than endocrine functions; however, other cell types have been shown to express and respond to the components of the endothelin axis. For example, mutations in ET<sub>B</sub> in the colon are associated with Hirschprung disease and selective expression of both receptors is seen in cancer cells and cancer-associated stromal cells (see below). In human, the genes encoding for ET<sub>A</sub> and ET<sub>B</sub> are located on chromosomes 4 and 13, respectively.</div><div class="NLM_p">Both ET<sub>A</sub> and ET<sub>B</sub> receptors share common signal-transduction pathways through phosphatidylinositol hydrolysis and an increase in cytosolic calcium. The two receptors can also signal through different G proteins and stimulate a variety of other effector systems such as phospholipases D and A2, PKC, or the protein tyrosine kinase-MAP-kinase/ERK pathways.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> The transactivation of the EGF receptor by ET-1 has also been reported.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In addition to its potent vasoconstrictor activity, ET-1 is an autocrine/paracrine (co)mitogen in many cell types, involving several intracellular signaling pathways. Antagonists to endothelin receptors have been developed for the treatment of several cardiovascular diseases<a onclick="showRef(event, 'ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26 ref27">(23-27)</a> and have reached clinical use in the case of pulmonary hypertension.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Unexpectedly, they have also shown promising effects in the context of cancer, with the potential to control tumor growth and potentiate apoptosis, as well as in fibrotic processes in kidney disorders.</div><div class="NLM_p last">Variants of both endothelin receptors have been described,<a onclick="showRef(event, 'ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38">(29-38)</a> and mutagenesis and chimeric receptor studies have indicated that splice variants of the endothelin receptors may undergo conformational changes. It can be speculated that these changes may allow either the binding of ligands other than the ETs or the binding of cellular proteins able to modify the biological functions of the receptors, resulting in either increased or decreased binding affinities for receptor agonists and antagonists and changes in signaling pathways. Several studies have shown that the loss of ET<sub>B</sub> receptor functions plays an important role in ET-induced cell proliferation and death, as well as the activation of intracellular signal transduction pathways that regulate ET production. These effects of ET<sub>B</sub> receptor functions may be important in tumor development, in both cancer cells and cancer-associated stromal cells. We have searched for ET<sub>B</sub> variants in human glioblastoma (GBM) cells (Y. Berger and L. Juillerat-Jeanneret, unpublished data) and in human melanoma cells.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Our results suggested cell-selective effects and possibly methylation of the ET<sub>B</sub> promoter. Methylation of the <i>EDNRB</i> gene was also observed by others in cancer but was not predictive of survival.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> However, a quantitative analysis comparing promoter methylation of the <i>EDNRB</i> gene in paired human normal and gastric tumors found a correlation between higher methylation rates and the aggressiveness and progression of the cancer.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec1_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7"> Therapeutic Control of the Endothelin Axis in Human Diseases</h4><div class="NLM_p">The endothelin axis has been widely implicated in the pathophysiology of various human diseases. As ET-1 is a very potent vasoconstrictor peptide, the first therapeutic attempts aimed at treating hypertensive disorders, then it was realized that the components of this axis may also be valuable therapeutic targets in cancer, inflammation, fibrosis, and metabolic diseases. For therapeutic purposes, the endothelin axis may be blocked using chemical tools, either at the level of big-ET activation (using inhibitors of ECE-1) or by using antagonists to the ET<sub>A</sub> and/or ET<sub>B</sub> endothelin receptors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). In many academic and industrial groups, programs were initiated for the design, preparation, and evaluation of molecules aimed at controlling the functions of the endothelin axis, the bioprocessing of ET-1 by its activating enzymes, and its binding to its cognate receptors, ET<sub>A</sub> and/or ET<sub>B</sub>. These two strategies have been evaluated in animal experimental models of human diseases; however, only receptor antagonists have reached clinical trials and clinical use.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Metabolic processing of the components of the endothelin axis and the potential sites of control of the functions of the endothelin axis (insert, 1â7): ET, endothelin; ECE, endothelin converting enzyme 1. Many different types of cells can secrete the ET peptides and express the ET receptors. Following <i>ET</i> gene activation, a precursor polypeptide is sequentially hydrolyzed by a signal peptidase, a furin-like convertase, and then the ECE-1, either by intracellular ECE isoforms or at the cell surface by cell-membrane inserted ECE, to yield the 21-aa active ET. ET can be either constitutively secreted or can be secreted according to a regulated pathway in response to a stimulus. Then, ET acts on two distinct receptors ET<sub>A</sub> and ET<sub>B</sub> to induce intracellular signaling. In this drawing, a paracrine effect of ET is shown; however, the effects of the ET axis may be autocrine or endocrine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01781&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Therapeutic Agents</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10477" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10477" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Endothelin-Receptor Antagonists</h3><div class="NLM_p">As the diseases for which endothelin-receptor antagonists are targeted for therapy are chronic diseases, including hypertensive and fibrogenic disorders, requesting drug intake once or sometimes twice a day for many years, oral bioavailability is required for patient compliance to their treatment. Due to the nanomolar/picomolar IC<sub>50</sub> values of ET-1 binding to its cognate receptors, receptor antagonists have to be of low nanomolar affinity. Thus, the molecules developed as therapeutic endothelin-receptor antagonists must have these two properties: oral bioavailability and high affinity. Many research groups have begun work on the discovery and development of endothelin-receptor antagonists for the treatment of such diseases. Many synthetic molecules have been designed, prepared, and evaluated, first in in vitro cellular models, then in in vivo experimental animal models of human diseases, and finally, for some of them, in human clinical trials. Whereas some compounds are being marketed to treat pulmonary arterial hypertension (PAH), several other compounds have been evaluated in late clinical trials for various indications. The compounds were generally active at low nanomolar concentrations and orally bioavailable. They were designed to be either ET<sub>A</sub>-selective antagonists (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) with selectivity ET<sub>A</sub>/ET<sub>B</sub> > 100 or dual ET<sub>A</sub>/ET<sub>B</sub> antagonists (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) with selectivity ET<sub>A</sub> â¼ ET<sub>B</sub>, whereas very few ET<sub>B</sub>-selective antagonists (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) with selectivity ET<sub>A</sub>/ET<sub>B</sub> < 100 have been developed and evaluated in clinical trials. Only two types of endothelin-receptor antagonists have reached clinical use: ET<sub>A</sub>-selective and dual antagonists. However, at high concentrations, ET<sub>A</sub>-selective antagonists may display dual antagonistic properties for ET<sub>A</sub>/ET<sub>B</sub>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. ET<sub>A</sub>-Selective Antagonists<a onclick="showRef(event, 'ref58 ref59 ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60 ref61 ref62">()</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0005.gif" alt="" id="fx1" /></img><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Dual ET<sub>A</sub>/ET<sub>B</sub> Antagonists<a onclick="showRef(event, 'ref70 ref71 ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref70 ref71 ref72 ref73">()</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0006.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. ET<sub>B</sub>-Selective Antagonists<a onclick="showRef(event, 'ref75 ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref75 ref76 ref77">()</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0007.gif" alt="" id="fx3" /></img><div></div></div><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Side Effects</h4><div class="NLM_p last">The side effects linked to this class of therapeutics, mainly studied for sitaxsentan (<b>1</b>),<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> bosentan (<b>2</b>),<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(-43, 44)</a> and ambrisentan (<b>3</b>),<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> are dual, either drug-related side effects, such as drugâdrug interaction or liver toxicity, or target-related, such as fluid retention or teratogenicity. Liver toxicity is the major side effect of endothelin-receptor antagonists, involving two main biological processes. Endothelin-receptor antagonists inhibit the canalicular bile salt export pump which translates into a dose-dependent increase of liver enzymes, leading to dose adjustment or discontinuation of the treatment. For <b>2</b>,<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> elevation of transaminases is observed in approximately 10% of patients under the standard 125 mg b.i.d. regimen. In contrast to <b>1</b>, elevation of liver enzymes is usually reversible when <b>2</b> is discontinued. The regulatory agencies recommend a monthly control of liver enzymes for patients treated with <b>2</b>. Liver toxicity appears to be less frequent with <b>3</b>,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> occurring in 1â5% of patients. A more severe and sometimes irreversible liver toxicity is also encountered. Its severity and incidence vary, however, with each compound. After three cases of irreversible and fatal liver failure under <b>1</b>,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> published in 2009 and 2010, Pfizer decided to withdraw this drug from the market in 2010. Another common side effect and problematic drawback of endothelin-receptor antagonists is fluid retention. This side effect is mediated by the ET<sub>A</sub> receptor and is due to a direct effect of this class of drugs on the renal collecting duct. It is partially related to the vascular action of the drugs and does not arise from alterations in cardiac function, according to animal studies. This side effect is more frequent with <b>2</b>, occurring in 10â20% of cases, depending on the daily dose. Older patients are more likely than younger patients to suffer from this side effect. All endothelin-receptor antagonists are teratogenic; therefore, administration to women with child-bearing potential should be accompanied by expert contraception counseling. Drug interactions may also occur. Compound <b>2</b> is metabolized by cytochrome P450, CYP2C9, and CYP3A4, and numerous drug interactions have been described. Among the most clinically relevant are a decrease in estrogens and progesterone levels for oral contraception, a decrease in sildenafil levels with concomitant administration, a rise in <b>2</b> blood levels with HIV-protease inhibitors, a decrease in the efficacy of anticoagulation with anti-vitamin K agents such as warfarin. Drug interactions are less severe and less prevalent with <b>3</b> and macitentan (<b>4</b>).<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a></div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Molecules Developed for Therapeutic Purposes</h4><div class="NLM_p">Several previous reviews have described the clinical characteristics of endothelin-receptor antagonists, the âsentanâ family of drugs.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28 ref48'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28 ref48">(24-28, 48)</a> Thus, this information will not be discussed in detail in this Perspective. Only brief comments concerning some selected compounds are provided here, in particular concerning the biochemical characteristics of the most recently approved dual ET<sub>A</sub>/ET<sub>B</sub> endothelin-receptor antagonist <b>4</b>. The detailed clinical information is provided in the dedicated sections below. Several ET<sub>A</sub>-specific endothelin-receptor antagonists have reached human clinical evaluation for diseases such as PAH, cancer, or kidney diseases,<a onclick="showRef(event, 'ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51 ref52">(49-52)</a> including <b>1</b>, <b>3</b>, atrasentan (<b>5</b>),<a onclick="showRef(event, 'ref24 ref53'); return false;" href="javascript:void(0);" class="ref ref24 ref53">(24, 53)</a> clazosentan (<b>6</b>),<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> zibosentan (<b>7</b>),<a onclick="showRef(event, 'ref27 ref55'); return false;" href="javascript:void(0);" class="ref ref27 ref55">(27, 55)</a> which are discussed below.</div><div class="NLM_p">The dual ET<sub>A</sub>/ET<sub>B</sub> antagonist <b>2</b><a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> was the first molecule approved for clinical use; however, clinical trials rapidly revealed that <b>2</b> tended to induce liver toxicity. Structural modification of <b>2</b> produced <b>4</b>,<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a> which has improved the toxicity profile and biological characteristics and is presently approved for clinical treatment of PAH.<a onclick="showRef(event, 'ref47 ref48 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref63 ref64">(47, 48, 63, 64)</a> Minimal accumulation of <b>4</b> in the liver suggests that it will be less prone to drugâdrug interaction than <b>2</b>, an advantage for combination therapies necessary in cancer treatment.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The interaction profile of <b>4</b> in vitro has shown it is also an inhibitor of the drug-resistance molecule P-glycoprotein (P-Gp), as well as of other proteins involved in cancer chemoresistance, which may enhance its anticancer properties, in particular for multidrug-resistant cancers (see below). A comparison of the biochemical characteristics of <b>2</b> and <b>4</b> is also of interest. Molecular-homology docking of <b>2</b> on ET<sub>B</sub> showed the involvement and importance of Arg82, Arg84, and His197 in hydrogen bonding between the antagonist and ET<sub>B</sub>.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Compound <b>4</b> shows slow apparent ET<sub>A</sub>-receptor association kinetics, consistent with a competitive mode. <b>2</b> and structurally related molecules are characterized by fast dissociation kinetics and very short (â¼1 min) occupancy half-lives at ET<sub>A</sub>, whereas <b>4</b> and structurally related molecules display a 20-fold slower dissociation half-life, resulting in insurmountable antagonism. The interaction of <b>4</b> with ET<sub>A</sub> depends predominantly on hydrophobic interaction, not on chargeâcharge interactions, and the tightly packed conformation adopted by <b>4</b> fits into a defined pocket of ET<sub>A</sub>, in contrast to the noncompacted structure of <b>2</b>. Mutagenesis studies showed that Arg326 and Ile355 are important for <b>2</b> but not <b>4</b>, binding to ET<sub>A</sub>. The opposite is true for Leu322.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67, 68)</a></div><div class="NLM_p">ET<sub>B</sub>-selective antagonists, exemplified by BQ788<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (<b>19</b>), have mostly been used in preclinical cellular and animal experimental models.</div><div class="NLM_p">Inspired by the structure of the molecules developed early in experimentation, novel series of endothelin-receptor antagonists have been designed and evaluated. A few examples are shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. For compound <b>24</b>,<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> this series is based on a 1,3,4,5-tetrahydro-1<i>H</i>-benzo[<i>e</i>][1,4]diazepin-2-one scaffold producing derivatives that are potent dual ET<sub>A</sub>/ET<sub>B</sub> receptor antagonists with affinities in the low-nanomolar range. For compound <b>25</b>,<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> this series of ET<sub>A</sub>-selective receptor antagonists has a 2<i>H</i>-chromene skeleton and is based on a series of angiotensin-II receptor 1 (AT1) antagonists. The most potent compound binds to the ET<sub>A</sub> with an IC<sub>50</sub> value of 0.19 nM and is 630-fold selective for ET<sub>A</sub> compared to ET<sub>B</sub>. For compound <b>26</b>,<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> based on the ET<sub>A</sub>-selective antagonist (<i>S</i>)-3-methoxy-2-(4,6-dimethoxypyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 135252), structural modifications resulted in the antagonist (<i>S</i>)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), with <i>K</i><sub>i</sub> = 2.15 nM for ET<sub>A</sub> and <i>K</i><sub>i</sub> = 4.75 nM for ET<sub>B</sub>. For compound <b>27</b>,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> this series of 1,3,6-trisubsituted-4-oxo-1,4-dihyroquinoline-2-carboxylic acid analogs were prepared as ET<sub>A</sub>-selective antagonists, with the most potent displaying IC<sub>50</sub> = 0.11 nM and a ET<sub>B</sub>/ET<sub>A</sub> selectivity of >8000Ã. For compound <b>28</b>,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> this series of novel 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3,3-diphenylbutyric acid derivatives were synthesized and evaluated, with the most potent displaying potency comparable to that of <b>2</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Examples of Endothelin-Receptor Antagonists Based on Chemical Modifications of Previously Developed Compounds</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01781&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Approaches other than modifying previously developed compounds have also been attempted. For example, inhibition of ET-1 precursor activation by ECE-1 (EC 3.4.24.71) may be an alternative to using receptor antagonists. A series of nonpeptidic thiol-based ECE-1 inhibitors were able to inhibit DNA synthesis in human GBM cells. This effect was not reversed by exogenous addition of ET-1, suggesting an intracellular effect of ECE-1 inhibitors not involving extracellular production of ET-1.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Receptor-specific antibodies may also represent an alternative to synthetic compounds as endothelin-receptor antagonists. In melanoma cell lines, the binding characteristics of a monoclonal antibody (mAb) developed against tumor-specific epitopes of ET<sub>B</sub>, possibly N-terminal truncation at Arg64-Ser65 by ligand-induced hydrolysis by a metalloprotease, suggest other therapeutic possibilities. This hydrolytic truncation was also shown to abolish ET<sub>B</sub>-mediated EGFR transactivation.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Clinical Trials</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00603" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00603" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Clinical Trials of Endothelin-Receptor(s) Antagonists in Human Diseases</h3><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Endothelin-Receptor Antagonists in Cardiovascular Diseases Other than PAH</h4><div class="NLM_p">We have previously reviewed in detail clinical trials performed before 2009.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> In this section, therefore, we will summarize only the main results of these early trials. We will present the more recent trials, in particular clinical trials for PAH and development of the dual ET<sub>A</sub>/ET<sub>B</sub> antagonist <b>4</b> for PAH, cancer, and fibrosis, in more detail. Antagonists of ET<sub>A</sub> or ET<sub>B</sub> and inhibitors of ECE-1 were initially developed for the treatment of cardiovascular diseases. The first antagonists to be tested in healthy human volunteers and patients with chronic heart failure (CHF) were peptidomimetics, the ET<sub>A</sub>-selective BQ123<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> (<b>8</b>) and the ET<sub>B</sub>-selective BQ788<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (<b>19</b>). The usual problems of peptide-like molecules, such as poor bioavailability and susceptibility to proteolytic enzymes, arose, but these trials were very useful in defining the physiological functions of ET-1 in health and disease. The information gained<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85, 86)</a> suggested that ET-1 maintains vascular tone via basal activation of ET<sub>A</sub> on vascular smooth-muscle cells, whereas ET<sub>B</sub> activation reduces basal vascular tone and vasodilatation, which are mediated by nitric oxide (NO) generation in the endothelium. Patients with hypertension responded to infusion of <b>8</b> and <b>19</b> with more vasodilatation than did healthy subjects. Additionally, ET<sub>A</sub>-selective antagonists, but not dual ET<sub>A</sub>/ET<sub>B</sub> antagonists, improved hypertension. In animal models, dual or ET<sub>A</sub>-selective antagonism ameliorated left-ventricular functions, prevented ventricular remodeling, and resulted in prolonged survival, properties not shared by ET<sub>B</sub> antagonists. Altogether, the information obtained from these early molecules suggested an advantage in the treatment of cardiovascular disease to the development of nonpeptidomimetic antagonists to modulate the functions of ET-1 receptors. Therefore, low-molecular-weight synthetic ET<sub>A</sub>-selective or dual ET<sub>A</sub>/ET<sub>B</sub> antagonists, but only very few ET<sub>B</sub>-selective antagonists, were developed and evaluated in clinical trials. From the published results of these early clinical trials, it can be inferred that the endothelin axis, in addition to regulating vascular tone, may also promote vascular-cell migration, proliferation, differentiation, and/or growth. In patients with CHF, ET<sub>A</sub> blockade was more favorable than ET<sub>B</sub> blockade; however, in the long term, a lack of beneficial effects of endothelin-receptor antagonists in heart failure mortality/morbidity was observed.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> The results of these trials did not meet expectations for CHF patients; however, some encouraging information was obtained for patients with primary and secondary PAH.</div><div class="NLM_p last">Due to its inherent ability to produce potent and prolonged vasoconstriction, ET-1 has been postulated to be a critical mediator of cerebral vasospasm. A phase IIa trial conducted with the ET<sub>A</sub> antagonist <b>6</b> demonstrated a benefit for patients in terms of the severity and incidence of vasospasm. ET<sub>B</sub> antagonism, however, may be detrimental due to inhibition of ET<sub>B</sub>-mediated NO production, as was observed for the dual ET<sub>A</sub>/ET<sub>B</sub> antagonist TAK-044 (<b>14</b>).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Endothelin-Receptor Antagonists for the Treatment of PAH</h4><div class="NLM_p">PAH is a pathological lung condition arising from multiple etiological causes leading to vascular remodeling, an abnormal thickening of the arterial wall and an increase in pulmonary vascular resistance. The hemodynamic consequences of PAH are an increased afterload for the right ventricle and, eventually, right heart failure and ultimately death. When untreated, PAH has a grim prognosis, with a median survival of approximately 2â4 years from diagnosis. The basic defect in the pathogenesis of PAH is thought to be an endothelial dysfunction with impaired paracrine signaling from endothelial to smooth-muscle cells.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> A number of biological systems have been implicated, including increased ET-1 expression in vascular endothelial cells from human pulmonary arteries.<a onclick="showRef(event, 'ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref88 ref89">(88, 89)</a> Three therapeutics are presently registered with the FDA (U.S. Federal Drug Administration) and/or the EMA (European Medicines Agency) for the treatment of PAH. The first endothelin-receptor antagonist, the dual ET<sub>A</sub>/ET<sub>B</sub> antagonist <b>2</b>,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> was approved in the U.S. in 2001 and Europe in 2002. Then the ET<sub>A</sub>-selective antagonists <b>1</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and <b>3</b><a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> were approved, respectively, in 2006 by EMA and in 2007 by FDA and in 2008 only by EMA, followed by the dual ET<sub>A</sub>/ET<sub>B</sub> antagonist <b>4</b>,<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a> approved by both institutions in 2013. Compound <b>1</b> has been withdrawn by Pfizer in 2010.</div><div class="NLM_p">The potential advantage of selective ET<sub>A</sub> antagonism over dual ET<sub>A</sub>/ET<sub>B</sub> blockade remains controversial in the field of PAH.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Physiologically, ET<sub>B</sub> mediates vasodilatation through the NO pathway, and it may appear counterproductive to inhibit that pathway; however, in pathological states, cross-talk between ET<sub>A</sub> and ET<sub>B</sub> may occur with heterodimerization of both types of receptors. Under these conditions, ET<sub>B</sub> may also mediate vasoconstriction<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> and proliferation of smooth-muscle cells.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> As there has been to date no direct comparison of both classes of antagonists in a randomized and blinded trial, there is no formal evidence for clinical use. While ET-1 receptor antagonists have been demonstrated to be clinically useful in PAH, their use as a monotherapy is often insufficient to lastingly relieve symptoms in affected patients, suggesting the value of combination-therapy regimens, which are presently under evaluation.</div><div class="NLM_p">For the present review, the databases PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" class="extLink">www.ncbi.nlm.nih.gov/pubmed</a>), the NIH registry for clinical trials (<a href="http://clinicaltrials.gov" class="extLink">clinicaltrials.gov</a>), the WHO international clinical trials platform (<a href="http://apps.who.int/trialsearch" class="extLink">http://apps.who.int/trialsearch</a>), and reviews from the past 5 years<a onclick="showRef(event, 'ref93 ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref93 ref94 ref95">(93-95)</a> were consulted. In particular, the systematic review by the Cochrane collaboration published in 2013<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> remains of high interest, as it included and analyzed all but three trials available to date. Fourteen studies were identified according to the search criteria: four for <b>3</b>, six for <b>2</b>, three for <b>1</b>, and one for <b>4</b>. These studies are summarized in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Clinical Trials of Endothelin-Receptor Antagonists for Patients with PAH<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">dose [mg]</th><th class="colsep0 rowsep0" align="center">code trial</th><th class="colsep0 rowsep0" align="center">comparator</th><th class="colsep0 rowsep0" align="center">duration  [weeks]</th><th class="colsep0 rowsep0" align="center">patients</th><th class="colsep0 rowsep0" align="center">outcome</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">100/300</td><td class="colsep0 rowsep0" align="left">STRIDE<b>-</b>1<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">increased peak VO<sub>2</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">50/100</td><td class="colsep0 rowsep0" align="left">STRIDE-2<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">improved 6-MDW</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">6-MWD neutral</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">50/100</td><td class="colsep0 rowsep0" align="left">STRIDE-4<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">worsened 6-MWD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">125/250</td><td class="colsep0 rowsep0" align="left">ASSET-1<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">improved PVR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">125</td><td class="colsep0 rowsep0" align="left">Study-351<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">improved 6-MWD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">125/250</td><td class="colsep0 rowsep0" align="left">BREATHE-1<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">improved 6-MWD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">125 b.i.d.</td><td class="colsep0 rowsep0" align="left">BREATHE-2<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></td><td class="colsep0 rowsep0" align="left">epoprostanol</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">neutral PVR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">125 b.i.d.</td><td class="colsep0 rowsep0" align="left">BREATHE-5<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">improved PVR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">125 b.i.d.</td><td class="colsep0 rowsep0" align="left">COMPASS-2<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">>16</td><td class="colsep0 rowsep0" align="left">sildenafil</td><td class="colsep0 rowsep0" align="left">neutral TCW</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">125 b.i.d.</td><td class="colsep0 rowsep0" align="left">EARLY<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">untreated NYHAÂ II</td><td class="colsep0 rowsep0" align="left">decreased PVR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">neutral 6-MWD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">125 b.i.d.</td><td class="colsep0 rowsep0" align="left">SERAPH<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></td><td class="colsep0 rowsep0" align="left">sildenafil</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">no arm difference</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">5/10</td><td class="colsep0 rowsep0" align="left">ARIES-1<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">improved 6-MWD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">2.5/5</td><td class="colsep0 rowsep0" align="left">ARIES-2<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">improved 6-MWD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">ATHENA-1</td><td class="colsep0 rowsep0" align="left">none and PVR compared to baseline</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">PDEVi</td><td class="colsep0 rowsep0" align="left">improved 6-MWD, neutral PVR compared to baseline</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">AMBITION<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></td><td class="colsep0 rowsep0" align="left">sildenafil</td><td class="colsep0 rowsep0" align="left">â¥24</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">no arm difference in TCW</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">3/10</td><td class="colsep0 rowsep0" align="left">SERAPHIN<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">115</td><td class="colsep0 rowsep0" align="left">untreated</td><td class="colsep0 rowsep0" align="left">improved TCW</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">placebo</td><td class="colsep0 rowsep0" align="left">115</td><td class="colsep0 rowsep0" align="left">PDEVi or prost</td><td class="colsep0 rowsep0" align="left">improved TCW</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">6-MWD, 6 min walking distance; PVR, pulmonary vascular resistance; peak VO<sub>2</sub>, maximal oxygen consumption on exercise; TCW, time to clinical worsening; PDEVi, phosphodiesterase V inhibitor; RV, right ventricle; prost, prostanoids.</p></div></div></div><div class="NLM_p">In previously untreated patients, all studies but one yielded a positive primary outcome. The earlier trials were of short duration (12â16 weeks) and used mainly the distance achieved during the 6 min walking test (6-MWD) as the primary outcome.<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109, 110)</a> Only the STRIDE-4 study yielded a negative result in patients treated with 50 mg of <b>1</b>. The gain was also modest in the SERAPHIN study, but 63% of the patients included in this study had already been treated, mostly with phosphodiesterase V (PDEV) inhibitors. The short duration of most studies was also criticized by experts and regulatory agencies.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> For these reasons, more recent trials have been designed with a new composite primary index: time to clinical worsening (TCW). The two most recent studies that applied this new primary outcome (SERAPHIN and AMBITION) were also of longer duration and included significantly more patients than the earlier studies. Most studies have published data on the improvement in symptoms and mortality (REVEAL registry).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Overall, one-half to two-thirds of patients did not worsen while the remaining improved.</div><div class="NLM_p">The most recently approved antagonist <b>4</b> has been studied in SERAPHIN,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> a multicenter, double-blind, placebo-controlled, parallel-group, event-driven, phase III outcome study involving 742 patients with symptomatic PAH randomized to three treatment groups (placebo, 3 mg or 10 mg of <b>4</b> once daily) to assess the long-term effects on morbidity and mortality. Treatment with 10 mg of <b>4</b> resulted in a sustained 45% relative risk reduction early in treatment. The efficacy of 10 mg of <b>4</b> on the primary end point was consistent across subgroups of age, sex, ethnic origin, geographical region, etiology, monotherapy, and combination with another PAH therapy. The majority of adverse reactions were mild to moderate in intensity. Therefore, <b>4</b> was approved in 2013 by the FDA and the EU Commission as an orally available dual ET<sub>A</sub>/ET<sub>B</sub> antagonist for the treatment of PAH.</div><div class="NLM_p">While earlier studies compared essentially single-drug regimens with a placebo, three more recent trials included patients already treated with a drug of another therapeutic class, such as PDEV inhibitors or prostanoids (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Not surprisingly, positive results are more difficult to demonstrate for this group than for treatment-naive patients. Only the study with <b>4</b>, 10 mg, which included a large number of patients for an extended period of time, was able to show a benefit of adding an endothelin-receptor antagonist to a preexisting PAH therapy.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The design of the AMBITION study was different, as <b>3</b> and tadalafil were introduced together, not sequentially. This simultaneous double therapy proved superior to single-drug therapy in terms of TCW.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> On the basis of this latter study, the most recent guidelines advocate the concurrent use of a dual-drug regimen while also offering the possibility of starting with a single-drug regimen, as not every drug combination has been tested in randomized clinical trials (RCT).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a></div><div class="NLM_p">It comes as no surprise that pharmaceutical companies have avoided direct comparison of their product with other available drugs; only very few investigator-driven comparative studies are available. It was not the design of the AMBITION study to compare the two single-drug arms (tadalafil and <b>3</b>). Nevertheless, the TCW was similar in these two groups in patients of comparable PAH severity (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Another study has compared two endothelin-receptor antagonists, <b>1</b> and <b>2</b>.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> No difference was found in the 6-MWD, the primary outcome of this trial. Overall, no striking difference in efficacy was observed among the four endothelin-receptor antagonists tested in PAH.</div><div class="NLM_p">None of the 14 RCT performed with endothelin-receptor antagonists in PAH had death as the primary outcome; however, deaths were duly recorded in every study. These data showed a trend for less deaths in patients treated with endothelin-receptor antagonists compared to placebo.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> The Cochrane review published in 2013 concluded that âthere is uncertainty as to whether endothelin-receptor antagonists reduce mortality in this populationâ.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> The two most recent trials, SERAPHIN and AMBITION, analyzed morbidity and mortality in PAH; however, as nonfatal events define the end of study for the participant, it is logical that mortality was not different between the treated and placebo arms in both studies.<a onclick="showRef(event, 'ref47 ref108'); return false;" href="javascript:void(0);" class="ref ref47 ref108">(47, 108)</a> Finally, as more than eight substances have proven efficacy for PAH, it is becoming unethical to perform placebo-controlled studies, especially with mortality as the major end point.</div><div class="NLM_p">In conclusion, the three clinically available oral endothelin-receptor antagonists are considered as first-line therapies for PAH functional class II and III, intravenous epoprostenol being the first choice for patients in class IV.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> According to the AMBITION study, concurrent therapy with <b>3</b> and tadalafil is also recommended as a first-line treatment. In the case of unsatisfactory response to a single-drug regimen, sequential use of a double- or triple-drug regimen is proposed.</div><div class="NLM_p">Several studies with <b>3</b> and <b>4</b> are presently ongoing (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). These trials address mainly specific subtypes of PAH, such as Eisenmenger syndrome or portopulmonary hypertension. In addition, some trials explore the benefit of endothelin-receptor antagonists in other PAH groups such as PAH due to left heart disease or inoperable chronic thromboembolic pulmonary hypertension.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Ongoing Studies of Endothelin-Receptor Antagonists<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">study and NCT no.</th><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">primary outcome</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ATPAHSS NCT01042158</td><td class="colsep0 rowsep0" align="left"><b>3</b>, 10 mg of Â±sildenafil</td><td class="colsep0 rowsep0" align="left">scleroderma-associated PAH</td><td class="colsep0 rowsep0" align="left">6-MWD published Sep 2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCT02253394</td><td class="colsep0 rowsep0" align="left"><b>3</b>, 10 mg of Â±spironolactone</td><td class="colsep0 rowsep0" align="left">PAH</td><td class="colsep0 rowsep0" align="left">6-MWD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAESTRO NCT01743001</td><td class="colsep0 rowsep0" align="left"><b>4</b>, 10Â mg</td><td class="colsep0 rowsep0" align="left">Eisenmenger syndrome</td><td class="colsep0 rowsep0" align="left">6-MWD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MELODY NCT02070991</td><td class="colsep0 rowsep0" align="left"><b>4</b>, 10Â mg</td><td class="colsep0 rowsep0" align="left">pulmonary hypertension due to left heart disease</td><td class="colsep0 rowsep0" align="left">hemodynamics</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MERIT NCT02060721</td><td class="colsep0 rowsep0" align="left"><b>4</b>, 10Â mg</td><td class="colsep0 rowsep0" align="left">chronic thromboembolic pulmonary hypertension</td><td class="colsep0 rowsep0" align="left">6-MWD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PORTICO NCT02382016</td><td class="colsep0 rowsep0" align="left"><b>4</b>, 10Â mg</td><td class="colsep0 rowsep0" align="left">portopulmonary hypertension</td><td class="colsep0 rowsep0" align="left">PVR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SCOBA-PH NCT01330108</td><td class="colsep0 rowsep0" align="left">switch <b>2</b> to <b>3</b>, 10Â mg</td><td class="colsep0 rowsep0" align="left">PAH</td><td class="colsep0 rowsep0" align="left">safety, 6-MWD</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">6-MWD, 6 min walking distance; PVR, pulmonary vascular resistance.</p></div></div></div><div class="NLM_p last">In summary, endothelin-receptor antagonists of <i>both</i> ET<sub>A</sub>-selective and dual ET<sub>A</sub>/ET<sub>B</sub> subtypes have shown clinical interest and benefit for patients with PAH; however, even if these therapeutics can delay disease progression, they are not curative.</div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Functions of the Endothelin Axis beyond PAH: Cancer</h4><div class="NLM_p">As stated above, ET-1 besides being a potent vasoconstrictor is also an antiapoptotic and mitogenic peptide whose expression, as well as that of the components of the whole endothelin axis, is largely increased in human cancers.<a onclick="showRef(event, 'ref115 ref116 ref117 ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref115 ref116 ref117 ref118 ref119">(115-119)</a> Cancer is a proliferative disorder of the cancer cells themselves, as well as of the cancer-associated stromal cells, mainly endothelial cells and fibroblasts. The transformation of fibroblasts into myofibroblasts is a characteristic not only of cancer but also of fibrogenic diseases. In human cancers, depending on the relative expression of ET<sub>A</sub> and ET<sub>B</sub>, the endothelin axis may act as a growth-promoting or an apoptosis-promoting effector. The main source of ET-1 is the tumor-associated endothelium, whereas ET-1 production by human tumor cell lines has also been demonstrated.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> By use of ex vivo, in vivo, and in vitro approaches, the expression of ET-1, ECE-1<sub>aâd</sub>, ET<sub>A</sub>, and ET<sub>B</sub> was determined in human prostate, ovarian, breast, cervix, oral, lung, and colon carcinoma, GBM, melanoma, and Kaposi sarcoma and the relevant human tumor cells in culture.<a onclick="showRef(event, 'ref13 ref39 ref115 ref116 ref121 ref122 ref123 ref124 ref125 ref126 ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref13 ref39 ref115 ref116 ref121 ref122 ref123 ref124 ref125 ref126 ref127 ref128">(13, 39, 115, 116, 121-128)</a> In these human cancers, ETs were survival factors, protecting tumor cells against apoptosis.<a onclick="showRef(event, 'ref115 ref116 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref115 ref116 ref128 ref129">(115, 116, 128, 129)</a> From these data, ET-1, ET<sub>A</sub>, and/or ET<sub>B</sub> receptors have been proposed to be involved in cancer progression. In human cancer samples it was generally observed that the ET-1 precursors, ECE-1, and the ET<sub>A</sub> and/or ET<sub>B</sub> receptors were also expressed by the tumor-associated stroma. Thus, in human cancers, depending on the type of cancer, the main source of ETs may be either the cancer cells, mainly in carcinomas, or the cancer-associated stroma, including the tumor-associated vasculature, in noncarcinoma tumors. Published data indicate that the main endothelin receptor implicated in human carcinomas is the ET<sub>A</sub> receptor, whereas in human GBM and melanoma, it is the ET<sub>B</sub> receptors. The role and the mechanisms of ET-1-mediated effects in cancer have been mainly studied in preclinical models and have been previously reviewed in detail by others.<a onclick="showRef(event, 'ref123 ref124 ref125 ref126 ref127 ref130 ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref123 ref124 ref125 ref126 ref127 ref130 ref131 ref132">(123-127, 130-132)</a> Thus, we will not repeat the details of these previous reviews. Only some information discussed in previous reviews will be outlined here.</div><div class="NLM_p">Preclinical cellular and animal experimental models have implicated all components of the endothelin axis in cancer development and progression. ET-1 is a direct cell-proliferation and cell-survival factor for cancer cells and is involved in the transactivation of other tumor-cell receptors, mainly the EGF receptor. ET-1 also promotes cancer-cell epithelial-to-mesenchymal transdifferentiation (EMT), migration, invasion and metastasis, and resistance to chemotherapy; however, ET-1 is also involved in the interactions between tumor cells and their environment. ET-1 induces tumor-associated angiogenesis, increasing the release of VEGF and stimulating (myo)fibroblasts and cancer cells to produce proangiogenic proteases. ET-1 mediates the recruitment, proliferation, and differentiation of fibroblasts into tumor-associated myofibroblasts and the interaction of cancer cells with inflammatory/immune cells, protumoral macrophages (type 2 macrophages), and antitumoral T-lymphocytes. ET-1 also upregulates profibrotic growth factors, contraction- and migration-enhancing factors, thus favoring the development of tumor stroma.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><div class="NLM_p">Most <i>preclinical</i> studies of endothelin-receptor antagonists have been conducted in experimental models of ovarian and prostate carcinomas.<a onclick="showRef(event, 'ref121 ref123 ref124 ref127 ref132 ref134'); return false;" href="javascript:void(0);" class="ref ref121 ref123 ref124 ref127 ref132 ref134">(121, 123, 124, 127, 132, 134)</a> In epithelial ovarian cancer cells, a link between an autocrine ET-1/ET<sub>A</sub> pathway, EGFR, and Î²-catenin-Î²-arrestin-mediated transcriptional activity, EMT, chemoresistance, and possibly metastasis was proposed.<a onclick="showRef(event, 'ref135 ref136 ref137 ref138'); return false;" href="javascript:void(0);" class="ref ref135 ref136 ref137 ref138">(135-138)</a> ET-1 via ET<sub>A</sub> transactivates EGF receptors in ovarian cancer cells, and combination of the ET<sub>A</sub> antagonist <b>7</b> with an EGFR antagonist (gefitinib) strongly reduced proliferation and invasion of ovarian tumor cells. In an experimental model of multidrug-resistant (Taxol or cisplatinum) ovarian tumors, <b>4</b> in combination, but not alone, was highly antitumoral, reversing drug resistance, suggesting that drug combination should be considered in cancer therapy.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> In a preclinical study of colon cancer, the specific ET<sub>A</sub> antagonist <b>7</b> inhibited cell proliferation, but cell migration was more inhibited by an ET<sub>B</sub> antagonist than by an ET<sub>A</sub> antagonist and cell contraction was more inhibited by combined ET<sub>A</sub> and ET<sub>B</sub> blockage; however, it has to be emphasized that in vitro, the concentration of the antagonists necessary to induce or potentiate apoptosis in cancer cells was much higher than the concentrations effective in the context of cardiovascular diseases. These concentration-dependent effects resemble the effects observed when modifications were introduced in the transmembrane domain 3 and cytoplasmic domain 2 of ET-receptors using either mutagenesis or chimeric receptors. Alternatively, the localization of the endothelin receptor(s) is intracellular in tumor cells, rendering them poorly accessible to the antagonists. Another explanation may be that endothelin-receptor antagonists are substrates for ATP-dependent membrane transporters involved in drug resistance, such as P-Gp.</div><div class="NLM_p">However, most of these preclinical data, in particular the expression of mainly ET<sub>A</sub> by tumor cells, were established using experimental models of <i>epithelial</i> tumors, the so-called âcarcinomasâ. It was realized only recently that the picture may be different in noncarcinoma cancers, the âmesenchymalâ tumors. In human noncarcinoma cancer, the pattern of expression of endothelin receptors is more complex. For example, we observed that in human GBM surgical samples, ET<sub>A</sub> receptors were mostly expressed by blood vessels, while ET<sub>B</sub> receptors were mainly expressed by the tumor cells. The prosurvival functions of ET-1 for GBM and melanoma cells in culture were exerted via the ET<sub>B</sub> receptor.<a onclick="showRef(event, 'ref13 ref116 ref140'); return false;" href="javascript:void(0);" class="ref ref13 ref116 ref140">(13, 116, 140)</a> In GBM cells in culture, exogenous ET-1 enhanced tumor-cell migration and MMP-9 and MMP-13 expression.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> ET-3 is mainly expressed in the central nervous system and has been involved via ET<sub>B</sub> in the progression of GBM via an autocrine pathway in GBM stem cells able to maintain their stemness-associated properties. Compound <b>19</b>, A192621<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> (<b>20</b>, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), and ET-3 RNA interference blocked growth and induced GBM stem-cell apoptosis. Thus, ET<sub>B</sub> antagonists may be valuable in GBM and oligidendroglioma therapy.<a onclick="showRef(event, 'ref142 ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref142 ref143 ref144">(142-144)</a></div><div class="NLM_p">Interaction with cancer-associated stroma has also been studied. ET<sub>A</sub> is critical in mediating immune-cell recruitment and T-cell-mediated antitumor activity, while ET<sub>B</sub> is a barrier to this recruitment.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Neither <b>4</b> nor the combination of <b>8</b> and <b>19</b> modified immune-cell recruitment to cancer.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> In an experimental model of breast cancer, macrophages were shown to induce the endothelinâintegrin axis in endothelial cells, favoring the adhesion and migration of breast tumor cells across the vascular wall, the early steps of metastasis.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> ET-1 may stimulate the growth of fibroblasts, and it was shown that in coculture of ovarian carcinoma cells and fibroblasts the growth of both populations was reciprocally stimulated.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The high rate of binding of ET-1 to (myo)fibroblasts, implicates these cells in tumor progression and ET-1 receptors as potential therapeutic targets.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Induction and overexpression of ET<sub>B</sub> receptors were observed in colon cancer-associated (myo)fibroblasts and endothelial cells.<a onclick="showRef(event, 'ref115 ref148'); return false;" href="javascript:void(0);" class="ref ref115 ref148">(115, 148)</a> These observations were later confirmed in different human cancers, suggesting that tumor cells can induce ET<sub>B</sub> in their stroma. These stroma-expressed ET<sub>B</sub> can participate in the progression of cancer and be relevant targets for therapeutic purposes. In brain cancers, expression of ET<sub>A</sub> was demonstrated in human gliomas and meningiomas, with high affinity for ET<sub>A</sub> antagonists. In human surgical samples from patients with GBM, ET-1, ECE-1, and ET<sub>A</sub> were mainly expressed by GBM neovessels, while ET<sub>B</sub> is mainly expressed by the tumor cells, suggesting that GBM vessels are likely a source of ET-1 acting on cancer cells via ET<sub>B</sub>. ET<sub>A</sub> was also expressed by tumor-associated vessels. Induction of the ET<sub>B</sub>-type receptor in tumor stroma, mainly in reactive astrocytes and in myofibroblasts ensheathing tumor neovessels in GBM,<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> indicated that the endothelin axis is also important in the interactions between nonepithelial human cancers and their stroma. The dual ET<sub>A</sub>/ET<sub>B</sub>-antagonist <b>2</b> induced apoptosis in human GBM cells. ET-1 via ET<sub>B</sub> is a survival factor but not a proliferation factor for GBM cells.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Meningiomas have been shown to express mainly ET<sub>A</sub>.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The ET-1/ET<sub>B</sub> axis was shown to reduce P-Gp functions at the bloodâbrain barrier (BBB), an important effect for the transport of chemotherapeutics in brain cancer and other cerebral disorders.<a onclick="showRef(event, 'ref148 ref150'); return false;" href="javascript:void(0);" class="ref ref148 ref150">(148, 150)</a> Thus, tumor cells can induce ET<sub>B</sub> in their stroma and stromal ET<sub>B</sub> can participate in the progression of brain cancer and be an additional target of the endothelin axis for therapeutic purposes.</div><div class="NLM_p">The endothelin axis was also involved in maintaining the properties of cancer stem cells (CSC). Compound <b>4</b> alone did not show significant antitumor activity, while in combination with chemotherapy, <b>4</b> demonstrated specific anti-CSC activity. Lack of stromal ET<sub>B</sub> is associated with diminished infiltration of tumor-associated macrophages.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Endothelin receptors also play a permissive role in tumor metastasis, the main cause of mortality of cancer patients. In an experimental murine model, the ET-1/ET<sub>A</sub> axis was shown to enhance lung metastasis of bladder cancer, preceded by and depending on macrophage infiltration of the lung. Thus, the proinflammatory functions of the ET-1 axis are important in the context of tumor progression.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div><div class="NLM_p">Antagonists of either ET<sub>A</sub>, ET<sub>B</sub>, or the combination of both have involved the couple ET-1/ET<sub>A</sub> in modulating the functions of cancers in many of these preclinical experiments. However, altogether the results suggest that in the context of cancer, dual ET<sub>A</sub>/ET<sub>B</sub> antagonism may be superior to single antagonism. Moreover, many of these beneficial effects of blocking the endothelin receptors were observed when the antagonists were applied very early in the development of these experimental tumors.</div><div class="NLM_p">Other components of the endothelin axis may also be involved in cancer, such as the expression of variants of ECE-1 (ECE-1a, ECE-1b, ECE-1c, and ECE-1d), variants of the receptors, or the ET-2 and/or ET-3 peptides. Only limited information exists concerning the inhibition of ECE-1 to control the activation of big-ET-1 to ET-1.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> It was shown in a murine model that germ-line mutations and subsequent promoter hypermethylation of the ET<sub>B</sub> gene and the absence of ET<sub>B</sub> transcripts may be responsible for susceptibility to cancer.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Promoter methylation of the <i>EDNRB</i> gene in gastric cancer and in oral squamous-cell carcinoma is correlated with the aggressiveness and progression of the cancer.<a onclick="showRef(event, 'ref41 ref153'); return false;" href="javascript:void(0);" class="ref ref41 ref153">(41, 153)</a></div><div class="NLM_p last">In summary, preclinical experimental cancer models and ex vivo studies suggest that malignant cell growth and survival are dependent on ET-1-mediated pathways. Endothelin-receptor antagonists demonstrated promising effects in the context of experimental cancer as molecules with the potential to control survival of tumor cells and regulate vascular functions and angiogenesis induced by tumor cells, an important factor in the mechanisms of cancer progression. In cancer, ET-1 is not a growth factor by itself, but it appears to potentiate tumor-cell growth induced by other growth factors such as bFGF, EGF, IGF-I, and IGF-II, through a PKC-mediated pathway, involving several intracellular signaling pathways. Antagonists of the receptors of the endothelin axis have antitumor effects in human cells and in animal cancer models, which have been attributed to their direct antisurvival effects on tumor cells and/or on the tumor-associated vasculature. On the basis of promising preclinical results, clinical trials in human cancers mostly evaluated the effects of antagonists of ET<sub>A</sub>; however, while ET<sub>A</sub> is important in tumor-cell migration, metastasis, and proliferation, ET<sub>B</sub> is critical for angiogenesis and inhibition of antitumor immune-cell recruitment and possibly also for tumor growth and metastasis. Thus, dual ET<sub>A</sub>/ET<sub>B</sub> blockade may be a valid strategy, which was not taken into account in the design of the early clinical trials.</div></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Human Clinical Trials of Endothelin-Receptor Antagonists in Cancer</h4><div class="NLM_p">The encouraging results of cell and animal experimental models of cancer led to the evaluation of the two ET<sub>A</sub> antagonists <b>5</b> and <b>7</b><a onclick="showRef(event, 'ref154 ref155'); return false;" href="javascript:void(0);" class="ref ref154 ref155">(154, 155)</a> in several human clinical trials (up to phase III) for ovarian, prostate, breast, colon, lung, or kidney cancer either alone or in combination with cytotoxic drugs. Owing to the observed interactions between endothelin receptors and EGFR, combinations of ET<sub>A</sub> antagonists and EGFR antagonists were also attempted. Unfortunately, these clinical trials did not show significant effects on their primary end-points, defined as time to progression, onset of metastases, and/or overall survival. The main conclusions resulting from the most important human clinical trials of endothelin-receptor antagonists in human cancer are summarized in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a> and discussed below.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Some Examples of Clinical Trials of ET-1-Receptor(s) Antagonists in Cancer</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">company</th><th class="colsep0 rowsep0" align="center">disease</th><th class="colsep0 rowsep0" align="center">end-points</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">(A) ET<sub>A</sub>-Selective Antagonists</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" colspan="2" align="center"><i><u class="uu">prostate, renal carcinomas, glioma</u></i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">II (<i>N</i> = 288)</td><td class="colsep0 rowsep0" align="left">Abbott</td><td class="colsep0 rowsep0" align="left">hormone-refractory</td><td class="colsep0 rowsep0" align="left">time to progression</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">bone metastasis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">IIIÂ (<i>N</i>Â =Â 942)</td><td class="colsep0 rowsep0" align="left">Abbott</td><td class="colsep0 rowsep0" align="left">nonmetastatic</td><td class="colsep0 rowsep0" align="left">time to progression</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">hormone-refractory</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="left">Abbott</td><td class="colsep0 rowsep0" align="left">metastatic</td><td class="colsep0 rowsep0" align="left">time to progression</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">hormone-refractory</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" colspan="2" align="center"><i><u class="uu">prostate carcinoma</u></i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">II (<i>N</i> = 312)</td><td class="colsep0 rowsep0" align="left">AstraZenecca</td><td class="colsep0 rowsep0" align="left">hormone-resistant</td><td class="colsep0 rowsep0" align="left">time to progression and survival</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">bone metastatic</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">III (<i>N</i> = 312)</td><td class="colsep0 rowsep0" align="left">AstraZenecca</td><td class="colsep0 rowsep0" align="left">hormone-resistant</td><td class="colsep0 rowsep0" align="left">safety and efficacy and overall survival</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">ENTHUSEMI</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">bone metastatic</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="center">(B) Dual ET<sub>A</sub>/ET<sub>B</sub> Antagonists</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" colspan="2" align="center"><i><u class="uu">melanoma and GBM</u></i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">II (<i>N</i> = 35)</td><td class="colsep0 rowsep0" align="left">Actelion</td><td class="colsep0 rowsep0" align="left">melanoma</td><td class="colsep0 rowsep0" align="left">safety/tolerability and disease progression</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">II (<i>N</i> = 40)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Actelion</td><td class="colsep0 rowsep0" align="left">GBM</td><td class="colsep0 rowsep0" align="left">launched December 2011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">completion October 2017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">safety and tolerability, markers of brain tumors</td></tr></tbody></table></div></div><div class="NLM_p">We have previously reviewed in detail the clinical trials performed for cancer indications before 2009,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> and others have reviewed in detail the clinical trials performed more recently.<a onclick="showRef(event, 'ref123 ref125 ref127 ref156 ref157'); return false;" href="javascript:void(0);" class="ref ref123 ref125 ref127 ref156 ref157">(123, 125, 127, 156, 157)</a> Therefore, we will only summarize the main outcomes of these early trials. We will present in more detail the most recent trials, in particular the clinical evaluation of the dual ET<sub>A</sub>/ET<sub>B</sub> antagonist <b>4</b> in GBM.</div><div class="NLM_p">Early clinical trials evaluating the efficacy of endothelin-receptor(s) antagonists in human cancers mostly concentrated on prostate carcinomas and ET<sub>A</sub>-selective antagonists. ET-1 is produced in the normal prostate, and ET<sub>B</sub> is mainly expressed by prostate luminal epithelial cells, whereas ET<sub>A</sub> is found predominantly in the stromal component of the prostate. ET<sub>A</sub> expression is increased in prostate cancer and is associated with progression and osteoblastic bone metastasis,<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> whereas ET<sub>B</sub> may be silenced by methylation of its promoter. The effect of ET-1 receptor antagonism in prostate cancer has been evaluated, mainly using <b>5</b> (a very potent ET<sub>A</sub> antagonist; <i>K</i><sub>i</sub> = 0.034 nM) and <b>7</b> (a very selective ET<sub>A</sub> antagonist). Results of these early clinical trials generally demonstrated safety and tolerability but no significant improvement in survival or time to disease progression. For the treatment of castration-resistant prostate cancer, combination therapies based on docetaxel are the standard. Following attempts to add endothelin-receptor antagonists, the results for ET<sub>A</sub> antagonists were initially encouraging in preclinical assays and early human clinical trials. Drug combinations have been attempted in a phase I/II trial of <b>5</b> in combination with paclitaxel, docetaxel, carboplatin, or liposomal doxorubicin,<a onclick="showRef(event, 'ref156 ref157 ref158 ref159'); return false;" href="javascript:void(0);" class="ref ref156 ref157 ref158 ref159">(156-159)</a> demonstrating no differences in efficacy and patient survival over standard therapeutic regimens but no added toxicity compared to chemotherapeutics. A phase I/II clinical trial of <b>5</b> combined with docetaxel in patients with hormone-refractory prostate cancer showed that <b>5</b> pharmacokinetics was not influenced by docetaxel, though docetaxel clearance was increased by concomitant administration of <b>5</b>, suggesting a pharmacokinetic drugâdrug interaction. Compound <b>5</b> combined with doxorubicin was evaluated in a phase I/II trial in patients with platinum-resistant recurrent ovarian cancer. No obvious toxicity was observed, with some indication of prolonged survival in a limited number of patients.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Phase III trials have nevertheless been launched, combining an ET<sub>A</sub> antagonist with standard chemotherapeutics, and the results are now available. Docetaxel and <b>5</b> versus docetaxel and placebo was evaluated in men with advanced castration-resistant prostate cancer in a randomized phase III trial (SWOG 50421). In combination with docetaxel, <b>5</b> did not improve overall survival and disease-free survival compared to placebo. A phase III, randomized, placebo-controlled study of docetaxel in combination with <b>7</b> in patients with metastatic castration-resistant prostate cancer (ENTHUSE trial) did not result in any benefit compared to docetaxel alone.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> A large phase III placebo-controlled trial evaluating the use of <b>7</b> for bone metastasis in patients with castration-resistant prostate cancer did not show a statistically significant advantage; however, it has an acceptable toxicity profile.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div><div class="NLM_p">In noncarcinoma cancer, <b>5</b> has been evaluated in phase I in patients with recurrent GBM. No dose-limiting toxicities were observed, but its efficacy was not better than those of other cytotoxic regimens.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> On the basis of data suggesting that endothelin may play a role in the pathophysiology of melanoma<a onclick="showRef(event, 'ref39 ref140'); return false;" href="javascript:void(0);" class="ref ref39 ref140">(39, 140)</a> and that the dual endothelin-receptor antagonist <b>2</b> may have antitumor activity in human melanoma cells,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> a multicenter, open-label, single-arm, prospective, proof-of-concept phase II study assessed the effects of <b>2</b> monotherapy on tumor response in patients with stage IV metastatic melanoma. Among the 35 patients included in this study, disease stabilization was observed in 6 of the 32 patients analyzed. These results suggest that <b>2</b> might have benefits in disease stabilization in certain patients with metastatic melanoma.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> No adverse events were observed. Thus, a larger, open-label, single-arm phase II trial combining first-line dacarbazine and either <b>2</b> or placebo (<i>N</i> = 40 patients per group) was launched in patients naive to chemotherapy or immunotherapy for stage IV metastatic cutaneous melanoma. Median time to tumor progression (primary end point) was not significantly different between the two groups.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> However, some hope of a clinical benefit of blocking the endothelin receptors in human cancer was raised by evaluating the newly developed dual ET<sub>A</sub>/ET<sub>B</sub> antagonist <b>4</b>. Compound <b>4</b> in combination with dose-dense temozolomide, a standard chemotherapeutic for GBM therapy, is being evaluated in two phase I/Ib open-label studies in patients with newly diagnosed and recurring GBM (clinical trial NCT01499251. Sponsor: Actelion. Start date: December 2011. Estimated completion date: October 2017. An open-label, single-arm phase I study to assess safety and tolerability and expression of markers of brain-tumor tissues). On the basis of the promising preliminary results of these trials, Actelion will approach Health Authorities for further discussions about the future development of <b>4</b> in new and recurring GBM in a phase-IIb/III study (information posted on the Actelion Web site).</div><div class="NLM_p last">The deceptive results of most human clinical trials with endothelin-receptor antagonists<a onclick="showRef(event, 'ref156 ref165'); return false;" href="javascript:void(0);" class="ref ref156 ref165">(156, 165)</a> merit evaluation and discussion. For progression, cancer cells require key pathways that influence cell growth and death, cell migration, and the development of a vascular network and a permissive environment mainly composed of stromal cells, vascular cells, (myo)fibroblasts, and immune/inflammatory cells. These pathways include the endothelin axis but also other pathways. Preclinical models have demonstrated that the blockade of the endothelin axis may reduce tumor growth, driving the development of antagonists of endothelin receptors and their evaluation in human clinical trials for various cancers.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> However, in these preclinical models, mainly the ET<sub>A</sub>-dependent pathways and the antiproliferative effects of antagonists on the carcinoma tumor cells were evaluated. Human tumors develop according to a time frame that is much longer than and very likely very different from the time frame and development of animal experimental tumors. Moreover, novel compounds are often tested in patients with cancer after one and sometimes two or more established therapies have failed, meaning that many compounds, including ET receptor antagonists, are tested at the later stages of cancer. Thus, the expression of <i>both</i> ET<sub>A</sub> and ET<sub>B</sub> endothelin receptors might be very different and much more complex in human cancers than in experimental models. The type of human tumors (epithelial versus nonepithelial origin) is also relevant. It has also been shown that stromal cells, including tumor-associated (myo)fibroblasts and macrophages expressing both ET<sub>A</sub> and ET<sub>B</sub>, are mandatory for tumor progression in humans. This fact has not been considered in early clinical trials. Therefore, we believe, but this reflects only our opinion, that in cancer dual antagonists are more appropriate and promising than single antagonists. We also believe that combination therapy with ET antagonists are also mandatory. But it has to be kept in mind that patients that failed antitumor therapies many times have also developed drug resistance and would likely have failed any therapy. Thus, in our opinion, ET antagonist must be added early in therapy, in addition to standard treatments.</div></div><div id="sec3_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Endothelin-Receptor Antagonists beyond PAH: Fibrotic Diseases and Inflammation</h4><div class="NLM_p">In response to tissue injury including wounding, surgery, cancer, or drug-induced injury, the repair processes may result in two distinct phenomena: a normal regenerative process, limited in time, in which injured cells are replaced by cells of the same type, and a chronic, uncontrolled fibrotic process, in which connective tissue replaces normal tissue, associated with abnormal deposition of extracellular matrix (ECM). Fibrosis is defined by the overgrowth, hardening, and scarring of tissues, mainly by activated (myo)fibroblasts, and finally in the replacement of normal tissue with permanent scar tissue.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> Myofibroblasts may be generated from a variety of cellular sources: resident mesenchymal cells, circulating bone-marrow-derived fibrocytes, or epithelial and endothelial cells by cell-transition mechanisms. Myofibroblasts are activated by a variety of stimuli, including ET-1.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> ET-1 plays a fundamental role in the pathogenesis of fibrosis and may be a key mediator of profibrotic effects of other agents, such as TGFÎ²1 which induces ET-1 expression, forming an autocrine amplifying loop. ET-1 is chemotactic for cells of the fibroblast lineage and causes fibroblast proliferation and ECM accumulation and contraction, mediated by the two ET-1 receptors, ET<sub>A</sub> and ET<sub>B</sub>, expressed on these cells.<a onclick="showRef(event, 'ref115 ref168'); return false;" href="javascript:void(0);" class="ref ref115 ref168">(115, 168)</a> Thus, antagonists of both ET-1 receptors may have therapeutic potential to prevent the development of fibrosis. Correspondingly, the dual ET-1 receptor antagonist <b>2</b> was shown to decrease collagen I and collagen III synthesis by fibroblasts.</div><div class="NLM_p">In the lung, fibrosis encompasses a variety of idiopathic disorders characterized by a progressive replacement of normal alveolar wall by dense connective tissue that eventually prevents normal gas exchange. The endothelin axis may be implicated in the pathogenesis of lung fibrosis according to experiments in animal models and immunohistochemistry performed on human lung tissue from affected individuals. ET-1 was demonstrated to induce Î±-smooth muscle actin (Î±-SMA) expression and the myofibroblast phenotype in human lung fibroblasts through the ET<sub>A</sub>-JNK-AP-1 pathway.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Despite its enormous impact on human health, there are currently no approved treatments to cure this disease. Two compounds have nevertheless been recently approved for the treatment of idiopathic lung fibrosis, as they demonstrated involvement in slowing down the disease: pirfenidone and nintedanib. On the basis of preliminary data, a 1-year clinical double-blind and randomized study has been performed using <b>2</b> versus placebo in 158 patients (build 1).<a onclick="showRef(event, 'ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref170 ref171">(170, 171)</a> The primary end point was the exercise capacity. This study was negative concerning this primary end point. A post hoc analysis revealed, however, a positive trend in less severely ill patients for the criteria âTCW or deathâ. Similar findings were published for the build 2 study that involved patients with lung fibrosis secondary to systemic sclerosis. According to these findings, a new randomized clinical study has been launched (build 3)<a onclick="showRef(event, 'ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref170 ref171">(170, 171)</a> involving 390 patients with established pulmonary fibrosis. A similar three-year phase III study was launched in early 2009 with the ET<sub>A</sub>-selective antagonist <b>3</b> (Artemis study). A phase II study (MUSIC) evaluated <b>4</b> for the treatment of idiopathic pulmonary fibrosis.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> These studies evaluated TCW as the primary end point. Unfortunately, all studies produced negative results, the Artemis study being prematurely stopped due to an increased progression of the disease in the treated arm.</div><div class="NLM_p">Within the kidney, injury to glomerular or tubular cells is the initiating cause of many acute and chronic diseases, leading to progressive dysfunction and end-stage renal disease. The glomerulus is the main filtration barrier that determines global kidney function. Inflammatory and noninflammatory stresses affect the glomerulus and lead to alterations in its structure and thus in its permeability and functions, resulting in chronic kidney disease (CKD). In hypertension, diabetes, and other kidney diseases, the standard treatment is angiotensin II antagonism; however, this treatment only modestly slows disease progression. ET-1 via ET<sub>A</sub> activation has also been implicated, in addition to the reninâangiotensin system, in the pathophysiology of CKD, and particularly in diabetic nephropathy. Animal models have shown beneficial effects of the blockade of the endothelin axis on proteinuria and kidney functions. ET-1 is the major isoform of the endothelin peptides in the kidney, regulating sodium and water excretion, and the vast majority of endothelin receptors of renal cells are of the ET<sub>B</sub> subtype, in contrast to most peripheral organs. Smooth muscle cells of the renal vasculature mainly express ET<sub>A</sub>, while the endothelium expresses ET<sub>B</sub>, stimulating the release of vasodilators. Most of the dilatory effects of ET-1 as well as vasoconstriction, mesangial cell proliferation, and inflammation mainly occur via ET<sub>A</sub>; thus, selective ET<sub>A</sub> blockade may be more beneficial in renal disease, and dual antagonists may block the beneficial vasodilatory effects of ET<sub>B</sub>, causing sodium retention.<a onclick="showRef(event, 'ref173 ref174'); return false;" href="javascript:void(0);" class="ref ref173 ref174">(173, 174)</a> Thus, in the diseased kidney, ET-1-promoting effects on renal cell injury, proteinuria, glomerulosclerosis, inflammation, fibrosis, and hypertrophy associated with CKD are mainly mediated by ET<sub>A</sub>.</div><div class="NLM_p">Preclinical models of CKD and of type I and type II diabetic nephropathy have suggested that endothelin-receptor antagonists may be of therapeutic interest in renal diseases. In particular, ET<sub>A</sub> antagonists have been shown to improve renal injury and fibrosis, and this possibility has been evaluated in clinical trials.<a onclick="showRef(event, 'ref173 ref174'); return false;" href="javascript:void(0);" class="ref ref173 ref174">(173, 174)</a> A phase II study with the dual ET<sub>A</sub>/ET<sub>B</sub> antagonist <b>14</b> has revealed favorable systemic hemodynamic effects with a trend toward increased renal plasma flow in seven patients. A phase III study with the ET<sub>A</sub> selective antagonist 9,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> performed in 286 patients with diabetic nephropathy and already taking angiotensin blockers, showed that albuminuria decreased significantly in the <b>9</b>-treated group compared to placebo. The ASCEND trial testing <b>9</b> versus placebo in patients with type II diabetes and nephropathy has been prematurely terminated due to an increase in congestive heart failure events and mortality in the <b>9</b> arm. The RADAR phase II study evaluating <b>5</b> for albuminuria reduction in patients with type II diabetes and nephropathy showed some positive outcomes without obvious edema.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Completed and ongoing clinical trials for endothelin-receptor antagonists are summarized in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a> (adapted from ref <a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">174</a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Completed and Ongoing Clinical Trials for Endothelin-Receptor Antagonists for Kidney Diseases<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">studyÂ phase, <i>N</i>Â patients</th><th class="colsep0 rowsep0" align="center">disease</th><th class="colsep0 rowsep0" align="center">end-points and outcome</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left"><i>N</i> = 22</td><td class="colsep0 rowsep0" align="left">nondiabetic CKD</td><td class="colsep0 rowsep0" align="left">reduced proteinuria</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left"><i>N</i> = 7</td><td class="colsep0 rowsep0" align="left">nondiabetic CKD</td><td class="colsep0 rowsep0" align="left">tendency to increased renal blood flow</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">phase II, <i>N</i> = 286</td><td class="colsep0 rowsep0" align="left">diabetic nephropathy</td><td class="colsep0 rowsep0" align="left">modifiedÂ albumin/creatinine ratio dose-dependent</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">phase III (ASCEND), <i>N</i> = 1392</td><td class="colsep0 rowsep0" align="left">diabetic nephropathy</td><td class="colsep0 rowsep0" align="left">reduced albumin/creatinine ratio in the long term</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">phase II, <i>N</i> = 27</td><td class="colsep0 rowsep0" align="left">nondiabetic CKD</td><td class="colsep0 rowsep0" align="left">reduced proteinuria better than nifedipine</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">phase IIa, <i>N</i> = 89</td><td class="colsep0 rowsep0" align="left">diabetic nephropathy</td><td class="colsep0 rowsep0" align="left">reduced albumin/creatinine ratio</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">phase IIb (RADAR), <i>N</i> = 211</td><td class="colsep0 rowsep0" align="left">diabetic nephropathy</td><td class="colsep0 rowsep0" align="left">reduced albumin/creatinine ratio</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">phaseÂ IIIÂ (SONAR),Â <i>N</i>Â =Â 4150Â (planed)</td><td class="colsep0 rowsep0" align="left">diabetic nephropathy</td><td class="colsep0 rowsep0" align="left">primary end point: time to serum creatinine doubling</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>a</sup><p class="last">Adapted from ref <a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">174</a>.</p></div></div></div><div class="NLM_p">In summary, the outcomes of preclinical and early clinical phase II trials suggest that ET<sub>A</sub> antagonists may be of therapeutic interest and benefit in patients with kidney diseases, the main side effects being fluid retention, which may be minimized by careful drug dosing and the use of diuretics.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> This information has yet to be confirmed in large multicenter phase III trials. As several studies suggested an interest in the antagonists of the endothelin axis in these disorders in addition to the reninâangiotensin system, dual angiotensin receptor type 1 (AT<sub>1</sub>)/ET<sub>A</sub> antagonists were also designed and evaluated in preclinical setting only. Combining key structural elements present in an AT<sub>1</sub> receptor antagonist (irbesartan, structure not disclosed) with structural elements in a biphenylsulfonamide ET<sub>A</sub> receptor antagonist provided compound <b>29</b><a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> which potently blocked both AT<sub>1</sub> and ET<sub>A</sub> receptors, with improved pharmacokinetic properties and efficacy compared to AT<sub>1</sub> or ET<sub>A</sub> receptor antagonists alone.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Another dual angiotensin receptor type 1 (AT<sub>1</sub>, IC<sub>50</sub> = 8.5 nM)/ET<sub>A</sub> (IC<sub>50</sub> = 8.9 nM) antagonist, compound <b>30</b>,<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> was designed and evaluated in a rodent model, showing increased potency compared to losartan (a standard AT<sub>1</sub> antagonist in clinical use) without detrimental effects on heart rate.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> However, to the best of our knowledge, no clinical trial has been launched with these dual antagonists (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Dual Angiotensin Type 1 (AT<sub>1</sub>R) and ET<sub>A</sub> Receptors Antagonists</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01781&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Other Potential Clinical Indications for Endothelin-Receptor Antagonists</h3><div class="NLM_p last">Compound <b>8</b> or the combination of <b>8</b> and <b>19</b> is presently being evaluated in a clinical trial (NCT02062346; start date, April 2014; completion, March 2017) in patients with vasculitis. The CONSCIOUS-3 phase III clinical trial assessed the efficacy of <b>5</b> in patients with aneurysmal subarachnoid hemorrhage, improving vasospasm-related morbidity and mortality.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> In an experimental model of arthritis, <b>2</b> was shown to have a beneficial effect. The results suggested that the detrimental effects of the endothelin axis in arthritis were mediated by TNF-Î±.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> ETs have immunomodulatory properties as proinflammatory cytokines and inducers of leukocyte adhesion molecules and have been involved in sepsis. In an experimental model of LPS-induced lung injury, an ET<sub>A</sub> antagonist reduced neutrophil recruitment and lung injury. Endothelin receptor antagonists may be useful as an adjunctive therapy for preserving the organs during infectious diseases.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> In Crohnâ disease, ECE-1, ET<sub>A</sub>, and ET<sub>B</sub> are key players of the inflammatory and fibrogenic process, in particular involving the submucosal smooth muscle proliferation.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> In inflammation and sepsis, blockage of both endothelin receptors attenuated the inflammatory responses.<a onclick="showRef(event, 'ref181 ref182'); return false;" href="javascript:void(0);" class="ref ref181 ref182">(181, 182)</a> However, very few clinical trials have evaluated these possibilities, which will not be discussed further in the present Perspective.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Conclusions and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32871" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32871" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The selective expression of the components of the endothelin axis in human diseases has been demonstrated, and some information has emerged suggesting that targeting specific components of this axis may be of therapeutic interest in human diseases. Within 5 years of the discovery of the endothelin axis, orally available endothelin-receptor antagonists became available, and their effects were first evaluated in human clinical trials in the context of cardiovascular diseases, heart failure, PAH, resistant arterial hypertension, stroke, subarachnoid hemorrhage, then for kidney diseases and various cancers. They were of greatest interest for the treatment of PAH and are now in clinical use for this indication. The results of most clinical trials for other indications were either neutral or negative, leading to the discontinuation of endothelin-receptor antagonist programs in many but not all pharmaceutical companies. Several clinical reviews have analyzed the causes of the failures of clinical trials,<a onclick="showRef(event, 'ref25 ref121 ref123 ref131 ref156 ref183 ref184 ref185'); return false;" href="javascript:void(0);" class="ref ref25 ref121 ref123 ref131 ref156 ref183 ref184 ref185">(25, 121, 123, 131, 156, 183-185)</a> some of which may raise further questions about the therapeutic value of endothelin-receptor antagonists.</div><div class="NLM_p">Since the very initial stages of development of antagonists of ET-1 receptors, there has been a debate about whether blocking ET<sub>A</sub> selectively or whether additional blocking of ET<sub>B</sub> with dual ET<sub>A</sub>/ET<sub>B</sub> antagonists would be an optimal therapeutic option. ET<sub>B</sub>-selective antagonists were rapidly eliminated from development programs due to side effects. Thus, the debate no longer concerns the usefulness of antagonists of endothelin receptors in human pathologies. Instead, it is concerned with whether ET<sub>A</sub>-selective or dual ET<sub>A</sub>/ET<sub>B</sub> blockers should be used. It is therefore of importance to consider not only receptor selectivity (ET<sub>A</sub>, ET<sub>B</sub>, or dual selectivity) but also the particular disease involved when developing new antagonists.</div><div class="NLM_p">The selectivity profile of the ideal endothelin-receptor antagonist depends on the clinical indications, the organs and the type of cells involved in the disease, the stage of progression of the disease, and the therapeutic context. Of utmost importance, the heterogeneity of human chronic diseases which develop over long-term must be considered, contrary to acute experimental animal models. In PAH, presently, ET<sub>A</sub>-selective and dual ET<sub>A</sub>/ET<sub>B</sub> antagonists have been approved, and it was not possible to identify a clinically relevant advantage for one class of drug or the other in this context. However, it was observed in clinical trials for PAH that the ET<sub>A</sub>-selective drug <b>3</b> induced more fluid retention than the dual ET<sub>A</sub>/ET<sub>B</sub> compound <b>2</b> or <b>4</b>. In fibrosis-related disorders, the evaluation of the clinical interest of endothelin receptor(s) antagonists has been only very recently initiated, and more feedback is necessary to reach conclusive information; however, human clinical trials have clearly noted a deleterious effect, in particular fluid retention, of blocking endothelin receptors. For example, phase III clinical trials of <b>9</b> for diabetic nephropathy or <b>5</b> in the context of oncology of ET<sub>A</sub>-selective compounds led to early study termination due to water retention or increased mortality. However, it has been observed in most studies that the side effects are dose-related and that for most trials the dosages applied were likely too high. In cancer, the situation is more complex. ET<sub>A</sub> is important in tumor cell migration, metastasis, and proliferation, while ET<sub>B</sub> is critical to angiogenesis and inhibition of antitumor immune cell recruitment. However, the type and grade of cancer, its tissue origin, its stage of progression, the exact cells involved, and the level of heterogeneity of the tumor must be considered. In human cancer, but possibly not in experimental animal tumors, long-term cancer progression also impacted on the expression of the endothelin axis in cancer stroma, and blocking both receptors may be more appropriate for cancer indications.</div><div class="NLM_p">A second conclusion reached by clinical trials, and it is not surprising in human therapy, was that to achieve optimal therapeutic efficacy, drug combination must be considered, adding endothelin-receptor antagonists as an adjuvant to other regimens, either concurrent or sequential double or even triple therapy. It remains to be demonstrated, however, which receptor is the better target and which combined-schedule therapy should be proposed to patients according to their level of risk. In unpublished experiments using human GBM cells in culture and drug combination of the dual ET<sub>A</sub>/ET<sub>B</sub> antagonist <b>2</b> and alkylating agents (carmustine, temozolomide, or alkeran), we have shown that cell growth (defined as inhibition of DNA synthesis) was additively, rather than synergistically, decreased by combination of <b>2</b> with either carmustine or alkeran.</div><div class="NLM_p last">In summary, several excellent, orally available, ET<sub>A</sub>-selective or dual ET<sub>A</sub>/ET<sub>B</sub> endothelin-receptor antagonists, as well as agonists and inhibitors, with acceptable side effects<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> have been designed, developed, and evaluated in preclinical and human clinical settings, showing beneficial therapeutic effects in several life-threatening diseases, By themselves, they are not curative for these diseases, but they are beneficial in several ways; however, improvement is still needed, in particular, to develop a means to control the side effects associated with endothelin-receptor antagonism and achieve more tissue-selective delivery of the therapeutics. Strategies to consider may include the design of cell-, tissue-, or organ-specific targeting therapies, the development of drugs with disease-specific markers, or the use of functionalized targeted nanoparticles.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01781" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John-David Aubert</span> - <span class="hlFld-Affiliation affiliation">Pneumology
Division and Transplantation Center, Centre
Hospitalier Universitaire Vaudois (CHUV), 	CH1011 Lausanne, Switzerland</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7913161117541d180f101d57180c1b1c0b0d391a110c0f571a11"><span class="__cf_email__" data-cfemail="f993969197d49d988f909dd7988c9b9c8b8db99a918c8fd79a91">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lucienne Juillerat-Jeanneret</span> - <span class="hlFld-Affiliation affiliation">University Institute
of Pathology and Transplantation Center, Centre Hospitalier Universitaire
Vaudois (CHUV), and University of Lausanne (UNIL), CH1011 Lausanne, Switzerland</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#761a03151f13181813581c031f1a1a1304170236151e030058151e"><span class="__cf_email__" data-cfemail="d3bfa6b0bab6bdbdb6fdb9a6babfbfb6a1b2a793b0bba6a5fdb0bb">[emailÂ protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): J.-D.A. has received travel support from Actelion and has been invited to be in advisory boards for Glaxo Smith Kline and Actelion.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">John-David Aubert</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01781&amp;id=BIO-d767e3474-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>John-David Aubert</b> graduated from the Faculty of Biology and Medicine of the University of Lausanne (UNIL), Switzerland, and specialized in internal and respiratory medicine, first in Lausanne University Hospital, then in UBC Research Laboratory in Vancouver (Prof. J. C. Hogg) as a postdoctoral assistant. In Lausanne in 1993, he was involved in the creation of the new lung-transplantation program and is now its medical director and associate professor. He also leads the pulmonary hypertension clinic and has been president of the Swiss Society for Pulmonary Hypertension. He has been appointed president of the Research Committee of the Swiss Lung League for 2016â2018. His main research interests focus on chronic allograft dysfunction after lung transplantation and clinical aspects of pulmonary hypertension.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Lucienne Juillerat-Jeanneret</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01781&amp;id=BIO-d767e3479-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lucienne Juillerat-Jeanneret</b> obtained her Ph.D. from the University of Geneva, Switzerland. After postdoctoral experiences at the University of Geneva and the University Hospital of Lausanne (CHUV-UNIL), she joined the University Institute of Pathology of Lausanne as a tenured senior lecturer and a teacher at the University of Lausanne (UNIL) and the Swiss Federal Institute of Technology of Lausanne (EPFL). Her main research interests are focused on the interface between biomedicine, chemistry, and biomaterials, the design and development of innovative devices or modified drugs to deliver therapeutics. The strategies investigated include nanotherapeutics and targeted chemotherapeutics for the treatment of cancer and degenerative diseases. She is also involved in the development of novel approaches for diagnosis and tissue engineering.</p></figure></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i32" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i32"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i33" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i33"> Abbreviations Used</h2><tr><td class="NLM_term">AT</td><td class="NLM_def"><p class="first last">angiotensin receptor</p></td></tr><tr><td class="NLM_term">CHF</td><td class="NLM_def"><p class="first last">chronic heart failure</p></td></tr><tr><td class="NLM_term">CKD</td><td class="NLM_def"><p class="first last">chronic kidney disease</p></td></tr><tr><td class="NLM_term">EMA</td><td class="NLM_def"><p class="first last">European Medicines Agency</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial to mesenchymal transition</p></td></tr><tr><td class="NLM_term">ET</td><td class="NLM_def"><p class="first last">endothelin</p></td></tr><tr><td class="NLM_term">ET<sub>A</sub></td><td class="NLM_def"><p class="first last">endothelin receptor A</p></td></tr><tr><td class="NLM_term">ET<sub>B</sub></td><td class="NLM_def"><p class="first last">endothelin receptor B</p></td></tr><tr><td class="NLM_term">ECE</td><td class="NLM_def"><p class="first last">endothelin converting enzyme</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Federal Drug Administration</p></td></tr><tr><td class="NLM_term">GBM</td><td class="NLM_def"><p class="first last">glioblastoma</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">6MWD</td><td class="NLM_def"><p class="first last">6 min walking distance</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matrix metalloproteinase</p></td></tr><tr><td class="NLM_term">NEP</td><td class="NLM_def"><p class="first last">neutral endopeptidase</p></td></tr><tr><td class="NLM_term">NYHA</td><td class="NLM_def"><p class="first last">New York Heart Association</p></td></tr><tr><td class="NLM_term">PAH</td><td class="NLM_def"><p class="first last">pulmonary arterial hypertension</p></td></tr><tr><td class="NLM_term">P-Gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">RCT</td><td class="NLM_def"><p class="first last">randomized clinical trial</p></td></tr><tr><td class="NLM_term">TCW</td><td class="NLM_def"><p class="first last">time to clinical worsening</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 186 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaid, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaughter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Wit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">CE-1: A Membrane-bound Metalloprotease that Catalyzes the Proteolytic Activation of Big Endothelin-1</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span><span class="NLM_x">â</span> <span class="NLM_lpage">485</span><span class="refDoi">Â DOI: 10.1016/0092-8674(94)90425-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2F0092-8674%2894%2990425-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1994&pages=473-485&author=D.+Xuauthor=N.+Emotoauthor=A.+Giaidauthor=C.+Slaughterauthor=S.+Kawauthor=D.+de+Witauthor=M.+Yanagisawa&title=CE-1%3A+A+Membrane-bound+Metalloprotease+that+Catalyzes+the+Proteolytic+Activation+of+Big+Endothelin-1&doi=10.1016%2F0092-8674%2894%2990425-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2894%2990425-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252894%252990425-1%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DEmoto%26aufirst%3DN.%26aulast%3DGiaid%26aufirst%3DA.%26aulast%3DSlaughter%26aufirst%3DC.%26aulast%3DKaw%26aufirst%3DS.%26aulast%3Dde%2BWit%26aufirst%3DD.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DCE-1%253A%2520A%2520Membrane-bound%2520Metalloprotease%2520that%2520Catalyzes%2520the%2520Proteolytic%2520Activation%2520of%2520Big%2520Endothelin-1%26jtitle%3DCell%26date%3D1994%26volume%3D78%26spage%3D473%26epage%3D485%26doi%3D10.1016%2F0092-8674%2894%2990425-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Russell, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skepper, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title">Human Endothelial Cell Storage Granules: A Novel Intracellular Site for Isoforms of the Endothelin-converting Enzyme</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">â</span> <span class="NLM_lpage">321</span><span class="refDoi">Â DOI: 10.1161/01.RES.83.3.314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1161%2F01.RES.83.3.314" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1998&pages=314-321&author=F.+D.+Russellauthor=J.+N.+Skepperauthor=A.+P.+Davenport&title=Human+Endothelial+Cell+Storage+Granules%3A+A+Novel+Intracellular+Site+for+Isoforms+of+the+Endothelin-converting+Enzyme&doi=10.1161%2F01.RES.83.3.314"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1161%2F01.RES.83.3.314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.83.3.314%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DF.%2BD.%26aulast%3DSkepper%26aufirst%3DJ.%2BN.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DHuman%2520Endothelial%2520Cell%2520Storage%2520Granules%253A%2520A%2520Novel%2520Intracellular%2520Site%2520for%2520Isoforms%2520of%2520the%2520Endothelin-converting%2520Enzyme%26jtitle%3DCirc.%2520Res.%26date%3D1998%26volume%3D83%26spage%3D314%26epage%3D321%26doi%3D10.1161%2F01.RES.83.3.314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">226</span><span class="refDoi">Â DOI: 10.1124/pr.54.2.219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1124%2Fpr.54.2.219" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=219-226&author=A.+P.+Davenport&title=International+Union+of+Pharmacology.+XXIX.+Update+on+Endothelin+Receptor+Nomenclature&doi=10.1124%2Fpr.54.2.219"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.219%26sid%3Dliteratum%253Aachs%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXIX.%2520Update%2520on%2520Endothelin%2520Receptor%2520Nomenclature%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D219%26epage%3D226%26doi%3D10.1124%2Fpr.54.2.219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Yanagisawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomobe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masaki, T.</span><span> </span><span class="NLM_article-title">A Novel Potent Vasoconstrictor Peptide Produced by Vascular Endothelial Cells</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">â</span> <span class="NLM_lpage">415</span><span class="refDoi">Â DOI: 10.1038/332411a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2F332411a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=2451132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaL1cXlsVaks78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=1988&pages=411-415&author=M.+Yanagisawaauthor=H.+Kuriharaauthor=S.+Kimuraauthor=Y.+Tomobeauthor=M.+Kobayashiauthor=Y.+Mitsuiauthor=Y.+Yazakiauthor=K.+Gotoauthor=T.+Masaki&title=A+Novel+Potent+Vasoconstrictor+Peptide+Produced+by+Vascular+Endothelial+Cells&doi=10.1038%2F332411a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A novel potent vasoconstrictor peptide produced by vascular endothelial cells</span></div><div class="casAuthors">Yanagisawa, Masashi; Kurihara, Hiroki; Kimura, Sadao; Tomobe, Yoko; Kobayashi, Mieko; Mitsui, Youji; Yazaki, Yoshio; Goto, Katsutoshi; Masaki, Tomoh</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">6163</span>),
    <span class="NLM_cas:pages">411-15</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">An endothelium-derived 21-residue vasoconstrictor peptide, endothelin, was isolated from the culture supernatant of porcine aortic endothelial cells and was shown to be one of the most potent vasoconstrictors known.  The 50% EC for endothelin on porcine right coronary artery strips was 4.0 Ã 10-10M.  The cloning and sequencing of preproendothelin cDNA showed that mature endothelin is generated through unusual proteolytic processing, and regional homologies to a group of neurotoxins suggested that endothelin is an endogenous modulator of voltage-dependent ion channels.  Expression of the endothelin gene was regulated by several vasoactive agents (thrombin, A 23187, and adrenaline), indicating the existence of a novel cardiovascular control system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBMuYNmuQpM7Vg90H21EOLACvtfcHk0liaDupf96TUuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlsVaks78%253D&md5=0f0a5542c8a52f981c8d88bfea1acfbf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F332411a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F332411a0%26sid%3Dliteratum%253Aachs%26aulast%3DYanagisawa%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DTomobe%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DMitsui%26aufirst%3DY.%26aulast%3DYazaki%26aufirst%3DY.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DMasaki%26aufirst%3DT.%26atitle%3DA%2520Novel%2520Potent%2520Vasoconstrictor%2520Peptide%2520Produced%2520by%2520Vascular%2520Endothelial%2520Cells%26jtitle%3DNature%26date%3D1988%26volume%3D332%26spage%3D411%26epage%3D415%26doi%3D10.1038%2F332411a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ling, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maguire, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title">Endothelin-2, the Forgotten Isoform: Emerging Role of Endothelin-2 in the Cardiovascular System, Ovarian Development, Immunology and Cancer</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">168</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">â</span> <span class="NLM_lpage">295</span><span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01786.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fj.1476-5381.2011.01786.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22118774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFOgug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2013&pages=283-295&author=L.+Lingauthor=J.+J.+Maguireauthor=A.+P.+Davenport&title=Endothelin-2%2C+the+Forgotten+Isoform%3A+Emerging+Role+of+Endothelin-2+in+the+Cardiovascular+System%2C+Ovarian+Development%2C+Immunology+and+Cancer&doi=10.1111%2Fj.1476-5381.2011.01786.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer</span></div><div class="casAuthors">Ling, Lowell; Maguire, Janet J.; Davenport, Anthony P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-295</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Endothelin-2 [ET-2; also known as vasoactive intestinal contractor (VIC), in rodents] differs from endothelin-1 (ET-1) by only two amino acids, and unlike the third isoform, endothelin-3 (ET-3), it has the same affinity as ET-1 for both ETA and ETB receptors.  It is often assumed that ET-2 would mimic the actions of the more abundant ET-1 and current pharmacol. interventions used to inhibit the ET system would also block the actions of ET-2.  These assumptions have focused research on ET-1 with ET-2 studied in much less detail.  Recent research suggests that our understanding of the ET family requires re-evaluation.  Although ET-2 is very similar in structure as well as pharmacol. to ET-1, and may co-exist in the same tissue compartments, there is converging evidence for an important and distinct ET-2 pathway.  Specifically is has been demonstrated that ET-2 has a key role in ovarian physiol., with ET-2-mediated contraction proposed as a final signal facilitating ovulation.  Furthermore, ET-2 may also have a pathophysiol. role in heart failure, immunol. and cancer.  Comparison of ET-2 vs. ET-1 mRNA expression suggests this may be accomplished at the level of gene expression but differences may also exist in peptide synthesis by enzymes such as endothelin converting enzymes (ECEs) and chymase, which may allow the two pathways to be distinguished pharmacol. and become sep. drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra8zZjS7cPGbVg90H21EOLACvtfcHk0liaDupf96TUuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFOgug%253D%253D&md5=a8772fe66d1a7884fe173bc40618a95e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01786.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01786.x%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DL.%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DEndothelin-2%252C%2520the%2520Forgotten%2520Isoform%253A%2520Emerging%2520Role%2520of%2520Endothelin-2%2520in%2520the%2520Cardiovascular%2520System%252C%2520Ovarian%2520Development%252C%2520Immunology%2520and%2520Cancer%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D168%26spage%3D283%26epage%3D295%26doi%3D10.1111%2Fj.1476-5381.2011.01786.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶hr, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashktorab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, R. H.</span><span> </span><span class="NLM_article-title">Epigenetic Inactivation of Endothelin-2 and Endothelin-3 in Colon Cancer</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">â</span> <span class="NLM_lpage">1012</span><span class="refDoi">Â DOI: 10.1002/ijc.27762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fijc.27762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22865632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ciur3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2013&pages=1004-1012&author=R.+Wangauthor=C.+V.+L%C3%B6hrauthor=K.+Fischerauthor=W.+M.+Dashwoodauthor=J.+A.+Greenwoodauthor=E.+Hoauthor=D.+E.+Williamsauthor=H.+Ashktorabauthor=M.+R.+Dashwoodauthor=R.+H.+Dashwood&title=Epigenetic+Inactivation+of+Endothelin-2+and+Endothelin-3+in+Colon+Cancer&doi=10.1002%2Fijc.27762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer</span></div><div class="casAuthors">Wang, Rong; Loehr, Christiane V.; Fischer, Kay; Dashwood, W. Mohaiza; Greenwood, Jeffrey A.; Ho, Emily; Williams, David E.; Ashktorab, Hassan; Dashwood, Michael R.; Dashwood, Roderick H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1004-1012</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Endothelin-1 (ET-1) and its receptors are overexpressed in human cancers, but much less is known about the roles of ET-2 and ET-3 in cancer etiol.  We sought to examine human and rat colon tumors for dysregulation of ET-2 and ET-3 expression and det. the underlying mechanisms.  Human primary colon cancers and carcinogen-induced rat colon tumors were subjected to real-time RT-PCR, immunoblotting and immunohistochem.; EDN2 and EDN3 genes were examd. by methylation-specific PCR, bisulfite sequencing and pyrosequencing; and forced expression of ET-2 and ET-3 was conducted in human colon cancer cells followed by real-time cell migration and invasion assays.  Rat and human colon tumors had markedly reduced expression of ET-2 and ET-3 mRNA and protein compared with matched controls.  Mechanistic studies revealed hypermethylation of EDN2 and EDN3 genes in human primary colon cancers and in a panel of human colon cancer cell lines.  Forced expression of ET-2 and ET-3 attenuated significantly the migration and invasion of human colon cancer cells.  We conclude that epigenetic inactivation of ET-2 and ET-3 occurs frequently in both rat and human colon cancers.  Current therapeutic strategies target overexpressed members of the ET axis via small mol. inhibitors and receptor antagonists, but this work supports a complementary approach based on the re-expression of ET-2 and ET-3 as natural antagonists of ET-1 in colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Q37xFNGv3bVg90H21EOLACvtfcHk0ljDOzAZEW5e_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ciur3P&md5=0609b867f0e2394dedbb660ca2011328</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fijc.27762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.27762%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DL%25C3%25B6hr%26aufirst%3DC.%2BV.%26aulast%3DFischer%26aufirst%3DK.%26aulast%3DDashwood%26aufirst%3DW.%2BM.%26aulast%3DGreenwood%26aufirst%3DJ.%2BA.%26aulast%3DHo%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DD.%2BE.%26aulast%3DAshktorab%26aufirst%3DH.%26aulast%3DDashwood%26aufirst%3DM.%2BR.%26aulast%3DDashwood%26aufirst%3DR.%2BH.%26atitle%3DEpigenetic%2520Inactivation%2520of%2520Endothelin-2%2520and%2520Endothelin-3%2520in%2520Colon%2520Cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2013%26volume%3D132%26spage%3D1004%26epage%3D1012%26doi%3D10.1002%2Fijc.27762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Denault, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâOrlÃ©ans-Juste, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leduc, R.</span><span> </span><span class="NLM_article-title">Processing of Proendothelin-1 by Human Furin Convertase</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">276</span><span class="NLM_x">â</span> <span class="NLM_lpage">280</span><span class="refDoi">Â DOI: 10.1016/0014-5793(95)00249-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2F0014-5793%2895%2900249-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=1995&pages=276-280&author=J.+B.+Denaultauthor=A.+Claingauthor=P.+D%E2%80%99Orl%C3%A9ans-Justeauthor=T.+Sawamuraauthor=T.+Kidoauthor=T.+Masakiauthor=R.+Leduc&title=Processing+of+Proendothelin-1+by+Human+Furin+Convertase&doi=10.1016%2F0014-5793%2895%2900249-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2895%2900249-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252895%252900249-9%26sid%3Dliteratum%253Aachs%26aulast%3DDenault%26aufirst%3DJ.%2BB.%26aulast%3DClaing%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Orl%25C3%25A9ans-Juste%26aufirst%3DP.%26aulast%3DSawamura%26aufirst%3DT.%26aulast%3DKido%26aufirst%3DT.%26aulast%3DMasaki%26aufirst%3DT.%26aulast%3DLeduc%26aufirst%3DR.%26atitle%3DProcessing%2520of%2520Proendothelin-1%2520by%2520Human%2520Furin%2520Convertase%26jtitle%3DFEBS%2520Lett.%26date%3D1995%26volume%3D362%26spage%3D276%26epage%3D280%26doi%3D10.1016%2F0014-5793%2895%2900249-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Coppola, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhojani, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehemtulla, A.</span><span> </span><span class="NLM_article-title">Identification of Inhibitors Using a Cell-based Assay for Monitoring Golgi-resident Protease Activity</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">â</span> <span class="NLM_lpage">29</span><span class="refDoi">Â DOI: 10.1016/j.ab.2007.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.ab.2007.01.013" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2007&pages=19-29&author=J.+M.+Coppolaauthor=C.+A.+Hamiltonauthor=M.+S.+Bhojaniauthor=M.+J.+Larsenauthor=B.+D.+Rossauthor=A.+Rehemtulla&title=Identification+of+Inhibitors+Using+a+Cell-based+Assay+for+Monitoring+Golgi-resident+Protease+Activity&doi=10.1016%2Fj.ab.2007.01.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2007.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2007.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DCoppola%26aufirst%3DJ.%2BM.%26aulast%3DHamilton%26aufirst%3DC.%2BA.%26aulast%3DBhojani%26aufirst%3DM.%2BS.%26aulast%3DLarsen%26aufirst%3DM.%2BJ.%26aulast%3DRoss%26aufirst%3DB.%2BD.%26aulast%3DRehemtulla%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520Inhibitors%2520Using%2520a%2520Cell-based%2520Assay%2520for%2520Monitoring%2520Golgi-resident%2520Protease%2520Activity%26jtitle%3DAnal.%2520Biochem.%26date%3D2007%26volume%3D364%26spage%3D19%26epage%3D29%26doi%3D10.1016%2Fj.ab.2007.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Muller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barret, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meidan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdenaire, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvol, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tougard, C.</span><span> </span><span class="NLM_article-title">Heterodimerization of Endothelin-Converting-Enzyme-1 Isoforms Regulates the Subcellular Distribution of this Metalloprotease</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">â</span> <span class="NLM_lpage">555</span><span class="refDoi">Â DOI: 10.1074/jbc.M208949200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1074%2Fjbc.M208949200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=545-555&author=L.+Mullerauthor=A.+Barretauthor=E.+Etienneauthor=R.+Meidanauthor=O.+Valdenaireauthor=P.+Corvolauthor=C.+Tougard&title=Heterodimerization+of+Endothelin-Converting-Enzyme-1+Isoforms+Regulates+the+Subcellular+Distribution+of+this+Metalloprotease&doi=10.1074%2Fjbc.M208949200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M208949200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M208949200%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DBarret%26aufirst%3DA.%26aulast%3DEtienne%26aufirst%3DE.%26aulast%3DMeidan%26aufirst%3DR.%26aulast%3DValdenaire%26aufirst%3DO.%26aulast%3DCorvol%26aufirst%3DP.%26aulast%3DTougard%26aufirst%3DC.%26atitle%3DHeterodimerization%2520of%2520Endothelin-Converting-Enzyme-1%2520Isoforms%2520Regulates%2520the%2520Subcellular%2520Distribution%2520of%2520this%2520Metalloprotease%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D545%26epage%3D555%26doi%3D10.1074%2Fjbc.M208949200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Azarani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boileau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crine, P.</span><span> </span><span class="NLM_article-title">Recombinant Human Endothelin-converting Enzyme ECE-1b Is Located in an Intracellular Compartment When Expressed in Polarized Madin-Darby Canine Kidney Cells</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">333</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">â</span> <span class="NLM_lpage">448</span><span class="refDoi">Â DOI: 10.1042/bj3330439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1042%2Fbj3330439" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=1998&pages=439-448&author=A.+Azaraniauthor=G.+Boileauauthor=P.+Crine&title=Recombinant+Human+Endothelin-converting+Enzyme+ECE-1b+Is+Located+in+an+Intracellular+Compartment+When+Expressed+in+Polarized+Madin-Darby+Canine+Kidney+Cells&doi=10.1042%2Fbj3330439"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1042%2Fbj3330439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3330439%26sid%3Dliteratum%253Aachs%26aulast%3DAzarani%26aufirst%3DA.%26aulast%3DBoileau%26aufirst%3DG.%26aulast%3DCrine%26aufirst%3DP.%26atitle%3DRecombinant%2520Human%2520Endothelin-converting%2520Enzyme%2520ECE-1b%2520Is%2520Located%2520in%2520an%2520Intracellular%2520Compartment%2520When%2520Expressed%2520in%2520Polarized%2520Madin-Darby%2520Canine%2520Kidney%2520Cells%26jtitle%3DBiochem.%2520J.%26date%3D1998%26volume%3D333%26spage%3D439%26epage%3D448%26doi%3D10.1042%2Fbj3330439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Turner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweizer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdenaire, O.</span><span> </span><span class="NLM_article-title">Isoforms of Endothelin-converting Enzyme: Why and Where?</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">â</span> <span class="NLM_lpage">486</span><span class="refDoi">Â DOI: 10.1016/S0165-6147(98)01251-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0165-6147%2898%2901251-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1998&pages=483-486&author=A.+J.+Turnerauthor=K.+Barnesauthor=A.+Schweizerauthor=O.+Valdenaire&title=Isoforms+of+Endothelin-converting+Enzyme%3A+Why+and+Where%3F&doi=10.1016%2FS0165-6147%2898%2901251-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2898%2901251-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252898%252901251-6%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DA.%2BJ.%26aulast%3DBarnes%26aufirst%3DK.%26aulast%3DSchweizer%26aufirst%3DA.%26aulast%3DValdenaire%26aufirst%3DO.%26atitle%3DIsoforms%2520of%2520Endothelin-converting%2520Enzyme%253A%2520Why%2520and%2520Where%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1998%26volume%3D19%26spage%3D483%26epage%3D486%26doi%3D10.1016%2FS0165-6147%2898%2901251-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Valdenaire, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepailleur-Enouf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egidy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thouhard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barret, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranckx, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tougard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, J. B.</span><span> </span><span class="NLM_article-title">A Fourth Isoform of Endothelin-Converting Enzyme (ECE-1) Is Generated from an Additional Promoter: Molecular Cloning and Characterization</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">â</span> <span class="NLM_lpage">349</span><span class="refDoi">Â DOI: 10.1046/j.1432-1327.1999.00602.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1046%2Fj.1432-1327.1999.00602.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10491078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFWku78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1999&pages=341-349&author=O.+Valdenaireauthor=D.+Lepailleur-Enoufauthor=G.+Egidyauthor=A.+Thouhardauthor=A.+Barretauthor=R.+Vranckxauthor=C.+Tougardauthor=J.+B.+Michel&title=A+Fourth+Isoform+of+Endothelin-Converting+Enzyme+%28ECE-1%29+Is+Generated+from+an+Additional+Promoter%3A+Molecular+Cloning+and+Characterization&doi=10.1046%2Fj.1432-1327.1999.00602.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter: molecular cloning and characterization</span></div><div class="casAuthors">Valdenaire, Olivier; Lepailleur-Enouf, Delphine; Egidy, Giorgia; Thouard, Anne; Barret, Alain; Vranckx, Roger; Tougard, Claude; Michel, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-349</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Human endothelin-converting enzyme (ECE-1) has been shown to exist as three isoforms (ECE-1a, ECE-1b and ECE-1c) diverging in their N-terminal sequence and displaying different patterns of subcellular localization.  We report here the cloning of ECE-1d, a novel isoform of 767 amino acids, which is generated from the same gene via the existence of an addnl. promoter located upstream from the third exon of the ECE-1 gene.  ECE-1d converting activity is comparable to that of the other three isoenzymes.  In contrast to ECE-1b, ECE-1d is expressed at the cell surface, although less strongly than ECE-1a.  We have also shown, by identifying ECE-1b and ECE-1d in rat, that the ECE-1 diversity is conserved between human and rodent, suggesting its physiol. relevance.  The mRNA levels of the four isoforms were assessed in the two species in various cell types, revealing some differences.  In particular, the ECE-1a isoform, strongly expressed at the plasma membrane, was found to be highly expressed in primary cultures of endothelial cells but absent from primary cultures of smooth muscle cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqta6cysNvJkbVg90H21EOLACvtfcHk0lhERUqKDuDa7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFWku78%253D&md5=9e71dea34e387e43f1d69cdc3052b8f9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.1999.00602.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.1999.00602.x%26sid%3Dliteratum%253Aachs%26aulast%3DValdenaire%26aufirst%3DO.%26aulast%3DLepailleur-Enouf%26aufirst%3DD.%26aulast%3DEgidy%26aufirst%3DG.%26aulast%3DThouhard%26aufirst%3DA.%26aulast%3DBarret%26aufirst%3DA.%26aulast%3DVranckx%26aufirst%3DR.%26aulast%3DTougard%26aufirst%3DC.%26aulast%3DMichel%26aufirst%3DJ.%2BB.%26atitle%3DA%2520Fourth%2520Isoform%2520of%2520Endothelin-Converting%2520Enzyme%2520%2528ECE-1%2529%2520Is%2520Generated%2520from%2520an%2520Additional%2520Promoter%253A%2520Molecular%2520Cloning%2520and%2520Characterization%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1999%26volume%3D264%26spage%3D341%26epage%3D349%26doi%3D10.1046%2Fj.1432-1327.1999.00602.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Berger, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehmlow, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum-Kaelin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitas, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶ffler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aebi, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Endothelin-converting Enzyme-1 Inhibition and Growth of Human Glioblastoma Cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">â</span> <span class="NLM_lpage">498</span><span class="refDoi">Â DOI: 10.1021/jm040857x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040857x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVKn" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=483-498&author=Y.+Bergerauthor=H.+Dehmlowauthor=D.+Blum-Kaelinauthor=E.+A.+Kitasauthor=B.+M.+L%C3%B6fflerauthor=J.+D.+Aebiauthor=L.+Juillerat-Jeanneret&title=Endothelin-converting+Enzyme-1+Inhibition+and+Growth+of+Human+Glioblastoma+Cells&doi=10.1021%2Fjm040857x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-Converting Enzyme-1 Inhibition and Growth of Human Glioblastoma Cells</span></div><div class="casAuthors">Berger, Yann; Dehmlow, Henrietta; Blum-Kaelin, Denise; Kitas, Eric A.; Loeffler, Bernd-Michael; Aebi, Johannes D.; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">483-498</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Endothelin-1 (ET-1) is mitogenic and/or antiapoptotic in human cancers, and antagonists to ET-1 receptors are under evaluation for cancer treatment.  Inhibition of ET-1 activation by the endothelin-converting enzymes 1a-d (ECE-1a-d; EC 3.4.24.71) represents another approach to block the ET-1 effect in cancer.  To evaluate this potential, we synthesized and characterized a series of low nanomolar nonpeptidic thiol-contg. ECE-1 inhibitors, and evaluated their effect, as well as the effect of inhibitors for the related metalloproteases neprilysin (NEP; EC 3.4.24.11) and angiotensin-converting enzyme (ACE; EC 3.4.15.1), on human glioblastoma cell growth.  Only ECE-1 inhibitors inhibited DNA synthesis by human glioblastoma cells.  Exogenous addn. of ET-1 or bigET-1 to glioblastoma cells did not counterbalance the growth inhibition elicited by ECE-1 inhibitors, suggesting that ECE-1 inhibitors block the proliferation of human glioblastoma cells most likely via a mechanism not involving extracellular prodn. of ET-1.  This class of mols. may thus represent novel therapeutic agents for the potential treatment of human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAHZSGjdYuurVg90H21EOLACvtfcHk0lhERUqKDuDa7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVKn&md5=e7eb909f11107fa8dc0bcfea1f88804b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm040857x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040857x%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DY.%26aulast%3DDehmlow%26aufirst%3DH.%26aulast%3DBlum-Kaelin%26aufirst%3DD.%26aulast%3DKitas%26aufirst%3DE.%2BA.%26aulast%3DL%25C3%25B6ffler%26aufirst%3DB.%2BM.%26aulast%3DAebi%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin-converting%2520Enzyme-1%2520Inhibition%2520and%2520Growth%2520of%2520Human%2520Glioblastoma%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D483%26epage%3D498%26doi%3D10.1021%2Fjm040857x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Inhibiting the Enzymes of the Endothelin and Renin-angiotensin Systems in Cancer</span> <span class="citation_source-journal">Curr. Enzyme Inhib.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">â</span> <span class="NLM_lpage">362</span><span class="refDoi">Â DOI: 10.2174/157340806778699253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2174%2F157340806778699253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFartrfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=353-362&author=L.+Juillerat-Jeanneret&title=Inhibiting+the+Enzymes+of+the+Endothelin+and+Renin-angiotensin+Systems+in+Cancer&doi=10.2174%2F157340806778699253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the enzymes of the endothelin and renin-angiotensin systems in cancer</span></div><div class="casAuthors">Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Current Enzyme Inhibition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-362</span>CODEN:
                <span class="NLM_cas:coden">CEIUAG</span>;
        ISSN:<span class="NLM_cas:issn">1573-4080</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renin-angiotensin (RAS) and endothelin/ET-1,-2,-3 systems comprise families of precursor peptides, angiotensinogen and big-endothelins resp., activated by families of proteases.  Angiotensinogen is activated by the sequential action of an aspartyl-protease, renin, then a metalloprotease, angiotensin converting enzyme (ACE).  Big-endothelins are activated by the metalloproteases endothelin converting enzyme/ECE-1a-d, and to a lesser extent neprilysin (NEP/CD10).  These proteolytic cascades produce the system-representative active peptides angiotensin II (Ang II) and endothelin-1 (ET-1).  Then several exopeptidases, which include aminopeptidases or carboxypeptidases, and endopeptidases, in particular NEP, further process these active peptides to either inactive fragments or intermediate peptides with various biol. activities.  The RAS and ET systems have been mainly studied in the context of cardiovascular disorders, and either agonists or antagonists of their receptors, and inhibitors for the enzymes metabolizing the precursors and/or the active peptides have been developed for the treatment of these disorders.  However, the RAS and ET systems, in addn. to controlling the vascular tone and natriohydric balance, may be involved in cell growth and/or death in cancer, fibrotic or degenerative diseases.  Therefore the protease inhibitors developed for treating cardiovascular disorders may have wider application in cancer than initially envisioned, which will be reviewed in this manuscript.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIvsOFfYSmx7Vg90H21EOLACvtfcHk0liFVNZ-ru4oGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFartrfK&md5=ad92071ca036b87ead7621e0b52e132e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F157340806778699253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157340806778699253%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DInhibiting%2520the%2520Enzymes%2520of%2520the%2520Endothelin%2520and%2520Renin-angiotensin%2520Systems%2520in%2520Cancer%26jtitle%3DCurr.%2520Enzyme%2520Inhib.%26date%3D2006%26volume%3D2%26spage%3D353%26epage%3D362%26doi%3D10.2174%2F157340806778699253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Russell, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coppell, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title">In Vitro Enzymatic Processing of Radiolabel Led Big ET-1 in Human Kidney</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">â</span> <span class="NLM_lpage">701</span><span class="refDoi">Â DOI: 10.1016/S0006-2952(97)00515-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0006-2952%2897%2900515-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1998&pages=697-701&author=F.+D.+Russellauthor=A.+L.+Coppellauthor=A.+P.+Davenport&title=In+Vitro+Enzymatic+Processing+of+Radiolabel+Led+Big+ET-1+in+Human+Kidney&doi=10.1016%2FS0006-2952%2897%2900515-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2897%2900515-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252897%252900515-7%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DF.%2BD.%26aulast%3DCoppell%26aufirst%3DA.%2BL.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DIn%2520Vitro%2520Enzymatic%2520Processing%2520of%2520Radiolabel%2520Led%2520Big%2520ET-1%2520in%2520Human%2520Kidney%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1998%26volume%3D55%26spage%3D697%26epage%3D701%26doi%3D10.1016%2FS0006-2952%2897%2900515-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hayasaki-Kajiwara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, M.</span><span> </span><span class="NLM_article-title">Endothelin Generating Pathway through Endothelin1-31 in Human Cultured Bronchial Smooth Muscle Cells</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">â</span> <span class="NLM_lpage">1421</span><span class="refDoi">Â DOI: 10.1038/sj.bjp.0702664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fsj.bjp.0702664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10455291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK1MXlt1emtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=1999&pages=1415-1421&author=Y.+Hayasaki-Kajiwaraauthor=N.+Nayaauthor=T.+Shimamuraauthor=T.+Iwasakiauthor=M.+Nakajima&title=Endothelin+Generating+Pathway+through+Endothelin1-31+in+Human+Cultured+Bronchial+Smooth+Muscle+Cells&doi=10.1038%2Fsj.bjp.0702664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin generating pathway through endothelin1-31 in human cultured bronchial smooth muscle cells</span></div><div class="casAuthors">Hayasaki-Kajiwara, Yoko; Naya, Noriyuki; Shimamura, Toshitake; Iwasaki, Takanori; Nakajima, Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1415-1421</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The effects of endothelin (ET)-11-31 and ET-21-31, human chymase products of the corresponding big ETs, on the intracellular free Ca2+ concn. ([Ca2+]i) and [125I]-ET-1 binding were investigated using human cultured bronchial smooth muscle cells (BSMC).  ET-11-31 (10-8 M - 3Ã10-7 M) and ET-21-31 (3Ã10-8 M - 3Ã10-6 M) caused an increase in [Ca2+]i in a concn.-dependent manner.  Big ET-1 (3Ã10-8 M - 10-6 M) also caused this increase, but not big ET-2 at concns. up to 10-6 M.  The [Ca2+]i increase induced by ET-1 was inhibited by both BQ123, an ETA-receptor antagonist, and BQ788, an ETB-receptor antagonist, whereas that induced by ET-3 was inhibited by BQ788 but not by BQ123.  Increases in [Ca2+]i caused by ET-11-31, big ET-1 and ET-21-31 were completely inhibited by 10-4 M phosphoramidon, a dual neutral endopeptidase (NEP)/endothelin-converting enzyme (ECE) inhibitor, and 10-5 M thiorphan, a NEP inhibitor.  Scatchard plot analyses of the satn. curves of [125I]-ET-1 and [125I]-ET-3 showed that both ETA- and ETB- receptors at the ratio of 4:1 were expressed on BSMC.  ET-11-31, big ET-1 and ET-21-31 inhibited [125I]-ET-1 binding in a concn.-dependent manner, and these effects were attenuated by treatment with thiorphan.  On the other hand, big ET-2 slightly inhibited the binding at a high concn. and this was not affected by thiorphan.  These results suggest that ET-11-31, big ET-1 and ET-21-31 cause an increase in [Ca2+]i by being converted into the corresponding ET-1 and ET-2 by NEP, but this did not occur with big ET-2 in human BSMC.  ET-21-31 produced by human chymase from big ET-2 might be important for the generation of ET-2 in human bronchial tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIXRbqc7V5drVg90H21EOLACvtfcHk0liFVNZ-ru4oGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt1emtLY%253D&md5=4e9cac151eed2f462fd94d677792f13a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702664%26sid%3Dliteratum%253Aachs%26aulast%3DHayasaki-Kajiwara%26aufirst%3DY.%26aulast%3DNaya%26aufirst%3DN.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DIwasaki%26aufirst%3DT.%26aulast%3DNakajima%26aufirst%3DM.%26atitle%3DEndothelin%2520Generating%2520Pathway%2520through%2520Endothelin1-31%2520in%2520Human%2520Cultured%2520Bronchial%2520Smooth%2520Muscle%2520Cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D127%26spage%3D1415%26epage%3D1421%26doi%3D10.1038%2Fsj.bjp.0702664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Tabrizchi, R.</span><span> </span><span class="NLM_article-title">SLV-306 Solvay</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">â</span> <span class="NLM_lpage">332</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=329-332&author=R.+Tabrizchi&title=SLV-306+Solvay"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTabrizchi%26aufirst%3DR.%26atitle%3DSLV-306%2520Solvay%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2003%26volume%3D4%26spage%3D329%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Parvanova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Meer, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iliev, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaspari, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevisan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benigni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggenenti, P.</span><span> </span><span class="NLM_article-title">Effect on Blood Pressure of Combined Inhibition of Endothelin-converting Enzyme and Neutral Endopeptidase with Daglutril in Patients with Type 2 Diabetes Who Have Albuminuria: a Randomised, Crossover, Double-blind, Placebo-controlled Trial</span> <span class="citation_source-journal">Lancet Diabetes Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">â</span> <span class="NLM_lpage">27</span><span class="refDoi">Â DOI: 10.1016/S2213-8587(13)70029-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS2213-8587%2813%2970029-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24622263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslaqsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=19-27&author=A.+Parvanovaauthor=I.+M.+van+der+Meerauthor=I.+Ilievauthor=A.+Pernaauthor=F.+Gaspariauthor=R.+Trevisanauthor=A.+Bossiauthor=G.+Remuzziauthor=A.+Benigniauthor=P.+Ruggenenti&title=Effect+on+Blood+Pressure+of+Combined+Inhibition+of+Endothelin-converting+Enzyme+and+Neutral+Endopeptidase+with+Daglutril+in+Patients+with+Type+2+Diabetes+Who+Have+Albuminuria%3A+a+Randomised%2C+Crossover%2C+Double-blind%2C+Placebo-controlled+Trial&doi=10.1016%2FS2213-8587%2813%2970029-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Parvanova, Aneliya; van der Meer, Irene M.; Iliev, Ilian; Perna, Annalisa; Gaspari, Flavio; Trevisan, Roberto; Bossi, Antonio; Remuzzi, Giuseppe; Benigni, Ariela; Ruggenenti, Piero</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Diabetes & Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-27</span>CODEN:
                <span class="NLM_cas:coden">LDEAAS</span>;
        ISSN:<span class="NLM_cas:issn">2213-8587</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Effective redn. of albuminuria and blood pressure in patients with type 2 diabetes who have nephropathy is seldom achieved with available treatments.  We tested the effects of treatment of such patients with daglutril, a combined endothelin-converting enzyme and neutral endopeptidase inhibitor.  We did this randomized, crossover trial in two hospitals in Italy.  Eligibility criteria were: age 18 years or older, urinary albumin excretion 20-999 Î¼g/min, systolic blood pressure (BP) less than 140 mm Hg, and diastolic BP less than 90 mm Hg.  Patients were randomly assigned (1:1) with a computer-generated randomized sequence to receive either daglutril (300 mg/day) then placebo for 8 wk each or vice versa, with a 4-wk washout period.  Patients also took losartan throughout.  Participants and investigators were masked to treatment allocation.  The primary endpoint was 24-h urinary albumin excretion in the intention-to-treat population.  Secondary endpoints were median office and ambulatory (24 h, daytime, and night-time) BP, renal hemodynamics and sieving function, and metabolic and lab. test results.  This study is registered with ClinicalTrials.gov, no. NCT00160225.  We screened 58 patients, of whom 45 were enrolled (22 assigned to daglutril then placebo, 23 to placebo then daglutril; enrollment from May, 2005, to Dec., 2006) and 42 (20 vs 22) were included in the primary anal.  Daglutril did not significantly affect 24-h urinary albumin excretion compared with placebo (difference in change -7Â·6 Î¼g/min, IQR -78Â·7 to 19Â·0; p=0Â·559). 34 patients had complete 24-h BP readings; compared with placebo, daglutril significantly reduced 24-h systolic (difference -5Â·2 mm Hg, SD 9Â·4; p=0Â·0013), diastolic (-2Â·5, 6Â·2; p=0Â·015), pulse (-3Â·0, 6Â·3; p=0Â·019), and mean (-3Â·1, 6Â·2; p=0Â·003) BP, as well as all night-time BP readings and daytime systolic, pulse, and mean BP, but not diastolic BP.  Compared with placebo, daglutril also significantly reduced office systolic BP (-5Â·4, 15Â·4; p=0Â·028), but not diastolic (-1Â·8, 9Â·9; p=0Â·245), pulse (-3Â·1, 10Â·6; p=0Â·210), or mean (-2Â·1, 10Â·4; p=0Â·205) BP, and increased big endothelin serum concn.  Other secondary outcomes did not differ significantly between treatment periods.  Three patients taking placebo and six patients taking daglutril had mild treatment-related adverse events-the most common was facial or peripheral edema (in four patients taking daglutril).  Daglutril improved control of BP in hypertensive patients with type 2 diabetes and nephropathy and had an acceptable safety profile.  Combined endothelin-converting enzyme and neutral endopeptidase inhibition could provide a new approach to hypertension in this high-risk population.Solvay Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOwpv9vNQmrrVg90H21EOLACvtfcHk0lgzJahZmPgL_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslaqsrY%253D&md5=e56eec8321ce0bf7eba9dd0e10c8c59a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS2213-8587%2813%2970029-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-8587%252813%252970029-9%26sid%3Dliteratum%253Aachs%26aulast%3DParvanova%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BMeer%26aufirst%3DI.%2BM.%26aulast%3DIliev%26aufirst%3DI.%26aulast%3DPerna%26aufirst%3DA.%26aulast%3DGaspari%26aufirst%3DF.%26aulast%3DTrevisan%26aufirst%3DR.%26aulast%3DBossi%26aufirst%3DA.%26aulast%3DRemuzzi%26aufirst%3DG.%26aulast%3DBenigni%26aufirst%3DA.%26aulast%3DRuggenenti%26aufirst%3DP.%26atitle%3DEffect%2520on%2520Blood%2520Pressure%2520of%2520Combined%2520Inhibition%2520of%2520Endothelin-converting%2520Enzyme%2520and%2520Neutral%2520Endopeptidase%2520with%2520Daglutril%2520in%2520Patients%2520with%2520Type%25202%2520Diabetes%2520Who%2520Have%2520Albuminuria%253A%2520a%2520Randomised%252C%2520Crossover%252C%2520Double-blind%252C%2520Placebo-controlled%2520Trial%26jtitle%3DLancet%2520Diabetes%2520Endocrinol.%26date%3D2013%26volume%3D1%26spage%3D19%26epage%3D27%26doi%3D10.1016%2FS2213-8587%2813%2970029-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Cabrera-Vera, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhauwe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medkova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preininger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzoni, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamm, H. E.</span><span> </span><span class="NLM_article-title">Insights into G Protein Structure, Function, and Regulation</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">â</span> <span class="NLM_lpage">781</span><span class="refDoi">Â DOI: 10.1210/er.2000-0026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1210%2Fer.2000-0026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=14671004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVegsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2003&pages=765-781&author=T.+M.+Cabrera-Veraauthor=J.+Vanhauweauthor=T.+O.+Thomasauthor=M.+Medkovaauthor=A.+Preiningerauthor=M.+R.+Mazzoniauthor=H.+E.+Hamm&title=Insights+into+G+Protein+Structure%2C+Function%2C+and+Regulation&doi=10.1210%2Fer.2000-0026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into G protein structure, function, and regulation</span></div><div class="casAuthors">Cabrera-Vera, Theresa M.; Vanhauwe, Jurgen; Thomas, Tarita O.; Medkova, Martina; Preininger, Anita; Mazzoni, Maria R.; Hamm, Heidi E.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">765-781</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  In multicellular organisms from Caenorhabditis elegans to Homo sapiens, the maintenance of homeostasis is dependent on the continual flow and processing of information through a complex network of cells.  Moreover, in order for the organism to respond to an ever-changing environment, intercellular signals must be transduced, amplified, and ultimately converted to the appropriate physiol. response.  The resoln. of the mol. events underlying signal response and integration forms the basis of the signal transduction field of research.  An evolutionarily highly conserved group of mols. known as heterotrimeric guanine nucleotide-binding proteins (G proteins) are key determinants of the specificity and temporal characteristics of many signaling processes and are the topic of this review.  Numerous hormones, neurotransmitters, chemokines, local mediators, and sensory stimuli exert their effects on cells by binding to heptahelical membrane receptors coupled to heterotrimeric G proteins.  These highly specialized transducers can modulate the activity of multiple signaling pathways leading to diverse biol. responses.  In vivo, specific combinations of GÎ±- and GÎ²Î³-subunits are likely required for connecting individual receptors to signaling pathways.  The structural determinants of receptor-G protein-effector specificity are not completely understood and, in addn. to involving interaction domains of these primary acting proteins, also require the participation of scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw0JbJJZOw7LVg90H21EOLACvtfcHk0lgzJahZmPgL_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVegsg%253D%253D&md5=afd2763ad05d9a0475ce4bdbed3ade4d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1210%2Fer.2000-0026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2000-0026%26sid%3Dliteratum%253Aachs%26aulast%3DCabrera-Vera%26aufirst%3DT.%2BM.%26aulast%3DVanhauwe%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DT.%2BO.%26aulast%3DMedkova%26aufirst%3DM.%26aulast%3DPreininger%26aufirst%3DA.%26aulast%3DMazzoni%26aufirst%3DM.%2BR.%26aulast%3DHamm%26aufirst%3DH.%2BE.%26atitle%3DInsights%2520into%2520G%2520Protein%2520Structure%252C%2520Function%252C%2520and%2520Regulation%26jtitle%3DEndocr.%2520Rev.%26date%3D2003%26volume%3D24%26spage%3D765%26epage%3D781%26doi%3D10.1210%2Fer.2000-0026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lappano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggiolini, M.</span><span> </span><span class="NLM_article-title">G Protein-coupled Receptors: Novel Targets for Drug Discovery in Cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">â</span> <span class="NLM_lpage">60</span><span class="refDoi">Â DOI: 10.1038/nrd3320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fnrd3320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21193867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFCl" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=47-60&author=R.+Lappanoauthor=M.+Maggiolini&title=G+Protein-coupled+Receptors%3A+Novel+Targets+for+Drug+Discovery+in+Cancer&doi=10.1038%2Fnrd3320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptors: novel targets for drug discovery in cancer</span></div><div class="casAuthors">Lappano, Rosamaria; Maggiolini, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-60</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) belong to a superfamily of cell surface signalling proteins that have a pivotal role in many physiol. functions and in multiple diseases, including the development of cancer and cancer metastasis.  Current drugs that target GPCRs - many of which have excellent therapeutic benefits - are directed towards only a few GPCR members.  Therefore, huge efforts are currently underway to develop new GPCR-based drugs, particularly for cancer.  We review recent findings that present unexpected opportunities to interfere with major tumorigenic signals by manipulating GPCR-mediated pathways.  We also discuss current data regarding novel GPCR targets that may provide promising opportunities for drug discovery in cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUpj1HOTd_iLVg90H21EOLACvtfcHk0lgzJahZmPgL_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFCl&md5=d2ccada1529dc84d499396d0e1c1954e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd3320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3320%26sid%3Dliteratum%253Aachs%26aulast%3DLappano%26aufirst%3DR.%26aulast%3DMaggiolini%26aufirst%3DM.%26atitle%3DG%2520Protein-coupled%2520Receptors%253A%2520Novel%2520Targets%2520for%2520Drug%2520Discovery%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D47%26epage%3D60%26doi%3D10.1038%2Fnrd3320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Sasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takimoto, M.</span><span> </span><span class="NLM_article-title">Both ET(A) and ET(B) Receptors Are Involved in Mitogen-activated Protein Kinase Activation and DNA Synthesis of Astrocytes: Study Using ET(B) Receptor-deficient Rats (aganglionosis Rats)</span> <span class="citation_source-journal">Eur. J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2984</span><span class="NLM_x">â</span> <span class="NLM_lpage">2993</span><span class="refDoi">Â DOI: 10.1111/j.1460-9568.1998.00305.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fj.1460-9568.1998.00305.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=9758168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADyaK1cvivFWgtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=2984-2993&author=Y.+Sasakiauthor=S.+Horiauthor=K.+Odaauthor=T.+Okadaauthor=M.+Takimoto&title=Both+ET%28A%29+and+ET%28B%29+Receptors+Are+Involved+in+Mitogen-activated+Protein+Kinase+Activation+and+DNA+Synthesis+of+Astrocytes%3A+Study+Using+ET%28B%29+Receptor-deficient+Rats+%28aganglionosis+Rats%29&doi=10.1111%2Fj.1460-9568.1998.00305.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Both ET(A) and ET(B) receptors are involved in mitogen-activated protein kinase activation and DNA synthesis of astrocytes: study using ET(B) receptor-deficient rats (aganglionosis rats)</span></div><div class="casAuthors">Sasaki Y; Hori S; Oda K; Okada T; Takimoto M</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2984-93</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Endothelin (ET) is known to be a potent mitogen in astrocytes.  However, the contribution and signalling pathway of ET(A) and/or ET(B) receptor to the proliferation of astrocytes remain unclear.  We investigated ET-induced DNA synthesis in astrocytes using ET(B) receptor-deficient mutant rats (aganglionosis rats: sl/sl).  Western blotting with anti-ET receptor subtype-specific antibodies and Scatchard analysis of binding revealed that ET(B) receptor expression in astrocytes depended on gene dosage (+/+: sl/+: sl/sl=2: 1:0), whereas ET(A) receptor expression was unchanged among the three genotypes.  ET-1 (10 nM) stimulated [3H]thymidine incorporation and mitogen-activated protein kinase (MAP kinase) activity not only in +/+ via both ET(A) and ET(B) receptors, but also in sl/sl astrocytes via ET(A) receptor with about half the extent of those observed in +/+ astrocytes.  Treatment with pertussis toxin (PTX) suppressed the ET-1-induced increases in the incorporation and MAP kinase activity in +/+, but not sl/sl astrocytes, indicating that the ET(B) receptor-, but not the ET(A) receptor-, mediated pathway to DNA synthesis involves PTX-sensitive G proteins, e.g.  Gi and/or Go (Gi/o).  In +/+ astrocytes, ET-1 (1 nM) stimulated cAMP accumulation, and the ET(B) receptor-selective agonist IRL 1620 (1 nM) suppressed 10 microM forskolin-induced cAMP accumulation, suggesting Gs coupling to the ET(A) receptor and Gi/o coupling to the ET(B) receptor.  On the other hand, ET-1 did not increase cAMP accumulation in sl/sl astrocytes, although ET-1 (1 nM) suppressed the forskolin-induced response, suggesting Gi/o coupling to the ET(A) receptor.  Our results suggest the possibility that the selectivity of G protein for ET(A) receptor is changed from Gs to Gi/o in ET(B) receptor-deficient astrocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyYIMfSanqsH6oPH0mYWL1fW6udTcc2ea98JDcwSCuRrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1cvivFWgtw%253D%253D&md5=0744d2618ceef4e5cd74e126e1812527</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.1998.00305.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.1998.00305.x%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DHori%26aufirst%3DS.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DTakimoto%26aufirst%3DM.%26atitle%3DBoth%2520ET%2528A%2529%2520and%2520ET%2528B%2529%2520Receptors%2520Are%2520Involved%2520in%2520Mitogen-activated%2520Protein%2520Kinase%2520Activation%2520and%2520DNA%2520Synthesis%2520of%2520Astrocytes%253A%2520Study%2520Using%2520ET%2528B%2529%2520Receptor-deficient%2520Rats%2520%2528aganglionosis%2520Rats%2529%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D1998%26volume%3D10%26spage%3D2984%26epage%3D2993%26doi%3D10.1111%2Fj.1460-9568.1998.00305.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Bremnes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paasche, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehlum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremnes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attramadal, H.</span><span> </span><span class="NLM_article-title">Regulation and Intracellular Trafficking Pathways of the Endothelin Receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">17596</span><span class="NLM_x">â</span> <span class="NLM_lpage">17604</span><span class="refDoi">Â DOI: 10.1074/jbc.M000142200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1074%2Fjbc.M000142200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=17596-17604&author=T.+Bremnesauthor=J.+D.+Paascheauthor=A.+Mehlumauthor=C.+Sandbergauthor=B.+Bremnesauthor=H.+Attramadal&title=Regulation+and+Intracellular+Trafficking+Pathways+of+the+Endothelin+Receptors&doi=10.1074%2Fjbc.M000142200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M000142200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M000142200%26sid%3Dliteratum%253Aachs%26aulast%3DBremnes%26aufirst%3DT.%26aulast%3DPaasche%26aufirst%3DJ.%2BD.%26aulast%3DMehlum%26aufirst%3DA.%26aulast%3DSandberg%26aufirst%3DC.%26aulast%3DBremnes%26aufirst%3DB.%26aulast%3DAttramadal%26aufirst%3DH.%26atitle%3DRegulation%2520and%2520Intracellular%2520Trafficking%2520Pathways%2520of%2520the%2520Endothelin%2520Receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D17596%26epage%3D17604%26doi%3D10.1074%2Fjbc.M000142200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Ishikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuroda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, T.</span><span> </span><span class="NLM_article-title">Biochemical and Pharmacological Profile of a Potent and Selective Endothelin B-receptor Antagonist, BQ788</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">4892</span><span class="NLM_x">â</span> <span class="NLM_lpage">4896</span><span class="refDoi">Â DOI: 10.1073/pnas.91.11.4892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1073%2Fpnas.91.11.4892" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=4892-4896&author=K.+Ishikawaauthor=M.+Iharaauthor=K.+Noguchiauthor=T.+Maseauthor=N.+Minoauthor=T.+Saekiauthor=T.+Fukurodaauthor=T.+Fukamiauthor=S.+Ozakiauthor=T.+Nagase&title=Biochemical+and+Pharmacological+Profile+of+a+Potent+and+Selective+Endothelin+B-receptor+Antagonist%2C+BQ788&doi=10.1073%2Fpnas.91.11.4892"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.11.4892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.11.4892%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DIhara%26aufirst%3DM.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DMase%26aufirst%3DT.%26aulast%3DMino%26aufirst%3DN.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DFukuroda%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DOzaki%26aufirst%3DS.%26aulast%3DNagase%26aufirst%3DT.%26atitle%3DBiochemical%2520and%2520Pharmacological%2520Profile%2520of%2520a%2520Potent%2520and%2520Selective%2520Endothelin%2520B-receptor%2520Antagonist%252C%2520BQ788%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D4892%26epage%3D4896%26doi%3D10.1073%2Fpnas.91.11.4892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Jimeno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M.</span><span> </span><span class="NLM_article-title">Atrasentan: Targeting the Endothelin Axis in Prostate Cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1631</span><span class="NLM_x">â</span> <span class="NLM_lpage">1640</span><span class="refDoi">Â DOI: 10.1517/13543784.13.12.1631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1517%2F13543784.13.12.1631" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=1631-1640&author=A.+Jimenoauthor=M.+Carducci&title=Atrasentan%3A+Targeting+the+Endothelin+Axis+in+Prostate+Cancer&doi=10.1517%2F13543784.13.12.1631"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1517%2F13543784.13.12.1631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.13.12.1631%26sid%3Dliteratum%253Aachs%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DCarducci%26aufirst%3DM.%26atitle%3DAtrasentan%253A%2520Targeting%2520the%2520Endothelin%2520Axis%2520in%2520Prostate%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2004%26volume%3D13%26spage%3D1631%26epage%3D1640%26doi%3D10.1517%2F13543784.13.12.1631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Battistini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthiaume, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelland, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohan, D. E.</span><span> </span><span class="NLM_article-title">Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel âSentanâ Class of Drug</span> <span class="citation_source-journal">Exp. Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">653</span><span class="NLM_x">â</span> <span class="NLM_lpage">695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD28Xlt1eku70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2006&pages=653-695&author=B.+Battistiniauthor=N.+Berthiaumeauthor=N.+F.+Kellandauthor=D.+J.+Webbauthor=D.+E.+Kohan&title=Profile+of+Past+and+Current+Clinical+Trials+Involving+Endothelin+Receptor+Antagonists%3A+The+Novel+%E2%80%9CSentan%E2%80%9D+Class+of+Drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug</span></div><div class="casAuthors">Battistini, Bruno; Berthiaume, Nathalie; Kelland, Nicholas F.; Webb, David J.; Kohan, Donald E.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (Maywood, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">653-695</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3702</span>.
    
            (<span class="NLM_cas:orgname">Society for Experimental Biology and Medicine</span>)
        </div><div class="casAbstract">A review.  Since its initial characterization in 1988, over 18,236 papers, including 2,485 reviews, have been published in the endothelin (ET) field.  Over this period, several generations of selective and mixed (dual) ET receptor antagonists (ERAs), from peptidic backbones to orally active potent (subnanomolar) small mol. compds., have been developed.  These agents have been studied in many exptl. animal models of various pathol. conditions (cardiovascular, respiratory, and neuro-immunol.).  Continued basic research has led to a better understanding of the complex interactions between the ET axis and other biol. systems in human pathophysiol.  The first clin. trial involved patients with idiopathic pulmonary arterial hypertension and led to approval of bosentan (Tracleer) for use in the United States and Europe in 2002.  Since then, bosentan, the only currently approved dual (mixed) ERA, has been used in numerous other clin. trials.  In addn., more selective ETA receptor antagonists (ambrisentan, atrasentan, avosentan, clazosentan, darusentan, and sitaxsentan) are undergoing clin. trials.  Here we outline the ERAs undergoing development and summarize the standing of completed and ongoing trials at the time of the Ninth International Conference on Endothelin and even thereafter.  This review is intended to provide a useful ref. for those interested in the current state of clin. trials involving ERAs, and to identify lessons that might apply to the design of future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg8ZjYCNDwRbVg90H21EOLACvtfcHk0li4jbPzK0PfPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xlt1eku70%253D&md5=8cd2fa42705effee0d58ca029bb9b76c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBattistini%26aufirst%3DB.%26aulast%3DBerthiaume%26aufirst%3DN.%26aulast%3DKelland%26aufirst%3DN.%2BF.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26aulast%3DKohan%26aufirst%3DD.%2BE.%26atitle%3DProfile%2520of%2520Past%2520and%2520Current%2520Clinical%2520Trials%2520Involving%2520Endothelin%2520Receptor%2520Antagonists%253A%2520The%2520Novel%2520%25E2%2580%259CSentan%25E2%2580%259D%2520Class%2520of%2520Drug%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2006%26volume%3D231%26spage%3D653%26epage%3D695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Liu, G.</span><span> </span><span class="NLM_article-title">Recent Advances in Endothelin Antagonism</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">â</span> <span class="NLM_lpage">82</span><span class="refDoi">Â DOI: 10.1016/S0065-7743(00)35009-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0065-7743%2800%2935009-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=73-82&author=G.+Liu&title=Recent+Advances+in+Endothelin+Antagonism&doi=10.1016%2FS0065-7743%2800%2935009-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2800%2935009-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252800%252935009-6%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DRecent%2520Advances%2520in%2520Endothelin%2520Antagonism%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2000%26volume%3D35%26spage%3D73%26epage%3D82%26doi%3D10.1016%2FS0065-7743%2800%2935009-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Morris, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. J.</span><span> </span><span class="NLM_article-title">Specific Inhibition of the Endothelin A Receptor with ZD4054: Clinical and Pre-clinical Evidence</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">2148</span><span class="NLM_x">â</span> <span class="NLM_lpage">2152</span><span class="refDoi">Â DOI: 10.1038/sj.bjc.6602676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fsj.bjc.6602676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15956965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVygur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=2148-2152&author=C.+D.+Morrisauthor=A.+Roseauthor=J.+Curwenauthor=A.+M.+Hughesauthor=D.+J.+Wilsonauthor=D.+J.+Webb&title=Specific+Inhibition+of+the+Endothelin+A+Receptor+with+ZD4054%3A+Clinical+and+Pre-clinical+Evidence&doi=10.1038%2Fsj.bjc.6602676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence</span></div><div class="casAuthors">Morris, C. D.; Rose, A.; Curwen, J.; Hughes, A. M.; Wilson, D. J.; Webb, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2148-2152</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the endothelin A receptor (ETA) by endothelin-1 (ET-1) mediates events that regulate mitogenesis, apoptosis, angiogenesis and metastasis in tumors.  Specific blockade of ETA may have anticancer effects, while retaining beneficial endothelin B receptor (ETB)-mediated effects such as apoptosis and clearance of ET-1.  ZD4054 is an orally active, specific ETA antagonist in clin. development.  In receptor-binding studies, ZD4054 specifically bound to ETA with high affinity; no binding was detected at ETB.  In a randomized placebo-controlled trial in eight healthy volunteers, a single oral dose of ZD4054 reduced forearm vasoconstriction in response to brachial artery infusion of ET-1, thus providing clin. evidence of ETA blockade.  ETB blockade was assessed in an ascending, single-dose, placebo-controlled trial in 28 volunteers.  For all doses of ZD4054, mean plasma ET-1 concns. measured at 4 and 24 h were within the placebo ref. range (a rise in ET-1 would indicate ETB blockade) and there was no evidence of dose-related changes.  These data confirm the specificity of ZD4054 for ETA, with no activity at ETB in a clin. or preclin. setting.  As a result of this specificity, ZD4054 has the potential to block multiple ETA-induced pathol. processes, while allowing beneficial ETB-mediated processes to continue, which may, in turn, lead to an effective cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ4WG1oODdkrVg90H21EOLACvtfcHk0lhH2RVv_qd_gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVygur0%253D&md5=1855e8ee995ac28e9a737d13bcfb1613</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6602676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6602676%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DC.%2BD.%26aulast%3DRose%26aufirst%3DA.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DHughes%26aufirst%3DA.%2BM.%26aulast%3DWilson%26aufirst%3DD.%2BJ.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26atitle%3DSpecific%2520Inhibition%2520of%2520the%2520Endothelin%2520A%2520Receptor%2520with%2520ZD4054%253A%2520Clinical%2520and%2520Pre-clinical%2520Evidence%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26spage%3D2148%26epage%3D2152%26doi%3D10.1038%2Fsj.bjc.6602676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Price, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, L. S.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension: Rationale and Place in Therapy</span> <span class="citation_source-journal">Am. J. Cardiovasc. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">â</span> <span class="NLM_lpage">185</span><span class="refDoi">Â DOI: 10.2165/00129784-200808030-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2165%2F00129784-200808030-00004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=171-185&author=L.+C.+Priceauthor=L.+S.+Howard&title=Endothelin+Receptor+Antagonists+for+Pulmonary+Arterial+Hypertension%3A+Rationale+and+Place+in+Therapy&doi=10.2165%2F00129784-200808030-00004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2165%2F00129784-200808030-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00129784-200808030-00004%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DL.%2BC.%26aulast%3DHoward%26aufirst%3DL.%2BS.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%2520for%2520Pulmonary%2520Arterial%2520Hypertension%253A%2520Rationale%2520and%2520Place%2520in%2520Therapy%26jtitle%3DAm.%2520J.%2520Cardiovasc.%2520Drugs%26date%3D2008%26volume%3D8%26spage%3D171%26epage%3D185%26doi%3D10.2165%2F00129784-200808030-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Bourgeois, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebourcet, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mondon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mignot, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duc-Goiran, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FerrÃ©, F.</span><span> </span><span class="NLM_article-title">Endothelin-1 and ETA Receptor Expression in Vascular Smooth Muscle Cells from Human Placenta: A New ETA Receptor Messenger Ribonucleic Acid Is Generated by Alternative Splicing of Exon 3</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">3116</span><span class="NLM_x">â</span> <span class="NLM_lpage">3123</span><span class="refDoi">Â DOI: 10.1210/jcem.82.9.4209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1210%2Fjcem.82.9.4209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=9284755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK2sXlvFemtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1997&pages=3116-3123&author=C.+Bourgeoisauthor=B.+Robertauthor=R.+Rebourcetauthor=F.+Mondonauthor=T.+M.+Mignotauthor=P.+Duc-Goiranauthor=F.+Ferr%C3%A9&title=Endothelin-1+and+ETA+Receptor+Expression+in+Vascular+Smooth+Muscle+Cells+from+Human+Placenta%3A+A+New+ETA+Receptor+Messenger+Ribonucleic+Acid+Is+Generated+by+Alternative+Splicing+of+Exon+3&doi=10.1210%2Fjcem.82.9.4209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1 and ETA receptor expression in vascular smooth muscle cells from human placenta: a new ETA receptor messenger ribonucleic acid is generated by alternative splicing of exon 3</span></div><div class="casAuthors">Bourgeois, Christelle; Robert, Brigitte; Rebourcet, Regis; Mondon, Francoise; Mignot, Therese-Marie; Duc-Goiran, Paulette; Ferre, Francoise</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3116-3123</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Endothelin-1 (ET-1) is a potent vasoactive peptide in stem villi vessels, which are considered to be the major sites of placental vascular resistance.  To investigate the influence of pregnancy-specific hormonal environment on ET and ET receptor (ET-R) expression, we first developed and characterized a culture of vascular smooth muscle cells from stem villi vessels.  Secondly, we investigated whether the muscular layer of stem villi vessels could be a site of the ET expression described in the placenta, and we examd. this expression in placental vascular smooth muscle cells (PVSMCs).  Prepro-ET-1 and prepro-ET-3 mRNA were identified in stem villi vessels, whereas only prepro-ET-1 mRNA was obsd. in PVSMCs.  Third, with the goal of using PVSMCs as ET target cells, we characterized the ET-R expressed by these cells in comparison with the muscular layer of stem villi vessels.  Whereas both ETA-R and ETB-R are present in stem villi vessels, we found that PVSMCs express exclusively ETA-R.  In addn. to the previously reported ETA-R spliced transcripts, we described a new ETA-R transcripts, ETA-RÎ3, generated by exclusion of exon 3 in stem villi vessels and PVSMCs.  Alternative splicing mechanisms of ETA-R mRNA could constitute a control of the abundance of active ETA-R in terms of contractility.  PVSMCs will be a useful model to study the environmental stimuli involved in the regulation of ET and ET-R expression in the muscular layer of feto-placental vasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcw1O2OXAL07Vg90H21EOLACvtfcHk0lhH2RVv_qd_gA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvFemtbk%253D&md5=2ab073fc2de80e881afd4fb4ba38d337</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1210%2Fjcem.82.9.4209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.82.9.4209%26sid%3Dliteratum%253Aachs%26aulast%3DBourgeois%26aufirst%3DC.%26aulast%3DRobert%26aufirst%3DB.%26aulast%3DRebourcet%26aufirst%3DR.%26aulast%3DMondon%26aufirst%3DF.%26aulast%3DMignot%26aufirst%3DT.%2BM.%26aulast%3DDuc-Goiran%26aufirst%3DP.%26aulast%3DFerr%25C3%25A9%26aufirst%3DF.%26atitle%3DEndothelin-1%2520and%2520ETA%2520Receptor%2520Expression%2520in%2520Vascular%2520Smooth%2520Muscle%2520Cells%2520from%2520Human%2520Placenta%253A%2520A%2520New%2520ETA%2520Receptor%2520Messenger%2520Ribonucleic%2520Acid%2520Is%2520Generated%2520by%2520Alternative%2520Splicing%2520of%2520Exon%25203%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1997%26volume%3D82%26spage%3D3116%26epage%3D3123%26doi%3D10.1210%2Fjcem.82.9.4209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Elshourbagy, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamou, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagnon, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambi, P.</span><span> </span><span class="NLM_article-title">Molecular Characterization of a Novel Human Endothelin Receptor Splice Variant</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">25300</span><span class="NLM_x">â</span> <span class="NLM_lpage">25307</span><span class="refDoi">Â DOI: 10.1074/jbc.271.41.25300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1074%2Fjbc.271.41.25300" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=25300-25307&author=N.+A.+Elshourbagyauthor=J.+E.+Adamouauthor=A.+W.+Gagnonauthor=H.+L.+Wuauthor=M.+Pullenauthor=P.+Nambi&title=Molecular+Characterization+of+a+Novel+Human+Endothelin+Receptor+Splice+Variant&doi=10.1074%2Fjbc.271.41.25300"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.41.25300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.41.25300%26sid%3Dliteratum%253Aachs%26aulast%3DElshourbagy%26aufirst%3DN.%2BA.%26aulast%3DAdamou%26aufirst%3DJ.%2BE.%26aulast%3DGagnon%26aufirst%3DA.%2BW.%26aulast%3DWu%26aufirst%3DH.%2BL.%26aulast%3DPullen%26aufirst%3DM.%26aulast%3DNambi%26aufirst%3DP.%26atitle%3DMolecular%2520Characterization%2520of%2520a%2520Novel%2520Human%2520Endothelin%2520Receptor%2520Splice%2520Variant%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D25300%26epage%3D25307%26doi%3D10.1074%2Fjbc.271.41.25300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Imamura, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arimoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiyoshi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, T.</span><span> </span><span class="NLM_article-title">W276 Mutation in the Endothelin Receptor Subtype B Impairs G<sub>q</sub> Coupling but Not G<sub>i</sub> or G<sub>o</sub> Coupling</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">686</span><span class="NLM_x">â</span> <span class="NLM_lpage">692</span><span class="refDoi">Â DOI: 10.1021/bi991981z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi991981z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=686-692&author=F.+Imamuraauthor=I.+Arimotoauthor=Y.+Fujiyoshiauthor=T.+Doi&title=W276+Mutation+in+the+Endothelin+Receptor+Subtype+B+Impairs+Gq+Coupling+but+Not+Gi+or+Go+Coupling&doi=10.1021%2Fbi991981z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fbi991981z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi991981z%26sid%3Dliteratum%253Aachs%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DArimoto%26aufirst%3DI.%26aulast%3DFujiyoshi%26aufirst%3DY.%26aulast%3DDoi%26aufirst%3DT.%26atitle%3DW276%2520Mutation%2520in%2520the%2520Endothelin%2520Receptor%2520Subtype%2520B%2520Impairs%2520Gq%2520Coupling%2520but%2520Not%2520Gi%2520or%2520Go%2520Coupling%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D686%26epage%3D692%26doi%3D10.1021%2Fbi991981z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Lo, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, D. P.</span><span> </span><span class="NLM_article-title">Promoter Hypermethylation of the EDNRB Gene in Nasopharyngeal Carcinoma</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">â</span> <span class="NLM_lpage">655</span><span class="refDoi">Â DOI: 10.1002/ijc.10271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fijc.10271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=11920632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Wrurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2002&pages=651-655&author=K.+W.+Loauthor=Y.+S.+Tsangauthor=J.+Kwongauthor=K.+F.+Toauthor=P.+M.+Teoauthor=D.+P.+Huang&title=Promoter+Hypermethylation+of+the+EDNRB+Gene+in+Nasopharyngeal+Carcinoma&doi=10.1002%2Fijc.10271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma</span></div><div class="casAuthors">Lo, Kwok-Wai; Tsang, Yuen-Shan; Kwong, Joseph; To, Ka-Fai; Teo, Peter M. L.; Huang, Dolly P.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">651-655</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">To identify the epigenetic changes in nasopharyngeal carcinoma (NPC), we performed methylation-sensitive restriction fingerprinting (MSRF) anal. on NPC cell lines and xenografts.  A 190 bp sequence methylated in NPC tumors was isolated and showed high homol. to the 5' CpG island of the endothelin receptor B (EDNRB) gene.  Since the EDNRB gene is commonly inactivated in prostate and bladder cancers, it may be a candidate target gene involved in NPC tumorigenesis.  By bisulfite sequencing, we have confirmed that hypermethylation of the 5' CpG island of EDNRB occurred in both xenografts and all 4 cell lines but not in 2 normal nasopharyngeal outgrowths.  RT-PCR demonstrated that only original EDNRB transcripts, but not the splicing transcripts, were expressed in normal nasopharyngeal epithelial cells.  Loss of the original EDNRB expression was consistently found in 2 xenografts and 3 cell lines with dense methylation patterns.  Treatment of these 3 cell lines with 5'-aza-2'-deoxycytidine led to re-expression of the EDNRB transcript and demethylation of its promoter regions.  Our results demonstrate that silencing of EDNRB gene expression in NPC is assocd. with promoter hypermethylation.  Using methylation-specific PCR, we also detected methylation of the 5' CpG island of EDNRB in 19/21 (90.5%) primary tumors, while no methylation was found in all 6 normal nasopharyngeal epithelia.  The high frequencies of promoter hypermethylation suggest that repression of the EDNRB gene may play a role in the development of NPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr827IJhzPEGLVg90H21EOLACvtfcHk0ljbX0wOjG_ERA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Wrurw%253D&md5=d5a2fe49125f9acc745209c9d9413e72</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fijc.10271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10271%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DK.%2BW.%26aulast%3DTsang%26aufirst%3DY.%2BS.%26aulast%3DKwong%26aufirst%3DJ.%26aulast%3DTo%26aufirst%3DK.%2BF.%26aulast%3DTeo%26aufirst%3DP.%2BM.%26aulast%3DHuang%26aufirst%3DD.%2BP.%26atitle%3DPromoter%2520Hypermethylation%2520of%2520the%2520EDNRB%2520Gene%2520in%2520Nasopharyngeal%2520Carcinoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D98%26spage%3D651%26epage%3D655%26doi%3D10.1002%2Fijc.10271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Miyamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimasa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakao, K.</span><span> </span><span class="NLM_article-title">Alternative RNA Splicing of the Human Endothelin-A Receptor Generates Multiple Transcripts</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">â</span> <span class="NLM_lpage">801</span><span class="refDoi">Â DOI: 10.1042/bj3130795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1042%2Fbj3130795" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=1996&pages=795-801&author=Y.+Miyamotoauthor=T.+Yoshimasaauthor=H.+Araiauthor=K.+Takayaauthor=Y.+Ogawaauthor=H.+Itohauthor=K.+Nakao&title=Alternative+RNA+Splicing+of+the+Human+Endothelin-A+Receptor+Generates+Multiple+Transcripts&doi=10.1042%2Fbj3130795"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1042%2Fbj3130795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3130795%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DY.%26aulast%3DYoshimasa%26aufirst%3DT.%26aulast%3DArai%26aufirst%3DH.%26aulast%3DTakaya%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DH.%26aulast%3DNakao%26aufirst%3DK.%26atitle%3DAlternative%2520RNA%2520Splicing%2520of%2520the%2520Human%2520Endothelin-A%2520Receptor%2520Generates%2520Multiple%2520Transcripts%26jtitle%3DBiochem.%2520J.%26date%3D1996%26volume%3D313%26spage%3D795%26epage%3D801%26doi%3D10.1042%2Fbj3130795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Nambi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagnon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elshourbagy, N.</span><span> </span><span class="NLM_article-title">Characterization of a Novel Porcine Endothelin-B Receptor Splice Variant</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">292</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">â</span> <span class="NLM_lpage">253</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10604954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslGlug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2000&pages=247-253&author=P.+Nambiauthor=H.+L.+Wuauthor=D.+Yeauthor=A.+Gagnonauthor=N.+Elshourbagy&title=Characterization+of+a+Novel+Porcine+Endothelin-B+Receptor+Splice+Variant"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a novel porcine endothelinB receptor splice variant</span></div><div class="casAuthors">Nambi, Ponnal; Wu, Hsiao-Ling; Ye, Diana; Gagnon, Alison; Elshourbagy, Nabil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">247-253</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Screening of porcine cerebellum cDNA library with porcine endothelinB (ETB) receptor cDNA revealed a novel ETB receptor cDNA that is distinctly different from the wild-type ETB receptor in length and the amino acid sequence at the C-terminal end.  This sequence appears to represent alternate splicing of the carboxy terminal end of ETB receptor, resulting in a polypeptide of 429 amino acids in length, which is 14 amino acids shorter than the wild-type porcine ETB receptor.  Characterization of the wild-type and alternatively spliced ETB receptors expressed in COS cells revealed that both receptors displayed very similar binding [apparent dissocn. const. (Kd) and max. binding (Bmax) for 125I-ET-1 were 71 pM and 1.6 pmol/mg protein for wild-type and 81 pM and 1.2 pmol/mg protein for splice variant ETB receptors] as well as functional properties.  These data suggest that the differences in the amino acids at the C-terminal end had no effect on binding or functional coupling of these alternately spliced ETB receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrb1FU3PjVsLVg90H21EOLACvtfcHk0ljbX0wOjG_ERA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslGlug%253D%253D&md5=929cbd10c76cd58ba06d72f741f17b5e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNambi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DH.%2BL.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DGagnon%26aufirst%3DA.%26aulast%3DElshourbagy%26aufirst%3DN.%26atitle%3DCharacterization%2520of%2520a%2520Novel%2520Porcine%2520Endothelin-B%2520Receptor%2520Splice%2520Variant%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D292%26spage%3D247%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Pao, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzvolgyi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">The Endothelin Receptor B (EDNRB) Promoter Displays Heterogeneous, Site Specific Methylation Patterns in Normal and Tumor Cells</span> <span class="citation_source-journal">Hum. Mol. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">â</span> <span class="NLM_lpage">910</span><span class="refDoi">Â DOI: 10.1093/hmg/10.9.903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1093%2Fhmg%2F10.9.903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=11309363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVels7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2001&pages=903-910&author=M.+M.+Paoauthor=M.+Tsutsumiauthor=G.+Liangauthor=E.+Uzvolgyiauthor=F.+A.+Gonzalesauthor=P.+A.+Jones&title=The+Endothelin+Receptor+B+%28EDNRB%29+Promoter+Displays+Heterogeneous%2C+Site+Specific+Methylation+Patterns+in+Normal+and+Tumor+Cells&doi=10.1093%2Fhmg%2F10.9.903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells</span></div><div class="casAuthors">Pao, Martha M.; Tsutsumi, Masakazu; Liang, Gangning; Uzvolgyi, Eva; Gonzales, Felicidad A.; Jones, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">903-910</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The 5' region for the endothelin receptor B (EDNRB) gene is a complex CpG island giving rise to four individual transcripts initiating within the island.  Here, for the first time, we analyze the relationship between methylation and gene expression in a CpG island located in the 5' region of a gene with multiple transcription start sites.  The CpG island was unmethylated in normal prostate and bladder tissue, whereas it became methylated in apparently normal colonic epithelium.  Tumors derived from these tissues were frequently hypermethylated relative to the resp. normal tissues.  Anal. of 11 individual CpG sites located throughout the CpG island showed that specific sites with high methylation levels in several tumors were also methylated in normal tissues, suggesting that they might serve as foci for further de novo methylation.  This region also had high levels of methylation in several cancer cell lines, and we found that a low methylation level in a small region within the 5' region correlated with expression of the 5'-most transcript.  Interestingly, almost complete methylation 200-1000 bp downstream of the transcriptional start site did not block expression of this transcript.  Finally, we show that treatment with 5-aza-2'-deoxycytidine can induce transcriptional activation of the four EDNRB transcripts.  Our results show the existence of differential, tissue-dependent methylation at the EDNRB5' region, suggest the existence of a spreading mechanism for de novo methylation, starting from methylation hotspots, and show that hypermethylation immediately 3' to a transcriptional start site does not prevent initiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp4YIFTQVMK7Vg90H21EOLACvtfcHk0lhUcKCHnn0hGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVels7w%253D&md5=a64ad13d2665939666437b73a6b31ba3</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2F10.9.903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252F10.9.903%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DM.%2BM.%26aulast%3DTsutsumi%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DUzvolgyi%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DF.%2BA.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DThe%2520Endothelin%2520Receptor%2520B%2520%2528EDNRB%2529%2520Promoter%2520Displays%2520Heterogeneous%252C%2520Site%2520Specific%2520Methylation%2520Patterns%2520in%2520Normal%2520and%2520Tumor%2520Cells%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2001%26volume%3D10%26spage%3D903%26epage%3D910%26doi%3D10.1093%2Fhmg%2F10.9.903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Shyamala, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moulthrop, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton-Thomas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tekamp-Olson, P.</span><span> </span><span class="NLM_article-title">Two Distinct Human Endothelin B Receptors Generated by Alternative Splicing Form a Single Gene</span> <span class="citation_source-journal">Cell. Mol. Biol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">â</span> <span class="NLM_lpage">296</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=7866430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK2MXit1Okuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1994&pages=285-296&author=V.+Shyamalaauthor=T.+H.+Moulthropauthor=J.+Stratton-Thomasauthor=P.+Tekamp-Olson&title=Two+Distinct+Human+Endothelin+B+Receptors+Generated+by+Alternative+Splicing+Form+a+Single+Gene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Two distinct human endothelin B receptors generated by alternative splicing from a single gene</span></div><div class="casAuthors">Shyamala, Venkatakrishna; Moulthrop, Thomas H. M.; Stratton-Thomas, Jennifer; Tekamp-Olson, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Biology Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">285-96</span>CODEN:
                <span class="NLM_cas:coden">CMBREW</span>;
        ISSN:<span class="NLM_cas:issn">0968-8773</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A novel variant of endothelin B receptor (ETB) has been found in human brain, placenta, lung, and heart by reverse transcriptase polymerase chain reaction.  This variant ETB1 has an addnl. 30 nucleotide sequence with splice sites at both ends.  This results in a 10-amino acid increase in the length of the second cytoplasmic domain of ETB.  Polymerase chain reaction on genomic DNA indicates that this sequence is part of the 134 bp intron which separates the 2nd and 3rd exons and is contiguous with the 3rd exon of the ETB gene.  Southern blot anal. of chromosomal DNA and genomic PCR results indicate that ETB1 arises by alternative RNA splicing of the single copy ETB gene.  The insert sequence in ETB1 gene is absent in bovine, rat, and porcine DNA, and is unique to human DNA.  Both ETB and ETB1 have been expressed in heterologous systems to examine their ligand binding and functional properties.  Reverse transcriptase polymerase chain reaction of RNA from ETB1 expressing cells indicate that the addnl. sequence is stably expressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom4C1cNuQgt7Vg90H21EOLACvtfcHk0lhUcKCHnn0hGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXit1Okuro%253D&md5=5c0ed0a5574e30a73dc7c0c0cacbcbc3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShyamala%26aufirst%3DV.%26aulast%3DMoulthrop%26aufirst%3DT.%2BH.%26aulast%3DStratton-Thomas%26aufirst%3DJ.%26aulast%3DTekamp-Olson%26aufirst%3DP.%26atitle%3DTwo%2520Distinct%2520Human%2520Endothelin%2520B%2520Receptors%2520Generated%2520by%2520Alternative%2520Splicing%2520Form%2520a%2520Single%2520Gene%26jtitle%3DCell.%2520Mol.%2520Biol.%2520Res.%26date%3D1994%26volume%3D40%26spage%3D285%26epage%3D296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Tsutsumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">Novel Endothelin B Receptor Transcripts with the Potential of Generating a New Receptor</span> <span class="citation_source-journal">Gene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">â</span> <span class="NLM_lpage">49</span><span class="refDoi">Â DOI: 10.1016/S0378-1119(99)00014-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0378-1119%2899%2900014-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=1999&pages=43-49&author=M.+Tsutsumiauthor=G.+Liangauthor=P.+A.+Jones&title=Novel+Endothelin+B+Receptor+Transcripts+with+the+Potential+of+Generating+a+New+Receptor&doi=10.1016%2FS0378-1119%2899%2900014-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0378-1119%2899%2900014-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-1119%252899%252900014-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsutsumi%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Endothelin%2520B%2520Receptor%2520Transcripts%2520with%2520the%2520Potential%2520of%2520Generating%2520a%2520New%2520Receptor%26jtitle%3DGene%26date%3D1999%26volume%3D228%26spage%3D43%26epage%3D49%26doi%3D10.1016%2FS0378-1119%2899%2900014-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Zhang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burchill, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaski, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, N. D.</span><span> </span><span class="NLM_article-title">Truncated Human Endothelin Receptor A Produced by Alternative Splicing and Its Expression in Melanoma</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">1141</span><span class="NLM_x">â</span> <span class="NLM_lpage">1146</span><span class="refDoi">Â DOI: 10.1038/bjc.1998.643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fbjc.1998.643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=9820169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK1cXntlSqs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1998&pages=1141-1146&author=Y.+F.+Zhangauthor=S.+Jefferyauthor=S.+A.+Burchillauthor=P.+A.+Berryauthor=J.+C.+Kaskiauthor=N.+D.+Carter&title=Truncated+Human+Endothelin+Receptor+A+Produced+by+Alternative+Splicing+and+Its+Expression+in+Melanoma&doi=10.1038%2Fbjc.1998.643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Truncated human endothelin receptor A produced by alternative splicing and its expression in melanoma</span></div><div class="casAuthors">Zhang, Y. F.; Jeffery, S.; Burchill, S. A.; Berry, P. A.; Kaski, J. C.; Carter, N. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1141-1146</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">In this study, reverse transcriptase polymerase chain reaction was used to amplify human endothelin receptor A (ETA) and ETB receptor mRNA.  A truncated ETA receptor transcript with exons 3 and 4 skipped was found.  The skipping of these two exons results in 109 amino acids being deleted from the receptor.  The truncated receptor was expressed in all tissues and cells examd., but the level of expression varied.  In melanoma cell lines and melanoma tissues, the truncated receptor gene was the major species, whereas the wild-type ETA was predominant in other tissues.  A 1.9-kb ETA transcript was identified in melanoma cell lines by Northern blot, which was much smaller than the transcript in heart and in other tissues reported previously (4.3 kb).  The cDNA coding regions of the truncated and wild-type ETA receptors were stably transfected into Chinese hamster ovary (CHO) cells.  The truncated ETA receptor-transfected CHO cells did not show binding affinity to endothelin 1 (ET-1) or endothelin 3 (ET-3).  The function and biol. significance of this truncated ETA receptor is not clear, but it may have regulatory roles for cell responses to ETs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooR2Ds53UeILVg90H21EOLACvtfcHk0lhodRtFazzFFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntlSqs7o%253D&md5=8a1602c1f24fb37497ffcc72a3a23500</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1998.643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1998.643%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BF.%26aulast%3DJeffery%26aufirst%3DS.%26aulast%3DBurchill%26aufirst%3DS.%2BA.%26aulast%3DBerry%26aufirst%3DP.%2BA.%26aulast%3DKaski%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DN.%2BD.%26atitle%3DTruncated%2520Human%2520Endothelin%2520Receptor%2520A%2520Produced%2520by%2520Alternative%2520Splicing%2520and%2520Its%2520Expression%2520in%2520Melanoma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1998%26volume%3D78%26spage%3D1141%26epage%3D1146%26doi%3D10.1038%2Fbjc.1998.643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Berger, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernasconi, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Targeting the Endothelin Axis in Human Melanoma: Combination of Endothelin Receptor Antagonism and Alkylating Agents</span> <span class="citation_source-journal">Exp. Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">â</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD28Xlt1ertb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2006&pages=1111-1119&author=Y.+Bergerauthor=C.+C.+Bernasconiauthor=L.+Juillerat-Jeanneret&title=Targeting+the+Endothelin+Axis+in+Human+Melanoma%3A+Combination+of+Endothelin+Receptor+Antagonism+and+Alkylating+Agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents</span></div><div class="casAuthors">Berger, Yann; Bernasconi, Catherine Chapuis; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (Maywood, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1111-1119</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3702</span>.
    
            (<span class="NLM_cas:orgname">Society for Experimental Biology and Medicine</span>)
        </div><div class="casAbstract">Endothelin (ET)-1 is an autocrine/paracrine growth factor or an antiapoptotic factor in human cancers, and blockade of ET-1 receptors can sensitize human tumor cells to apoptosis.  The role of the ET-1 axis in the proliferation and/or apoptosis of melanoma cells and in their response to the alkylating agent, dacarbazine (DTIC), used in clin. treatment of human melanoma were investigated in five human melanoma cell lines obtained form surgical resection specimens.  Melanoma cells expressed the mRNAs for the components of the ET-1 axis.  ET-1 binding was mediated by ETB but was inhomogeneous among melanoma cells.  Exogenous ET-1 did not induce human melanoma cell proliferation.  Bosentan, a dual ETA/B-receptor antagonist, decreased melanoma cell viability and DNA synthesis and induced melanoma cell apoptosis in defined human melanoma cells.  Bosentan potentiated Fas ligand-induced apoptosis only in one melanoma cell line.  Variants of ETB were detd. using reverse transcriptase (RT) polymerase chain reaction (PCR) and primers spanning the whole sequence of the ETB gene.  ETB variants were demonstrated only in one of the five cell lines, corresponding to the absence of ET-1 binding by these cells.  Bosentan did not inhibit the effects of alkylating agents, and the effects of bosentan and alkylating agents were additive in melanoma cells.  In conclusion, exogenous ET-1 is not a growth factor for human melanoma cells, but blockade of ET receptors decreases proliferation, induces apoptosis, and potentiates the effects of anticancer agents in defined melanoma cells, suggesting that combination therapy of ET-receptor antagonists with alkylating agents may improve their efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB67LiHJL8srVg90H21EOLACvtfcHk0lhodRtFazzFFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xlt1ertb8%253D&md5=5a26d6190d1a598df50aacf949607419</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DY.%26aulast%3DBernasconi%26aufirst%3DC.%2BC.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DTargeting%2520the%2520Endothelin%2520Axis%2520in%2520Human%2520Melanoma%253A%2520Combination%2520of%2520Endothelin%2520Receptor%2520Antagonism%2520and%2520Alkylating%2520Agents%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2006%26volume%3D231%26spage%3D1111%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Roh, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manola, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidransky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forastiere, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, W. M.</span><span> </span><span class="NLM_article-title">Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2528</span><span class="NLM_x">â</span> <span class="NLM_lpage">2540</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-12-3047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1078-0432.CCR-12-3047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23444219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWqs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2528-2540&author=J.+L.+Rohauthor=X.+V.+Wangauthor=J.+Manolaauthor=D.+Sidranskyauthor=A.+A.+Forastiereauthor=W.+M.+Koch&title=Clinical+Correlates+of+Promoter+Hypermethylation+of+Four+Target+Genes+in+Head+and+Neck+Cancer%3A+A+Cooperative+Group+Correlative+Study&doi=10.1158%2F1078-0432.CCR-12-3047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study</span></div><div class="casAuthors">Roh, Jong-Lyel; Wang, Xin Victoria; Manola, Judith; Sidransky, David; Forastiere, Arlene A.; Koch, Wayne M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2528-2540</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Promoter hypermethylation is a well-documented mechanism for tumor-specific alteration of suppressor gene activity in human malignancy including head and neck cancer (HNC).  The abrogation of specific suppressor gene activity may influence tumor behavior and clin. outcome.  In this study we examd. methylation of DCC, KIF1A, EDNRB, and p16INK4a in a large cohort of HNC patients from Eastern Cooperative Group (ECOG) 4393/Radiation Therapy Oncol. Group (RTOG) 9614 to identify clin. correlates of methylation of these genes.  Exptl. Design: Methylation was assessed by quant. methylation-specific PCR in DNA from tumor specimens and was considered as a continuous and a binary variable.  Clin. data including demographics, stage, risk factor exposure, treatment, and outcome were collected by ECOG and RTOG.  Methylation status was also correlated with mutation of TP53 (previously reported) and human papilloma virus status.  Results: Methylation results were available for 368 cases, 353 of which also have p53 mutation status.  At least one methylation event was present in all tumors.  In multivariate anal. of the entire cohort, methylation of p16 was assocd. with decreased survival (HR = 1.008; P = 0.045).  However, in tumors with disruptive TP53 mutation (poor prognostic group), the addnl. presence of methylation of p16 was protective (P = 0.019 considering p16 methylation as a continuous variable).  Conclusion: Methylation of tumor-related genes contributes to the biol. behavior of HNC and influences overall survival in conjunction with other known prognostic mol. events.  Clin Cancer Res; 19(9); 2528-40. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppMqVZ4qLqirVg90H21EOLACvtfcHk0lhodRtFazzFFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWqs7o%253D&md5=850214505b612d101275c72f4fb78f95</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3047%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BV.%26aulast%3DManola%26aufirst%3DJ.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DForastiere%26aufirst%3DA.%2BA.%26aulast%3DKoch%26aufirst%3DW.%2BM.%26atitle%3DClinical%2520Correlates%2520of%2520Promoter%2520Hypermethylation%2520of%2520Four%2520Target%2520Genes%2520in%2520Head%2520and%2520Neck%2520Cancer%253A%2520A%2520Cooperative%2520Group%2520Correlative%2520Study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2528%26epage%3D2540%26doi%3D10.1158%2F1078-0432.CCR-12-3047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Tao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G.</span><span> </span><span class="NLM_article-title">Quantitative Analysis of Promoter Methylation of the EDNRB Gene in Gastric Cancer</span> <span class="citation_source-journal">Med. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">â</span> <span class="NLM_lpage">112</span><span class="refDoi">Â DOI: 10.1007/s12032-010-9805-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs12032-010-9805-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21264540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1ejurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=107-112&author=K.+Taoauthor=C.+Wuauthor=K.+Wuauthor=W.+Liauthor=G.+Hanauthor=X.+Shuaiauthor=G.+Wang&title=Quantitative+Analysis+of+Promoter+Methylation+of+the+EDNRB+Gene+in+Gastric+Cancer&doi=10.1007%2Fs12032-010-9805-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of promoter methylation of the EDNRB gene in gastric cancer</span></div><div class="casAuthors">Tao, Kaixiong; Wu, Chuanqing; Wu, Ke; Li, Wei; Han, Gaoxiong; Shuai, Xiaoming; Wang, Guobin</div><div class="citationInfo"><span class="NLM_cas:title">Medical Oncology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-112</span>CODEN:
                <span class="NLM_cas:coden">MONCEZ</span>;
        ISSN:<span class="NLM_cas:issn">1357-0560</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Hypermethylation has been shown in the promoter region of the endothelin receptor B (EDNRB) gene in several human tumors.  However, its role in gastric cancer formation is still unclear.  In this study, the methylation status of the EDNRB gene in paired gastric cancer tissues and adjacent normal tissues from 96 patients was detected quant. using pyrosequencing.  The results showed the methylation of promoter of EDNRB gene in gastric cancer (50.42 Â± 9.03%) was significantly higher than in adjacent normal tissues (6.47 Â± 2.98%) (P < 0.01).  Among 96 tumor tissues, promoter hypermethylation of the EDNRB gene was correlated with tumor infiltration (T1: 47.4 Â± 7.31% T2:48.2 Â± 9.17% T3:52.9 Â± 6.48% T4:53.2 Â± 10.45%), lymph node metastasis (N0:45.4 Â± 6.99% N1:49.0 Â± 9.10% N2:52.0 Â± 8.40% N3:53.7 Â± 9.92%), and distant metastasis (M0:48.9 Â± 6.99% M1:53.9 Â± 11.98%) (P < 0.05), but it was not assocd. with other clinicopathol. characteristics.  In addn., the treatment of the human gastric cancer cell line, SGC-7901, with demethylation agent can restore the expression of EDNRB.  Our results suggest that promoter hypermethylation of EDNRB gene is highly prevalent in gastric cancer, which may play a role in the pathogenesis of gastric cancer.  Furthermore, hypermethylation of EDNRB gene was remarkably related to infiltration and metastasis of gastric cancer and may attribute to the tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpViRjU67w4SbVg90H21EOLACvtfcHk0lhodRtFazzFFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1ejurk%253D&md5=52a391fba71c655de3b2a662ceace2b0</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs12032-010-9805-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-010-9805-8%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DG.%26aulast%3DShuai%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DQuantitative%2520Analysis%2520of%2520Promoter%2520Methylation%2520of%2520the%2520EDNRB%2520Gene%2520in%2520Gastric%2520Cancer%26jtitle%3DMed.%2520Oncol.%26date%3D2012%26volume%3D29%26spage%3D107%26epage%3D112%26doi%3D10.1007%2Fs12032-010-9805-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langleben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudiz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapson, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwicke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frumkin, L. R.</span><span> </span><span class="NLM_article-title">STRIDE-1 Study Group. Sitaxsentan Therapy for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">447</span><span class="refDoi">Â DOI: 10.1164/rccm.200307-957OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1164%2Frccm.200307-957OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=14630619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FmsV2gtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2004&pages=441-447&author=R.+J.+Barstauthor=D.+Langlebenauthor=A.+Frostauthor=E.+M.+Hornauthor=R.+Oudizauthor=S.+Shapiroauthor=V.+McLaughlinauthor=N.+Hillauthor=V.+F.+Tapsonauthor=I.+M.+Robbinsauthor=D.+Zwickeauthor=B.+Duncanauthor=R.+A.+Dixonauthor=L.+R.+Frumkin&title=STRIDE-1+Study+Group.+Sitaxsentan+Therapy+for+Pulmonary+Arterial+Hypertension&doi=10.1164%2Frccm.200307-957OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Sitaxsentan therapy for pulmonary arterial hypertension</span></div><div class="casAuthors">Barst Robyn J; Langleben David; Frost Adaani; Horn Evelyn M; Oudiz Ronald; Shapiro Shelley; McLaughlin Vallerie; Hill Nicholas; Tapson Victor F; Robbins Ivan M; Zwicke Diane; Duncan Benjamin; Dixon Richard A F; Frumkin Lyn R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-7</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Sitaxsentan may benefit patients with pulmonary arterial hypertension by blocking the vasoconstrictor effects of endothelin-A while maintaining the vasodilator/clearance functions of endothelin-B receptors.  Patients with pulmonary arterial hypertension that was idiopathic, related to connective tissue disease or congenital heart disease, were randomized to receive placebo (n = 60), sitaxsentan 100 mg (n = 55), or sitaxsentan 300 mg (n = 63) orally once daily for 12 weeks.  The primary endpoint was change in peak VO(2) at Week 12.  Secondary endpoints included 6-minute walk, New York Heart Association class, VO(2) at anaerobic threshold, VE per carbon dioxide production at anaerobic threshold, hemodynamics, quality of life, and time to clinical worsening.  Although the 300-mg group increased peak VO(2) compared with placebo (+3.1%, p < 0.01), none of the other endpoints derived from cardiopulmonary exercise testing were met.  However, both the 100-mg dose and the 300-mg dose, compared with placebo, increased 6-minute walk distance (100 mg: +35 m, p < 0.01; 300 mg: +33 m, p < 0.01); functional class, cardiac index, and pulmonary vascular resistance also improved (p < 0.02 for each parameter at both doses).  The incidence of elevated aminotransferase values (> three times normal) was 3% for the placebo group, 0% for the 100-mg group, and 10% for the 300-mg group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAfmQEGkmCwYUSrryheKE6fW6udTcc2eb0d7Ml0jGo3Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FmsV2gtg%253D%253D&md5=e05785158b1043c250aa6643734bbbff</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1164%2Frccm.200307-957OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200307-957OC%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DHorn%26aufirst%3DE.%2BM.%26aulast%3DOudiz%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DMcLaughlin%26aufirst%3DV.%26aulast%3DHill%26aufirst%3DN.%26aulast%3DTapson%26aufirst%3DV.%2BF.%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DZwicke%26aufirst%3DD.%26aulast%3DDuncan%26aufirst%3DB.%26aulast%3DDixon%26aufirst%3DR.%2BA.%26aulast%3DFrumkin%26aufirst%3DL.%2BR.%26atitle%3DSTRIDE-1%2520Study%2520Group.%2520Sitaxsentan%2520Therapy%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2004%26volume%3D169%26spage%3D441%26epage%3D447%26doi%3D10.1164%2Frccm.200307-957OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalina, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶ffler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¼ller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidhart, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramuz, H.</span><span> </span><span class="NLM_article-title">Pharmacological Characteristics of Bosentan, a New Potent Orally Active Nonpeptide Endothelin Receptor Antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">â</span> <span class="NLM_lpage">235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=8035319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK2cXkvF2nsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1994&pages=228-235&author=M.+Clozelauthor=V.+Breuauthor=G.+A.+Grayauthor=B.+Kalinaauthor=B.+M.+L%C3%B6fflerauthor=K.+Burriauthor=J.+M.+Cassalauthor=G.+Hirthauthor=M.+M%C3%BCllerauthor=W.+Neidhartauthor=H.+Ramuz&title=Pharmacological+Characteristics+of+Bosentan%2C+a+New+Potent+Orally+Active+Nonpeptide+Endothelin+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist</span></div><div class="casAuthors">Clozel, Martine; Breu, Volker; Gray, Gillian A.; Kalina, Barbara; Loeffler, Bernd-Michael; Burri, Kaspar; Cassal, Jean-Marie; Hirth, Georges; Mueller, Marcel; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-35</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The authors describe here the pharmacol. properties of bosentan, a new nonpeptide mixed antagonist of endothelin (ET) receptors, obtained by structural optimization of the less potent Ro 46-2005 (4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide).  Bosentan (Ro 47-0203, 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,2'-bipyrimidin-4-yl]-benzenesulfonamide) competitively antagonized the specific binding of [125I]-labeled ET-1 on human smooth muscle cells (ETA receptors) with a Ki of 4.7 nM and on human placenta (ETB receptors) with a Ki of 95 nM.  It also inhibited the binding of selective ETB ligands on porcine trachea.  Contractions induced by ET-1 in isolated rat aorta (ETA) and by the selective ETB agonist sarafotoxin S6C in rat trachea were competitively inhibited by bosentan (pA2 = 7.2 and 6.0, resp.), as was the endothelium-dependent relaxation to sarafotoxin S6C in rabbit superior mesenteric artery (pA2 = 6.7).  The binding of 40 other peptides, prostaglandins, ions and neurotransmitters was not significantly affected by bosentan, which shows its specificity for ET receptors.  In vivo, bosentan inhibited the pressor response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity.  It also inhibited the depressor and pressor effect of ET-1 and sarafotoxin S6C.  Thus, bosentan is the most potent orally active antagonist of ET receptors described so far.  Its pharmacol. profile makes bosentan a potentially useful drug in the management of clin. disorders assocd. with vasoconstriction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopDyWdkz1crbVg90H21EOLACvtfcHk0ljz2eZ4E_lurg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvF2nsb4%253D&md5=a257c4e2f71ed82feea0a3742609f428</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DBreu%26aufirst%3DV.%26aulast%3DGray%26aufirst%3DG.%2BA.%26aulast%3DKalina%26aufirst%3DB.%26aulast%3DL%25C3%25B6ffler%26aufirst%3DB.%2BM.%26aulast%3DBurri%26aufirst%3DK.%26aulast%3DCassal%26aufirst%3DJ.%2BM.%26aulast%3DHirth%26aufirst%3DG.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DRamuz%26aufirst%3DH.%26atitle%3DPharmacological%2520Characteristics%2520of%2520Bosentan%252C%2520a%2520New%2520Potent%2520Orally%2520Active%2520Nonpeptide%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1994%26volume%3D270%26spage%3D228%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galie, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keogh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulido, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leconte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landzberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span> </span><span class="NLM_article-title">Bosentan Therapy for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">â</span> <span class="NLM_lpage">903</span><span class="refDoi">Â DOI: 10.1056/NEJMoa012212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1056%2FNEJMoa012212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=11907289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1ekur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2002&pages=896-903&author=L.+J.+Rubinauthor=D.+B.+Badeschauthor=R.+J.+Barstauthor=N.+Galieauthor=C.+M.+Blackauthor=A.+Keoghauthor=T.+Pulidoauthor=A.+Frostauthor=S.+Rouxauthor=I.+Leconteauthor=M.+Landzbergauthor=G.+Simonneau&title=Bosentan+Therapy+for+Pulmonary+Arterial+Hypertension&doi=10.1056%2FNEJMoa012212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Bosentan therapy for pulmonary arterial hypertension</span></div><div class="casAuthors">Rubin, Lewis J.; Badesch, David B.; Barst, Robyn J.; Galie, Nazzareno; Black, Carol M.; Keogh, Anne; Pulido, Tomas; Frost, Adaani; Roux, Sebastien; Leconte, Isabelle; Landzberg, Michael; Simonneau, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">896-903</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen.  In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension.  The present trial investigated the effect of bosentan on exercise capacity in a larger no. of patients and compared two doses.  Methods: In this double-blind, placebo-controlled study, we randomly assigned 213 patients with pulmonary arterial hypertension (primary or assocd. with connective-tissue disease) to receive placebo or to receive 6.25 mg of bosentan twice daily for 4 wk followed by either of two doses of bosentan (125 or 250 mg twice daily) for a min. of 12 wk.  The primary end point was the degree of change in exercise capacity.  Secondary end points included the change in the Borg dyspnea index, the change in the World Health Organization (WHO) functional class, and the time to clin. worsening.  Results: At week 16, patients treated with bosentan had an improved six-minute walking distance; the mean difference between the placebo group and the combined bosentan groups was 44 m (95 percent confidence interval, 21 to 67; P<0.001).  Bosentan also improved the Borg dyspnea index and WHO functional class and increased the time to clin. worsening.  Conclusions: The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily.  Endothelin-receptor antagonism with oral bosentan is an effective approach to therapy for pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruF1yf9lFcM7Vg90H21EOLACvtfcHk0lisDbH2-BdgHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1ekur0%253D&md5=b729b9ccfe57829af31cefe1325f5c25</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa012212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa012212%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DBlack%26aufirst%3DC.%2BM.%26aulast%3DKeogh%26aufirst%3DA.%26aulast%3DPulido%26aufirst%3DT.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DRoux%26aufirst%3DS.%26aulast%3DLeconte%26aufirst%3DI.%26aulast%3DLandzberg%26aufirst%3DM.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DBosentan%2520Therapy%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D346%26spage%3D896%26epage%3D903%26doi%3D10.1056%2FNEJMoa012212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">GaliÃ©, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudiz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGoon, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keogh, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwicke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeije, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olschewski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">Ambrisentan Therapy for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">â</span> <span class="NLM_lpage">535</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2005.04.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.jacc.2005.04.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=16053970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVKnsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=529-535&author=N.+Gali%C3%A9author=D.+Badeschauthor=R.+Oudizauthor=G.+Simonneauauthor=M.+D.+McGoonauthor=A.+M.+Keoghauthor=A.+E.+Frostauthor=D.+Zwickeauthor=R.+Naeijeauthor=S.+Shapiroauthor=H.+Olschewskiauthor=L.+J.+Rubin&title=Ambrisentan+Therapy+for+Pulmonary+Arterial+Hypertension&doi=10.1016%2Fj.jacc.2005.04.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Ambrisentan therapy for pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, Nazzareno; Badesch, David; Oudiz, Ronald; Simonneau, Gerald; McGoon, Michael D.; Keogh, Anne M.; Frost, Adaani E.; Zwicke, Diane; Naeije, Robert; Shapiro, Shelley; Olschewski, Horst; Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">529-535</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial hypertension (PAH).  Pulmonary arterial hypertension is a life-threatening and progressive disease with limited treatment options.  Endothelin is a vasoconstrictor and smooth muscle cell mitogen that plays a crit. role in the pathogenesis and progression of PAH.  In this double-blind, dose-ranging study, 64 patients with idiopathic PAH or PAH assocd. with collagen vascular disease, anorexigen use, or human immunodeficiency virus infection were randomized to receive 1, 2.5, 5, or 10 mg of ambrisentan once daily for 12 wk followed by 12 wk of open-label ambrisentan.  The primary end point was an improvement from baseline in 6-min walk distance (6MWD); secondary end points included Borg dyspnea index, World Health Organization (WHO) functional class, a subject global assessment, and cardiopulmonary hemodynamics.  At 12 wk, ambrisentan increased 6MWD (+36.1 m, p < 0.0001) with similar and statistically significant increases for each dose group (range, +33.9 to +38.1 m).  Improvements were also obsd. in Borg dyspnea index, WHO functional class, subject global assessment, mean pulmonary arterial pressure (-5.2 mm Hg, p < 0.0001), and cardiac index (+0.33 l/min/m2, p < 0.0008).  Adverse events were mild and unrelated to dose, including the incidence of elevated serum aminotransferase concns. >3 times the upper limit of normal (3.1%).  Ambrisentan appears to improve exercise capacity, symptoms, and hemodynamics in patients with PAH.  The incidence and severity of liver enzyme abnormalities appear to be low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEgbxTL0ZlRLVg90H21EOLACvtfcHk0lisDbH2-BdgHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVKnsrk%253D&md5=526b6be0c15ac7ca41720557e51e127f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2005.04.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2005.04.050%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A9%26aufirst%3DN.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DOudiz%26aufirst%3DR.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26aulast%3DKeogh%26aufirst%3DA.%2BM.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DZwicke%26aufirst%3DD.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DAmbrisentan%2520Therapy%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2005%26volume%3D46%26spage%3D529%26epage%3D535%26doi%3D10.1016%2Fj.jacc.2005.04.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binkert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iglarz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span> </span><span class="NLM_article-title">The Discovery of <i>N</i>-5-(4-bromophenyl-6-2-(5-Bromo-2-Pyrimidinyl)oxyethoxy-4-pyrimidinyl-<i>Nâ²</i>-propyl-sulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7849</span><span class="NLM_x">â</span> <span class="NLM_lpage">7861</span><span class="refDoi">Â DOI: 10.1021/jm3009103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7849-7861&author=M.+H.+Bolliauthor=C.+Bossauthor=C.+Binkertauthor=S.+Buchmannauthor=D.+Burauthor=P.+Hessauthor=M.+Iglarzauthor=S.+Meyerauthor=J.+Reinauthor=M.+Reyauthor=A.+Treiberauthor=M.+Clozelauthor=W.+Fischliauthor=T.+Weller&title=The+Discovery+of+N-5-%284-bromophenyl-6-2-%285-Bromo-2-Pyrimidinyl%29oxyethoxy-4-pyrimidinyl-N%E2%80%B2-propyl-sulfamide+%28Macitentan%29%2C+an+Orally+Active%2C+Potent+Dual+Endothelin+Receptor+Antagonist&doi=10.1021%2Fjm3009103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm3009103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009103%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DIglarz%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DRein%26aufirst%3DJ.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DThe%2520Discovery%2520of%2520N-5-%25284-bromophenyl-6-2-%25285-Bromo-2-Pyrimidinyl%2529oxyethoxy-4-pyrimidinyl-N%25E2%2580%25B2-propyl-sulfamide%2520%2528Macitentan%2529%252C%2520an%2520Orally%2520Active%252C%2520Potent%2520Dual%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7849%26epage%3D7861%26doi%3D10.1021%2Fjm3009103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Pulido, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adzerikho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Channick, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcroix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Brun, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittelholzer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perchenet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sastry, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitbon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torbicki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span> </span><span class="NLM_article-title">SERAPHIN Investigators Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">â</span> <span class="NLM_lpage">818</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1213917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1056%2FNEJMoa1213917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23984728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyis7fP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=809-818&author=T.+Pulidoauthor=I.+Adzerikhoauthor=R.+N.+Channickauthor=M.+Delcroixauthor=N.+Gali%C3%A8author=H.+A.+Ghofraniauthor=P.+Jansaauthor=Z.+C.+Jingauthor=F.+O.+Le+Brunauthor=S.+Mehtaauthor=C.+M.+Mittelholzerauthor=L.+Perchenetauthor=B.+K.+Sastryauthor=O.+Sitbonauthor=R.+Souzaauthor=A.+Torbickiauthor=X.+Zengauthor=L.+J.+Rubinauthor=G.+Simonneau&title=SERAPHIN+Investigators+Macitentan+and+Morbidity+and+Mortality+in+Pulmonary+Arterial+Hypertension&doi=10.1056%2FNEJMoa1213917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Macitentan and morbidity and mortality in pulmonary arterial hypertension</span></div><div class="casAuthors">Pulido, Tomas; Adzerikho, Igor; Channick, Richard N.; Delcroix, Marion; Galie, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Jing, Zhi-Cheng; Le Brun, Franck-Olivier; Mehta, Sanjay; Mittelholzer, Camilla M.; Perchenet, Loic; Sastry, B. K. S.; Sitbon, Olivier; Souza, Rogerio; Torbicki, Adam; Zeng, Xiaofeng; Rubin, Lewis J.; Simonneau, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-818</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point.  We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial.  METHODS We randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg.  Stable use of oral or inhaled therapy for pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study entry.  The primary end point was the time from the initiation of treatment to the first occurrence of a composite end point of death, atrial septostomy, lung transplantation, initiation of treatment with i.v. or s.c. prostanoids, or worsening of pulmonary arterial hypertension.  RESULTS A total of 250 patients were randomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose.  The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, resp.  The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5% confidence interval [CI], 0.52 to 0.96; P = 0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5% CI, 0.39 to 0.76; P<0.001).  Worsening of pulmonary arterial hypertension was the most frequent primary end-point event.  The effect of macitentan on this end point was obsd. regardless of whether the patient was receiving therapy for pulmonary arterial hypertension at baseline.  Adverse events more frequently assocd. with macitentan than with placebo were headache, nasopharyngitis, and anemia.  CONCLUSIONS Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAWzzZ3N-2NrVg90H21EOLACvtfcHk0lgyLEK2_RdfTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyis7fP&md5=430d59843298eaa407aa8a67acc84f81</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1213917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1213917%26sid%3Dliteratum%253Aachs%26aulast%3DPulido%26aufirst%3DT.%26aulast%3DAdzerikho%26aufirst%3DI.%26aulast%3DChannick%26aufirst%3DR.%2BN.%26aulast%3DDelcroix%26aufirst%3DM.%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DJing%26aufirst%3DZ.%2BC.%26aulast%3DLe%2BBrun%26aufirst%3DF.%2BO.%26aulast%3DMehta%26aufirst%3DS.%26aulast%3DMittelholzer%26aufirst%3DC.%2BM.%26aulast%3DPerchenet%26aufirst%3DL.%26aulast%3DSastry%26aufirst%3DB.%2BK.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DSouza%26aufirst%3DR.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DX.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DSERAPHIN%2520Investigators%2520Macitentan%2520and%2520Morbidity%2520and%2520Mortality%2520in%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D809%26epage%3D818%26doi%3D10.1056%2FNEJMoa1213917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Houde, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LabontÃ©, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâOrlÃ©ans-Juste, P.</span><span> </span><span class="NLM_article-title">Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2613</span><span class="NLM_x">â</span> <span class="NLM_lpage">2625</span><span class="refDoi">Â DOI: 10.2174/138161211797416101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2174%2F138161211797416101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21728984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7rI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2613-2625&author=M.+Houdeauthor=J.+Labont%C3%A9author=P.+D%E2%80%99Orl%C3%A9ans-Juste&title=Peptide+and+Non-peptide+Antagonists+Targeting+Endothelin+Receptors+in+Physiology+and+Pathology&doi=10.2174%2F138161211797416101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide and non-peptide antagonists targeting endothelin receptors in physiology and pathology</span></div><div class="casAuthors">Houde, Martin; Labonte, Julie; D'Orleans-Juste, Pedro</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2613-2625</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  As for other peptides such as bradykinin, neurokinins, and angiotensins, peptide antagonists for endothelin-1 (ET-1) were early on developed towards the pharmacol. characterization of both ETA and ETB receptors.  Interestingly, unlike the previously mentioned 3 peptides, receptors for ET-1 were cloned and purified prior to the report of ETA and ETB receptor antagonists such as BQ-123 and BQ-788.  The availability of such pharmacol. tools and the use of mol. approaches have certainly fast-tracked the development of non-peptide ET receptor antagonists for clin. applications.  Albeit rapid degrdn. by gastric enzymes and short half life in blood plasma of peptide receptor antagonists limit their use in clin. settings, those mols. were of importance in the identification of mediators and modulators of ET-1 induced properties in vitro and in vivo, as described further in this review.  Peptide antagonists acting selectively or, with equiv. affinities against ETA and ETB receptors were reported prior to the advent of clin. relevant non-peptide blockers such as Bosentan.  Confounding mechanisms involving, for example, the endogenous modulators nitric oxide and prostacyclin as well as allosteric interactions between ET receptor types, were also clarified with the use of peptide antagonists for endothelins.  Finally, peptide antagonists were also used to identify the precise pharmacol. of ET-1 precursors such as big-endothelin-1 and ET-1 (1-31).  The present review will thus attempt to summarize the knowledge to date and future perspectives related to use of peptide antagonists targeting endothelin receptors in physiol. and pathol. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMof3XutTAibVg90H21EOLACvtfcHk0lgyLEK2_RdfTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7rI&md5=e35b4d5b46113bc420d7fdfcb99c729e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.2174%2F138161211797416101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161211797416101%26sid%3Dliteratum%253Aachs%26aulast%3DHoude%26aufirst%3DM.%26aulast%3DLabont%25C3%25A9%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Orl%25C3%25A9ans-Juste%26aufirst%3DP.%26atitle%3DPeptide%2520and%2520Non-peptide%2520Antagonists%2520Targeting%2520Endothelin%2520Receptors%2520in%2520Physiology%2520and%2520Pathology%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2011%26volume%3D17%26spage%3D2613%26epage%3D2625%26doi%3D10.2174%2F138161211797416101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Ishikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niiyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, M.</span><span> </span><span class="NLM_article-title">Cyclic Pentapeptide Endothelin Antagonists with High ETA Selectivity. Potency- and Solubility-Enhancing Modifications</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2139</span><span class="NLM_x">â</span> <span class="NLM_lpage">2142</span><span class="refDoi">Â DOI: 10.1021/jm00089a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00089a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2139-2142&author=K.+Ishikawaauthor=T.+Fukamiauthor=T.+Nagaseauthor=K.+Fujitaauthor=T.+Hayamaauthor=K.+Niiyamaauthor=T.+Maseauthor=M.+Iharaauthor=M.+Yano&title=Cyclic+Pentapeptide+Endothelin+Antagonists+with+High+ETA+Selectivity.+Potency-+and+Solubility-Enhancing+Modifications&doi=10.1021%2Fjm00089a028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm00089a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00089a028%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DHayama%26aufirst%3DT.%26aulast%3DNiiyama%26aufirst%3DK.%26aulast%3DMase%26aufirst%3DT.%26aulast%3DIhara%26aufirst%3DM.%26aulast%3DYano%26aufirst%3DM.%26atitle%3DCyclic%2520Pentapeptide%2520Endothelin%2520Antagonists%2520with%2520High%2520ETA%2520Selectivity.%2520Potency-%2520and%2520Solubility-Enhancing%2520Modifications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D2139%26epage%3D2142%26doi%3D10.1021%2Fjm00089a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Chiappori, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulware, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuger, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lush, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bepler, G.</span><span> </span><span class="NLM_article-title">Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-line Therapy in Advanced Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1464</span><span class="NLM_x">â</span> <span class="NLM_lpage">1469</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-07-1508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1078-0432.CCR-07-1508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=18316570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislSrsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1464-1469&author=A.+A.+Chiapporiauthor=E.+Hauraauthor=F.+A.+Rodriguezauthor=D.+Boulwareauthor=R.+Kapoorauthor=A.+M.+Neugerauthor=R.+Lushauthor=B.+Padillaauthor=M.+Burtonauthor=C.+Williamsauthor=G.+Simonauthor=S.+Antoniaauthor=D.+M.+Sullivanauthor=G.+Bepler&title=Phase+I%2FII+Study+of+Atrasentan%2C+an+Endothelin+A+Receptor+Antagonist%2C+in+Combination+with+Paclitaxel+and+Carboplatin+as+First-line+Therapy+in+Advanced+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-07-1508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer</span></div><div class="casAuthors">Chiappori, Alberto A.; Haura, Eric; Rodriguez, Francisco A.; Boulware, David; Kapoor, Rachna; Neuger, Anthony M.; Lush, Richard; Padilla, Barbara; Burton, Michelle; Williams, Charles; Simon, George; Antonia, Scott; Sullivan, Daniel M.; Bepler, Gerold</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1464-1469</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Endothelins and their cell membrane receptors (ETAR and ETBR) are implicated in neoplastic pathogenesis.  Atrasentan, a potent, selective ETAR antagonist, has a direct effect on tumor proliferation, apoptosis, and angiogenesis.  This study was designed to assess the influence of atrasentan on paclitaxel pharmacokinetics and to det. the safety and efficacy of atrasentan in combination with paclitaxel-carboplatin.  Chemonaive patients with stage IIIB (malignant pleural effusion) and IV non-small cell lung cancer were enrolled.  Toxicity and response were detd. using the National Cancer Institute Common Toxicity Criteria version 2.0 and Response Evaluation Criteria in Solid Tumors criteria, resp.  Treatment consisted of paclitaxel (225 mg/m2) and carboplatin (area under the curve, 6) administered on day 1 every 3 wk.  A fixed 10 mg daily oral dose of atrasentan was administered continuously, starting on day 4 of cycle 1.  Paclitaxel clearance was calcd. during the first two cycles (pre- and post-atrasentan) in the first 10 patients.  All 44 patients were evaluable for survival, toxicity, and response.  No significant change in mean paclitaxel clearance was detected (mean Â± SD, 21.2 Â± 4.5 L/h vs. 21.3 Â± 4.9 L/h) for pre- and post-atrasentan values, resp. (P = 0.434).  Grade 3/4 toxicities â¥10% were lymphopenia (22.7%), neutropenia (20.5%), dyspnea (11.4%), and hyperglycemia (11.4%).  Response rate was 18.2%, with progression-free survival of 4.2 mo, median survival of 10.6 mo, and 1-yr survival of 43%.  Atrasentan plus paclitaxel-carboplatin was safe and well tolerated, with no apparent paclitaxel-atrasentan pharmacokinetic interaction.  Efficacy and survival in advanced non-small cell lung cancer were comparable with studies of chemotherapy alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjFBMZZDlGOLVg90H21EOLACvtfcHk0ljN6KdP81f1zA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislSrsLY%253D&md5=f29525151a2d9e869d03e9c4c5a2c418</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1508%26sid%3Dliteratum%253Aachs%26aulast%3DChiappori%26aufirst%3DA.%2BA.%26aulast%3DHaura%26aufirst%3DE.%26aulast%3DRodriguez%26aufirst%3DF.%2BA.%26aulast%3DBoulware%26aufirst%3DD.%26aulast%3DKapoor%26aufirst%3DR.%26aulast%3DNeuger%26aufirst%3DA.%2BM.%26aulast%3DLush%26aufirst%3DR.%26aulast%3DPadilla%26aufirst%3DB.%26aulast%3DBurton%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DG.%26aulast%3DAntonia%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DBepler%26aufirst%3DG.%26atitle%3DPhase%2520I%252FII%2520Study%2520of%2520Atrasentan%252C%2520an%2520Endothelin%2520A%2520Receptor%2520Antagonist%252C%2520in%2520Combination%2520with%2520Paclitaxel%2520and%2520Carboplatin%2520as%2520First-line%2520Therapy%2520in%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D1464%26epage%3D1469%26doi%3D10.1158%2F1078-0432.CCR-07-1508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">de Zeeuw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coll, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andress, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa-Rotter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambers Heerspink, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchett, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobe, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viberti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parving, H. H.</span><span> </span><span class="NLM_article-title">The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with type 2 Diabetic Nephropathy</span> <span class="citation_source-journal">J. Am. Soc. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1083</span><span class="NLM_x">â</span> <span class="NLM_lpage">1093</span><span class="refDoi">Â DOI: 10.1681/ASN.2013080830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1681%2FASN.2013080830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24722445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1Crtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1083-1093&author=D.+de+Zeeuwauthor=B.+Collauthor=D.+Andressauthor=J.+J.+Brennanauthor=H.+Tangauthor=M.+Houserauthor=R.+Correa-Rotterauthor=D.+Kohanauthor=H.+J.+Lambers+Heerspinkauthor=H.+Makinoauthor=V.+Perkovicauthor=Y.+Pritchettauthor=G.+Remuzziauthor=S.+W.+Tobeauthor=R.+Totoauthor=G.+Vibertiauthor=H.+H.+Parving&title=The+Endothelin+Antagonist+Atrasentan+Lowers+Residual+Albuminuria+in+Patients+with+type+2+Diabetic+Nephropathy&doi=10.1681%2FASN.2013080830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy</span></div><div class="casAuthors">de Zeeuw, Dick; Coll, Blai; Andress, Dennis; Brennan, John J.; Tang, Hui; Houser, Mark; Correa-Rotter, Ricardo; Kohan, Donald; Heerspink, Hiddo J. Lambers; Makino, Hirofumi; Perkovic, Vlado; Pritchett, Yili; Remuzzi, Giuseppe; Tobe, Sheldon W.; Toto, Robert; Viberti, Giancarlo; Parving, Hans-Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1083-1093</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Despite optimal treatment, including renin-angiotensin system (RAS) inhibitors, patients with type 2 diabetic nephropathy have high cardiorenal morbidity and mortality related to residual albuminuria.  We evaluated whether or not atrasentan, a selective endothelin A receptor antagonist, further reduces albuminuria when administered concomitantly with max. tolerated labeled doses of RAS inhibitors.  We enrolled 211 patients with type 2 diabetes, urine albumin/creatinine ratios of 300-3500 mg/g, and eGFRs of 30-75 mL/min per 1.73 m2 in two identically designed, parallel, multinational, double-blind studies.  Participants were randomized to placebo (n = 50) or to 0.75 mg/d (n = 78) or 1.25 mg/d (n = 83) atrasentan for 12 wk.  Compared with placebo, 0.75 mg and 1.25 mg atrasentan reduced urine albumin/creatinine ratios by an av. of 35% and 38% (95% confidence intervals of 24 to 45 and 28 to 47, resp.) and reduced albuminuriaâ¥30% in 51% and 55% of participants, resp.  EGFR and office BP measurements did not change, whereas 24-h systolic and diastolic BP, LDL cholesterol, and triglyceride levels decreased significantly in both treatment groups.  Use of atrasentan was assocd. with a significant increase in wt. and a redn. in Hb, but rates of peripheral edema, heart failure, or other side effects did not differ between groups.  However, more patients treated with 1.25 mg/d atrasentan discontinued due to adverse events.  After stopping atrasentan for 30 days, measured parameters returned to pretreatment levels.  In conclusion, atrasentan reduced albuminuria and improved BP and lipid spectrum with manageable fluid overload-related adverse events in patients with type 2 diabetic nephropathy receiving RAS inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwIPOoNpJUvrVg90H21EOLACvtfcHk0ljN6KdP81f1zA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1Crtrc%253D&md5=3d638d67a35d5255923c0ee9f576fd52</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1681%2FASN.2013080830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2013080830%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DColl%26aufirst%3DB.%26aulast%3DAndress%26aufirst%3DD.%26aulast%3DBrennan%26aufirst%3DJ.%2BJ.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DHouser%26aufirst%3DM.%26aulast%3DCorrea-Rotter%26aufirst%3DR.%26aulast%3DKohan%26aufirst%3DD.%26aulast%3DLambers%2BHeerspink%26aufirst%3DH.%2BJ.%26aulast%3DMakino%26aufirst%3DH.%26aulast%3DPerkovic%26aufirst%3DV.%26aulast%3DPritchett%26aufirst%3DY.%26aulast%3DRemuzzi%26aufirst%3DG.%26aulast%3DTobe%26aufirst%3DS.%2BW.%26aulast%3DToto%26aufirst%3DR.%26aulast%3DViberti%26aufirst%3DG.%26aulast%3DParving%26aufirst%3DH.%2BH.%26atitle%3DThe%2520Endothelin%2520Antagonist%2520Atrasentan%2520Lowers%2520Residual%2520Albuminuria%2520in%2520Patients%2520with%2520type%25202%2520Diabetic%2520Nephropathy%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2014%26volume%3D25%26spage%3D1083%26epage%3D1093%26doi%3D10.1681%2FASN.2013080830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Quinn, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tangen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lara, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldkorn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moinpour, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garzotto, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monk, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twardowski, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Veldhuizen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higano, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelzang, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, I. M.</span><span> </span><span class="NLM_article-title">Docetaxel and Atrasentan Versus Docetaxel and Placebo for Men with Advanced Castration-resistant Prostate Cancer (SWOG S0421): A Randomized Phase 3 Trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">893</span><span class="NLM_x">â</span> <span class="NLM_lpage">900</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(13)70294-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS1470-2045%2813%2970294-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23871417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCitr7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=893-900&author=D.+I.+Quinnauthor=C.+M.+Tangenauthor=M.+Hussainauthor=P.+N.+Laraauthor=A.+Goldkornauthor=C.+M.+Moinpourauthor=M.+G.+Garzottoauthor=P.+C.+Mackauthor=M.+A.+Carducciauthor=J.+P.+Monkauthor=P.+W.+Twardowskiauthor=P.+J.+Van+Veldhuizenauthor=N.+Agarwalauthor=C.+S.+Higanoauthor=N.+J.+Vogelzangauthor=I.+M.+Thompson&title=Docetaxel+and+Atrasentan+Versus+Docetaxel+and+Placebo+for+Men+with+Advanced+Castration-resistant+Prostate+Cancer+%28SWOG+S0421%29%3A+A+Randomized+Phase+3+Trial&doi=10.1016%2FS1470-2045%2813%2970294-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial</span></div><div class="casAuthors">Quinn, David I.; Tangen, Catherine M.; Hussain, Maha; Lara, Primo N.; Goldkorn, Amir; Moinpour, Carol M.; Garzotto, Mark G.; Mack, Philip C.; Carducci, Michael A.; Monk, J. Paul; Twardowski, Przemyslaw W.; Van Veldhuizen, Peter J.; Agarwal, Neeraj; Higano, Celestia S.; Vogelzang, Nicholas J.; Thompson, Ian M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">893-900</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer.  Atrasentan, an endothelin receptor antagonist, has shown activity in prostate cancer.  We therefore assessed its effect on survival in patients with castration-resistant prostate cancer with bone metastases.In a double-blind phase 3 trial, men with metastatic castration-resistant prostate cancer, stratified for progression type (prostate-specific antigen or radiol.), baseline pain, extraskeletal metastases, and bisphosphonate use, were randomly assigned in a 1:1 ratio to docetaxel (75 mg/m2 every 21 days, i.v.) with atrasentan (10 mg/day, orally) or placebo for up to 12 cycles and treated until disease progression or unacceptable toxicity.  Patients who did not progress on treatment were permitted to continue atrasentan or placebo for up to 52 wk.  Coprimary endpoints were progression-free survival (PFS) and overall survival.  Anal. was by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT00134056.498 patients were randomly assigned to the atrasentan group and 496 to the placebo group.  The trial was halted early for futility in Apr., 2011, after a planned interim anal.  Median PFS was 9Â·2 mo (95% CI 8Â·5-9Â·9) in the atrasentan group and 9Â·1 mo (8Â·4-10Â·2) in the placebo group (hazard ratio 1Â·02, 0Â·89-1Â·16; p=0Â·81).  Median overall survival was 17Â·8 mo (16Â·4-19Â·8) in the atrasentan group vs. 17Â·6 mo (16Â·4-20Â·1) in the placebo group (1Â·04, 0Â·90-1Â·19; p=0Â·64). 278 (57%) of 492 patients in the atrasentan group had grade 3 and greater toxicity compared with 294 (60%) of 486 in the placebo group (p=0Â·22).  Three deaths in the atrasentan group and seven in the placebo group were judged to be possibly or probably due to protocol treatment.Atrasentan, when added to docetaxel, does not improve overall survival or PFS in men with castration-resistant prostate cancer and bone metastases; therefore, single-agent docetaxel should remain as one of the std. treatments.National Cancer Institute, Sanofi-Aventis, and Abbott Labs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjlYVsRNXb77Vg90H21EOLACvtfcHk0ljN6KdP81f1zA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCitr7J&md5=36a81b40100edc690d0cd92d6b13372c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970294-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970294-8%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DD.%2BI.%26aulast%3DTangen%26aufirst%3DC.%2BM.%26aulast%3DHussain%26aufirst%3DM.%26aulast%3DLara%26aufirst%3DP.%2BN.%26aulast%3DGoldkorn%26aufirst%3DA.%26aulast%3DMoinpour%26aufirst%3DC.%2BM.%26aulast%3DGarzotto%26aufirst%3DM.%2BG.%26aulast%3DMack%26aufirst%3DP.%2BC.%26aulast%3DCarducci%26aufirst%3DM.%2BA.%26aulast%3DMonk%26aufirst%3DJ.%2BP.%26aulast%3DTwardowski%26aufirst%3DP.%2BW.%26aulast%3DVan%2BVeldhuizen%26aufirst%3DP.%2BJ.%26aulast%3DAgarwal%26aufirst%3DN.%26aulast%3DHigano%26aufirst%3DC.%2BS.%26aulast%3DVogelzang%26aufirst%3DN.%2BJ.%26aulast%3DThompson%26aufirst%3DI.%2BM.%26atitle%3DDocetaxel%2520and%2520Atrasentan%2520Versus%2520Docetaxel%2520and%2520Placebo%2520for%2520Men%2520with%2520Advanced%2520Castration-resistant%2520Prostate%2520Cancer%2520%2528SWOG%2520S0421%2529%253A%2520A%2520Randomized%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D893%26epage%3D900%26doi%3D10.1016%2FS1470-2045%2813%2970294-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Buchholz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reissig, H. U.</span><span> </span><span class="NLM_article-title">Enantioselective Synthesis of the Pyrrolidine Core of Endothelin Antagonist ABT-627 (Atrasentan) via 1,2-Oxazines</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2003</span><span class="NLM_x">, </span> <span class="NLM_fpage">3524</span><span class="NLM_x">â</span> <span class="NLM_lpage">3533</span><span class="refDoi">Â DOI: 10.1002/ejoc.200300234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fejoc.200300234" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2003&publication_year=2003&pages=3524-3533&author=M.+Buchholzauthor=H.+U.+Reissig&title=Enantioselective+Synthesis+of+the+Pyrrolidine+Core+of+Endothelin+Antagonist+ABT-627+%28Atrasentan%29+via+1%2C2-Oxazines&doi=10.1002%2Fejoc.200300234"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200300234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200300234%26sid%3Dliteratum%253Aachs%26aulast%3DBuchholz%26aufirst%3DM.%26aulast%3DReissig%26aufirst%3DH.%2BU.%26atitle%3DEnantioselective%2520Synthesis%2520of%2520the%2520Pyrrolidine%2520Core%2520of%2520Endothelin%2520Antagonist%2520ABT-627%2520%2528Atrasentan%2529%2520via%25201%252C2-Oxazines%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2003%26volume%3D2003%26spage%3D3524%26epage%3D3533%26doi%3D10.1002%2Fejoc.200300234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Paul, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giersbergen, P. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span> </span><span class="NLM_article-title">Tolerability, Pharmacokinetics, and Pharmacodynamics of Clazosentan, a Parenteral Endothelin Receptor Antagonist</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">â</span> <span class="NLM_lpage">158</span><span class="refDoi">Â DOI: 10.1007/s00228-006-0117-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00228-006-0117-z" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=151-158&author=L.+M.+Paulauthor=P.+L.+M.+van+Giersbergenauthor=J.+Dingemanse&title=Tolerability%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+Clazosentan%2C+a+Parenteral+Endothelin+Receptor+Antagonist&doi=10.1007%2Fs00228-006-0117-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs00228-006-0117-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-006-0117-z%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DL.%2BM.%26aulast%3Dvan%2BGiersbergen%26aufirst%3DP.%2BL.%2BM.%26aulast%3DDingemanse%26aufirst%3DJ.%26atitle%3DTolerability%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520Clazosentan%252C%2520a%2520Parenteral%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D63%26spage%3D151%26epage%3D158%26doi%3D10.1007%2Fs00228-006-0117-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Tomkinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemp, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taboada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and Tolerability of Zibotentan (ZD4054) in Subjects with Hepatic or Renal Impairment: Two Open-label Comparative Studies</span> <span class="citation_source-journal">BMC Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="refDoi">Â DOI: 10.1186/1472-6904-11-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1186%2F1472-6904-11-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21414193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvV2gtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=3&author=H.+Tomkinsonauthor=J.+Kempauthor=S.+Oliverauthor=H.+Swaislandauthor=M.+Taboadaauthor=T.+Morris&title=Pharmacokinetics+and+Tolerability+of+Zibotentan+%28ZD4054%29+in+Subjects+with+Hepatic+or+Renal+Impairment%3A+Two+Open-label+Comparative+Studies&doi=10.1186%2F1472-6904-11-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies</span></div><div class="casAuthors">Tomkinson, Helen; Kemp, John; Oliver, Stuart; Swaisland, Helen; Taboada, Maria; Morris, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">BMC Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3</span>CODEN:
                <span class="NLM_cas:coden">BCPMC4</span>;
        ISSN:<span class="NLM_cas:issn">1472-6904</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Zibotentan (ZD4054) is a specific endothelin A (ETA) receptor antagonist being investigated for the treatment of prostate cancer.  As zibotentan is eliminated by renal and metabolic routes, clearance may be reduced in patients with hepatic or renal impairment, leading to greater drug exposure.  Methods: Open-label studies investigated the PK and tolerability of zibotentan in subjects with hepatic or renal impairment, compared with those with normal organ function.  In the hepatic and renal studies, resp., subjects were divided into categories using Child-Pugh classification or 24-h urine creatinine clearance (mild, moderate, or severe impairment and normal function).  Each subject received a single oral dose of zibotentan 10 mg and PK sampling was undertaken.  Within the hepatic study, AUC and Cmax were expressed as the ratio of geometric means and 90% CI for each impairment group compared with the normal function group.  The possibility that hepatic impairment had a clin. relevant effect on exposure was considered if the upper 90% CI for the ratio exceeded 2.  In the renal study, AUC, Cmax and t1/2 were analyzed using linear regression fitting effects for creatinine clearance and age.  Results: In the hepatic and renal studies resp., 32 subjects (eight per group) and 48 subjects received treatment (n = 18 normal, n = 12 mild, n = 9 moderate, n = 9 severe).  Zibotentan Cmax was not significantly affected by hepatic or renal impairment.  Compared with the normal function group, zibotentan AUC was 40% (1.40; 90% CI 0.91-2.17), 45% (1.45; 90% CI 0.94-2.24) and 190% (2.90; 90% CI 1.88-4.49) higher in subjects with mild, moderate and severe hepatic impairment, resp., and 66% (1.66; 90% CI 1.38-1.99), 89% (1.89; 90% CI 1.50-2.39) and 117% (2.17; 90% CI 1.64-2.86) higher in subjects with mild, moderate and severe renal impairment, resp.  In both studies mean t1/2 increased and zibotentan clearance decreased with the degree of impairment.  Headache was the most common AE in all groups.  Conclusions: Zibotentan absorption was unchanged, however, exposure was higher in subjects with hepatic or renal impairment due to slower clearance.  This increased exposure did not result in differences in the range or severity of AEs obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF1S2f3_ykNrVg90H21EOLACvtfcHk0liVSLydRbXkTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvV2gtbc%253D&md5=4f895b05fecd8d3cdf27d57d46321e39</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1186%2F1472-6904-11-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6904-11-3%26sid%3Dliteratum%253Aachs%26aulast%3DTomkinson%26aufirst%3DH.%26aulast%3DKemp%26aufirst%3DJ.%26aulast%3DOliver%26aufirst%3DS.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DTaboada%26aufirst%3DM.%26aulast%3DMorris%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520Tolerability%2520of%2520Zibotentan%2520%2528ZD4054%2529%2520in%2520Subjects%2520with%2520Hepatic%2520or%2520Renal%2520Impairment%253A%2520Two%2520Open-label%2520Comparative%2520Studies%26jtitle%3DBMC%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D3%26doi%3D10.1186%2F1472-6904-11-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Ishikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, K.i</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niiyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, M.</span><span> </span><span class="NLM_article-title">Cyclic Pentapeptide Endothelin Antagonists with High ETA Selectivity. Potency- and Solubility-Enhancing Modifications</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2139</span><span class="NLM_x">â</span> <span class="NLM_lpage">2142</span><span class="refDoi">Â DOI: 10.1021/jm00089a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00089a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2139-2142&author=K.+Ishikawaauthor=T.+Fukamiauthor=T.+Nagaseauthor=K.i+Fujitaauthor=T.+Hayamaauthor=K.+Niiyamaauthor=T.+Maseauthor=M.+Iharaauthor=M.+Yano&title=Cyclic+Pentapeptide+Endothelin+Antagonists+with+High+ETA+Selectivity.+Potency-+and+Solubility-Enhancing+Modifications&doi=10.1021%2Fjm00089a028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm00089a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00089a028%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DK.i%26aulast%3DHayama%26aufirst%3DT.%26aulast%3DNiiyama%26aufirst%3DK.%26aulast%3DMase%26aufirst%3DT.%26aulast%3DIhara%26aufirst%3DM.%26aulast%3DYano%26aufirst%3DM.%26atitle%3DCyclic%2520Pentapeptide%2520Endothelin%2520Antagonists%2520with%2520High%2520ETA%2520Selectivity.%2520Potency-%2520and%2520Solubility-Enhancing%2520Modifications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D2139%26epage%3D2142%26doi%3D10.1021%2Fjm00089a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Dutzler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hediger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidhart, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¤rki, H. P.</span><span> </span><span class="NLM_article-title">Channels and Transporters</span> <span class="citation_source-journal">Chimia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">662</span><span class="NLM_x">â</span> <span class="NLM_lpage">666</span><span class="refDoi">Â DOI: 10.2533/chimia.2010.662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2533%2Fchimia.2010.662" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2010&pages=662-666&author=R.+Dutzlerauthor=B.+Ernstauthor=M.+A.+Hedigerauthor=D.+Kepplerauthor=P.+Mohrauthor=W.+Neidhartauthor=H.+P.+M%C3%A4rki&title=Channels+and+Transporters&doi=10.2533%2Fchimia.2010.662"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.2533%2Fchimia.2010.662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2533%252Fchimia.2010.662%26sid%3Dliteratum%253Aachs%26aulast%3DDutzler%26aufirst%3DR.%26aulast%3DErnst%26aufirst%3DB.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DM%25C3%25A4rki%26aufirst%3DH.%2BP.%26atitle%3DChannels%2520and%2520Transporters%26jtitle%3DChimia%26date%3D2010%26volume%3D64%26spage%3D662%26epage%3D666%26doi%3D10.2533%2Fchimia.2010.662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Epstein, B. J.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of Darusentan: a Novel Endothelin Receptor Antagonist</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1060</span><span class="NLM_x">â</span> <span class="NLM_lpage">1069</span><span class="refDoi">Â DOI: 10.1345/aph.1L024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1345%2Faph.1L024" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2008&pages=1060-1069&author=B.+J.+Epstein&title=Efficacy+and+Safety+of+Darusentan%3A+a+Novel+Endothelin+Receptor+Antagonist&doi=10.1345%2Faph.1L024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1345%2Faph.1L024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1L024%26sid%3Dliteratum%253Aachs%26aulast%3DEpstein%26aufirst%3DB.%2BJ.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Darusentan%253A%2520a%2520Novel%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2008%26volume%3D42%26spage%3D1060%26epage%3D1069%26doi%3D10.1345%2Faph.1L024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Murugesan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spergel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermsmeier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bird, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koplowitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreland, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trippodo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span> </span><span class="NLM_article-title">Biphenylsulfonamide Endothelin Receptor Antagonists. 4. Discovery of N-[[2<i>â²</i>-[[(4,5-Dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1<i>â²</i>-biphenyl]-2-yl]methyl]-N,3,3-trimethyl butanamide (BMS-207940), a Highly Potent and Orally Active ET(A) Selective Antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">137</span><span class="refDoi">Â DOI: 10.1021/jm020289q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020289q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=125-137&author=N.+Murugesanauthor=Z.+Guauthor=S.+Spergelauthor=M.+Youngauthor=P.+Chenauthor=A.+Mathurauthor=L.+Leithauthor=M.+Hermsmeierauthor=E.+C.+Liuauthor=R.+Zhangauthor=E.+Birdauthor=T.+Waldronauthor=A.+Marinoauthor=B.+Koplowitzauthor=W.+G.+Humphreysauthor=S.+Chongauthor=R.+A.+Morrisonauthor=M.+L.+Webbauthor=S.+Morelandauthor=N.+Trippodoauthor=J.+C.+Barrish&title=Biphenylsulfonamide+Endothelin+Receptor+Antagonists.+4.+Discovery+of+N-%5B%5B2%E2%80%B2-%5B%5B%284%2C5-Dimethyl-3-isoxazolyl%29amino%5Dsulfonyl%5D-4-%282-oxazolyl%29%5B1%2C1%E2%80%B2-biphenyl%5D-2-yl%5Dmethyl%5D-N%2C3%2C3-trimethyl+butanamide+%28BMS-207940%29%2C+a+Highly+Potent+and+Orally+Active+ET%28A%29+Selective+Antagonist&doi=10.1021%2Fjm020289q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm020289q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020289q%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DHermsmeier%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DE.%2BC.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DBird%26aufirst%3DE.%26aulast%3DWaldron%26aufirst%3DT.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DKoplowitz%26aufirst%3DB.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DChong%26aufirst%3DS.%26aulast%3DMorrison%26aufirst%3DR.%2BA.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DMoreland%26aufirst%3DS.%26aulast%3DTrippodo%26aufirst%3DN.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3DBiphenylsulfonamide%2520Endothelin%2520Receptor%2520Antagonists.%25204.%2520Discovery%2520of%2520N-%255B%255B2%25E2%2580%25B2-%255B%255B%25284%252C5-Dimethyl-3-isoxazolyl%2529amino%255Dsulfonyl%255D-4-%25282-oxazolyl%2529%255B1%252C1%25E2%2580%25B2-biphenyl%255D-2-yl%255Dmethyl%255D-N%252C3%252C3-trimethyl%2520butanamide%2520%2528BMS-207940%2529%252C%2520a%2520Highly%2520Potent%2520and%2520Orally%2520Active%2520ET%2528A%2529%2520Selective%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D125%26epage%3D137%26doi%3D10.1021%2Fjm020289q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Sudoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuyama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasamata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, K.</span><span> </span><span class="NLM_article-title">Pharmacological Characterization of YM598, a Selective Endothelin-A Receptor Antagonist</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">S1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S390</span><span class="NLM_x">â</span> <span class="NLM_lpage">S393</span><span class="refDoi">Â DOI: 10.1097/01.fjc.0000166296.25690.ca</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2F01.fjc.0000166296.25690.ca" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=S390-S393&issue=S1&author=K.+Sudohauthor=H.+Yuyamaauthor=Y.+Noguchiauthor=A.+Fujimoriauthor=M.+Ukaiauthor=A.+Ohtakeauthor=S.+Satoauthor=M.+Sasamataauthor=K.+Miyata&title=Pharmacological+Characterization+of+YM598%2C+a+Selective+Endothelin-A+Receptor+Antagonist&doi=10.1097%2F01.fjc.0000166296.25690.ca"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1097%2F01.fjc.0000166296.25690.ca&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.fjc.0000166296.25690.ca%26sid%3Dliteratum%253Aachs%26aulast%3DSudoh%26aufirst%3DK.%26aulast%3DYuyama%26aufirst%3DH.%26aulast%3DNoguchi%26aufirst%3DY.%26aulast%3DFujimori%26aufirst%3DA.%26aulast%3DUkai%26aufirst%3DM.%26aulast%3DOhtake%26aufirst%3DA.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DSasamata%26aufirst%3DM.%26aulast%3DMiyata%26aufirst%3DK.%26atitle%3DPharmacological%2520Characterization%2520of%2520YM598%252C%2520a%2520Selective%2520Endothelin-A%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2004%26volume%3D44%26issue%3DS1%26spage%3DS390%26epage%3DS393%26doi%3D10.1097%2F01.fjc.0000166296.25690.ca" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶ffler, B. M.</span><span> </span><span class="NLM_article-title">In Vivo Pharmacology of Ro 46-2005, the First Synthetic Nonpeptide Endothelin Receptor Antagonist: Implications for Endothelin Physiology</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">S8</span><span class="NLM_x">) </span> <span class="NLM_fpage">S377</span><span class="NLM_x">â</span> <span class="NLM_lpage">S379</span><span class="refDoi">Â DOI: 10.1097/00005344-199322008-00099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2F00005344-199322008-00099" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1993&pages=S377-S379&issue=S8&author=M.+Clozelauthor=V.+Breuauthor=G.+A.+Grayauthor=B.+M.+L%C3%B6ffler&title=In+Vivo+Pharmacology+of+Ro+46-2005%2C+the+First+Synthetic+Nonpeptide+Endothelin+Receptor+Antagonist%3A+Implications+for+Endothelin+Physiology&doi=10.1097%2F00005344-199322008-00099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1097%2F00005344-199322008-00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199322008-00099%26sid%3Dliteratum%253Aachs%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DBreu%26aufirst%3DV.%26aulast%3DGray%26aufirst%3DG.%2BA.%26aulast%3DL%25C3%25B6ffler%26aufirst%3DB.%2BM.%26atitle%3DIn%2520Vivo%2520Pharmacology%2520of%2520Ro%252046-2005%252C%2520the%2520First%2520Synthetic%2520Nonpeptide%2520Endothelin%2520Receptor%2520Antagonist%253A%2520Implications%2520for%2520Endothelin%2520Physiology%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1993%26volume%3D22%26issue%3DS8%26spage%3DS377%26epage%3DS379%26doi%3D10.1097%2F00005344-199322008-00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Breu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶ffler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span> </span><span class="NLM_article-title">In Vitro Characterization of Ro 46-2005, a Novel Synthetic Non-Peptide Endothelin Antagonist of ET<sub>A</sub> and ET<sub>B</sub> Receptors</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">334</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">â</span> <span class="NLM_lpage">214</span><span class="refDoi">Â DOI: 10.1016/0014-5793(93)81713-A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2F0014-5793%2893%2981713-A" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=1993&pages=210-214&author=V.+Breuauthor=B.+M.+L%C3%B6fflerauthor=M.+Clozel&title=In+Vitro+Characterization+of+Ro+46-2005%2C+a+Novel+Synthetic+Non-Peptide+Endothelin+Antagonist+of+ETA+and+ETB+Receptors&doi=10.1016%2F0014-5793%2893%2981713-A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2893%2981713-A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252893%252981713-A%26sid%3Dliteratum%253Aachs%26aulast%3DBreu%26aufirst%3DV.%26aulast%3DL%25C3%25B6ffler%26aufirst%3DB.%2BM.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Characterization%2520of%2520Ro%252046-2005%252C%2520a%2520Novel%2520Synthetic%2520Non-Peptide%2520Endothelin%2520Antagonist%2520of%2520ETA%2520and%2520ETB%2520Receptors%26jtitle%3DFEBS%2520Lett.%26date%3D1993%26volume%3D334%26spage%3D210%26epage%3D214%26doi%3D10.1016%2F0014-5793%2893%2981713-A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Sidharta, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giersbergen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halabi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span> </span><span class="NLM_article-title">Macitentan: Entry-into-humans Study with a New Endothelin Receptor Antagonist</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">â</span> <span class="NLM_lpage">984</span><span class="refDoi">Â DOI: 10.1007/s00228-011-1043-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00228-011-1043-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21541781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKiu7zL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=977-984&author=P.+N.+Sidhartaauthor=M.+van+Giersbergenauthor=A.+Halabiauthor=J.+Dingemanse&title=Macitentan%3A+Entry-into-humans+Study+with+a+New+Endothelin+Receptor+Antagonist&doi=10.1007%2Fs00228-011-1043-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Macitentan: entry-into-humans study with a new endothelin receptor antagonist</span></div><div class="casAuthors">Sidharta, Patricia N.; Giersbergen, Paul L. M.; Halabi, Atef; Dingemanse, Jasper</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">977-984</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose To study the pharmacokinetics, pharmacodynamics, and tolerability of rising single doses of macitentan, an endothelin receptor antagonist, in healthy male subjects.  Methods This double-blind, placebo-controlled study was performed in seven groups of eight healthy male subjects.  Doses of 0.2, 1, 5, 25, 100, 300 and 600 mg or placebo (two subjects per group) were administered.  Plasma macitentan and endothelin-1 and serum total bile salt concns. were measured and analyzed non-compartmentally.  Plasma and urine were analyzed qual. for the presence of metabolites and one of these, ACT-132577, was also measured quant. in plasma.  Std. tolerability measurements were performed throughout the study.  Results Macitentan was slowly absorbed and, at a dose of 300 mg, the t1/2 (95% confidence interval, CI) was 17.5 h (14.1, 21.8).  The dose-proportionality coeff. Î² for Cmax (95% CI) was 0.83 (0.79, 0.87) indicating less than dose-proportional pharmacokinetics of macitentan.  In plasma, a pharmacol. active oxidative depropyl metabolite, ACT-132577, was found whereas in urine two minor metabolites were detected.  The t1/2 of ACT-132577 (95% CI) was 65.6 h (53.1, 80.9).  Macitentan dose-dependently increased endothelin-1 concns. up to 2.2-fold (95% CI 1.4, 2.4) at a dose of 600 mg, but had no consistent effect on total bile salts.  Macitentan was well tolerated up to and including a dose of 300 mg, the max. tolerated dose.  Headache, nausea and vomiting were dose-limiting adverse events.  Conclusion The pharmacokinetic and tolerability profile of macitentan is consistent with a once-a-day dosing regimen and warrants further investigation in clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoWeQTz7cdvrVg90H21EOLACvtfcHk0lhkWftVcVXklA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKiu7zL&md5=573cc52b7f797f7c9f27ea3148dff418</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs00228-011-1043-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-011-1043-2%26sid%3Dliteratum%253Aachs%26aulast%3DSidharta%26aufirst%3DP.%2BN.%26aulast%3Dvan%2BGiersbergen%26aufirst%3DM.%26aulast%3DHalabi%26aufirst%3DA.%26aulast%3DDingemanse%26aufirst%3DJ.%26atitle%3DMacitentan%253A%2520Entry-into-humans%2520Study%2520with%2520a%2520New%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D67%26spage%3D977%26epage%3D984%26doi%3D10.1007%2Fs00228-011-1043-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Patel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeage, K.</span><span> </span><span class="NLM_article-title">Macitentan: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">133</span><span class="refDoi">Â DOI: 10.1007/s40265-013-0156-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs40265-013-0156-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=127-133&author=T.+Patelauthor=K.+McKeage&title=Macitentan%3A+First+Global+Approval&doi=10.1007%2Fs40265-013-0156-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0156-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0156-6%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DT.%26aulast%3DMcKeage%26aufirst%3DK.%26atitle%3DMacitentan%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D127%26epage%3D133%26doi%3D10.1007%2Fs40265-013-0156-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theile, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">RÃ¼ppell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speck, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalwisz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haefeli, W. E.</span><span> </span><span class="NLM_article-title">Interaction Profile of Macitentan, a new Non-selective Endothelin-1 Receptors Antagonist, In Vitro</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">701</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">â</span> <span class="NLM_lpage">175</span><span class="refDoi">Â DOI: 10.1016/j.ejphar.2013.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.ejphar.2013.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23353592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFCjtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=701&publication_year=2013&pages=168-175&author=J.+Weissauthor=D.+Theileauthor=M.+A.+R%C3%BCppellauthor=T.+Speckauthor=A.+Spalwiszauthor=W.+E.+Haefeli&title=Interaction+Profile+of+Macitentan%2C+a+new+Non-selective+Endothelin-1+Receptors+Antagonist%2C+In+Vitro&doi=10.1016%2Fj.ejphar.2013.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro</span></div><div class="casAuthors">Weiss, Johanna; Theile, Dirk; Rueppell, Maximilian Alexander; Speck, Tobias; Spalwisz, Adriana; Haefeli, Walter Emil</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">701</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">168-175</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Macitentan is a new non-selective endothelin-1 receptor antagonist under development for the treatment of pulmonary arterial hypertension.  Information on the potential for macitentan to influence the pharmacokinetics of concomitantly administered drugs by inhibition or induction of drug metabolizing enzymes or drug transporters is sparse.  We therefore studied the potential of macitentan to inhibit and induce crit. targets of drug metab. and drug distribution (transporters) in vitro.  Induction was quantified at the mRNA level by real-time RT-PCR in LS180 cells and revealed that macitentan significantly induced mRNA expression of cytochrome P 450 3A4 (CYP3A4), P-glycoprotein (P-gp, ABCB1), solute carrier of org. anions 1B1 (SLCO1B1), and uridinediphosphate-glucuronosyltransferase 1A3 (UGT1A9).  By means of a reporter gene assay our study establishes macitentan as a potent activator of pregnane X receptor (PXR).  Inhibition of drug transporters was evaluated by using transporter over-expressing cell lines and fluorescent specific substrates of the resp. transporters and revealed that macitentan is an inhibitor of P-gp, breast cancer resistance protein (BCRP), SLCO1B1, and SLCO1B3.  Using com. kits macitentan was demonstrated to be a moderate inhibitor of CYP3A4 and CYP2C19.  In conclusion our data provide a comprehensive anal. of the interaction profile of macitentan with drug metabolizing and transporting enzymes in vitro.  Although macitentan has a similar or higher potency for induction and inhibition of drug metabolizing enzymes and transporters than bosentan, its low plasma concns. and minimal accumulation in the liver suggest that it will be markedly less prone to drug-drug interactions than bosentan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUMjcF34OrqLVg90H21EOLACvtfcHk0lgvyQLTcHjPnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFCjtrw%253D&md5=d6515d8fba08a7a8e8d7dee1bd8f69dd</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DTheile%26aufirst%3DD.%26aulast%3DR%25C3%25BCppell%26aufirst%3DM.%2BA.%26aulast%3DSpeck%26aufirst%3DT.%26aulast%3DSpalwisz%26aufirst%3DA.%26aulast%3DHaefeli%26aufirst%3DW.%2BE.%26atitle%3DInteraction%2520Profile%2520of%2520Macitentan%252C%2520a%2520new%2520Non-selective%2520Endothelin-1%2520Receptors%2520Antagonist%252C%2520In%2520Vitro%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D701%26spage%3D168%26epage%3D175%26doi%3D10.1016%2Fj.ejphar.2013.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Rayalu, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvaraj, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganeshan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, N. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshapani, P.</span><span> </span><span class="NLM_article-title">Homology Modeling, Active Site Prediction, and Targeting the Anti-hypertension Activity through Molecular Docking on Endothelin-B Receptor Domain</span> <span class="citation_source-journal">Bioinformation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">â</span> <span class="NLM_lpage">86</span><span class="refDoi">Â DOI: 10.6026/97320630008081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.6026%2F97320630008081" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=81-86&author=D.+J.+Rayaluauthor=C.+Selvarajauthor=S.+K.+Singhauthor=R.+Ganeshanauthor=N.+U.+Kumarauthor=P.+Seshapani&title=Homology+Modeling%2C+Active+Site+Prediction%2C+and+Targeting+the+Anti-hypertension+Activity+through+Molecular+Docking+on+Endothelin-B+Receptor+Domain&doi=10.6026%2F97320630008081"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.6026%2F97320630008081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6026%252F97320630008081%26sid%3Dliteratum%253Aachs%26aulast%3DRayalu%26aufirst%3DD.%2BJ.%26aulast%3DSelvaraj%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DS.%2BK.%26aulast%3DGaneshan%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DN.%2BU.%26aulast%3DSeshapani%26aufirst%3DP.%26atitle%3DHomology%2520Modeling%252C%2520Active%2520Site%2520Prediction%252C%2520and%2520Targeting%2520the%2520Anti-hypertension%2520Activity%2520through%2520Molecular%2520Docking%2520on%2520Endothelin-B%2520Receptor%2520Domain%26jtitle%3DBioinformation%26date%3D2012%26volume%3D8%26spage%3D81%26epage%3D86%26doi%3D10.6026%2F97320630008081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Gatfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller Grandjean, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasse, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span> </span><span class="NLM_article-title">Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e47662</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0047662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1371%2Fjournal.pone.0047662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23077657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Sitb%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e47662&author=J.+Gatfieldauthor=C.+Mueller+Grandjeanauthor=T.+Sasseauthor=M.+Clozelauthor=O.+Nayler&title=Slow+Receptor+Dissociation+Kinetics+Differentiate+Macitentan+from+Other+Endothelin+Receptor+Antagonists+in+Pulmonary+Arterial+Smooth+Muscle+Cells&doi=10.1371%2Fjournal.pone.0047662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells</span></div><div class="casAuthors">Gatfield, John; Grandjean, Celia Mueller; Sasse, Thomas; Clozel, Martine; Nayler, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e47662</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and proliferation of pulmonary arterial smooth muscle cells (PASMC).  The novel ERA macitentan has recently concluded testing in a Phase III morbidity/mortality clin. trial in PAH patients.  Since the assocn. and dissocn. rates of G protein-coupled receptor antagonists can influence their pharmacol. activity in vivo, we used human PASMC to characterize inhibitory potency and receptor inhibition kinetics of macitentan, ambrisentan and bosentan using calcium release and inositol-1-phosphate (IP1) assays.  In calcium release assays macitentan, ambrisentan and bosentan were highly potent ERAs with Kb values of 0.14 nM, 0.12 nM and 1.1 nM, resp.  Macitentan, but not ambrisentan and bosentan, displayed slow apparent receptor assocn. kinetics as evidenced by increased antagonistic potency upon prolongation of antagonist pre-incubation times.  In compd. washout expts., macitentan displayed a significantly lower receptor dissocn. rate and longer receptor occupancy half-life (ROt1/2) compared to bosentan and ambrisentan (ROt1/2:17 min vs. 70 s and 40 s, resp.).  Because of its lower dissocn. rate macitentan behaved as an insurmountable antagonist in calcium release and IP1 assays and unlike bosentan and ambrisentan it blocked endothelin receptor activation across a wide range of endothelin-1 (ET-1) concns.  However, prolongation of the ET-1 stimulation time beyond ROt1/2 rendered macitentan a surmountable antagonist, revealing its competitive binding mode.  Bosentan and ambrisentan behaved as surmountable antagonists irresp. of the assay duration and they lacked inhibitory activity at high ET-1 concns.  Thus, macitentan is a competitive ERA with significantly slower receptor dissocn. kinetics than the currently approved ERAs.  Slow dissocn. caused insurmountable antagonism in functional PASMC-based assays and this could contribute to an enhanced pharmacol. activity of macitentan in ET-1-dependent pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDbQHugB0eIbVg90H21EOLACvtfcHk0lgvyQLTcHjPnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Sitb%252FM&md5=f6065e4b60e74802847bb886b65a38d7</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0047662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0047662%26sid%3Dliteratum%253Aachs%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DMueller%2BGrandjean%26aufirst%3DC.%26aulast%3DSasse%26aufirst%3DT.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DNayler%26aufirst%3DO.%26atitle%3DSlow%2520Receptor%2520Dissociation%2520Kinetics%2520Differentiate%2520Macitentan%2520from%2520Other%2520Endothelin%2520Receptor%2520Antagonists%2520in%2520Pulmonary%2520Arterial%2520Smooth%2520Muscle%2520Cells%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De47662%26doi%3D10.1371%2Fjournal.pone.0047662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Gatfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller Grandjean, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span> </span><span class="NLM_article-title">Distinct ET<sub>A</sub> Receptor Binding Mode of macitentan as Determined by Site Directed Mutagenesis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e107809</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0107809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1371%2Fjournal.pone.0107809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=25226600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslShtr7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e107809&author=J.+Gatfieldauthor=C.+Mueller+Grandjeanauthor=D.+Burauthor=M.+H.+Bolliauthor=O.+Nayler&title=Distinct+ETA+Receptor+Binding+Mode+of+macitentan+as+Determined+by+Site+Directed+Mutagenesis&doi=10.1371%2Fjournal.pone.0107809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis</span></div><div class="casAuthors">Gatfield, John; Grandjean, Celia Mueller; Bur, Daniel; Bolli, Martin H.; Nayler, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e107809/1-e107809/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A review.  The competitive endothelin receptor antagonists (ERA) bosentan and ambrisentan, which have long been approved for the treatment of pulmonary arterial hypertension, are characterized by very short (1 min) occupancy half-lives at the ETA receptor.  The novel ERA macitentan, displays a 20-fold increased receptor occupancy half-life, causing insurmountable antagonism of ET-1-induced signaling in pulmonary arterial smooth muscle cells.  We show here that the slow ETA receptor dissocn. rate of macitentan was shared with a set of structural analogs, whereas compds. structurally related to bosentan displayed fast dissocn. kinetics.  NMR anal. showed that macitentan adopts a compact structure in aq. soln. and mol. modeling suggests that this conformation tightly fits into a well-defined ETA receptor binding pocket.  In contrast the structurally different and neg. charged bosentan-type mols. only partially filled this pocket and expanded into an extended endothelin binding site.  To further investigate these different ETA receptor-antagonist interaction modes, we performed functional studies using ETA receptor variants harboring amino acid point mutations in the presumed ERA interaction site.  Three ETA receptor residues significantly and differentially affected ERA activity: Mutation R326Q did not affect the antagonist activity of macitentan, however the potencies of bosentan and ambrisentan were significantly reduced; mutation L322A rendered macitentan less potent, whereas bosentan and ambrisentan were unaffected; mutation I355A significantly reduced bosentan potency, but not ambrisentan and macitentan potencies.  This suggests that - in contrast to bosentan and ambrisentan - macitentan-ETA receptor binding is not dependent on strong charge-charge interactions, but depends predominantly on hydrophobic interactions.  This different binding mode could be the reason for macitentan's sustained target occupancy and insurmountable antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Mz62J3R5E7Vg90H21EOLACvtfcHk0lgRWSvmP421bw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslShtr7O&md5=007edafae066ab62cf11936f50557ff9</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0107809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0107809%26sid%3Dliteratum%253Aachs%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DMueller%2BGrandjean%26aufirst%3DC.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DNayler%26aufirst%3DO.%26atitle%3DDistinct%2520ETA%2520Receptor%2520Binding%2520Mode%2520of%2520macitentan%2520as%2520Determined%2520by%2520Site%2520Directed%2520Mutagenesis%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De107809%26doi%3D10.1371%2Fjournal.pone.0107809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Shaw, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeulen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickard, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teasdale, G. M.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of the Endothelin Receptor Antagonist TAK-044 in Treating Subarachnoid Hemorrhage</span> <span class="citation_source-journal">J. Neurosurg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">992</span><span class="NLM_x">â</span> <span class="NLM_lpage">997</span><span class="refDoi">Â DOI: 10.3171/jns.2000.93.6.0992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.3171%2Fjns.2000.93.6.0992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=11117873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3cXptValsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2000&pages=992-997&author=M.+D.+Shawauthor=M.+Vermeulenauthor=G.+D.+Murrayauthor=J.+D.+Pickardauthor=B.+A.+Bellauthor=G.+M.+Teasdale&title=Efficacy+and+Safety+of+the+Endothelin+Receptor+Antagonist+TAK-044+in+Treating+Subarachnoid+Hemorrhage&doi=10.3171%2Fjns.2000.93.6.0992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of the endothelinA/B receptor antagonist TAK-044 in treating subarachnoid hemorrhage: A report by the steering committee on behalf of the UK/Netherlands/Eire TAK-044 subarachnoid hemorrhage study group</span></div><div class="casAuthors">Shaw, Malcolm D. M.; Vermeulen, Marinus; Murray, Gordon D.; Pickard, John D.; Bell, B. Anthony; Teasdale, Graham M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurosurgery</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">992-997</span>CODEN:
                <span class="NLM_cas:coden">JONSAC</span>;
        ISSN:<span class="NLM_cas:issn">0022-3085</span>.
    
            (<span class="NLM_cas:orgname">American Association of Neurological Surgeons</span>)
        </div><div class="casAbstract">Delayed cerebral ischemia remains an important cause of death and disability in patients who have suffered subarachnoid hemorrhage (SAH).  Endothelin (ET) has a potent contractile effect on cerebral arteries and arterioles and has been implicated in vasospasm.  The authors administered ETA/B receptor antagonist (TAK-044) to patients suffering from aneurysmal SAH.  They then assessed whether this agent reduced the occurrence of delayed cerebral ischemic events and examd. its safety profile in this group of patients.  Four hundred twenty patients who had suffered an SAH were recruited into a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II trial.  The primary end point was whether a delayed ischemic event occurred within 3 mo after the first dose of the study drug and the secondary end points included detg. whether a delayed ischemic event occurred by 10 days after the first dose of the study drug, whether a new cerebral infarct was demonstrated on a computerized tomog. scan or at postmortem examn. by 3 mo after administration of the initial dose, the patient's Glasgow Outcome Scale scores at 3 mo after the initial dose, and adverse events.  There was a lower incidence of delayed ischemic events at 3 mo in the TAK-044-treated group: 29.5% compared with 36.6% in a group of patients receiving placebo.  The estd. relative risk was 0.8 with a 95% confidence interval of 0.61 to 1.06.  There were no significant differences in the secondary end points, including clin. outcomes in the placebo-treated and TAK-044-treated groups.  The TAK-044 was well tolerated by patients who had suffered an SAH, even though hypotension and headache-side effects compatible with the drug's vasodilatory properties-occurred.  It would be valuable to proceed to a fully powered phase III trial of an ET receptor antagonist in treating aneurysmal SAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBwENB_SA2wLVg90H21EOLACvtfcHk0lgRWSvmP421bw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXptValsr0%253D&md5=5a00b40d783396e0a7d292de64723179</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.3171%2Fjns.2000.93.6.0992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3171%252Fjns.2000.93.6.0992%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DM.%2BD.%26aulast%3DVermeulen%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DG.%2BD.%26aulast%3DPickard%26aufirst%3DJ.%2BD.%26aulast%3DBell%26aufirst%3DB.%2BA.%26aulast%3DTeasdale%26aufirst%3DG.%2BM.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520the%2520Endothelin%2520Receptor%2520Antagonist%2520TAK-044%2520in%2520Treating%2520Subarachnoid%2520Hemorrhage%26jtitle%3DJ.%2520Neurosurg.%26date%3D2000%26volume%3D93%26spage%3D992%26epage%3D997%26doi%3D10.3171%2Fjns.2000.93.6.0992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramuz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶ffler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coassolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, S.</span><span> </span><span class="NLM_article-title">Pharmacology of Tezosentan, New Endothelin Receptor Antagonist Designed for Parenteral Use</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">840</span><span class="NLM_x">â</span> <span class="NLM_lpage">846</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10411600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK1MXkvVKnsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=1999&pages=840-846&author=M.+Clozelauthor=H.+Ramuzauthor=J.+P.+Clozelauthor=V.+Breuauthor=P.+Hessauthor=B.+M.+L%C3%B6fflerauthor=P.+Coassoloauthor=S.+Roux&title=Pharmacology+of+Tezosentan%2C+New+Endothelin+Receptor+Antagonist+Designed+for+Parenteral+Use"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use</span></div><div class="casAuthors">Clozel, Martine; Ramuz, Henri; Clozel, Jean-Paul; Breu, Volker; Hess, Patrick; Loffler, Bernd-Michael; Coassolo, Philippe; Roux, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">840-846</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Tezosentan (Ro 61-0612) [5-isopropylpyridine-2-sulfonic acid 6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)pyrimidin-4-ylamide] is a new endothelin (ET) receptor antagonist specifically designed for parenteral use.  Tezosentan competitively antagonizes the specific binding of 125I-labeled ET-1 and of the selective ETB receptor ligands 125I-labeled ET-3 and 125I-labeled sarafotoxin S6c to cells and tissues carrying ETA and ETB receptors, with inhibitory consts. in the nanomolar range, and it has high water soly.  Tezosentan exhibits high functional inhibitory potency for inhibiting contraction induced by ET-1 on isolated rat aorta (ETA receptors; pA2 = 9.5) and by sarafotoxin S6c on rat trachea (ETB receptors; pA2 = 7.7).  In vivo, tezosentan inhibits the pressor effect of big ET-1 in pithed rats and increases plasma ET-1 concns. in conscious rats in a dose-dependent fashion.  In spontaneously hypertensive rats, i.v. injection of tezosentan has acute hemodynamic effects and decreases blood pressure.  Tezosentan is also able to prevent the acute renal failure that complicates rhabdomyolysis in a rat model of myoglobinuric nephropathy.  Finally, tezosentan exhibits an apparent elimination half-life of <1 h in rabbits and primates and of 2 h in rats.  In conclusion, tezosentan, a potent mixed ET receptor antagonist with a short half-life, may offer a novel medical approach for the i.v. treatment of acute pathol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGSGjuqLVaWrVg90H21EOLACvtfcHk0lgRWSvmP421bw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvVKnsbs%253D&md5=f85a49d96779b4e9c394795db5cd1180</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DRamuz%26aufirst%3DH.%26aulast%3DClozel%26aufirst%3DJ.%2BP.%26aulast%3DBreu%26aufirst%3DV.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DL%25C3%25B6ffler%26aufirst%3DB.%2BM.%26aulast%3DCoassolo%26aufirst%3DP.%26aulast%3DRoux%26aufirst%3DS.%26atitle%3DPharmacology%2520of%2520Tezosentan%252C%2520New%2520Endothelin%2520Receptor%2520Antagonist%2520Designed%2520for%2520Parenteral%2520Use%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D290%26spage%3D840%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Hoshino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamauchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikkawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabana, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, S.</span><span> </span><span class="NLM_article-title">Pharmacological Profile of T-0201, a Highly Potent and Orally Active Endothelin Receptor Antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">643</span><span class="NLM_x">â</span> <span class="NLM_lpage">649</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=9694915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK1cXlsVWiur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1998&pages=643-649&author=T.+Hoshinoauthor=R.+Yamauchiauthor=K.+Kikkawaauthor=H.+Yabanaauthor=S.+Murata&title=Pharmacological+Profile+of+T-0201%2C+a+Highly+Potent+and+Orally+Active+Endothelin+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist</span></div><div class="casAuthors">Hoshino, Tomoko; Yamauchi, Rikako; Kikkawa, Kohei; Yabana, Hideo; Murata, Sakae</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">643-649</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The pharmacol. properties of N-(6-(2-(5-bromopyrimidin-4-yl)-4-(2-hydroxy-1,1-dimethylethyl)benzensulfonamide sodium salt sesquihydrate (T-0201) was studied , a new nonpeptide endothelin (ET) receptor antagonist, in vitro and in vivo.  In binding studies, T-0201 competitively antagonized the specific binding of [125I]-ET-1 to human cloned ETA receptors (the Ki value was 0.015 nM).  T-0201 weakly inhibited [125I]-ET-1-binding to human cloned ETB receptors; the Ki value was 41 nM.  T-0201 shifted the concn.-response curve of ET-1-induced contraction of the isolated rat aorta (ETA receptors) to the right (pA2 = 9.0).  In the isolated rat trachea, a selective ETB agonist sarafotoxin S6c-induced contraction was inhibited by T-0201 (pA2 = 6.8).  T-0201 also caused the inhibition of ET-1-induced contraction of the isolated rabbit pulmonary artery (pA2 = 5.7).  In anesthetized rats, T-0201 (0.01-1 mg/kg) inhibited the pressor response to exogenous big ET-1 (1 nmol/kg i.v.), after both i.v. and p.o. administration, in a dose-dependent manner.  The significant inhibitory effect of orally administered T-0201 on big ET-1-induced pressor response lasted for 4 h at 0.1 mg/kg and for 8 h at 1 mg/kg.  Thus the present study demonstrates that T-0201 is a highly potent, long-lasting, orally active active and selective ETA receptor antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfn4EJzzFBcrVg90H21EOLACvtfcHk0lhW1Dj2jKla7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlsVWiur8%253D&md5=b73aa3c5da3b7bd6e0673bfc151ddcb9</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoshino%26aufirst%3DT.%26aulast%3DYamauchi%26aufirst%3DR.%26aulast%3DKikkawa%26aufirst%3DK.%26aulast%3DYabana%26aufirst%3DH.%26aulast%3DMurata%26aufirst%3DS.%26atitle%3DPharmacological%2520Profile%2520of%2520T-0201%252C%2520a%2520Highly%2520Potent%2520and%2520Orally%2520Active%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D286%26spage%3D643%26epage%3D649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Ohlstein, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lago, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leber, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cousins, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peishoff, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bean, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggleston, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elshourbagy, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feuerstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poste, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruffolo, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleason, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. D.</span><span> </span><span class="NLM_article-title">SB 209670, a Rationally Designed Potent Nonpeptide Endothelin Receptor Antagonist</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">8052</span><span class="NLM_x">â</span> <span class="NLM_lpage">8056</span><span class="refDoi">Â DOI: 10.1073/pnas.91.17.8052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1073%2Fpnas.91.17.8052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=8052-8056&author=E.+H.+Ohlsteinauthor=P.+Nambiauthor=S.+A.+Douglasauthor=R.+M.+Edwardsauthor=M.+Gellaiauthor=A.+Lagoauthor=J.+D.+Leberauthor=R.+D.+Cousinsauthor=A.+Gaoauthor=J.+S.+Frazeeauthor=C.+E.+Peishoffauthor=J.+W.+Beanauthor=D.+S.+Egglestonauthor=N.+A.+Elshourbagyauthor=C.+Kumarauthor=J.+A.+Leeauthor=T.+L.+Yueauthor=C.+Loudenauthor=D.+P.+Brooksauthor=J.+Weinstockauthor=G.+Feuersteinauthor=G.+Posteauthor=R.+R.+Ruffoloauthor=J.+G.+Gleasonauthor=J.+D.+Elliott&title=SB+209670%2C+a+Rationally+Designed+Potent+Nonpeptide+Endothelin+Receptor+Antagonist&doi=10.1073%2Fpnas.91.17.8052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.17.8052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.17.8052%26sid%3Dliteratum%253Aachs%26aulast%3DOhlstein%26aufirst%3DE.%2BH.%26aulast%3DNambi%26aufirst%3DP.%26aulast%3DDouglas%26aufirst%3DS.%2BA.%26aulast%3DEdwards%26aufirst%3DR.%2BM.%26aulast%3DGellai%26aufirst%3DM.%26aulast%3DLago%26aufirst%3DA.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DCousins%26aufirst%3DR.%2BD.%26aulast%3DGao%26aufirst%3DA.%26aulast%3DFrazee%26aufirst%3DJ.%2BS.%26aulast%3DPeishoff%26aufirst%3DC.%2BE.%26aulast%3DBean%26aufirst%3DJ.%2BW.%26aulast%3DEggleston%26aufirst%3DD.%2BS.%26aulast%3DElshourbagy%26aufirst%3DN.%2BA.%26aulast%3DKumar%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DYue%26aufirst%3DT.%2BL.%26aulast%3DLouden%26aufirst%3DC.%26aulast%3DBrooks%26aufirst%3DD.%2BP.%26aulast%3DWeinstock%26aufirst%3DJ.%26aulast%3DFeuerstein%26aufirst%3DG.%26aulast%3DPoste%26aufirst%3DG.%26aulast%3DRuffolo%26aufirst%3DR.%2BR.%26aulast%3DGleason%26aufirst%3DJ.%2BG.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26atitle%3DSB%2520209670%252C%2520a%2520Rationally%2520Designed%2520Potent%2520Nonpeptide%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D8052%26epage%3D8056%26doi%3D10.1073%2Fpnas.91.17.8052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Ohlstein, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lago, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eddy, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. D.</span><span> </span><span class="NLM_article-title">Nonpeptide Endothelin Receptor Antagonists. VI: Pharmacological Characterization of SB 217242, a Potent and Highly Bioavailable Endothelin Receptor Antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">â</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=8632328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK28XhtFaktrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1996&pages=609-615&author=E.+H.+Ohlsteinauthor=P.+Nambiauthor=A.+Lagoauthor=D.+W.+Hayauthor=G.+Beckauthor=K.+L.+Fongauthor=E.+P.+Eddyauthor=P.+Smithauthor=H.+Ellensauthor=J.+D.+Elliott&title=Nonpeptide+Endothelin+Receptor+Antagonists.+VI%3A+Pharmacological+Characterization+of+SB+217242%2C+a+Potent+and+Highly+Bioavailable+Endothelin+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist</span></div><div class="casAuthors">Ohlstein, Eliot H.; Nambi, Ponnal; Largo, Amparo; Hay, Douglas W. P.; Beck, George; Fong, Kei-Lai; Eddy, E. Priya; Smith, Philip; Ellens, Harma; Elliott, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-15</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">This study describes the pharmacol. characterization of SB 217242, a highly potent orally bioavailable nonpeptide antagonist of both endothelin type A (ETA) and endothelin type B (ETB) receptors.  In human cloned ETA and ETB receptors, SB 217242 produced concn.-dependent displacement of [125]I-endothelin-1 (ET-1) in both receptor subtypes with Ki values of 1.1 and 111 nM, resp.  SB 217242 produced concn.-dependent, parallel rightward shifts in the ET-1 concn.-response curves in rat isolated aorta and human isolated pulmonary artery (ETA receptor-mediated vascular contraction) with Kb values of 4.4 and 5.0 nM, resp.  SB 217242 was 4-, 62- and 125-fold more potent as an ETA receptor antagonist than the previously reported compds. BQ-123, PD 142893 and Ro 46-2005, resp.  SB 217242 (10 Î¼M) did not produce significant effects against contraction produced by other vasoactive agents.  SB 21742 produced concn.-dependent antagonism of responses produced by ETB receptor activation as demonstrated by antagonism of sarafotoxin S6c-mediated contraction in the rabbit isolated pulmonary artery with a Kb value of 352 nM.  In vitro cell monolayers of Caco-2 cells had high permeability of SB 217242.  In vivo pharmacokinetics in the rat confirmed that SB 217242 was rapidly absorbed from the gastrointestinal tract with a bioavailability of 66%.  The Sb 217242 plasma half-life in rats after intraduodenal administration was 3.3 h, with a systemic clearance of 27.3 mL/min/kg.  Orally administered SB 217242 (0.3-30 mg/kg) produced dose-dependent inhibition of the pressor response to exogenous ET-1 in conscious rats; with a dose of 30 mg/kg p.o., inhibition was obsd. for at least 5.5 h.  The present study demonstrates that SB 217242 is a highly potent antagonist of both ETA and ETB receptors.  In addn., SB 217242 has high in vitro permeability and high oral bioavailability.  SB 217242 represents a new orally active pharmacol. tool that should assist in the elucidation of the chronic role of endothelin in pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2rt-NUxVpy7Vg90H21EOLACvtfcHk0lhW1Dj2jKla7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtFaktrY%253D&md5=16ebb073ac6142f3ab7fc04c89b18422</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOhlstein%26aufirst%3DE.%2BH.%26aulast%3DNambi%26aufirst%3DP.%26aulast%3DLago%26aufirst%3DA.%26aulast%3DHay%26aufirst%3DD.%2BW.%26aulast%3DBeck%26aufirst%3DG.%26aulast%3DFong%26aufirst%3DK.%2BL.%26aulast%3DEddy%26aufirst%3DE.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DEllens%26aufirst%3DH.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26atitle%3DNonpeptide%2520Endothelin%2520Receptor%2520Antagonists.%2520VI%253A%2520Pharmacological%2520Characterization%2520of%2520SB%2520217242%252C%2520a%2520Potent%2520and%2520Highly%2520Bioavailable%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1996%26volume%3D276%26spage%3D609%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">von Geldern, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorensen, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczepankiewicz, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessale, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opgenorth, T. J.</span><span> </span><span class="NLM_article-title">Pyrrolidine-3-Carboxylic Acids as Endothelin Antagonists. 4. Side Chain Conformational Restriction Leads to ET<sub>B</sub> selectivity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3668</span><span class="NLM_x">â</span> <span class="NLM_lpage">3678</span><span class="refDoi">Â DOI: 10.1021/jm990170q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990170q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3668-3678&author=T.+W.+von+Geldernauthor=A.+S.+Taskerauthor=B.+K.+Sorensenauthor=M.+Winnauthor=B.+G.+Szczepankiewiczauthor=D.+B.+Dixonauthor=W.+J.+Chiouauthor=L.+Wangauthor=J.+L.+Wessaleauthor=A.+Adlerauthor=K.+C.+Marshauthor=B.+Nguyenauthor=T.+J.+Opgenorth&title=Pyrrolidine-3-Carboxylic+Acids+as+Endothelin+Antagonists.+4.+Side+Chain+Conformational+Restriction+Leads+to+ETB+selectivity&doi=10.1021%2Fjm990170q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm990170q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990170q%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BGeldern%26aufirst%3DT.%2BW.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DSorensen%26aufirst%3DB.%2BK.%26aulast%3DWinn%26aufirst%3DM.%26aulast%3DSzczepankiewicz%26aufirst%3DB.%2BG.%26aulast%3DDixon%26aufirst%3DD.%2BB.%26aulast%3DChiou%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWessale%26aufirst%3DJ.%2BL.%26aulast%3DAdler%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DOpgenorth%26aufirst%3DT.%2BJ.%26atitle%3DPyrrolidine-3-Carboxylic%2520Acids%2520as%2520Endothelin%2520Antagonists.%25204.%2520Side%2520Chain%2520Conformational%2520Restriction%2520Leads%2520to%2520ETB%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D3668%26epage%3D3678%26doi%3D10.1021%2Fjm990170q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Balwierczak, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruseo, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DelGrande, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shetty, S. S.</span><span> </span><span class="NLM_article-title">Characterization of a Potent and Selective Endothelin-B Receptor Antagonist, IRL 2500</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S393</span><span class="NLM_x">â</span> <span class="NLM_lpage">S396</span><span class="refDoi">Â DOI: 10.1097/00005344-199526003-00116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2F00005344-199526003-00116" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1995&pages=S393-S396&issue=Suppl.+3&author=J.+L.+Balwierczakauthor=C.+W.+Bruseoauthor=D.+DelGrandeauthor=A.+Y.+Jengauthor=P.+Savageauthor=S.+S.+Shetty&title=Characterization+of+a+Potent+and+Selective+Endothelin-B+Receptor+Antagonist%2C+IRL+2500&doi=10.1097%2F00005344-199526003-00116"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1097%2F00005344-199526003-00116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199526003-00116%26sid%3Dliteratum%253Aachs%26aulast%3DBalwierczak%26aufirst%3DJ.%2BL.%26aulast%3DBruseo%26aufirst%3DC.%2BW.%26aulast%3DDelGrande%26aufirst%3DD.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DSavage%26aufirst%3DP.%26aulast%3DShetty%26aufirst%3DS.%2BS.%26atitle%3DCharacterization%2520of%2520a%2520Potent%2520and%2520Selective%2520Endothelin-B%2520Receptor%2520Antagonist%252C%2520IRL%25202500%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1995%26volume%3D26%26issue%3DSuppl.%25203%26spage%3DS393%26epage%3DS396%26doi%3D10.1097%2F00005344-199526003-00116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Ikemura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohmori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, S.</span><span> </span><span class="NLM_article-title">Effects of Endothelin B Antagonist RES-701-1 on Endothelin-induced Contractile Responses In-vivo and In-vitro in Guinea-pigs</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">â</span> <span class="NLM_lpage">105</span><span class="refDoi">Â DOI: 10.1111/j.2042-7158.1996.tb05886.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fj.2042-7158.1996.tb05886.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=8722505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK28XisFCrtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1996&pages=100-105&author=T.+Ikemuraauthor=K.+Ohmoriauthor=T.+Tanakaauthor=Y.+Matsudaauthor=S.+Kitamura&title=Effects+of+Endothelin+B+Antagonist+RES-701-1+on+Endothelin-induced+Contractile+Responses+In-vivo+and+In-vitro+in+Guinea-pigs&doi=10.1111%2Fj.2042-7158.1996.tb05886.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of endothelin B antagonist RES-701-1 on endothelin-induced contractile responses in vivo and in vitro in guinea pigs</span></div><div class="casAuthors">Ikemura, Toshihide; Ohmori, Kenji; Tanaka, Takeo; Matsuda, Yuzuru; Kitamura, Shigeto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-5</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Royal Pharmaceutical Society of Great Britain</span>)
        </div><div class="casAbstract">The effects of an endothelin (ET)-receptor B-specific antagonist, RES-701-1, on ET-induced contraction of guinea pig trachea and on ET-induced bronchoconstriction in anesthetized guinea pigs were investigated.  In the epithelium-removed tracheal prepn., 1 Ã 10-5 M RES-701-1 inhibited contractions induced by the ETB-specific agonist sarafotoxin S6c (pKB = 6.10).  In the epithelium-intact tracheal prepn., RES-701-1 (1 Ã 10-5 M) inhibited the ET-3-induced contraction (pKB = 5.27), but enhanced the ET-1-induced contraction significantly and shifted the concn. response curve to the left.  The maximal responses to ET-1 and ET-3-induced contraction were augmented by epithelium removal by 1.5 and 1.8-fold, resp.  Against ET-3-induced contraction in the tracheal prepn. without epithelium, RES-701-1 (0.3-10 Ã 10-6 M) antagonized the contraction in a concn.-dependent manner (pA2 = 5.9).  On the other hand, RES-701-1 (1 Ã 10-5 M) did not affect ET-1-evoked responses in the trachea without epithelium.  The i.v. administration of ET-1 (1.5 nmol/kg) or ET-3 (1.5 nmol/kg) evoked a biphasic, fast and sustained bronchoconstriction in anesthetized guinea pigs pretreated with propranolol (1.0 mg/kg).  When administered i.v., RES-701-1 (0.3 or 1.0 mg/kg) showed significant redn. in both phases of bronchoconstriction induced by ET-3.  As in the case of ET-1-induced bronchoconstriction, RES-701-1 augmented the sustained phase although a significant redn. of the fast phase was obsd.  These results indicate that RES-701-1 can inhibit the ET-3-induced airway responses not only in vitro but also in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmMmYjQZZCSbVg90H21EOLACvtfcHk0lhTzFZg235a8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XisFCrtL4%253D&md5=a294a9cd7fe603941647ac574b3d6d3a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.1996.tb05886.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.1996.tb05886.x%26sid%3Dliteratum%253Aachs%26aulast%3DIkemura%26aufirst%3DT.%26aulast%3DOhmori%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DMatsuda%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DS.%26atitle%3DEffects%2520of%2520Endothelin%2520B%2520Antagonist%2520RES-701-1%2520on%2520Endothelin-induced%2520Contractile%2520Responses%2520In-vivo%2520and%2520In-vitro%2520in%2520Guinea-pigs%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D1996%26volume%3D48%26spage%3D100%26epage%3D105%26doi%3D10.1111%2Fj.2042-7158.1996.tb05886.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Breu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidhart, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramuz, H.</span><span> </span><span class="NLM_article-title">In-vitro Characterisation of Ro 46-8443, the First Non-peptide Antagonist Selective for the Endothelin ET<sub>B</sub> Receptor</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">383</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">â</span> <span class="NLM_lpage">41</span><span class="refDoi">Â DOI: 10.1016/0014-5793(96)00213-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2F0014-5793%2896%2900213-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=1996&pages=37-41&author=V.+Breuauthor=M.+Clozelauthor=K.+Burriauthor=G.+Hirthauthor=W.+Neidhartauthor=H.+Ramuz&title=In-vitro+Characterisation+of+Ro+46-8443%2C+the+First+Non-peptide+Antagonist+Selective+for+the+Endothelin+ETB+Receptor&doi=10.1016%2F0014-5793%2896%2900213-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2896%2900213-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252896%252900213-X%26sid%3Dliteratum%253Aachs%26aulast%3DBreu%26aufirst%3DV.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DBurri%26aufirst%3DK.%26aulast%3DHirth%26aufirst%3DG.%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DRamuz%26aufirst%3DH.%26atitle%3DIn-vitro%2520Characterisation%2520of%2520Ro%252046-8443%252C%2520the%2520First%2520Non-peptide%2520Antagonist%2520Selective%2520for%2520the%2520Endothelin%2520ETB%2520Receptor%26jtitle%3DFEBS%2520Lett.%26date%3D1996%26volume%3D383%26spage%3D37%26epage%3D41%26doi%3D10.1016%2F0014-5793%2896%2900213-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marfurt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grisostomi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binkert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramuz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span> </span><span class="NLM_article-title">Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2776</span><span class="NLM_x">â</span> <span class="NLM_lpage">2795</span><span class="refDoi">Â DOI: 10.1021/jm031115r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031115r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2776-2795&author=M.+H.+Bolliauthor=J.+Marfurtauthor=C.+Grisostomiauthor=C.+Bossauthor=C.+Binkertauthor=P.+Hessauthor=A.+Treiberauthor=E.+Thorinauthor=K.+Morrisonauthor=S.+Buchmannauthor=D.+Burauthor=H.+Ramuzauthor=M.+Clozelauthor=W.+Fischliauthor=T.+Weller&title=Novel+Benzo%5B1%2C4%5Ddiazepin-2-one+Derivatives+as+Endothelin+Receptor+Antagonists&doi=10.1021%2Fjm031115r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm031115r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031115r%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DGrisostomi%26aufirst%3DC.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DThorin%26aufirst%3DE.%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DRamuz%26aufirst%3DH.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DNovel%2520Benzo%255B1%252C4%255Ddiazepin-2-one%2520Derivatives%2520as%2520Endothelin%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2776%26epage%3D2795%26doi%3D10.1021%2Fjm031115r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Ishizuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamori, T.</span><span> </span><span class="NLM_article-title">Structure-Activity Relationships of a Novel Class of Endothelin-A Receptor Antagonists and Discovery of Potent and Selective Receptor Antagonist, 2-(Benzo[1,3]Dioxol-5-yl)-6-isopropyloxy-4-(4-Methoxyphenyl)-2<i>H</i>-chromene-3-carboxylic Acid (S-1255). 1. Study on Structure-activity Relationships and Basic Structure Crucial for ET<sub>A</sub> Antagonism</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2041</span><span class="NLM_x">â</span> <span class="NLM_lpage">2055</span><span class="refDoi">Â DOI: 10.1021/jm010382z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010382z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2041-2055&author=N.+Ishizukaauthor=K.+Matsumuraauthor=K.+Sakaiauthor=M.+Fujimotoauthor=S.+Miharaauthor=T.+Yamamori&title=Structure-Activity+Relationships+of+a+Novel+Class+of+Endothelin-A+Receptor+Antagonists+and+Discovery+of+Potent+and+Selective+Receptor+Antagonist%2C+2-%28Benzo%5B1%2C3%5DDioxol-5-yl%29-6-isopropyloxy-4-%284-Methoxyphenyl%29-2H-chromene-3-carboxylic+Acid+%28S-1255%29.+1.+Study+on+Structure-activity+Relationships+and+Basic+Structure+Crucial+for+ETA+Antagonism&doi=10.1021%2Fjm010382z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm010382z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010382z%26sid%3Dliteratum%253Aachs%26aulast%3DIshizuka%26aufirst%3DN.%26aulast%3DMatsumura%26aufirst%3DK.%26aulast%3DSakai%26aufirst%3DK.%26aulast%3DFujimoto%26aufirst%3DM.%26aulast%3DMihara%26aufirst%3DS.%26aulast%3DYamamori%26aufirst%3DT.%26atitle%3DStructure-Activity%2520Relationships%2520of%2520a%2520Novel%2520Class%2520of%2520Endothelin-A%2520Receptor%2520Antagonists%2520and%2520Discovery%2520of%2520Potent%2520and%2520Selective%2520Receptor%2520Antagonist%252C%25202-%2528Benzo%255B1%252C3%255DDioxol-5-yl%2529-6-isopropyloxy-4-%25284-Methoxyphenyl%2529-2H-chromene-3-carboxylic%2520Acid%2520%2528S-1255%2529.%25201.%2520Study%2520on%2520Structure-activity%2520Relationships%2520and%2520Basic%2520Structure%2520Crucial%2520for%2520ETA%2520Antagonism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2041%26epage%3D2055%26doi%3D10.1021%2Fjm010382z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Amberg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">HergenrÃ¶der, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettschau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschack, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riechers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, L.</span><span> </span><span class="NLM_article-title">Discovery and Synthesis of (<i>S</i>)-3-[2-(3,4-Dimethoxyphenyl)Ethoxy]-2-(4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic Acid (LU 302872), a Novel Orally Active Mixed ET<sub>A</sub>/ET<sub>B</sub> Receptor Antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3026</span><span class="NLM_x">â</span> <span class="NLM_lpage">3032</span><span class="refDoi">Â DOI: 10.1021/jm9910425</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9910425" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3026-3032&author=W.+Ambergauthor=S.+Hergenr%C3%B6derauthor=H.+Hillenauthor=R.+Jansenauthor=G.+Kettschauauthor=A.+Klingauthor=D.+Klingeauthor=M.+Raschackauthor=H.+Riechersauthor=L.+Unger&title=Discovery+and+Synthesis+of+%28S%29-3-%5B2-%283%2C4-Dimethoxyphenyl%29Ethoxy%5D-2-%284%2C6-dimethylpyrimidin-2-yloxy%29-3%2C3-diphenylpropionic+Acid+%28LU+302872%29%2C+a+Novel+Orally+Active+Mixed+ETA%2FETB+Receptor+Antagonist&doi=10.1021%2Fjm9910425"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm9910425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9910425%26sid%3Dliteratum%253Aachs%26aulast%3DAmberg%26aufirst%3DW.%26aulast%3DHergenr%25C3%25B6der%26aufirst%3DS.%26aulast%3DHillen%26aufirst%3DH.%26aulast%3DJansen%26aufirst%3DR.%26aulast%3DKettschau%26aufirst%3DG.%26aulast%3DKling%26aufirst%3DA.%26aulast%3DKlinge%26aufirst%3DD.%26aulast%3DRaschack%26aufirst%3DM.%26aulast%3DRiechers%26aufirst%3DH.%26aulast%3DUnger%26aufirst%3DL.%26atitle%3DDiscovery%2520and%2520Synthesis%2520of%2520%2528S%2529-3-%255B2-%25283%252C4-Dimethoxyphenyl%2529Ethoxy%255D-2-%25284%252C6-dimethylpyrimidin-2-yloxy%2529-3%252C3-diphenylpropionic%2520Acid%2520%2528LU%2520302872%2529%252C%2520a%2520Novel%2520Orally%2520Active%2520Mixed%2520ETA%252FETB%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D3026%26epage%3D3032%26doi%3D10.1021%2Fjm9910425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Patel, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olgun, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengyel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reznik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephani, R. A.</span><span> </span><span class="NLM_article-title">Synthesis and Pharmacological Activity of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic Acids as Selective ET<sub>A</sub> Antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6840</span><span class="NLM_x">â</span> <span class="NLM_lpage">6844</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2010.08.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.bmcl.2010.08.074" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6840-6844&author=H.+J.+Patelauthor=N.+Olgunauthor=I.+Lengyelauthor=S.+Reznikauthor=R.+A.+Stephani&title=Synthesis+and+Pharmacological+Activity+of+1%2C3%2C6-trisubstituted-4-oxo-1%2C4-dihydroquinoline-2-carboxylic+Acids+as+Selective+ETA+Antagonists&doi=10.1016%2Fj.bmcl.2010.08.074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.08.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.08.074%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BJ.%26aulast%3DOlgun%26aufirst%3DN.%26aulast%3DLengyel%26aufirst%3DI.%26aulast%3DReznik%26aufirst%3DS.%26aulast%3DStephani%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Activity%2520of%25201%252C3%252C6-trisubstituted-4-oxo-1%252C4-dihydroquinoline-2-carboxylic%2520Acids%2520as%2520Selective%2520ETA%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6840%26epage%3D6844%26doi%3D10.1016%2Fj.bmcl.2010.08.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Xia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span> </span><span class="NLM_article-title">Synthesis and In-vitro Evaluation of Ambrisentan Analogues as Potential Endothelin Receptor Antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3894</span><span class="NLM_x">â</span> <span class="NLM_lpage">3897</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.05.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.bmcl.2011.05.034" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3894-3897&author=J.+Xiaauthor=J.+Songauthor=L.+Zhenauthor=X.+Zhangauthor=X.+Leiauthor=L.+Zhengauthor=Q.+Wangauthor=H.+Sun&title=Synthesis+and+In-vitro+Evaluation+of+Ambrisentan+Analogues+as+Potential+Endothelin+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2011.05.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.05.034%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DZhen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLei%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520In-vitro%2520Evaluation%2520of%2520Ambrisentan%2520Analogues%2520as%2520Potential%2520Endothelin%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3894%26epage%3D3897%26doi%3D10.1016%2Fj.bmcl.2011.05.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Allard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijkhuisen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrull, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshayes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamourette, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducancel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boquet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couraud, J. Y.</span><span> </span><span class="NLM_article-title">Generation and Characterization of Rendomab-B1, a Monoclonal Antibody Displaying Potent and Specific Antagonism of the Human Endothelin B Receptor</span> <span class="citation_source-journal">MAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">â</span> <span class="NLM_lpage">69</span><span class="refDoi">Â DOI: 10.4161/mabs.22696</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.4161%2Fmabs.22696" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=56-69&author=B.+Allardauthor=A.+Wijkhuisenauthor=A.+Borrullauthor=F.+Deshayesauthor=F.+Priamauthor=P.+Lamouretteauthor=F.+Ducancelauthor=D.+Boquetauthor=J.+Y.+Couraud&title=Generation+and+Characterization+of+Rendomab-B1%2C+a+Monoclonal+Antibody+Displaying+Potent+and+Specific+Antagonism+of+the+Human+Endothelin+B+Receptor&doi=10.4161%2Fmabs.22696"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.4161%2Fmabs.22696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fmabs.22696%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DWijkhuisen%26aufirst%3DA.%26aulast%3DBorrull%26aufirst%3DA.%26aulast%3DDeshayes%26aufirst%3DF.%26aulast%3DPriam%26aufirst%3DF.%26aulast%3DLamourette%26aufirst%3DP.%26aulast%3DDucancel%26aufirst%3DF.%26aulast%3DBoquet%26aufirst%3DD.%26aulast%3DCouraud%26aufirst%3DJ.%2BY.%26atitle%3DGeneration%2520and%2520Characterization%2520of%2520Rendomab-B1%252C%2520a%2520Monoclonal%2520Antibody%2520Displaying%2520Potent%2520and%2520Specific%2520Antagonism%2520of%2520the%2520Human%2520Endothelin%2520B%2520Receptor%26jtitle%3DMAbs%26date%3D2013%26volume%3D5%26spage%3D56%26epage%3D69%26doi%3D10.4161%2Fmabs.22696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Aubert, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Therapeutic Potential of Endothelin Receptor Modulators: Lessons from Human Clinical Trials</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1069</span><span class="NLM_x">â</span> <span class="NLM_lpage">1084</span><span class="refDoi">Â DOI: 10.1517/14728220903074570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1517%2F14728220903074570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=19659448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFaltL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=1069-1084&author=J.+D.+Aubertauthor=L.+Juillerat-Jeanneret&title=Therapeutic+Potential+of+Endothelin+Receptor+Modulators%3A+Lessons+from+Human+Clinical+Trials&doi=10.1517%2F14728220903074570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials</span></div><div class="casAuthors">Aubert, John-David; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1069-1084</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The endothelin system, and in particular endothelin receptors, are targets for therapeutic intervention in human diseases.  Endothelin receptor antagonists have reached clin. use for treating pulmonary arterial hypertension, and are under clin. investigation for several other diseases, such as cancer, vasospasm or fibrogenic diseases.  We review the mols. that have been evaluated in the main clin. trials, from the point of view of receptor selectivity and of their chem. characteristics which were important for efficacy in pulmonary hypertension.  We will also discuss future use of antagonists to endothelin receptor(s) in several human diseases and what should be the necessary properties of the future mols. for efficacy in diseases where the presently tested mols. displayed suboptimal efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAwp9dwjsEbbVg90H21EOLACvtfcHk0lhIt7JpC58tiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFaltL8%253D&md5=81343b0ba9cb9b9d4640ddecc4e0d22d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1517%2F14728220903074570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728220903074570%26sid%3Dliteratum%253Aachs%26aulast%3DAubert%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DTherapeutic%2520Potential%2520of%2520Endothelin%2520Receptor%2520Modulators%253A%2520Lessons%2520from%2520Human%2520Clinical%2520Trials%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2009%26volume%3D13%26spage%3D1069%26epage%3D1084%26doi%3D10.1517%2F14728220903074570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Kiowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¼scher, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BÃ¼hler, F. R.</span><span> </span><span class="NLM_article-title">Endothelin-1-induced Vasoconstriction in Humans. Reversal by Calcium Channel Blockade but Not by Nitrovasodilators or Endothelium-derived Relaxing Factor</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">â</span> <span class="NLM_lpage">475</span><span class="refDoi">Â DOI: 10.1161/01.CIR.83.2.469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1161%2F01.CIR.83.2.469" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1991&pages=469-475&author=W.+Kiowskiauthor=T.+F.+L%C3%BCscherauthor=L.+Linderauthor=F.+R.+B%C3%BChler&title=Endothelin-1-induced+Vasoconstriction+in+Humans.+Reversal+by+Calcium+Channel+Blockade+but+Not+by+Nitrovasodilators+or+Endothelium-derived+Relaxing+Factor&doi=10.1161%2F01.CIR.83.2.469"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.83.2.469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.83.2.469%26sid%3Dliteratum%253Aachs%26aulast%3DKiowski%26aufirst%3DW.%26aulast%3DL%25C3%25BCscher%26aufirst%3DT.%2BF.%26aulast%3DLinder%26aufirst%3DL.%26aulast%3DB%25C3%25BChler%26aufirst%3DF.%2BR.%26atitle%3DEndothelin-1-induced%2520Vasoconstriction%2520in%2520Humans.%2520Reversal%2520by%2520Calcium%2520Channel%2520Blockade%2520but%2520Not%2520by%2520Nitrovasodilators%2520or%2520Endothelium-derived%2520Relaxing%2520Factor%26jtitle%3DCirculation%26date%3D1991%26volume%3D83%26spage%3D469%26epage%3D475%26doi%3D10.1161%2F01.CIR.83.2.469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Haynes, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. J.</span><span> </span><span class="NLM_article-title">Contribution of Endogenous Generation of Endothelin-1 to Basal Vascular Tone</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">â</span> <span class="NLM_lpage">854</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(94)92827-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0140-6736%2894%2992827-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=1994&pages=852-854&author=W.+G.+Haynesauthor=D.+J.+Webb&title=Contribution+of+Endogenous+Generation+of+Endothelin-1+to+Basal+Vascular+Tone&doi=10.1016%2FS0140-6736%2894%2992827-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2894%2992827-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252894%252992827-4%26sid%3Dliteratum%253Aachs%26aulast%3DHaynes%26aufirst%3DW.%2BG.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26atitle%3DContribution%2520of%2520Endogenous%2520Generation%2520of%2520Endothelin-1%2520to%2520Basal%2520Vascular%2520Tone%26jtitle%3DLancet%26date%3D1994%26volume%3D344%26spage%3D852%26epage%3D854%26doi%3D10.1016%2FS0140-6736%2894%2992827-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Ertl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauersachs, J.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists in Heart Failure: Current Status and Future Directions</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">â</span> <span class="NLM_lpage">1040</span><span class="refDoi">Â DOI: 10.2165/00003495-200464100-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2165%2F00003495-200464100-00001" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=1029-1040&author=G.+Ertlauthor=J.+Bauersachs&title=Endothelin+Receptor+Antagonists+in+Heart+Failure%3A+Current+Status+and+Future+Directions&doi=10.2165%2F00003495-200464100-00001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2165%2F00003495-200464100-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200464100-00001%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DG.%26aulast%3DBauersachs%26aufirst%3DJ.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%2520in%2520Heart%2520Failure%253A%2520Current%2520Status%2520and%2520Future%2520Directions%26jtitle%3DDrugs%26date%3D2004%26volume%3D64%26spage%3D1029%26epage%3D1040%26doi%3D10.2165%2F00003495-200464100-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Morrell, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLean, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurtry, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenmark, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thistlethwaite, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissmann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, E. K.</span><span> </span><span class="NLM_article-title">Cellular and Molecular Basis of Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">S20</span><span class="NLM_x">â</span> <span class="NLM_lpage">S31</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2009.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.jacc.2009.04.018" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=S20-S31&author=N.+W.+Morrellauthor=S.+Adnotauthor=S.+L.+Archerauthor=J.+Dupuisauthor=P.+L.+Jonesauthor=M.+R.+MacLeanauthor=I.+F.+McMurtryauthor=K.+R.+Stenmarkauthor=P.+A.+Thistlethwaiteauthor=N.+Weissmannauthor=J.+X.+Yuanauthor=E.+K.+Weir&title=Cellular+and+Molecular+Basis+of+Pulmonary+Arterial+Hypertension&doi=10.1016%2Fj.jacc.2009.04.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2009.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2009.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DMorrell%26aufirst%3DN.%2BW.%26aulast%3DAdnot%26aufirst%3DS.%26aulast%3DArcher%26aufirst%3DS.%2BL.%26aulast%3DDupuis%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DP.%2BL.%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26aulast%3DMcMurtry%26aufirst%3DI.%2BF.%26aulast%3DStenmark%26aufirst%3DK.%2BR.%26aulast%3DThistlethwaite%26aufirst%3DP.%2BA.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DYuan%26aufirst%3DJ.%2BX.%26aulast%3DWeir%26aufirst%3DE.%2BK.%26atitle%3DCellular%2520and%2520Molecular%2520Basis%2520of%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2009%26volume%3D54%26spage%3DS20%26epage%3DS31%26doi%3D10.1016%2Fj.jacc.2009.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Tuder, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DorfmÃ¼ller, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erzurum, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guignabert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michelakis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovitch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schermuly, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenmark, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrell, N. W.</span><span> </span><span class="NLM_article-title">Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">D4</span><span class="NLM_x">â</span> <span class="NLM_lpage">D12</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2013.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.jacc.2013.10.025" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=D4-D12&author=R.+M.+Tuderauthor=S.+L.+Archerauthor=P.+Dorfm%C3%BCllerauthor=S.+C.+Erzurumauthor=C.+Guignabertauthor=E.+Michelakisauthor=M.+Rabinovitchauthor=R.+Schermulyauthor=K.+R.+Stenmarkauthor=N.+W.+Morrell&title=Relevant+Issues+in+the+Pathology+and+Pathobiology+of+Pulmonary+Hypertension&doi=10.1016%2Fj.jacc.2013.10.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2013.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2013.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DTuder%26aufirst%3DR.%2BM.%26aulast%3DArcher%26aufirst%3DS.%2BL.%26aulast%3DDorfm%25C3%25BCller%26aufirst%3DP.%26aulast%3DErzurum%26aufirst%3DS.%2BC.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DMichelakis%26aufirst%3DE.%26aulast%3DRabinovitch%26aufirst%3DM.%26aulast%3DSchermuly%26aufirst%3DR.%26aulast%3DStenmark%26aufirst%3DK.%2BR.%26aulast%3DMorrell%26aufirst%3DN.%2BW.%26atitle%3DRelevant%2520Issues%2520in%2520the%2520Pathology%2520and%2520Pathobiology%2520of%2520Pulmonary%2520Hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2013%26volume%3D62%26spage%3DD4%26epage%3DD12%26doi%3D10.1016%2Fj.jacc.2013.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Macchia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchioli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tognoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marfisi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavazzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, S.</span><span> </span><span class="NLM_article-title">Systematic Review of Trials Using Vasodilators in Pulmonary Arterial Hypertension: Why a New Approach is Needed</span> <span class="citation_source-journal">Am. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">â</span> <span class="NLM_lpage">257</span><span class="refDoi">Â DOI: 10.1016/j.ahj.2009.11.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.ahj.2009.11.028" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2010&pages=245-257&author=A.+Macchiaauthor=R.+Marchioliauthor=G.+Tognoniauthor=M.+Scaranoauthor=R.+Marfisiauthor=L.+Tavazziauthor=S.+Rich&title=Systematic+Review+of+Trials+Using+Vasodilators+in+Pulmonary+Arterial+Hypertension%3A+Why+a+New+Approach+is+Needed&doi=10.1016%2Fj.ahj.2009.11.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2009.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2009.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DMacchia%26aufirst%3DA.%26aulast%3DMarchioli%26aufirst%3DR.%26aulast%3DTognoni%26aufirst%3DG.%26aulast%3DScarano%26aufirst%3DM.%26aulast%3DMarfisi%26aufirst%3DR.%26aulast%3DTavazzi%26aufirst%3DL.%26aulast%3DRich%26aufirst%3DS.%26atitle%3DSystematic%2520Review%2520of%2520Trials%2520Using%2520Vasodilators%2520in%2520Pulmonary%2520Arterial%2520Hypertension%253A%2520Why%2520a%2520New%2520Approach%2520is%2520Needed%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2010%26volume%3D159%26spage%3D245%26epage%3D257%26doi%3D10.1016%2Fj.ahj.2009.11.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Sauvageau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, J.</span><span> </span><span class="NLM_article-title">Endothelin-1-induced Pulmonary Vasoreactivity is Regulated by ET(A) and ET(B) Receptor Interactions</span> <span class="citation_source-journal">J. Vasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">â</span> <span class="NLM_lpage">381</span><span class="refDoi">Â DOI: 10.1159/000102534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1159%2F000102534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=17495482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsVaqt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2007&pages=375-381&author=S.+Sauvageauauthor=E.+Thorinauthor=A.+Caronauthor=J.+Dupuis&title=Endothelin-1-induced+Pulmonary+Vasoreactivity+is+Regulated+by+ET%28A%29+and+ET%28B%29+Receptor+Interactions&doi=10.1159%2F000102534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1-Induced Pulmonary Vasoreactivity Is Regulated by ETA and ETB Receptor Interactions</span></div><div class="casAuthors">Sauvageau, Stephanie; Thorin, Eric; Caron, Alexandre; Dupuis, Jocelyn</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Vascular Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">375-381</span>CODEN:
                <span class="NLM_cas:coden">JVREE9</span>;
        ISSN:<span class="NLM_cas:issn">1018-1172</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Roles of endothelin (ET) receptors (R) and of the endothelium on ET-1-induced pulmonary vasoreactivity are subjects of debate.  This stems from endothelial ETB-R that can release both vasodilators and vasoconstrictors.  The aim of this study was to evaluate the roles of the endothelium and of ET-Rs on ET-1-induced pulmonary vasoreactivity.  Methods: Pharmacol. expts. were performed in isolated rat lungs and in pulmonary resistance arteries.  Results: In isolated lungs, ET-1 and the selective ETB-R agonist sarafotoxin 6c (S6c) induced a similar vasoconstriction.  ET-1 constriction was reduced by a selective ETA-R antagonist; however, the selective ETB-R antagonist had no significant effect.  In preconstricted lungs, ETB-R stimulation caused mild vasodilation at low concns. but severe vasoconstriction at higher concns.  In isolated arteries, responses to ET-1 and S6c were not different and unaffected by removal of endothelium.  Interestingly, concns. of ETA-R and ETB-R antagonists that only mildly reduced ET-1 vasoconstriction when used alone, prevented maximal constriction and greatly reduced vascular sensitivity to ET-1 when used in combination.  Conclusion: In rat lungs, both ETA-R and ETB-R contribute to ET-1-induced pulmonary vasoconstriction with evidence of interaction between receptors.  A mild vasodilator role of the endothelial ETB-R is evident only at low agonist concn. and when baseline vascular tone is increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqwehQuhFm_LVg90H21EOLACvtfcHk0lj5C3mmM2jFBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsVaqt7c%253D&md5=d569b0f014a406d1e75a842f58cfbc2a</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1159%2F000102534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000102534%26sid%3Dliteratum%253Aachs%26aulast%3DSauvageau%26aufirst%3DS.%26aulast%3DThorin%26aufirst%3DE.%26aulast%3DCaron%26aufirst%3DA.%26aulast%3DDupuis%26aufirst%3DJ.%26atitle%3DEndothelin-1-induced%2520Pulmonary%2520Vasoreactivity%2520is%2520Regulated%2520by%2520ET%2528A%2529%2520and%2520ET%2528B%2529%2520Receptor%2520Interactions%26jtitle%3DJ.%2520Vasc.%2520Res.%26date%3D2007%26volume%3D44%26spage%3D375%26epage%3D381%26doi%3D10.1159%2F000102534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Porter, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riches, K.</span><span> </span><span class="NLM_article-title">Vascular Smooth Muscle as a Target for Novel Therapeutics</span> <span class="citation_source-journal">Curr. Diabetes Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="refDoi">Â DOI: 10.1007/s11892-015-0647-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs11892-015-0647-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=26277484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC287jsVeiuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=72&author=K.+E.+Porterauthor=K.+Riches&title=Vascular+Smooth+Muscle+as+a+Target+for+Novel+Therapeutics&doi=10.1007%2Fs11892-015-0647-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Smooth Muscle as a Target for Novel Therapeutics</span></div><div class="casAuthors">Porter Karen E; Riches Kirsten</div><div class="citationInfo"><span class="NLM_cas:title">Current diabetes reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cardiovascular disease is the principal cause of death in patients with type 2 diabetes (T2DM).  Exposure of the vasculature to metabolic disturbances leaves a persistent imprint on vascular walls, and specifically on smooth muscle cells (SMC) that favours their dysfunction and potentially underlies macrovascular complications of T2DM.  Current diabetes therapies and continued development of newer treatments has led to the ability to achieve more efficient glycaemic control.  There is also some evidence to suggest that some of these treatments may exert favourable pleiotropic effects, some of which may be at the level of SMC.  However, emerging interest in epigenetic markers as determinants of vascular disease, and a putative link with diabetes, opens the possibility for new avenues to develop robust and specific new therapies.  These will likely need to target cell-specific epigenetic changes such as effectors of DNA histone modifications that promote or inhibit gene transcription, and/or microRNAs capable of regulating entire cellular pathways through target gene repression.  The growing epidemic of T2DM worldwide, and its attendant cardiovascular mortality, dictates a need for novel therapies and personalised approaches to ameliorate vascular complications in this vulnerable population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0Eyf06DQ28EPI-fCgwosgfW6udTcc2eZlVoEYli_Lxrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287jsVeiuw%253D%253D&md5=d96ce55a7399c10c9bf591a6a84f255d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1007%2Fs11892-015-0647-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11892-015-0647-9%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DK.%2BE.%26aulast%3DRiches%26aufirst%3DK.%26atitle%3DVascular%2520Smooth%2520Muscle%2520as%2520a%2520Target%2520for%2520Novel%2520Therapeutics%26jtitle%3DCurr.%2520Diabetes%2520Rep.%26date%3D2015%26volume%3D15%26spage%3D72%26doi%3D10.1007%2Fs11892-015-0647-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Tonelli, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, J. P.</span><span> </span><span class="NLM_article-title">Geometry of the Randomized Evidence for Treatments of Pulmonary Hypertension</span> <span class="citation_source-journal">Cardiovasc. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">e138</span><span class="NLM_x">â</span> <span class="NLM_lpage">e146</span><span class="refDoi">Â DOI: 10.1111/1755-5922.12050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2F1755-5922.12050" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=e138-e146&author=A.+R.+Tonelliauthor=J.+Zeinauthor=J.+P.+Ioannidis&title=Geometry+of+the+Randomized+Evidence+for+Treatments+of+Pulmonary+Hypertension&doi=10.1111%2F1755-5922.12050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1111%2F1755-5922.12050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1755-5922.12050%26sid%3Dliteratum%253Aachs%26aulast%3DTonelli%26aufirst%3DA.%2BR.%26aulast%3DZein%26aufirst%3DJ.%26aulast%3DIoannidis%26aufirst%3DJ.%2BP.%26atitle%3DGeometry%2520of%2520the%2520Randomized%2520Evidence%2520for%2520Treatments%2520of%2520Pulmonary%2520Hypertension%26jtitle%3DCardiovasc.%2520Ther.%26date%3D2013%26volume%3D31%26spage%3De138%26epage%3De146%26doi%3D10.1111%2F1755-5922.12050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Montani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaumais, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guignabert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GÃ¼nther, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girerd, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JaÃ¯s, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Algalarrondo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savale, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitbon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbert, M.</span><span> </span><span class="NLM_article-title">Targeted Therapies in Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">â</span> <span class="NLM_lpage">191</span><span class="refDoi">Â DOI: 10.1016/j.pharmthera.2013.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.pharmthera.2013.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24134901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsleru7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2014&pages=172-191&author=D.+Montaniauthor=M.+C.+Chaumaisauthor=C.+Guignabertauthor=S.+G%C3%BCntherauthor=B.+Girerdauthor=X.+Ja%C3%AFsauthor=V.+Algalarrondoauthor=L.+C.+Priceauthor=L.+Savaleauthor=O.+Sitbonauthor=G.+Simonneauauthor=M.+Humbert&title=Targeted+Therapies+in+Pulmonary+Arterial+Hypertension&doi=10.1016%2Fj.pharmthera.2013.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapies in pulmonary arterial hypertension</span></div><div class="casAuthors">Montani, David; Chaumais, Marie-Camille; Guignabert, Christophe; Gunther, Sven; Girerd, Barbara; Jais, Xavier; Algalarrondo, Vincent; Price, Laura C.; Savale, Laurent; Sitbon, Olivier; Simonneau, Gerald; Humbert, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-191</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Pulmonary arterial hypertension (PAH) is a rare disorder characterized by progressive obliteration of small pulmonary arteries that leads to elevated pulmonary arterial pressure and right heart failure.  During the last decades, an improved understanding of the pathophysiol. of the disease has resulted in the development of effective therapies targeting endothelial dysfunction (epoprostenol and derivs., endothelin receptor antagonists and phosphodiesterase type 5 inhibitors).  These drugs allow clin., functional and hemodynamic improvement.  Even though, no cure exists for PAH and prognosis remains poor.  Recently, several addnl. pathways have been suggested to be involved in the pathogenesis of PAH, and may represent innovative therapies.  In this summary, we review conventional therapy, pharmacol. agents currently available for the treatment of PAH and the benefit/risk ratio of potential future therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRWQUrsAAiHbVg90H21EOLACvtfcHk0lhZlNoOMVx8fg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsleru7zO&md5=ac19ee640f860eda78ed2e09caa083dc</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2013.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2013.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DChaumais%26aufirst%3DM.%2BC.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DG%25C3%25BCnther%26aufirst%3DS.%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DJa%25C3%25AFs%26aufirst%3DX.%26aulast%3DAlgalarrondo%26aufirst%3DV.%26aulast%3DPrice%26aufirst%3DL.%2BC.%26aulast%3DSavale%26aufirst%3DL.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DHumbert%26aufirst%3DM.%26atitle%3DTargeted%2520Therapies%2520in%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DPharmacol.%2520Ther.%26date%3D2014%26volume%3D141%26spage%3D172%26epage%3D191%26doi%3D10.1016%2Fj.pharmthera.2013.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Humbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span> </span><span class="NLM_article-title">The Molecular Targets of Approved Treatments for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">â</span> <span class="NLM_lpage">83</span><span class="refDoi">Â DOI: 10.1136/thoraxjnl-2015-207170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1136%2Fthoraxjnl-2015-207170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=26219978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FnsFyntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2016&pages=73-83&author=M.+Humbertauthor=H.+A.+Ghofrani&title=The+Molecular+Targets+of+Approved+Treatments+for+Pulmonary+Arterial+Hypertension&doi=10.1136%2Fthoraxjnl-2015-207170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular targets of approved treatments for pulmonary arterial hypertension</span></div><div class="casAuthors">Humbert Marc; Ghofrani Hossein-Ardeschir</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)--prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors.  With the approval of the soluble guanylate cyclase stimulator riociguat, an additional drug class has become available targeting a distinct molecular target in the same pathway as PDE5 inhibitors.  Treatment recommendations currently include the use of all four drug classes to treat PAH, but there is a lack of comparative data for these therapies.  Therefore, an understanding of the mechanistic differences between these agents is critical when making treatment decisions.  Combination therapy is often used to treat PAH and it is therefore important that physicians understand how the modes of action of these drugs may interact to work as complementary partners, or potentially with unwanted consequences.  Furthermore, different patient phenotypes mean that patients respond differently to treatment; while a certain monotherapy may be adequate for some patients, for others it will be important to consider alternating or combining compounds with different molecular targets.  This review describes how the four currently approved drug classes target the complex pathobiology of PAH and will consider the distinct target molecules of each drug class, their modes of action, and review the pivotal clinical trial data supporting their use.  It will also discuss the rationale for combining drugs (or not) from the different classes, and review the clinical data from studies on combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJNcbGvIMVpe2mnZh2OgS0fW6udTcc2eZlVoEYli_Lxrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FnsFyntA%253D%253D&md5=a03f21a28cd4481cf38ddbb1cc6e636a</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2015-207170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2015-207170%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26atitle%3DThe%2520Molecular%2520Targets%2520of%2520Approved%2520Treatments%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DThorax%26date%3D2016%26volume%3D71%26spage%3D73%26epage%3D83%26doi%3D10.1136%2Fthoraxjnl-2015-207170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">68</span><span class="refDoi">Â DOI: 10.1002/14651858.CD004434.pub5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2F14651858.CD004434.pub5" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=1-68&author=C.+Liuauthor=J.+Chenauthor=Y.+Gaoauthor=B.+Dengauthor=K.+Liu&title=Endothelin+Receptor+Antagonists+for+Pulmonary+Arterial+Hypertension&doi=10.1002%2F14651858.CD004434.pub5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD004434.pub5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD004434.pub5%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2013%26volume%3D2%26spage%3D1%26epage%3D68%26doi%3D10.1002%2F14651858.CD004434.pub5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Langleben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brock, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">STRIDE-1 Study Group.</span><span> </span><span class="NLM_article-title">Stride 1: Effects of the Selective ET(A) Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension That Meets Traditional Inclusion Criteria of Previous Pulmonary Arterial Hypertension Trials</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S80</span><span class="NLM_x">â</span> <span class="NLM_lpage">S84</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=S80-S84&issue=Suppl.+1&author=D.+Langlebenauthor=T.+Brockauthor=R.+Dixonauthor=R.+Barstauthor=STRIDE-1+Study+Group.&title=Stride+1%3A+Effects+of+the+Selective+ET%28A%29+Receptor+Antagonist%2C+Sitaxsentan+Sodium%2C+in+a+Patient+Population+with+Pulmonary+Arterial+Hypertension+That+Meets+Traditional+Inclusion+Criteria+of+Previous+Pulmonary+Arterial+Hypertension+Trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DBrock%26aufirst%3DT.%26aulast%3DDixon%26aufirst%3DR.%26aulast%3DBarst%26aufirst%3DR.%26aulast%3D%26atitle%3DStride%25201%253A%2520Effects%2520of%2520the%2520Selective%2520ET%2528A%2529%2520Receptor%2520Antagonist%252C%2520Sitaxsentan%2520Sodium%252C%2520in%2520a%2520Patient%2520Population%2520with%2520Pulmonary%2520Arterial%2520Hypertension%2520That%2520Meets%2520Traditional%2520Inclusion%2520Criteria%2520of%2520Previous%2520Pulmonary%2520Arterial%2520Hypertension%2520Trials%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2004%26volume%3D44%26issue%3DSuppl.%25201%26spage%3DS80%26epage%3DS84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langleben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeije, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galie, N.</span><span> </span><span class="NLM_article-title">Treatment of Pulmonary Arterial Hypertension with the Selective Endothelin-A Receptor Antagonist Sitaxsentan</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2049</span><span class="NLM_x">â</span> <span class="NLM_lpage">2056</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2006.01.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.jacc.2006.01.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=16697324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFalsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=2049-2056&author=R.+J.+Barstauthor=D.+Langlebenauthor=D.+Badeschauthor=A.+Frostauthor=E.+C.+Lawrenceauthor=S.+Shapiroauthor=R.+Naeijeauthor=N.+Galie&title=Treatment+of+Pulmonary+Arterial+Hypertension+with+the+Selective+Endothelin-A+Receptor+Antagonist+Sitaxsentan&doi=10.1016%2Fj.jacc.2006.01.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan</span></div><div class="casAuthors">Barst, Robyn J.; Langleben, David; Badesch, David; Frost, Adaani; Lawrence, E. Clinton; Shapiro, Shelley; Naeije, Robert; Galie, Nazzareno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2049-2056</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We sought to det. the optimal dose of the selective endothelin A (ETA) receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for observation only, an open-label (OL) bosentan arm was included.  Endothelin is a mediator of PAH.  In a preliminary PAH study, the selective ETA receptor antagonist sitaxsentan improved six-min walk (6MW) distance, World Health Organization (WHO) functional class (FC), and hemodynamics.  In this double-blind, placebo-controlled 18-wk study, 247 PAH patients (idiopathic, or assocd. with connective tissue disease or congenital heart disease) were randomized; 245 patients were treated: placebo (n = 62), sitaxsentan 50 mg (n = 62) or 100 mg (n = 61), or OL (6MW tests, Borg dyspnea scores, and WHO FC assessments third-party blind) bosentan (n = 60).  The primary end point was change in 6MW distance from baseline to week 18.  Secondary end points included change in WHO FC, time to clin. worsening, and change in Borg dyspnea score.  At week 18, patients treated with sitaxsentan 100 mg had an increased 6MW distance compared with the placebo group (31.4 m, p = 0.03), and an improved WHO FC (p = 0.04).  The placebo-subtracted treatment effect for sitaxsentan 50 mg was 24.2 m (p = 0.07) and for OL bosentan, 29.5 m (p = 0.05).  The incidence of elevated hepatic transaminases (>3Ã the upper limit of normal) was 6% for placebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100 mg, and 11% for bosentan.  Treatment with the selective ETA receptor antagonist sitaxsentan, orally once daily at a dose of 100 mg, improves exercise capacity and WHO FC in PAH patients, with a low incidence of hepatic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ8rFM0c55NLVg90H21EOLACvtfcHk0liBDCscHiEm7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFalsbs%253D&md5=b68081ed4dccf86d36293b82f765a9b6</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2006.01.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2006.01.057%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DLawrence%26aufirst%3DE.%2BC.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DGalie%26aufirst%3DN.%26atitle%3DTreatment%2520of%2520Pulmonary%2520Arterial%2520Hypertension%2520with%2520the%2520Selective%2520Endothelin-A%2520Receptor%2520Antagonist%2520Sitaxsentan%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2006%26volume%3D47%26spage%3D2049%26epage%3D2056%26doi%3D10.1016%2Fj.jacc.2006.01.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Sandoval, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torbicki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzyna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jardim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerjes-Sanchez Diaz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teal, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulido, T.</span><span> </span><span class="NLM_article-title">Safety and Efficacy of Sitaxsentan 50 and 100 mg in Patients with Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">â</span> <span class="NLM_lpage">39</span><span class="refDoi">Â DOI: 10.1016/j.pupt.2011.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.pupt.2011.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22079088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFOktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=33-39&author=J.+Sandovalauthor=A.+Torbickiauthor=R.+Souzaauthor=A.+Ramirezauthor=M.+Kurzynaauthor=C.+Jardimauthor=C.+Jerjes-Sanchez+Diazauthor=S.+A.+Tealauthor=L.+J.+Hwangauthor=T.+Pulido&title=Safety+and+Efficacy+of+Sitaxsentan+50+and+100+mg+in+Patients+with+Pulmonary+Arterial+Hypertension&doi=10.1016%2Fj.pupt.2011.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension</span></div><div class="casAuthors">Sandoval, Julio; Torbicki, Adam; Souza, Rogerio; Ramirez, Alicia; Kurzyna, Marcin; Jardim, Carlos; Jerjes-Sanchez Diaz, Carlos; Teal, Simon A.; Hwang, Lie-Ju; Pulido, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-39</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To assess safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension (PAH).  Sitaxsentan is a highly selective endothelin-A receptor antagonist that was recently withdrawn by the manufacturer because of a pattern of idiosyncratic liver injury.  Before sitaxsentan withdrawal, this 18-wk double-blind, placebo-controlled study randomized patients with PAH to receive placebo or sitaxsentan 50 or 100 mg once daily.  The primary efficacy endpoint was change from baseline in 6-min walk distance (6MWD) at week 18.  Changes in World Health Organization (WHO) functional class and time to clin. worsening (TTCW) were secondary endpoints.  The primary efficacy anal. was powered for sitaxsentan 100 mg vs. placebo.  Of 98 randomized patients, 61% were WHO functional class II at baseline.  Improvement from baseline to week 18 in 6MWD occurred with sitaxsentan 100 but not 50 mg; a strong placebo effect was obsd.  At week 18, WHO functional class was improved or maintained in more patients receiving sitaxsentan 100 mg than placebo (P = 0.038); 0% vs. 12% of patients deteriorated, resp.  TTCW was not significantly different for 100-mg sitaxsentan patients than placebo (P = 0.090).  Adverse events (AEs) occurring more frequently with sitaxsentan (50 or 100 mg) included headache, peripheral edema, dizziness, nausea, extremity pain, and fatigue; most AEs were of mild or moderate severity.  Sitaxsentan 100 mg improved functional class but not 6MWD in PAH patients who were mostly WHO functional class II at baseline.  No patient receiving sitaxsentan 100 mg experienced clin. worsening; sitaxsentan was well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ZyDN7nwdbbVg90H21EOLACvtfcHk0liBDCscHiEm7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFOktLg%253D&md5=2d9aaf20d6ebdad24b9ba841a02cfc44</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2011.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2011.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DSandoval%26aufirst%3DJ.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DSouza%26aufirst%3DR.%26aulast%3DRamirez%26aufirst%3DA.%26aulast%3DKurzyna%26aufirst%3DM.%26aulast%3DJardim%26aufirst%3DC.%26aulast%3DJerjes-Sanchez%2BDiaz%26aufirst%3DC.%26aulast%3DTeal%26aufirst%3DS.%2BA.%26aulast%3DHwang%26aufirst%3DL.%2BJ.%26aulast%3DPulido%26aufirst%3DT.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Sitaxsentan%252050%2520and%2520100%2520mg%2520in%2520Patients%2520with%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D25%26spage%3D33%26epage%3D39%26doi%3D10.1016%2Fj.pupt.2011.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mubarak, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machado, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ataga, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benza, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeije, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sood, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swerdlow, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hildesheim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gladwin, M. T.</span><span> </span><span class="NLM_article-title">Exercise Capacity and Haemodynamics in Patients with Sickle Cell Disease with Pulmonary Hypertension Treated with Bosentan: Results of the ASSET Studies</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">â</span> <span class="NLM_lpage">435</span><span class="refDoi">Â DOI: 10.1111/j.1365-2141.2010.08097.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fj.1365-2141.2010.08097.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=20175775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3cXms1yjs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2010&pages=426-435&author=R.+J.+Barstauthor=K.+K.+Mubarakauthor=R.+F.+Machadoauthor=K.+I.+Atagaauthor=R.+L.+Benzaauthor=O.+Castroauthor=R.+Naeijeauthor=N.+Soodauthor=P.+S.+Swerdlowauthor=M.+Hildesheimauthor=M.+T.+Gladwin&title=Exercise+Capacity+and+Haemodynamics+in+Patients+with+Sickle+Cell+Disease+with+Pulmonary+Hypertension+Treated+with+Bosentan%3A+Results+of+the+ASSET+Studies&doi=10.1111%2Fj.1365-2141.2010.08097.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies</span></div><div class="casAuthors">Barst, Robyn J.; Mubarak, Kamal K.; Machado, Roberto F.; Ataga, Kenneth I.; Benza, Raymond L.; Castro, Oswaldo; Naeije, Robert; Sood, Namita; Swerdlow, Paul S.; Hildesheim, Mariana; Gladwin, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">426-435</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Doppler-defined pulmonary hypertension (PH) in sickle cell disease (SCD) is assocd. with 40% mortality at 40 mo.  To assess the effect of bosentan in SCD-PH, two randomized, double-blind, placebo-controlled, 16-wk studies were initiated.  Safety concerns are particularly relevant in SCD due to comorbid conditions.  ASSET-1 and -2 enrolled patients with pulmonary arterial hypertension (PAH) and pulmonary venous hypertension (PH), resp.  Haemodynamics and 6-min walk distance (6MWD) were obtained at baseline and week 16.  The studies were terminated due to slow site initiation and patient enrollment (n = 26).  Bosentan appeared to be well tolerated.  Although sample sizes were limited, in ASSET-1 at baseline, 6MWD correlated with cardiac output (CO; P = 0.006) with non-significant inverse correlations between 6MWD and pulmonary vascular resistance (PVR; P = 0.07) and between 6MWD and right atrial pressure (P = 0.08).  In ASSET-2 at baseline, there was a non-significant correlation between 6MWD and CO (P = 0.06).  Due to limited sample sizes, efficacy endpoints were not analyzed.  However, in both studies, non-significant increases in CO were obsd. with bosentan compared to placebo.  Similarly, non-significant decreases in PVR were obsd. with bosentan.  Limited data in SCD-PH suggest that a low 6MWD predicts a low CO.  Std.-dose bosentan appears to be well tolerated.  Further investigation is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeA982uMAHvbVg90H21EOLACvtfcHk0liQqb-Wz2Fb6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXms1yjs7Y%253D&md5=3308ec2b88bc8224ef71ac372b960335</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08097.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08097.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DMubarak%26aufirst%3DK.%2BK.%26aulast%3DMachado%26aufirst%3DR.%2BF.%26aulast%3DAtaga%26aufirst%3DK.%2BI.%26aulast%3DBenza%26aufirst%3DR.%2BL.%26aulast%3DCastro%26aufirst%3DO.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DSood%26aufirst%3DN.%26aulast%3DSwerdlow%26aufirst%3DP.%2BS.%26aulast%3DHildesheim%26aufirst%3DM.%26aulast%3DGladwin%26aufirst%3DM.%2BT.%26atitle%3DExercise%2520Capacity%2520and%2520Haemodynamics%2520in%2520Patients%2520with%2520Sickle%2520Cell%2520Disease%2520with%2520Pulmonary%2520Hypertension%2520Treated%2520with%2520Bosentan%253A%2520Results%2520of%2520the%2520ASSET%2520Studies%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2010%26volume%3D149%26spage%3D426%26epage%3D435%26doi%3D10.1111%2Fj.1365-2141.2010.08097.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Channick, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitbon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapson, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainisio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">Effects of the Dual Endothelin-receptor Antagonist Bosentan in Patients with Pulmonary Hypertension: A Randomized Placebo-controlled Study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">â</span> <span class="NLM_lpage">1123</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(01)06250-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0140-6736%2801%2906250-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2001&pages=1119-1123&author=R.+N.+Channickauthor=G.+Simonneauauthor=O.+Sitbonauthor=I.+M.+Robbinsauthor=A.+Frostauthor=V.+F.+Tapsonauthor=D.+B.+Badeschauthor=S.+Rouxauthor=M.+Rainisioauthor=F.+Bodinauthor=L.+J.+Rubin&title=Effects+of+the+Dual+Endothelin-receptor+Antagonist+Bosentan+in+Patients+with+Pulmonary+Hypertension%3A+A+Randomized+Placebo-controlled+Study&doi=10.1016%2FS0140-6736%2801%2906250-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2801%2906250-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252801%252906250-X%26sid%3Dliteratum%253Aachs%26aulast%3DChannick%26aufirst%3DR.%2BN.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DTapson%26aufirst%3DV.%2BF.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DRoux%26aufirst%3DS.%26aulast%3DRainisio%26aufirst%3DM.%26aulast%3DBodin%26aufirst%3DF.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DEffects%2520of%2520the%2520Dual%2520Endothelin-receptor%2520Antagonist%2520Bosentan%2520in%2520Patients%2520with%2520Pulmonary%2520Hypertension%253A%2520A%2520Randomized%2520Placebo-controlled%2520Study%26jtitle%3DLancet%26date%3D2001%26volume%3D358%26spage%3D1119%26epage%3D1123%26doi%3D10.1016%2FS0140-6736%2801%2906250-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Humbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Channick, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boonstra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span> </span><span class="NLM_article-title">Combination of Bosentan with Epoprostenol in Pulmonary Arterial Hypertension: BREATHE-2</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">â</span> <span class="NLM_lpage">359</span><span class="refDoi">Â DOI: 10.1183/09031936.04.00028404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1183%2F09031936.04.00028404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15358690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotlyrtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=353-359&author=M.+Humbertauthor=R.+J.+Barstauthor=I.+M.+Robbinsauthor=R.+N.+Channickauthor=N.+Gali%C3%A8author=A.+Boonstraauthor=L.+J.+Rubinauthor=E.+M.+Hornauthor=A.+Manesauthor=G.+Simonneau&title=Combination+of+Bosentan+with+Epoprostenol+in+Pulmonary+Arterial+Hypertension%3A+BREATHE-2&doi=10.1183%2F09031936.04.00028404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2</span></div><div class="casAuthors">Humbert, M.; Barst, R. J.; Robbins, I. M.; Channick, R. N.; Galie, N.; Boonstra, A.; Rubin, L. J.; Horn, E. M.; Manes, A.; Simonneau, G.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of pulmonary arterial hypertension (PAH) was investigated.  In this double-blind, placebo-controlled prospective study, 33 patients with PAH started epoprostenol treatment (2 ngÂ·kg-1min-1 starting dose, up to 14Â±2 ngÂ·kg-1min-1 at week 16) and were randomized for 16 wk in a 2:1 ratio to bosentan (62.5 mg b.i.d for 4 wk then 125 mg b.i.d) or placebo.  Hemodynamics, exercise capacity and functional class improved in both groups at week 16.  In the combination treatment group, there was a trend for a greater (although nonsignificant) improvement in all measured hemodynamic parameters.  There were four withdrawals in the bosentan/epoprostenol group (two deaths due to cardio-pulmonary failure, one clin. worsening, and one adverse event) and one withdrawal in the placebo/epoprostenol group (adverse event).  This study showed a trend but no statistical significance towards hemodynamics or clin. improvement due to the combination of bosentan and epoprostenol therapy in patients with pulmonary arterial hypertension.  Several cases of early and late major complications were reported.  Addnl. information is needed to evaluate the risk/benefit ratio of combined bosentan-epoprostenol therapy in pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh63MpV9Xg-7Vg90H21EOLACvtfcHk0liQqb-Wz2Fb6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotlyrtL4%253D&md5=5865cd016496c94d27463210bda238f4</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1183%2F09031936.04.00028404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.04.00028404%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DChannick%26aufirst%3DR.%2BN.%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DBoonstra%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DHorn%26aufirst%3DE.%2BM.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DCombination%2520of%2520Bosentan%2520with%2520Epoprostenol%2520in%2520Pulmonary%2520Arterial%2520Hypertension%253A%2520BREATHE-2%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2004%26volume%3D24%26spage%3D353%26epage%3D359%26doi%3D10.1183%2F09031936.04.00028404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beghetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatzoulis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiossi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landzberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators.</span><span> </span><span class="NLM_article-title">Bosentan Therapy in Patients with Eisenmenger Syndrome: A Multicenter, Double-blind, Randomized, Placebo-controlled Study</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">â</span> <span class="NLM_lpage">54</span><span class="refDoi">Â DOI: 10.1161/CIRCULATIONAHA.106.630715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1161%2FCIRCULATIONAHA.106.630715" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2006&pages=48-54&author=N.+Gali%C3%A8author=M.+Beghettiauthor=M.+A.+Gatzoulisauthor=J.+Grantonauthor=R.+M.+Bergerauthor=A.+Lauerauthor=E.+Chiossiauthor=M.+Landzbergauthor=Bosentan+Randomized+Trial+of+Endothelin+Antagonist+Therapy-5+%28BREATHE-5%29+Investigators.&title=Bosentan+Therapy+in+Patients+with+Eisenmenger+Syndrome%3A+A+Multicenter%2C+Double-blind%2C+Randomized%2C+Placebo-controlled+Study&doi=10.1161%2FCIRCULATIONAHA.106.630715"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.106.630715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.106.630715%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DBeghetti%26aufirst%3DM.%26aulast%3DGatzoulis%26aufirst%3DM.%2BA.%26aulast%3DGranton%26aufirst%3DJ.%26aulast%3DBerger%26aufirst%3DR.%2BM.%26aulast%3DLauer%26aufirst%3DA.%26aulast%3DChiossi%26aufirst%3DE.%26aulast%3DLandzberg%26aufirst%3DM.%26aulast%3D%26atitle%3DBosentan%2520Therapy%2520in%2520Patients%2520with%2520Eisenmenger%2520Syndrome%253A%2520A%2520Multicenter%252C%2520Double-blind%252C%2520Randomized%252C%2520Placebo-controlled%2520Study%26jtitle%3DCirculation%26date%3D2006%26volume%3D114%26spage%3D48%26epage%3D54%26doi%3D10.1161%2FCIRCULATIONAHA.106.630715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">McLaughlin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Channick, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LemariÃ©, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeije, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapson, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al Hiti, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M. M.</span><span> </span><span class="NLM_article-title">Bosentan Added to Sildenafil Therapy in Patients with Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">â</span> <span class="NLM_lpage">413</span><span class="refDoi">Â DOI: 10.1183/13993003.02044-2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1183%2F13993003.02044-2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=26113687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbnt1Onsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=405-413&author=V.+McLaughlinauthor=R.+N.+Channickauthor=H.+A.+Ghofraniauthor=J.+C.+Lemari%C3%A9author=R.+Naeijeauthor=M.+Packerauthor=R.+Souzaauthor=V.+F.+Tapsonauthor=J.+Tolsonauthor=H.+Al+Hitiauthor=G.+Meyerauthor=M.+M.+Hoeper&title=Bosentan+Added+to+Sildenafil+Therapy+in+Patients+with+Pulmonary+Arterial+Hypertension&doi=10.1183%2F13993003.02044-2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension</span></div><div class="casAuthors">McLaughlin Vallerie; Channick Richard N; Ghofrani Hossein-Ardeschir; Lemarie Jean-Christophe; Naeije Robert; Packer Milton; Souza Rogerio; Tapson Victor F; Tolson Jonathan; Al Hiti Hikmet; Meyer Gisela; Hoeper Marius M</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">405-13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated.In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (â¥20 mg three times daily) for â¥3 months were randomised (1:1) to placebo or bosentan (125 mg twice daily).  The composite primary end-point was the time to the first morbidity/mortality event, defined as all-cause death, hospitalisation for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or PAH worsening.  Secondary/exploratory end-points included change in 6-min walk distance and World Health Organization functional class at 16 weeks, change in N-terminal pro-brain natriuretic peptide (NT-proBNP) over time, and all-cause death.Overall, 334 PAH patients were randomised to placebo (n=175) or bosentan (n=159).  A primary end-point event occurred in 51.4% of patients randomised to placebo and 42.8% to bosentan (hazard ratio 0.83, 97.31% CI 0.58-1.19; p=0.2508).  The mean between-treatment difference in 6-min walk distance at 16 weeks was +21.8 m (95% CI +5.9-37.8 m; p=0.0106).  Except for NT-proBNP, no difference was observed for any other end-point.  The safety profile of bosentan added to sildenafil was consistent with the known bosentan safety profile.In COMPASS-2, adding bosentan to stable sildenafil therapy was not superior to sildenafil monotherapy in delaying the time to the first morbidity/mortality event.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBDudtqhw_bmlSCSgBhwJFfW6udTcc2eay3XrCC-76P7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbnt1Onsg%253D%253D&md5=b576a2cd4e1d3d8104e4af9a4eaf3d0d</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1183%2F13993003.02044-2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02044-2014%26sid%3Dliteratum%253Aachs%26aulast%3DMcLaughlin%26aufirst%3DV.%26aulast%3DChannick%26aufirst%3DR.%2BN.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DLemari%25C3%25A9%26aufirst%3DJ.%2BC.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DSouza%26aufirst%3DR.%26aulast%3DTapson%26aufirst%3DV.%2BF.%26aulast%3DTolson%26aufirst%3DJ.%26aulast%3DAl%2BHiti%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DG.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26atitle%3DBosentan%2520Added%2520to%2520Sildenafil%2520Therapy%2520in%2520Patients%2520with%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3D405%26epage%3D413%26doi%3D10.1183%2F13993003.02044-2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Hiti, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusic-Pajic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LemariÃ©, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">Long-term Results from the EARLY Study of Bosentan in WHO Functional Class II Pulmonary Arterial Hypertension Patients</span> <span class="citation_source-journal">Int. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">â</span> <span class="NLM_lpage">339</span><span class="refDoi">Â DOI: 10.1016/j.ijcard.2013.12.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.ijcard.2013.12.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24525158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC2cvkvFSmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2014&pages=332-339&author=G.+Simonneauauthor=N.+Gali%C3%A8author=P.+Jansaauthor=G.+M.+Meyerauthor=H.+Al-Hitiauthor=A.+Kusic-Pajicauthor=J.+C.+Lemari%C3%A9author=M.+M.+Hoeperauthor=L.+J.+Rubin&title=Long-term+Results+from+the+EARLY+Study+of+Bosentan+in+WHO+Functional+Class+II+Pulmonary+Arterial+Hypertension+Patients&doi=10.1016%2Fj.ijcard.2013.12.179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients</span></div><div class="casAuthors">Simonneau Gerald; Galie Nazzareno; Jansa Pavel; Meyer Gisela Martina Bohns; Al-Hiti Hikmet; Kusic-Pajic Andjela; Lemarie Jean-Christophe; Hoeper Marius M; Rubin Lewis J</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The double-blind phase of the EARLY study of bosentan remains the only randomized controlled trial of a PAH-targeted therapy in World Health Organization functional class (FC) II patients.  We report on the efficacy, safety, disease worsening, survival and prognostic factors in mildly symptomatic pulmonary arterial hypertension (PAH) patients treated with bosentan in the open-label extension phase of the EARLY study.  METHODS:  Exploratory efficacy outcomes included 6-minute walk distance (6 MWD) and WHO FC.  Adverse events were recorded.  Kaplan-Meier analysis was used to estimate time to first PAH worsening event (death, initiation of intravenous or subcutaneous prostanoids, atrial septostomy or lung transplantation) and survival.  Cox regression analysis determined factors prognostic of survival.  RESULTS:  Median exposure to bosentan (n=173) was 51 months.  At the end of the bosentan-treatment assessment period, 77.8% of patients were in WHO FC I/II.  Adverse events led to discontinuation of bosentan in 20.2% of patients.  Aminotransferase elevations>3Ã upper limit of normal occurred in 16.8%.  Four-year PAH-event-free survival and survival were 79.5% (95% confidence intervals [95% CI] 73.4, 85.6) and 84.8% [95% CI 79.4, 90.2], respectively.  Low 6 MWD, low mixed venous oxygenation, high N-terminal pro hormone of brain natriuretic peptide levels and PAH associated with connective tissue disease were associated with a higher risk of death.  CONCLUSIONS:  The majority of patients exposed to long-term bosentan maintained or improved their functional class.  Approximately 20% of the patients discontinued treatment because of adverse events, which were most commonly PAH worsening and elevated liver enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcl2qhPMOxQ1VwdslNBF-tfW6udTcc2eay3XrCC-76P7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvkvFSmsg%253D%253D&md5=fea3d9d24dec6f2fdd110117de4f7cb2</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2013.12.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2013.12.179%26sid%3Dliteratum%253Aachs%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DMeyer%26aufirst%3DG.%2BM.%26aulast%3DAl-Hiti%26aufirst%3DH.%26aulast%3DKusic-Pajic%26aufirst%3DA.%26aulast%3DLemari%25C3%25A9%26aufirst%3DJ.%2BC.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DLong-term%2520Results%2520from%2520the%2520EARLY%2520Study%2520of%2520Bosentan%2520in%2520WHO%2520Functional%2520Class%2520II%2520Pulmonary%2520Arterial%2520Hypertension%2520Patients%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2014%26volume%3D172%26spage%3D332%26epage%3D339%26doi%3D10.1016%2Fj.ijcard.2013.12.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Wilkins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strange, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunariu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gin-Sing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banya, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanidis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennell, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohiaddin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nihoyannopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, J. S.</span><span> </span><span class="NLM_article-title">Sildenafil Versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">1292</span><span class="NLM_x">â</span> <span class="NLM_lpage">1297</span><span class="refDoi">Â DOI: 10.1164/rccm.200410-1411OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1164%2Frccm.200410-1411OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15750042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2005&pages=1292-1297&author=M.+R.+Wilkinsauthor=G.+A.+Paulauthor=J.+W.+Strangeauthor=N.+Tunariuauthor=W.+Gin-Singauthor=W.+A.+Banyaauthor=M.+A.+Westwoodauthor=A.+Stefanidisauthor=L.+L.+Ngauthor=D.+J.+Pennellauthor=R.+H.+Mohiaddinauthor=P.+Nihoyannopoulosauthor=J.+S.+Gibbs&title=Sildenafil+Versus+Endothelin+Receptor+Antagonist+for+Pulmonary+Hypertension+%28SERAPH%29+Study&doi=10.1164%2Frccm.200410-1411OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study</span></div><div class="casAuthors">Wilkins Martin R; Paul Gideon A; Strange Julian W; Tunariu Nina; Gin-Sing Wendy; Banya Winston A; Westwood Mark A; Stefanidis Alexander; Ng Leong L; Pennell Dudley J; Mohiaddin Raad H; Nihoyannopoulos Petros; Gibbs J Simon R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1292-7</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">RATIONALE:  Phosphodiesterase type 5 (PDE5) inhibition has been proposed for the treatment for pulmonary arterial hypertension (PAH).  OBJECTIVE:  This study compared adding sildenafil, a PDE5 inhibitor, to conventional treatment with the current practice of adding bosentan, an endothelin receptor antagonist.  METHODS:  Twenty-six patients with PAH, idiopathic or associated with connective tissue disease, World Health Organization (WHO) functional class III, were randomized in a double-blind fashion to receive sildenafil (50 mg twice daily for 4 weeks, then 50 mg three times daily) or bosentan (62.5 mg twice daily for 4 weeks, then 125 mg twice daily) over 16 weeks.  MEASUREMENTS:  Changes in right ventricular (RV) mass (using cardiovascular magnetic resonance), 6-minute walk distance, cardiac function, brain natriuretic peptide, and Borg dyspnea index.  MAIN RESULTS:  When analyzed by intention to treat, there were no significant differences between the two treatment groups.  One patient on sildenafil died suddenly.  Patients on sildenafil who completed the protocol showed significant changes from baseline, namely, reductions in RV mass (-8.8 g; 95% confidence interval [CI], -2, -16; n = 13, p = 0.015) and plasma brain natriuretic peptide levels (-19.4 fmol x ml(-1); 95% CI, -5, -34; p = 0.014) and improvements in 6-minute walk distance (114 m; 95% CI, 67, 160; p = 0.0002), cardiac index (0.3 L x min(-1) x m(-2); 95% CI, 0.1, 0.4; p = 0.008), and systolic left ventricular eccentricity index (-0.2; 95% CI, -0.02, -0.37; p = 0.031).  Bosentan improved 6-minute walk distance (59 m; 95% CI, 29, 89; n = 12, p = 0.001) and cardiac index (0.3; 95% CI, 0.1, 0.4; p = 0.008).  CONCLUSIONS:  Sildenafil added to conventional treatment reduces RV mass and improves cardiac function and exercise capacity in patients with PAH, WHO functional class III.  Safety monitoring is important until more experience is obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6Hl7Y7MSGme2qxNLjzXe8fW6udTcc2eZv4gSyPvoHLLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtQ%253D%253D&md5=537fa548c4a1006d15fae4289b3f5875</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1164%2Frccm.200410-1411OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200410-1411OC%26sid%3Dliteratum%253Aachs%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DPaul%26aufirst%3DG.%2BA.%26aulast%3DStrange%26aufirst%3DJ.%2BW.%26aulast%3DTunariu%26aufirst%3DN.%26aulast%3DGin-Sing%26aufirst%3DW.%26aulast%3DBanya%26aufirst%3DW.%2BA.%26aulast%3DWestwood%26aufirst%3DM.%2BA.%26aulast%3DStefanidis%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DL.%2BL.%26aulast%3DPennell%26aufirst%3DD.%2BJ.%26aulast%3DMohiaddin%26aufirst%3DR.%2BH.%26aulast%3DNihoyannopoulos%26aufirst%3DP.%26aulast%3DGibbs%26aufirst%3DJ.%2BS.%26atitle%3DSildenafil%2520Versus%2520Endothelin%2520Receptor%2520Antagonist%2520for%2520Pulmonary%2520Hypertension%2520%2528SERAPH%2529%2520Study%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2005%26volume%3D171%26spage%3D1292%26epage%3D1297%26doi%3D10.1164%2Frccm.200410-1411OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olschewski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudiz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGoon, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roecker, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiens, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy (ARIES) Study 1 and 2</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">3010</span><span class="NLM_x">â</span> <span class="NLM_lpage">3019</span><span class="refDoi">Â DOI: 10.1161/CIRCULATIONAHA.107.742510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1161%2FCIRCULATIONAHA.107.742510" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2008&pages=3010-3019&author=N.+Gali%C3%A8author=H.+Olschewskiauthor=R.+J.+Oudizauthor=F.+Torresauthor=A.+Frostauthor=H.+A.+Ghofraniauthor=D.+B.+Badeschauthor=M.+D.+McGoonauthor=V.+V.+McLaughlinauthor=E.+B.+Roeckerauthor=M.+J.+Gerberauthor=C.+Duftonauthor=B.+L.+Wiensauthor=L.+J.+Rubin&title=Ambrisentan+in+Pulmonary+Arterial+Hypertension%2C+Randomized%2C+Double-blind%2C+Placebo-controlled%2C+Multicenter%2C+Efficacy+Studies+%28ARIES%29+Group.+Ambrisentan+for+the+Treatment+of+Pulmonary+Arterial+Hypertension%3A+Results+of+the+Ambrisentan+in+Pulmonary+Arterial+Hypertension%2C+Randomized%2C+Double-blind%2C+Placebo-controlled%2C+Multicenter%2C+Efficacy+%28ARIES%29+Study+1+and+2&doi=10.1161%2FCIRCULATIONAHA.107.742510"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.107.742510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.107.742510%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DRoecker%26aufirst%3DE.%2BB.%26aulast%3DGerber%26aufirst%3DM.%2BJ.%26aulast%3DDufton%26aufirst%3DC.%26aulast%3DWiens%26aufirst%3DB.%2BL.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DAmbrisentan%2520in%2520Pulmonary%2520Arterial%2520Hypertension%252C%2520Randomized%252C%2520Double-blind%252C%2520Placebo-controlled%252C%2520Multicenter%252C%2520Efficacy%2520Studies%2520%2528ARIES%2529%2520Group.%2520Ambrisentan%2520for%2520the%2520Treatment%2520of%2520Pulmonary%2520Arterial%2520Hypertension%253A%2520Results%2520of%2520the%2520Ambrisentan%2520in%2520Pulmonary%2520Arterial%2520Hypertension%252C%2520Randomized%252C%2520Double-blind%252C%2520Placebo-controlled%252C%2520Multicenter%252C%2520Efficacy%2520%2528ARIES%2529%2520Study%25201%2520and%25202%26jtitle%3DCirculation%26date%3D2008%26volume%3D117%26spage%3D3010%26epage%3D3019%26doi%3D10.1161%2FCIRCULATIONAHA.107.742510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BarberÃ , J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peacock, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vachiery, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GrÃ¼nig, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudiz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonk-Noordegraaf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">â</span> <span class="NLM_lpage">844</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1413687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1056%2FNEJMoa1413687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=26308684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFGisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=834-844&author=N.+Gali%C3%A8author=J.+A.+Barber%C3%A0author=A.+E.+Frostauthor=H.+A.+Ghofraniauthor=M.+M.+Hoeperauthor=V.+V.+McLaughlinauthor=A.+J.+Peacockauthor=G.+Simonneauauthor=J.+L.+Vachieryauthor=E.+Gr%C3%BCnigauthor=R.+J.+Oudizauthor=A.+Vonk-Noordegraafauthor=R.+J.+Whiteauthor=C.+Blairauthor=H.+Gilliesauthor=K.+L.+Millerauthor=J.+H.+Harrisauthor=J.+Langleyauthor=L.+J.+Rubin&title=AMBITION+Investigators.+Initial+Use+of+Ambrisentan+plus+Tadalafil+in+Pulmonary+Arterial+Hypertension&doi=10.1056%2FNEJMoa1413687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, N.; Barbera, J. A.; Frost, A. E.; Ghofrani, H.-A.; Hoeper, M. M.; McLaughlin, V. V.; Peacock, A. J.; Simonneau, G.; Vachiery, J.-L.; Grunig, E.; Oudiz, R. J.; Vonk-Noordegraaf, A.; White, R. J.; Blair, C.; Gillies, H.; Miller, K. L.; Harris, J. H. N.; Langley, J.; Rubin, L. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">834-844</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.  Methods: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil (combination-therapy group), 10 mg of ambrisentan plus placebo (ambrisentanmonotherapy group), or 40 mg of tadalafil plus placebo (tadalafil-monotherapy group), all administered once daily.  The primary end point in a time-to-event anal. was the first event of clin. failure, which was defined as the first occurrence of a composite of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or unsatisfactory long-term clin. response.  Results: The primary anal. included 500 participants; 253 were assigned to the combination- therapy group, 126 to the ambrisentan-monotherapy group, and 121 to the tadalafil-monotherapy group.  A primary end-point event occurred in 18%, 34%, and 28% of the participants in these groups, resp., and in 31% of the pooledmonotherapy group (the two monotherapy groups combined).  The hazard ratio for the primary end point in the combination-therapy group vs. the pooled-monotherapy group was 0.50 (95% confidence interval [CI], 0.35 to 0.72; P<0.001).  At week 24, the combination-therapy group had greater redns. from baseline in N-terminal pro-brain natriuretic peptide levels than did the pooled-monotherapy group (mean change, -67.2% vs. -50.4%; P<0.001), as well as a higher percentage of patients with a satisfactory clin. response (39% vs. 29%; odds ratio, 1.56 [95% CI, 1.05 to 2.32]; P = 0.03) and a greater improvement in the 6-min walk distance (median change from baseline, 48.98 m vs. 23.80 m; P<0.001).  The adverse events that occurred more frequently in the combination-therapy group than in either monotherapy group included peripheral edema, headache, nasal congestion, and anemia.  Conclusions: Among participants with pulmonary arterial hypertension who had not received previous treatment, initial combination therapy with ambrisentan and tadalafil resulted in a significantly lower risk of clin.-failure events than the risk with ambrisentan or tadalafil monotherapy. (Funded by Gilead Sciences and GlaxoSmithKline; AMBITION ClinicalTrials.gov no., NCT01178073).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe4zQLE95kVbVg90H21EOLACvtfcHk0liMqpNapEfyBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFGisA%253D%253D&md5=018dd6202fa784e3570c7dd6395218e4</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413687%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DBarber%25C3%25A0%26aufirst%3DJ.%2BA.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DPeacock%26aufirst%3DA.%2BJ.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DVachiery%26aufirst%3DJ.%2BL.%26aulast%3DGr%25C3%25BCnig%26aufirst%3DE.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DVonk-Noordegraaf%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DR.%2BJ.%26aulast%3DBlair%26aufirst%3DC.%26aulast%3DGillies%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DK.%2BL.%26aulast%3DHarris%26aufirst%3DJ.%2BH.%26aulast%3DLangley%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DAMBITION%2520Investigators.%2520Initial%2520Use%2520of%2520Ambrisentan%2520plus%2520Tadalafil%2520in%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D834%26epage%3D844%26doi%3D10.1056%2FNEJMoa1413687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Miyamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyotani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyatake, K.</span><span> </span><span class="NLM_article-title">Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension. Comparison with Cardiopulmonary Exercise Testing</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">â</span> <span class="NLM_lpage">492</span><span class="refDoi">Â DOI: 10.1164/ajrccm.161.2.9906015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1164%2Fajrccm.161.2.9906015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10673190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BD3c7otVamuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2000&pages=487-492&author=S.+Miyamotoauthor=N.+Nagayaauthor=T.+Satohauthor=S.+Kyotaniauthor=F.+Sakamakiauthor=M.+Fujitaauthor=N.+Nakanishiauthor=K.+Miyatake&title=Clinical+Correlates+and+Prognostic+Significance+of+Six-minute+Walk+Test+in+Patients+with+Primary+Pulmonary+Hypertension.+Comparison+with+Cardiopulmonary+Exercise+Testing&doi=10.1164%2Fajrccm.161.2.9906015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing</span></div><div class="casAuthors">Miyamoto S; Nagaya N; Satoh T; Kyotani S; Sakamaki F; Fujita M; Nakanishi N; Miyatake K</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2 Pt 1</span>),
    <span class="NLM_cas:pages">487-92</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">The six-minute walk test is a submaximal exercise test that can be performed even by a patient with heart failure not tolerating maximal exercise testing.  To elucidate the clinical significance and prognostic value of the six-minute walk test in patients with primary pulmonary hypertension (PPH), we sought (1) to assess the relation between distance walked during the six-minute walk test and exercise capacity determined by maximal cardiopulmonary exercise testing, and (2) to investigate the prognostic value of the six-minute walk test in comparison with other noninvasive parameters.  The six-minute walk test was performed in 43 patients with PPH, together with echocardiography, right heart catheterization, and measurement of plasma epinephrine and norepinephrine.  Symptom-limited cardiopulmonary exercise testing was performed in a subsample of patients (n = 27).  Distance walked in 6 min was significantly shorter in patients with PPH than in age- and sex-matched healthy subjects (297 +/- 188 versus 655 +/- 91 m, p < 0. 001).  The distance significantly decreased in proportion to the severity of New York Heart Association functional class.  The distance walked correlated modestly with baseline cardiac output (r = 0.48, p < 0.05) and total pulmonary resistance (r = -0.49, p < 0. 05), but not significantly with mean pulmonary arterial pressure.  In contrast, the distance walked correlated strongly with peak V O(2) (r = 0.70, p < 0.001), oxygen pulse (r = 0.57, p < 0.01), and V E-VCO(2) slope (r = -0.66, p < 0.001) determined by cardiopulmonary exercise testing.  During a mean follow-up period of 21 +/- 16 mo, 12 patients died of cardiopulmonary causes.  Among noninvasive parameters including clinical, echocardiographic, and neurohumoral parameters, only the distance walked in 6 min was independently related to mortality in PPH by multivariate analysis.  Patients walking < 332 m had a significantly lower survival rate than those walking farther, assessed by Kaplan-Meier survival curves (log-rank test, p < 0.01).  These results suggest that the six-minute walk test, a submaximal exercise test, reflects exercise capacity determined by maximal cardiopulmonary exercise testing in patients with PPH, and it is the distance walked in 6 min that has a strong, independent association with mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3Cxch47IYMG52AMpI4GK2fW6udTcc2ebwFsehmJwjC7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7otVamuw%253D%253D&md5=5febc88f23ce32c2e17108eab9b65078</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.161.2.9906015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.161.2.9906015%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DNagaya%26aufirst%3DN.%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DKyotani%26aufirst%3DS.%26aulast%3DSakamaki%26aufirst%3DF.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DNakanishi%26aufirst%3DN.%26aulast%3DMiyatake%26aufirst%3DK.%26atitle%3DClinical%2520Correlates%2520and%2520Prognostic%2520Significance%2520of%2520Six-minute%2520Walk%2520Test%2520in%2520Patients%2520with%2520Primary%2520Pulmonary%2520Hypertension.%2520Comparison%2520with%2520Cardiopulmonary%2520Exercise%2520Testing%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2000%26volume%3D161%26spage%3D487%26epage%3D492%26doi%3D10.1164%2Fajrccm.161.2.9906015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Hoeper, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarze, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehlerding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler-Schuermeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiekerkoetter, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedermeyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabel, H.</span><span> </span><span class="NLM_article-title">Long-term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">1866</span><span class="NLM_x">â</span> <span class="NLM_lpage">1870</span><span class="refDoi">Â DOI: 10.1056/NEJM200006223422503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1056%2FNEJM200006223422503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10861321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVCntL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2000&pages=1866-1870&author=M.+M.+Hoeperauthor=M.+Schwarzeauthor=S.+Ehlerdingauthor=A.+Adler-Schuermeyerauthor=E.+Spiekerkoetterauthor=J.+Niedermeyerauthor=M.+Hammauthor=H.+Fabel&title=Long-term+Treatment+of+Primary+Pulmonary+Hypertension+with+Aerosolized+Iloprost%2C+a+Prostacyclin+Analogue&doi=10.1056%2FNEJM200006223422503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue</span></div><div class="casAuthors">Hoeper, Marius M.; Schwarze, Michael; Ehlerding, Stefan; Adler-Schuermeyer, Angelika; Spiekerkoetter, Edda; Niedermeyer, Jost; Hamm, Michael; Fabel, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1866-1870</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Continuous i.v. infusion of epoprostenol (prostacyclin) is an effective treatment for primary pulmonary hypertension.  This approach requires the insertion of a permanent central venous catheter, with the assocd. risk of serious complications.  Recently, aerosolized iloprost, a stable prostacyclin analog, has been introduced as an alternative therapy for severe pulmonary hypertension.  Methods We evaluated the effects of aerosolized iloprost on exercise capacity and hemodynamic variables over a one-year period in patients with primary pulmonary hypertension.  Results Twenty-four patients with primary pulmonary hypertension received aerosolized iloprost at a daily dose of 100 or 150 Î¼g for at least one year.  The mean (Â±SD) distance covered in the six-minute walk test increased from 278Â±96 m at base line to 363Â±135 m after 12 mo (P<0.001).  During the same period, the mean pulmonary arterial pressure before the inhalation of iloprost declined from 59Â±10 mm Hg to 52Â±15 mm Hg (P=0.006), cardiac output increased from 3.8Â±1.4 L per min to 4.4Â±1.3 L per min (P=0.02), and pulmonary vascular resistance declined from 1205Â±467 dynÂ·secÂ·cm-5 to 925Â±469 dynÂ·secÂ·cm-5 (P<0.001).  The treatment was generally well tolerated, except for mild coughing, minor headache, and jaw pain in some patients.  Conclusions Long-term treatment with aerosolized iloprost is safe and has sustained effects on exercise capacity and pulmonary hemodynamics in patients with primary pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsJkw0ZmBShLVg90H21EOLACvtfcHk0lglDJMn11twnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVCntL4%253D&md5=8c4a05a65346764c958a0234bc47c6b0</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1056%2FNEJM200006223422503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200006223422503%26sid%3Dliteratum%253Aachs%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DSchwarze%26aufirst%3DM.%26aulast%3DEhlerding%26aufirst%3DS.%26aulast%3DAdler-Schuermeyer%26aufirst%3DA.%26aulast%3DSpiekerkoetter%26aufirst%3DE.%26aulast%3DNiedermeyer%26aufirst%3DJ.%26aulast%3DHamm%26aufirst%3DM.%26aulast%3DFabel%26aufirst%3DH.%26atitle%3DLong-term%2520Treatment%2520of%2520Primary%2520Pulmonary%2520Hypertension%2520with%2520Aerosolized%2520Iloprost%252C%2520a%2520Prostacyclin%2520Analogue%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D342%26spage%3D1866%26epage%3D1870%26doi%3D10.1056%2FNEJM200006223422503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Gomberg-Maitland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saggar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elgazayerly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimminger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainisio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockbridge, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ventura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">D82</span><span class="NLM_x">â</span> <span class="NLM_lpage">D91</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2013.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.jacc.2013.10.026" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=D82-D91&author=M.+Gomberg-Maitlandauthor=T.+M.+Bullauthor=R.+Saggarauthor=R.+J.+Barstauthor=A.+Elgazayerlyauthor=T.+R.+Flemingauthor=F.+Grimmingerauthor=M.+Rainisioauthor=D.+J.+Stewartauthor=N.+Stockbridgeauthor=C.+Venturaauthor=A.+H.+Ghofraniauthor=L.+J.+Rubin&title=New+Trial+Designs+and+Potential+Therapies+for+Pulmonary+Artery+Hypertension&doi=10.1016%2Fj.jacc.2013.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2013.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2013.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DGomberg-Maitland%26aufirst%3DM.%26aulast%3DBull%26aufirst%3DT.%2BM.%26aulast%3DSaggar%26aufirst%3DR.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DElgazayerly%26aufirst%3DA.%26aulast%3DFleming%26aufirst%3DT.%2BR.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DRainisio%26aufirst%3DM.%26aulast%3DStewart%26aufirst%3DD.%2BJ.%26aulast%3DStockbridge%26aufirst%3DN.%26aulast%3DVentura%26aufirst%3DC.%26aulast%3DGhofrani%26aufirst%3DA.%2BH.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DNew%2520Trial%2520Designs%2520and%2520Potential%2520Therapies%2520for%2520Pulmonary%2520Artery%2520Hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2013%26volume%3D62%26spage%3DD82%26epage%3DD91%26doi%3D10.1016%2Fj.jacc.2013.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Benza, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomberg-Maitland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frantz, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foreman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGoon, M. D.</span><span> </span><span class="NLM_article-title">The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed with Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">â</span> <span class="NLM_lpage">362</span><span class="refDoi">Â DOI: 10.1378/chest.11-0676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1378%2Fchest.11-0676" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2012&pages=354-362&author=R.+L.+Benzaauthor=M.+Gomberg-Maitlandauthor=D.+P.+Millerauthor=A.+Frostauthor=R.+P.+Frantzauthor=A.+J.+Foremanauthor=D.+B.+Badeschauthor=M.+D.+McGoon&title=The+REVEAL+Registry+Risk+Score+Calculator+in+Patients+Newly+Diagnosed+with+Pulmonary+Arterial+Hypertension&doi=10.1378%2Fchest.11-0676"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1378%2Fchest.11-0676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.11-0676%26sid%3Dliteratum%253Aachs%26aulast%3DBenza%26aufirst%3DR.%2BL.%26aulast%3DGomberg-Maitland%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DD.%2BP.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DFrantz%26aufirst%3DR.%2BP.%26aulast%3DForeman%26aufirst%3DA.%2BJ.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26atitle%3DThe%2520REVEAL%2520Registry%2520Risk%2520Score%2520Calculator%2520in%2520Patients%2520Newly%2520Diagnosed%2520with%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DChest%26date%3D2012%26volume%3D141%26spage%3D354%26epage%3D362%26doi%3D10.1378%2Fchest.11-0676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">GalliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vachiery, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torbicki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peacock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonk Noordegraaf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beghetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez Sanchez, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klepetko, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancellotti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matucci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonagh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierard, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trindade, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zompatori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M.</span><span> </span><span class="NLM_article-title">2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). International Society for Heart and Lung Transplantation (ISHLT)</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">â</span> <span class="NLM_lpage">119</span><span class="refDoi">Â DOI: 10.1093/eurheartj/ehv317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1093%2Feurheartj%2Fehv317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=26320113" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=67-119&author=N.+Galli%C3%A8author=M.+Humbertauthor=J.+L.+Vachieryauthor=S.+Gibbsauthor=I.+Langauthor=A.+Torbickiauthor=G.+Simonneauauthor=A.+Peacockauthor=A.+Vonk+Noordegraafauthor=M.+Beghettiauthor=A.+Ghofraniauthor=M.+A.+Gomez+Sanchezauthor=G.+Hansmannauthor=W.+Klepetkoauthor=P.+Lancellottiauthor=M.+Matucciauthor=T.+McDonaghauthor=L.+A.+Pierardauthor=P.+T.+Trindadeauthor=M.+Zompatoriauthor=M.+Hoeper&title=2015+ESC%2FERS+Guidelines+for+the+Diagnosis+and+Treatment+of+Pulmonary+Hypertension%3A+The+Joint+Task+Force+for+the+Diagnosis+and+Treatment+of+Pulmonary+Hypertension+of+the+European+Society+of+Cardiology+%28ESC%29+and+the+European+Respiratory+Society+%28ERS%29%3A+Endorsed+by%3A+Association+for+European+Paediatric+and+Congenital+Cardiology+%28AEPC%29.+International+Society+for+Heart+and+Lung+Transplantation+%28ISHLT%29&doi=10.1093%2Feurheartj%2Fehv317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehv317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehv317%26sid%3Dliteratum%253Aachs%26aulast%3DGalli%25C3%25A8%26aufirst%3DN.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DVachiery%26aufirst%3DJ.%2BL.%26aulast%3DGibbs%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DI.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DPeacock%26aufirst%3DA.%26aulast%3DVonk%2BNoordegraaf%26aufirst%3DA.%26aulast%3DBeghetti%26aufirst%3DM.%26aulast%3DGhofrani%26aufirst%3DA.%26aulast%3DGomez%2BSanchez%26aufirst%3DM.%2BA.%26aulast%3DHansmann%26aufirst%3DG.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DLancellotti%26aufirst%3DP.%26aulast%3DMatucci%26aufirst%3DM.%26aulast%3DMcDonagh%26aufirst%3DT.%26aulast%3DPierard%26aufirst%3DL.%2BA.%26aulast%3DTrindade%26aufirst%3DP.%2BT.%26aulast%3DZompatori%26aufirst%3DM.%26aulast%3DHoeper%26aufirst%3DM.%26atitle%3D2015%2520ESC%252FERS%2520Guidelines%2520for%2520the%2520Diagnosis%2520and%2520Treatment%2520of%2520Pulmonary%2520Hypertension%253A%2520The%2520Joint%2520Task%2520Force%2520for%2520the%2520Diagnosis%2520and%2520Treatment%2520of%2520Pulmonary%2520Hypertension%2520of%2520the%2520European%2520Society%2520of%2520Cardiology%2520%2528ESC%2529%2520and%2520the%2520European%2520Respiratory%2520Society%2520%2528ERS%2529%253A%2520Endorsed%2520by%253A%2520Association%2520for%2520European%2520Paediatric%2520and%2520Congenital%2520Cardiology%2520%2528AEPC%2529.%2520International%2520Society%2520for%2520Heart%2520and%2520Lung%2520Transplantation%2520%2528ISHLT%2529%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2016%26volume%3D37%26spage%3D67%26epage%3D119%26doi%3D10.1093%2Feurheartj%2Fehv317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâArmini, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimminger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span> </span><span class="NLM_article-title">Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">â</span> <span class="NLM_lpage">329</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1209657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1056%2FNEJMoa1209657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23883377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=319-329&author=H.+A.+Ghofraniauthor=A.+M.+D%E2%80%99Arminiauthor=F.+Grimmingerauthor=M.+M.+Hoeperauthor=P.+Jansaauthor=N.+H.+Kimauthor=E.+Mayerauthor=G.+Simonneauauthor=M.+R.+Wilkinsauthor=A.+Fritschauthor=D.+Neuserauthor=G.+Weimannauthor=C.+Wang&title=Riociguat+for+the+Treatment+of+Chronic+Thromboembolic+Pulmonary+Hypertension&doi=10.1056%2FNEJMoa1209657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Riociguat for the treatment of chronic thromboembolic pulmonary hypertension</span></div><div class="casAuthors">Ghofrani, Hossein-Ardeschir; D'Armini, Andrea M.; Grimminger, Friedrich; Hoeper, Marius M.; Jansa, Pavel; Kim, Nick H.; Mayer, Eckhard; Simonneau, Gerald; Wilkins, Martin R.; Fritsch, Arno; Neuser, Dieter; Weimann, Gerrit; Wang, Chen</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-329</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Riociguat, a member of a new class of compds. (sol. guanylate cyclase stimulators), has been shown in previous clin. studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension.  METHODS In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat.  The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 min.  Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clin. worsening, Borg dyspnea score, quality-of-life variables, and safety.  RESULTS By week 16, the 6-min walk distance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m in the placebo group (least-squares mean difference, 46 m; 95% confidence interval [CI], 25 to 67; P<0.001).  Pulmonary vascular resistance decreased by 226 dynÂ·secÂ·cm-5 in the riociguat group and increased by 23 dynÂ·secÂ·cm-5 in the placebo group (least-squares mean difference, -246 dynÂ·secÂ·cm-5; 95% CI, -303 to -190; P<0.001).  Riociguat was also assocd. with significant improvements in the NT-proBNP level (P<0.001) and WHO functional class (P = 0.003).  The most common serious adverse events were right ventricular failure (in 3% of patients in each group) and syncope (in 2% of the riociguat group and in 3% of the placebo group).  CONCLUSIONS Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2KTSYf5k0YLVg90H21EOLACvtfcHk0lgWxj4VXrkNpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7J&md5=4b274ffd0efef3d69383bd7d4d1c9275</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209657%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DD%25E2%2580%2599Armini%26aufirst%3DA.%2BM.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DN.%2BH.%26aulast%3DMayer%26aufirst%3DE.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DNeuser%26aufirst%3DD.%26aulast%3DWeimann%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DRiociguat%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Thromboembolic%2520Pulmonary%2520Hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D319%26epage%3D329%26doi%3D10.1056%2FNEJMoa1209657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Egidy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeannin, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosman, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinet, F.</span><span> </span><span class="NLM_article-title">Modulation of Human Colon Tumor-stromal Interactions by the Endothelin System</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">157</span><span class="NLM_x">, </span> <span class="NLM_fpage">1863</span><span class="NLM_x">â</span> <span class="NLM_lpage">1874</span><span class="refDoi">Â DOI: 10.1016/S0002-9440(10)64825-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0002-9440%2810%2964825-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=11106559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsVKrtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2000&pages=1863-1874&author=G.+Egidyauthor=L.+Juillerat-Jeanneretauthor=J.-F.+Jeanninauthor=P.+Korthauthor=F.+T.+Bosmanauthor=F.+Pinet&title=Modulation+of+Human+Colon+Tumor-stromal+Interactions+by+the+Endothelin+System&doi=10.1016%2FS0002-9440%2810%2964825-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of human colon tumor-stromal interactions by the endothelin system</span></div><div class="casAuthors">Egidy, Giorgia; Juillerat-Jeanneret, Lucienne; Jeannin, Jean-Francois; Korth, Petra; Bosman, Fred T.; Pinet, Florence</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1863-1874</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Tumor neovascularization is considered to be a crit. step in the development of a malignant tumor.  Endothelin (ET)-1 is a powerful vasoconstrictor and mitogenic peptide that is produced by many cancer cell lines.  The cellular distribution of the ET components was evaluated in human colon tumors and compared to normal colon.  There was more of the ET components (prepro-ET-1, endothelin-converting enzyme-1, and ETA and ETB receptors) in adenomas and adenocarcinomas than in the normal colon.  There was overprodn. of preproET-1 and endothelin-converting enzyme-1 in carcinoma cells and stromal vessels, suggesting that they are a local source of ET-1.  ETA receptors were present in stromal myofibroblasts of neoplastic tissue, and there were large amts. of ETB receptors in the endothelium and myofibroblasts.  There was also a redistribution of Î±-smooth muscle actin-pos. cells in the vascular structures of tumors.  An exptl. rat model of induced colon cancer treated for 30 days with bosentan, a mixed antagonist of both ET receptors, confirmed the morphol. changes obsd. during the tumor vascularization.  Our data suggest that ET-1 and its receptor play a role in colon cancer progression, with ET-1 functioning as a neg. modulator of the stromal response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppPtXX2Ad-MLVg90H21EOLACvtfcHk0lgWxj4VXrkNpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsVKrtg%253D%253D&md5=7a4dfadc4b03105642fc2389353ffdde</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2964825-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252964825-0%26sid%3Dliteratum%253Aachs%26aulast%3DEgidy%26aufirst%3DG.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DJeannin%26aufirst%3DJ.-F.%26aulast%3DKorth%26aufirst%3DP.%26aulast%3DBosman%26aufirst%3DF.%2BT.%26aulast%3DPinet%26aufirst%3DF.%26atitle%3DModulation%2520of%2520Human%2520Colon%2520Tumor-stromal%2520Interactions%2520by%2520the%2520Endothelin%2520System%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2000%26volume%3D157%26spage%3D1863%26epage%3D1874%26doi%3D10.1016%2FS0002-9440%2810%2964825-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Egidy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberl, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdenaire, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irmler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majdi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diserens, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzer, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">The Endothelin System in Human Glioblastoma</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">1681</span><span class="NLM_x">â</span> <span class="NLM_lpage">1689</span><span class="refDoi">Â DOI: 10.1038/labinvest.3780178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Flabinvest.3780178" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2000&pages=1681-1689&author=G.+Egidyauthor=L.+P.+Eberlauthor=O.+Valdenaireauthor=M.+Irmlerauthor=R.+Majdiauthor=A.+C.+Diserensauthor=A.+Fontanaauthor=R.+C.+Janzerauthor=F.+Pinetauthor=L.+Juillerat-Jeanneret&title=The+Endothelin+System+in+Human+Glioblastoma&doi=10.1038%2Flabinvest.3780178"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.3780178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.3780178%26sid%3Dliteratum%253Aachs%26aulast%3DEgidy%26aufirst%3DG.%26aulast%3DEberl%26aufirst%3DL.%2BP.%26aulast%3DValdenaire%26aufirst%3DO.%26aulast%3DIrmler%26aufirst%3DM.%26aulast%3DMajdi%26aufirst%3DR.%26aulast%3DDiserens%26aufirst%3DA.%2BC.%26aulast%3DFontana%26aufirst%3DA.%26aulast%3DJanzer%26aufirst%3DR.%2BC.%26aulast%3DPinet%26aufirst%3DF.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DThe%2520Endothelin%2520System%2520in%2520Human%2520Glioblastoma%26jtitle%3DLab.%2520Invest.%26date%3D2000%26volume%3D80%26spage%3D1681%26epage%3D1689%26doi%3D10.1038%2Flabinvest.3780178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Douglas, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicol, D. L.</span><span> </span><span class="NLM_article-title">Endothelin Axis Expression Is Markedly Different in the Two Main Subtypes of Renal Cell Carcinoma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">2118</span><span class="NLM_x">â</span> <span class="NLM_lpage">2124</span><span class="refDoi">Â DOI: 10.1002/cncr.20222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fcncr.20222" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2004&pages=2118-2124&author=M.+L.+Douglasauthor=M.+M.+Richardsonauthor=D.+L.+Nicol&title=Endothelin+Axis+Expression+Is+Markedly+Different+in+the+Two+Main+Subtypes+of+Renal+Cell+Carcinoma&doi=10.1002%2Fcncr.20222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fcncr.20222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.20222%26sid%3Dliteratum%253Aachs%26aulast%3DDouglas%26aufirst%3DM.%2BL.%26aulast%3DRichardson%26aufirst%3DM.%2BM.%26aulast%3DNicol%26aufirst%3DD.%2BL.%26atitle%3DEndothelin%2520Axis%2520Expression%2520Is%2520Markedly%2520Different%2520in%2520the%2520Two%2520Main%2520Subtypes%2520of%2520Renal%2520Cell%2520Carcinoma%26jtitle%3DCancer%26date%3D2004%26volume%3D100%26spage%3D2118%26epage%3D2124%26doi%3D10.1002%2Fcncr.20222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Grant, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span> </span><span class="NLM_article-title">Endothelin-1: A Multifunctional Molecule in Cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">â</span> <span class="NLM_lpage">166</span><span class="refDoi">Â DOI: 10.1038/sj.bjc.6700750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fsj.bjc.6700750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=12610497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsV2rtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=163-166&author=K.+Grantauthor=M.+Loizidouauthor=I.+Taylor&title=Endothelin-1%3A+A+Multifunctional+Molecule+in+Cancer&doi=10.1038%2Fsj.bjc.6700750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1: a multifunctional molecule in cancer</span></div><div class="casAuthors">Grant, K.; Loizidou, M.; Taylor, I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-166</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Endothelin-1 is a small vasoconstrictor peptide that was first identified in 1988.  Here the authors review the evidence implicating ET-1 in tumorigenesis.  In particular, the authors conc. on the role of ET-1 in mitogenesis, apoptosis, angiogenesis, tumor invasion and metastasis, and discuss the potential for endothelin-system modulation as an adjuvant therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9uaGOlyxOr7Vg90H21EOLACvtfcHk0lgHkgTstuPGlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsV2rtbo%253D&md5=2d42889b82f426e56665460b6dbb7922</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6700750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6700750%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DK.%26aulast%3DLoizidou%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DI.%26atitle%3DEndothelin-1%253A%2520A%2520Multifunctional%2520Molecule%2520in%2520Cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D88%26spage%3D163%26epage%3D166%26doi%3D10.1038%2Fsj.bjc.6700750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Grimshaw, M. J.</span><span> </span><span class="NLM_article-title">Endothelins in Breast Tumour Cell Invasion</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">222</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">â</span> <span class="NLM_lpage">138</span><span class="refDoi">Â DOI: 10.1016/j.canlet.2004.08.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.canlet.2004.08.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15863261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Ghs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2005&pages=129-138&author=M.+J.+Grimshaw&title=Endothelins+in+Breast+Tumour+Cell+Invasion&doi=10.1016%2Fj.canlet.2004.08.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelins in breast tumour cell invasion</span></div><div class="casAuthors">Grimshaw, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-138</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Endothelins are a family of small, structurally related, vasoactive peptides that have a great no. of physiol. roles in many tissues.  The endothelin axis' consists of three 21 amino acid peptides (ET-1, ET-2 and ET-3), two G-protein-coupled receptors (ET-RA and ET-RB), and two activating peptidases or endothelin-converting enzymes (ECE-1 and ECE-2).  There is increased expression of the endothelin axis in invasive breast cancer compared to the normal breast or non-invasive neoplastic tissue.  Endothelin expression is assocd. with invading regions of tumors in patient biopsies and is more common in tumors with high histol. grade and lymphovascular invasion, and there is increased systemic endothelin in patients with lymph node metastases compared to those without lymph node involvement.  Stimulation of breast tumor cell lines with endothelins leads to an invasive phenotype in vitro.  Over-expression of the endothelins and their receptors is insufficient to induce an invasive phenotype in benign cells, yet expression by tumor cells leads to markedly increased invasive ability indicating that endothelins act in concert with other factors-both autocrine and paracrine-including cytokines, matrix metalloproteinases and the activation of tumor-assocd. macrophages.  The assocn. between endothelins, poor prognosis and invasion may mean that the endothelin axis is a valid therapeutic target for the treatment of invasive breast cancer.  This review summarizes the authors' current knowledge of endothelins in breast cancer invasion and discusses the potential further directions of such research as well as the possibility of anti-endothelin-based therapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkaSckEJMuwLVg90H21EOLACvtfcHk0lgHkgTstuPGlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Ghs78%253D&md5=8dcf1ca6ac8ac525d21c749b61137114</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.08.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.08.029%26sid%3Dliteratum%253Aachs%26aulast%3DGrimshaw%26aufirst%3DM.%2BJ.%26atitle%3DEndothelins%2520in%2520Breast%2520Tumour%2520Cell%2520Invasion%26jtitle%3DCancer%2520Lett.%26date%3D2005%26volume%3D222%26spage%3D129%26epage%3D138%26doi%3D10.1016%2Fj.canlet.2004.08.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Kusuhara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, K.</span><span> </span><span class="NLM_article-title">Production of Endothelin in Human Cancer Cell Lines</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">3257</span><span class="NLM_x">â</span> <span class="NLM_lpage">3261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1990&pages=3257-3261&author=M.+Kusuharaauthor=K.+Yamaguchiauthor=K.+Nagasakiauthor=C.+Hayashiauthor=A.+Suzakiauthor=S.+Horiauthor=S.+Handaauthor=Y.+Nakamuraauthor=K.+Abe&title=Production+of+Endothelin+in+Human+Cancer+Cell+Lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKusuhara%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DNagasaki%26aufirst%3DK.%26aulast%3DHayashi%26aufirst%3DC.%26aulast%3DSuzaki%26aufirst%3DA.%26aulast%3DHori%26aufirst%3DS.%26aulast%3DHanda%26aufirst%3DS.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DK.%26atitle%3DProduction%2520of%2520Endothelin%2520in%2520Human%2520Cancer%2520Cell%2520Lines%26jtitle%3DCancer%2520Res.%26date%3D1990%26volume%3D50%26spage%3D3257%26epage%3D3261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Nelson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battistini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nisen, P.</span><span> </span><span class="NLM_article-title">The Endothelin Axis: Emerging Role in Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">â</span> <span class="NLM_lpage">116</span><span class="refDoi">Â DOI: 10.1038/nrc990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fnrc990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=12563310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVCqsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=110-116&author=J.+Nelsonauthor=A.+Bagnatoauthor=B.+Battistiniauthor=P.+Nisen&title=The+Endothelin+Axis%3A+Emerging+Role+in+Cancer&doi=10.1038%2Fnrc990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The endothelin axis: emerging role in cancer</span></div><div class="casAuthors">Nelson, Joel; Bagnato, Anna; Battistini, Bruno; Nisen, Perry</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">110-116</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Collectively, the endothelins and their receptors - referred to as the endothelin (ET) axis - have key physiol. functions in normal tissue, acting as modulators of vasomotor tone, tissue, differentiation, development, cell proliferation and hormone prodn.  Based on new data, the ET axis also functions in the growth and progression of various tumors.  Preliminary results from clin. trials, such as those with atrasentan - an ETA-receptor antagonist-in prostate cancer are encouraging.  The place of ET-receptor antagonists in cancer therapy for a range of malignancies merits further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiRW-JWyEHbbVg90H21EOLACvtfcHk0lhXTjlC2PxDmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVCqsr4%253D&md5=d405432e9766b126391159b8ef60e858</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fnrc990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc990%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DJ.%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DBattistini%26aufirst%3DB.%26aulast%3DNisen%26aufirst%3DP.%26atitle%3DThe%2520Endothelin%2520Axis%253A%2520Emerging%2520Role%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D110%26epage%3D116%26doi%3D10.1038%2Fnrc990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Nelson, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Love, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulman, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleep, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M.</span><span> </span><span class="NLM_article-title">Atrasentan Phase 3 Study Group. Phase 3, Randomized, Controlled Trial of Atrasentan in Patients with Nonmetaststic Hormone-refractory Prostate Cancer</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">2478</span><span class="NLM_x">â</span> <span class="NLM_lpage">2487</span><span class="refDoi">Â DOI: 10.1002/cncr.23864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fcncr.23864" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2008&pages=2478-2487&author=J.+B.+Nelsonauthor=W.+Loveauthor=J.+L.+Chinauthor=F.+Saadauthor=C.+C.+Schulmanauthor=D.+J.+Sleepauthor=J.+Qianauthor=J.+Steinbergauthor=M.+Carducci&title=Atrasentan+Phase+3+Study+Group.+Phase+3%2C+Randomized%2C+Controlled+Trial+of+Atrasentan+in+Patients+with+Nonmetaststic+Hormone-refractory+Prostate+Cancer&doi=10.1002%2Fcncr.23864"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2Fcncr.23864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.23864%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DJ.%2BB.%26aulast%3DLove%26aufirst%3DW.%26aulast%3DChin%26aufirst%3DJ.%2BL.%26aulast%3DSaad%26aufirst%3DF.%26aulast%3DSchulman%26aufirst%3DC.%2BC.%26aulast%3DSleep%26aufirst%3DD.%2BJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DSteinberg%26aufirst%3DJ.%26aulast%3DCarducci%26aufirst%3DM.%26atitle%3DAtrasentan%2520Phase%25203%2520Study%2520Group.%2520Phase%25203%252C%2520Randomized%252C%2520Controlled%2520Trial%2520of%2520Atrasentan%2520in%2520Patients%2520with%2520Nonmetaststic%2520Hormone-refractory%2520Prostate%2520Cancer%26jtitle%3DCancer%26date%3D2008%26volume%3D113%26spage%3D2478%26epage%3D2487%26doi%3D10.1002%2Fcncr.23864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">RosanÃ², L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span> </span><span class="NLM_article-title">Endothelin 1 in Cancer: Biological Implications and Therapeutic Opportunities</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">â</span> <span class="NLM_lpage">651</span><span class="refDoi">Â DOI: 10.1038/nrc3546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fnrc3546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23884378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKnurjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=637-651&author=L.+Rosan%C3%B2author=F.+Spinellaauthor=A.+Bagnato&title=Endothelin+1+in+Cancer%3A+Biological+Implications+and+Therapeutic+Opportunities&doi=10.1038%2Fnrc3546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin 1 in cancer: biological implications and therapeutic opportunities</span></div><div class="casAuthors">Rosano, Laura; Spinella, Francesca; Bagnato, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">637-651</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Activation of autocrine and paracrine signalling by endothelin 1 (ET1) binding to its receptors elicits pleiotropic effects on tumor cells and on the host microenvironment.  This activation modulates cell proliferation, apoptosis, migration, epithelial-to-mesenchymal transition, chemoresistance and neovascularization, thus providing a strong rationale for targeting ET1 receptors in cancer.  In this Review, we discuss the advances in our understanding of the diverse biol. roles of ET1 in cancer and describe the latest preclin. and clin. progress that has been made using small-mol. antagonists of ET1 receptors that inhibit ET1-driven signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxNs394LN35bVg90H21EOLACvtfcHk0lhXTjlC2PxDmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKnurjF&md5=3951fcbc98bf24c955d56f004164ec4e</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnrc3546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3546%26sid%3Dliteratum%253Aachs%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3DEndothelin%25201%2520in%2520Cancer%253A%2520Biological%2520Implications%2520and%2520Therapeutic%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D637%26epage%3D651%26doi%3D10.1038%2Fnrc3546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Bagnato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">RosanÃ², L.</span><span> </span><span class="NLM_article-title">Understanding and Overcoming Chemoresistance in Ovarian Cancer: Emerging Role of the Endothelin Axis</span> <span class="citation_source-journal">Curr. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">â</span> <span class="NLM_lpage">38</span><span class="refDoi">Â DOI: 10.3747/co.19.895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.3747%2Fco.19.895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22328840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC383is1ahtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=36-38&author=A.+Bagnatoauthor=L.+Rosan%C3%B2&title=Understanding+and+Overcoming+Chemoresistance+in+Ovarian+Cancer%3A+Emerging+Role+of+the+Endothelin+Axis&doi=10.3747%2Fco.19.895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis</span></div><div class="casAuthors">Bagnato A; Rosano L</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology (Toronto, Ont.)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTnlReWd_6rDEwO064Z95rfW6udTcc2eaqyMEGNgsycrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383is1ahtw%253D%253D&md5=416dfde251ce5c5497fa45faaa1ddd5e</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.3747%2Fco.19.895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3747%252Fco.19.895%26sid%3Dliteratum%253Aachs%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26atitle%3DUnderstanding%2520and%2520Overcoming%2520Chemoresistance%2520in%2520Ovarian%2520Cancer%253A%2520Emerging%2520Role%2520of%2520the%2520Endothelin%2520Axis%26jtitle%3DCurr.%2520Oncol.%26date%3D2012%26volume%3D19%26spage%3D36%26epage%3D38%26doi%3D10.3747%2Fco.19.895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Bagnato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflug, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Growcott, J.</span><span> </span><span class="NLM_article-title">Role of the Endothelin Axis and Its Antagonists in the Treatment of Cancer</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">â</span> <span class="NLM_lpage">233</span><span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01217.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fj.1476-5381.2011.01217.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21232046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Git7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=220-233&author=A.+Bagnatoauthor=M.+Loizidouauthor=B.+R.+Pflugauthor=J.+Curwenauthor=J.+Growcott&title=Role+of+the+Endothelin+Axis+and+Its+Antagonists+in+the+Treatment+of+Cancer&doi=10.1111%2Fj.1476-5381.2011.01217.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the endothelin axis and its antagonists in the treatment of cancer</span></div><div class="casAuthors">Bagnato, A.; Loizidou, M.; Pflug, B. R.; Curwen, J.; Growcott, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">220-233</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The endothelins (ET) are a group of proteins that act through G-protein coupled receptors.  Endothelin-1 (ET-1) was initially identified as a potent vasoconstrictor and dysregulation of the ET axis contributes to pathol. processes responsible for cardiovascular disease states.  More recently, the ET axis, in particular ET-1 acting through the endothelin A receptor (ETA), was implicated in the development of several cancers through activation of pathways involved in cell proliferation, migration, invasion, epithelial-mesenchymal transition, osteogenesis and angiogenesis.  The endothelin B receptor (ETB) may counter tumor progression by promoting apoptosis and clearing ET-1; however, it has recently been implicated in the development of some tumor types including melanomas and oligodendrogliomas.  Here, we review emerging preclin. and clin. data outlining the role of the ET axis in cancer, and its antagonism as an attractive and challenging approach to improve clin. cancer management.  Clin. data of ETA antagonists in patients with prostate cancer are encouraging and provide promise for new ETA antagonist-based treatment strategies.  Given the unexpected opportunities to affect pleiotrophic tumorigenic signals by targeting ETA-mediated pathways in a no. of cancers, the evaluation of ET-targeted therapy in cancer warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvXY6CHI2Fc7Vg90H21EOLACvtfcHk0li3VQcHQXAANw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Git7w%253D&md5=3dd34f827a5218ee031a461e7c36b770</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01217.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01217.x%26sid%3Dliteratum%253Aachs%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DLoizidou%26aufirst%3DM.%26aulast%3DPflug%26aufirst%3DB.%2BR.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DGrowcott%26aufirst%3DJ.%26atitle%3DRole%2520of%2520the%2520Endothelin%2520Axis%2520and%2520Its%2520Antagonists%2520in%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D220%26epage%3D233%26doi%3D10.1111%2Fj.1476-5381.2011.01217.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Bagnato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natali, P. G.</span><span> </span><span class="NLM_article-title">Endothelin Receptors as Novel Targets in Tumor Therapy</span> <span class="citation_source-journal">J. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="refDoi">Â DOI: 10.1186/1479-5876-2-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1186%2F1479-5876-2-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15165288" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=16&author=A.+Bagnatoauthor=P.+G.+Natali&title=Endothelin+Receptors+as+Novel+Targets+in+Tumor+Therapy&doi=10.1186%2F1479-5876-2-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1186%2F1479-5876-2-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1479-5876-2-16%26sid%3Dliteratum%253Aachs%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26atitle%3DEndothelin%2520Receptors%2520as%2520Novel%2520Targets%2520in%2520Tumor%2520Therapy%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2004%26volume%3D2%26spage%3D16%26doi%3D10.1186%2F1479-5876-2-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Bagnato, A.</span><span> </span><span class="NLM_article-title">The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2720</span><span class="NLM_x">â</span> <span class="NLM_lpage">2733</span><span class="refDoi">Â DOI: 10.2174/138161212800626157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2174%2F138161212800626157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22390759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslCrs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2720-2733&author=A.+Bagnato&title=The+Endothelin+Axis+as+Therapeutic+Target+in+Human+Malignancies%3A+Present+and+Future&doi=10.2174%2F138161212800626157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The endothelin axis as therapeutic target in human malignancies: present and future</span></div><div class="casAuthors">Bagnato, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2720-2733</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  To assure their growth advantage cancer cells require the appropriation of key pathways, such as those controlled by G-protein coupled receptor (GPCR), that influence cell growth, migration, and death, as well as the expansion of vascular networks.  Accumulating mol. and in vivo evidences demonstrate that the activation of the endothelin-1 (ET-1) axis elicites pleiotropic effects on tumor cells and on the tumor microenvironment as well, modulating epithelial to mesenchymal transition, chemoresistance, and other tumor-assocd. processes.  As ET-1 axis blockade has been shown to reduce tumor growth in preclin. models, several small mol. antagonists of ET-1 receptors are currently undergoing clin. trial as novel agents in cancer therapy.  To fully appreciate the potential hegemony of the ET-1 axis in cancer, here we review emerging preclin. and clin. data outlining the spectrum of cellular activities triggered by ET-1 signaling and the challenges facing mol. targeted therapy.  Because scaffold proteins, such as Î²-arrestin, create signalling platforms that drive cellular transformation upon GPCR activation, mechanisms mediated by Î²-arrestin in ET-1 signalling are discussed.  Deeper understanding of mol. mechanisms activated by ET-1 receptor, as well as of how pathway crosstalk can influence ET-1 signalling outcome in cancer, is of paramount translational relevance in the study of ET-1 receptor-targeted therapy.  The improved knowledge of the interconnected mol. mechanism promoted by ET-1 axis in cancer will certainly result in more effective and durable mechanism-guided combinations of ET-1 receptor antagonists with cytotoxic drugs or other targeted agents in the clin. management of ET-1 axis-dependent malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDUZofHp1_57Vg90H21EOLACvtfcHk0li3VQcHQXAANw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslCrs70%253D&md5=cbfdef8f8b701415c9472326ee9968e9</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.2174%2F138161212800626157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800626157%26sid%3Dliteratum%253Aachs%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3DThe%2520Endothelin%2520Axis%2520as%2520Therapeutic%2520Target%2520in%2520Human%2520Malignancies%253A%2520Present%2520and%2520Future%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2720%26epage%3D2733%26doi%3D10.2174%2F138161212800626157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Peduto Eberl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bovey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Endothelin-receptor Antagonists Are Pro-apoptotic and Anti-proliferative in Human Colon Cancer Cells</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">â</span> <span class="NLM_lpage">795</span><span class="refDoi">Â DOI: 10.1038/sj.bjc.6600810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fsj.bjc.6600810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=12618891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1CrsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=788-795&author=L.+Peduto+Eberlauthor=R.+Boveyauthor=L.+Juillerat-Jeanneret&title=Endothelin-receptor+Antagonists+Are+Pro-apoptotic+and+Anti-proliferative+in+Human+Colon+Cancer+Cells&doi=10.1038%2Fsj.bjc.6600810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells</span></div><div class="casAuthors">Peduto Eberl, L.; Bovey, R.; Juillerat-Jeanneret, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">788-795</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Endothelin (ET)-1 can act as an autocrine/paracrine growth factor or an antiapoptotic factor in human cancers.  To study the role of ET-1 in human colon cancer, proliferation and apoptosis of colon carcinoma cells was investigated using human HT-29 and SW480 colon carcinoma cells.  ET-1 was secreted by these cells.  Treatment of cells with bosentan, a dual ETA/B-receptor antagonist, decreased cell no.  Inhibition of DNA synthesis by bosentan was obsd. only in the presence of serum.  Exogenously added ET-1 did not increase DNA synthesis in serum-deprived cells.  SW480 cells were sensitive and HT-29 cells were resistant to FasL-induced apoptosis.  Bosentan sensitized resistant HT-29 cells to FasL-induced, caspase-mediated apoptosis, but not to TNF-Î±-induced apoptosis.  Bosentan and/or FasLigand (FasL) did not modulate the expression of caspase-8 or FLIP.  Bosentan sensitization to apoptosis was reversed by low concns. (10-13-10-10 M), but not by high concns. (10-9-10-7 M) of ET-1.  These results suggest that the binding of ET-1 to high-affinity sites inhibits FasL-induced apoptosis, while the binding of either ET-1 or receptor antagonists to low-affinity sites promotes FasL-induced apoptosis.  In conclusion, endothelin signalling pathways do not induce human colon cancer cell proliferation, but are survival signals controlling resistance to apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZXqLlBmWYirVg90H21EOLACvtfcHk0li3VQcHQXAANw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1CrsLo%253D&md5=3558e16edc9356773e58cfff54ea912d</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600810%26sid%3Dliteratum%253Aachs%26aulast%3DPeduto%2BEberl%26aufirst%3DL.%26aulast%3DBovey%26aufirst%3DR.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin-receptor%2520Antagonists%2520Are%2520Pro-apoptotic%2520and%2520Anti-proliferative%2520in%2520Human%2520Colon%2520Cancer%2520Cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D88%26spage%3D788%26epage%3D795%26doi%3D10.1038%2Fsj.bjc.6600810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Peduto Eberl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egidy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Blockade Potentiates FasL-induced Apoptosis in Colon Carcinoma Cells via the Protein Kinase C-pathway</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">S354</span><span class="NLM_x">â</span> <span class="NLM_lpage">S356</span><span class="refDoi">Â DOI: 10.1097/00005344-200036001-00103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2F00005344-200036001-00103" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=S354-S356&author=L.+Peduto+Eberlauthor=G.+Egidyauthor=F.+Pinetauthor=L.+Juillerat-Jeanneret&title=Endothelin+Receptor+Blockade+Potentiates+FasL-induced+Apoptosis+in+Colon+Carcinoma+Cells+via+the+Protein+Kinase+C-pathway&doi=10.1097%2F00005344-200036001-00103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1097%2F00005344-200036001-00103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-200036001-00103%26sid%3Dliteratum%253Aachs%26aulast%3DPeduto%2BEberl%26aufirst%3DL.%26aulast%3DEgidy%26aufirst%3DG.%26aulast%3DPinet%26aufirst%3DF.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin%2520Receptor%2520Blockade%2520Potentiates%2520FasL-induced%2520Apoptosis%2520in%2520Colon%2520Carcinoma%2520Cells%2520via%2520the%2520Protein%2520Kinase%2520C-pathway%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2000%26volume%3D35%26spage%3DS354%26epage%3DS356%26doi%3D10.1097%2F00005344-200036001-00103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Said, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theodorescu, D.</span><span> </span><span class="NLM_article-title">Permissive Role of Endothelin Receptors in Tumor Metastasis</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">522</span><span class="NLM_x">â</span> <span class="NLM_lpage">527</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2012.03.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.lfs.2012.03.040" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=522-527&author=N.+Saidauthor=D.+Theodorescu&title=Permissive+Role+of+Endothelin+Receptors+in+Tumor+Metastasis&doi=10.1016%2Fj.lfs.2012.03.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.03.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.03.040%26sid%3Dliteratum%253Aachs%26aulast%3DSaid%26aufirst%3DN.%26aulast%3DTheodorescu%26aufirst%3DD.%26atitle%3DPermissive%2520Role%2520of%2520Endothelin%2520Receptors%2520in%2520Tumor%2520Metastasis%26jtitle%3DLife%2520Sci.%26date%3D2012%26volume%3D91%26spage%3D522%26epage%3D527%26doi%3D10.1016%2Fj.lfs.2012.03.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Irani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salajegheh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. K.</span><span> </span><span class="NLM_article-title">A Review of the Profile of Endothelin Axis in Cancer and Its Management</span> <span class="citation_source-journal">Crit. Review Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">â</span> <span class="NLM_lpage">321</span><span class="refDoi">Â DOI: 10.1016/j.critrevonc.2013.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.critrevonc.2013.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24035584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC3sbotVylsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2014&pages=314-321&author=S.+Iraniauthor=A.+Salajeghehauthor=R.+A.+Smithauthor=A.+K.+Lam&title=A+Review+of+the+Profile+of+Endothelin+Axis+in+Cancer+and+Its+Management&doi=10.1016%2Fj.critrevonc.2013.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the profile of endothelin axis in cancer and its management</span></div><div class="casAuthors">Irani Soussan; Salajegheh Ali; Smith Robert Anthony; Lam Alfred King-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">314-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The endothelins and their associated receptors are important controllers of vascular growth, inflammation and vascular tone.  In cancer, they have roles in the control of numerous factors in cancer development and progression, including angiogenesis, stromal reaction, epithelial mesenchymal transitions, apoptosis, invasion, metastases and drug resistance.  Also, we consider current information on the role of this signalling system in cancer and examine the state of the current cell, animal and clinical trials utilizing endothelin targeted drugs for cancer management.  Although targeting the endothelin axis in cell lines and xenografts show some promise in retarding cellular growth, results from limited clinical trials in prostatic cancer are less encouraging and did not offer significant survival benefit.  The ability to target both cancer cells and vasculature via endothelin is an important consideration that necessitates the further refining of therapeutic strategies as we continue to explore the possibilities of the endothelin axis in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTizkEGuZWmMcScOqQTSkOffW6udTcc2eYQ_gaqN4BDlLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbotVylsw%253D%253D&md5=5f198ffa631e4b313b3bbcc063ec434f</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2013.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2013.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DIrani%26aufirst%3DS.%26aulast%3DSalajegheh%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DLam%26aufirst%3DA.%2BK.%26atitle%3DA%2520Review%2520of%2520the%2520Profile%2520of%2520Endothelin%2520Axis%2520in%2520Cancer%2520and%2520Its%2520Management%26jtitle%3DCrit.%2520Review%2520Oncol.%2520Hematol.%26date%3D2014%26volume%3D89%26spage%3D314%26epage%3D321%26doi%3D10.1016%2Fj.critrevonc.2013.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Knowles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span> </span><span class="NLM_article-title">Endothelin-1 and Angiogenesis in Cancer</span> <span class="citation_source-journal">Curr. Vasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">â</span> <span class="NLM_lpage">314</span><span class="refDoi">Â DOI: 10.2174/157016105774329462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2174%2F157016105774329462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=16248773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVaht7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=309-314&author=J.+Knowlesauthor=M.+Loizidouauthor=I.+Taylor&title=Endothelin-1+and+Angiogenesis+in+Cancer&doi=10.2174%2F157016105774329462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1 and angiogenesis in cancer</span></div><div class="casAuthors">Knowles, Jonathan; Loizidou, Marilena; Taylor, Irving</div><div class="citationInfo"><span class="NLM_cas:title">Current Vascular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-314</span>CODEN:
                <span class="NLM_cas:coden">CVPUAY</span>;
        ISSN:<span class="NLM_cas:issn">1570-1611</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumors require oxygenation, nutrition and a route for dissemination.  This necessitates the development of new vessels or angiogenesis.  High levels of new vessel development are indicators of poor prognosis in cancer; they also provide new avenues of anti-tumor therapy.  Angiogenesis in cancer produces structurally different vessels from angiogenesis in wound healing and inflammation.  This article reviews the differences between vessels in tumor angiogenesis and 'normal angiogenesis.  The main focus of the article is the role of the vasoactive peptide endothelin-1 (ET-1) in tumor angiogenesis.  The role of ET-1 in tumor development is reviewed, before the direct and indirect effects of ET-1 in angiogenesis are examd.  ET-1 has a direct angiogenic effect on endothelial and peri-vascular cells.  It also has an indirect action through the increased release of the potent pro-angiogenic substance vascular endothelial growth factor (VEGF), via hypoxia inducible factor-1.  ET-1 also indirectly stimulates angiogenesis by stimulating fibroblasts and cancer cells to produce pro-angiogenic proteases.  ET-1 is a novel stimulator of tumor angiogenesis and warrants further examn. as an anti-angiogenic treatment target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqePqs90AAhebVg90H21EOLACvtfcHk0liC1DUDzrQTHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVaht7jP&md5=521d02e0d22fe7c9c22992b7d2898fe6</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.2174%2F157016105774329462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157016105774329462%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DJ.%26aulast%3DLoizidou%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DI.%26atitle%3DEndothelin-1%2520and%2520Angiogenesis%2520in%2520Cancer%26jtitle%3DCurr.%2520Vasc.%2520Pharmacol.%26date%3D2005%26volume%3D3%26spage%3D309%26epage%3D314%26doi%3D10.2174%2F157016105774329462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Knowles, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi-Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haque, S. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winslet, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span> </span><span class="NLM_article-title">Endothelin-1 Stimulates Colon Cancer Adjacent Fibroblasts</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">â</span> <span class="NLM_lpage">1272</span><span class="refDoi">Â DOI: 10.1002/ijc.26090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fijc.26090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21445967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVSjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2012&pages=1264-1272&author=J.+P.+Knowlesauthor=X.+Shi-Wenauthor=S.+U.+Haqueauthor=A.+Bhallaauthor=M.+R.+Dashwoodauthor=S.+Yangauthor=I.+Taylorauthor=M.+C.+Winsletauthor=D.+J.+Abrahamauthor=M.+Loizidou&title=Endothelin-1+Stimulates+Colon+Cancer+Adjacent+Fibroblasts&doi=10.1002%2Fijc.26090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1 stimulates colon cancer adjacent fibroblasts</span></div><div class="casAuthors">Knowles, Jonathan P.; Xu, Shi-Wen; Haque, Samer-ul; Bhalla, Ashish; Dashwood, Michael R.; Yang, Shiyu; Taylor, Irving; Winslet, Marc C.; Abraham, David J.; Loizidou, Marilena</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1264-1272</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Endothelin-1 (ET-1) is produced by and stimulates colorectal cancer cells.  Fibroblasts produce tumor stroma required for cancer development.  We investigated whether ET-1 stimulated processes involved in tumor stroma prodn. by colonic fibroblasts.  Primary human fibroblasts, isolated from normal tissues adjacent to colon cancers, were cultured with or without ET-1 and its antagonists.  Cellular proliferation, migration and contraction were measured.  Expression of enzymes involved in tumor stroma development and alterations in gene transcription were detd. by Western blotting and genome microarrays.  ET-1 stimulated proliferation, contraction and migration (p < 0.01 v control) and the expression of matrix degrading enzymes TIMP-1 and MMP-2, but not MMP-3.  ET-1 upregulated genes for profibrotic growth factors and receptors, signalling mols., actin modulators and extracellular matrix components.  ET-1 stimulated colonic fibroblast cellular processes in vitro that are involved in developing tumor stroma.  Upregulated genes were consistent with these processes.  By acting as a strong stimulus for tumor stroma creation, ET-1 is proposed as a target for adjuvant cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk2uwuS_fnnrVg90H21EOLACvtfcHk0liC1DUDzrQTHQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVSjsA%253D%253D&md5=f2970124a0c36abfbfd90058f52b4960</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1002%2Fijc.26090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.26090%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DJ.%2BP.%26aulast%3DShi-Wen%26aufirst%3DX.%26aulast%3DHaque%26aufirst%3DS.%2BU.%26aulast%3DBhalla%26aufirst%3DA.%26aulast%3DDashwood%26aufirst%3DM.%2BR.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DWinslet%26aufirst%3DM.%2BC.%26aulast%3DAbraham%26aufirst%3DD.%2BJ.%26aulast%3DLoizidou%26aufirst%3DM.%26atitle%3DEndothelin-1%2520Stimulates%2520Colon%2520Cancer%2520Adjacent%2520Fibroblasts%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D130%26spage%3D1264%26epage%3D1272%26doi%3D10.1002%2Fijc.26090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Nelson, J. B.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists</span> <span class="citation_source-journal">World J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">â</span> <span class="NLM_lpage">27</span><span class="refDoi">Â DOI: 10.1007/s00345-004-0478-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00345-004-0478-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15654644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Ols7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=19-27&author=J.+B.+Nelson&title=Endothelin+Receptor+Antagonists&doi=10.1007%2Fs00345-004-0478-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin receptor antagonists</span></div><div class="casAuthors">Nelson, Joel B.</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Urology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-27</span>CODEN:
                <span class="NLM_cas:coden">WJURDJ</span>;
        ISSN:<span class="NLM_cas:issn">0724-4983</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Hormone refractory prostate cancer remains true to its middle name: it is largely refractory to attempts to delay its progression.  New targets and new therapies are demanded.  Through a review of the available literature on endothelin and several preclin. observations, the endothelin axis has emerged as one such target.  In phase II and III clin. trials of atrasentan, a potent and selective endothelin receptor A subtype (ETA) antagonist, disease progression was delayed in some men.  This well tolerated, oral agent may help convert advanced prostate cancer to a more chronic disease.  This review will discuss the endothelin axis, preclin. rationale and some of the available clin. trial data on this promising new approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5DvdTmNzgc7Vg90H21EOLACvtfcHk0ligr6KLyYB1yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Ols7k%253D&md5=40aacd331807c5d4c02f85e5c95b84de</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1007%2Fs00345-004-0478-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00345-004-0478-9%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DJ.%2BB.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%26jtitle%3DWorld%2520J.%2520Urol.%26date%3D2005%26volume%3D23%26spage%3D19%26epage%3D27%26doi%3D10.1007%2Fs00345-004-0478-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">RosanÃ², L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Castro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicotra, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dedhar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Herreros, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span> </span><span class="NLM_article-title">Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">11649</span><span class="NLM_x">â</span> <span class="NLM_lpage">11657</span><span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-05-2123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F0008-5472.CAN-05-2123" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=11649-11657&author=L.+Rosan%C3%B2author=F.+Spinellaauthor=V.+Di+Castroauthor=M.+R.+Nicotraauthor=S.+Dedharauthor=A.+G.+de+Herrerosauthor=P.+G.+Nataliauthor=A.+Bagnato&title=Endothelin-1+Promotes+Epithelial-to-Mesenchymal+Transition+in+Human+Ovarian+Cancer+Cells&doi=10.1158%2F0008-5472.CAN-05-2123"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2123%26sid%3Dliteratum%253Aachs%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DNicotra%26aufirst%3DM.%2BR.%26aulast%3DDedhar%26aufirst%3DS.%26aulast%3Dde%2BHerreros%26aufirst%3DA.%2BG.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3DEndothelin-1%2520Promotes%2520Epithelial-to-Mesenchymal%2520Transition%2520in%2520Human%2520Ovarian%2520Cancer%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D11649%26epage%3D11657%26doi%3D10.1158%2F0008-5472.CAN-05-2123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">RosanÃ², L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianfrocca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Castro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicotra, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucidi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span> </span><span class="NLM_article-title">Acquisition of Chemoresistance and EMT Phenotype is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2350</span><span class="NLM_x">â</span> <span class="NLM_lpage">2360</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-10-2325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1078-0432.CCR-10-2325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21220476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2350-2360&author=L.+Rosan%C3%B2author=R.+Cianfroccaauthor=F.+Spinellaauthor=V.+Di+Castroauthor=M.+R.+Nicotraauthor=A.+Lucidiauthor=G.+Ferrandinaauthor=P.+G.+Nataliauthor=A.+Bagnato&title=Acquisition+of+Chemoresistance+and+EMT+Phenotype+is+Linked+with+Activation+of+the+Endothelin+A+Receptor+Pathway+in+Ovarian+Carcinoma+Cells&doi=10.1158%2F1078-0432.CCR-10-2325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells</span></div><div class="casAuthors">Rosano, Laura; Cianfrocca, Roberta; Spinella, Francesca; Di Castro, Valeriana; Nicotra, Maria Rita; Lucidi, Alessandro; Ferrandina, Gabriella; Natali, Pier Giorgio; Bagnato, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2350-2360</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Emerging evidence suggests mol. and phenotypic assocn. between chemoresistance and epithelial-mesenchymal transition (EMT) in cancer.  Endothelin-1 (ET-1)/endothelin A receptor (ETAR) axis is implicated in the pathobiol. of epithelial ovarian cancer (EOC) by driving tumor-promoting effects, including EMT.  Here, we analyzed how ETAR regulates chemoresistance and EMT in EOC.  Exptl. Design: The effects of ET-1 axis on cell proliferation, drug-induced apoptosis, invasiveness, and EMT were analyzed in cultured EOC cells sensitive and resistant to cisplatinum and taxol.  Tumor growth in response to ETAR antagonist was examd. in EOC xenografts.  ETAR expression was examd. in 60 human EOC tumors by immunohistochem. and correlated with chemoresistance and EMT.  RESULTS: In resistant EOC cells ET-1 and ETAR are upregulated, paralleled by enhanced mitogen activated protein kinase (MAPK) and Akt phosphorylation and cell proliferation.  Moreover, in these cells the expression of E-cadherin transcriptional repressors, including Snail, Slug, and Twist, as well as of mesenchymal markers, such as vimentin and N-cadherin, were upregulated and linked with enhanced invasive behavior.  Interestingly, ETAR blockade with zibotentan, a specific ETAR antagonist, or its silencing, downregulated Snail activity, restored drug sensitivity to cytotoxic-induced apoptosis, and inhibited the invasiveness of resistant cells.  In vivo, zibotentan inhibited tumor growth of sensitive and resistant EOC xenografts, and sensitized to chemotherapy.  Anal. of EOC human tissues revealed that ETAR is overexpressed in resistant tumors and is assocd. with EMT phenotype.  CONCLUSIONS: Our data provide the first evidence that blockade of ETAR-driven EMT can overcome chemoresistance and inhibit tumor progression, improving the outcome of EOC patients' treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9X_Qbp2vGw7Vg90H21EOLACvtfcHk0ligr6KLyYB1yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgtrw%253D&md5=293bd24befd83097b960bb87626f1c20</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2325%26sid%3Dliteratum%253Aachs%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DNicotra%26aufirst%3DM.%2BR.%26aulast%3DLucidi%26aufirst%3DA.%26aulast%3DFerrandina%26aufirst%3DG.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3DAcquisition%2520of%2520Chemoresistance%2520and%2520EMT%2520Phenotype%2520is%2520Linked%2520with%2520Activation%2520of%2520the%2520Endothelin%2520A%2520Receptor%2520Pathway%2520in%2520Ovarian%2520Carcinoma%2520Cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2350%26epage%3D2360%26doi%3D10.1158%2F1078-0432.CCR-10-2325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">RosanÃ², L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianfrocca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tocci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Castro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spadaro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biroccio, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span> </span><span class="NLM_article-title">Beta-arrestin-1 is a Nuclear Transcriptional Regulator of Endothelin-1-induced Beta-catenin Signaling</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">5066</span><span class="NLM_x">â</span> <span class="NLM_lpage">5077</span><span class="refDoi">Â DOI: 10.1038/onc.2012.527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fonc.2012.527" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=5066-5077&author=L.+Rosan%C3%B2author=R.+Cianfroccaauthor=P.+Tocciauthor=F.+Spinellaauthor=V.+Di+Castroauthor=F.+Spadaroauthor=E.+Salvatiauthor=A.+M.+Biroccioauthor=P.+G.+Nataliauthor=A.+Bagnato&title=Beta-arrestin-1+is+a+Nuclear+Transcriptional+Regulator+of+Endothelin-1-induced+Beta-catenin+Signaling&doi=10.1038%2Fonc.2012.527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.527%26sid%3Dliteratum%253Aachs%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DTocci%26aufirst%3DP.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DSpadaro%26aufirst%3DF.%26aulast%3DSalvati%26aufirst%3DE.%26aulast%3DBiroccio%26aufirst%3DA.%2BM.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3DBeta-arrestin-1%2520is%2520a%2520Nuclear%2520Transcriptional%2520Regulator%2520of%2520Endothelin-1-induced%2520Beta-catenin%2520Signaling%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D5066%26epage%3D5077%26doi%3D10.1038%2Fonc.2012.527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Cianfrocca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tocci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Castro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">RosanÃ², L.</span><span> </span><span class="NLM_article-title">The Endothelin A Receptor and Epidermal Growth Factor Receptor Signaling Converge on Beta-catenin to Promote Ovarian Cancer Metastasis</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">â</span> <span class="NLM_lpage">556</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2012.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.lfs.2012.03.023" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=550-556&author=R.+Cianfroccaauthor=P.+Tocciauthor=F.+Spinellaauthor=V.+Di+Castroauthor=A.+Bagnatoauthor=L.+Rosan%C3%B2&title=The+Endothelin+A+Receptor+and+Epidermal+Growth+Factor+Receptor+Signaling+Converge+on+Beta-catenin+to+Promote+Ovarian+Cancer+Metastasis&doi=10.1016%2Fj.lfs.2012.03.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DTocci%26aufirst%3DP.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26atitle%3DThe%2520Endothelin%2520A%2520Receptor%2520and%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Signaling%2520Converge%2520on%2520Beta-catenin%2520to%2520Promote%2520Ovarian%2520Cancer%2520Metastasis%26jtitle%3DLife%2520Sci.%26date%3D2012%26volume%3D91%26spage%3D550%26epage%3D556%26doi%3D10.1016%2Fj.lfs.2012.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Coffman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckanovich, R. J.</span><span> </span><span class="NLM_article-title">Endothelin Receptor-A is Required for the Recruitment of Antitumor T Cells and Modulates Chemotherapy Induction of Cancer Stem Cells</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">â</span> <span class="NLM_lpage">192</span><span class="refDoi">Â DOI: 10.4161/cbt.22959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.4161%2Fcbt.22959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23192269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFOmurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=184-192&author=L.+Coffmanauthor=C.+Mooneyauthor=J.+Limauthor=S.+Baiauthor=I.+Silvaauthor=Y.+Gongauthor=K.+Yangauthor=R.+J.+Buckanovich&title=Endothelin+Receptor-A+is+Required+for+the+Recruitment+of+Antitumor+T+Cells+and+Modulates+Chemotherapy+Induction+of+Cancer+Stem+Cells&doi=10.4161%2Fcbt.22959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells</span></div><div class="casAuthors">Coffman, Lan; Mooney, Collin; Lim, Jaeyoung; Bai, Shoumei; Silva, Ines; Gong, Yusong; Yang, Kun; Buckanovich, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-192</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Background: The endothelin receptor-A (ETRA) plays an important role in tumor cell migration, metastasis, and proliferation.  The endothelin receptor B (ETRB) plays a crit. role in angiogenesis and the inhibition of antitumor immune cell recruitment.  Thus dual blockade of ETRA and ETRB could have significant antitumor effects.  Results: Dual ETRA/ETRB blockade with macitentan (or the combination of the ETRA and ETRB antagonists BQ123 and BQ788) did not enhance antitumor immune cell recruitment.  In vitro studies demonstrate that ETRA inhibition prevents the induction of ICAM1 necessary for immune cell recruitment.  When used as a single agent against human tumor xenografts, macitentan demonstrated non-significant antitumor activity.  However, when used in combination with chemotherapy, macitentan specifically reduced tumor growth in cell lines with CD133+ cancer stem cells.  We found that ETRA is primarily expressed on CD133+ CSC in both cell lines and primary human tumor cells.  ETRA inhibition of CSC prevented chemotherapy induced increases in tumor stem cells.  Furthermore, ETRA inhibition in combination with chemotherapy reduced the formation of tumor spheres.  Methods: We tested the dual ETRA/ETRB antagonist macitentan in conjunction with (1) an antitumor vaccine and (2) chemotherapy, in order to assess the impact of dual ETRA/ETRB blockade on antitumor immune cell infiltration and ovarian tumor growth.  In vitro murine and human cell line, tumor sphere assays and tumor xenograft models were utilized to evaluate the effect of ETRA/ETRB blockade on cell proliferation, immune cell infiltration and cancer stem cell populations.  Conclusions: These studies indicate a crit. role for ETRA in the regulation of immune cell recruitment and in the CSC resistance to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg_ZsXglJa8bVg90H21EOLACvtfcHk0lh-B8vi3oDing"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFOmurw%253D&md5=faa3e849b7607a8c6316f615c4dd5089</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.4161%2Fcbt.22959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.22959%26sid%3Dliteratum%253Aachs%26aulast%3DCoffman%26aufirst%3DL.%26aulast%3DMooney%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DS.%26aulast%3DSilva%26aufirst%3DI.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DBuckanovich%26aufirst%3DR.%2BJ.%26atitle%3DEndothelin%2520Receptor-A%2520is%2520Required%2520for%2520the%2520Recruitment%2520of%2520Antitumor%2520T%2520Cells%2520and%2520Modulates%2520Chemotherapy%2520Induction%2520of%2520Cancer%2520Stem%2520Cells%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2013%26volume%3D14%26spage%3D184%26epage%3D192%26doi%3D10.4161%2Fcbt.22959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Lahav, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffner, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, P. H.</span><span> </span><span class="NLM_article-title">An Endothelin Receptor B Antagonist Inhibits Growth and Induces Cell Death in Human Melanoma Cells In Vitro and In Vivo</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">11496</span><span class="NLM_x">â</span> <span class="NLM_lpage">11500</span><span class="refDoi">Â DOI: 10.1073/pnas.96.20.11496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1073%2Fpnas.96.20.11496" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=11496-11500&author=R.+Lahavauthor=G.+Heffnerauthor=P.+H.+Patterson&title=An+Endothelin+Receptor+B+Antagonist+Inhibits+Growth+and+Induces+Cell+Death+in+Human+Melanoma+Cells+In+Vitro+and+In+Vivo&doi=10.1073%2Fpnas.96.20.11496"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.20.11496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.20.11496%26sid%3Dliteratum%253Aachs%26aulast%3DLahav%26aufirst%3DR.%26aulast%3DHeffner%26aufirst%3DG.%26aulast%3DPatterson%26aufirst%3DP.%2BH.%26atitle%3DAn%2520Endothelin%2520Receptor%2520B%2520Antagonist%2520Inhibits%2520Growth%2520and%2520Induces%2520Cell%2520Death%2520in%2520Human%2520Melanoma%2520Cells%2520In%2520Vitro%2520and%2520In%2520Vivo%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D11496%26epage%3D11500%26doi%3D10.1073%2Fpnas.96.20.11496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Hsieh, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D. Y.</span><span> </span><span class="NLM_article-title">Exogenous Endothelin-1 Induces Cell Migration and Matrix Metalloproteinase Expression in U251 Human Glioblastoma Multiforme</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">â</span> <span class="NLM_lpage">269</span><span class="refDoi">Â DOI: 10.1007/s11060-014-1442-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs11060-014-1442-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24756349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFOltLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=257-269&author=W.+T.+Hsiehauthor=W.+L.+Yehauthor=R.+Y.+Chengauthor=C.+Linauthor=C.+F.+Tsaiauthor=B.+R.+Huangauthor=C.+Y.+Wuauthor=H.+Y.+Linauthor=S.+S.+Huangauthor=D.+Y.+Lu&title=Exogenous+Endothelin-1+Induces+Cell+Migration+and+Matrix+Metalloproteinase+Expression+in+U251+Human+Glioblastoma+Multiforme&doi=10.1007%2Fs11060-014-1442-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Exogenous endothelin-1 induces cell migration and matrix metalloproteinase expression in U251 human glioblastoma multiforme</span></div><div class="casAuthors">Hsieh, Wen-Tsong; Yeh, Wei-Lan; Cheng, Ruo-Yuo; Lin, Chingju; Tsai, Cheng-Fang; Huang, Bor-Ren; Wu, Caren Yu-Ju; Lin, Hsiao-Yun; Huang, Shiang-Suo; Lu, Dah-Yuu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-269</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common and lethal type of primary brain tumor characterized by its rapid infiltration to surrounding tissues during the early stages.  The fast spreading of GBM obscures the initiation of the tumor mass making the treatment outcome undesirable.  Endothelin-1 is known as a secretory protein presented in various types of brain cells, which has been indicated as a factor for cancer pathol.  The aim of the present study was to investigate the mol. mechanism of cell migration in GBM.  We found that various malignant glioma cells expressed higher amts. of endothelin-1, ETA, and ETB receptors than nonmalignant human astrocytes.  The application of endothelin-1 enhanced the migratory activity in human U251 glioma cells corresponding to increased expression of matrix metalloproteinase (MMP)-9 and MMP-13.  The endothelin-1-induced cell migration was attenuated by MMP-9 and MMP-13 inhibitors and inhibitors of mitogen-activated protein (MAP) kinase and PI3 kinase/Akt.  Furthermore, the elevated levels of phosphate c-Jun accumulation in the nucleus and activator protein-1 (AP-1)-DNA binding activity were also found in endothelin-1 treated glioma cells.  In migration-prone sublines, cells with greater migration ability showed higher endothelin-1, ETB receptor, and MMP expressions.  These results indicate that endothelin-1 activates MAP kinase and AP-1 signaling, resulting in enhanced MMP-9 and MMP-13 expressions and cell migration in GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq93zpEIigF1bVg90H21EOLACvtfcHk0lg2GCTGcqOsnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFOltLw%253D&md5=4fb0854d27a7a5dd029a0f2b703b3f3c</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1007%2Fs11060-014-1442-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-014-1442-1%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DW.%2BT.%26aulast%3DYeh%26aufirst%3DW.%2BL.%26aulast%3DCheng%26aufirst%3DR.%2BY.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DTsai%26aufirst%3DC.%2BF.%26aulast%3DHuang%26aufirst%3DB.%2BR.%26aulast%3DWu%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DHuang%26aufirst%3DS.%2BS.%26aulast%3DLu%26aufirst%3DD.%2BY.%26atitle%3DExogenous%2520Endothelin-1%2520Induces%2520Cell%2520Migration%2520and%2520Matrix%2520Metalloproteinase%2520Expression%2520in%2520U251%2520Human%2520Glioblastoma%2520Multiforme%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2014%26volume%3D118%26spage%3D257%26epage%3D269%26doi%3D10.1007%2Fs11060-014-1442-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tso, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dembo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eskin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischel, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornblum, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tso, C. L.</span><span> </span><span class="NLM_article-title">Autocrine endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1668</span><span class="NLM_x">â</span> <span class="NLM_lpage">1685</span><span class="refDoi">Â DOI: 10.1158/1541-7786.MCR-10-0563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1541-7786.MCR-10-0563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22013079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1elt7bP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=1668-1685&author=Y.+Liuauthor=F.+Yeauthor=K.+Yamadaauthor=J.+L.+Tsoauthor=Y.+Zhangauthor=D.+H.+Nguyenauthor=Q.+Dongauthor=H.+Sotoauthor=J.+Choeauthor=A.+Demboauthor=H.+Wheelerauthor=A.+Eskinauthor=I.+Schmidauthor=W.+H.+Yongauthor=P.+S.+Mischelauthor=T.+F.+Cloughesyauthor=H.+I.+Kornblumauthor=S.+F.+Nelsonauthor=L.+M.+Liauauthor=C.+L.+Tso&title=Autocrine+endothelin-3%2FEndothelin+Receptor+B+Signaling+Maintains+Cellular+and+Molecular+Properties+of+Glioblastoma+Stem+Cells&doi=10.1158%2F1541-7786.MCR-10-0563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine Endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells</span></div><div class="casAuthors">Liu, Yue; Ye, Fei; Yamada, Kazunari; Tso, Jonathan L.; Zhang, Yibei; Nguyen, David H.; Dong, Qinghua; Soto, Horacio; Choe, Jinny; Dembo, Anna; Wheeler, Hayley; Eskin, Ascia; Schmid, Ingrid; Yong, William H.; Mischel, Paul S.; Cloughesy, Timothy F.; Kornblum, Harley I.; Nelson, Stanley F.; Liau, Linda M.; Tso, Cho-Lea</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1668-1685</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Glioblastoma stem cells (GSC) express both radial glial cell and neural crest cell (NCC)-assocd. genes.  We report that endothelin 3 (EDN3), an essential mitogen for NCC development and migration, is highly produced by GSCs.  Serum-induced proliferative differentiation rapidly decreased EDN3 prodn. and downregulated the expression of stemness-assocd. genes, and reciprocally, two glioblastoma markers, EDN1 and YKL-40 transcripts, were induced.  Correspondingly, patient glioblastoma tissues express low levels of EDN3 mRNA and high levels of EDN1 and YKL-40 mRNA.  Blocking EDN3/EDN receptor B (EDNRB) signaling by an EDNRB antagonist (BQ788), or EDN3 RNA interference (siRNA), leads to cell apoptosis and functional impairment of tumor sphere formation and cell spreading/migration in culture and loss of tumorigenic capacity in animals.  Using exogenous EDN3 as the sole mitogen in culture does not support GSC propagation, but it can rescue GSCs from undergoing cell apoptosis.  Mol. anal. by gene expression profiling revealed that most genes downregulated by EDN3/EDNRB blockade were those involved in cytoskeleton organization, pause of growth and differentiation, and DNA damage response, implicating the involvement of EDN3/EDNRB signaling in maintaining GSC migration, undifferentiation, and survival.  These data suggest that autocrine EDN3/EDNRB signaling is essential for maintaining GSCs.  Incorporating END3/EDNRB-targeted therapies into conventional cancer treatments may have clin. implication for the prevention of tumor recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3alOjINGaqbVg90H21EOLACvtfcHk0lg2GCTGcqOsnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1elt7bP&md5=46cf7164714e61c7d872319e40b20d69</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-10-0563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-10-0563%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DTso%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DNguyen%26aufirst%3DD.%2BH.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DSoto%26aufirst%3DH.%26aulast%3DChoe%26aufirst%3DJ.%26aulast%3DDembo%26aufirst%3DA.%26aulast%3DWheeler%26aufirst%3DH.%26aulast%3DEskin%26aufirst%3DA.%26aulast%3DSchmid%26aufirst%3DI.%26aulast%3DYong%26aufirst%3DW.%2BH.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DKornblum%26aufirst%3DH.%2BI.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DLiau%26aufirst%3DL.%2BM.%26aulast%3DTso%26aufirst%3DC.%2BL.%26atitle%3DAutocrine%2520endothelin-3%252FEndothelin%2520Receptor%2520B%2520Signaling%2520Maintains%2520Cellular%2520and%2520Molecular%2520Properties%2520of%2520Glioblastoma%2520Stem%2520Cells%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2011%26volume%3D9%26spage%3D1668%26epage%3D1685%26doi%3D10.1158%2F1541-7786.MCR-10-0563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Paolillo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinelli, S.</span><span> </span><span class="NLM_article-title">Endothelin B Receptor Antagonists Block Proliferation and Induce Apoptosis in Glioma Cells</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">306</span><span class="NLM_x">â</span> <span class="NLM_lpage">315</span><span class="refDoi">Â DOI: 10.1016/j.phrs.2009.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.phrs.2009.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=19931393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1WjtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2010&pages=306-315&author=M.+Paolilloauthor=M.+A.+Russoauthor=D.+Curtiauthor=C.+Lanniauthor=S.+Schinelli&title=Endothelin+B+Receptor+Antagonists+Block+Proliferation+and+Induce+Apoptosis+in+Glioma+Cells&doi=10.1016%2Fj.phrs.2009.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin B receptor antagonists block proliferation and induce apoptosis in glioma cells</span></div><div class="casAuthors">Paolillo, Mayra; Russo, Marika A.; Curti, Daniela; Lanni, Cristina; Schinelli, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">306-315</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The proliferative and antiapoptotic actions of endothelin (ET)-1 in cancer cells have been documented and ET receptor antagonists have been exploited as potential anticancer drugs.  Glioblastoma cell lines express both ETA and ETB receptors and previous works have shown that ETB receptors are involved in the proliferation of different cancer cell types.  In this study we have investigated the effects of two structurally unrelated ETB receptor antagonists, BQ788 and A192621, on cell survival, proliferation and apoptosis in 1321-N1, U87 and IPDDCA2 glioma cell lines.  BQ788 and A192621 reduced glioma cells viability and proliferation assessed by BrdU incorporation and cell cycle anal. by flow cytometry, while in contrast the ETA receptor antagonist BQ123 had no effect on cell survival.  TUNEL assay and immunocytochem. expts. showed that BQ788 and A192621 trigger apoptotic processes mainly via activation of the intrinsic mitochondrial pathway involving caspase-9 activation, AIF release and cytochrome c translocation.  Furthermore, treatment with ETB antagonists downregulates ERK- and p38MAPK-dependent pathways but does not affect VEGF mRNA levels.  Our findings support the hypothesis that ETB antagonists represent a new promising therapeutic strategy for the treatment of high grade gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYIfmnQIogP7Vg90H21EOLACvtfcHk0lg2GCTGcqOsnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1WjtL8%253D&md5=52116b8f4e6f2e4a08ac77123cad0ebf</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2009.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2009.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DPaolillo%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DM.%2BA.%26aulast%3DCurti%26aufirst%3DD.%26aulast%3DLanni%26aufirst%3DC.%26aulast%3DSchinelli%26aufirst%3DS.%26atitle%3DEndothelin%2520B%2520Receptor%2520Antagonists%2520Block%2520Proliferation%2520and%2520Induce%2520Apoptosis%2520in%2520Glioma%2520Cells%26jtitle%3DPharmacol.%2520Res.%26date%3D2010%26volume%3D61%26spage%3D306%26epage%3D315%26doi%3D10.1016%2Fj.phrs.2009.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Anguelova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuvon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaverot, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varlet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couraud, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daumas-Duport, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cazaubon, S.</span><span> </span><span class="NLM_article-title">Functional Endothelin ET B Receptors Are Selectively Expressed in Human Oligodendrogliomas</span> <span class="citation_source-journal">Mol. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">88</span><span class="refDoi">Â DOI: 10.1016/j.molbrainres.2005.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.molbrainres.2005.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15950764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFarsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2005&pages=77-88&author=E.+Anguelovaauthor=F.+Beuvonauthor=N.+Leonardauthor=N.+Chaverotauthor=P.+Varletauthor=P.+O.+Couraudauthor=C.+Daumas-Duportauthor=S.+Cazaubon&title=Functional+Endothelin+ET+B+Receptors+Are+Selectively+Expressed+in+Human+Oligodendrogliomas&doi=10.1016%2Fj.molbrainres.2005.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Functional endothelin ETB receptors are selectively expressed in human oligodendrogliomas</span></div><div class="casAuthors">Anguelova, E.; Beuvon, F.; Leonard, N.; Chaverot, N.; Varlet, P.; Couraud, P.-O.; Daumas-Duport, C.; Cazaubon, S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">77-88</span>CODEN:
                <span class="NLM_cas:coden">MBREE4</span>;
        ISSN:<span class="NLM_cas:issn">0169-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Endothelin-1 (ET-1), a vasoactive and mitogenic peptide mainly produced by vascular endothelial cells, may be involved in the progression of several human tumors.  Here, the authors present an immunohistochem. anal. of the expression pattern of ET-1 receptor subtypes (ETA-R and ETB-R) and a functional study of their potential role in human oligodendrogliomas and oligoastrocytomas.  By comparison, the authors assessed the corresponding expression patterns of glioblastomas.  Interestingly, a nuclear localization of ET-1 receptor subtypes (assocd. or not with a cytoplasmic labeling) was constantly obsd. in tumor cells from all 3 glioma types.  Moreover, the authors noted a distinct receptor distribution in the different gliomas: a nuclear expression of ETB-R by tumor cells was found to be restricted to oligodendrogliomas and oligoastrocytomas, while a nuclear expression of ETA-R was only detected in tumor cells from some glioblastomas.  Using primary cultures of oligodendroglial tumor cells, the authors confirmed the selective expression of nuclear ETB-R, together with a plasma membrane expression, and further demonstrated that this receptor was functionally coupled to intracellular signaling pathways known to be involved in cell survival and/or proliferation: extracellular signal-regulated kinase and focal adhesion kinase activation, actin cytoskeleton reorganization.  In addn., impairment of ETB-R activation in these cells by in vitro treatment with an ETB-R-specific antagonist induced cell death.  These data point to ET-1 as a possible survival factor for oligodendrogliomas via ETB-R activation and suggest that ETB-R-specific antagonists might constitute a potential therapeutic alternative for oligodendrogliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreg8FMxCm2ubVg90H21EOLACvtfcHk0lhOqU8ctm-qPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFarsb0%253D&md5=e0556c4c0c6fa92488465cadc6fcad95</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.molbrainres.2005.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molbrainres.2005.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DAnguelova%26aufirst%3DE.%26aulast%3DBeuvon%26aufirst%3DF.%26aulast%3DLeonard%26aufirst%3DN.%26aulast%3DChaverot%26aufirst%3DN.%26aulast%3DVarlet%26aufirst%3DP.%26aulast%3DCouraud%26aufirst%3DP.%2BO.%26aulast%3DDaumas-Duport%26aufirst%3DC.%26aulast%3DCazaubon%26aufirst%3DS.%26atitle%3DFunctional%2520Endothelin%2520ET%2520B%2520Receptors%2520Are%2520Selectively%2520Expressed%2520in%2520Human%2520Oligodendrogliomas%26jtitle%3DMol.%2520Brain%2520Res.%26date%3D2005%26volume%3D137%26spage%3D77%26epage%3D88%26doi%3D10.1016%2Fj.molbrainres.2005.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Chen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T. S.</span><span> </span><span class="NLM_article-title">The Endothelin-integrin Axis is Involved in Macrophage-induced Breast Cancer Cell Chemotactic Interactions with Endothelial Cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">10029</span><span class="NLM_x">â</span> <span class="NLM_lpage">10044</span><span class="refDoi">Â DOI: 10.1074/jbc.M113.528406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1074%2Fjbc.M113.528406" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=10029-10044&author=C.+C.+Chenauthor=L.+L.+Chenauthor=Y.+T.+Hsuauthor=K.+J.+Liuauthor=C.+S.+Fanauthor=T.+S.+Huang&title=The+Endothelin-integrin+Axis+is+Involved+in+Macrophage-induced+Breast+Cancer+Cell+Chemotactic+Interactions+with+Endothelial+Cells&doi=10.1074%2Fjbc.M113.528406"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.528406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.528406%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BC.%26aulast%3DChen%26aufirst%3DL.%2BL.%26aulast%3DHsu%26aufirst%3DY.%2BT.%26aulast%3DLiu%26aufirst%3DK.%2BJ.%26aulast%3DFan%26aufirst%3DC.%2BS.%26aulast%3DHuang%26aufirst%3DT.%2BS.%26atitle%3DThe%2520Endothelin-integrin%2520Axis%2520is%2520Involved%2520in%2520Macrophage-induced%2520Breast%2520Cancer%2520Cell%2520Chemotactic%2520Interactions%2520with%2520Endothelial%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D10029%26epage%3D10044%26doi%3D10.1074%2Fjbc.M113.528406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Moraitis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langdon, S. P.</span><span> </span><span class="NLM_article-title">Paracrine Regulation of Ovarian Cancer by Endothelin</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1381</span><span class="NLM_x">â</span> <span class="NLM_lpage">1387</span><span class="refDoi">Â DOI: 10.1016/S0959-8049(99)00131-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0959-8049%2899%2900131-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1999&pages=1381-1387&author=S.+Moraitisauthor=W.+R.+Millerauthor=J.+F.+Smythauthor=S.+P.+Langdon&title=Paracrine+Regulation+of+Ovarian+Cancer+by+Endothelin&doi=10.1016%2FS0959-8049%2899%2900131-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2899%2900131-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252899%252900131-8%26sid%3Dliteratum%253Aachs%26aulast%3DMoraitis%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DW.%2BR.%26aulast%3DSmyth%26aufirst%3DJ.%2BF.%26aulast%3DLangdon%26aufirst%3DS.%2BP.%26atitle%3DParacrine%2520Regulation%2520of%2520Ovarian%2520Cancer%2520by%2520Endothelin%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1999%26volume%3D35%26spage%3D1381%26epage%3D1387%26doi%3D10.1016%2FS0959-8049%2899%2900131-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Haque, S. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heetun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiwen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farooqui, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramesh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogunbiyi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span> </span><span class="NLM_article-title">Efficacy of the Specific Endothelin A Receptor Antagonist Zibotentan (ZD4054) in Colorectal Cancer: A Preclinical Study</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1556</span><span class="NLM_x">â</span> <span class="NLM_lpage">1567</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-12-0975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1535-7163.MCT-12-0975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23723122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ChurjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1556-1567&author=S.+U.+Haqueauthor=M.+R.+Dashwoodauthor=M.+Heetunauthor=X.+Shiwenauthor=N.+Farooquiauthor=B.+Rameshauthor=H.+Welchauthor=F.+J.+Savageauthor=O.+Ogunbiyiauthor=D.+J.+Abrahamauthor=M.+Loizidou&title=Efficacy+of+the+Specific+Endothelin+A+Receptor+Antagonist+Zibotentan+%28ZD4054%29+in+Colorectal+Cancer%3A+A+Preclinical+Study&doi=10.1158%2F1535-7163.MCT-12-0975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of the Specific Endothelin A Receptor Antagonist Zibotentan (ZD4054) in Colorectal Cancer: A Preclinical Study</span></div><div class="casAuthors">Haque, Samer-ul; Dashwood, Michael R.; Heetun, Mohammed; Shiwen, Xu; Farooqui, Noreen; Ramesh, Bala; Welch, Hazel; Savage, Felicity J.; Ogunbiyi, Olagunju; Abraham, David J.; Loizidou, Marilena</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1556-1567</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Endothelin 1 (ET-1) is overexpressed in cancer, contributing to disease progression.  We previously showed that ET-1 stimulated proliferative, migratory, and contractile tumorigenic effects via the ETA receptor.  Here, for the first time, we evaluate zibotentan, a specific ETA receptor antagonist, in the setting of colorectal cancer, in cellular models.  Pharmacol. characteristics were further detd. in patient tissues.  Colorectal cancer lines (n = 4) and fibroblast strains (n = 6), isolated from uninvolved areas of colorectal cancer specimens, were exposed to ET-1 and/or ETA/B receptor antagonists.  Proliferation (methylene blue), migration (scratch wounds), and contraction (gel lattices) were assessed.  Receptor distribution and binding characteristics (Kd, Bmax) were detd. using autoradiog. on tissue sections and homogenates and cytospun cells, supported by immunohistochem.  Proliferation was inhibited by ETA (zibotentan > BQ123; P < 0.05), migration by ETB > ETA, and contraction by combined ETA and ETB antagonism.  Intense ET-1 stromal binding correlated with fibroblasts and endothelial cells.  Colorectal cancer lines and fibroblasts revealed high d. and affinity ET-1 binding (Bmax = 2.435 fmol/1 Ã 106 cells, Kd = 367.7 pmol/L; Bmax = 3.03 fmol/1 Ã 106 cells, Kd = 213.6 pmol/L).  In cancer tissues, ETA receptor antagonists (zibotentan; BQ123) reduced ET-1 binding more effectively (IC50: 0.1-10 Î¼mol/L) than ETB receptor antagonist BQ788 (â¼IC50, 1 mmol/L).  ET-1 stimulated cancer-contributory processes.  Its localization to tumor stroma, with greatest binding/affinity to fibroblasts, implicates these cells in tumor progression.  ETA receptor upregulation in cancer tissues and its role in tumorigenic processes show the receptor's importance in therapeutic targeting.  Zibotentan, the most specific ETA receptor antagonist available, showed the greatest inhibition of ET-1 binding.  With its known safety profile, we provide evidence for zibotentan's potential role as adjuvant therapy in colorectal cancer.  Mol Cancer Ther; 12(8); 1556-67. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfY8AQYsQIWLVg90H21EOLACvtfcHk0lhOqU8ctm-qPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ChurjO&md5=ffa3075c122338c86fd1c93214cba9aa</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0975%26sid%3Dliteratum%253Aachs%26aulast%3DHaque%26aufirst%3DS.%2BU.%26aulast%3DDashwood%26aufirst%3DM.%2BR.%26aulast%3DHeetun%26aufirst%3DM.%26aulast%3DShiwen%26aufirst%3DX.%26aulast%3DFarooqui%26aufirst%3DN.%26aulast%3DRamesh%26aufirst%3DB.%26aulast%3DWelch%26aufirst%3DH.%26aulast%3DSavage%26aufirst%3DF.%2BJ.%26aulast%3DOgunbiyi%26aufirst%3DO.%26aulast%3DAbraham%26aufirst%3DD.%2BJ.%26aulast%3DLoizidou%26aufirst%3DM.%26atitle%3DEfficacy%2520of%2520the%2520Specific%2520Endothelin%2520A%2520Receptor%2520Antagonist%2520Zibotentan%2520%2528ZD4054%2529%2520in%2520Colorectal%2520Cancer%253A%2520A%2520Preclinical%2520Study%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1556%26epage%3D1567%26doi%3D10.1158%2F1535-7163.MCT-12-0975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Hoosein, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span> </span><span class="NLM_article-title">Altered Endothelin Receptor Subtypes in Colorectal Cancer</span> <span class="citation_source-journal">Eur. J. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">â</span> <span class="NLM_lpage">782</span><span class="refDoi">Â DOI: 10.1097/MEG.0b013e3282c563de</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2FMEG.0b013e3282c563de" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=17700263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGmu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=775-782&author=M.+M.+Hooseinauthor=M.+R.+Dashwoodauthor=K.+Dawasauthor=H.+M.+Aliauthor=K.+Grantauthor=F.+Savageauthor=I.+Taylorauthor=M.+Loizidou&title=Altered+Endothelin+Receptor+Subtypes+in+Colorectal+Cancer&doi=10.1097%2FMEG.0b013e3282c563de"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Altered endothelin receptor subtypes in colorectal cancer</span></div><div class="casAuthors">Hoosein, Moinuddin M.; Dashwood, Michael R.; Dawas, Khaled; Ali, Haythem; Grant, Katherine; Savage, Felicity; Taylor, Irving; Loizidou, Marilena</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">775-782</span>CODEN:
                <span class="NLM_cas:coden">EJGHES</span>;
        ISSN:<span class="NLM_cas:issn">0954-691X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: The vasoactive peptide endothelin-1 (ET-1) acts via two endothelin receptor subtypes, ETA (ETAR) and ETB (ETBR).  ET-1 and ETAR are overexpressed in colorectal cancer tissues.  In vitro, ET-1 acting via ETAR, is a mitogen for colorectal cancer cells.  To identify other potential stimulatory loops, we investigated the distribution and cell-specific localization of both ETAR and ETBR in tissue sections from patients with colorectal cancer.  Methods: Frozen sections from specimens of colorectal cancer (n = 9) and normal colon (n = 9) were cut and subjected to either (i) autoradiog. or (ii) a combination of cell type-specific immunohistochem., using antibodies against fibroblasts (AS02), endothelial cells (CD31) or nerve fibers (NF200) and in-vitro receptor microautoradiog., using ETAR-specific and ETBR-specific radioligands.  Results: ETARs were upregulated in all cell types, apart from nerve, in cancer compared with normal colon (1 : 1.59 normal to cancer).  Specifically, ETAR binding was highest in cancer-assocd. blood vessels and fibroblasts and to a lesser extent in epithelial cancer cells.  In contrast, ETBRs were the predominant receptors in normal colon (1 : 0.59 normal to cancer) and were markedly down-regulated in cancer-assocd. blood vessels, fibroblasts and to a lesser extent in epithelial cells.  Nerve colocalization was demonstrated, but remained unchanged for all tissues.  Conclusion: The shift in ET receptor binding obsd. in epithelial cancer cells and cancer-assocd. fibroblasts and endothelial cells may favor ET-1 signals contributing to colorectal cancer growth and neovascularization via ETAR.  This may provide the basis for therapeutic use of specific ETAR antagonists as adjuvant treatment of colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1mTMXFLBxK7Vg90H21EOLACvtfcHk0ljXcKwgsKP8Lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGmu78%253D&md5=24d35f467c529eb52720a3e577f5e2ca</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1097%2FMEG.0b013e3282c563de&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMEG.0b013e3282c563de%26sid%3Dliteratum%253Aachs%26aulast%3DHoosein%26aufirst%3DM.%2BM.%26aulast%3DDashwood%26aufirst%3DM.%2BR.%26aulast%3DDawas%26aufirst%3DK.%26aulast%3DAli%26aufirst%3DH.%2BM.%26aulast%3DGrant%26aufirst%3DK.%26aulast%3DSavage%26aufirst%3DF.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLoizidou%26aufirst%3DM.%26atitle%3DAltered%2520Endothelin%2520Receptor%2520Subtypes%2520in%2520Colorectal%2520Cancer%26jtitle%3DEur.%2520J.%2520Gastroenterol.%2520Hepatol.%26date%3D2007%26volume%3D19%26spage%3D775%26epage%3D782%26doi%3D10.1097%2FMEG.0b013e3282c563de" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Harland, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuc, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickard, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title">Expression of Endothelin A Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707</span> <span class="citation_source-journal">Neurosurgery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">890</span><span class="NLM_x">â</span> <span class="NLM_lpage">898</span><span class="refDoi">Â DOI: 10.1097/00006123-199810000-00097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2F00006123-199810000-00097" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1998&pages=890-898&author=S.+P.+Harlandauthor=R.+E.+Kucauthor=J.+D.+Pickardauthor=A.+P.+Davenport&title=Expression+of+Endothelin+A+Receptors+in+Human+Gliomas+and+Meningiomas%2C+with+High+Affinity+for+the+Selective+Antagonist+PD156707&doi=10.1097%2F00006123-199810000-00097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1097%2F00006123-199810000-00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00006123-199810000-00097%26sid%3Dliteratum%253Aachs%26aulast%3DHarland%26aufirst%3DS.%2BP.%26aulast%3DKuc%26aufirst%3DR.%2BE.%26aulast%3DPickard%26aufirst%3DJ.%2BD.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DExpression%2520of%2520Endothelin%2520A%2520Receptors%2520in%2520Human%2520Gliomas%2520and%2520Meningiomas%252C%2520with%2520High%2520Affinity%2520for%2520the%2520Selective%2520Antagonist%2520PD156707%26jtitle%3DNeurosurgery%26date%3D1998%26volume%3D43%26spage%3D890%26epage%3D898%26doi%3D10.1097%2F00006123-199810000-00097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Hartz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fricker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. S.</span><span> </span><span class="NLM_article-title">Rapid Regulation of P-glycoprotein at the Blood-Brain Barrier by Endothelin-1</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">â</span> <span class="NLM_lpage">394</span><span class="refDoi">Â DOI: 10.1124/mol.104.001503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1124%2Fmol.104.001503" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2004&pages=387-394&author=A.+M.+Hartzauthor=B.+Bauerauthor=G.+Frickerauthor=D.+S.+Miller&title=Rapid+Regulation+of+P-glycoprotein+at+the+Blood-Brain+Barrier+by+Endothelin-1&doi=10.1124%2Fmol.104.001503"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1124%2Fmol.104.001503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.104.001503%26sid%3Dliteratum%253Aachs%26aulast%3DHartz%26aufirst%3DA.%2BM.%26aulast%3DBauer%26aufirst%3DB.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DD.%2BS.%26atitle%3DRapid%2520Regulation%2520of%2520P-glycoprotein%2520at%2520the%2520Blood-Brain%2520Barrier%2520by%2520Endothelin-1%26jtitle%3DMol.%2520Pharmacol.%26date%3D2004%26volume%3D66%26spage%3D387%26epage%3D394%26doi%3D10.1124%2Fmol.104.001503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Binder, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pukrop, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimshaw, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrenreich, H.</span><span> </span><span class="NLM_article-title">Stromal Endothelin B Receptor-deficiency Inhibits Breast Cancer Growth and Metastasis</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2452</span><span class="NLM_x">â</span> <span class="NLM_lpage">2460</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-09-0032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1535-7163.MCT-09-0032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=19671740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCms7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2452-2460&author=C.+Binderauthor=T.+Hagemannauthor=S.+Sperlingauthor=M.+Schulzauthor=T.+Pukropauthor=M.+J.+Grimshawauthor=H.+Ehrenreich&title=Stromal+Endothelin+B+Receptor-deficiency+Inhibits+Breast+Cancer+Growth+and+Metastasis&doi=10.1158%2F1535-7163.MCT-09-0032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis</span></div><div class="casAuthors">Binder, Claudia; Hagemann, Thorsten; Sperling, Swetlana; Schulz, Matthias; Pukrop, Tobias; Grimshaw, Matthew J.; Ehrenreich, Hannelore</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2452-2460</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The endothelin (ET) axis, often deregulated in cancers, is a promising target for anticancer strategies.  Whereas previous investigations have focused mostly on ET action in malignant cells, we chose a model allowing sep. assessment of the effects of ETs and their receptors ETAR and ETBR in the tumor cells and the stromal compartment, which is increasingly recognized as a key player in cancer progression.  In homozygous spotting lethal rats (sl/sl), a model of constitutive ETBR deficiency, we showed significant redn. of growth and metastasis of MAT B III rat mammary adenocarcinoma cells overexpressing ETAR and ET-1 but neg. for ETBR.  Lack of stromal ETBR expression did not influence angiogenesis.  However, it was correlated with diminished infiltration by tumor-assocd. macrophages and with reduced prodn. of tumor necrosis factor-Î±, both known as powerful promoters of tumor progression.  These effects were almost completely abolished in transgenic sl/sl rats, wherein ETBR function is restored by expression of an intact ETBR transgene.  This shows that tumor growth and metastasis are critically dependent on ETBR function in cells of the microenvironment and suggests that successful ETR antagonist therapy should also target the stromal component of ET signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlWtc62CcX5bVg90H21EOLACvtfcHk0ljXcKwgsKP8Lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCms7c%253D&md5=27e49405f97a0faaa4497abdfb1542f7</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0032%26sid%3Dliteratum%253Aachs%26aulast%3DBinder%26aufirst%3DC.%26aulast%3DHagemann%26aufirst%3DT.%26aulast%3DSperling%26aufirst%3DS.%26aulast%3DSchulz%26aufirst%3DM.%26aulast%3DPukrop%26aufirst%3DT.%26aulast%3DGrimshaw%26aufirst%3DM.%2BJ.%26aulast%3DEhrenreich%26aufirst%3DH.%26atitle%3DStromal%2520Endothelin%2520B%2520Receptor-deficiency%2520Inhibits%2520Breast%2520Cancer%2520Growth%2520and%2520Metastasis%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2452%26epage%3D2460%26doi%3D10.1158%2F1535-7163.MCT-09-0032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurosumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, Y.</span><span> </span><span class="NLM_article-title">High-incidence Spontaneous Tumors in JF1/Ms Mice: Relevance of Hypomorphic Germline Mutation and Subsequent Promoter Methylation of <i>Ednrb</i></span> <span class="citation_source-journal">J. Cancer Res. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">â</span> <span class="NLM_lpage">107</span><span class="refDoi">Â DOI: 10.1007/s00432-013-1546-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00432-013-1546-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2014&pages=99-107&author=J.+Watanabeauthor=Y.+Kanekoauthor=M.+Kurosumiauthor=Y.+Kobayashiauthor=M.+Sakamotoauthor=M.+A.+Yoshidaauthor=M.+Akiyamaauthor=Y.+Matsushima&title=High-incidence+Spontaneous+Tumors+in+JF1%2FMs+Mice%3A+Relevance+of+Hypomorphic+Germline+Mutation+and+Subsequent+Promoter+Methylation+of+Ednrb&doi=10.1007%2Fs00432-013-1546-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1007%2Fs00432-013-1546-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-013-1546-6%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DKaneko%26aufirst%3DY.%26aulast%3DKurosumi%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DSakamoto%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DM.%2BA.%26aulast%3DAkiyama%26aufirst%3DM.%26aulast%3DMatsushima%26aufirst%3DY.%26atitle%3DHigh-incidence%2520Spontaneous%2520Tumors%2520in%2520JF1%252FMs%2520Mice%253A%2520Relevance%2520of%2520Hypomorphic%2520Germline%2520Mutation%2520and%2520Subsequent%2520Promoter%2520Methylation%2520of%2520Ednrb%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D140%26spage%3D99%26epage%3D107%26doi%3D10.1007%2Fs00432-013-1546-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">De Freitas Cordeiro-Silva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agostini, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de PodestÃ¡, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Oliveira, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soares, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MendonÃ§a, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouvea, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Zeidler, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louro, D.</span><span> </span><span class="NLM_article-title">Promoter Hypermethylation in Primary Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: A Study of a Brazilian Cohort, I</span> <span class="citation_source-journal">Mol. Biol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">10111</span><span class="NLM_x">â</span> <span class="NLM_lpage">10119</span><span class="refDoi">Â DOI: 10.1007/s11033-012-1885-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs11033-012-1885-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22936053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC38bivVyktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=10111-10119&author=M.+De+Freitas+Cordeiro-Silvaauthor=E.+Sturauthor=L.+P.+Agostiniauthor=J.+R.+de+Podest%C3%A1author=J.+C.+de+Oliveiraauthor=M.+S.+Soaresauthor=E.+F.+Mendon%C3%A7aauthor=S.+A.+Gouveaauthor=S.+V.+Von+Zeidlerauthor=D.+Louro&title=Promoter+Hypermethylation+in+Primary+Squamous+Cell+Carcinoma+of+the+Oral+Cavity+and+Oropharynx%3A+A+Study+of+a+Brazilian+Cohort%2C+I&doi=10.1007%2Fs11033-012-1885-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Promoter hypermethylation in primary squamous cell carcinoma of the oral cavity and oropharynx: a study of a Brazilian cohort</span></div><div class="casAuthors">de Freitas Cordeiro-Silva Melissa; Stur Elaine; Agostini Lidiane Pignaton; de Podesta Jose Roberto Vasconcelos; de Oliveira Jose Carlos; Soares Mariana Silveira; Mendonca Elismauro Francisco; Gouvea Sonia Alves; Von Zeidler Sandra Ventorin; Louro Iuri Drumond</div><div class="citationInfo"><span class="NLM_cas:title">Molecular biology reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">10111-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epigenetic silencing of cancer-related genes plays an important role in oral/oropharyngeal squamous cell carcinoma (OSCC).  We evaluated promoter hypermethylation of 4 cancer-related genes in OSCCs of a Brazilian cohort and determined its relationship with exposure to alcohol, tobacco, HPV infection and clinicopathological parameters.  CDKN2A (cyclin-dependent kinase inhibitor 2A or p16), SFN (stratifin or 14-3-3 Ï), EDNRB (endothelin receptor B) and RUNX3 (runt-related transcript factor-3) had their methylation patterns evaluated by MSP analysis in OSCC tumors (n = 45).  HPV detection was carried out by PCR/RFLP.  Aberrant methylation was detected in 44/45 (97.8 %) OSCC; 24.4 % at CDKN2A, 77.8 % at EDNRB, 17.8 % at RUNX3 and 97.8 % at SFN gene.  There was no significant association between methylation patterns and clinical parameters.  HPV (subtype 16) was detected in 3 out of 45 patients (6 %).  Our findings indicate that HPV infection is uncommon and methylation is frequent in Brazilian OSCCs, however, EDNRB and SFN gene methylation are not suitable OSCC biomarkers due to indistinct methylation in tumoral and normal samples.  In contrast, CDKN2A and RUNX3 genes could be considered differentially methylated genes and potential tumor markers in OSCCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMYgBxJM9PvSsZ1x6zOs0vfW6udTcc2eY8mKtNNTCSaLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bivVyktQ%253D%253D&md5=aad70a9a56ba3d5d137da0c8ebe6962a</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1007%2Fs11033-012-1885-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11033-012-1885-4%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFreitas%2BCordeiro-Silva%26aufirst%3DM.%26aulast%3DStur%26aufirst%3DE.%26aulast%3DAgostini%26aufirst%3DL.%2BP.%26aulast%3Dde%2BPodest%25C3%25A1%26aufirst%3DJ.%2BR.%26aulast%3Dde%2BOliveira%26aufirst%3DJ.%2BC.%26aulast%3DSoares%26aufirst%3DM.%2BS.%26aulast%3DMendon%25C3%25A7a%26aufirst%3DE.%2BF.%26aulast%3DGouvea%26aufirst%3DS.%2BA.%26aulast%3DVon%2BZeidler%26aufirst%3DS.%2BV.%26aulast%3DLouro%26aufirst%3DD.%26atitle%3DPromoter%2520Hypermethylation%2520in%2520Primary%2520Squamous%2520Cell%2520Carcinoma%2520of%2520the%2520Oral%2520Cavity%2520and%2520Oropharynx%253A%2520A%2520Study%2520of%2520a%2520Brazilian%2520Cohort%252C%2520I%26jtitle%3DMol.%2520Biol.%2520Rep.%26date%3D2012%26volume%3D39%26spage%3D10111%26epage%3D10119%26doi%3D10.1007%2Fs11033-012-1885-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Jimeno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M.</span><span> </span><span class="NLM_article-title">Atrasentan: a Novel and Rationally Designed Therapeutic Alternative in the Management of Cancer</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">â</span> <span class="NLM_lpage">427</span><span class="refDoi">Â DOI: 10.1586/14737140.5.3.419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1586%2F14737140.5.3.419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=16001950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtF2it7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=419-427&author=A.+Jimenoauthor=M.+Carducci&title=Atrasentan%3A+a+Novel+and+Rationally+Designed+Therapeutic+Alternative+in+the+Management+of+Cancer&doi=10.1586%2F14737140.5.3.419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Atrasentan: A novel and rationally designed therapeutic alternative in the management of cancer</span></div><div class="casAuthors">Jimeno, Antonio; Carducci, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">419-427</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli.  Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/or reverse several of those events.  Biol. and clin. activity in patients with prostate cancer has been demonstrated in a Phase III, placebo-controlled setting by the suppression of markers of biochem. prostate cancer progression and a delay in time to disease progression.  Atrasentan represents a new therapeutic option in the management of prostate cancer, esp. in those patients with bone metastases.  However, its precise role in other diseases such as ovrian cancer is yet to be defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH4xDWXjpNn7Vg90H21EOLACvtfcHk0lgdL3K-qZWniw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtF2it7g%253D&md5=794db9428a3d0cfc4023414e594838c8</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1586%2F14737140.5.3.419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.5.3.419%26sid%3Dliteratum%253Aachs%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DCarducci%26aufirst%3DM.%26atitle%3DAtrasentan%253A%2520a%2520Novel%2520and%2520Rationally%2520Designed%2520Therapeutic%2520Alternative%2520in%2520the%2520Management%2520of%2520Cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2005%26volume%3D5%26spage%3D419%26epage%3D427%26doi%3D10.1586%2F14737140.5.3.419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Nelson, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fizazi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moul, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akaza, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleave, M.</span><span> </span><span class="NLM_article-title">Phase 3, Randomized, Placebo-controlled Study of zibotentan (ZD4054) in Patients with Castration-resistant Prostate Cancer Metastatic to Bone</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">5709</span><span class="NLM_x">â</span> <span class="NLM_lpage">5718</span><span class="refDoi">Â DOI: 10.1002/cncr.27674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fcncr.27674" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=5709-5718&author=J.+B.+Nelsonauthor=K.+Fizaziauthor=K.+Millerauthor=C.+Higanoauthor=J.+W.+Moulauthor=H.+Akazaauthor=T.+Morrisauthor=S.+McIntoshauthor=K.+Pembertonauthor=M.+Gleave&title=Phase+3%2C+Randomized%2C+Placebo-controlled+Study+of+zibotentan+%28ZD4054%29+in+Patients+with+Castration-resistant+Prostate+Cancer+Metastatic+to+Bone&doi=10.1002%2Fcncr.27674"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fcncr.27674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.27674%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DJ.%2BB.%26aulast%3DFizazi%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DHigano%26aufirst%3DC.%26aulast%3DMoul%26aufirst%3DJ.%2BW.%26aulast%3DAkaza%26aufirst%3DH.%26aulast%3DMorris%26aufirst%3DT.%26aulast%3DMcIntosh%26aufirst%3DS.%26aulast%3DPemberton%26aufirst%3DK.%26aulast%3DGleave%26aufirst%3DM.%26atitle%3DPhase%25203%252C%2520Randomized%252C%2520Placebo-controlled%2520Study%2520of%2520zibotentan%2520%2528ZD4054%2529%2520in%2520Patients%2520with%2520Castration-resistant%2520Prostate%2520Cancer%2520Metastatic%2520to%2520Bone%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26spage%3D5709%26epage%3D5718%26doi%3D10.1002%2Fcncr.27674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Kohan, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleland, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theodorescu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, M.</span><span> </span><span class="NLM_article-title">Clinical Trials with Endothelin Receptor Antagonists: What Went Wrong and Where Can We Improve?</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">528</span><span class="NLM_x">â</span> <span class="NLM_lpage">539</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2012.07.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.lfs.2012.07.034" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=528-539&author=D.+E.+Kohanauthor=J.+G.+Clelandauthor=L.+J.+Rubinauthor=D.+Theodorescuauthor=M.+Barton&title=Clinical+Trials+with+Endothelin+Receptor+Antagonists%3A+What+Went+Wrong+and+Where+Can+We+Improve%3F&doi=10.1016%2Fj.lfs.2012.07.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.07.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.07.034%26sid%3Dliteratum%253Aachs%26aulast%3DKohan%26aufirst%3DD.%2BE.%26aulast%3DCleland%26aufirst%3DJ.%2BG.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DTheodorescu%26aufirst%3DD.%26aulast%3DBarton%26aufirst%3DM.%26atitle%3DClinical%2520Trials%2520with%2520Endothelin%2520Receptor%2520Antagonists%253A%2520What%2520Went%2520Wrong%2520and%2520Where%2520Can%2520We%2520Improve%253F%26jtitle%3DLife%2520Sci.%26date%3D2012%26volume%3D91%26spage%3D528%26epage%3D539%26doi%3D10.1016%2Fj.lfs.2012.07.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Lalich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeel, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists in Cancer Therapy</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">785</span><span class="NLM_x">â</span> <span class="NLM_lpage">794</span><span class="refDoi">Â DOI: 10.1080/07357900701522588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1080%2F07357900701522588" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=785-794&author=M.+Lalichauthor=D.+G.+McNeelauthor=G.+Wildingauthor=G.+Liu&title=Endothelin+Receptor+Antagonists+in+Cancer+Therapy&doi=10.1080%2F07357900701522588"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1080%2F07357900701522588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07357900701522588%26sid%3Dliteratum%253Aachs%26aulast%3DLalich%26aufirst%3DM.%26aulast%3DMcNeel%26aufirst%3DD.%2BG.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%2520in%2520Cancer%2520Therapy%26jtitle%3DCancer%2520Invest.%26date%3D2007%26volume%3D25%26spage%3D785%26epage%3D794%26doi%3D10.1080%2F07357900701522588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Armstrong, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turnbull, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yenser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gockerman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleep, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurwitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, D. J.</span><span> </span><span class="NLM_article-title">A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-resistant Metastatic Prostate Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6270</span><span class="NLM_x">â</span> <span class="NLM_lpage">6276</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-08-1085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1078-0432.CCR-08-1085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=18829508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2nurnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=6270-6276&author=A.+J.+Armstrongauthor=P.+Creelauthor=J.+Turnbullauthor=C.+Mooreauthor=T.+A.+Jaffeauthor=S.+Haleyauthor=W.+Petrosauthor=S.+Yenserauthor=J.+P.+Gockermanauthor=D.+Sleepauthor=H.+Hurwitzauthor=D.+J.+George&title=A+Phase+I-II+Study+of+Docetaxel+and+Atrasentan+in+Men+with+Castration-resistant+Metastatic+Prostate+Cancer&doi=10.1158%2F1078-0432.CCR-08-1085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer</span></div><div class="casAuthors">Armstrong, Andrew J.; Creel, Patricia; Turnbull, James; Moore, Cassandra; Jaffe, Tracy A.; Haley, Sherri; Petros, William; Yenser, Sarah; Gockerman, Jon P.; Sleep, Darryl; Hurwitz, Herbert; George, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6270-6276</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The primary aims of this phase I-II study were to det. the max. tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary efficacy of the combination of docetaxel and the endothelin A receptor antagonist atrasentan as first-line treatment for men with metastatic castration-resistant prostate cancer.  Patients were treated with docetaxel at doses ranging from 60 to 75 mg/m2 every 21 days, with daily oral atrasentan 10 mg starting on day 3.  Patients were treated until evidence of disease progression or unacceptable toxicity.  Thirty-one patients were enrolled over three docetaxel dose levels (8 at 60 mg/m2, 19 at 70 mg/m2, and 4 at 75 mg/m2) including dose expansion at 70 mg/m2.  The max. tolerated dose of docetaxel was 70 to 75 mg/m2.  Drug-related grade 3-4 toxicities included neutropenia (50-63%) and febrile neutropenia (16-25%); other grade 1-2 toxicities included fatigue, peripheral edema, diarrhea, headache, rhinitis, anorexia, and nausea.  Confirmed prostate-specific antigen (PSA) responses were obsd. in 23% [95% confidence interval (95% CI), 10-41%]; the rate of >30% declines in PSA was 35% (95% CI, 19-55%).  Median overall survival was 17.6 mo (95% CI, 13.0-23.2) and median progression-free survival was 4.2 mo (95% CI, 2.3-5.8).  Significant declines in bone alk. phosphatase and serum N-telopeptides were obsd. with therapy.  The max. tolerated dose of every-3-wk docetaxel with 10 mg atrasentan is 70 to 75 mg/m2.  Overall survival and progression-free survival are comparable to that seen with docetaxel and prednisone, whereas the rates of PSA decline are slightly lower than expected.  A phase III study of this combination with prednisone has been initiated and is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov_UkRZorX97Vg90H21EOLACvtfcHk0lgdZgWvBn8nfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2nurnN&md5=cee90dcf963940bb53328daa6454a659</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1085%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DA.%2BJ.%26aulast%3DCreel%26aufirst%3DP.%26aulast%3DTurnbull%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DJaffe%26aufirst%3DT.%2BA.%26aulast%3DHaley%26aufirst%3DS.%26aulast%3DPetros%26aufirst%3DW.%26aulast%3DYenser%26aufirst%3DS.%26aulast%3DGockerman%26aufirst%3DJ.%2BP.%26aulast%3DSleep%26aufirst%3DD.%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DGeorge%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Phase%2520I-II%2520Study%2520of%2520Docetaxel%2520and%2520Atrasentan%2520in%2520Men%2520with%2520Castration-resistant%2520Metastatic%2520Prostate%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D6270%26epage%3D6276%26doi%3D10.1158%2F1078-0432.CCR-08-1085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Pinto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamora, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redondo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinosa, E.</span><span> </span><span class="NLM_article-title">Targeting the Endothelin Axis in Prostate Carcinoma</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">â</span> <span class="NLM_lpage">426</span><span class="refDoi">Â DOI: 10.1007/s13277-011-0299-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs13277-011-0299-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22203496" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=421-426&author=A.+Pintoauthor=M.+Merinoauthor=P.+Zamoraauthor=A.+Redondoauthor=B.+Casteloauthor=E.+Espinosa&title=Targeting+the+Endothelin+Axis+in+Prostate+Carcinoma&doi=10.1007%2Fs13277-011-0299-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1007%2Fs13277-011-0299-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-011-0299-6%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DA.%26aulast%3DMerino%26aufirst%3DM.%26aulast%3DZamora%26aufirst%3DP.%26aulast%3DRedondo%26aufirst%3DA.%26aulast%3DCastelo%26aufirst%3DB.%26aulast%3DEspinosa%26aufirst%3DE.%26atitle%3DTargeting%2520the%2520Endothelin%2520Axis%2520in%2520Prostate%2520Carcinoma%26jtitle%3DTumor%2520Biol.%26date%3D2012%26volume%3D33%26spage%3D421%26epage%3D426%26doi%3D10.1007%2Fs13277-011-0299-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Witteveen, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Mijn, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kronemeijer, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groenewegen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span> </span><span class="NLM_article-title">Phase 1/2 Study of Atrasentan Combined with Peggylated Liposomal Doxorubicin in Platinum-resistant Recurrent Ovarian Cancer</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">â</span> <span class="NLM_lpage">945</span><span class="refDoi">Â DOI: 10.1593/neo.10582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1593%2Fneo.10582" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=941-945&author=P.+O.+Witteveenauthor=K.+J.+van+der+Mijnauthor=M.+Losauthor=R.+H.+Kronemeijerauthor=G.+Groenewegenauthor=E.+E.+Voest&title=Phase+1%2F2+Study+of+Atrasentan+Combined+with+Peggylated+Liposomal+Doxorubicin+in+Platinum-resistant+Recurrent+Ovarian+Cancer&doi=10.1593%2Fneo.10582"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1593%2Fneo.10582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.10582%26sid%3Dliteratum%253Aachs%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3Dvan%2Bder%2BMijn%26aufirst%3DK.%2BJ.%26aulast%3DLos%26aufirst%3DM.%26aulast%3DKronemeijer%26aufirst%3DR.%2BH.%26aulast%3DGroenewegen%26aufirst%3DG.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26atitle%3DPhase%25201%252F2%2520Study%2520of%2520Atrasentan%2520Combined%2520with%2520Peggylated%2520Liposomal%2520Doxorubicin%2520in%2520Platinum-resistant%2520Recurrent%2520Ovarian%2520Cancer%26jtitle%3DNeoplasia%26date%3D2010%26volume%3D12%26spage%3D941%26epage%3D945%26doi%3D10.1593%2Fneo.10582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Fizazi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higano, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleave, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moul, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moul, J. W.</span><span> </span><span class="NLM_article-title">Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination with Zibotentan in Patients with Metastatic Castration-resistant Prostate Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1740</span><span class="NLM_x">â</span> <span class="NLM_lpage">1747</span><span class="refDoi">Â DOI: 10.1200/JCO.2012.46.4149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1200%2FJCO.2012.46.4149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23569308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOrt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1740-1747&author=K.+Fizaziauthor=J.+B.+Higanoauthor=J.+B.+Nelsonauthor=M.+Gleaveauthor=K.+Millerauthor=T.+Morrisauthor=F.+E.+Nathanauthor=S.+McIntoshauthor=K.+Pembertonauthor=J.+W.+Moulauthor=J.+W.+Moul&title=Phase+III%2C+Randomized%2C+Placebo-Controlled+Study+of+Docetaxel+in+Combination+with+Zibotentan+in+Patients+with+Metastatic+Castration-resistant+Prostate+Cancer&doi=10.1200%2FJCO.2012.46.4149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer</span></div><div class="casAuthors">Fizazi, Karim; Higano, Celestia S.; Nelson, Joel B.; Gleave, Martin; Miller, Kurt; Morris, Thomas; Nathan, Faith E.; McIntosh, Stuart; Pemberton, Kristine; Moul, Judd W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1740-1747</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">As part of the ENTHUSE (Endothelin A Use) program, the efficacy and safety of zibotentan (ZD4054), an oral specific endothelin A receptor antagonist, has been investigated in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (CRPC).  In this randomized, double-blind, placebo-controlled, phase III study, patients received i.v. docetaxel 75 mg/m2 on day 1 of 21-day cycles plus oral zibotentan 10 mg or placebo once daily.  The primary end point was overall survival (OS).  Secondary end points included time to pain and prostate-specific antigen (PSA) progression, pain and PSA response, progression-free survival, health-related quality of life, and safety.  A total of 1,052 patients received study treatment (docetaxel-zibotentan, n = 524; docetaxel-placebo, n = 528).  At the time of data cutoff, there had been 277 and 280 deaths, resp.  There was no difference in OS for patients receiving docetaxel-zibotentan compared with those receiving docetaxel-placebo (hazard ratio, 1.00; 95% CI, 0.84 to 1.18; P = .963).  No significant differences were obsd. on secondary end points, including time to pain progression (median 9.3 v 10.0 mo, resp.) or pain response (odds ratio, 0.84; 95% CI, 0.61 to 1.16; P = .283).  The median time to death was 20.0 and 19.2 mo for the zibotentan and placebo groups, resp.  The most commonly reported adverse events in zibotentan-treated patients were peripheral edema (52.7%), diarrhea (35.4%), alopecia (33.9%), and nausea (33.3%).  Docetaxel plus zibotentan 10 mg/d did not result in a significant improvement in OS compared with docetaxel plus placebo in patients with metastatic CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-X6MNO3V11LVg90H21EOLACvtfcHk0lgKXPG7i7rVEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOrt7o%253D&md5=a6ae86c349ec6829636a0d9b2aefbb36</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.46.4149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.46.4149%26sid%3Dliteratum%253Aachs%26aulast%3DFizazi%26aufirst%3DK.%26aulast%3DHigano%26aufirst%3DJ.%2BB.%26aulast%3DNelson%26aufirst%3DJ.%2BB.%26aulast%3DGleave%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DMorris%26aufirst%3DT.%26aulast%3DNathan%26aufirst%3DF.%2BE.%26aulast%3DMcIntosh%26aufirst%3DS.%26aulast%3DPemberton%26aufirst%3DK.%26aulast%3DMoul%26aufirst%3DJ.%2BW.%26aulast%3DMoul%26aufirst%3DJ.%2BW.%26atitle%3DPhase%2520III%252C%2520Randomized%252C%2520Placebo-Controlled%2520Study%2520of%2520Docetaxel%2520in%2520Combination%2520with%2520Zibotentan%2520in%2520Patients%2520with%2520Metastatic%2520Castration-resistant%2520Prostate%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1740%26epage%3D1747%26doi%3D10.1200%2FJCO.2012.46.4149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Phuphanich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesser, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikkelsen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desideri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, J. D.</span><span> </span><span class="NLM_article-title">New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium Phase I Safety Study of Escalating Doses of Atrasentan in Adults with Recurrent Malignant Glioma</span> <span class="citation_source-journal">Neuro-Oncology.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">â</span> <span class="NLM_lpage">623</span><span class="refDoi">Â DOI: 10.1215/15228517-2008-013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1215%2F15228517-2008-013" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=617-623&author=S.+Phuphanichauthor=K.+A.+Carsonauthor=S.+A.+Grossmanauthor=G.+Lesserauthor=J.+Olsonauthor=T.+Mikkelsenauthor=S.+Desideriauthor=J.+D.+Fisher&title=New+Approaches+to+Brain+Tumor+Therapy+%28NABTT%29+CNS+Consortium+Phase+I+Safety+Study+of+Escalating+Doses+of+Atrasentan+in+Adults+with+Recurrent+Malignant+Glioma&doi=10.1215%2F15228517-2008-013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1215%2F15228517-2008-013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1215%252F15228517-2008-013%26sid%3Dliteratum%253Aachs%26aulast%3DPhuphanich%26aufirst%3DS.%26aulast%3DCarson%26aufirst%3DK.%2BA.%26aulast%3DGrossman%26aufirst%3DS.%2BA.%26aulast%3DLesser%26aufirst%3DG.%26aulast%3DOlson%26aufirst%3DJ.%26aulast%3DMikkelsen%26aufirst%3DT.%26aulast%3DDesideri%26aufirst%3DS.%26aulast%3DFisher%26aufirst%3DJ.%2BD.%26atitle%3DNew%2520Approaches%2520to%2520Brain%2520Tumor%2520Therapy%2520%2528NABTT%2529%2520CNS%2520Consortium%2520Phase%2520I%2520Safety%2520Study%2520of%2520Escalating%2520Doses%2520of%2520Atrasentan%2520in%2520Adults%2520with%2520Recurrent%2520Malignant%2520Glioma%26jtitle%3DNeuro-Oncology.%26date%3D2008%26volume%3D10%26spage%3D617%26epage%3D623%26doi%3D10.1215%2F15228517-2008-013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Kefford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beith, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hazel, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trotter, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyld, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusic, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeniwas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morganti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span> </span><span class="NLM_article-title">A phase II Study of Bosentan, a Dual Endothelin Receptor Antagonist, as Monotherapy in Patients with Stage IV Metastatic Melanoma</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">â</span> <span class="NLM_lpage">252</span><span class="refDoi">Â DOI: 10.1007/s10637-006-9014-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs10637-006-9014-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=247-252&author=R.+Keffordauthor=J.+M.+Beithauthor=G.+A.+Van+Hazelauthor=M.+Millwardauthor=J.+M.+Trotterauthor=D.+K.+Wyldauthor=R.+Kusicauthor=R.+Shreeniwasauthor=A.+Morgantiauthor=A.+Ballmerauthor=E.+Segalauthor=O.+Naylerauthor=M.+Clozel&title=A+phase+II+Study+of+Bosentan%2C+a+Dual+Endothelin+Receptor+Antagonist%2C+as+Monotherapy+in+Patients+with+Stage+IV+Metastatic+Melanoma&doi=10.1007%2Fs10637-006-9014-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1007%2Fs10637-006-9014-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-006-9014-7%26sid%3Dliteratum%253Aachs%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DBeith%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BHazel%26aufirst%3DG.%2BA.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DTrotter%26aufirst%3DJ.%2BM.%26aulast%3DWyld%26aufirst%3DD.%2BK.%26aulast%3DKusic%26aufirst%3DR.%26aulast%3DShreeniwas%26aufirst%3DR.%26aulast%3DMorganti%26aufirst%3DA.%26aulast%3DBallmer%26aufirst%3DA.%26aulast%3DSegal%26aufirst%3DE.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DA%2520phase%2520II%2520Study%2520of%2520Bosentan%252C%2520a%2520Dual%2520Endothelin%2520Receptor%2520Antagonist%252C%2520as%2520Monotherapy%2520in%2520Patients%2520with%2520Stage%2520IV%2520Metastatic%2520Melanoma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2007%26volume%3D25%26spage%3D247%26epage%3D252%26doi%3D10.1007%2Fs10637-006-9014-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clingan, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morganti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, P.</span><span> </span><span class="NLM_article-title">A Randomized, Double-blind, Placebo-controlled Study of High-dose Bosentan in Patients with Stage IV Metastatic Melanoma Receiving First-line Dacarbazine Chemotherapy</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="refDoi">Â DOI: 10.1186/1476-4598-9-69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1186%2F1476-4598-9-69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=20350333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC3c3nt12ltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=69&author=R.+F.+Keffordauthor=P.+R.+Clinganauthor=B.+Bradyauthor=A.+Ballmerauthor=A.+Morgantiauthor=P.+Hersey&title=A+Randomized%2C+Double-blind%2C+Placebo-controlled+Study+of+High-dose+Bosentan+in+Patients+with+Stage+IV+Metastatic+Melanoma+Receiving+First-line+Dacarbazine+Chemotherapy&doi=10.1186%2F1476-4598-9-69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy</span></div><div class="casAuthors">Kefford Richard F; Clingan Philip R; Brady Benjamin; Ballmer Andrea; Morganti Adele; Hersey Peter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The endothelin system is implicated in the pathogenesis of melanoma.  We evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV metastatic cutaneous melanoma in a phase 2, proof-of-concept study.  RESULTS:  Eligible patients had metastatic cutaneous melanoma naive to chemotherapy or immunotherapy, no central nervous system involvement, and serum lactate dehydrogenase <1.5 x upper limit of normal.  Treatment comprised bosentan 500 mg twice daily or matching placebo, in addition to dacarbazine 1000 mg/m2 every three weeks.  Eighty patients were randomized (double-blind) and 38 in each group received study treatment.  Median time to tumor progression (primary endpoint) was not significantly different between the two groups (placebo, 2.8 months; bosentan, 1.6 months; bosentan/placebo hazard ratio, 1.144; 95% CI, 0.717-1.827; p = 0.5683).  Incidences of most adverse events and clinically relevant increases in hepatic transaminases were similar between treatment groups although hemoglobin decrease to >8 and < or = 10 g/dL and < or = 8 g/dL was more common in the bosentan group.  CONCLUSIONS:  In patients receiving dacarbazine as first-line chemotherapy for metastatic melanoma, the addition of high-dose bosentan had no effect on time to tumor progression or other efficacy parameters.  There were no unexpected safety findings.  TRIAL REGISTRATION:  This study is registered in ClinicalTrials.gov under the unique identifier NCT01009177.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnxCNyL99HbFw2ofyr07jXfW6udTcc2eatVOgwshfV_7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3nt12ltw%253D%253D&md5=4e9f2c9eceb1cbf04b419a2794458839</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-9-69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-9-69%26sid%3Dliteratum%253Aachs%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DClingan%26aufirst%3DP.%2BR.%26aulast%3DBrady%26aufirst%3DB.%26aulast%3DBallmer%26aufirst%3DA.%26aulast%3DMorganti%26aufirst%3DA.%26aulast%3DHersey%26aufirst%3DP.%26atitle%3DA%2520Randomized%252C%2520Double-blind%252C%2520Placebo-controlled%2520Study%2520of%2520High-dose%2520Bosentan%2520in%2520Patients%2520with%2520Stage%2520IV%2520Metastatic%2520Melanoma%2520Receiving%2520First-line%2520Dacarbazine%2520Chemotherapy%26jtitle%3DMol.%2520Cancer%26date%3D2010%26volume%3D9%26spage%3D69%26doi%3D10.1186%2F1476-4598-9-69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Shao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, N. H.</span><span> </span><span class="NLM_article-title">Immunotherapy and Endothelin Receptor Antagonists for Treatment of Castration-resistant Prostate Cancer</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">1743</span><span class="NLM_x">â</span> <span class="NLM_lpage">1750</span><span class="refDoi">Â DOI: 10.1002/ijc.28162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fijc.28162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23504603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltlOmtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2013&pages=1743-1750&author=N.+Shaoauthor=Y.+Wangauthor=W.+Y.+Jiangauthor=D.+Qiaoauthor=S.+G.+Zhangauthor=Y.+Wuauthor=X.+X.+Zhangauthor=J.+L.+Wangauthor=Y.+Dingauthor=N.+H.+Feng&title=Immunotherapy+and+Endothelin+Receptor+Antagonists+for+Treatment+of+Castration-resistant+Prostate+Cancer&doi=10.1002%2Fijc.28162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer</span></div><div class="casAuthors">Shao, Ning; Wang, Yang; Jiang, Wen Yu; Qiao, Di; Zhang, Shi Ge; Wu, Ye; Zhang, Xiang Xiang; Wang, Jiu Ling; Ding, Yi; Feng, Ning Han</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1743-1750</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Recently, novel therapies of prostate cancer, such as immunotherapy, endothelin receptor antagonists, novel androgen receptor antagonist and novel taxanes, and others have been introduced into clin. practice.  This study was performed to summarize these results of immunotherapy and endothelin receptor antagonists in the treatment of castration-resistant prostate cancer (CRPC) and derive a more precise estn. of their effect on future treatment.  The PubMed database, refs. of published trials, and review articles were searched.  Two reviewers independently extd. data of these trials.  We used hazard ratios (HRs) to assess the effects on overall survival (OS), progression-free survival (PFS), or time to disease progression (TTP), and relative risk (RR) for the different types of toxicity.  In addn., 95% confidence intervals (CIs) give a sense of the precision of the est.  Nine randomized controlled trials were ultimately identified.  The pooled HR showed that immunotherapy could prolong OS significantly in patients with CRPC compared to placebo (HR = 0.70, 95% CI: 0.58-0.83, p < 0.001).  Endothelin receptor antagonists also had modest benefits (HR = 0.90, 95% CI: 0.82-1.00, p = 0.046).  Nevertheless, there were no significant benefits from both therapies on PFS or TTP.  In addn., immunotherapy led to more fatigue, pyrexia, chills, and endothelin receptor antagonists led to more peripheral edema, anemia, and dyspnea.  Our article suggested that the very acceptable toxicity and improving OS in patients with CRPC made immunotherapy an attractive option for such patients.  However, future studies with thoughtful clin. trial designs are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkvX7EAY3w8rVg90H21EOLACvtfcHk0li1i_xM5hTiZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltlOmtLc%253D&md5=0694d3d0f0cde4b379b69d6d0f6dcb74</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1002%2Fijc.28162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.28162%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DW.%2BY.%26aulast%3DQiao%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%2BG.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%2BX.%26aulast%3DWang%26aufirst%3DJ.%2BL.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DN.%2BH.%26atitle%3DImmunotherapy%2520and%2520Endothelin%2520Receptor%2520Antagonists%2520for%2520Treatment%2520of%2520Castration-resistant%2520Prostate%2520Cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2013%26volume%3D133%26spage%3D1743%26epage%3D1750%26doi%3D10.1002%2Fijc.28162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Wynn, T. A.</span><span> </span><span class="NLM_article-title">Cellular and Molecular Mechanisms of Fibrosis</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">214</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">â</span> <span class="NLM_lpage">210</span><span class="refDoi">Â DOI: 10.1002/path.2277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fpath.2277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=18161745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvFCkt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2008&pages=199-210&author=T.+A.+Wynn&title=Cellular+and+Molecular+Mechanisms+of+Fibrosis&doi=10.1002%2Fpath.2277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular and molecular mechanisms of fibrosis</span></div><div class="casAuthors">Wynn, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-210</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibrosis is defined by the overgrowth, hardening, and/or scarring of various tissues and is attributed to excess deposition of extracellular matrix components including collagen.  Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli including persistent infections, autoimmune reactions, allergic responses, chem. insults, radiation, and tissue injury.  Although current treatments for fibrotic diseases such as idiopathic pulmonary fibrosis, liver cirrhosis, systemic sclerosis, progressive kidney disease, and cardiovascular fibrosis typically target the inflammatory response, there is accumulating evidence that the mechanisms driving fibrogenesis are distinct from those regulating inflammation.  In fact, some studies have suggested that ongoing inflammation is needed to reverse established and progressive fibrosis.  The key cellular mediator of fibrosis is the myofibroblast, which when activated serves as the primary collagen-producing cell.  Myofibroblasts are generated from a variety of sources including resident mesenchymal cells, epithelial and endothelial cells in processes termed epithelial/endothelial-mesenchymal (EMT/EndMT) transition, as well as from circulating fibroblast-like cells called fibrocytes that are derived from bone-marrow stem cells.  Myofibroblasts are activated by a variety of mechanisms, including paracrine signals derived from lymphocytes and macrophages, autocrine factors secreted by myofibroblasts, and pathogen-assocd. mol. patterns (PAMPS) produced by pathogenic organisms that interact with pattern recognition receptors (i.e. TLRs) on fibroblasts.  Cytokines (IL-13, IL-21, TGF-Î²1), chemokines (MCP-1, MIP-1Î²), angiogenic factors (VEGF), growth factors (PDGF), peroxisome proliferator-activated receptors (PPARs), acute phase proteins (SAP), caspases, and components of the renin-angiotensin-aldosterone system (ANG II) have been identified as important regulators of fibrosis and are being investigated as potential targets of antifibrotic drugs.  This review explores our current understanding of the cellular and mol. mechanisms of fibrogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0w_vXtFhJmrVg90H21EOLACvtfcHk0li1i_xM5hTiZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvFCkt7w%253D&md5=a6b143a20d478d96bc60b816f23370f1</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1002%2Fpath.2277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2277%26sid%3Dliteratum%253Aachs%26aulast%3DWynn%26aufirst%3DT.%2BA.%26atitle%3DCellular%2520and%2520Molecular%2520Mechanisms%2520of%2520Fibrosis%26jtitle%3DJ.%2520Pathol.%26date%3D2008%26volume%3D214%26spage%3D199%26epage%3D210%26doi%3D10.1002%2Fpath.2277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salloukh, H.</span><span> </span><span class="NLM_article-title">Role of Endothelin in Fibrosis and Anti-fibrotic Potential of Bosentan</span> <span class="citation_source-journal">Ann. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">â</span> <span class="NLM_lpage">12</span><span class="refDoi">Â DOI: 10.1080/07853890410018925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1080%2F07853890410018925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15902842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslenurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2005&pages=2-12&author=M.+Clozelauthor=H.+Salloukh&title=Role+of+Endothelin+in+Fibrosis+and+Anti-fibrotic+Potential+of+Bosentan&doi=10.1080%2F07853890410018925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Role of endothelin in fibrosis and anti-fibrotic potential of bosentan</span></div><div class="casAuthors">Clozel, Martine; Salloukh, Hashem</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Medicine (Basingstoke, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">ANMDEU</span>;
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent data demonstrate the fundamental role of endothelin in the pathogenesis of fibrosis, and the anti-fibrotic potential of dual endothelin receptor antagonists such as bosentan.  Although transforming growth factor-beta, aldosterone and connective tissue growth factor, have already been established as contributors to the process of fibrosis, endothelin now emerges as a key player, which may have a role both in the initiation and in maintenance of fibrosis, and may mediate the pro-fibrotic effects of the other agents.  Bosentan is an orally active, dual endothelin receptor antagonist, which competitively antagonizes the binding of endothelin to both endothelin receptors ETA and ETB.  Bosentan prevents endothelin-induced fibroblast proliferation and extracellular matrix deposition and contraction, and reduces cardiac, hepatic, pulmonary and renal fibrosis in different disease models characterized by the activation of the endothelin system.  Bosentan even reverses existing fibrosis, possibly by its effect of stimulating matrix metalloproteinase type 1 (collagenase) expression.  The anti-fibrotic effects of bosentan extend to fibrosis induced by mediators other than endothelin such as transforming growth factor-beta, angiotensin II and aldosterone, indicating a central role of endothelin and endothelin receptors in fibrotic processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOmwjYBPr9mbVg90H21EOLACvtfcHk0li1i_xM5hTiZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslenurk%253D&md5=76966435b0243748c07b0cc8fd77960c</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1080%2F07853890410018925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07853890410018925%26sid%3Dliteratum%253Aachs%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DSalloukh%26aufirst%3DH.%26atitle%3DRole%2520of%2520Endothelin%2520in%2520Fibrosis%2520and%2520Anti-fibrotic%2520Potential%2520of%2520Bosentan%26jtitle%3DAnn.%2520Med.%26date%3D2005%26volume%3D37%26spage%3D2%26epage%3D12%26doi%3D10.1080%2F07853890410018925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Poncet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">The Expression and Function of the Endothelin System in Contractile Properties of Vaginal Myofibroblasts of Women with Uterovaginal Prolapse</span> <span class="citation_source-journal">Am. J. Obstet. Gynecol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">â</span> <span class="NLM_lpage">432</span><span class="refDoi">Â DOI: 10.1016/j.ajog.2004.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.ajog.2004.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15695982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKhs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2005&pages=426-432&author=S.+Poncetauthor=S.+Meyerauthor=C.+Richardauthor=J.+Aubertauthor=L.+Juillerat-Jeanneret&title=The+Expression+and+Function+of+the+Endothelin+System+in+Contractile+Properties+of+Vaginal+Myofibroblasts+of+Women+with+Uterovaginal+Prolapse&doi=10.1016%2Fj.ajog.2004.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">The expression and function of the endothelin system in contractile properties of vaginal myofibroblasts of women with uterovaginal prolapse</span></div><div class="casAuthors">Poncet, Sebastien; Meyer, Sylvain; Richard, Christelle; Aubert, John-David; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Obstetrics and Gynecology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">426-432</span>CODEN:
                <span class="NLM_cas:coden">AJOGAH</span>;
        ISSN:<span class="NLM_cas:issn">0002-9378</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Objective: The endothelin-1 system regulates (myo)fibroblast contraction in wound healing.  Our aim was to det. endothelin-1 system expression and function in contractile properties of vaginal myofibroblasts of women with uterovaginal prolapse.  Study Design: Cultures of Î±-smooth muscle actin-pos. myofibroblasts that were established at the time of repair surgery for prolapse (n = 30; mean age, 56 Â± 14 years) were analyzed and compared for their expression of the endothelin-1 system and contractile properties to myofibroblasts from primiparous women.  Results: Myofibroblasts expressed the complete endothelin system but did not secrete endothelin-1.  Endothelin-1 binding was mediated exclusively by the endothelin B-receptor.  In 3-dimensional collagen gels, spontaneous contraction of myofibroblasts from estrogen-treated women with prolapse was statistically significantly lower than from young primiparous women.  Exogenous addn. of endothelin-1 decreased the spontaneous contraction of myofibroblasts.  Conclusion: Genital myofibroblasts of women with uterovaginal prolapse are poorly contractile, and endothelin-1 further decreases vaginal myofibroblast contraction, which is opposite to observations in skin myofibroblasts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkVqtu6jAV17Vg90H21EOLACvtfcHk0li37_e8abPzTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKhs7g%253D&md5=fcfdcb942eb21c939aa699ec32f57032</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.ajog.2004.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajog.2004.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DPoncet%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DRichard%26aufirst%3DC.%26aulast%3DAubert%26aufirst%3DJ.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DThe%2520Expression%2520and%2520Function%2520of%2520the%2520Endothelin%2520System%2520in%2520Contractile%2520Properties%2520of%2520Vaginal%2520Myofibroblasts%2520of%2520Women%2520with%2520Uterovaginal%2520Prolapse%26jtitle%3DAm.%2520J.%2520Obstet.%2520Gynecol.%26date%3D2005%26volume%3D192%26spage%3D426%26epage%3D432%26doi%3D10.1016%2Fj.ajog.2004.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Weng, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span> </span><span class="NLM_article-title">Endothelin-1 Induces Connective Tissue Growth Factor Expression in Human Lung Fibroblasts by ETAR-dependent JNK/AP-1 Pathway</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">â</span> <span class="NLM_lpage">411</span><span class="refDoi">Â DOI: 10.1016/j.bcp.2014.01.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.bcp.2014.01.030" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=402-411&author=C.+M.+Wengauthor=C.+C.+Yuauthor=M.+L.+Kuoauthor=B.+C.+Chenauthor=C.+H.+Lin&title=Endothelin-1+Induces+Connective+Tissue+Growth+Factor+Expression+in+Human+Lung+Fibroblasts+by+ETAR-dependent+JNK%2FAP-1+Pathway&doi=10.1016%2Fj.bcp.2014.01.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.01.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.01.030%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DC.%2BM.%26aulast%3DYu%26aufirst%3DC.%2BC.%26aulast%3DKuo%26aufirst%3DM.%2BL.%26aulast%3DChen%26aufirst%3DB.%2BC.%26aulast%3DLin%26aufirst%3DC.%2BH.%26atitle%3DEndothelin-1%2520Induces%2520Connective%2520Tissue%2520Growth%2520Factor%2520Expression%2520in%2520Human%2520Lung%2520Fibroblasts%2520by%2520ETAR-dependent%2520JNK%252FAP-1%2520Pathway%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D88%26spage%3D402%26epage%3D411%26doi%3D10.1016%2Fj.bcp.2014.01.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Antoniu, S. A.</span><span> </span><span class="NLM_article-title">Targeting the Endothelin Pathway in the Idiopathic Pulmonary Fibrosis: The Role of Bosentan</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1077</span><span class="NLM_x">â</span> <span class="NLM_lpage">1084</span><span class="refDoi">Â DOI: 10.1517/14728222.12.9.1077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1517%2F14728222.12.9.1077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=18694375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslaltrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=1077-1084&author=S.+A.+Antoniu&title=Targeting+the+Endothelin+Pathway+in+the+Idiopathic+Pulmonary+Fibrosis%3A+The+Role+of+Bosentan&doi=10.1517%2F14728222.12.9.1077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan</span></div><div class="casAuthors">Antoniu, Sabina A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1077-1084</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Idiopathic pulmonary fibrosis (IPF) is a rapidly lethal disease characterized by anarchic, progressive fibrosis.  Pulmonary fibrosis is the result of interactions between many effector cells and cytokines and better understanding of this can help with identification of novel therapeutic targets.  To evaluate the role of the endothelin-1 (ET-1) pathway in IPF pathogenesis and the effects of therapeutic targeting with bosentan, an ET-1 antagonist.  Data on ET-1's pathogenic involvement in IPF and the preclin. and clin. data on bosentan in this context are discussed and analyzed.  A parallel overview of existing and upcoming therapies for IPF is presented.  Bosentan is a promising antifibrotic therapy for IPF and clin. data on its long-term efficacy support its use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMCqTyzHxsq7Vg90H21EOLACvtfcHk0li37_e8abPzTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslaltrY%253D&md5=d89da7ab5e42f12fb8f4dc4eb8061cf7</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.9.1077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.9.1077%26sid%3Dliteratum%253Aachs%26aulast%3DAntoniu%26aufirst%3DS.%2BA.%26atitle%3DTargeting%2520the%2520Endothelin%2520Pathway%2520in%2520the%2520Idiopathic%2520Pulmonary%2520Fibrosis%253A%2520The%2520Role%2520of%2520Bosentan%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2008%26volume%3D12%26spage%3D1077%26epage%3D1084%26doi%3D10.1517%2F14728222.12.9.1077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">King, T. E.</span><span> </span><span class="NLM_article-title">Bosentan for Idiopathic Pulmonary Fibrosis</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">â</span> <span class="NLM_lpage">1179</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=1171-1179&author=T.+E.+King&title=Bosentan+for+Idiopathic+Pulmonary+Fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DT.%2BE.%26atitle%3DBosentan%2520for%2520Idiopathic%2520Pulmonary%2520Fibrosis%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs.%26date%3D2008%26volume%3D9%26spage%3D1171%26epage%3D1179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Million-Rousseau, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morganti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perchenet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MUSIC Study Group.</span><span> </span><span class="NLM_article-title">Macitentan for the Treatment of Idiopathic Pulmonary Fibrosis: The Randomized Controlled MUSIC Trial</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1622</span><span class="NLM_x">â</span> <span class="NLM_lpage">1632</span><span class="refDoi">Â DOI: 10.1183/09031936.00104612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1183%2F09031936.00104612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23682110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlagtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=1622-1632&author=G.+Raghuauthor=R.+Million-Rousseauauthor=A.+Morgantiauthor=L.+Perchenetauthor=J.+Behrauthor=MUSIC+Study+Group.&title=Macitentan+for+the+Treatment+of+Idiopathic+Pulmonary+Fibrosis%3A+The+Randomized+Controlled+MUSIC+Trial&doi=10.1183%2F09031936.00104612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomized controlled MUSIC trial</span></div><div class="casAuthors">Raghu, Ganesh; Million-Rousseau, Rachel; Morganti, Adele; Perchenet, Loic; Behr, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1622-1632</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive, fatal disease.  This prospective, randomized, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis.  Eligible subjects were adults with idiopathic pulmonary fibrosis of <3 years duration and a histol. pattern of usual interstitial pneumonia on surgical lung biopsy.  The primary objective was to demonstrate that macitentan (10 mg once daily) pos. affected forced vital capacity vs. placebo.  Using a centralized system, 178 subjects were randomized (2:1) to macitentan (n = 119) or placebo (n = 59).  The median change from baseline up to month 12 in forced vital capacity was -0.20 L in the macitentan arm and -0.20 L in the placebo arm.  Overall, no differences between treatments were obsd. in pulmonary function tests or time to disease worsening or death.  Median exposures to macitentan and placebo were 14.5 mo and 15.0 mo, resp.  Alanine and/or aspartate aminotransferase elevations over three times upper limit of normal arose in 3.4% of macitentan-treated subjects and 5.1% of placebo recipients.  In conclusion, the primary objective was not met.  Long-term exposure to macitentan was well tolerated with a similar, low incidence of elevated hepatic aminotransferases in each treatment group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEeb0nFAw0JLVg90H21EOLACvtfcHk0lgd1_7Q8CgLHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlagtQ%253D%253D&md5=4d3495bc6413416a511a50a447acee62</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1183%2F09031936.00104612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00104612%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DMillion-Rousseau%26aufirst%3DR.%26aulast%3DMorganti%26aufirst%3DA.%26aulast%3DPerchenet%26aufirst%3DL.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3D%26atitle%3DMacitentan%2520for%2520the%2520Treatment%2520of%2520Idiopathic%2520Pulmonary%2520Fibrosis%253A%2520The%2520Randomized%2520Controlled%2520MUSIC%2520Trial%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D42%26spage%3D1622%26epage%3D1632%26doi%3D10.1183%2F09031936.00104612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Yuan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, P.</span><span> </span><span class="NLM_article-title">Endothelin-receptor Antagonists for Diabetic Nephropathy: A Meta-Analysis</span> <span class="citation_source-journal">Nephrology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">â</span> <span class="NLM_lpage">466</span><span class="refDoi">Â DOI: 10.1111/nep.12442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fnep.12442" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=459-466&author=W.+Yuanauthor=Y.+Liauthor=J.+Wangauthor=J.+Liauthor=S.+Gouauthor=P.+Fu&title=Endothelin-receptor+Antagonists+for+Diabetic+Nephropathy%3A+A+Meta-Analysis&doi=10.1111%2Fnep.12442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1111%2Fnep.12442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnep.12442%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DFu%26aufirst%3DP.%26atitle%3DEndothelin-receptor%2520Antagonists%2520for%2520Diabetic%2520Nephropathy%253A%2520A%2520Meta-Analysis%26jtitle%3DNephrology%26date%3D2015%26volume%3D20%26spage%3D459%26epage%3D466%26doi%3D10.1111%2Fnep.12442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Kohan, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, M.</span><span> </span><span class="NLM_article-title">Endothelin and Endothelin Antagonists in Chronic Kidney Disease</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">â</span> <span class="NLM_lpage">904</span><span class="refDoi">Â DOI: 10.1038/ki.2014.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fki.2014.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24805108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsl2nsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=896-904&author=D.+E.+Kohanauthor=M.+Barton&title=Endothelin+and+Endothelin+Antagonists+in+Chronic+Kidney+Disease&doi=10.1038%2Fki.2014.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin and endothelin antagonists in chronic kidney disease</span></div><div class="casAuthors">Kohan, Donald E.; Barton, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">896-904</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension accounting for the majority of cases, is on the rise, with up to 160 million individuals worldwide predicted to be affected by 2020.  Given that current treatment options, primarily targeted at the renin-angiotensin system, only modestly slow down progression to end-stage renal disease, the urgent need for addnl. effective therapeutics is evident.  Endothelin-1 (ET-1), largely through activation of endothelin A receptors, has been strongly implicated in renal cell injury, proteinuria, inflammation, and fibrosis leading to CKD.  Endothelin receptor antagonists (ERAs) have been demonstrated to ameliorate or even reverse renal injury and/or fibrosis in exptl. models of CKD, whereas clin. trials indicate a substantial antiproteinuric effect of ERAs in diabetic and nondiabetic CKD patients even on top of maximal renin-angiotensin system blockade.  This review summarizes the role of ET in CKD pathogenesis and discusses the potential therapeutic benefit of targeting the ET system in CKD, with attention to the risks and benefits of such an approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_WvqbVbFpLbVg90H21EOLACvtfcHk0lgd1_7Q8CgLHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsl2nsro%253D&md5=b839dd0254aa519bc4707fbe784e464c</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fki.2014.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2014.143%26sid%3Dliteratum%253Aachs%26aulast%3DKohan%26aufirst%3DD.%2BE.%26aulast%3DBarton%26aufirst%3DM.%26atitle%3DEndothelin%2520and%2520Endothelin%2520Antagonists%2520in%2520Chronic%2520Kidney%2520Disease%26jtitle%3DKidney%2520Int.%26date%3D2014%26volume%3D86%26spage%3D896%26epage%3D904%26doi%3D10.1038%2Fki.2014.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Murugesan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadnis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tellew, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baska, R. A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monshizadegan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowala, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macor, J. E.</span><span> </span><span class="NLM_article-title">Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2<i>â²</i>-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">â</span> <span class="NLM_lpage">179</span><span class="refDoi">Â DOI: 10.1021/jm049548x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049548x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=171-179&author=N.+Murugesanauthor=Z.+Guauthor=L.+Fadnisauthor=J.+E.+Tellewauthor=R.+A.+F.+Baskaauthor=Y.+Yangauthor=S.+M.+Beyerauthor=H.+Monshizadeganauthor=K.+E.+Dickinsonauthor=M.+T.+Valentineauthor=W.+G.+Humphreysauthor=S.+J.+Lanauthor=W.+R.+Ewingauthor=K.+E.+Carlsonauthor=M.+C.+Kowalaauthor=R.+Zahlerauthor=J.+E.+Macor&title=Dual+Angiotensin+II+and+Endothelin+A+Receptor+Antagonists%3A+Synthesis+of+2%E2%80%B2-Substituted+N-3-Isoxazolyl+Biphenylsulfonamides+with+Improved+Potency+and+Pharmacokinetics&doi=10.1021%2Fjm049548x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2'-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics</span></div><div class="casAuthors">Murugesan, Natesan; Gu, Zhengxiang; Fadnis, Leena; Tellew, John E.; Baska, Rose Ann F.; Yang, Yifan; Beyer, Sophie M.; Monshizadegan, Hossain; Dickinson, Kenneth E.; Valentine, Maria T.; Humphreys, W. Griffith; Lan, Shih-Jung; Ewing, William R.; Carlson, Kenneth E.; Kowala, Mark C.; Zahler, Robert; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previous report its was demonstrated that merging together key structural elements present in an AT1 receptor antagonist (irbesartan) with key structural elements in a biphenylsulfonamide ETA receptor antagonist followed by addnl. optimization provided a product which is a dual-action receptor antagonist (DARA), which potently blocked both AT1 and ETA receptors.  Described herein are our efforts directed toward improving both the pharmacokinetic profile as well as the AT1 and ETA receptor potency of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-2-sulfonamide (I).  Efforts centered on modifying the 2'-side chain of I and examg. the (isoxazolyl)sulfonamide moiety in I.  This effort resulted in the discovery of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)[1,1'-biphenyl]-2-sulfonamide (II) as a highly potent second-generation DARA.  This compd. also showed substantially improved pharmacokinetic properties compared to I.  In rats, DARA II reduced blood pressure elevations caused by i.v. infusion of Ang II or big ET-1 to a greater extent and with longer duration than DARA I or AT1 or ETA receptor antagonists alone.  II clearly demonstrated superiority over irbesartan (an AT1 receptor antagonist) in the normal SHR model of hypertension in a dose-dependent manner, demonstrating the synergy of AT1 and ETA receptor blockade in a single mol.  The crystal and mol. structures of II were reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2G8_AfjEVOrVg90H21EOLACvtfcHk0lhcsdPVwZpO9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO&md5=d4e66dc82cd65970cde8ca8f3094c8c6</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fjm049548x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049548x%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DFadnis%26aufirst%3DL.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DBaska%26aufirst%3DR.%2BA.%2BF.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBeyer%26aufirst%3DS.%2BM.%26aulast%3DMonshizadegan%26aufirst%3DH.%26aulast%3DDickinson%26aufirst%3DK.%2BE.%26aulast%3DValentine%26aufirst%3DM.%2BT.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DLan%26aufirst%3DS.%2BJ.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DKowala%26aufirst%3DM.%2BC.%26aulast%3DZahler%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DDual%2520Angiotensin%2520II%2520and%2520Endothelin%2520A%2520Receptor%2520Antagonists%253A%2520Synthesis%2520of%25202%25E2%2580%25B2-Substituted%2520N-3-Isoxazolyl%2520Biphenylsulfonamides%2520with%2520Improved%2520Potency%2520and%2520Pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D171%26epage%3D179%26doi%3D10.1021%2Fjm049548x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of 4<i>â²</i>-(Benzimidazole-1-yl)methylbiphenyl-2-sulfonamide Derivatives as Dual Angiotensin II/Endothelin a Receptor Antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4661</span><span class="NLM_x">â</span> <span class="NLM_lpage">4667</span><span class="refDoi">Â DOI: 10.1016/j.bmc.2012.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.bmc.2012.06.011" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4661-4667&author=R.+Baiauthor=Z.+Weiauthor=J.+Liuauthor=W.+Xieauthor=H.+Yaoauthor=X.+Wuauthor=J.+Jiangauthor=Q.+Wangauthor=J.+Xu&title=Synthesis+and+Biological+Evaluation+of+4%E2%80%B2-%28Benzimidazole-1-yl%29methylbiphenyl-2-sulfonamide+Derivatives+as+Dual+Angiotensin+II%2FEndothelin+a+Receptor+Antagonists&doi=10.1016%2Fj.bmc.2012.06.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%25204%25E2%2580%25B2-%2528Benzimidazole-1-yl%2529methylbiphenyl-2-sulfonamide%2520Derivatives%2520as%2520Dual%2520Angiotensin%2520II%252FEndothelin%2520a%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D4661%26epage%3D4667%26doi%3D10.1016%2Fj.bmc.2012.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Macdonald, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashida, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molyneux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raabe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vajkoczy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanke, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowbakht, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassell, N.</span><span> </span><span class="NLM_article-title">Randomized Trial of Clazosentan in Patients with Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling</span> <span class="citation_source-journal">Stroke</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1463</span><span class="NLM_x">â</span> <span class="NLM_lpage">1469</span><span class="refDoi">Â DOI: 10.1161/STROKEAHA.111.648980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1161%2FSTROKEAHA.111.648980" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2012&pages=1463-1469&author=R.+L.+Macdonaldauthor=R.+T.+Higashidaauthor=E.+Kellerauthor=S.+A.+Mayerauthor=A.+Molyneuxauthor=A.+Raabeauthor=P.+Vajkoczyauthor=I.+Wankeauthor=D.+Bachauthor=A.+Freyauthor=P.+Nowbakhtauthor=S.+Rouxauthor=N.+Kassell&title=Randomized+Trial+of+Clazosentan+in+Patients+with+Aneurysmal+Subarachnoid+Hemorrhage+Undergoing+Endovascular+Coiling&doi=10.1161%2FSTROKEAHA.111.648980"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1161%2FSTROKEAHA.111.648980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FSTROKEAHA.111.648980%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DR.%2BL.%26aulast%3DHigashida%26aufirst%3DR.%2BT.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DMayer%26aufirst%3DS.%2BA.%26aulast%3DMolyneux%26aufirst%3DA.%26aulast%3DRaabe%26aufirst%3DA.%26aulast%3DVajkoczy%26aufirst%3DP.%26aulast%3DWanke%26aufirst%3DI.%26aulast%3DBach%26aufirst%3DD.%26aulast%3DFrey%26aufirst%3DA.%26aulast%3DNowbakht%26aufirst%3DP.%26aulast%3DRoux%26aufirst%3DS.%26aulast%3DKassell%26aufirst%3DN.%26atitle%3DRandomized%2520Trial%2520of%2520Clazosentan%2520in%2520Patients%2520with%2520Aneurysmal%2520Subarachnoid%2520Hemorrhage%2520Undergoing%2520Endovascular%2520Coiling%26jtitle%3DStroke%26date%3D2012%26volume%3D43%26spage%3D1463%26epage%3D1469%26doi%3D10.1161%2FSTROKEAHA.111.648980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Donate, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verri, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junta, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lima, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peres, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bombonato-Prado, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louzada, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donadi, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passos, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, F. Q.</span><span> </span><span class="NLM_article-title">Bosentan, an Endothelin Receptor Antagonist, Ameliorates Collagen-induced Arthritis: The Role of TNF-Î± in the Induction of Endothelin System Genes</span> <span class="citation_source-journal">Inflammation Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">â</span> <span class="NLM_lpage">348</span><span class="refDoi">Â DOI: 10.1007/s00011-011-0415-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00011-011-0415-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22249931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1eks74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=337-348&author=P.+B.+Donateauthor=T.+M.+Cunhaauthor=W.+A.+Verriauthor=C.+M.+Juntaauthor=F.+O.+Limaauthor=S.+M.+Vieiraauthor=R.+S.+Peresauthor=K.+F.+Bombonato-Pradoauthor=P.+Louzadaauthor=S.+H.+Ferreiraauthor=E.+A.+Donadiauthor=G.+A.+Passosauthor=F.+Q.+Cunha&title=Bosentan%2C+an+Endothelin+Receptor+Antagonist%2C+Ameliorates+Collagen-induced+Arthritis%3A+The+Role+of+TNF-%CE%B1+in+the+Induction+of+Endothelin+System+Genes&doi=10.1007%2Fs00011-011-0415-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Bosentan, an endothelin receptor antagonist, ameliorates collagen-induced arthritis: the role of TNF-Î± in the induction of endothelin system genes</span></div><div class="casAuthors">Donate, Paula B.; Cunha, Thiago M.; Verri, Waldiceu A., Jr.; Junta, Cristina M.; Lima, Flavia O.; Vieira, Silvio M.; Peres, Rafael S.; Bombonato-Prado, Karina F.; Louzada, Paulo, Jr.; Ferreira, Sergio H.; Donadi, Eduardo A.; Passos, Geraldo A. S.; Cunha, Fernando Q.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-348</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Endothelins (ETs) are involved in several inflammatory events.  The present study investigated the efficacy of bosentan, a dual ETA/ETB receptor antagonist, in collagen-induced arthritis (CIA) in mice.  Treatment CIA was induced in DBA/1J mice.  Arthritic mice were treated with bosentan (100 mg/kg) once a day, starting from the day when arthritis was clin. detectable.  CIA progression was assessed by measurements of visual clin. score, paw swelling and hypernociception.  Histol. changes, neutrophil infiltration and pro-inflammatory cytokines were evaluated in the joints.  Gene expression in the lymph nodes of arthritic mice was evaluated by microarray technol.  PreproET-1 mRNA expression in the lymph nodes of mice and in peripheral blood mononuclear cells (PBMCs) was evaluated by real-time PCR.  The differences were evaluated by one-way ANOVA or Student's t test.  Oral treatment with bosentan markedly ameliorated the clin. aspects of CIA (visual clin. score, paw swelling and hyperalgesia).  Bosentan treatment also reduced joint damage, leukocyte infiltration and pro-inflammatory cytokine levels (IL-1Î², TNFÎ± and IL-17) in the joint tissues.  Changes in gene expression in the lymph nodes of arthritic mice returned to the levels of the control mice after bosentan treatment.  PreproET mRNA expression increased in PBMCs from rheumatoid arthritis (RA) patients but returned to basal level in PBMCs from patients under anti-TNF therapy.  In-vitro treatment of PBMCs with TNFÎ± upregulated ET system genes.  These findings indicate that ET receptor antagonists, such as bosentan, might be useful in controlling RA.  Moreover, it seems that ET mediation of arthritis is triggered by TNFÎ±.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYw3uModkXmrVg90H21EOLACvtfcHk0lhcsdPVwZpO9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1eks74%253D&md5=633fb63a37acb2d0fa40aea74a85dfc0</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1007%2Fs00011-011-0415-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00011-011-0415-5%26sid%3Dliteratum%253Aachs%26aulast%3DDonate%26aufirst%3DP.%2BB.%26aulast%3DCunha%26aufirst%3DT.%2BM.%26aulast%3DVerri%26aufirst%3DW.%2BA.%26aulast%3DJunta%26aufirst%3DC.%2BM.%26aulast%3DLima%26aufirst%3DF.%2BO.%26aulast%3DVieira%26aufirst%3DS.%2BM.%26aulast%3DPeres%26aufirst%3DR.%2BS.%26aulast%3DBombonato-Prado%26aufirst%3DK.%2BF.%26aulast%3DLouzada%26aufirst%3DP.%26aulast%3DFerreira%26aufirst%3DS.%2BH.%26aulast%3DDonadi%26aufirst%3DE.%2BA.%26aulast%3DPassos%26aufirst%3DG.%2BA.%26aulast%3DCunha%26aufirst%3DF.%2BQ.%26atitle%3DBosentan%252C%2520an%2520Endothelin%2520Receptor%2520Antagonist%252C%2520Ameliorates%2520Collagen-induced%2520Arthritis%253A%2520The%2520Role%2520of%2520TNF-%25CE%25B1%2520in%2520the%2520Induction%2520of%2520Endothelin%2520System%2520Genes%26jtitle%3DInflammation%2520Res.%26date%3D2012%26volume%3D61%26spage%3D337%26epage%3D348%26doi%3D10.1007%2Fs00011-011-0415-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Freeman, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machado, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanowitz, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desruisseaux, M. S.</span><span> </span><span class="NLM_article-title">Endothelin-1 and Its Role in the Pathogenesis of Infectious Diseases</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">â</span> <span class="NLM_lpage">119</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2014.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.lfs.2014.04.021" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=110-119&author=B.+D.+Freemanauthor=F.+S.+Machadoauthor=H.+B.+Tanowitzauthor=M.+S.+Desruisseaux&title=Endothelin-1+and+Its+Role+in+the+Pathogenesis+of+Infectious+Diseases&doi=10.1016%2Fj.lfs.2014.04.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2014.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2014.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DB.%2BD.%26aulast%3DMachado%26aufirst%3DF.%2BS.%26aulast%3DTanowitz%26aufirst%3DH.%2BB.%26aulast%3DDesruisseaux%26aufirst%3DM.%2BS.%26atitle%3DEndothelin-1%2520and%2520Its%2520Role%2520in%2520the%2520Pathogenesis%2520of%2520Infectious%2520Diseases%26jtitle%3DLife%2520Sci.%26date%3D2014%26volume%3D118%26spage%3D110%26epage%3D119%26doi%3D10.1016%2Fj.lfs.2014.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Suekane, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitabayashi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naruko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oshitani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanzawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirakawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, M.</span><span> </span><span class="NLM_article-title">Enhanced Expression of Endothelin-converting Enzyme and Endothelin Receptors in Human Colonic Tissues of Crohnâs Disease</span> <span class="citation_source-journal">J. Clin. Biochem. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">126</span><span class="NLM_x">â</span> <span class="NLM_lpage">132</span><span class="refDoi">Â DOI: 10.3164/jcbn.2008018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.3164%2Fjcbn.2008018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=18385829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BD1c3is1Kluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2008&pages=126-132&author=T.+Suekaneauthor=Y.+Ikuraauthor=J.+Arimotoauthor=M.+Nakagawaauthor=C.+Kitabayashiauthor=T.+Narukoauthor=T.+Watanabeauthor=Y.+Fujiwaraauthor=N.+Oshitaniauthor=K.+Maedaauthor=K.+Tanzawaauthor=K.+Hirakawaauthor=T.+Arakawaauthor=M.+Ueda&title=Enhanced+Expression+of+Endothelin-converting+Enzyme+and+Endothelin+Receptors+in+Human+Colonic+Tissues+of+Crohn%E2%80%99s+Disease&doi=10.3164%2Fjcbn.2008018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced expressions of endothelin-converting enzyme and endothelin receptors in human colonic tissues of Crohn's disease</span></div><div class="casAuthors">Suekane Takehisa; Ikura Yoshihiro; Arimoto Junko; Nakagawa Masashi; Kitabayashi Chizuko; Naruko Takahiko; Watanabe Toshio; Fujiwara Yasuhiro; Oshitani Nobuhide; Maeda Kiyoshi; Tanzawa Kazuhiko; Hirakawa Kosei; Arakawa Tetsuo; Ueda Makiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical biochemistry and nutrition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-32</span>
        ISSN:<span class="NLM_cas:issn">0912-0009</span>.
    </div><div class="casAbstract">Endothelin-1, a powerful vasoconstrictor, forms the endothelin system together with endothelin-converting enzyme and endothelin type A and type B receptors.  These endothelin system components are considered to participate in inflammatory and wound healing responses.  Previous reports have suggested a role for the endothelin-1 in the pathology of Crohn's disease.  In the present study, we immunohistochemically investigated the expressions of the endothelin system components in affected human intestinal tissues of Crohn's disease.  Eighteen surgical specimens of colonic tissue obtained from patients with Crohn's disease and 12 normal colonic tissues as controls were examined.  Frozen tissue sections cut from the samples were subjected to the immunohistochemical single and double staining.  The endothelin system components were expressed mainly in the muscular layers and blood vessels.  In diseased colonic tissues, inflammatory infiltration and fibrotic tissue reactions with marked smooth muscle cell proliferation were frequently seen, and were closely associated with increased expressions of the endothelin system components.  These results strongly suggest that endothelin-converting enzyme and endothelin type A and type B receptors collectively play a role in the inflammatory and fibrogenic processes of Crohn's disease.  Especially, submucosal smooth muscle proliferation, a histological hallmark of strictures, may be attributable to the upregulated endothelin system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkpeTSiwkiwCsZ1x6zOs0vfW6udTcc2ea-rx5c7kauhrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3is1Kluw%253D%253D&md5=1778d3bb28fcebf735237b0c47302436</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.3164%2Fjcbn.2008018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3164%252Fjcbn.2008018%26sid%3Dliteratum%253Aachs%26aulast%3DSuekane%26aufirst%3DT.%26aulast%3DIkura%26aufirst%3DY.%26aulast%3DArimoto%26aufirst%3DJ.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DKitabayashi%26aufirst%3DC.%26aulast%3DNaruko%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DOshitani%26aufirst%3DN.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DTanzawa%26aufirst%3DK.%26aulast%3DHirakawa%26aufirst%3DK.%26aulast%3DArakawa%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DM.%26atitle%3DEnhanced%2520Expression%2520of%2520Endothelin-converting%2520Enzyme%2520and%2520Endothelin%2520Receptors%2520in%2520Human%2520Colonic%2520Tissues%2520of%2520Crohn%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Clin.%2520Biochem.%2520Nutr.%26date%3D2008%26volume%3D42%26spage%3D126%26epage%3D132%26doi%3D10.3164%2Fjcbn.2008018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Kowalczyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleniewska, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolodziejczyk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skibska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goraca, A.</span><span> </span><span class="NLM_article-title">The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis</span> <span class="citation_source-journal">Arch. Immunol. Ther. Exp.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">â</span> <span class="NLM_lpage">52</span><span class="refDoi">Â DOI: 10.1007/s00005-014-0310-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00005-014-0310-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=25288367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslCis7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=41-52&author=A.+Kowalczykauthor=P.+Kleniewskaauthor=M.+Kolodziejczykauthor=B.+Skibskaauthor=A.+Goraca&title=The+Role+of+Endothelin-1+and+Endothelin+Receptor+Antagonists+in+Inflammatory+Response+and+Sepsis&doi=10.1007%2Fs00005-014-0310-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis</span></div><div class="casAuthors">Kowalczyk, Agata; Kleniewska, Paulina; Kolodziejczyk, Michal; Skibska, Beata; Goraca, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Archivum Immunologiae et Therapiae Experimentalis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-52</span>CODEN:
                <span class="NLM_cas:coden">AITEAT</span>;
        ISSN:<span class="NLM_cas:issn">0004-069X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor, mainly secreted by endothelial cells.  It acts through two types of receptors: ETA and ETB.  Apart from a vasoconstrictive action, ET-1 causes fibrosis of the vascular cells and stimulates prodn. of reactive oxygen species.  It is claimed that ET-1 induces proinflammatory mechanisms, increasing superoxide anion prodn. and cytokine secretion.  A recent study has shown that ET-1 is involved in the activation of transcription factors such as NF-ÎºB and expression of proinflammatory cytokines including TNF-Î±, IL-1, and IL-6.  It has been also indicated that during endotoxemia, the plasma level of ET-1 is increased in various animal species.  Some authors indicate a clear correlation between endothelin plasma level and morbidity/mortality rate in septic patients.  These pathol. effects of ET-1 may be abrogated at least partly by endothelin receptor blockade.  ET-1 receptor antagonists may be useful for prevention of various vascular diseases.  This review summarizes the current knowledge regarding endothelin receptor antagonists and the role of ET-1 in sepsis and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp42UEJnkObarVg90H21EOLACvtfcHk0liATDw69hozyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslCis7%252FM&md5=3ebd9c077169c1b10d1fa095a762e671</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1007%2Fs00005-014-0310-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00005-014-0310-1%26sid%3Dliteratum%253Aachs%26aulast%3DKowalczyk%26aufirst%3DA.%26aulast%3DKleniewska%26aufirst%3DP.%26aulast%3DKolodziejczyk%26aufirst%3DM.%26aulast%3DSkibska%26aufirst%3DB.%26aulast%3DGoraca%26aufirst%3DA.%26atitle%3DThe%2520Role%2520of%2520Endothelin-1%2520and%2520Endothelin%2520Receptor%2520Antagonists%2520in%2520Inflammatory%2520Response%2520and%2520Sepsis%26jtitle%3DArch.%2520Immunol.%2520Ther.%2520Exp.%26date%3D2015%26volume%3D63%26spage%3D41%26epage%3D52%26doi%3D10.1007%2Fs00005-014-0310-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span> </span><span class="NLM_article-title">Targeting Endothelin Receptors A and B Attenuates the Inflammatory Response and Improves Locomotor Function Following Spinal Cord Injury in Mice</span> <span class="citation_source-journal">Int. J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">74</span><span class="NLM_x">â</span> <span class="NLM_lpage">82</span><span class="refDoi">Â DOI: 10.3892/ijmm.2014.1751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.3892%2Fijmm.2014.1751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24756152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlyktbvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=74-82&author=J.+Guoauthor=Y.+Liauthor=Z.+Heauthor=B.+Zhangauthor=Y.+Liauthor=J.+Huauthor=M.+Hanauthor=Y.+Xuauthor=Y.+Liauthor=J.+Guauthor=B.+Daiauthor=Z.+Chen&title=Targeting+Endothelin+Receptors+A+and+B+Attenuates+the+Inflammatory+Response+and+Improves+Locomotor+Function+Following+Spinal+Cord+Injury+in+Mice&doi=10.3892%2Fijmm.2014.1751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting endothelin receptors A and B attenuates the inflammatory response and improves locomotor function following spinal cord injury in mice</span></div><div class="casAuthors">Guo, Jian; Li, Yiqiao; He, Zhennian; Zhang, Bin; Li, Yonghuan; Hu, Jianghua; Han, Mingyuan; Xu, Yuanlin; Li, Yongfu; Gu, Jie; Dai, Bo; Chen, Zhong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-82</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">After spinal cord injury (SCI), the disruption of blood-spinal cord barrier by activation of the endothelin (ET) system is a crit. event leading to leukocyte infiltration, inflammatory response and oxidative stress, contributing to neurol. disability.  In the present study, we showed that blockade of ET receptor A (ETAR) and/or ET receptor B (ETBR) prevented early inflammatory responses directly via the inhibition of neutrophil and monocyte diapedesis and inflammatory mediator prodn. following traumatic SCI in mice.  Long-term neurol. improvement, based on a series of tests of locomotor performance, occurred only in the spinal cord-injured mice following blockade of ETAR and ETBR.  We also examd. the post-traumatic changes of the microenvironment within the injured spinal cord of mice following blockade of ET receptors.  Oxidative stress reflects an imbalance between malondialdehyde and superoxide dismutase in spinal cord-injured mice treated with vehicle, whereas blockade of ETAR and ETBR reversed the oxidn. state imbalance.  In addn., hemeoxygenase-1, a protective protease involved in early SCI, was increased in spinal cord-injured mice following the blockade of ETAR and ETBR, or only ETBR.  Matrix metalloproteinase-9, a tissue-destructive protease involved in early damage, was decreased in the injured spinal cord of mice following blockade of ETAR, ETBR or a combination thereof.  The findings of the present study therefore suggested an assocn. between ETAR and ETBR in regulating early pathogenesis of SCI and detg. the outcomes of long-term neurol. recovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqi9-6bl8Kt7Vg90H21EOLACvtfcHk0liHOsCbIuGh0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlyktbvF&md5=a392f903b924d80f21846c3c7c26ae26</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.3892%2Fijmm.2014.1751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijmm.2014.1751%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DTargeting%2520Endothelin%2520Receptors%2520A%2520and%2520B%2520Attenuates%2520the%2520Inflammatory%2520Response%2520and%2520Improves%2520Locomotor%2520Function%2520Following%2520Spinal%2520Cord%2520Injury%2520in%2520Mice%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2014%26volume%3D34%26spage%3D74%26epage%3D82%26doi%3D10.3892%2Fijmm.2014.1751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group">Reichetzeder, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuprykov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocher, B.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists in Clinical Research-lessons Learned from Preclinical and Clinical Kidney Studies</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">â</span> <span class="NLM_lpage">148</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2014.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.lfs.2014.02.025" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=141-148&author=C.+Reichetzederauthor=O.+Tsuprykovauthor=B.+Hocher&title=Endothelin+Receptor+Antagonists+in+Clinical+Research-lessons+Learned+from+Preclinical+and+Clinical+Kidney+Studies&doi=10.1016%2Fj.lfs.2014.02.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2014.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2014.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DReichetzeder%26aufirst%3DC.%26aulast%3DTsuprykov%26aufirst%3DO.%26aulast%3DHocher%26aufirst%3DB.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%2520in%2520Clinical%2520Research-lessons%2520Learned%2520from%2520Preclinical%2520and%2520Clinical%2520Kidney%2520Studies%26jtitle%3DLife%2520Sci.%26date%3D2014%26volume%3D118%26spage%3D141%26epage%3D148%26doi%3D10.1016%2Fj.lfs.2014.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group">Remuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perico, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benigni, A.</span><span> </span><span class="NLM_article-title">New Therapeutics that Antagonize Endothelin: Promises and Frustrations</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">986</span><span class="NLM_x">â</span> <span class="NLM_lpage">1001</span><span class="refDoi">Â DOI: 10.1038/nrd962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fnrd962" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=986-1001&author=G.+Remuzziauthor=N.+Pericoauthor=A.+Benigni&title=New+Therapeutics+that+Antagonize+Endothelin%3A+Promises+and+Frustrations&doi=10.1038%2Fnrd962"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fnrd962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd962%26sid%3Dliteratum%253Aachs%26aulast%3DRemuzzi%26aufirst%3DG.%26aulast%3DPerico%26aufirst%3DN.%26aulast%3DBenigni%26aufirst%3DA.%26atitle%3DNew%2520Therapeutics%2520that%2520Antagonize%2520Endothelin%253A%2520Promises%2520and%2520Frustrations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D986%26epage%3D1001%26doi%3D10.1038%2Fnrd962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Gagliardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoja, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benigni, A.</span><span> </span><span class="NLM_article-title">ET and Diabetic Nephropathy: Preclinical and Clinical Studies</span> <span class="citation_source-journal">Semin. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">â</span> <span class="NLM_lpage">196</span><span class="refDoi">Â DOI: 10.1016/j.semnephrol.2015.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.semnephrol.2015.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=25966350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhslOrsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=188-196&author=E.+Gagliardiniauthor=C.+Zojaauthor=A.+Benigni&title=ET+and+Diabetic+Nephropathy%3A+Preclinical+and+Clinical+Studies&doi=10.1016%2Fj.semnephrol.2015.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Et and diabetic nephropathy: preclinical and clinical studies</span></div><div class="casAuthors">Gagliardini Elena; Zoja Carlamaria; Benigni Ariela</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in nephrology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The incidence of progressive kidney disease associated with diabetes continues to increase worldwide.  Only partial renoprotection is achieved by current standard therapy with angiotensin-converting enzyme inhibitors and/or angiotensin-receptor blockers, increasing the need for novel therapeutic approaches.  Experimental studies have provided evidence of a pathogenic role for endothelin-1 (ET-1) and its cognate receptors in the development and progression of diabetic nephropathy.  ET-1, mainly through the activation of ETA receptor, contributes to renal cell injury, inflammation, and fibrosis.  In animal models of type 1 and type 2 diabetes, ETA-selective antagonists have been shown to provide renoprotective effects, supplying the rationale for clinical trials in patients with diabetic nephropathy with ETA-receptor antagonists administered in addition to renin-angiotensin system blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnSdLVzfLCnbesJRIHUP1ofW6udTcc2eYFkF9YqAMRsLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhslOrsg%253D%253D&md5=cbea1b55345cf9294a9616d55331211a</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.semnephrol.2015.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semnephrol.2015.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DGagliardini%26aufirst%3DE.%26aulast%3DZoja%26aufirst%3DC.%26aulast%3DBenigni%26aufirst%3DA.%26atitle%3DET%2520and%2520Diabetic%2520Nephropathy%253A%2520Preclinical%2520and%2520Clinical%2520Studies%26jtitle%3DSemin.%2520Nephrol.%26date%3D2015%26volume%3D35%26spage%3D188%26epage%3D196%26doi%3D10.1016%2Fj.semnephrol.2015.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">Maguire, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="2d684349425945484144436d1f18">[emailÂ protected]</a> - New Agonists, Antagonists, Inhibitors and Emerging Research Frontiers: IUPHAR Review 12</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">5555</span><span class="NLM_x">â</span> <span class="NLM_lpage">5572</span><span class="refDoi">Â DOI: 10.1111/bph.12874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fbph.12874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=25131455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVamtLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=5555-5572&author=J.+J.+Maguireauthor=A.+P.+Davenport&title=Endothelin%4025+-+New+Agonists%2C+Antagonists%2C+Inhibitors+and+Emerging+Research+Frontiers%3A+IUPHAR+Review+12&doi=10.1111%2Fbph.12874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="6d280309021905080104032d5f58">[emailÂ protected]</a> - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12</span></div><div class="casAuthors">Maguire, J. J.; Davenport, A. P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5555-5572</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Since the discovery of endothelin (ET)-1 in 1988, the main components of the signalling pathway have become established, comprising three structurally similar endogenous 21-amino acid peptides, ET-1, ET-2 and ET-3, that activate two GPCRs, ETA and ETB.  Our aim in this review is to highlight the recent progress in ET research.  The ET-like domain peptide, corresponding to prepro-ET-193-166, has been proposed to be co-synthesized and released with ET-1, to modulate the actions of the peptide.  ET-1 remains the most potent vasoconstrictor in the human cardiovascular system with a particularly long-lasting action.  To date, the major therapeutic strategy to block the unwanted actions of ET in disease, principally in pulmonary arterial hypertension, has been to use antagonists that are selective for the ETA receptor (ambrisentan) or that block both receptor subtypes (bosentan).  Macitentan represents the next generation of antagonists, being more potent than bosentan, with longer receptor occupancy and it is converted to an active metabolite; properties contributing to greater pharmacodynamic and pharmacokinetic efficacy.  A second strategy is now being more widely tested in clin. trials and uses combined inhibitors of ET-converting enzyme and neutral endopeptidase such as SLV306 (daglutril).  A third strategy based on activating the ETB receptor, has led to the renaissance of the modified peptide agonist IRL1620 as a clin. candidate in delivering anti-tumor drugs and as a pharmacol. tool to investigate exptl. pathophysiol. conditions.  Finally, we discuss biased signalling, epigenetic regulation and targeting with monoclonal antibodies as prospective new areas for ET research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0sVvlUszqFrVg90H21EOLACvtfcHk0liHOsCbIuGh0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVamtLjE&md5=fa0c85b807532f68e298675218239332</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1111%2Fbph.12874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12874%26sid%3Dliteratum%253Aachs%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DEndothelin%254025%2520-%2520New%2520Agonists%252C%2520Antagonists%252C%2520Inhibitors%2520and%2520Emerging%2520Research%2520Frontiers%253A%2520IUPHAR%2520Review%252012%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D5555%26epage%3D5572%26doi%3D10.1111%2Fbph.12874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wei Zheng, Zhen Wang, Xiangrui Jiang, Qingjie Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Jingshan Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15153-15186. <a href="https://doi.org/10.1021/acs.jmedchem.0c01093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BDrugs%252Bfor%252BTreatment%252Bof%252BPulmonary%252BArterial%252BHypertension%25253A%252BPast%25252C%252BPresent%25252C%252Band%252BFuture%252BPerspectives%26aulast%3DZheng%26aufirst%3DWei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26062020%26date%3D14122020%26volume%3D63%26issue%3D24%26spage%3D15153%26epage%3D15186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lucienne Juillerat-Jeanneret, John-David Aubert, Josip Mikulic, <span class="NLM_string-name hlFld-ContribAuthor">Dela Golshayan</span>. </span><span class="cited-content_cbyCitation_article-title">Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 9811-9840. <a href="https://doi.org/10.1021/acs.jmedchem.8b00294" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00294</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00294%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFibrogenic%252BDisorders%252Bin%252BHuman%252BDiseases%25253A%252BFrom%252BInflammation%252Bto%252BOrgan%252BDysfunction%26aulast%3DJuillerat-Jeanneret%26aufirst%3DLucienne%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D21022018%26date%3D17072018%26date%3D03072018%26volume%3D61%26issue%3D22%26spage%3D9811%26epage%3D9840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liang Tan, Wenzhong Yan, John D. McCorvy, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Biased Ligands of G Protein-Coupled Receptors (GPCRs): StructureâFunctional Selectivity Relationships (SFSRs) and Therapeutic Potential. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 9841-9878. <a href="https://doi.org/10.1021/acs.jmedchem.8b00435" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00435%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBiased%252BLigands%252Bof%252BG%252BProtein-Coupled%252BReceptors%252B%252528GPCRs%252529%25253A%252BStructure%2525E2%252580%252593Functional%252BSelectivity%252BRelationships%252B%252528SFSRs%252529%252Band%252BTherapeutic%252BPotential%26aulast%3DTan%26aufirst%3DLiang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D10072018%26date%3D25062018%26volume%3D61%26issue%3D22%26spage%3D9841%26epage%3D9878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marie  Fisk</span>, <span class="hlFld-ContribAuthor ">Magnus  Althage</span>, <span class="hlFld-ContribAuthor ">Sven  Moosmang</span>, <span class="hlFld-ContribAuthor ">Peter J.  Greasley</span>, <span class="hlFld-ContribAuthor ">Andrew P.  Cope</span>, <span class="hlFld-ContribAuthor ">David RW.  Jayne</span>, <span class="hlFld-ContribAuthor ">James  Galloway</span>, <span class="hlFld-ContribAuthor ">Frances  Hall</span>, <span class="hlFld-ContribAuthor ">Ian B.  Wilkinson</span>, <span class="hlFld-ContribAuthor ">Philip  Ambery</span>, <span class="hlFld-ContribAuthor ">Joseph  Cheriyan</span>. </span><span class="cited-content_cbyCitation_article-title">Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. </span><span class="cited-content_cbyCitation_journal-name">Pulmonary Pharmacology & Therapeutics</span><span> <strong>2021,</strong> <em>69 </em>, 102035. <a href="https://doi.org/10.1016/j.pupt.2021.102035" title="DOI URL">https://doi.org/10.1016/j.pupt.2021.102035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pupt.2021.102035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pupt.2021.102035%26sid%3Dliteratum%253Aachs%26jtitle%3DPulmonary%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DEndothelin%252Bantagonism%252Band%252Bsodium%252Bglucose%252BCo-transporter%252B2%252Binhibition.%252BA%252Bpotential%252Bcombination%252Btherapeutic%252Bstrategy%252Bfor%252BCOVID-19%26aulast%3DFisk%26aufirst%3DMarie%26date%3D2021%26volume%3D69%26spage%3D102035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juliano T.  Freitas</span>, <span class="hlFld-ContribAuthor ">Jesus  Lopez</span>, <span class="hlFld-ContribAuthor ">Claudia  Llorian</span>, <span class="hlFld-ContribAuthor ">Mariana  Boroni</span>, <span class="hlFld-ContribAuthor ">Lidia  Kos</span>. </span><span class="cited-content_cbyCitation_article-title">The immunosuppressive role of Edn3 overexpression in the melanoma microenvironment. </span><span class="cited-content_cbyCitation_journal-name">Pigment Cell & Melanoma Research</span><span> <strong>2021,</strong> <em>59 </em><a href="https://doi.org/10.1111/pcmr.13002" title="DOI URL">https://doi.org/10.1111/pcmr.13002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/pcmr.13002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fpcmr.13002%26sid%3Dliteratum%253Aachs%26jtitle%3DPigment%2520Cell%2520%2526%2520Melanoma%2520Research%26atitle%3DThe%252Bimmunosuppressive%252Brole%252Bof%252BEdn3%252Boverexpression%252Bin%252Bthe%252Bmelanoma%252Bmicroenvironment%26aulast%3DFreitas%26aufirst%3DJuliano%2BT.%26date%3D2021%26date%3D2021%26volume%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Dai</span>, <span class="hlFld-ContribAuthor ">Zhihua  Qiu</span>, <span class="hlFld-ContribAuthor ">Wenrui  Ma</span>, <span class="hlFld-ContribAuthor ">Chang  Li</span>, <span class="hlFld-ContribAuthor ">Xiao  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoxiao  Song</span>, <span class="hlFld-ContribAuthor ">Zeyang  Bai</span>, <span class="hlFld-ContribAuthor ">Dingyang  Shi</span>, <span class="hlFld-ContribAuthor ">Jiayu  Zheng</span>, <span class="hlFld-ContribAuthor ">Guangwei  Pan</span>, <span class="hlFld-ContribAuthor ">Yuhua  Liao</span>, <span class="hlFld-ContribAuthor ">Mengyang  Liao</span>, <span class="hlFld-ContribAuthor ">Zihua  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Long-Term Effect of a Vaccine Targeting Endothelin-1 Receptor Type A in Pulmonary Arterial Hypertension. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cardiovascular Medicine</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.3389/fcvm.2021.683436" title="DOI URL">https://doi.org/10.3389/fcvm.2021.683436</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcvm.2021.683436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcvm.2021.683436%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cardiovascular%2520Medicine%26atitle%3DLong-Term%252BEffect%252Bof%252Ba%252BVaccine%252BTargeting%252BEndothelin-1%252BReceptor%252BType%252BA%252Bin%252BPulmonary%252BArterial%252BHypertension%26aulast%3DDai%26aufirst%3DYong%26date%3D2021%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miriam  StÃ¶lting</span>, <span class="hlFld-ContribAuthor ">Christiane  Geyer</span>, <span class="hlFld-ContribAuthor ">Anne  Helfen</span>, <span class="hlFld-ContribAuthor ">Anke  Hahnenkamp</span>, <span class="hlFld-ContribAuthor ">Marco V.  Usai</span>, <span class="hlFld-ContribAuthor ">Eva  Wardelmann</span>, <span class="hlFld-ContribAuthor ">Michael T.  Kuhlmann</span>, <span class="hlFld-ContribAuthor ">Moritz  Wildgruber</span>, <span class="hlFld-ContribAuthor ">Carsten  HÃ¶ltke</span>. </span><span class="cited-content_cbyCitation_article-title">Monitoring Endothelin-A Receptor Expression during the Progression of Atherosclerosis. </span><span class="cited-content_cbyCitation_journal-name">Biomedicines</span><span> <strong>2020,</strong> <em>8 </em>
                                    (12)
                                     , 538. <a href="https://doi.org/10.3390/biomedicines8120538" title="DOI URL">https://doi.org/10.3390/biomedicines8120538</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biomedicines8120538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiomedicines8120538%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicines%26atitle%3DMonitoring%252BEndothelin-A%252BReceptor%252BExpression%252Bduring%252Bthe%252BProgression%252Bof%252BAtherosclerosis%26aulast%3DSt%25C3%25B6lting%26aufirst%3DMiriam%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D12%26spage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongyan  Kong</span>, <span class="hlFld-ContribAuthor ">Jinan  He</span>, <span class="hlFld-ContribAuthor ">Shusen  Guo</span>, <span class="hlFld-ContribAuthor ">Qiqin  Song</span>, <span class="hlFld-ContribAuthor ">Dandan  Xiang</span>, <span class="hlFld-ContribAuthor ">Ran  Tao</span>, <span class="hlFld-ContribAuthor ">Haijing  Yu</span>, <span class="hlFld-ContribAuthor ">Guang  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiyong  Huang</span>, <span class="hlFld-ContribAuthor ">Qin  Ning</span>, <span class="hlFld-ContribAuthor ">Jiaquan  Huang</span>, . </span><span class="cited-content_cbyCitation_article-title">Endothelin receptors promote schistosomiasis-induced hepatic fibrosis via splenic B cells. </span><span class="cited-content_cbyCitation_journal-name">PLOS Pathogens</span><span> <strong>2020,</strong> <em>16 </em>
                                    (10)
                                     , e1008947. <a href="https://doi.org/10.1371/journal.ppat.1008947" title="DOI URL">https://doi.org/10.1371/journal.ppat.1008947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.ppat.1008947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.ppat.1008947%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520Pathogens%26atitle%3DEndothelin%252Breceptors%252Bpromote%252Bschistosomiasis-induced%252Bhepatic%252Bfibrosis%252Bvia%252Bsplenic%252BB%252Bcells%26aulast%3DKong%26aufirst%3DHongyan%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D10%26spage%3De1008947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin-Biao  Xu</span>, <span class="hlFld-ContribAuthor ">Guang-Chun  Gao</span>, <span class="hlFld-ContribAuthor ">Ming-Jing  Yuan</span>, <span class="hlFld-ContribAuthor ">Xuan  Huang</span>, <span class="hlFld-ContribAuthor ">Hong-Yu  Zhou</span>, <span class="hlFld-ContribAuthor ">Yang  Zhang</span>, <span class="hlFld-ContribAuthor ">Ya-Xin  Zheng</span>, <span class="hlFld-ContribAuthor ">Zhe  Wu</span>, <span class="hlFld-ContribAuthor ">Jun-Miao  Feng</span>, <span class="hlFld-ContribAuthor ">Ji-Ming  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Lignans from Schisandra chinensis ameliorate alcohol and CCl4-induced long-term liver injury and reduce hepatocellular degeneration via blocking ETBR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Ethnopharmacology</span><span> <strong>2020,</strong> <em>258 </em>, 112813. <a href="https://doi.org/10.1016/j.jep.2020.112813" title="DOI URL">https://doi.org/10.1016/j.jep.2020.112813</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jep.2020.112813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jep.2020.112813%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Ethnopharmacology%26atitle%3DLignans%252Bfrom%252BSchisandra%252Bchinensis%252Bameliorate%252Balcohol%252Band%252BCCl4-induced%252Blong-term%252Bliver%252Binjury%252Band%252Breduce%252Bhepatocellular%252Bdegeneration%252Bvia%252Bblocking%252BETBR%26aulast%3DXu%26aufirst%3DJin-Biao%26date%3D2020%26volume%3D258%26spage%3D112813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frederik C.  Enevoldsen</span>, <span class="hlFld-ContribAuthor ">Jayashree  Sahana</span>, <span class="hlFld-ContribAuthor ">Markus  Wehland</span>, <span class="hlFld-ContribAuthor ">Daniela  Grimm</span>, <span class="hlFld-ContribAuthor ">Manfred  Infanger</span>, <span class="hlFld-ContribAuthor ">Marcus  KrÃ¼ger</span>. </span><span class="cited-content_cbyCitation_article-title">Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2020,</strong> <em>9 </em>
                                    (3)
                                     , 824. <a href="https://doi.org/10.3390/jcm9030824" title="DOI URL">https://doi.org/10.3390/jcm9030824</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm9030824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm9030824%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DEndothelin%252BReceptor%252BAntagonists%25253A%252BStatus%252BQuo%252Band%252BFuture%252BPerspectives%252Bfor%252BTargeted%252BTherapy%26aulast%3DEnevoldsen%26aufirst%3DFrederik%2BC.%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D3%26spage%3D824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suprit  Gupta</span>, <span class="hlFld-ContribAuthor ">Avi  Prajapati</span>, <span class="hlFld-ContribAuthor ">Mansi  Gulati</span>, <span class="hlFld-ContribAuthor ">Shailendra K.  Gautam</span>, <span class="hlFld-ContribAuthor ">Sushil  Kumar</span>, <span class="hlFld-ContribAuthor ">Vipin  Dalal</span>, <span class="hlFld-ContribAuthor ">Geoffrey A.  Talmon</span>, <span class="hlFld-ContribAuthor ">Satyanarayana  Rachagani</span>, <span class="hlFld-ContribAuthor ">Maneesh  Jain</span>. </span><span class="cited-content_cbyCitation_article-title">Irreversible and sustained upregulation of endothelin axis during oncogene-associated pancreatic inflammation and cancer. </span><span class="cited-content_cbyCitation_journal-name">Neoplasia</span><span> <strong>2020,</strong> <em>22 </em>
                                    (2)
                                     , 98-110. <a href="https://doi.org/10.1016/j.neo.2019.11.001" title="DOI URL">https://doi.org/10.1016/j.neo.2019.11.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neo.2019.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neo.2019.11.001%26sid%3Dliteratum%253Aachs%26jtitle%3DNeoplasia%26atitle%3DIrreversible%252Band%252Bsustained%252Bupregulation%252Bof%252Bendothelin%252Baxis%252Bduring%252Boncogene-associated%252Bpancreatic%252Binflammation%252Band%252Bcancer%26aulast%3DGupta%26aufirst%3DSuprit%26date%3D2020%26volume%3D22%26issue%3D2%26spage%3D98%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julio C.  Tapia</span>, <span class="hlFld-ContribAuthor ">Ignacio  Niechi</span>. </span><span class="cited-content_cbyCitation_article-title">Endothelin-converting enzyme-1 in cancer aggressiveness. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>452 </em>, 152-157. <a href="https://doi.org/10.1016/j.canlet.2019.03.033" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.03.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.03.033%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DEndothelin-converting%252Benzyme-1%252Bin%252Bcancer%252Baggressiveness%26aulast%3DTapia%26aufirst%3DJulio%2BC.%26date%3D2019%26volume%3D452%26spage%3D152%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid I.  Belenâkii</span>, <span class="hlFld-ContribAuthor ">Yulia B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The Literature of Heterocyclic Chemistry, Part XVI, 2016. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 173-254. <a href="https://doi.org/10.1016/bs.aihch.2018.02.003" title="DOI URL">https://doi.org/10.1016/bs.aihch.2018.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2018.02.003%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BLiterature%252Bof%252BHeterocyclic%252BChemistry%25252C%252BPart%252BXVI%25252C%252B2016%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DLeonid%2BI.%26date%3D2018%26spage%3D173%26epage%3D254%26pub%3DElsevier%26date%3D2018%26volume%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcus M  MÃ¼cke</span>, <span class="hlFld-ContribAuthor ">Dominik  Bettenworth</span>, <span class="hlFld-ContribAuthor ">Christiane  Geyer</span>, <span class="hlFld-ContribAuthor ">Katrin  Schwegmann</span>, <span class="hlFld-ContribAuthor ">Christopher  Poremba</span>, <span class="hlFld-ContribAuthor ">Michael  SchÃ¤fers</span>, <span class="hlFld-ContribAuthor ">Dirk  Domagk</span>, <span class="hlFld-ContribAuthor ">Carsten  HÃ¶ltke</span>, <span class="hlFld-ContribAuthor ">Philipp  Lenz</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Mucosal Endothelin-A-Receptor Expression by Fluorescence Endoscopy is Feasible to Detect and Characterize Colitis-Associated Cancer in Mice. </span><span class="cited-content_cbyCitation_journal-name">Inflammatory Bowel Diseases</span><span> <strong>2018,</strong> <em>24 </em>
                                    (1)
                                     , 111-122. <a href="https://doi.org/10.1093/ibd/izx032" title="DOI URL">https://doi.org/10.1093/ibd/izx032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ibd/izx032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fibd%2Fizx032%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammatory%2520Bowel%2520Diseases%26atitle%3DTargeting%252BMucosal%252BEndothelin-A-Receptor%252BExpression%252Bby%252BFluorescence%252BEndoscopy%252Bis%252BFeasible%252Bto%252BDetect%252Band%252BCharacterize%252BColitis-Associated%252BCancer%252Bin%252BMice%26aulast%3DM%25C3%25BCcke%26aufirst%3DMarcus%2BM%26date%3D2018%26date%3D2017%26volume%3D24%26issue%3D1%26spage%3D111%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jale  Yuzugulen</span>, <span class="hlFld-ContribAuthor ">Julie A.  Douthwaite</span>, <span class="hlFld-ContribAuthor ">Elizabeth G.  Wood</span>, <span class="hlFld-ContribAuthor ">Inmaculada C.  Villar</span>, <span class="hlFld-ContribAuthor ">Nimesh S. A.  Patel</span>, <span class="hlFld-ContribAuthor ">James  Jegard</span>, <span class="hlFld-ContribAuthor ">Hubert  Gaertner</span>, <span class="hlFld-ContribAuthor ">IrÃ¨ne  Rossitto-Borlat</span>, <span class="hlFld-ContribAuthor ">Keith  Rose</span>, <span class="hlFld-ContribAuthor ">Oliver  Hartley</span>, <span class="hlFld-ContribAuthor ">Pedro R.  Cutillas</span>, <span class="hlFld-ContribAuthor ">Amrita  Ahluwalia</span>, <span class="hlFld-ContribAuthor ">Roger  Corder</span>. </span><span class="cited-content_cbyCitation_article-title">Characterisation of preproendothelin-1 derived peptides identifies Endothelin-Like Domain Peptide as a modulator of Endothelin-1. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-05365-2" title="DOI URL">https://doi.org/10.1038/s41598-017-05365-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-05365-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-05365-2%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DCharacterisation%252Bof%252Bpreproendothelin-1%252Bderived%252Bpeptides%252Bidentifies%252BEndothelin-Like%252BDomain%252BPeptide%252Bas%252Ba%252Bmodulator%252Bof%252BEndothelin-1%26aulast%3DYuzugulen%26aufirst%3DJale%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikhil  Khadtare</span>, <span class="hlFld-ContribAuthor ">Ralph  Stephani</span>, <span class="hlFld-ContribAuthor ">Vijaya  Korlipara</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acid derivatives as ET A receptor selective antagonists using FRET assay. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (11)
                                     , 2281-2285. <a href="https://doi.org/10.1016/j.bmcl.2017.04.049" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.04.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.04.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252B1%25252C3%25252C6-trisubstituted-4-oxo-1%25252C4-dihydroquinoline-2-carboxylic%252Bacid%252Bderivatives%252Bas%252BET%252BA%252Breceptor%252Bselective%252Bantagonists%252Busing%252BFRET%252Bassay%26aulast%3DKhadtare%26aufirst%3DNikhil%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2281%26epage%3D2285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01781&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Metabolic processing of the components of the endothelin axis and the potential sites of control of the functions of the endothelin axis (insert, 1â7): ET, endothelin; ECE, endothelin converting enzyme 1. Many different types of cells can secrete the ET peptides and express the ET receptors. Following <i>ET</i> gene activation, a precursor polypeptide is sequentially hydrolyzed by a signal peptidase, a furin-like convertase, and then the ECE-1, either by intracellular ECE isoforms or at the cell surface by cell-membrane inserted ECE, to yield the 21-aa active ET. ET can be either constitutively secreted or can be secreted according to a regulated pathway in response to a stimulus. Then, ET acts on two distinct receptors ET<sub>A</sub> and ET<sub>B</sub> to induce intracellular signaling. In this drawing, a paracrine effect of ET is shown; however, the effects of the ET axis may be autocrine or endocrine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01781&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Examples of Endothelin-Receptor Antagonists Based on Chemical Modifications of Previously Developed Compounds</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01781&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/medium/jm-2015-01781t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Dual Angiotensin Type 1 (AT<sub>1</sub>R) and ET<sub>A</sub> Receptors Antagonists</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.5b01781/20160916/images/large/jm-2015-01781t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01781&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i34">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 186 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaid, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaughter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Wit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">CE-1: A Membrane-bound Metalloprotease that Catalyzes the Proteolytic Activation of Big Endothelin-1</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span><span class="NLM_x">â</span> <span class="NLM_lpage">485</span><span class="refDoi">Â DOI: 10.1016/0092-8674(94)90425-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2F0092-8674%2894%2990425-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1994&pages=473-485&author=D.+Xuauthor=N.+Emotoauthor=A.+Giaidauthor=C.+Slaughterauthor=S.+Kawauthor=D.+de+Witauthor=M.+Yanagisawa&title=CE-1%3A+A+Membrane-bound+Metalloprotease+that+Catalyzes+the+Proteolytic+Activation+of+Big+Endothelin-1&doi=10.1016%2F0092-8674%2894%2990425-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2894%2990425-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252894%252990425-1%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DEmoto%26aufirst%3DN.%26aulast%3DGiaid%26aufirst%3DA.%26aulast%3DSlaughter%26aufirst%3DC.%26aulast%3DKaw%26aufirst%3DS.%26aulast%3Dde%2BWit%26aufirst%3DD.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DCE-1%253A%2520A%2520Membrane-bound%2520Metalloprotease%2520that%2520Catalyzes%2520the%2520Proteolytic%2520Activation%2520of%2520Big%2520Endothelin-1%26jtitle%3DCell%26date%3D1994%26volume%3D78%26spage%3D473%26epage%3D485%26doi%3D10.1016%2F0092-8674%2894%2990425-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Russell, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skepper, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title">Human Endothelial Cell Storage Granules: A Novel Intracellular Site for Isoforms of the Endothelin-converting Enzyme</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">â</span> <span class="NLM_lpage">321</span><span class="refDoi">Â DOI: 10.1161/01.RES.83.3.314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1161%2F01.RES.83.3.314" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1998&pages=314-321&author=F.+D.+Russellauthor=J.+N.+Skepperauthor=A.+P.+Davenport&title=Human+Endothelial+Cell+Storage+Granules%3A+A+Novel+Intracellular+Site+for+Isoforms+of+the+Endothelin-converting+Enzyme&doi=10.1161%2F01.RES.83.3.314"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1161%2F01.RES.83.3.314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.83.3.314%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DF.%2BD.%26aulast%3DSkepper%26aufirst%3DJ.%2BN.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DHuman%2520Endothelial%2520Cell%2520Storage%2520Granules%253A%2520A%2520Novel%2520Intracellular%2520Site%2520for%2520Isoforms%2520of%2520the%2520Endothelin-converting%2520Enzyme%26jtitle%3DCirc.%2520Res.%26date%3D1998%26volume%3D83%26spage%3D314%26epage%3D321%26doi%3D10.1161%2F01.RES.83.3.314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">226</span><span class="refDoi">Â DOI: 10.1124/pr.54.2.219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1124%2Fpr.54.2.219" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=219-226&author=A.+P.+Davenport&title=International+Union+of+Pharmacology.+XXIX.+Update+on+Endothelin+Receptor+Nomenclature&doi=10.1124%2Fpr.54.2.219"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.219%26sid%3Dliteratum%253Aachs%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXIX.%2520Update%2520on%2520Endothelin%2520Receptor%2520Nomenclature%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D219%26epage%3D226%26doi%3D10.1124%2Fpr.54.2.219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Yanagisawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomobe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masaki, T.</span><span> </span><span class="NLM_article-title">A Novel Potent Vasoconstrictor Peptide Produced by Vascular Endothelial Cells</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">â</span> <span class="NLM_lpage">415</span><span class="refDoi">Â DOI: 10.1038/332411a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2F332411a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=2451132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaL1cXlsVaks78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=1988&pages=411-415&author=M.+Yanagisawaauthor=H.+Kuriharaauthor=S.+Kimuraauthor=Y.+Tomobeauthor=M.+Kobayashiauthor=Y.+Mitsuiauthor=Y.+Yazakiauthor=K.+Gotoauthor=T.+Masaki&title=A+Novel+Potent+Vasoconstrictor+Peptide+Produced+by+Vascular+Endothelial+Cells&doi=10.1038%2F332411a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A novel potent vasoconstrictor peptide produced by vascular endothelial cells</span></div><div class="casAuthors">Yanagisawa, Masashi; Kurihara, Hiroki; Kimura, Sadao; Tomobe, Yoko; Kobayashi, Mieko; Mitsui, Youji; Yazaki, Yoshio; Goto, Katsutoshi; Masaki, Tomoh</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">6163</span>),
    <span class="NLM_cas:pages">411-15</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">An endothelium-derived 21-residue vasoconstrictor peptide, endothelin, was isolated from the culture supernatant of porcine aortic endothelial cells and was shown to be one of the most potent vasoconstrictors known.  The 50% EC for endothelin on porcine right coronary artery strips was 4.0 Ã 10-10M.  The cloning and sequencing of preproendothelin cDNA showed that mature endothelin is generated through unusual proteolytic processing, and regional homologies to a group of neurotoxins suggested that endothelin is an endogenous modulator of voltage-dependent ion channels.  Expression of the endothelin gene was regulated by several vasoactive agents (thrombin, A 23187, and adrenaline), indicating the existence of a novel cardiovascular control system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBMuYNmuQpM7Vg90H21EOLACvtfcHk0liuTtxP8iEMUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlsVaks78%253D&md5=0f0a5542c8a52f981c8d88bfea1acfbf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F332411a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F332411a0%26sid%3Dliteratum%253Aachs%26aulast%3DYanagisawa%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DTomobe%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DMitsui%26aufirst%3DY.%26aulast%3DYazaki%26aufirst%3DY.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DMasaki%26aufirst%3DT.%26atitle%3DA%2520Novel%2520Potent%2520Vasoconstrictor%2520Peptide%2520Produced%2520by%2520Vascular%2520Endothelial%2520Cells%26jtitle%3DNature%26date%3D1988%26volume%3D332%26spage%3D411%26epage%3D415%26doi%3D10.1038%2F332411a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ling, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maguire, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title">Endothelin-2, the Forgotten Isoform: Emerging Role of Endothelin-2 in the Cardiovascular System, Ovarian Development, Immunology and Cancer</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">168</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">â</span> <span class="NLM_lpage">295</span><span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01786.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fj.1476-5381.2011.01786.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22118774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFOgug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2013&pages=283-295&author=L.+Lingauthor=J.+J.+Maguireauthor=A.+P.+Davenport&title=Endothelin-2%2C+the+Forgotten+Isoform%3A+Emerging+Role+of+Endothelin-2+in+the+Cardiovascular+System%2C+Ovarian+Development%2C+Immunology+and+Cancer&doi=10.1111%2Fj.1476-5381.2011.01786.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer</span></div><div class="casAuthors">Ling, Lowell; Maguire, Janet J.; Davenport, Anthony P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-295</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Endothelin-2 [ET-2; also known as vasoactive intestinal contractor (VIC), in rodents] differs from endothelin-1 (ET-1) by only two amino acids, and unlike the third isoform, endothelin-3 (ET-3), it has the same affinity as ET-1 for both ETA and ETB receptors.  It is often assumed that ET-2 would mimic the actions of the more abundant ET-1 and current pharmacol. interventions used to inhibit the ET system would also block the actions of ET-2.  These assumptions have focused research on ET-1 with ET-2 studied in much less detail.  Recent research suggests that our understanding of the ET family requires re-evaluation.  Although ET-2 is very similar in structure as well as pharmacol. to ET-1, and may co-exist in the same tissue compartments, there is converging evidence for an important and distinct ET-2 pathway.  Specifically is has been demonstrated that ET-2 has a key role in ovarian physiol., with ET-2-mediated contraction proposed as a final signal facilitating ovulation.  Furthermore, ET-2 may also have a pathophysiol. role in heart failure, immunol. and cancer.  Comparison of ET-2 vs. ET-1 mRNA expression suggests this may be accomplished at the level of gene expression but differences may also exist in peptide synthesis by enzymes such as endothelin converting enzymes (ECEs) and chymase, which may allow the two pathways to be distinguished pharmacol. and become sep. drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra8zZjS7cPGbVg90H21EOLACvtfcHk0lht1bWziKyRBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFOgug%253D%253D&md5=a8772fe66d1a7884fe173bc40618a95e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01786.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01786.x%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DL.%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DEndothelin-2%252C%2520the%2520Forgotten%2520Isoform%253A%2520Emerging%2520Role%2520of%2520Endothelin-2%2520in%2520the%2520Cardiovascular%2520System%252C%2520Ovarian%2520Development%252C%2520Immunology%2520and%2520Cancer%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D168%26spage%3D283%26epage%3D295%26doi%3D10.1111%2Fj.1476-5381.2011.01786.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶hr, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashktorab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, R. H.</span><span> </span><span class="NLM_article-title">Epigenetic Inactivation of Endothelin-2 and Endothelin-3 in Colon Cancer</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">â</span> <span class="NLM_lpage">1012</span><span class="refDoi">Â DOI: 10.1002/ijc.27762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fijc.27762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22865632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ciur3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2013&pages=1004-1012&author=R.+Wangauthor=C.+V.+L%C3%B6hrauthor=K.+Fischerauthor=W.+M.+Dashwoodauthor=J.+A.+Greenwoodauthor=E.+Hoauthor=D.+E.+Williamsauthor=H.+Ashktorabauthor=M.+R.+Dashwoodauthor=R.+H.+Dashwood&title=Epigenetic+Inactivation+of+Endothelin-2+and+Endothelin-3+in+Colon+Cancer&doi=10.1002%2Fijc.27762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer</span></div><div class="casAuthors">Wang, Rong; Loehr, Christiane V.; Fischer, Kay; Dashwood, W. Mohaiza; Greenwood, Jeffrey A.; Ho, Emily; Williams, David E.; Ashktorab, Hassan; Dashwood, Michael R.; Dashwood, Roderick H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1004-1012</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Endothelin-1 (ET-1) and its receptors are overexpressed in human cancers, but much less is known about the roles of ET-2 and ET-3 in cancer etiol.  We sought to examine human and rat colon tumors for dysregulation of ET-2 and ET-3 expression and det. the underlying mechanisms.  Human primary colon cancers and carcinogen-induced rat colon tumors were subjected to real-time RT-PCR, immunoblotting and immunohistochem.; EDN2 and EDN3 genes were examd. by methylation-specific PCR, bisulfite sequencing and pyrosequencing; and forced expression of ET-2 and ET-3 was conducted in human colon cancer cells followed by real-time cell migration and invasion assays.  Rat and human colon tumors had markedly reduced expression of ET-2 and ET-3 mRNA and protein compared with matched controls.  Mechanistic studies revealed hypermethylation of EDN2 and EDN3 genes in human primary colon cancers and in a panel of human colon cancer cell lines.  Forced expression of ET-2 and ET-3 attenuated significantly the migration and invasion of human colon cancer cells.  We conclude that epigenetic inactivation of ET-2 and ET-3 occurs frequently in both rat and human colon cancers.  Current therapeutic strategies target overexpressed members of the ET axis via small mol. inhibitors and receptor antagonists, but this work supports a complementary approach based on the re-expression of ET-2 and ET-3 as natural antagonists of ET-1 in colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Q37xFNGv3bVg90H21EOLACvtfcHk0lht1bWziKyRBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ciur3P&md5=0609b867f0e2394dedbb660ca2011328</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fijc.27762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.27762%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DL%25C3%25B6hr%26aufirst%3DC.%2BV.%26aulast%3DFischer%26aufirst%3DK.%26aulast%3DDashwood%26aufirst%3DW.%2BM.%26aulast%3DGreenwood%26aufirst%3DJ.%2BA.%26aulast%3DHo%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DD.%2BE.%26aulast%3DAshktorab%26aufirst%3DH.%26aulast%3DDashwood%26aufirst%3DM.%2BR.%26aulast%3DDashwood%26aufirst%3DR.%2BH.%26atitle%3DEpigenetic%2520Inactivation%2520of%2520Endothelin-2%2520and%2520Endothelin-3%2520in%2520Colon%2520Cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2013%26volume%3D132%26spage%3D1004%26epage%3D1012%26doi%3D10.1002%2Fijc.27762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Denault, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâOrlÃ©ans-Juste, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leduc, R.</span><span> </span><span class="NLM_article-title">Processing of Proendothelin-1 by Human Furin Convertase</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">276</span><span class="NLM_x">â</span> <span class="NLM_lpage">280</span><span class="refDoi">Â DOI: 10.1016/0014-5793(95)00249-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2F0014-5793%2895%2900249-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=1995&pages=276-280&author=J.+B.+Denaultauthor=A.+Claingauthor=P.+D%E2%80%99Orl%C3%A9ans-Justeauthor=T.+Sawamuraauthor=T.+Kidoauthor=T.+Masakiauthor=R.+Leduc&title=Processing+of+Proendothelin-1+by+Human+Furin+Convertase&doi=10.1016%2F0014-5793%2895%2900249-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2895%2900249-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252895%252900249-9%26sid%3Dliteratum%253Aachs%26aulast%3DDenault%26aufirst%3DJ.%2BB.%26aulast%3DClaing%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Orl%25C3%25A9ans-Juste%26aufirst%3DP.%26aulast%3DSawamura%26aufirst%3DT.%26aulast%3DKido%26aufirst%3DT.%26aulast%3DMasaki%26aufirst%3DT.%26aulast%3DLeduc%26aufirst%3DR.%26atitle%3DProcessing%2520of%2520Proendothelin-1%2520by%2520Human%2520Furin%2520Convertase%26jtitle%3DFEBS%2520Lett.%26date%3D1995%26volume%3D362%26spage%3D276%26epage%3D280%26doi%3D10.1016%2F0014-5793%2895%2900249-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Coppola, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhojani, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehemtulla, A.</span><span> </span><span class="NLM_article-title">Identification of Inhibitors Using a Cell-based Assay for Monitoring Golgi-resident Protease Activity</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">â</span> <span class="NLM_lpage">29</span><span class="refDoi">Â DOI: 10.1016/j.ab.2007.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.ab.2007.01.013" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2007&pages=19-29&author=J.+M.+Coppolaauthor=C.+A.+Hamiltonauthor=M.+S.+Bhojaniauthor=M.+J.+Larsenauthor=B.+D.+Rossauthor=A.+Rehemtulla&title=Identification+of+Inhibitors+Using+a+Cell-based+Assay+for+Monitoring+Golgi-resident+Protease+Activity&doi=10.1016%2Fj.ab.2007.01.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2007.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2007.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DCoppola%26aufirst%3DJ.%2BM.%26aulast%3DHamilton%26aufirst%3DC.%2BA.%26aulast%3DBhojani%26aufirst%3DM.%2BS.%26aulast%3DLarsen%26aufirst%3DM.%2BJ.%26aulast%3DRoss%26aufirst%3DB.%2BD.%26aulast%3DRehemtulla%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520Inhibitors%2520Using%2520a%2520Cell-based%2520Assay%2520for%2520Monitoring%2520Golgi-resident%2520Protease%2520Activity%26jtitle%3DAnal.%2520Biochem.%26date%3D2007%26volume%3D364%26spage%3D19%26epage%3D29%26doi%3D10.1016%2Fj.ab.2007.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Muller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barret, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meidan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdenaire, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvol, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tougard, C.</span><span> </span><span class="NLM_article-title">Heterodimerization of Endothelin-Converting-Enzyme-1 Isoforms Regulates the Subcellular Distribution of this Metalloprotease</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">â</span> <span class="NLM_lpage">555</span><span class="refDoi">Â DOI: 10.1074/jbc.M208949200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1074%2Fjbc.M208949200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=545-555&author=L.+Mullerauthor=A.+Barretauthor=E.+Etienneauthor=R.+Meidanauthor=O.+Valdenaireauthor=P.+Corvolauthor=C.+Tougard&title=Heterodimerization+of+Endothelin-Converting-Enzyme-1+Isoforms+Regulates+the+Subcellular+Distribution+of+this+Metalloprotease&doi=10.1074%2Fjbc.M208949200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M208949200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M208949200%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DBarret%26aufirst%3DA.%26aulast%3DEtienne%26aufirst%3DE.%26aulast%3DMeidan%26aufirst%3DR.%26aulast%3DValdenaire%26aufirst%3DO.%26aulast%3DCorvol%26aufirst%3DP.%26aulast%3DTougard%26aufirst%3DC.%26atitle%3DHeterodimerization%2520of%2520Endothelin-Converting-Enzyme-1%2520Isoforms%2520Regulates%2520the%2520Subcellular%2520Distribution%2520of%2520this%2520Metalloprotease%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D545%26epage%3D555%26doi%3D10.1074%2Fjbc.M208949200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Azarani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boileau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crine, P.</span><span> </span><span class="NLM_article-title">Recombinant Human Endothelin-converting Enzyme ECE-1b Is Located in an Intracellular Compartment When Expressed in Polarized Madin-Darby Canine Kidney Cells</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">333</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">â</span> <span class="NLM_lpage">448</span><span class="refDoi">Â DOI: 10.1042/bj3330439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1042%2Fbj3330439" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=1998&pages=439-448&author=A.+Azaraniauthor=G.+Boileauauthor=P.+Crine&title=Recombinant+Human+Endothelin-converting+Enzyme+ECE-1b+Is+Located+in+an+Intracellular+Compartment+When+Expressed+in+Polarized+Madin-Darby+Canine+Kidney+Cells&doi=10.1042%2Fbj3330439"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1042%2Fbj3330439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3330439%26sid%3Dliteratum%253Aachs%26aulast%3DAzarani%26aufirst%3DA.%26aulast%3DBoileau%26aufirst%3DG.%26aulast%3DCrine%26aufirst%3DP.%26atitle%3DRecombinant%2520Human%2520Endothelin-converting%2520Enzyme%2520ECE-1b%2520Is%2520Located%2520in%2520an%2520Intracellular%2520Compartment%2520When%2520Expressed%2520in%2520Polarized%2520Madin-Darby%2520Canine%2520Kidney%2520Cells%26jtitle%3DBiochem.%2520J.%26date%3D1998%26volume%3D333%26spage%3D439%26epage%3D448%26doi%3D10.1042%2Fbj3330439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Turner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweizer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdenaire, O.</span><span> </span><span class="NLM_article-title">Isoforms of Endothelin-converting Enzyme: Why and Where?</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">â</span> <span class="NLM_lpage">486</span><span class="refDoi">Â DOI: 10.1016/S0165-6147(98)01251-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0165-6147%2898%2901251-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1998&pages=483-486&author=A.+J.+Turnerauthor=K.+Barnesauthor=A.+Schweizerauthor=O.+Valdenaire&title=Isoforms+of+Endothelin-converting+Enzyme%3A+Why+and+Where%3F&doi=10.1016%2FS0165-6147%2898%2901251-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2898%2901251-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252898%252901251-6%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DA.%2BJ.%26aulast%3DBarnes%26aufirst%3DK.%26aulast%3DSchweizer%26aufirst%3DA.%26aulast%3DValdenaire%26aufirst%3DO.%26atitle%3DIsoforms%2520of%2520Endothelin-converting%2520Enzyme%253A%2520Why%2520and%2520Where%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1998%26volume%3D19%26spage%3D483%26epage%3D486%26doi%3D10.1016%2FS0165-6147%2898%2901251-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Valdenaire, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepailleur-Enouf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egidy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thouhard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barret, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranckx, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tougard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, J. B.</span><span> </span><span class="NLM_article-title">A Fourth Isoform of Endothelin-Converting Enzyme (ECE-1) Is Generated from an Additional Promoter: Molecular Cloning and Characterization</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">â</span> <span class="NLM_lpage">349</span><span class="refDoi">Â DOI: 10.1046/j.1432-1327.1999.00602.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1046%2Fj.1432-1327.1999.00602.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10491078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFWku78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1999&pages=341-349&author=O.+Valdenaireauthor=D.+Lepailleur-Enoufauthor=G.+Egidyauthor=A.+Thouhardauthor=A.+Barretauthor=R.+Vranckxauthor=C.+Tougardauthor=J.+B.+Michel&title=A+Fourth+Isoform+of+Endothelin-Converting+Enzyme+%28ECE-1%29+Is+Generated+from+an+Additional+Promoter%3A+Molecular+Cloning+and+Characterization&doi=10.1046%2Fj.1432-1327.1999.00602.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter: molecular cloning and characterization</span></div><div class="casAuthors">Valdenaire, Olivier; Lepailleur-Enouf, Delphine; Egidy, Giorgia; Thouard, Anne; Barret, Alain; Vranckx, Roger; Tougard, Claude; Michel, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-349</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Human endothelin-converting enzyme (ECE-1) has been shown to exist as three isoforms (ECE-1a, ECE-1b and ECE-1c) diverging in their N-terminal sequence and displaying different patterns of subcellular localization.  We report here the cloning of ECE-1d, a novel isoform of 767 amino acids, which is generated from the same gene via the existence of an addnl. promoter located upstream from the third exon of the ECE-1 gene.  ECE-1d converting activity is comparable to that of the other three isoenzymes.  In contrast to ECE-1b, ECE-1d is expressed at the cell surface, although less strongly than ECE-1a.  We have also shown, by identifying ECE-1b and ECE-1d in rat, that the ECE-1 diversity is conserved between human and rodent, suggesting its physiol. relevance.  The mRNA levels of the four isoforms were assessed in the two species in various cell types, revealing some differences.  In particular, the ECE-1a isoform, strongly expressed at the plasma membrane, was found to be highly expressed in primary cultures of endothelial cells but absent from primary cultures of smooth muscle cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqta6cysNvJkbVg90H21EOLACvtfcHk0ljtZkQDJK8QYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFWku78%253D&md5=9e71dea34e387e43f1d69cdc3052b8f9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.1999.00602.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.1999.00602.x%26sid%3Dliteratum%253Aachs%26aulast%3DValdenaire%26aufirst%3DO.%26aulast%3DLepailleur-Enouf%26aufirst%3DD.%26aulast%3DEgidy%26aufirst%3DG.%26aulast%3DThouhard%26aufirst%3DA.%26aulast%3DBarret%26aufirst%3DA.%26aulast%3DVranckx%26aufirst%3DR.%26aulast%3DTougard%26aufirst%3DC.%26aulast%3DMichel%26aufirst%3DJ.%2BB.%26atitle%3DA%2520Fourth%2520Isoform%2520of%2520Endothelin-Converting%2520Enzyme%2520%2528ECE-1%2529%2520Is%2520Generated%2520from%2520an%2520Additional%2520Promoter%253A%2520Molecular%2520Cloning%2520and%2520Characterization%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1999%26volume%3D264%26spage%3D341%26epage%3D349%26doi%3D10.1046%2Fj.1432-1327.1999.00602.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Berger, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehmlow, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum-Kaelin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitas, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶ffler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aebi, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Endothelin-converting Enzyme-1 Inhibition and Growth of Human Glioblastoma Cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">â</span> <span class="NLM_lpage">498</span><span class="refDoi">Â DOI: 10.1021/jm040857x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040857x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVKn" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=483-498&author=Y.+Bergerauthor=H.+Dehmlowauthor=D.+Blum-Kaelinauthor=E.+A.+Kitasauthor=B.+M.+L%C3%B6fflerauthor=J.+D.+Aebiauthor=L.+Juillerat-Jeanneret&title=Endothelin-converting+Enzyme-1+Inhibition+and+Growth+of+Human+Glioblastoma+Cells&doi=10.1021%2Fjm040857x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-Converting Enzyme-1 Inhibition and Growth of Human Glioblastoma Cells</span></div><div class="casAuthors">Berger, Yann; Dehmlow, Henrietta; Blum-Kaelin, Denise; Kitas, Eric A.; Loeffler, Bernd-Michael; Aebi, Johannes D.; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">483-498</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Endothelin-1 (ET-1) is mitogenic and/or antiapoptotic in human cancers, and antagonists to ET-1 receptors are under evaluation for cancer treatment.  Inhibition of ET-1 activation by the endothelin-converting enzymes 1a-d (ECE-1a-d; EC 3.4.24.71) represents another approach to block the ET-1 effect in cancer.  To evaluate this potential, we synthesized and characterized a series of low nanomolar nonpeptidic thiol-contg. ECE-1 inhibitors, and evaluated their effect, as well as the effect of inhibitors for the related metalloproteases neprilysin (NEP; EC 3.4.24.11) and angiotensin-converting enzyme (ACE; EC 3.4.15.1), on human glioblastoma cell growth.  Only ECE-1 inhibitors inhibited DNA synthesis by human glioblastoma cells.  Exogenous addn. of ET-1 or bigET-1 to glioblastoma cells did not counterbalance the growth inhibition elicited by ECE-1 inhibitors, suggesting that ECE-1 inhibitors block the proliferation of human glioblastoma cells most likely via a mechanism not involving extracellular prodn. of ET-1.  This class of mols. may thus represent novel therapeutic agents for the potential treatment of human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAHZSGjdYuurVg90H21EOLACvtfcHk0lgJUtBW0S0AQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVKn&md5=e7eb909f11107fa8dc0bcfea1f88804b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm040857x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040857x%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DY.%26aulast%3DDehmlow%26aufirst%3DH.%26aulast%3DBlum-Kaelin%26aufirst%3DD.%26aulast%3DKitas%26aufirst%3DE.%2BA.%26aulast%3DL%25C3%25B6ffler%26aufirst%3DB.%2BM.%26aulast%3DAebi%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin-converting%2520Enzyme-1%2520Inhibition%2520and%2520Growth%2520of%2520Human%2520Glioblastoma%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D483%26epage%3D498%26doi%3D10.1021%2Fjm040857x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Inhibiting the Enzymes of the Endothelin and Renin-angiotensin Systems in Cancer</span> <span class="citation_source-journal">Curr. Enzyme Inhib.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">â</span> <span class="NLM_lpage">362</span><span class="refDoi">Â DOI: 10.2174/157340806778699253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2174%2F157340806778699253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFartrfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=353-362&author=L.+Juillerat-Jeanneret&title=Inhibiting+the+Enzymes+of+the+Endothelin+and+Renin-angiotensin+Systems+in+Cancer&doi=10.2174%2F157340806778699253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the enzymes of the endothelin and renin-angiotensin systems in cancer</span></div><div class="casAuthors">Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Current Enzyme Inhibition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-362</span>CODEN:
                <span class="NLM_cas:coden">CEIUAG</span>;
        ISSN:<span class="NLM_cas:issn">1573-4080</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renin-angiotensin (RAS) and endothelin/ET-1,-2,-3 systems comprise families of precursor peptides, angiotensinogen and big-endothelins resp., activated by families of proteases.  Angiotensinogen is activated by the sequential action of an aspartyl-protease, renin, then a metalloprotease, angiotensin converting enzyme (ACE).  Big-endothelins are activated by the metalloproteases endothelin converting enzyme/ECE-1a-d, and to a lesser extent neprilysin (NEP/CD10).  These proteolytic cascades produce the system-representative active peptides angiotensin II (Ang II) and endothelin-1 (ET-1).  Then several exopeptidases, which include aminopeptidases or carboxypeptidases, and endopeptidases, in particular NEP, further process these active peptides to either inactive fragments or intermediate peptides with various biol. activities.  The RAS and ET systems have been mainly studied in the context of cardiovascular disorders, and either agonists or antagonists of their receptors, and inhibitors for the enzymes metabolizing the precursors and/or the active peptides have been developed for the treatment of these disorders.  However, the RAS and ET systems, in addn. to controlling the vascular tone and natriohydric balance, may be involved in cell growth and/or death in cancer, fibrotic or degenerative diseases.  Therefore the protease inhibitors developed for treating cardiovascular disorders may have wider application in cancer than initially envisioned, which will be reviewed in this manuscript.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIvsOFfYSmx7Vg90H21EOLACvtfcHk0lgJUtBW0S0AQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFartrfK&md5=ad92071ca036b87ead7621e0b52e132e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F157340806778699253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157340806778699253%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DInhibiting%2520the%2520Enzymes%2520of%2520the%2520Endothelin%2520and%2520Renin-angiotensin%2520Systems%2520in%2520Cancer%26jtitle%3DCurr.%2520Enzyme%2520Inhib.%26date%3D2006%26volume%3D2%26spage%3D353%26epage%3D362%26doi%3D10.2174%2F157340806778699253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Russell, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coppell, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title">In Vitro Enzymatic Processing of Radiolabel Led Big ET-1 in Human Kidney</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">â</span> <span class="NLM_lpage">701</span><span class="refDoi">Â DOI: 10.1016/S0006-2952(97)00515-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0006-2952%2897%2900515-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1998&pages=697-701&author=F.+D.+Russellauthor=A.+L.+Coppellauthor=A.+P.+Davenport&title=In+Vitro+Enzymatic+Processing+of+Radiolabel+Led+Big+ET-1+in+Human+Kidney&doi=10.1016%2FS0006-2952%2897%2900515-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2897%2900515-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252897%252900515-7%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DF.%2BD.%26aulast%3DCoppell%26aufirst%3DA.%2BL.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DIn%2520Vitro%2520Enzymatic%2520Processing%2520of%2520Radiolabel%2520Led%2520Big%2520ET-1%2520in%2520Human%2520Kidney%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1998%26volume%3D55%26spage%3D697%26epage%3D701%26doi%3D10.1016%2FS0006-2952%2897%2900515-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hayasaki-Kajiwara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, M.</span><span> </span><span class="NLM_article-title">Endothelin Generating Pathway through Endothelin1-31 in Human Cultured Bronchial Smooth Muscle Cells</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">â</span> <span class="NLM_lpage">1421</span><span class="refDoi">Â DOI: 10.1038/sj.bjp.0702664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fsj.bjp.0702664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10455291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK1MXlt1emtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=1999&pages=1415-1421&author=Y.+Hayasaki-Kajiwaraauthor=N.+Nayaauthor=T.+Shimamuraauthor=T.+Iwasakiauthor=M.+Nakajima&title=Endothelin+Generating+Pathway+through+Endothelin1-31+in+Human+Cultured+Bronchial+Smooth+Muscle+Cells&doi=10.1038%2Fsj.bjp.0702664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin generating pathway through endothelin1-31 in human cultured bronchial smooth muscle cells</span></div><div class="casAuthors">Hayasaki-Kajiwara, Yoko; Naya, Noriyuki; Shimamura, Toshitake; Iwasaki, Takanori; Nakajima, Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1415-1421</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The effects of endothelin (ET)-11-31 and ET-21-31, human chymase products of the corresponding big ETs, on the intracellular free Ca2+ concn. ([Ca2+]i) and [125I]-ET-1 binding were investigated using human cultured bronchial smooth muscle cells (BSMC).  ET-11-31 (10-8 M - 3Ã10-7 M) and ET-21-31 (3Ã10-8 M - 3Ã10-6 M) caused an increase in [Ca2+]i in a concn.-dependent manner.  Big ET-1 (3Ã10-8 M - 10-6 M) also caused this increase, but not big ET-2 at concns. up to 10-6 M.  The [Ca2+]i increase induced by ET-1 was inhibited by both BQ123, an ETA-receptor antagonist, and BQ788, an ETB-receptor antagonist, whereas that induced by ET-3 was inhibited by BQ788 but not by BQ123.  Increases in [Ca2+]i caused by ET-11-31, big ET-1 and ET-21-31 were completely inhibited by 10-4 M phosphoramidon, a dual neutral endopeptidase (NEP)/endothelin-converting enzyme (ECE) inhibitor, and 10-5 M thiorphan, a NEP inhibitor.  Scatchard plot analyses of the satn. curves of [125I]-ET-1 and [125I]-ET-3 showed that both ETA- and ETB- receptors at the ratio of 4:1 were expressed on BSMC.  ET-11-31, big ET-1 and ET-21-31 inhibited [125I]-ET-1 binding in a concn.-dependent manner, and these effects were attenuated by treatment with thiorphan.  On the other hand, big ET-2 slightly inhibited the binding at a high concn. and this was not affected by thiorphan.  These results suggest that ET-11-31, big ET-1 and ET-21-31 cause an increase in [Ca2+]i by being converted into the corresponding ET-1 and ET-2 by NEP, but this did not occur with big ET-2 in human BSMC.  ET-21-31 produced by human chymase from big ET-2 might be important for the generation of ET-2 in human bronchial tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIXRbqc7V5drVg90H21EOLACvtfcHk0lgJUtBW0S0AQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt1emtLY%253D&md5=4e9cac151eed2f462fd94d677792f13a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702664%26sid%3Dliteratum%253Aachs%26aulast%3DHayasaki-Kajiwara%26aufirst%3DY.%26aulast%3DNaya%26aufirst%3DN.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DIwasaki%26aufirst%3DT.%26aulast%3DNakajima%26aufirst%3DM.%26atitle%3DEndothelin%2520Generating%2520Pathway%2520through%2520Endothelin1-31%2520in%2520Human%2520Cultured%2520Bronchial%2520Smooth%2520Muscle%2520Cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D127%26spage%3D1415%26epage%3D1421%26doi%3D10.1038%2Fsj.bjp.0702664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Tabrizchi, R.</span><span> </span><span class="NLM_article-title">SLV-306 Solvay</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">â</span> <span class="NLM_lpage">332</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=329-332&author=R.+Tabrizchi&title=SLV-306+Solvay"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTabrizchi%26aufirst%3DR.%26atitle%3DSLV-306%2520Solvay%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2003%26volume%3D4%26spage%3D329%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Parvanova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Meer, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iliev, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaspari, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevisan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benigni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggenenti, P.</span><span> </span><span class="NLM_article-title">Effect on Blood Pressure of Combined Inhibition of Endothelin-converting Enzyme and Neutral Endopeptidase with Daglutril in Patients with Type 2 Diabetes Who Have Albuminuria: a Randomised, Crossover, Double-blind, Placebo-controlled Trial</span> <span class="citation_source-journal">Lancet Diabetes Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">â</span> <span class="NLM_lpage">27</span><span class="refDoi">Â DOI: 10.1016/S2213-8587(13)70029-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS2213-8587%2813%2970029-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24622263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslaqsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=19-27&author=A.+Parvanovaauthor=I.+M.+van+der+Meerauthor=I.+Ilievauthor=A.+Pernaauthor=F.+Gaspariauthor=R.+Trevisanauthor=A.+Bossiauthor=G.+Remuzziauthor=A.+Benigniauthor=P.+Ruggenenti&title=Effect+on+Blood+Pressure+of+Combined+Inhibition+of+Endothelin-converting+Enzyme+and+Neutral+Endopeptidase+with+Daglutril+in+Patients+with+Type+2+Diabetes+Who+Have+Albuminuria%3A+a+Randomised%2C+Crossover%2C+Double-blind%2C+Placebo-controlled+Trial&doi=10.1016%2FS2213-8587%2813%2970029-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Parvanova, Aneliya; van der Meer, Irene M.; Iliev, Ilian; Perna, Annalisa; Gaspari, Flavio; Trevisan, Roberto; Bossi, Antonio; Remuzzi, Giuseppe; Benigni, Ariela; Ruggenenti, Piero</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Diabetes & Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-27</span>CODEN:
                <span class="NLM_cas:coden">LDEAAS</span>;
        ISSN:<span class="NLM_cas:issn">2213-8587</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Effective redn. of albuminuria and blood pressure in patients with type 2 diabetes who have nephropathy is seldom achieved with available treatments.  We tested the effects of treatment of such patients with daglutril, a combined endothelin-converting enzyme and neutral endopeptidase inhibitor.  We did this randomized, crossover trial in two hospitals in Italy.  Eligibility criteria were: age 18 years or older, urinary albumin excretion 20-999 Î¼g/min, systolic blood pressure (BP) less than 140 mm Hg, and diastolic BP less than 90 mm Hg.  Patients were randomly assigned (1:1) with a computer-generated randomized sequence to receive either daglutril (300 mg/day) then placebo for 8 wk each or vice versa, with a 4-wk washout period.  Patients also took losartan throughout.  Participants and investigators were masked to treatment allocation.  The primary endpoint was 24-h urinary albumin excretion in the intention-to-treat population.  Secondary endpoints were median office and ambulatory (24 h, daytime, and night-time) BP, renal hemodynamics and sieving function, and metabolic and lab. test results.  This study is registered with ClinicalTrials.gov, no. NCT00160225.  We screened 58 patients, of whom 45 were enrolled (22 assigned to daglutril then placebo, 23 to placebo then daglutril; enrollment from May, 2005, to Dec., 2006) and 42 (20 vs 22) were included in the primary anal.  Daglutril did not significantly affect 24-h urinary albumin excretion compared with placebo (difference in change -7Â·6 Î¼g/min, IQR -78Â·7 to 19Â·0; p=0Â·559). 34 patients had complete 24-h BP readings; compared with placebo, daglutril significantly reduced 24-h systolic (difference -5Â·2 mm Hg, SD 9Â·4; p=0Â·0013), diastolic (-2Â·5, 6Â·2; p=0Â·015), pulse (-3Â·0, 6Â·3; p=0Â·019), and mean (-3Â·1, 6Â·2; p=0Â·003) BP, as well as all night-time BP readings and daytime systolic, pulse, and mean BP, but not diastolic BP.  Compared with placebo, daglutril also significantly reduced office systolic BP (-5Â·4, 15Â·4; p=0Â·028), but not diastolic (-1Â·8, 9Â·9; p=0Â·245), pulse (-3Â·1, 10Â·6; p=0Â·210), or mean (-2Â·1, 10Â·4; p=0Â·205) BP, and increased big endothelin serum concn.  Other secondary outcomes did not differ significantly between treatment periods.  Three patients taking placebo and six patients taking daglutril had mild treatment-related adverse events-the most common was facial or peripheral edema (in four patients taking daglutril).  Daglutril improved control of BP in hypertensive patients with type 2 diabetes and nephropathy and had an acceptable safety profile.  Combined endothelin-converting enzyme and neutral endopeptidase inhibition could provide a new approach to hypertension in this high-risk population.Solvay Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOwpv9vNQmrrVg90H21EOLACvtfcHk0ljNeVyuaI80yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslaqsrY%253D&md5=e56eec8321ce0bf7eba9dd0e10c8c59a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS2213-8587%2813%2970029-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-8587%252813%252970029-9%26sid%3Dliteratum%253Aachs%26aulast%3DParvanova%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BMeer%26aufirst%3DI.%2BM.%26aulast%3DIliev%26aufirst%3DI.%26aulast%3DPerna%26aufirst%3DA.%26aulast%3DGaspari%26aufirst%3DF.%26aulast%3DTrevisan%26aufirst%3DR.%26aulast%3DBossi%26aufirst%3DA.%26aulast%3DRemuzzi%26aufirst%3DG.%26aulast%3DBenigni%26aufirst%3DA.%26aulast%3DRuggenenti%26aufirst%3DP.%26atitle%3DEffect%2520on%2520Blood%2520Pressure%2520of%2520Combined%2520Inhibition%2520of%2520Endothelin-converting%2520Enzyme%2520and%2520Neutral%2520Endopeptidase%2520with%2520Daglutril%2520in%2520Patients%2520with%2520Type%25202%2520Diabetes%2520Who%2520Have%2520Albuminuria%253A%2520a%2520Randomised%252C%2520Crossover%252C%2520Double-blind%252C%2520Placebo-controlled%2520Trial%26jtitle%3DLancet%2520Diabetes%2520Endocrinol.%26date%3D2013%26volume%3D1%26spage%3D19%26epage%3D27%26doi%3D10.1016%2FS2213-8587%2813%2970029-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Cabrera-Vera, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhauwe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medkova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preininger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzoni, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamm, H. E.</span><span> </span><span class="NLM_article-title">Insights into G Protein Structure, Function, and Regulation</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">â</span> <span class="NLM_lpage">781</span><span class="refDoi">Â DOI: 10.1210/er.2000-0026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1210%2Fer.2000-0026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=14671004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVegsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2003&pages=765-781&author=T.+M.+Cabrera-Veraauthor=J.+Vanhauweauthor=T.+O.+Thomasauthor=M.+Medkovaauthor=A.+Preiningerauthor=M.+R.+Mazzoniauthor=H.+E.+Hamm&title=Insights+into+G+Protein+Structure%2C+Function%2C+and+Regulation&doi=10.1210%2Fer.2000-0026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into G protein structure, function, and regulation</span></div><div class="casAuthors">Cabrera-Vera, Theresa M.; Vanhauwe, Jurgen; Thomas, Tarita O.; Medkova, Martina; Preininger, Anita; Mazzoni, Maria R.; Hamm, Heidi E.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">765-781</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  In multicellular organisms from Caenorhabditis elegans to Homo sapiens, the maintenance of homeostasis is dependent on the continual flow and processing of information through a complex network of cells.  Moreover, in order for the organism to respond to an ever-changing environment, intercellular signals must be transduced, amplified, and ultimately converted to the appropriate physiol. response.  The resoln. of the mol. events underlying signal response and integration forms the basis of the signal transduction field of research.  An evolutionarily highly conserved group of mols. known as heterotrimeric guanine nucleotide-binding proteins (G proteins) are key determinants of the specificity and temporal characteristics of many signaling processes and are the topic of this review.  Numerous hormones, neurotransmitters, chemokines, local mediators, and sensory stimuli exert their effects on cells by binding to heptahelical membrane receptors coupled to heterotrimeric G proteins.  These highly specialized transducers can modulate the activity of multiple signaling pathways leading to diverse biol. responses.  In vivo, specific combinations of GÎ±- and GÎ²Î³-subunits are likely required for connecting individual receptors to signaling pathways.  The structural determinants of receptor-G protein-effector specificity are not completely understood and, in addn. to involving interaction domains of these primary acting proteins, also require the participation of scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw0JbJJZOw7LVg90H21EOLACvtfcHk0ljNeVyuaI80yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVegsg%253D%253D&md5=afd2763ad05d9a0475ce4bdbed3ade4d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1210%2Fer.2000-0026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2000-0026%26sid%3Dliteratum%253Aachs%26aulast%3DCabrera-Vera%26aufirst%3DT.%2BM.%26aulast%3DVanhauwe%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DT.%2BO.%26aulast%3DMedkova%26aufirst%3DM.%26aulast%3DPreininger%26aufirst%3DA.%26aulast%3DMazzoni%26aufirst%3DM.%2BR.%26aulast%3DHamm%26aufirst%3DH.%2BE.%26atitle%3DInsights%2520into%2520G%2520Protein%2520Structure%252C%2520Function%252C%2520and%2520Regulation%26jtitle%3DEndocr.%2520Rev.%26date%3D2003%26volume%3D24%26spage%3D765%26epage%3D781%26doi%3D10.1210%2Fer.2000-0026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lappano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggiolini, M.</span><span> </span><span class="NLM_article-title">G Protein-coupled Receptors: Novel Targets for Drug Discovery in Cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">â</span> <span class="NLM_lpage">60</span><span class="refDoi">Â DOI: 10.1038/nrd3320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fnrd3320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21193867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFCl" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=47-60&author=R.+Lappanoauthor=M.+Maggiolini&title=G+Protein-coupled+Receptors%3A+Novel+Targets+for+Drug+Discovery+in+Cancer&doi=10.1038%2Fnrd3320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptors: novel targets for drug discovery in cancer</span></div><div class="casAuthors">Lappano, Rosamaria; Maggiolini, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-60</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) belong to a superfamily of cell surface signalling proteins that have a pivotal role in many physiol. functions and in multiple diseases, including the development of cancer and cancer metastasis.  Current drugs that target GPCRs - many of which have excellent therapeutic benefits - are directed towards only a few GPCR members.  Therefore, huge efforts are currently underway to develop new GPCR-based drugs, particularly for cancer.  We review recent findings that present unexpected opportunities to interfere with major tumorigenic signals by manipulating GPCR-mediated pathways.  We also discuss current data regarding novel GPCR targets that may provide promising opportunities for drug discovery in cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUpj1HOTd_iLVg90H21EOLACvtfcHk0lj-kKz8dN5Jrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFCl&md5=d2ccada1529dc84d499396d0e1c1954e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd3320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3320%26sid%3Dliteratum%253Aachs%26aulast%3DLappano%26aufirst%3DR.%26aulast%3DMaggiolini%26aufirst%3DM.%26atitle%3DG%2520Protein-coupled%2520Receptors%253A%2520Novel%2520Targets%2520for%2520Drug%2520Discovery%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D47%26epage%3D60%26doi%3D10.1038%2Fnrd3320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Sasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takimoto, M.</span><span> </span><span class="NLM_article-title">Both ET(A) and ET(B) Receptors Are Involved in Mitogen-activated Protein Kinase Activation and DNA Synthesis of Astrocytes: Study Using ET(B) Receptor-deficient Rats (aganglionosis Rats)</span> <span class="citation_source-journal">Eur. J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2984</span><span class="NLM_x">â</span> <span class="NLM_lpage">2993</span><span class="refDoi">Â DOI: 10.1111/j.1460-9568.1998.00305.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fj.1460-9568.1998.00305.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=9758168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADyaK1cvivFWgtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=2984-2993&author=Y.+Sasakiauthor=S.+Horiauthor=K.+Odaauthor=T.+Okadaauthor=M.+Takimoto&title=Both+ET%28A%29+and+ET%28B%29+Receptors+Are+Involved+in+Mitogen-activated+Protein+Kinase+Activation+and+DNA+Synthesis+of+Astrocytes%3A+Study+Using+ET%28B%29+Receptor-deficient+Rats+%28aganglionosis+Rats%29&doi=10.1111%2Fj.1460-9568.1998.00305.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Both ET(A) and ET(B) receptors are involved in mitogen-activated protein kinase activation and DNA synthesis of astrocytes: study using ET(B) receptor-deficient rats (aganglionosis rats)</span></div><div class="casAuthors">Sasaki Y; Hori S; Oda K; Okada T; Takimoto M</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2984-93</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Endothelin (ET) is known to be a potent mitogen in astrocytes.  However, the contribution and signalling pathway of ET(A) and/or ET(B) receptor to the proliferation of astrocytes remain unclear.  We investigated ET-induced DNA synthesis in astrocytes using ET(B) receptor-deficient mutant rats (aganglionosis rats: sl/sl).  Western blotting with anti-ET receptor subtype-specific antibodies and Scatchard analysis of binding revealed that ET(B) receptor expression in astrocytes depended on gene dosage (+/+: sl/+: sl/sl=2: 1:0), whereas ET(A) receptor expression was unchanged among the three genotypes.  ET-1 (10 nM) stimulated [3H]thymidine incorporation and mitogen-activated protein kinase (MAP kinase) activity not only in +/+ via both ET(A) and ET(B) receptors, but also in sl/sl astrocytes via ET(A) receptor with about half the extent of those observed in +/+ astrocytes.  Treatment with pertussis toxin (PTX) suppressed the ET-1-induced increases in the incorporation and MAP kinase activity in +/+, but not sl/sl astrocytes, indicating that the ET(B) receptor-, but not the ET(A) receptor-, mediated pathway to DNA synthesis involves PTX-sensitive G proteins, e.g.  Gi and/or Go (Gi/o).  In +/+ astrocytes, ET-1 (1 nM) stimulated cAMP accumulation, and the ET(B) receptor-selective agonist IRL 1620 (1 nM) suppressed 10 microM forskolin-induced cAMP accumulation, suggesting Gs coupling to the ET(A) receptor and Gi/o coupling to the ET(B) receptor.  On the other hand, ET-1 did not increase cAMP accumulation in sl/sl astrocytes, although ET-1 (1 nM) suppressed the forskolin-induced response, suggesting Gi/o coupling to the ET(A) receptor.  Our results suggest the possibility that the selectivity of G protein for ET(A) receptor is changed from Gs to Gi/o in ET(B) receptor-deficient astrocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyYIMfSanqsH6oPH0mYWL1fW6udTcc2eaNndlcmShlw7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1cvivFWgtw%253D%253D&md5=0744d2618ceef4e5cd74e126e1812527</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fj.1460-9568.1998.00305.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1460-9568.1998.00305.x%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DHori%26aufirst%3DS.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DOkada%26aufirst%3DT.%26aulast%3DTakimoto%26aufirst%3DM.%26atitle%3DBoth%2520ET%2528A%2529%2520and%2520ET%2528B%2529%2520Receptors%2520Are%2520Involved%2520in%2520Mitogen-activated%2520Protein%2520Kinase%2520Activation%2520and%2520DNA%2520Synthesis%2520of%2520Astrocytes%253A%2520Study%2520Using%2520ET%2528B%2529%2520Receptor-deficient%2520Rats%2520%2528aganglionosis%2520Rats%2529%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D1998%26volume%3D10%26spage%3D2984%26epage%3D2993%26doi%3D10.1111%2Fj.1460-9568.1998.00305.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Bremnes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paasche, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehlum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremnes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attramadal, H.</span><span> </span><span class="NLM_article-title">Regulation and Intracellular Trafficking Pathways of the Endothelin Receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">17596</span><span class="NLM_x">â</span> <span class="NLM_lpage">17604</span><span class="refDoi">Â DOI: 10.1074/jbc.M000142200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1074%2Fjbc.M000142200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=17596-17604&author=T.+Bremnesauthor=J.+D.+Paascheauthor=A.+Mehlumauthor=C.+Sandbergauthor=B.+Bremnesauthor=H.+Attramadal&title=Regulation+and+Intracellular+Trafficking+Pathways+of+the+Endothelin+Receptors&doi=10.1074%2Fjbc.M000142200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M000142200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M000142200%26sid%3Dliteratum%253Aachs%26aulast%3DBremnes%26aufirst%3DT.%26aulast%3DPaasche%26aufirst%3DJ.%2BD.%26aulast%3DMehlum%26aufirst%3DA.%26aulast%3DSandberg%26aufirst%3DC.%26aulast%3DBremnes%26aufirst%3DB.%26aulast%3DAttramadal%26aufirst%3DH.%26atitle%3DRegulation%2520and%2520Intracellular%2520Trafficking%2520Pathways%2520of%2520the%2520Endothelin%2520Receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D17596%26epage%3D17604%26doi%3D10.1074%2Fjbc.M000142200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Ishikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuroda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, T.</span><span> </span><span class="NLM_article-title">Biochemical and Pharmacological Profile of a Potent and Selective Endothelin B-receptor Antagonist, BQ788</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">4892</span><span class="NLM_x">â</span> <span class="NLM_lpage">4896</span><span class="refDoi">Â DOI: 10.1073/pnas.91.11.4892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1073%2Fpnas.91.11.4892" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=4892-4896&author=K.+Ishikawaauthor=M.+Iharaauthor=K.+Noguchiauthor=T.+Maseauthor=N.+Minoauthor=T.+Saekiauthor=T.+Fukurodaauthor=T.+Fukamiauthor=S.+Ozakiauthor=T.+Nagase&title=Biochemical+and+Pharmacological+Profile+of+a+Potent+and+Selective+Endothelin+B-receptor+Antagonist%2C+BQ788&doi=10.1073%2Fpnas.91.11.4892"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.11.4892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.11.4892%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DIhara%26aufirst%3DM.%26aulast%3DNoguchi%26aufirst%3DK.%26aulast%3DMase%26aufirst%3DT.%26aulast%3DMino%26aufirst%3DN.%26aulast%3DSaeki%26aufirst%3DT.%26aulast%3DFukuroda%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DOzaki%26aufirst%3DS.%26aulast%3DNagase%26aufirst%3DT.%26atitle%3DBiochemical%2520and%2520Pharmacological%2520Profile%2520of%2520a%2520Potent%2520and%2520Selective%2520Endothelin%2520B-receptor%2520Antagonist%252C%2520BQ788%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D4892%26epage%3D4896%26doi%3D10.1073%2Fpnas.91.11.4892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Jimeno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M.</span><span> </span><span class="NLM_article-title">Atrasentan: Targeting the Endothelin Axis in Prostate Cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1631</span><span class="NLM_x">â</span> <span class="NLM_lpage">1640</span><span class="refDoi">Â DOI: 10.1517/13543784.13.12.1631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1517%2F13543784.13.12.1631" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=1631-1640&author=A.+Jimenoauthor=M.+Carducci&title=Atrasentan%3A+Targeting+the+Endothelin+Axis+in+Prostate+Cancer&doi=10.1517%2F13543784.13.12.1631"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1517%2F13543784.13.12.1631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.13.12.1631%26sid%3Dliteratum%253Aachs%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DCarducci%26aufirst%3DM.%26atitle%3DAtrasentan%253A%2520Targeting%2520the%2520Endothelin%2520Axis%2520in%2520Prostate%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2004%26volume%3D13%26spage%3D1631%26epage%3D1640%26doi%3D10.1517%2F13543784.13.12.1631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Battistini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthiaume, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelland, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohan, D. E.</span><span> </span><span class="NLM_article-title">Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel âSentanâ Class of Drug</span> <span class="citation_source-journal">Exp. Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">653</span><span class="NLM_x">â</span> <span class="NLM_lpage">695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD28Xlt1eku70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2006&pages=653-695&author=B.+Battistiniauthor=N.+Berthiaumeauthor=N.+F.+Kellandauthor=D.+J.+Webbauthor=D.+E.+Kohan&title=Profile+of+Past+and+Current+Clinical+Trials+Involving+Endothelin+Receptor+Antagonists%3A+The+Novel+%E2%80%9CSentan%E2%80%9D+Class+of+Drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug</span></div><div class="casAuthors">Battistini, Bruno; Berthiaume, Nathalie; Kelland, Nicholas F.; Webb, David J.; Kohan, Donald E.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (Maywood, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">653-695</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3702</span>.
    
            (<span class="NLM_cas:orgname">Society for Experimental Biology and Medicine</span>)
        </div><div class="casAbstract">A review.  Since its initial characterization in 1988, over 18,236 papers, including 2,485 reviews, have been published in the endothelin (ET) field.  Over this period, several generations of selective and mixed (dual) ET receptor antagonists (ERAs), from peptidic backbones to orally active potent (subnanomolar) small mol. compds., have been developed.  These agents have been studied in many exptl. animal models of various pathol. conditions (cardiovascular, respiratory, and neuro-immunol.).  Continued basic research has led to a better understanding of the complex interactions between the ET axis and other biol. systems in human pathophysiol.  The first clin. trial involved patients with idiopathic pulmonary arterial hypertension and led to approval of bosentan (Tracleer) for use in the United States and Europe in 2002.  Since then, bosentan, the only currently approved dual (mixed) ERA, has been used in numerous other clin. trials.  In addn., more selective ETA receptor antagonists (ambrisentan, atrasentan, avosentan, clazosentan, darusentan, and sitaxsentan) are undergoing clin. trials.  Here we outline the ERAs undergoing development and summarize the standing of completed and ongoing trials at the time of the Ninth International Conference on Endothelin and even thereafter.  This review is intended to provide a useful ref. for those interested in the current state of clin. trials involving ERAs, and to identify lessons that might apply to the design of future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg8ZjYCNDwRbVg90H21EOLACvtfcHk0li2XQe951HrtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xlt1eku70%253D&md5=8cd2fa42705effee0d58ca029bb9b76c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBattistini%26aufirst%3DB.%26aulast%3DBerthiaume%26aufirst%3DN.%26aulast%3DKelland%26aufirst%3DN.%2BF.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26aulast%3DKohan%26aufirst%3DD.%2BE.%26atitle%3DProfile%2520of%2520Past%2520and%2520Current%2520Clinical%2520Trials%2520Involving%2520Endothelin%2520Receptor%2520Antagonists%253A%2520The%2520Novel%2520%25E2%2580%259CSentan%25E2%2580%259D%2520Class%2520of%2520Drug%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2006%26volume%3D231%26spage%3D653%26epage%3D695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Liu, G.</span><span> </span><span class="NLM_article-title">Recent Advances in Endothelin Antagonism</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">â</span> <span class="NLM_lpage">82</span><span class="refDoi">Â DOI: 10.1016/S0065-7743(00)35009-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0065-7743%2800%2935009-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=73-82&author=G.+Liu&title=Recent+Advances+in+Endothelin+Antagonism&doi=10.1016%2FS0065-7743%2800%2935009-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2800%2935009-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252800%252935009-6%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DRecent%2520Advances%2520in%2520Endothelin%2520Antagonism%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2000%26volume%3D35%26spage%3D73%26epage%3D82%26doi%3D10.1016%2FS0065-7743%2800%2935009-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Morris, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. J.</span><span> </span><span class="NLM_article-title">Specific Inhibition of the Endothelin A Receptor with ZD4054: Clinical and Pre-clinical Evidence</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">2148</span><span class="NLM_x">â</span> <span class="NLM_lpage">2152</span><span class="refDoi">Â DOI: 10.1038/sj.bjc.6602676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fsj.bjc.6602676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15956965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVygur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=2148-2152&author=C.+D.+Morrisauthor=A.+Roseauthor=J.+Curwenauthor=A.+M.+Hughesauthor=D.+J.+Wilsonauthor=D.+J.+Webb&title=Specific+Inhibition+of+the+Endothelin+A+Receptor+with+ZD4054%3A+Clinical+and+Pre-clinical+Evidence&doi=10.1038%2Fsj.bjc.6602676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence</span></div><div class="casAuthors">Morris, C. D.; Rose, A.; Curwen, J.; Hughes, A. M.; Wilson, D. J.; Webb, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2148-2152</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the endothelin A receptor (ETA) by endothelin-1 (ET-1) mediates events that regulate mitogenesis, apoptosis, angiogenesis and metastasis in tumors.  Specific blockade of ETA may have anticancer effects, while retaining beneficial endothelin B receptor (ETB)-mediated effects such as apoptosis and clearance of ET-1.  ZD4054 is an orally active, specific ETA antagonist in clin. development.  In receptor-binding studies, ZD4054 specifically bound to ETA with high affinity; no binding was detected at ETB.  In a randomized placebo-controlled trial in eight healthy volunteers, a single oral dose of ZD4054 reduced forearm vasoconstriction in response to brachial artery infusion of ET-1, thus providing clin. evidence of ETA blockade.  ETB blockade was assessed in an ascending, single-dose, placebo-controlled trial in 28 volunteers.  For all doses of ZD4054, mean plasma ET-1 concns. measured at 4 and 24 h were within the placebo ref. range (a rise in ET-1 would indicate ETB blockade) and there was no evidence of dose-related changes.  These data confirm the specificity of ZD4054 for ETA, with no activity at ETB in a clin. or preclin. setting.  As a result of this specificity, ZD4054 has the potential to block multiple ETA-induced pathol. processes, while allowing beneficial ETB-mediated processes to continue, which may, in turn, lead to an effective cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ4WG1oODdkrVg90H21EOLACvtfcHk0li2XQe951HrtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVygur0%253D&md5=1855e8ee995ac28e9a737d13bcfb1613</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6602676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6602676%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DC.%2BD.%26aulast%3DRose%26aufirst%3DA.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DHughes%26aufirst%3DA.%2BM.%26aulast%3DWilson%26aufirst%3DD.%2BJ.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26atitle%3DSpecific%2520Inhibition%2520of%2520the%2520Endothelin%2520A%2520Receptor%2520with%2520ZD4054%253A%2520Clinical%2520and%2520Pre-clinical%2520Evidence%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26spage%3D2148%26epage%3D2152%26doi%3D10.1038%2Fsj.bjc.6602676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Price, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, L. S.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension: Rationale and Place in Therapy</span> <span class="citation_source-journal">Am. J. Cardiovasc. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">â</span> <span class="NLM_lpage">185</span><span class="refDoi">Â DOI: 10.2165/00129784-200808030-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2165%2F00129784-200808030-00004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=171-185&author=L.+C.+Priceauthor=L.+S.+Howard&title=Endothelin+Receptor+Antagonists+for+Pulmonary+Arterial+Hypertension%3A+Rationale+and+Place+in+Therapy&doi=10.2165%2F00129784-200808030-00004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2165%2F00129784-200808030-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00129784-200808030-00004%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DL.%2BC.%26aulast%3DHoward%26aufirst%3DL.%2BS.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%2520for%2520Pulmonary%2520Arterial%2520Hypertension%253A%2520Rationale%2520and%2520Place%2520in%2520Therapy%26jtitle%3DAm.%2520J.%2520Cardiovasc.%2520Drugs%26date%3D2008%26volume%3D8%26spage%3D171%26epage%3D185%26doi%3D10.2165%2F00129784-200808030-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Bourgeois, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebourcet, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mondon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mignot, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duc-Goiran, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FerrÃ©, F.</span><span> </span><span class="NLM_article-title">Endothelin-1 and ETA Receptor Expression in Vascular Smooth Muscle Cells from Human Placenta: A New ETA Receptor Messenger Ribonucleic Acid Is Generated by Alternative Splicing of Exon 3</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">3116</span><span class="NLM_x">â</span> <span class="NLM_lpage">3123</span><span class="refDoi">Â DOI: 10.1210/jcem.82.9.4209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1210%2Fjcem.82.9.4209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=9284755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK2sXlvFemtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1997&pages=3116-3123&author=C.+Bourgeoisauthor=B.+Robertauthor=R.+Rebourcetauthor=F.+Mondonauthor=T.+M.+Mignotauthor=P.+Duc-Goiranauthor=F.+Ferr%C3%A9&title=Endothelin-1+and+ETA+Receptor+Expression+in+Vascular+Smooth+Muscle+Cells+from+Human+Placenta%3A+A+New+ETA+Receptor+Messenger+Ribonucleic+Acid+Is+Generated+by+Alternative+Splicing+of+Exon+3&doi=10.1210%2Fjcem.82.9.4209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1 and ETA receptor expression in vascular smooth muscle cells from human placenta: a new ETA receptor messenger ribonucleic acid is generated by alternative splicing of exon 3</span></div><div class="casAuthors">Bourgeois, Christelle; Robert, Brigitte; Rebourcet, Regis; Mondon, Francoise; Mignot, Therese-Marie; Duc-Goiran, Paulette; Ferre, Francoise</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3116-3123</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Endothelin-1 (ET-1) is a potent vasoactive peptide in stem villi vessels, which are considered to be the major sites of placental vascular resistance.  To investigate the influence of pregnancy-specific hormonal environment on ET and ET receptor (ET-R) expression, we first developed and characterized a culture of vascular smooth muscle cells from stem villi vessels.  Secondly, we investigated whether the muscular layer of stem villi vessels could be a site of the ET expression described in the placenta, and we examd. this expression in placental vascular smooth muscle cells (PVSMCs).  Prepro-ET-1 and prepro-ET-3 mRNA were identified in stem villi vessels, whereas only prepro-ET-1 mRNA was obsd. in PVSMCs.  Third, with the goal of using PVSMCs as ET target cells, we characterized the ET-R expressed by these cells in comparison with the muscular layer of stem villi vessels.  Whereas both ETA-R and ETB-R are present in stem villi vessels, we found that PVSMCs express exclusively ETA-R.  In addn. to the previously reported ETA-R spliced transcripts, we described a new ETA-R transcripts, ETA-RÎ3, generated by exclusion of exon 3 in stem villi vessels and PVSMCs.  Alternative splicing mechanisms of ETA-R mRNA could constitute a control of the abundance of active ETA-R in terms of contractility.  PVSMCs will be a useful model to study the environmental stimuli involved in the regulation of ET and ET-R expression in the muscular layer of feto-placental vasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcw1O2OXAL07Vg90H21EOLACvtfcHk0lg3ehIw1P84lw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvFemtbk%253D&md5=2ab073fc2de80e881afd4fb4ba38d337</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1210%2Fjcem.82.9.4209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.82.9.4209%26sid%3Dliteratum%253Aachs%26aulast%3DBourgeois%26aufirst%3DC.%26aulast%3DRobert%26aufirst%3DB.%26aulast%3DRebourcet%26aufirst%3DR.%26aulast%3DMondon%26aufirst%3DF.%26aulast%3DMignot%26aufirst%3DT.%2BM.%26aulast%3DDuc-Goiran%26aufirst%3DP.%26aulast%3DFerr%25C3%25A9%26aufirst%3DF.%26atitle%3DEndothelin-1%2520and%2520ETA%2520Receptor%2520Expression%2520in%2520Vascular%2520Smooth%2520Muscle%2520Cells%2520from%2520Human%2520Placenta%253A%2520A%2520New%2520ETA%2520Receptor%2520Messenger%2520Ribonucleic%2520Acid%2520Is%2520Generated%2520by%2520Alternative%2520Splicing%2520of%2520Exon%25203%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1997%26volume%3D82%26spage%3D3116%26epage%3D3123%26doi%3D10.1210%2Fjcem.82.9.4209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Elshourbagy, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamou, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagnon, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambi, P.</span><span> </span><span class="NLM_article-title">Molecular Characterization of a Novel Human Endothelin Receptor Splice Variant</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">25300</span><span class="NLM_x">â</span> <span class="NLM_lpage">25307</span><span class="refDoi">Â DOI: 10.1074/jbc.271.41.25300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1074%2Fjbc.271.41.25300" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=25300-25307&author=N.+A.+Elshourbagyauthor=J.+E.+Adamouauthor=A.+W.+Gagnonauthor=H.+L.+Wuauthor=M.+Pullenauthor=P.+Nambi&title=Molecular+Characterization+of+a+Novel+Human+Endothelin+Receptor+Splice+Variant&doi=10.1074%2Fjbc.271.41.25300"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.41.25300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.41.25300%26sid%3Dliteratum%253Aachs%26aulast%3DElshourbagy%26aufirst%3DN.%2BA.%26aulast%3DAdamou%26aufirst%3DJ.%2BE.%26aulast%3DGagnon%26aufirst%3DA.%2BW.%26aulast%3DWu%26aufirst%3DH.%2BL.%26aulast%3DPullen%26aufirst%3DM.%26aulast%3DNambi%26aufirst%3DP.%26atitle%3DMolecular%2520Characterization%2520of%2520a%2520Novel%2520Human%2520Endothelin%2520Receptor%2520Splice%2520Variant%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D25300%26epage%3D25307%26doi%3D10.1074%2Fjbc.271.41.25300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Imamura, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arimoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiyoshi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doi, T.</span><span> </span><span class="NLM_article-title">W276 Mutation in the Endothelin Receptor Subtype B Impairs G<sub>q</sub> Coupling but Not G<sub>i</sub> or G<sub>o</sub> Coupling</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">686</span><span class="NLM_x">â</span> <span class="NLM_lpage">692</span><span class="refDoi">Â DOI: 10.1021/bi991981z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi991981z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=686-692&author=F.+Imamuraauthor=I.+Arimotoauthor=Y.+Fujiyoshiauthor=T.+Doi&title=W276+Mutation+in+the+Endothelin+Receptor+Subtype+B+Impairs+Gq+Coupling+but+Not+Gi+or+Go+Coupling&doi=10.1021%2Fbi991981z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fbi991981z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi991981z%26sid%3Dliteratum%253Aachs%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DArimoto%26aufirst%3DI.%26aulast%3DFujiyoshi%26aufirst%3DY.%26aulast%3DDoi%26aufirst%3DT.%26atitle%3DW276%2520Mutation%2520in%2520the%2520Endothelin%2520Receptor%2520Subtype%2520B%2520Impairs%2520Gq%2520Coupling%2520but%2520Not%2520Gi%2520or%2520Go%2520Coupling%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D686%26epage%3D692%26doi%3D10.1021%2Fbi991981z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Lo, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, D. P.</span><span> </span><span class="NLM_article-title">Promoter Hypermethylation of the EDNRB Gene in Nasopharyngeal Carcinoma</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">â</span> <span class="NLM_lpage">655</span><span class="refDoi">Â DOI: 10.1002/ijc.10271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fijc.10271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=11920632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Wrurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2002&pages=651-655&author=K.+W.+Loauthor=Y.+S.+Tsangauthor=J.+Kwongauthor=K.+F.+Toauthor=P.+M.+Teoauthor=D.+P.+Huang&title=Promoter+Hypermethylation+of+the+EDNRB+Gene+in+Nasopharyngeal+Carcinoma&doi=10.1002%2Fijc.10271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma</span></div><div class="casAuthors">Lo, Kwok-Wai; Tsang, Yuen-Shan; Kwong, Joseph; To, Ka-Fai; Teo, Peter M. L.; Huang, Dolly P.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">651-655</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">To identify the epigenetic changes in nasopharyngeal carcinoma (NPC), we performed methylation-sensitive restriction fingerprinting (MSRF) anal. on NPC cell lines and xenografts.  A 190 bp sequence methylated in NPC tumors was isolated and showed high homol. to the 5' CpG island of the endothelin receptor B (EDNRB) gene.  Since the EDNRB gene is commonly inactivated in prostate and bladder cancers, it may be a candidate target gene involved in NPC tumorigenesis.  By bisulfite sequencing, we have confirmed that hypermethylation of the 5' CpG island of EDNRB occurred in both xenografts and all 4 cell lines but not in 2 normal nasopharyngeal outgrowths.  RT-PCR demonstrated that only original EDNRB transcripts, but not the splicing transcripts, were expressed in normal nasopharyngeal epithelial cells.  Loss of the original EDNRB expression was consistently found in 2 xenografts and 3 cell lines with dense methylation patterns.  Treatment of these 3 cell lines with 5'-aza-2'-deoxycytidine led to re-expression of the EDNRB transcript and demethylation of its promoter regions.  Our results demonstrate that silencing of EDNRB gene expression in NPC is assocd. with promoter hypermethylation.  Using methylation-specific PCR, we also detected methylation of the 5' CpG island of EDNRB in 19/21 (90.5%) primary tumors, while no methylation was found in all 6 normal nasopharyngeal epithelia.  The high frequencies of promoter hypermethylation suggest that repression of the EDNRB gene may play a role in the development of NPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr827IJhzPEGLVg90H21EOLACvtfcHk0lg3ehIw1P84lw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Wrurw%253D&md5=d5a2fe49125f9acc745209c9d9413e72</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fijc.10271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10271%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DK.%2BW.%26aulast%3DTsang%26aufirst%3DY.%2BS.%26aulast%3DKwong%26aufirst%3DJ.%26aulast%3DTo%26aufirst%3DK.%2BF.%26aulast%3DTeo%26aufirst%3DP.%2BM.%26aulast%3DHuang%26aufirst%3DD.%2BP.%26atitle%3DPromoter%2520Hypermethylation%2520of%2520the%2520EDNRB%2520Gene%2520in%2520Nasopharyngeal%2520Carcinoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D98%26spage%3D651%26epage%3D655%26doi%3D10.1002%2Fijc.10271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Miyamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimasa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakao, K.</span><span> </span><span class="NLM_article-title">Alternative RNA Splicing of the Human Endothelin-A Receptor Generates Multiple Transcripts</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">â</span> <span class="NLM_lpage">801</span><span class="refDoi">Â DOI: 10.1042/bj3130795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1042%2Fbj3130795" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=1996&pages=795-801&author=Y.+Miyamotoauthor=T.+Yoshimasaauthor=H.+Araiauthor=K.+Takayaauthor=Y.+Ogawaauthor=H.+Itohauthor=K.+Nakao&title=Alternative+RNA+Splicing+of+the+Human+Endothelin-A+Receptor+Generates+Multiple+Transcripts&doi=10.1042%2Fbj3130795"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1042%2Fbj3130795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3130795%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DY.%26aulast%3DYoshimasa%26aufirst%3DT.%26aulast%3DArai%26aufirst%3DH.%26aulast%3DTakaya%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DH.%26aulast%3DNakao%26aufirst%3DK.%26atitle%3DAlternative%2520RNA%2520Splicing%2520of%2520the%2520Human%2520Endothelin-A%2520Receptor%2520Generates%2520Multiple%2520Transcripts%26jtitle%3DBiochem.%2520J.%26date%3D1996%26volume%3D313%26spage%3D795%26epage%3D801%26doi%3D10.1042%2Fbj3130795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Nambi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagnon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elshourbagy, N.</span><span> </span><span class="NLM_article-title">Characterization of a Novel Porcine Endothelin-B Receptor Splice Variant</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">292</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">â</span> <span class="NLM_lpage">253</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10604954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslGlug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2000&pages=247-253&author=P.+Nambiauthor=H.+L.+Wuauthor=D.+Yeauthor=A.+Gagnonauthor=N.+Elshourbagy&title=Characterization+of+a+Novel+Porcine+Endothelin-B+Receptor+Splice+Variant"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a novel porcine endothelinB receptor splice variant</span></div><div class="casAuthors">Nambi, Ponnal; Wu, Hsiao-Ling; Ye, Diana; Gagnon, Alison; Elshourbagy, Nabil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">247-253</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Screening of porcine cerebellum cDNA library with porcine endothelinB (ETB) receptor cDNA revealed a novel ETB receptor cDNA that is distinctly different from the wild-type ETB receptor in length and the amino acid sequence at the C-terminal end.  This sequence appears to represent alternate splicing of the carboxy terminal end of ETB receptor, resulting in a polypeptide of 429 amino acids in length, which is 14 amino acids shorter than the wild-type porcine ETB receptor.  Characterization of the wild-type and alternatively spliced ETB receptors expressed in COS cells revealed that both receptors displayed very similar binding [apparent dissocn. const. (Kd) and max. binding (Bmax) for 125I-ET-1 were 71 pM and 1.6 pmol/mg protein for wild-type and 81 pM and 1.2 pmol/mg protein for splice variant ETB receptors] as well as functional properties.  These data suggest that the differences in the amino acids at the C-terminal end had no effect on binding or functional coupling of these alternately spliced ETB receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrb1FU3PjVsLVg90H21EOLACvtfcHk0lj3ozm7ngh90w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslGlug%253D%253D&md5=929cbd10c76cd58ba06d72f741f17b5e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNambi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DH.%2BL.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DGagnon%26aufirst%3DA.%26aulast%3DElshourbagy%26aufirst%3DN.%26atitle%3DCharacterization%2520of%2520a%2520Novel%2520Porcine%2520Endothelin-B%2520Receptor%2520Splice%2520Variant%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D292%26spage%3D247%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Pao, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uzvolgyi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">The Endothelin Receptor B (EDNRB) Promoter Displays Heterogeneous, Site Specific Methylation Patterns in Normal and Tumor Cells</span> <span class="citation_source-journal">Hum. Mol. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">â</span> <span class="NLM_lpage">910</span><span class="refDoi">Â DOI: 10.1093/hmg/10.9.903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1093%2Fhmg%2F10.9.903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=11309363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVels7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2001&pages=903-910&author=M.+M.+Paoauthor=M.+Tsutsumiauthor=G.+Liangauthor=E.+Uzvolgyiauthor=F.+A.+Gonzalesauthor=P.+A.+Jones&title=The+Endothelin+Receptor+B+%28EDNRB%29+Promoter+Displays+Heterogeneous%2C+Site+Specific+Methylation+Patterns+in+Normal+and+Tumor+Cells&doi=10.1093%2Fhmg%2F10.9.903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells</span></div><div class="casAuthors">Pao, Martha M.; Tsutsumi, Masakazu; Liang, Gangning; Uzvolgyi, Eva; Gonzales, Felicidad A.; Jones, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">903-910</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The 5' region for the endothelin receptor B (EDNRB) gene is a complex CpG island giving rise to four individual transcripts initiating within the island.  Here, for the first time, we analyze the relationship between methylation and gene expression in a CpG island located in the 5' region of a gene with multiple transcription start sites.  The CpG island was unmethylated in normal prostate and bladder tissue, whereas it became methylated in apparently normal colonic epithelium.  Tumors derived from these tissues were frequently hypermethylated relative to the resp. normal tissues.  Anal. of 11 individual CpG sites located throughout the CpG island showed that specific sites with high methylation levels in several tumors were also methylated in normal tissues, suggesting that they might serve as foci for further de novo methylation.  This region also had high levels of methylation in several cancer cell lines, and we found that a low methylation level in a small region within the 5' region correlated with expression of the 5'-most transcript.  Interestingly, almost complete methylation 200-1000 bp downstream of the transcriptional start site did not block expression of this transcript.  Finally, we show that treatment with 5-aza-2'-deoxycytidine can induce transcriptional activation of the four EDNRB transcripts.  Our results show the existence of differential, tissue-dependent methylation at the EDNRB5' region, suggest the existence of a spreading mechanism for de novo methylation, starting from methylation hotspots, and show that hypermethylation immediately 3' to a transcriptional start site does not prevent initiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp4YIFTQVMK7Vg90H21EOLACvtfcHk0lj3ozm7ngh90w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVels7w%253D&md5=a64ad13d2665939666437b73a6b31ba3</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2F10.9.903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252F10.9.903%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DM.%2BM.%26aulast%3DTsutsumi%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DUzvolgyi%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DF.%2BA.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DThe%2520Endothelin%2520Receptor%2520B%2520%2528EDNRB%2529%2520Promoter%2520Displays%2520Heterogeneous%252C%2520Site%2520Specific%2520Methylation%2520Patterns%2520in%2520Normal%2520and%2520Tumor%2520Cells%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2001%26volume%3D10%26spage%3D903%26epage%3D910%26doi%3D10.1093%2Fhmg%2F10.9.903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Shyamala, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moulthrop, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton-Thomas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tekamp-Olson, P.</span><span> </span><span class="NLM_article-title">Two Distinct Human Endothelin B Receptors Generated by Alternative Splicing Form a Single Gene</span> <span class="citation_source-journal">Cell. Mol. Biol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">â</span> <span class="NLM_lpage">296</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=7866430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK2MXit1Okuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1994&pages=285-296&author=V.+Shyamalaauthor=T.+H.+Moulthropauthor=J.+Stratton-Thomasauthor=P.+Tekamp-Olson&title=Two+Distinct+Human+Endothelin+B+Receptors+Generated+by+Alternative+Splicing+Form+a+Single+Gene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Two distinct human endothelin B receptors generated by alternative splicing from a single gene</span></div><div class="casAuthors">Shyamala, Venkatakrishna; Moulthrop, Thomas H. M.; Stratton-Thomas, Jennifer; Tekamp-Olson, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Biology Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">285-96</span>CODEN:
                <span class="NLM_cas:coden">CMBREW</span>;
        ISSN:<span class="NLM_cas:issn">0968-8773</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A novel variant of endothelin B receptor (ETB) has been found in human brain, placenta, lung, and heart by reverse transcriptase polymerase chain reaction.  This variant ETB1 has an addnl. 30 nucleotide sequence with splice sites at both ends.  This results in a 10-amino acid increase in the length of the second cytoplasmic domain of ETB.  Polymerase chain reaction on genomic DNA indicates that this sequence is part of the 134 bp intron which separates the 2nd and 3rd exons and is contiguous with the 3rd exon of the ETB gene.  Southern blot anal. of chromosomal DNA and genomic PCR results indicate that ETB1 arises by alternative RNA splicing of the single copy ETB gene.  The insert sequence in ETB1 gene is absent in bovine, rat, and porcine DNA, and is unique to human DNA.  Both ETB and ETB1 have been expressed in heterologous systems to examine their ligand binding and functional properties.  Reverse transcriptase polymerase chain reaction of RNA from ETB1 expressing cells indicate that the addnl. sequence is stably expressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom4C1cNuQgt7Vg90H21EOLACvtfcHk0lj3ozm7ngh90w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXit1Okuro%253D&md5=5c0ed0a5574e30a73dc7c0c0cacbcbc3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShyamala%26aufirst%3DV.%26aulast%3DMoulthrop%26aufirst%3DT.%2BH.%26aulast%3DStratton-Thomas%26aufirst%3DJ.%26aulast%3DTekamp-Olson%26aufirst%3DP.%26atitle%3DTwo%2520Distinct%2520Human%2520Endothelin%2520B%2520Receptors%2520Generated%2520by%2520Alternative%2520Splicing%2520Form%2520a%2520Single%2520Gene%26jtitle%3DCell.%2520Mol.%2520Biol.%2520Res.%26date%3D1994%26volume%3D40%26spage%3D285%26epage%3D296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Tsutsumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">Novel Endothelin B Receptor Transcripts with the Potential of Generating a New Receptor</span> <span class="citation_source-journal">Gene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">â</span> <span class="NLM_lpage">49</span><span class="refDoi">Â DOI: 10.1016/S0378-1119(99)00014-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0378-1119%2899%2900014-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=1999&pages=43-49&author=M.+Tsutsumiauthor=G.+Liangauthor=P.+A.+Jones&title=Novel+Endothelin+B+Receptor+Transcripts+with+the+Potential+of+Generating+a+New+Receptor&doi=10.1016%2FS0378-1119%2899%2900014-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0378-1119%2899%2900014-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-1119%252899%252900014-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsutsumi%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520Endothelin%2520B%2520Receptor%2520Transcripts%2520with%2520the%2520Potential%2520of%2520Generating%2520a%2520New%2520Receptor%26jtitle%3DGene%26date%3D1999%26volume%3D228%26spage%3D43%26epage%3D49%26doi%3D10.1016%2FS0378-1119%2899%2900014-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Zhang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burchill, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaski, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, N. D.</span><span> </span><span class="NLM_article-title">Truncated Human Endothelin Receptor A Produced by Alternative Splicing and Its Expression in Melanoma</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">1141</span><span class="NLM_x">â</span> <span class="NLM_lpage">1146</span><span class="refDoi">Â DOI: 10.1038/bjc.1998.643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fbjc.1998.643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=9820169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK1cXntlSqs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1998&pages=1141-1146&author=Y.+F.+Zhangauthor=S.+Jefferyauthor=S.+A.+Burchillauthor=P.+A.+Berryauthor=J.+C.+Kaskiauthor=N.+D.+Carter&title=Truncated+Human+Endothelin+Receptor+A+Produced+by+Alternative+Splicing+and+Its+Expression+in+Melanoma&doi=10.1038%2Fbjc.1998.643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Truncated human endothelin receptor A produced by alternative splicing and its expression in melanoma</span></div><div class="casAuthors">Zhang, Y. F.; Jeffery, S.; Burchill, S. A.; Berry, P. A.; Kaski, J. C.; Carter, N. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1141-1146</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">In this study, reverse transcriptase polymerase chain reaction was used to amplify human endothelin receptor A (ETA) and ETB receptor mRNA.  A truncated ETA receptor transcript with exons 3 and 4 skipped was found.  The skipping of these two exons results in 109 amino acids being deleted from the receptor.  The truncated receptor was expressed in all tissues and cells examd., but the level of expression varied.  In melanoma cell lines and melanoma tissues, the truncated receptor gene was the major species, whereas the wild-type ETA was predominant in other tissues.  A 1.9-kb ETA transcript was identified in melanoma cell lines by Northern blot, which was much smaller than the transcript in heart and in other tissues reported previously (4.3 kb).  The cDNA coding regions of the truncated and wild-type ETA receptors were stably transfected into Chinese hamster ovary (CHO) cells.  The truncated ETA receptor-transfected CHO cells did not show binding affinity to endothelin 1 (ET-1) or endothelin 3 (ET-3).  The function and biol. significance of this truncated ETA receptor is not clear, but it may have regulatory roles for cell responses to ETs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooR2Ds53UeILVg90H21EOLACvtfcHk0ljJ_Bu6u3-Q3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntlSqs7o%253D&md5=8a1602c1f24fb37497ffcc72a3a23500</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1998.643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1998.643%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BF.%26aulast%3DJeffery%26aufirst%3DS.%26aulast%3DBurchill%26aufirst%3DS.%2BA.%26aulast%3DBerry%26aufirst%3DP.%2BA.%26aulast%3DKaski%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DN.%2BD.%26atitle%3DTruncated%2520Human%2520Endothelin%2520Receptor%2520A%2520Produced%2520by%2520Alternative%2520Splicing%2520and%2520Its%2520Expression%2520in%2520Melanoma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1998%26volume%3D78%26spage%3D1141%26epage%3D1146%26doi%3D10.1038%2Fbjc.1998.643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Berger, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernasconi, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Targeting the Endothelin Axis in Human Melanoma: Combination of Endothelin Receptor Antagonism and Alkylating Agents</span> <span class="citation_source-journal">Exp. Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">â</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD28Xlt1ertb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2006&pages=1111-1119&author=Y.+Bergerauthor=C.+C.+Bernasconiauthor=L.+Juillerat-Jeanneret&title=Targeting+the+Endothelin+Axis+in+Human+Melanoma%3A+Combination+of+Endothelin+Receptor+Antagonism+and+Alkylating+Agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents</span></div><div class="casAuthors">Berger, Yann; Bernasconi, Catherine Chapuis; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (Maywood, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1111-1119</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3702</span>.
    
            (<span class="NLM_cas:orgname">Society for Experimental Biology and Medicine</span>)
        </div><div class="casAbstract">Endothelin (ET)-1 is an autocrine/paracrine growth factor or an antiapoptotic factor in human cancers, and blockade of ET-1 receptors can sensitize human tumor cells to apoptosis.  The role of the ET-1 axis in the proliferation and/or apoptosis of melanoma cells and in their response to the alkylating agent, dacarbazine (DTIC), used in clin. treatment of human melanoma were investigated in five human melanoma cell lines obtained form surgical resection specimens.  Melanoma cells expressed the mRNAs for the components of the ET-1 axis.  ET-1 binding was mediated by ETB but was inhomogeneous among melanoma cells.  Exogenous ET-1 did not induce human melanoma cell proliferation.  Bosentan, a dual ETA/B-receptor antagonist, decreased melanoma cell viability and DNA synthesis and induced melanoma cell apoptosis in defined human melanoma cells.  Bosentan potentiated Fas ligand-induced apoptosis only in one melanoma cell line.  Variants of ETB were detd. using reverse transcriptase (RT) polymerase chain reaction (PCR) and primers spanning the whole sequence of the ETB gene.  ETB variants were demonstrated only in one of the five cell lines, corresponding to the absence of ET-1 binding by these cells.  Bosentan did not inhibit the effects of alkylating agents, and the effects of bosentan and alkylating agents were additive in melanoma cells.  In conclusion, exogenous ET-1 is not a growth factor for human melanoma cells, but blockade of ET receptors decreases proliferation, induces apoptosis, and potentiates the effects of anticancer agents in defined melanoma cells, suggesting that combination therapy of ET-receptor antagonists with alkylating agents may improve their efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB67LiHJL8srVg90H21EOLACvtfcHk0ljJ_Bu6u3-Q3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xlt1ertb8%253D&md5=5a26d6190d1a598df50aacf949607419</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DY.%26aulast%3DBernasconi%26aufirst%3DC.%2BC.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DTargeting%2520the%2520Endothelin%2520Axis%2520in%2520Human%2520Melanoma%253A%2520Combination%2520of%2520Endothelin%2520Receptor%2520Antagonism%2520and%2520Alkylating%2520Agents%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2006%26volume%3D231%26spage%3D1111%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Roh, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manola, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidransky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forastiere, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, W. M.</span><span> </span><span class="NLM_article-title">Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2528</span><span class="NLM_x">â</span> <span class="NLM_lpage">2540</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-12-3047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1078-0432.CCR-12-3047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23444219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWqs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2528-2540&author=J.+L.+Rohauthor=X.+V.+Wangauthor=J.+Manolaauthor=D.+Sidranskyauthor=A.+A.+Forastiereauthor=W.+M.+Koch&title=Clinical+Correlates+of+Promoter+Hypermethylation+of+Four+Target+Genes+in+Head+and+Neck+Cancer%3A+A+Cooperative+Group+Correlative+Study&doi=10.1158%2F1078-0432.CCR-12-3047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study</span></div><div class="casAuthors">Roh, Jong-Lyel; Wang, Xin Victoria; Manola, Judith; Sidransky, David; Forastiere, Arlene A.; Koch, Wayne M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2528-2540</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Promoter hypermethylation is a well-documented mechanism for tumor-specific alteration of suppressor gene activity in human malignancy including head and neck cancer (HNC).  The abrogation of specific suppressor gene activity may influence tumor behavior and clin. outcome.  In this study we examd. methylation of DCC, KIF1A, EDNRB, and p16INK4a in a large cohort of HNC patients from Eastern Cooperative Group (ECOG) 4393/Radiation Therapy Oncol. Group (RTOG) 9614 to identify clin. correlates of methylation of these genes.  Exptl. Design: Methylation was assessed by quant. methylation-specific PCR in DNA from tumor specimens and was considered as a continuous and a binary variable.  Clin. data including demographics, stage, risk factor exposure, treatment, and outcome were collected by ECOG and RTOG.  Methylation status was also correlated with mutation of TP53 (previously reported) and human papilloma virus status.  Results: Methylation results were available for 368 cases, 353 of which also have p53 mutation status.  At least one methylation event was present in all tumors.  In multivariate anal. of the entire cohort, methylation of p16 was assocd. with decreased survival (HR = 1.008; P = 0.045).  However, in tumors with disruptive TP53 mutation (poor prognostic group), the addnl. presence of methylation of p16 was protective (P = 0.019 considering p16 methylation as a continuous variable).  Conclusion: Methylation of tumor-related genes contributes to the biol. behavior of HNC and influences overall survival in conjunction with other known prognostic mol. events.  Clin Cancer Res; 19(9); 2528-40. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppMqVZ4qLqirVg90H21EOLACvtfcHk0ljJ_Bu6u3-Q3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWqs7o%253D&md5=850214505b612d101275c72f4fb78f95</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3047%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BV.%26aulast%3DManola%26aufirst%3DJ.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DForastiere%26aufirst%3DA.%2BA.%26aulast%3DKoch%26aufirst%3DW.%2BM.%26atitle%3DClinical%2520Correlates%2520of%2520Promoter%2520Hypermethylation%2520of%2520Four%2520Target%2520Genes%2520in%2520Head%2520and%2520Neck%2520Cancer%253A%2520A%2520Cooperative%2520Group%2520Correlative%2520Study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2528%26epage%3D2540%26doi%3D10.1158%2F1078-0432.CCR-12-3047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Tao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G.</span><span> </span><span class="NLM_article-title">Quantitative Analysis of Promoter Methylation of the EDNRB Gene in Gastric Cancer</span> <span class="citation_source-journal">Med. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">â</span> <span class="NLM_lpage">112</span><span class="refDoi">Â DOI: 10.1007/s12032-010-9805-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs12032-010-9805-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21264540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1ejurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=107-112&author=K.+Taoauthor=C.+Wuauthor=K.+Wuauthor=W.+Liauthor=G.+Hanauthor=X.+Shuaiauthor=G.+Wang&title=Quantitative+Analysis+of+Promoter+Methylation+of+the+EDNRB+Gene+in+Gastric+Cancer&doi=10.1007%2Fs12032-010-9805-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of promoter methylation of the EDNRB gene in gastric cancer</span></div><div class="casAuthors">Tao, Kaixiong; Wu, Chuanqing; Wu, Ke; Li, Wei; Han, Gaoxiong; Shuai, Xiaoming; Wang, Guobin</div><div class="citationInfo"><span class="NLM_cas:title">Medical Oncology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-112</span>CODEN:
                <span class="NLM_cas:coden">MONCEZ</span>;
        ISSN:<span class="NLM_cas:issn">1357-0560</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Hypermethylation has been shown in the promoter region of the endothelin receptor B (EDNRB) gene in several human tumors.  However, its role in gastric cancer formation is still unclear.  In this study, the methylation status of the EDNRB gene in paired gastric cancer tissues and adjacent normal tissues from 96 patients was detected quant. using pyrosequencing.  The results showed the methylation of promoter of EDNRB gene in gastric cancer (50.42 Â± 9.03%) was significantly higher than in adjacent normal tissues (6.47 Â± 2.98%) (P < 0.01).  Among 96 tumor tissues, promoter hypermethylation of the EDNRB gene was correlated with tumor infiltration (T1: 47.4 Â± 7.31% T2:48.2 Â± 9.17% T3:52.9 Â± 6.48% T4:53.2 Â± 10.45%), lymph node metastasis (N0:45.4 Â± 6.99% N1:49.0 Â± 9.10% N2:52.0 Â± 8.40% N3:53.7 Â± 9.92%), and distant metastasis (M0:48.9 Â± 6.99% M1:53.9 Â± 11.98%) (P < 0.05), but it was not assocd. with other clinicopathol. characteristics.  In addn., the treatment of the human gastric cancer cell line, SGC-7901, with demethylation agent can restore the expression of EDNRB.  Our results suggest that promoter hypermethylation of EDNRB gene is highly prevalent in gastric cancer, which may play a role in the pathogenesis of gastric cancer.  Furthermore, hypermethylation of EDNRB gene was remarkably related to infiltration and metastasis of gastric cancer and may attribute to the tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpViRjU67w4SbVg90H21EOLACvtfcHk0lh3KA6M4ta7yA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1ejurk%253D&md5=52a391fba71c655de3b2a662ceace2b0</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs12032-010-9805-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-010-9805-8%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DG.%26aulast%3DShuai%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DG.%26atitle%3DQuantitative%2520Analysis%2520of%2520Promoter%2520Methylation%2520of%2520the%2520EDNRB%2520Gene%2520in%2520Gastric%2520Cancer%26jtitle%3DMed.%2520Oncol.%26date%3D2012%26volume%3D29%26spage%3D107%26epage%3D112%26doi%3D10.1007%2Fs12032-010-9805-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langleben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudiz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapson, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwicke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frumkin, L. R.</span><span> </span><span class="NLM_article-title">STRIDE-1 Study Group. Sitaxsentan Therapy for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">447</span><span class="refDoi">Â DOI: 10.1164/rccm.200307-957OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1164%2Frccm.200307-957OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=14630619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FmsV2gtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2004&pages=441-447&author=R.+J.+Barstauthor=D.+Langlebenauthor=A.+Frostauthor=E.+M.+Hornauthor=R.+Oudizauthor=S.+Shapiroauthor=V.+McLaughlinauthor=N.+Hillauthor=V.+F.+Tapsonauthor=I.+M.+Robbinsauthor=D.+Zwickeauthor=B.+Duncanauthor=R.+A.+Dixonauthor=L.+R.+Frumkin&title=STRIDE-1+Study+Group.+Sitaxsentan+Therapy+for+Pulmonary+Arterial+Hypertension&doi=10.1164%2Frccm.200307-957OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Sitaxsentan therapy for pulmonary arterial hypertension</span></div><div class="casAuthors">Barst Robyn J; Langleben David; Frost Adaani; Horn Evelyn M; Oudiz Ronald; Shapiro Shelley; McLaughlin Vallerie; Hill Nicholas; Tapson Victor F; Robbins Ivan M; Zwicke Diane; Duncan Benjamin; Dixon Richard A F; Frumkin Lyn R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-7</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Sitaxsentan may benefit patients with pulmonary arterial hypertension by blocking the vasoconstrictor effects of endothelin-A while maintaining the vasodilator/clearance functions of endothelin-B receptors.  Patients with pulmonary arterial hypertension that was idiopathic, related to connective tissue disease or congenital heart disease, were randomized to receive placebo (n = 60), sitaxsentan 100 mg (n = 55), or sitaxsentan 300 mg (n = 63) orally once daily for 12 weeks.  The primary endpoint was change in peak VO(2) at Week 12.  Secondary endpoints included 6-minute walk, New York Heart Association class, VO(2) at anaerobic threshold, VE per carbon dioxide production at anaerobic threshold, hemodynamics, quality of life, and time to clinical worsening.  Although the 300-mg group increased peak VO(2) compared with placebo (+3.1%, p < 0.01), none of the other endpoints derived from cardiopulmonary exercise testing were met.  However, both the 100-mg dose and the 300-mg dose, compared with placebo, increased 6-minute walk distance (100 mg: +35 m, p < 0.01; 300 mg: +33 m, p < 0.01); functional class, cardiac index, and pulmonary vascular resistance also improved (p < 0.02 for each parameter at both doses).  The incidence of elevated aminotransferase values (> three times normal) was 3% for the placebo group, 0% for the 100-mg group, and 10% for the 300-mg group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAfmQEGkmCwYUSrryheKE6fW6udTcc2eaRmvyaslqNqbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FmsV2gtg%253D%253D&md5=e05785158b1043c250aa6643734bbbff</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1164%2Frccm.200307-957OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200307-957OC%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DHorn%26aufirst%3DE.%2BM.%26aulast%3DOudiz%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DMcLaughlin%26aufirst%3DV.%26aulast%3DHill%26aufirst%3DN.%26aulast%3DTapson%26aufirst%3DV.%2BF.%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DZwicke%26aufirst%3DD.%26aulast%3DDuncan%26aufirst%3DB.%26aulast%3DDixon%26aufirst%3DR.%2BA.%26aulast%3DFrumkin%26aufirst%3DL.%2BR.%26atitle%3DSTRIDE-1%2520Study%2520Group.%2520Sitaxsentan%2520Therapy%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2004%26volume%3D169%26spage%3D441%26epage%3D447%26doi%3D10.1164%2Frccm.200307-957OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalina, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶ffler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¼ller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidhart, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramuz, H.</span><span> </span><span class="NLM_article-title">Pharmacological Characteristics of Bosentan, a New Potent Orally Active Nonpeptide Endothelin Receptor Antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">â</span> <span class="NLM_lpage">235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=8035319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK2cXkvF2nsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1994&pages=228-235&author=M.+Clozelauthor=V.+Breuauthor=G.+A.+Grayauthor=B.+Kalinaauthor=B.+M.+L%C3%B6fflerauthor=K.+Burriauthor=J.+M.+Cassalauthor=G.+Hirthauthor=M.+M%C3%BCllerauthor=W.+Neidhartauthor=H.+Ramuz&title=Pharmacological+Characteristics+of+Bosentan%2C+a+New+Potent+Orally+Active+Nonpeptide+Endothelin+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist</span></div><div class="casAuthors">Clozel, Martine; Breu, Volker; Gray, Gillian A.; Kalina, Barbara; Loeffler, Bernd-Michael; Burri, Kaspar; Cassal, Jean-Marie; Hirth, Georges; Mueller, Marcel; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-35</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The authors describe here the pharmacol. properties of bosentan, a new nonpeptide mixed antagonist of endothelin (ET) receptors, obtained by structural optimization of the less potent Ro 46-2005 (4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide).  Bosentan (Ro 47-0203, 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,2'-bipyrimidin-4-yl]-benzenesulfonamide) competitively antagonized the specific binding of [125I]-labeled ET-1 on human smooth muscle cells (ETA receptors) with a Ki of 4.7 nM and on human placenta (ETB receptors) with a Ki of 95 nM.  It also inhibited the binding of selective ETB ligands on porcine trachea.  Contractions induced by ET-1 in isolated rat aorta (ETA) and by the selective ETB agonist sarafotoxin S6C in rat trachea were competitively inhibited by bosentan (pA2 = 7.2 and 6.0, resp.), as was the endothelium-dependent relaxation to sarafotoxin S6C in rabbit superior mesenteric artery (pA2 = 6.7).  The binding of 40 other peptides, prostaglandins, ions and neurotransmitters was not significantly affected by bosentan, which shows its specificity for ET receptors.  In vivo, bosentan inhibited the pressor response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity.  It also inhibited the depressor and pressor effect of ET-1 and sarafotoxin S6C.  Thus, bosentan is the most potent orally active antagonist of ET receptors described so far.  Its pharmacol. profile makes bosentan a potentially useful drug in the management of clin. disorders assocd. with vasoconstriction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopDyWdkz1crbVg90H21EOLACvtfcHk0lh3KA6M4ta7yA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvF2nsb4%253D&md5=a257c4e2f71ed82feea0a3742609f428</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DBreu%26aufirst%3DV.%26aulast%3DGray%26aufirst%3DG.%2BA.%26aulast%3DKalina%26aufirst%3DB.%26aulast%3DL%25C3%25B6ffler%26aufirst%3DB.%2BM.%26aulast%3DBurri%26aufirst%3DK.%26aulast%3DCassal%26aufirst%3DJ.%2BM.%26aulast%3DHirth%26aufirst%3DG.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DRamuz%26aufirst%3DH.%26atitle%3DPharmacological%2520Characteristics%2520of%2520Bosentan%252C%2520a%2520New%2520Potent%2520Orally%2520Active%2520Nonpeptide%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1994%26volume%3D270%26spage%3D228%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galie, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keogh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulido, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leconte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landzberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span> </span><span class="NLM_article-title">Bosentan Therapy for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">â</span> <span class="NLM_lpage">903</span><span class="refDoi">Â DOI: 10.1056/NEJMoa012212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1056%2FNEJMoa012212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=11907289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1ekur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2002&pages=896-903&author=L.+J.+Rubinauthor=D.+B.+Badeschauthor=R.+J.+Barstauthor=N.+Galieauthor=C.+M.+Blackauthor=A.+Keoghauthor=T.+Pulidoauthor=A.+Frostauthor=S.+Rouxauthor=I.+Leconteauthor=M.+Landzbergauthor=G.+Simonneau&title=Bosentan+Therapy+for+Pulmonary+Arterial+Hypertension&doi=10.1056%2FNEJMoa012212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Bosentan therapy for pulmonary arterial hypertension</span></div><div class="casAuthors">Rubin, Lewis J.; Badesch, David B.; Barst, Robyn J.; Galie, Nazzareno; Black, Carol M.; Keogh, Anne; Pulido, Tomas; Frost, Adaani; Roux, Sebastien; Leconte, Isabelle; Landzberg, Michael; Simonneau, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">896-903</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen.  In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension.  The present trial investigated the effect of bosentan on exercise capacity in a larger no. of patients and compared two doses.  Methods: In this double-blind, placebo-controlled study, we randomly assigned 213 patients with pulmonary arterial hypertension (primary or assocd. with connective-tissue disease) to receive placebo or to receive 6.25 mg of bosentan twice daily for 4 wk followed by either of two doses of bosentan (125 or 250 mg twice daily) for a min. of 12 wk.  The primary end point was the degree of change in exercise capacity.  Secondary end points included the change in the Borg dyspnea index, the change in the World Health Organization (WHO) functional class, and the time to clin. worsening.  Results: At week 16, patients treated with bosentan had an improved six-minute walking distance; the mean difference between the placebo group and the combined bosentan groups was 44 m (95 percent confidence interval, 21 to 67; P<0.001).  Bosentan also improved the Borg dyspnea index and WHO functional class and increased the time to clin. worsening.  Conclusions: The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily.  Endothelin-receptor antagonism with oral bosentan is an effective approach to therapy for pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruF1yf9lFcM7Vg90H21EOLACvtfcHk0litMpwRY1nQcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1ekur0%253D&md5=b729b9ccfe57829af31cefe1325f5c25</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa012212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa012212%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DBlack%26aufirst%3DC.%2BM.%26aulast%3DKeogh%26aufirst%3DA.%26aulast%3DPulido%26aufirst%3DT.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DRoux%26aufirst%3DS.%26aulast%3DLeconte%26aufirst%3DI.%26aulast%3DLandzberg%26aufirst%3DM.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DBosentan%2520Therapy%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D346%26spage%3D896%26epage%3D903%26doi%3D10.1056%2FNEJMoa012212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">GaliÃ©, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudiz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGoon, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keogh, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwicke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeije, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olschewski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">Ambrisentan Therapy for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">â</span> <span class="NLM_lpage">535</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2005.04.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.jacc.2005.04.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=16053970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVKnsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=529-535&author=N.+Gali%C3%A9author=D.+Badeschauthor=R.+Oudizauthor=G.+Simonneauauthor=M.+D.+McGoonauthor=A.+M.+Keoghauthor=A.+E.+Frostauthor=D.+Zwickeauthor=R.+Naeijeauthor=S.+Shapiroauthor=H.+Olschewskiauthor=L.+J.+Rubin&title=Ambrisentan+Therapy+for+Pulmonary+Arterial+Hypertension&doi=10.1016%2Fj.jacc.2005.04.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Ambrisentan therapy for pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, Nazzareno; Badesch, David; Oudiz, Ronald; Simonneau, Gerald; McGoon, Michael D.; Keogh, Anne M.; Frost, Adaani E.; Zwicke, Diane; Naeije, Robert; Shapiro, Shelley; Olschewski, Horst; Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">529-535</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial hypertension (PAH).  Pulmonary arterial hypertension is a life-threatening and progressive disease with limited treatment options.  Endothelin is a vasoconstrictor and smooth muscle cell mitogen that plays a crit. role in the pathogenesis and progression of PAH.  In this double-blind, dose-ranging study, 64 patients with idiopathic PAH or PAH assocd. with collagen vascular disease, anorexigen use, or human immunodeficiency virus infection were randomized to receive 1, 2.5, 5, or 10 mg of ambrisentan once daily for 12 wk followed by 12 wk of open-label ambrisentan.  The primary end point was an improvement from baseline in 6-min walk distance (6MWD); secondary end points included Borg dyspnea index, World Health Organization (WHO) functional class, a subject global assessment, and cardiopulmonary hemodynamics.  At 12 wk, ambrisentan increased 6MWD (+36.1 m, p < 0.0001) with similar and statistically significant increases for each dose group (range, +33.9 to +38.1 m).  Improvements were also obsd. in Borg dyspnea index, WHO functional class, subject global assessment, mean pulmonary arterial pressure (-5.2 mm Hg, p < 0.0001), and cardiac index (+0.33 l/min/m2, p < 0.0008).  Adverse events were mild and unrelated to dose, including the incidence of elevated serum aminotransferase concns. >3 times the upper limit of normal (3.1%).  Ambrisentan appears to improve exercise capacity, symptoms, and hemodynamics in patients with PAH.  The incidence and severity of liver enzyme abnormalities appear to be low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEgbxTL0ZlRLVg90H21EOLACvtfcHk0litMpwRY1nQcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVKnsrk%253D&md5=526b6be0c15ac7ca41720557e51e127f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2005.04.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2005.04.050%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A9%26aufirst%3DN.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DOudiz%26aufirst%3DR.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26aulast%3DKeogh%26aufirst%3DA.%2BM.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DZwicke%26aufirst%3DD.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DAmbrisentan%2520Therapy%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2005%26volume%3D46%26spage%3D529%26epage%3D535%26doi%3D10.1016%2Fj.jacc.2005.04.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binkert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iglarz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span> </span><span class="NLM_article-title">The Discovery of <i>N</i>-5-(4-bromophenyl-6-2-(5-Bromo-2-Pyrimidinyl)oxyethoxy-4-pyrimidinyl-<i>Nâ²</i>-propyl-sulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7849</span><span class="NLM_x">â</span> <span class="NLM_lpage">7861</span><span class="refDoi">Â DOI: 10.1021/jm3009103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7849-7861&author=M.+H.+Bolliauthor=C.+Bossauthor=C.+Binkertauthor=S.+Buchmannauthor=D.+Burauthor=P.+Hessauthor=M.+Iglarzauthor=S.+Meyerauthor=J.+Reinauthor=M.+Reyauthor=A.+Treiberauthor=M.+Clozelauthor=W.+Fischliauthor=T.+Weller&title=The+Discovery+of+N-5-%284-bromophenyl-6-2-%285-Bromo-2-Pyrimidinyl%29oxyethoxy-4-pyrimidinyl-N%E2%80%B2-propyl-sulfamide+%28Macitentan%29%2C+an+Orally+Active%2C+Potent+Dual+Endothelin+Receptor+Antagonist&doi=10.1021%2Fjm3009103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm3009103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009103%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DIglarz%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DRein%26aufirst%3DJ.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DThe%2520Discovery%2520of%2520N-5-%25284-bromophenyl-6-2-%25285-Bromo-2-Pyrimidinyl%2529oxyethoxy-4-pyrimidinyl-N%25E2%2580%25B2-propyl-sulfamide%2520%2528Macitentan%2529%252C%2520an%2520Orally%2520Active%252C%2520Potent%2520Dual%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7849%26epage%3D7861%26doi%3D10.1021%2Fjm3009103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Pulido, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adzerikho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Channick, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcroix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Brun, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittelholzer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perchenet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sastry, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitbon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torbicki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span> </span><span class="NLM_article-title">SERAPHIN Investigators Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">â</span> <span class="NLM_lpage">818</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1213917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1056%2FNEJMoa1213917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23984728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyis7fP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=809-818&author=T.+Pulidoauthor=I.+Adzerikhoauthor=R.+N.+Channickauthor=M.+Delcroixauthor=N.+Gali%C3%A8author=H.+A.+Ghofraniauthor=P.+Jansaauthor=Z.+C.+Jingauthor=F.+O.+Le+Brunauthor=S.+Mehtaauthor=C.+M.+Mittelholzerauthor=L.+Perchenetauthor=B.+K.+Sastryauthor=O.+Sitbonauthor=R.+Souzaauthor=A.+Torbickiauthor=X.+Zengauthor=L.+J.+Rubinauthor=G.+Simonneau&title=SERAPHIN+Investigators+Macitentan+and+Morbidity+and+Mortality+in+Pulmonary+Arterial+Hypertension&doi=10.1056%2FNEJMoa1213917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Macitentan and morbidity and mortality in pulmonary arterial hypertension</span></div><div class="casAuthors">Pulido, Tomas; Adzerikho, Igor; Channick, Richard N.; Delcroix, Marion; Galie, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Jing, Zhi-Cheng; Le Brun, Franck-Olivier; Mehta, Sanjay; Mittelholzer, Camilla M.; Perchenet, Loic; Sastry, B. K. S.; Sitbon, Olivier; Souza, Rogerio; Torbicki, Adam; Zeng, Xiaofeng; Rubin, Lewis J.; Simonneau, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-818</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point.  We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial.  METHODS We randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg.  Stable use of oral or inhaled therapy for pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study entry.  The primary end point was the time from the initiation of treatment to the first occurrence of a composite end point of death, atrial septostomy, lung transplantation, initiation of treatment with i.v. or s.c. prostanoids, or worsening of pulmonary arterial hypertension.  RESULTS A total of 250 patients were randomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose.  The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, resp.  The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5% confidence interval [CI], 0.52 to 0.96; P = 0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5% CI, 0.39 to 0.76; P<0.001).  Worsening of pulmonary arterial hypertension was the most frequent primary end-point event.  The effect of macitentan on this end point was obsd. regardless of whether the patient was receiving therapy for pulmonary arterial hypertension at baseline.  Adverse events more frequently assocd. with macitentan than with placebo were headache, nasopharyngitis, and anemia.  CONCLUSIONS Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAWzzZ3N-2NrVg90H21EOLACvtfcHk0litMpwRY1nQcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyis7fP&md5=430d59843298eaa407aa8a67acc84f81</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1213917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1213917%26sid%3Dliteratum%253Aachs%26aulast%3DPulido%26aufirst%3DT.%26aulast%3DAdzerikho%26aufirst%3DI.%26aulast%3DChannick%26aufirst%3DR.%2BN.%26aulast%3DDelcroix%26aufirst%3DM.%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DJing%26aufirst%3DZ.%2BC.%26aulast%3DLe%2BBrun%26aufirst%3DF.%2BO.%26aulast%3DMehta%26aufirst%3DS.%26aulast%3DMittelholzer%26aufirst%3DC.%2BM.%26aulast%3DPerchenet%26aufirst%3DL.%26aulast%3DSastry%26aufirst%3DB.%2BK.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DSouza%26aufirst%3DR.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DX.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DSERAPHIN%2520Investigators%2520Macitentan%2520and%2520Morbidity%2520and%2520Mortality%2520in%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D809%26epage%3D818%26doi%3D10.1056%2FNEJMoa1213917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Houde, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LabontÃ©, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâOrlÃ©ans-Juste, P.</span><span> </span><span class="NLM_article-title">Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2613</span><span class="NLM_x">â</span> <span class="NLM_lpage">2625</span><span class="refDoi">Â DOI: 10.2174/138161211797416101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2174%2F138161211797416101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21728984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7rI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2613-2625&author=M.+Houdeauthor=J.+Labont%C3%A9author=P.+D%E2%80%99Orl%C3%A9ans-Juste&title=Peptide+and+Non-peptide+Antagonists+Targeting+Endothelin+Receptors+in+Physiology+and+Pathology&doi=10.2174%2F138161211797416101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide and non-peptide antagonists targeting endothelin receptors in physiology and pathology</span></div><div class="casAuthors">Houde, Martin; Labonte, Julie; D'Orleans-Juste, Pedro</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2613-2625</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  As for other peptides such as bradykinin, neurokinins, and angiotensins, peptide antagonists for endothelin-1 (ET-1) were early on developed towards the pharmacol. characterization of both ETA and ETB receptors.  Interestingly, unlike the previously mentioned 3 peptides, receptors for ET-1 were cloned and purified prior to the report of ETA and ETB receptor antagonists such as BQ-123 and BQ-788.  The availability of such pharmacol. tools and the use of mol. approaches have certainly fast-tracked the development of non-peptide ET receptor antagonists for clin. applications.  Albeit rapid degrdn. by gastric enzymes and short half life in blood plasma of peptide receptor antagonists limit their use in clin. settings, those mols. were of importance in the identification of mediators and modulators of ET-1 induced properties in vitro and in vivo, as described further in this review.  Peptide antagonists acting selectively or, with equiv. affinities against ETA and ETB receptors were reported prior to the advent of clin. relevant non-peptide blockers such as Bosentan.  Confounding mechanisms involving, for example, the endogenous modulators nitric oxide and prostacyclin as well as allosteric interactions between ET receptor types, were also clarified with the use of peptide antagonists for endothelins.  Finally, peptide antagonists were also used to identify the precise pharmacol. of ET-1 precursors such as big-endothelin-1 and ET-1 (1-31).  The present review will thus attempt to summarize the knowledge to date and future perspectives related to use of peptide antagonists targeting endothelin receptors in physiol. and pathol. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMof3XutTAibVg90H21EOLACvtfcHk0ljsp7CwUREUoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7rI&md5=e35b4d5b46113bc420d7fdfcb99c729e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.2174%2F138161211797416101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161211797416101%26sid%3Dliteratum%253Aachs%26aulast%3DHoude%26aufirst%3DM.%26aulast%3DLabont%25C3%25A9%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Orl%25C3%25A9ans-Juste%26aufirst%3DP.%26atitle%3DPeptide%2520and%2520Non-peptide%2520Antagonists%2520Targeting%2520Endothelin%2520Receptors%2520in%2520Physiology%2520and%2520Pathology%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2011%26volume%3D17%26spage%3D2613%26epage%3D2625%26doi%3D10.2174%2F138161211797416101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Ishikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niiyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, M.</span><span> </span><span class="NLM_article-title">Cyclic Pentapeptide Endothelin Antagonists with High ETA Selectivity. Potency- and Solubility-Enhancing Modifications</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2139</span><span class="NLM_x">â</span> <span class="NLM_lpage">2142</span><span class="refDoi">Â DOI: 10.1021/jm00089a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00089a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2139-2142&author=K.+Ishikawaauthor=T.+Fukamiauthor=T.+Nagaseauthor=K.+Fujitaauthor=T.+Hayamaauthor=K.+Niiyamaauthor=T.+Maseauthor=M.+Iharaauthor=M.+Yano&title=Cyclic+Pentapeptide+Endothelin+Antagonists+with+High+ETA+Selectivity.+Potency-+and+Solubility-Enhancing+Modifications&doi=10.1021%2Fjm00089a028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm00089a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00089a028%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DHayama%26aufirst%3DT.%26aulast%3DNiiyama%26aufirst%3DK.%26aulast%3DMase%26aufirst%3DT.%26aulast%3DIhara%26aufirst%3DM.%26aulast%3DYano%26aufirst%3DM.%26atitle%3DCyclic%2520Pentapeptide%2520Endothelin%2520Antagonists%2520with%2520High%2520ETA%2520Selectivity.%2520Potency-%2520and%2520Solubility-Enhancing%2520Modifications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D2139%26epage%3D2142%26doi%3D10.1021%2Fjm00089a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Chiappori, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulware, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuger, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lush, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bepler, G.</span><span> </span><span class="NLM_article-title">Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-line Therapy in Advanced Non-Small Cell Lung Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1464</span><span class="NLM_x">â</span> <span class="NLM_lpage">1469</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-07-1508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1078-0432.CCR-07-1508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=18316570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislSrsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1464-1469&author=A.+A.+Chiapporiauthor=E.+Hauraauthor=F.+A.+Rodriguezauthor=D.+Boulwareauthor=R.+Kapoorauthor=A.+M.+Neugerauthor=R.+Lushauthor=B.+Padillaauthor=M.+Burtonauthor=C.+Williamsauthor=G.+Simonauthor=S.+Antoniaauthor=D.+M.+Sullivanauthor=G.+Bepler&title=Phase+I%2FII+Study+of+Atrasentan%2C+an+Endothelin+A+Receptor+Antagonist%2C+in+Combination+with+Paclitaxel+and+Carboplatin+as+First-line+Therapy+in+Advanced+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-07-1508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer</span></div><div class="casAuthors">Chiappori, Alberto A.; Haura, Eric; Rodriguez, Francisco A.; Boulware, David; Kapoor, Rachna; Neuger, Anthony M.; Lush, Richard; Padilla, Barbara; Burton, Michelle; Williams, Charles; Simon, George; Antonia, Scott; Sullivan, Daniel M.; Bepler, Gerold</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1464-1469</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Endothelins and their cell membrane receptors (ETAR and ETBR) are implicated in neoplastic pathogenesis.  Atrasentan, a potent, selective ETAR antagonist, has a direct effect on tumor proliferation, apoptosis, and angiogenesis.  This study was designed to assess the influence of atrasentan on paclitaxel pharmacokinetics and to det. the safety and efficacy of atrasentan in combination with paclitaxel-carboplatin.  Chemonaive patients with stage IIIB (malignant pleural effusion) and IV non-small cell lung cancer were enrolled.  Toxicity and response were detd. using the National Cancer Institute Common Toxicity Criteria version 2.0 and Response Evaluation Criteria in Solid Tumors criteria, resp.  Treatment consisted of paclitaxel (225 mg/m2) and carboplatin (area under the curve, 6) administered on day 1 every 3 wk.  A fixed 10 mg daily oral dose of atrasentan was administered continuously, starting on day 4 of cycle 1.  Paclitaxel clearance was calcd. during the first two cycles (pre- and post-atrasentan) in the first 10 patients.  All 44 patients were evaluable for survival, toxicity, and response.  No significant change in mean paclitaxel clearance was detected (mean Â± SD, 21.2 Â± 4.5 L/h vs. 21.3 Â± 4.9 L/h) for pre- and post-atrasentan values, resp. (P = 0.434).  Grade 3/4 toxicities â¥10% were lymphopenia (22.7%), neutropenia (20.5%), dyspnea (11.4%), and hyperglycemia (11.4%).  Response rate was 18.2%, with progression-free survival of 4.2 mo, median survival of 10.6 mo, and 1-yr survival of 43%.  Atrasentan plus paclitaxel-carboplatin was safe and well tolerated, with no apparent paclitaxel-atrasentan pharmacokinetic interaction.  Efficacy and survival in advanced non-small cell lung cancer were comparable with studies of chemotherapy alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjFBMZZDlGOLVg90H21EOLACvtfcHk0ljsp7CwUREUoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislSrsLY%253D&md5=f29525151a2d9e869d03e9c4c5a2c418</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1508%26sid%3Dliteratum%253Aachs%26aulast%3DChiappori%26aufirst%3DA.%2BA.%26aulast%3DHaura%26aufirst%3DE.%26aulast%3DRodriguez%26aufirst%3DF.%2BA.%26aulast%3DBoulware%26aufirst%3DD.%26aulast%3DKapoor%26aufirst%3DR.%26aulast%3DNeuger%26aufirst%3DA.%2BM.%26aulast%3DLush%26aufirst%3DR.%26aulast%3DPadilla%26aufirst%3DB.%26aulast%3DBurton%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DG.%26aulast%3DAntonia%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3DBepler%26aufirst%3DG.%26atitle%3DPhase%2520I%252FII%2520Study%2520of%2520Atrasentan%252C%2520an%2520Endothelin%2520A%2520Receptor%2520Antagonist%252C%2520in%2520Combination%2520with%2520Paclitaxel%2520and%2520Carboplatin%2520as%2520First-line%2520Therapy%2520in%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D1464%26epage%3D1469%26doi%3D10.1158%2F1078-0432.CCR-07-1508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">de Zeeuw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coll, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andress, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa-Rotter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambers Heerspink, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchett, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobe, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viberti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parving, H. H.</span><span> </span><span class="NLM_article-title">The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with type 2 Diabetic Nephropathy</span> <span class="citation_source-journal">J. Am. Soc. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1083</span><span class="NLM_x">â</span> <span class="NLM_lpage">1093</span><span class="refDoi">Â DOI: 10.1681/ASN.2013080830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1681%2FASN.2013080830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24722445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1Crtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1083-1093&author=D.+de+Zeeuwauthor=B.+Collauthor=D.+Andressauthor=J.+J.+Brennanauthor=H.+Tangauthor=M.+Houserauthor=R.+Correa-Rotterauthor=D.+Kohanauthor=H.+J.+Lambers+Heerspinkauthor=H.+Makinoauthor=V.+Perkovicauthor=Y.+Pritchettauthor=G.+Remuzziauthor=S.+W.+Tobeauthor=R.+Totoauthor=G.+Vibertiauthor=H.+H.+Parving&title=The+Endothelin+Antagonist+Atrasentan+Lowers+Residual+Albuminuria+in+Patients+with+type+2+Diabetic+Nephropathy&doi=10.1681%2FASN.2013080830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy</span></div><div class="casAuthors">de Zeeuw, Dick; Coll, Blai; Andress, Dennis; Brennan, John J.; Tang, Hui; Houser, Mark; Correa-Rotter, Ricardo; Kohan, Donald; Heerspink, Hiddo J. Lambers; Makino, Hirofumi; Perkovic, Vlado; Pritchett, Yili; Remuzzi, Giuseppe; Tobe, Sheldon W.; Toto, Robert; Viberti, Giancarlo; Parving, Hans-Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1083-1093</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Despite optimal treatment, including renin-angiotensin system (RAS) inhibitors, patients with type 2 diabetic nephropathy have high cardiorenal morbidity and mortality related to residual albuminuria.  We evaluated whether or not atrasentan, a selective endothelin A receptor antagonist, further reduces albuminuria when administered concomitantly with max. tolerated labeled doses of RAS inhibitors.  We enrolled 211 patients with type 2 diabetes, urine albumin/creatinine ratios of 300-3500 mg/g, and eGFRs of 30-75 mL/min per 1.73 m2 in two identically designed, parallel, multinational, double-blind studies.  Participants were randomized to placebo (n = 50) or to 0.75 mg/d (n = 78) or 1.25 mg/d (n = 83) atrasentan for 12 wk.  Compared with placebo, 0.75 mg and 1.25 mg atrasentan reduced urine albumin/creatinine ratios by an av. of 35% and 38% (95% confidence intervals of 24 to 45 and 28 to 47, resp.) and reduced albuminuriaâ¥30% in 51% and 55% of participants, resp.  EGFR and office BP measurements did not change, whereas 24-h systolic and diastolic BP, LDL cholesterol, and triglyceride levels decreased significantly in both treatment groups.  Use of atrasentan was assocd. with a significant increase in wt. and a redn. in Hb, but rates of peripheral edema, heart failure, or other side effects did not differ between groups.  However, more patients treated with 1.25 mg/d atrasentan discontinued due to adverse events.  After stopping atrasentan for 30 days, measured parameters returned to pretreatment levels.  In conclusion, atrasentan reduced albuminuria and improved BP and lipid spectrum with manageable fluid overload-related adverse events in patients with type 2 diabetic nephropathy receiving RAS inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwIPOoNpJUvrVg90H21EOLACvtfcHk0lhJr0tRGvfDfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1Crtrc%253D&md5=3d638d67a35d5255923c0ee9f576fd52</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1681%2FASN.2013080830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2013080830%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DColl%26aufirst%3DB.%26aulast%3DAndress%26aufirst%3DD.%26aulast%3DBrennan%26aufirst%3DJ.%2BJ.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DHouser%26aufirst%3DM.%26aulast%3DCorrea-Rotter%26aufirst%3DR.%26aulast%3DKohan%26aufirst%3DD.%26aulast%3DLambers%2BHeerspink%26aufirst%3DH.%2BJ.%26aulast%3DMakino%26aufirst%3DH.%26aulast%3DPerkovic%26aufirst%3DV.%26aulast%3DPritchett%26aufirst%3DY.%26aulast%3DRemuzzi%26aufirst%3DG.%26aulast%3DTobe%26aufirst%3DS.%2BW.%26aulast%3DToto%26aufirst%3DR.%26aulast%3DViberti%26aufirst%3DG.%26aulast%3DParving%26aufirst%3DH.%2BH.%26atitle%3DThe%2520Endothelin%2520Antagonist%2520Atrasentan%2520Lowers%2520Residual%2520Albuminuria%2520in%2520Patients%2520with%2520type%25202%2520Diabetic%2520Nephropathy%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2014%26volume%3D25%26spage%3D1083%26epage%3D1093%26doi%3D10.1681%2FASN.2013080830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Quinn, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tangen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lara, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldkorn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moinpour, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garzotto, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monk, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twardowski, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Veldhuizen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higano, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelzang, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, I. M.</span><span> </span><span class="NLM_article-title">Docetaxel and Atrasentan Versus Docetaxel and Placebo for Men with Advanced Castration-resistant Prostate Cancer (SWOG S0421): A Randomized Phase 3 Trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">893</span><span class="NLM_x">â</span> <span class="NLM_lpage">900</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(13)70294-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS1470-2045%2813%2970294-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23871417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCitr7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=893-900&author=D.+I.+Quinnauthor=C.+M.+Tangenauthor=M.+Hussainauthor=P.+N.+Laraauthor=A.+Goldkornauthor=C.+M.+Moinpourauthor=M.+G.+Garzottoauthor=P.+C.+Mackauthor=M.+A.+Carducciauthor=J.+P.+Monkauthor=P.+W.+Twardowskiauthor=P.+J.+Van+Veldhuizenauthor=N.+Agarwalauthor=C.+S.+Higanoauthor=N.+J.+Vogelzangauthor=I.+M.+Thompson&title=Docetaxel+and+Atrasentan+Versus+Docetaxel+and+Placebo+for+Men+with+Advanced+Castration-resistant+Prostate+Cancer+%28SWOG+S0421%29%3A+A+Randomized+Phase+3+Trial&doi=10.1016%2FS1470-2045%2813%2970294-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial</span></div><div class="casAuthors">Quinn, David I.; Tangen, Catherine M.; Hussain, Maha; Lara, Primo N.; Goldkorn, Amir; Moinpour, Carol M.; Garzotto, Mark G.; Mack, Philip C.; Carducci, Michael A.; Monk, J. Paul; Twardowski, Przemyslaw W.; Van Veldhuizen, Peter J.; Agarwal, Neeraj; Higano, Celestia S.; Vogelzang, Nicholas J.; Thompson, Ian M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">893-900</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer.  Atrasentan, an endothelin receptor antagonist, has shown activity in prostate cancer.  We therefore assessed its effect on survival in patients with castration-resistant prostate cancer with bone metastases.In a double-blind phase 3 trial, men with metastatic castration-resistant prostate cancer, stratified for progression type (prostate-specific antigen or radiol.), baseline pain, extraskeletal metastases, and bisphosphonate use, were randomly assigned in a 1:1 ratio to docetaxel (75 mg/m2 every 21 days, i.v.) with atrasentan (10 mg/day, orally) or placebo for up to 12 cycles and treated until disease progression or unacceptable toxicity.  Patients who did not progress on treatment were permitted to continue atrasentan or placebo for up to 52 wk.  Coprimary endpoints were progression-free survival (PFS) and overall survival.  Anal. was by intention to treat.  This trial is registered with ClinicalTrials.gov, no. NCT00134056.498 patients were randomly assigned to the atrasentan group and 496 to the placebo group.  The trial was halted early for futility in Apr., 2011, after a planned interim anal.  Median PFS was 9Â·2 mo (95% CI 8Â·5-9Â·9) in the atrasentan group and 9Â·1 mo (8Â·4-10Â·2) in the placebo group (hazard ratio 1Â·02, 0Â·89-1Â·16; p=0Â·81).  Median overall survival was 17Â·8 mo (16Â·4-19Â·8) in the atrasentan group vs. 17Â·6 mo (16Â·4-20Â·1) in the placebo group (1Â·04, 0Â·90-1Â·19; p=0Â·64). 278 (57%) of 492 patients in the atrasentan group had grade 3 and greater toxicity compared with 294 (60%) of 486 in the placebo group (p=0Â·22).  Three deaths in the atrasentan group and seven in the placebo group were judged to be possibly or probably due to protocol treatment.Atrasentan, when added to docetaxel, does not improve overall survival or PFS in men with castration-resistant prostate cancer and bone metastases; therefore, single-agent docetaxel should remain as one of the std. treatments.National Cancer Institute, Sanofi-Aventis, and Abbott Labs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjlYVsRNXb77Vg90H21EOLACvtfcHk0lhJr0tRGvfDfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCitr7J&md5=36a81b40100edc690d0cd92d6b13372c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970294-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970294-8%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DD.%2BI.%26aulast%3DTangen%26aufirst%3DC.%2BM.%26aulast%3DHussain%26aufirst%3DM.%26aulast%3DLara%26aufirst%3DP.%2BN.%26aulast%3DGoldkorn%26aufirst%3DA.%26aulast%3DMoinpour%26aufirst%3DC.%2BM.%26aulast%3DGarzotto%26aufirst%3DM.%2BG.%26aulast%3DMack%26aufirst%3DP.%2BC.%26aulast%3DCarducci%26aufirst%3DM.%2BA.%26aulast%3DMonk%26aufirst%3DJ.%2BP.%26aulast%3DTwardowski%26aufirst%3DP.%2BW.%26aulast%3DVan%2BVeldhuizen%26aufirst%3DP.%2BJ.%26aulast%3DAgarwal%26aufirst%3DN.%26aulast%3DHigano%26aufirst%3DC.%2BS.%26aulast%3DVogelzang%26aufirst%3DN.%2BJ.%26aulast%3DThompson%26aufirst%3DI.%2BM.%26atitle%3DDocetaxel%2520and%2520Atrasentan%2520Versus%2520Docetaxel%2520and%2520Placebo%2520for%2520Men%2520with%2520Advanced%2520Castration-resistant%2520Prostate%2520Cancer%2520%2528SWOG%2520S0421%2529%253A%2520A%2520Randomized%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3D893%26epage%3D900%26doi%3D10.1016%2FS1470-2045%2813%2970294-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Buchholz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reissig, H. U.</span><span> </span><span class="NLM_article-title">Enantioselective Synthesis of the Pyrrolidine Core of Endothelin Antagonist ABT-627 (Atrasentan) via 1,2-Oxazines</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2003</span><span class="NLM_x">, </span> <span class="NLM_fpage">3524</span><span class="NLM_x">â</span> <span class="NLM_lpage">3533</span><span class="refDoi">Â DOI: 10.1002/ejoc.200300234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fejoc.200300234" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2003&publication_year=2003&pages=3524-3533&author=M.+Buchholzauthor=H.+U.+Reissig&title=Enantioselective+Synthesis+of+the+Pyrrolidine+Core+of+Endothelin+Antagonist+ABT-627+%28Atrasentan%29+via+1%2C2-Oxazines&doi=10.1002%2Fejoc.200300234"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200300234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200300234%26sid%3Dliteratum%253Aachs%26aulast%3DBuchholz%26aufirst%3DM.%26aulast%3DReissig%26aufirst%3DH.%2BU.%26atitle%3DEnantioselective%2520Synthesis%2520of%2520the%2520Pyrrolidine%2520Core%2520of%2520Endothelin%2520Antagonist%2520ABT-627%2520%2528Atrasentan%2529%2520via%25201%252C2-Oxazines%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2003%26volume%3D2003%26spage%3D3524%26epage%3D3533%26doi%3D10.1002%2Fejoc.200300234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Paul, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giersbergen, P. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span> </span><span class="NLM_article-title">Tolerability, Pharmacokinetics, and Pharmacodynamics of Clazosentan, a Parenteral Endothelin Receptor Antagonist</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">â</span> <span class="NLM_lpage">158</span><span class="refDoi">Â DOI: 10.1007/s00228-006-0117-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00228-006-0117-z" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=151-158&author=L.+M.+Paulauthor=P.+L.+M.+van+Giersbergenauthor=J.+Dingemanse&title=Tolerability%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+Clazosentan%2C+a+Parenteral+Endothelin+Receptor+Antagonist&doi=10.1007%2Fs00228-006-0117-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs00228-006-0117-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-006-0117-z%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DL.%2BM.%26aulast%3Dvan%2BGiersbergen%26aufirst%3DP.%2BL.%2BM.%26aulast%3DDingemanse%26aufirst%3DJ.%26atitle%3DTolerability%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520Clazosentan%252C%2520a%2520Parenteral%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D63%26spage%3D151%26epage%3D158%26doi%3D10.1007%2Fs00228-006-0117-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Tomkinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemp, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taboada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and Tolerability of Zibotentan (ZD4054) in Subjects with Hepatic or Renal Impairment: Two Open-label Comparative Studies</span> <span class="citation_source-journal">BMC Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="refDoi">Â DOI: 10.1186/1472-6904-11-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1186%2F1472-6904-11-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21414193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvV2gtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=3&author=H.+Tomkinsonauthor=J.+Kempauthor=S.+Oliverauthor=H.+Swaislandauthor=M.+Taboadaauthor=T.+Morris&title=Pharmacokinetics+and+Tolerability+of+Zibotentan+%28ZD4054%29+in+Subjects+with+Hepatic+or+Renal+Impairment%3A+Two+Open-label+Comparative+Studies&doi=10.1186%2F1472-6904-11-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies</span></div><div class="casAuthors">Tomkinson, Helen; Kemp, John; Oliver, Stuart; Swaisland, Helen; Taboada, Maria; Morris, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">BMC Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3</span>CODEN:
                <span class="NLM_cas:coden">BCPMC4</span>;
        ISSN:<span class="NLM_cas:issn">1472-6904</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Zibotentan (ZD4054) is a specific endothelin A (ETA) receptor antagonist being investigated for the treatment of prostate cancer.  As zibotentan is eliminated by renal and metabolic routes, clearance may be reduced in patients with hepatic or renal impairment, leading to greater drug exposure.  Methods: Open-label studies investigated the PK and tolerability of zibotentan in subjects with hepatic or renal impairment, compared with those with normal organ function.  In the hepatic and renal studies, resp., subjects were divided into categories using Child-Pugh classification or 24-h urine creatinine clearance (mild, moderate, or severe impairment and normal function).  Each subject received a single oral dose of zibotentan 10 mg and PK sampling was undertaken.  Within the hepatic study, AUC and Cmax were expressed as the ratio of geometric means and 90% CI for each impairment group compared with the normal function group.  The possibility that hepatic impairment had a clin. relevant effect on exposure was considered if the upper 90% CI for the ratio exceeded 2.  In the renal study, AUC, Cmax and t1/2 were analyzed using linear regression fitting effects for creatinine clearance and age.  Results: In the hepatic and renal studies resp., 32 subjects (eight per group) and 48 subjects received treatment (n = 18 normal, n = 12 mild, n = 9 moderate, n = 9 severe).  Zibotentan Cmax was not significantly affected by hepatic or renal impairment.  Compared with the normal function group, zibotentan AUC was 40% (1.40; 90% CI 0.91-2.17), 45% (1.45; 90% CI 0.94-2.24) and 190% (2.90; 90% CI 1.88-4.49) higher in subjects with mild, moderate and severe hepatic impairment, resp., and 66% (1.66; 90% CI 1.38-1.99), 89% (1.89; 90% CI 1.50-2.39) and 117% (2.17; 90% CI 1.64-2.86) higher in subjects with mild, moderate and severe renal impairment, resp.  In both studies mean t1/2 increased and zibotentan clearance decreased with the degree of impairment.  Headache was the most common AE in all groups.  Conclusions: Zibotentan absorption was unchanged, however, exposure was higher in subjects with hepatic or renal impairment due to slower clearance.  This increased exposure did not result in differences in the range or severity of AEs obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF1S2f3_ykNrVg90H21EOLACvtfcHk0lj1UEYNGUtP7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvV2gtbc%253D&md5=4f895b05fecd8d3cdf27d57d46321e39</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1186%2F1472-6904-11-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1472-6904-11-3%26sid%3Dliteratum%253Aachs%26aulast%3DTomkinson%26aufirst%3DH.%26aulast%3DKemp%26aufirst%3DJ.%26aulast%3DOliver%26aufirst%3DS.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DTaboada%26aufirst%3DM.%26aulast%3DMorris%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520Tolerability%2520of%2520Zibotentan%2520%2528ZD4054%2529%2520in%2520Subjects%2520with%2520Hepatic%2520or%2520Renal%2520Impairment%253A%2520Two%2520Open-label%2520Comparative%2520Studies%26jtitle%3DBMC%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D3%26doi%3D10.1186%2F1472-6904-11-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Ishikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, K.i</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niiyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, M.</span><span> </span><span class="NLM_article-title">Cyclic Pentapeptide Endothelin Antagonists with High ETA Selectivity. Potency- and Solubility-Enhancing Modifications</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">2139</span><span class="NLM_x">â</span> <span class="NLM_lpage">2142</span><span class="refDoi">Â DOI: 10.1021/jm00089a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00089a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2139-2142&author=K.+Ishikawaauthor=T.+Fukamiauthor=T.+Nagaseauthor=K.i+Fujitaauthor=T.+Hayamaauthor=K.+Niiyamaauthor=T.+Maseauthor=M.+Iharaauthor=M.+Yano&title=Cyclic+Pentapeptide+Endothelin+Antagonists+with+High+ETA+Selectivity.+Potency-+and+Solubility-Enhancing+Modifications&doi=10.1021%2Fjm00089a028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm00089a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00089a028%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DK.i%26aulast%3DHayama%26aufirst%3DT.%26aulast%3DNiiyama%26aufirst%3DK.%26aulast%3DMase%26aufirst%3DT.%26aulast%3DIhara%26aufirst%3DM.%26aulast%3DYano%26aufirst%3DM.%26atitle%3DCyclic%2520Pentapeptide%2520Endothelin%2520Antagonists%2520with%2520High%2520ETA%2520Selectivity.%2520Potency-%2520and%2520Solubility-Enhancing%2520Modifications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D2139%26epage%3D2142%26doi%3D10.1021%2Fjm00089a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Dutzler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hediger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidhart, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MÃ¤rki, H. P.</span><span> </span><span class="NLM_article-title">Channels and Transporters</span> <span class="citation_source-journal">Chimia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">662</span><span class="NLM_x">â</span> <span class="NLM_lpage">666</span><span class="refDoi">Â DOI: 10.2533/chimia.2010.662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2533%2Fchimia.2010.662" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2010&pages=662-666&author=R.+Dutzlerauthor=B.+Ernstauthor=M.+A.+Hedigerauthor=D.+Kepplerauthor=P.+Mohrauthor=W.+Neidhartauthor=H.+P.+M%C3%A4rki&title=Channels+and+Transporters&doi=10.2533%2Fchimia.2010.662"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.2533%2Fchimia.2010.662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2533%252Fchimia.2010.662%26sid%3Dliteratum%253Aachs%26aulast%3DDutzler%26aufirst%3DR.%26aulast%3DErnst%26aufirst%3DB.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DM%25C3%25A4rki%26aufirst%3DH.%2BP.%26atitle%3DChannels%2520and%2520Transporters%26jtitle%3DChimia%26date%3D2010%26volume%3D64%26spage%3D662%26epage%3D666%26doi%3D10.2533%2Fchimia.2010.662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Epstein, B. J.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of Darusentan: a Novel Endothelin Receptor Antagonist</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1060</span><span class="NLM_x">â</span> <span class="NLM_lpage">1069</span><span class="refDoi">Â DOI: 10.1345/aph.1L024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1345%2Faph.1L024" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2008&pages=1060-1069&author=B.+J.+Epstein&title=Efficacy+and+Safety+of+Darusentan%3A+a+Novel+Endothelin+Receptor+Antagonist&doi=10.1345%2Faph.1L024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1345%2Faph.1L024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1L024%26sid%3Dliteratum%253Aachs%26aulast%3DEpstein%26aufirst%3DB.%2BJ.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Darusentan%253A%2520a%2520Novel%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2008%26volume%3D42%26spage%3D1060%26epage%3D1069%26doi%3D10.1345%2Faph.1L024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Murugesan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spergel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermsmeier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bird, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldron, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koplowitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreland, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trippodo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span> </span><span class="NLM_article-title">Biphenylsulfonamide Endothelin Receptor Antagonists. 4. Discovery of N-[[2<i>â²</i>-[[(4,5-Dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1<i>â²</i>-biphenyl]-2-yl]methyl]-N,3,3-trimethyl butanamide (BMS-207940), a Highly Potent and Orally Active ET(A) Selective Antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">137</span><span class="refDoi">Â DOI: 10.1021/jm020289q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020289q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=125-137&author=N.+Murugesanauthor=Z.+Guauthor=S.+Spergelauthor=M.+Youngauthor=P.+Chenauthor=A.+Mathurauthor=L.+Leithauthor=M.+Hermsmeierauthor=E.+C.+Liuauthor=R.+Zhangauthor=E.+Birdauthor=T.+Waldronauthor=A.+Marinoauthor=B.+Koplowitzauthor=W.+G.+Humphreysauthor=S.+Chongauthor=R.+A.+Morrisonauthor=M.+L.+Webbauthor=S.+Morelandauthor=N.+Trippodoauthor=J.+C.+Barrish&title=Biphenylsulfonamide+Endothelin+Receptor+Antagonists.+4.+Discovery+of+N-%5B%5B2%E2%80%B2-%5B%5B%284%2C5-Dimethyl-3-isoxazolyl%29amino%5Dsulfonyl%5D-4-%282-oxazolyl%29%5B1%2C1%E2%80%B2-biphenyl%5D-2-yl%5Dmethyl%5D-N%2C3%2C3-trimethyl+butanamide+%28BMS-207940%29%2C+a+Highly+Potent+and+Orally+Active+ET%28A%29+Selective+Antagonist&doi=10.1021%2Fjm020289q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm020289q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020289q%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DHermsmeier%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DE.%2BC.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DBird%26aufirst%3DE.%26aulast%3DWaldron%26aufirst%3DT.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DKoplowitz%26aufirst%3DB.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DChong%26aufirst%3DS.%26aulast%3DMorrison%26aufirst%3DR.%2BA.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DMoreland%26aufirst%3DS.%26aulast%3DTrippodo%26aufirst%3DN.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3DBiphenylsulfonamide%2520Endothelin%2520Receptor%2520Antagonists.%25204.%2520Discovery%2520of%2520N-%255B%255B2%25E2%2580%25B2-%255B%255B%25284%252C5-Dimethyl-3-isoxazolyl%2529amino%255Dsulfonyl%255D-4-%25282-oxazolyl%2529%255B1%252C1%25E2%2580%25B2-biphenyl%255D-2-yl%255Dmethyl%255D-N%252C3%252C3-trimethyl%2520butanamide%2520%2528BMS-207940%2529%252C%2520a%2520Highly%2520Potent%2520and%2520Orally%2520Active%2520ET%2528A%2529%2520Selective%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D125%26epage%3D137%26doi%3D10.1021%2Fjm020289q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Sudoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuyama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtake, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasamata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, K.</span><span> </span><span class="NLM_article-title">Pharmacological Characterization of YM598, a Selective Endothelin-A Receptor Antagonist</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">S1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S390</span><span class="NLM_x">â</span> <span class="NLM_lpage">S393</span><span class="refDoi">Â DOI: 10.1097/01.fjc.0000166296.25690.ca</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2F01.fjc.0000166296.25690.ca" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=S390-S393&issue=S1&author=K.+Sudohauthor=H.+Yuyamaauthor=Y.+Noguchiauthor=A.+Fujimoriauthor=M.+Ukaiauthor=A.+Ohtakeauthor=S.+Satoauthor=M.+Sasamataauthor=K.+Miyata&title=Pharmacological+Characterization+of+YM598%2C+a+Selective+Endothelin-A+Receptor+Antagonist&doi=10.1097%2F01.fjc.0000166296.25690.ca"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1097%2F01.fjc.0000166296.25690.ca&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.fjc.0000166296.25690.ca%26sid%3Dliteratum%253Aachs%26aulast%3DSudoh%26aufirst%3DK.%26aulast%3DYuyama%26aufirst%3DH.%26aulast%3DNoguchi%26aufirst%3DY.%26aulast%3DFujimori%26aufirst%3DA.%26aulast%3DUkai%26aufirst%3DM.%26aulast%3DOhtake%26aufirst%3DA.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DSasamata%26aufirst%3DM.%26aulast%3DMiyata%26aufirst%3DK.%26atitle%3DPharmacological%2520Characterization%2520of%2520YM598%252C%2520a%2520Selective%2520Endothelin-A%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2004%26volume%3D44%26issue%3DS1%26spage%3DS390%26epage%3DS393%26doi%3D10.1097%2F01.fjc.0000166296.25690.ca" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶ffler, B. M.</span><span> </span><span class="NLM_article-title">In Vivo Pharmacology of Ro 46-2005, the First Synthetic Nonpeptide Endothelin Receptor Antagonist: Implications for Endothelin Physiology</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">S8</span><span class="NLM_x">) </span> <span class="NLM_fpage">S377</span><span class="NLM_x">â</span> <span class="NLM_lpage">S379</span><span class="refDoi">Â DOI: 10.1097/00005344-199322008-00099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2F00005344-199322008-00099" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1993&pages=S377-S379&issue=S8&author=M.+Clozelauthor=V.+Breuauthor=G.+A.+Grayauthor=B.+M.+L%C3%B6ffler&title=In+Vivo+Pharmacology+of+Ro+46-2005%2C+the+First+Synthetic+Nonpeptide+Endothelin+Receptor+Antagonist%3A+Implications+for+Endothelin+Physiology&doi=10.1097%2F00005344-199322008-00099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1097%2F00005344-199322008-00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199322008-00099%26sid%3Dliteratum%253Aachs%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DBreu%26aufirst%3DV.%26aulast%3DGray%26aufirst%3DG.%2BA.%26aulast%3DL%25C3%25B6ffler%26aufirst%3DB.%2BM.%26atitle%3DIn%2520Vivo%2520Pharmacology%2520of%2520Ro%252046-2005%252C%2520the%2520First%2520Synthetic%2520Nonpeptide%2520Endothelin%2520Receptor%2520Antagonist%253A%2520Implications%2520for%2520Endothelin%2520Physiology%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1993%26volume%3D22%26issue%3DS8%26spage%3DS377%26epage%3DS379%26doi%3D10.1097%2F00005344-199322008-00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Breu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶ffler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span> </span><span class="NLM_article-title">In Vitro Characterization of Ro 46-2005, a Novel Synthetic Non-Peptide Endothelin Antagonist of ET<sub>A</sub> and ET<sub>B</sub> Receptors</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">334</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">â</span> <span class="NLM_lpage">214</span><span class="refDoi">Â DOI: 10.1016/0014-5793(93)81713-A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2F0014-5793%2893%2981713-A" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=1993&pages=210-214&author=V.+Breuauthor=B.+M.+L%C3%B6fflerauthor=M.+Clozel&title=In+Vitro+Characterization+of+Ro+46-2005%2C+a+Novel+Synthetic+Non-Peptide+Endothelin+Antagonist+of+ETA+and+ETB+Receptors&doi=10.1016%2F0014-5793%2893%2981713-A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2893%2981713-A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252893%252981713-A%26sid%3Dliteratum%253Aachs%26aulast%3DBreu%26aufirst%3DV.%26aulast%3DL%25C3%25B6ffler%26aufirst%3DB.%2BM.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Characterization%2520of%2520Ro%252046-2005%252C%2520a%2520Novel%2520Synthetic%2520Non-Peptide%2520Endothelin%2520Antagonist%2520of%2520ETA%2520and%2520ETB%2520Receptors%26jtitle%3DFEBS%2520Lett.%26date%3D1993%26volume%3D334%26spage%3D210%26epage%3D214%26doi%3D10.1016%2F0014-5793%2893%2981713-A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Sidharta, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giersbergen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halabi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span> </span><span class="NLM_article-title">Macitentan: Entry-into-humans Study with a New Endothelin Receptor Antagonist</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">â</span> <span class="NLM_lpage">984</span><span class="refDoi">Â DOI: 10.1007/s00228-011-1043-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00228-011-1043-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21541781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKiu7zL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=977-984&author=P.+N.+Sidhartaauthor=M.+van+Giersbergenauthor=A.+Halabiauthor=J.+Dingemanse&title=Macitentan%3A+Entry-into-humans+Study+with+a+New+Endothelin+Receptor+Antagonist&doi=10.1007%2Fs00228-011-1043-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Macitentan: entry-into-humans study with a new endothelin receptor antagonist</span></div><div class="casAuthors">Sidharta, Patricia N.; Giersbergen, Paul L. M.; Halabi, Atef; Dingemanse, Jasper</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">977-984</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose To study the pharmacokinetics, pharmacodynamics, and tolerability of rising single doses of macitentan, an endothelin receptor antagonist, in healthy male subjects.  Methods This double-blind, placebo-controlled study was performed in seven groups of eight healthy male subjects.  Doses of 0.2, 1, 5, 25, 100, 300 and 600 mg or placebo (two subjects per group) were administered.  Plasma macitentan and endothelin-1 and serum total bile salt concns. were measured and analyzed non-compartmentally.  Plasma and urine were analyzed qual. for the presence of metabolites and one of these, ACT-132577, was also measured quant. in plasma.  Std. tolerability measurements were performed throughout the study.  Results Macitentan was slowly absorbed and, at a dose of 300 mg, the t1/2 (95% confidence interval, CI) was 17.5 h (14.1, 21.8).  The dose-proportionality coeff. Î² for Cmax (95% CI) was 0.83 (0.79, 0.87) indicating less than dose-proportional pharmacokinetics of macitentan.  In plasma, a pharmacol. active oxidative depropyl metabolite, ACT-132577, was found whereas in urine two minor metabolites were detected.  The t1/2 of ACT-132577 (95% CI) was 65.6 h (53.1, 80.9).  Macitentan dose-dependently increased endothelin-1 concns. up to 2.2-fold (95% CI 1.4, 2.4) at a dose of 600 mg, but had no consistent effect on total bile salts.  Macitentan was well tolerated up to and including a dose of 300 mg, the max. tolerated dose.  Headache, nausea and vomiting were dose-limiting adverse events.  Conclusion The pharmacokinetic and tolerability profile of macitentan is consistent with a once-a-day dosing regimen and warrants further investigation in clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoWeQTz7cdvrVg90H21EOLACvtfcHk0liPryuH_7BuTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKiu7zL&md5=573cc52b7f797f7c9f27ea3148dff418</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs00228-011-1043-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-011-1043-2%26sid%3Dliteratum%253Aachs%26aulast%3DSidharta%26aufirst%3DP.%2BN.%26aulast%3Dvan%2BGiersbergen%26aufirst%3DM.%26aulast%3DHalabi%26aufirst%3DA.%26aulast%3DDingemanse%26aufirst%3DJ.%26atitle%3DMacitentan%253A%2520Entry-into-humans%2520Study%2520with%2520a%2520New%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D67%26spage%3D977%26epage%3D984%26doi%3D10.1007%2Fs00228-011-1043-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Patel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeage, K.</span><span> </span><span class="NLM_article-title">Macitentan: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">133</span><span class="refDoi">Â DOI: 10.1007/s40265-013-0156-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs40265-013-0156-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=127-133&author=T.+Patelauthor=K.+McKeage&title=Macitentan%3A+First+Global+Approval&doi=10.1007%2Fs40265-013-0156-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0156-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0156-6%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DT.%26aulast%3DMcKeage%26aufirst%3DK.%26atitle%3DMacitentan%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D127%26epage%3D133%26doi%3D10.1007%2Fs40265-013-0156-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theile, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">RÃ¼ppell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speck, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalwisz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haefeli, W. E.</span><span> </span><span class="NLM_article-title">Interaction Profile of Macitentan, a new Non-selective Endothelin-1 Receptors Antagonist, In Vitro</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">701</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">â</span> <span class="NLM_lpage">175</span><span class="refDoi">Â DOI: 10.1016/j.ejphar.2013.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.ejphar.2013.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23353592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFCjtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=701&publication_year=2013&pages=168-175&author=J.+Weissauthor=D.+Theileauthor=M.+A.+R%C3%BCppellauthor=T.+Speckauthor=A.+Spalwiszauthor=W.+E.+Haefeli&title=Interaction+Profile+of+Macitentan%2C+a+new+Non-selective+Endothelin-1+Receptors+Antagonist%2C+In+Vitro&doi=10.1016%2Fj.ejphar.2013.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro</span></div><div class="casAuthors">Weiss, Johanna; Theile, Dirk; Rueppell, Maximilian Alexander; Speck, Tobias; Spalwisz, Adriana; Haefeli, Walter Emil</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">701</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">168-175</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Macitentan is a new non-selective endothelin-1 receptor antagonist under development for the treatment of pulmonary arterial hypertension.  Information on the potential for macitentan to influence the pharmacokinetics of concomitantly administered drugs by inhibition or induction of drug metabolizing enzymes or drug transporters is sparse.  We therefore studied the potential of macitentan to inhibit and induce crit. targets of drug metab. and drug distribution (transporters) in vitro.  Induction was quantified at the mRNA level by real-time RT-PCR in LS180 cells and revealed that macitentan significantly induced mRNA expression of cytochrome P 450 3A4 (CYP3A4), P-glycoprotein (P-gp, ABCB1), solute carrier of org. anions 1B1 (SLCO1B1), and uridinediphosphate-glucuronosyltransferase 1A3 (UGT1A9).  By means of a reporter gene assay our study establishes macitentan as a potent activator of pregnane X receptor (PXR).  Inhibition of drug transporters was evaluated by using transporter over-expressing cell lines and fluorescent specific substrates of the resp. transporters and revealed that macitentan is an inhibitor of P-gp, breast cancer resistance protein (BCRP), SLCO1B1, and SLCO1B3.  Using com. kits macitentan was demonstrated to be a moderate inhibitor of CYP3A4 and CYP2C19.  In conclusion our data provide a comprehensive anal. of the interaction profile of macitentan with drug metabolizing and transporting enzymes in vitro.  Although macitentan has a similar or higher potency for induction and inhibition of drug metabolizing enzymes and transporters than bosentan, its low plasma concns. and minimal accumulation in the liver suggest that it will be markedly less prone to drug-drug interactions than bosentan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUMjcF34OrqLVg90H21EOLACvtfcHk0liEnIi_GOY0kQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFCjtrw%253D&md5=d6515d8fba08a7a8e8d7dee1bd8f69dd</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DTheile%26aufirst%3DD.%26aulast%3DR%25C3%25BCppell%26aufirst%3DM.%2BA.%26aulast%3DSpeck%26aufirst%3DT.%26aulast%3DSpalwisz%26aufirst%3DA.%26aulast%3DHaefeli%26aufirst%3DW.%2BE.%26atitle%3DInteraction%2520Profile%2520of%2520Macitentan%252C%2520a%2520new%2520Non-selective%2520Endothelin-1%2520Receptors%2520Antagonist%252C%2520In%2520Vitro%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D701%26spage%3D168%26epage%3D175%26doi%3D10.1016%2Fj.ejphar.2013.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Rayalu, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvaraj, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganeshan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, N. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshapani, P.</span><span> </span><span class="NLM_article-title">Homology Modeling, Active Site Prediction, and Targeting the Anti-hypertension Activity through Molecular Docking on Endothelin-B Receptor Domain</span> <span class="citation_source-journal">Bioinformation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">â</span> <span class="NLM_lpage">86</span><span class="refDoi">Â DOI: 10.6026/97320630008081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.6026%2F97320630008081" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=81-86&author=D.+J.+Rayaluauthor=C.+Selvarajauthor=S.+K.+Singhauthor=R.+Ganeshanauthor=N.+U.+Kumarauthor=P.+Seshapani&title=Homology+Modeling%2C+Active+Site+Prediction%2C+and+Targeting+the+Anti-hypertension+Activity+through+Molecular+Docking+on+Endothelin-B+Receptor+Domain&doi=10.6026%2F97320630008081"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.6026%2F97320630008081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6026%252F97320630008081%26sid%3Dliteratum%253Aachs%26aulast%3DRayalu%26aufirst%3DD.%2BJ.%26aulast%3DSelvaraj%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DS.%2BK.%26aulast%3DGaneshan%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DN.%2BU.%26aulast%3DSeshapani%26aufirst%3DP.%26atitle%3DHomology%2520Modeling%252C%2520Active%2520Site%2520Prediction%252C%2520and%2520Targeting%2520the%2520Anti-hypertension%2520Activity%2520through%2520Molecular%2520Docking%2520on%2520Endothelin-B%2520Receptor%2520Domain%26jtitle%3DBioinformation%26date%3D2012%26volume%3D8%26spage%3D81%26epage%3D86%26doi%3D10.6026%2F97320630008081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Gatfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller Grandjean, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasse, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span> </span><span class="NLM_article-title">Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e47662</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0047662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1371%2Fjournal.pone.0047662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23077657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Sitb%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e47662&author=J.+Gatfieldauthor=C.+Mueller+Grandjeanauthor=T.+Sasseauthor=M.+Clozelauthor=O.+Nayler&title=Slow+Receptor+Dissociation+Kinetics+Differentiate+Macitentan+from+Other+Endothelin+Receptor+Antagonists+in+Pulmonary+Arterial+Smooth+Muscle+Cells&doi=10.1371%2Fjournal.pone.0047662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells</span></div><div class="casAuthors">Gatfield, John; Grandjean, Celia Mueller; Sasse, Thomas; Clozel, Martine; Nayler, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e47662</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and proliferation of pulmonary arterial smooth muscle cells (PASMC).  The novel ERA macitentan has recently concluded testing in a Phase III morbidity/mortality clin. trial in PAH patients.  Since the assocn. and dissocn. rates of G protein-coupled receptor antagonists can influence their pharmacol. activity in vivo, we used human PASMC to characterize inhibitory potency and receptor inhibition kinetics of macitentan, ambrisentan and bosentan using calcium release and inositol-1-phosphate (IP1) assays.  In calcium release assays macitentan, ambrisentan and bosentan were highly potent ERAs with Kb values of 0.14 nM, 0.12 nM and 1.1 nM, resp.  Macitentan, but not ambrisentan and bosentan, displayed slow apparent receptor assocn. kinetics as evidenced by increased antagonistic potency upon prolongation of antagonist pre-incubation times.  In compd. washout expts., macitentan displayed a significantly lower receptor dissocn. rate and longer receptor occupancy half-life (ROt1/2) compared to bosentan and ambrisentan (ROt1/2:17 min vs. 70 s and 40 s, resp.).  Because of its lower dissocn. rate macitentan behaved as an insurmountable antagonist in calcium release and IP1 assays and unlike bosentan and ambrisentan it blocked endothelin receptor activation across a wide range of endothelin-1 (ET-1) concns.  However, prolongation of the ET-1 stimulation time beyond ROt1/2 rendered macitentan a surmountable antagonist, revealing its competitive binding mode.  Bosentan and ambrisentan behaved as surmountable antagonists irresp. of the assay duration and they lacked inhibitory activity at high ET-1 concns.  Thus, macitentan is a competitive ERA with significantly slower receptor dissocn. kinetics than the currently approved ERAs.  Slow dissocn. caused insurmountable antagonism in functional PASMC-based assays and this could contribute to an enhanced pharmacol. activity of macitentan in ET-1-dependent pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDbQHugB0eIbVg90H21EOLACvtfcHk0liEnIi_GOY0kQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Sitb%252FM&md5=f6065e4b60e74802847bb886b65a38d7</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0047662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0047662%26sid%3Dliteratum%253Aachs%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DMueller%2BGrandjean%26aufirst%3DC.%26aulast%3DSasse%26aufirst%3DT.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DNayler%26aufirst%3DO.%26atitle%3DSlow%2520Receptor%2520Dissociation%2520Kinetics%2520Differentiate%2520Macitentan%2520from%2520Other%2520Endothelin%2520Receptor%2520Antagonists%2520in%2520Pulmonary%2520Arterial%2520Smooth%2520Muscle%2520Cells%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De47662%26doi%3D10.1371%2Fjournal.pone.0047662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Gatfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller Grandjean, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span> </span><span class="NLM_article-title">Distinct ET<sub>A</sub> Receptor Binding Mode of macitentan as Determined by Site Directed Mutagenesis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e107809</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0107809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1371%2Fjournal.pone.0107809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=25226600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslShtr7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e107809&author=J.+Gatfieldauthor=C.+Mueller+Grandjeanauthor=D.+Burauthor=M.+H.+Bolliauthor=O.+Nayler&title=Distinct+ETA+Receptor+Binding+Mode+of+macitentan+as+Determined+by+Site+Directed+Mutagenesis&doi=10.1371%2Fjournal.pone.0107809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis</span></div><div class="casAuthors">Gatfield, John; Grandjean, Celia Mueller; Bur, Daniel; Bolli, Martin H.; Nayler, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e107809/1-e107809/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A review.  The competitive endothelin receptor antagonists (ERA) bosentan and ambrisentan, which have long been approved for the treatment of pulmonary arterial hypertension, are characterized by very short (1 min) occupancy half-lives at the ETA receptor.  The novel ERA macitentan, displays a 20-fold increased receptor occupancy half-life, causing insurmountable antagonism of ET-1-induced signaling in pulmonary arterial smooth muscle cells.  We show here that the slow ETA receptor dissocn. rate of macitentan was shared with a set of structural analogs, whereas compds. structurally related to bosentan displayed fast dissocn. kinetics.  NMR anal. showed that macitentan adopts a compact structure in aq. soln. and mol. modeling suggests that this conformation tightly fits into a well-defined ETA receptor binding pocket.  In contrast the structurally different and neg. charged bosentan-type mols. only partially filled this pocket and expanded into an extended endothelin binding site.  To further investigate these different ETA receptor-antagonist interaction modes, we performed functional studies using ETA receptor variants harboring amino acid point mutations in the presumed ERA interaction site.  Three ETA receptor residues significantly and differentially affected ERA activity: Mutation R326Q did not affect the antagonist activity of macitentan, however the potencies of bosentan and ambrisentan were significantly reduced; mutation L322A rendered macitentan less potent, whereas bosentan and ambrisentan were unaffected; mutation I355A significantly reduced bosentan potency, but not ambrisentan and macitentan potencies.  This suggests that - in contrast to bosentan and ambrisentan - macitentan-ETA receptor binding is not dependent on strong charge-charge interactions, but depends predominantly on hydrophobic interactions.  This different binding mode could be the reason for macitentan's sustained target occupancy and insurmountable antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Mz62J3R5E7Vg90H21EOLACvtfcHk0lhq7vJKQF4e7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslShtr7O&md5=007edafae066ab62cf11936f50557ff9</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0107809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0107809%26sid%3Dliteratum%253Aachs%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DMueller%2BGrandjean%26aufirst%3DC.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DNayler%26aufirst%3DO.%26atitle%3DDistinct%2520ETA%2520Receptor%2520Binding%2520Mode%2520of%2520macitentan%2520as%2520Determined%2520by%2520Site%2520Directed%2520Mutagenesis%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De107809%26doi%3D10.1371%2Fjournal.pone.0107809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Shaw, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeulen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickard, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teasdale, G. M.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of the Endothelin Receptor Antagonist TAK-044 in Treating Subarachnoid Hemorrhage</span> <span class="citation_source-journal">J. Neurosurg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">992</span><span class="NLM_x">â</span> <span class="NLM_lpage">997</span><span class="refDoi">Â DOI: 10.3171/jns.2000.93.6.0992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.3171%2Fjns.2000.93.6.0992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=11117873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3cXptValsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2000&pages=992-997&author=M.+D.+Shawauthor=M.+Vermeulenauthor=G.+D.+Murrayauthor=J.+D.+Pickardauthor=B.+A.+Bellauthor=G.+M.+Teasdale&title=Efficacy+and+Safety+of+the+Endothelin+Receptor+Antagonist+TAK-044+in+Treating+Subarachnoid+Hemorrhage&doi=10.3171%2Fjns.2000.93.6.0992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of the endothelinA/B receptor antagonist TAK-044 in treating subarachnoid hemorrhage: A report by the steering committee on behalf of the UK/Netherlands/Eire TAK-044 subarachnoid hemorrhage study group</span></div><div class="casAuthors">Shaw, Malcolm D. M.; Vermeulen, Marinus; Murray, Gordon D.; Pickard, John D.; Bell, B. Anthony; Teasdale, Graham M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurosurgery</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">992-997</span>CODEN:
                <span class="NLM_cas:coden">JONSAC</span>;
        ISSN:<span class="NLM_cas:issn">0022-3085</span>.
    
            (<span class="NLM_cas:orgname">American Association of Neurological Surgeons</span>)
        </div><div class="casAbstract">Delayed cerebral ischemia remains an important cause of death and disability in patients who have suffered subarachnoid hemorrhage (SAH).  Endothelin (ET) has a potent contractile effect on cerebral arteries and arterioles and has been implicated in vasospasm.  The authors administered ETA/B receptor antagonist (TAK-044) to patients suffering from aneurysmal SAH.  They then assessed whether this agent reduced the occurrence of delayed cerebral ischemic events and examd. its safety profile in this group of patients.  Four hundred twenty patients who had suffered an SAH were recruited into a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II trial.  The primary end point was whether a delayed ischemic event occurred within 3 mo after the first dose of the study drug and the secondary end points included detg. whether a delayed ischemic event occurred by 10 days after the first dose of the study drug, whether a new cerebral infarct was demonstrated on a computerized tomog. scan or at postmortem examn. by 3 mo after administration of the initial dose, the patient's Glasgow Outcome Scale scores at 3 mo after the initial dose, and adverse events.  There was a lower incidence of delayed ischemic events at 3 mo in the TAK-044-treated group: 29.5% compared with 36.6% in a group of patients receiving placebo.  The estd. relative risk was 0.8 with a 95% confidence interval of 0.61 to 1.06.  There were no significant differences in the secondary end points, including clin. outcomes in the placebo-treated and TAK-044-treated groups.  The TAK-044 was well tolerated by patients who had suffered an SAH, even though hypotension and headache-side effects compatible with the drug's vasodilatory properties-occurred.  It would be valuable to proceed to a fully powered phase III trial of an ET receptor antagonist in treating aneurysmal SAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBwENB_SA2wLVg90H21EOLACvtfcHk0lhq7vJKQF4e7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXptValsr0%253D&md5=5a00b40d783396e0a7d292de64723179</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.3171%2Fjns.2000.93.6.0992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3171%252Fjns.2000.93.6.0992%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DM.%2BD.%26aulast%3DVermeulen%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DG.%2BD.%26aulast%3DPickard%26aufirst%3DJ.%2BD.%26aulast%3DBell%26aufirst%3DB.%2BA.%26aulast%3DTeasdale%26aufirst%3DG.%2BM.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520the%2520Endothelin%2520Receptor%2520Antagonist%2520TAK-044%2520in%2520Treating%2520Subarachnoid%2520Hemorrhage%26jtitle%3DJ.%2520Neurosurg.%26date%3D2000%26volume%3D93%26spage%3D992%26epage%3D997%26doi%3D10.3171%2Fjns.2000.93.6.0992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramuz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¶ffler, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coassolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, S.</span><span> </span><span class="NLM_article-title">Pharmacology of Tezosentan, New Endothelin Receptor Antagonist Designed for Parenteral Use</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">840</span><span class="NLM_x">â</span> <span class="NLM_lpage">846</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10411600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK1MXkvVKnsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=1999&pages=840-846&author=M.+Clozelauthor=H.+Ramuzauthor=J.+P.+Clozelauthor=V.+Breuauthor=P.+Hessauthor=B.+M.+L%C3%B6fflerauthor=P.+Coassoloauthor=S.+Roux&title=Pharmacology+of+Tezosentan%2C+New+Endothelin+Receptor+Antagonist+Designed+for+Parenteral+Use"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use</span></div><div class="casAuthors">Clozel, Martine; Ramuz, Henri; Clozel, Jean-Paul; Breu, Volker; Hess, Patrick; Loffler, Bernd-Michael; Coassolo, Philippe; Roux, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">840-846</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Tezosentan (Ro 61-0612) [5-isopropylpyridine-2-sulfonic acid 6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)pyrimidin-4-ylamide] is a new endothelin (ET) receptor antagonist specifically designed for parenteral use.  Tezosentan competitively antagonizes the specific binding of 125I-labeled ET-1 and of the selective ETB receptor ligands 125I-labeled ET-3 and 125I-labeled sarafotoxin S6c to cells and tissues carrying ETA and ETB receptors, with inhibitory consts. in the nanomolar range, and it has high water soly.  Tezosentan exhibits high functional inhibitory potency for inhibiting contraction induced by ET-1 on isolated rat aorta (ETA receptors; pA2 = 9.5) and by sarafotoxin S6c on rat trachea (ETB receptors; pA2 = 7.7).  In vivo, tezosentan inhibits the pressor effect of big ET-1 in pithed rats and increases plasma ET-1 concns. in conscious rats in a dose-dependent fashion.  In spontaneously hypertensive rats, i.v. injection of tezosentan has acute hemodynamic effects and decreases blood pressure.  Tezosentan is also able to prevent the acute renal failure that complicates rhabdomyolysis in a rat model of myoglobinuric nephropathy.  Finally, tezosentan exhibits an apparent elimination half-life of <1 h in rabbits and primates and of 2 h in rats.  In conclusion, tezosentan, a potent mixed ET receptor antagonist with a short half-life, may offer a novel medical approach for the i.v. treatment of acute pathol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGSGjuqLVaWrVg90H21EOLACvtfcHk0lhq7vJKQF4e7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvVKnsbs%253D&md5=f85a49d96779b4e9c394795db5cd1180</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DRamuz%26aufirst%3DH.%26aulast%3DClozel%26aufirst%3DJ.%2BP.%26aulast%3DBreu%26aufirst%3DV.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DL%25C3%25B6ffler%26aufirst%3DB.%2BM.%26aulast%3DCoassolo%26aufirst%3DP.%26aulast%3DRoux%26aufirst%3DS.%26atitle%3DPharmacology%2520of%2520Tezosentan%252C%2520New%2520Endothelin%2520Receptor%2520Antagonist%2520Designed%2520for%2520Parenteral%2520Use%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D290%26spage%3D840%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Hoshino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamauchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikkawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabana, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, S.</span><span> </span><span class="NLM_article-title">Pharmacological Profile of T-0201, a Highly Potent and Orally Active Endothelin Receptor Antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">643</span><span class="NLM_x">â</span> <span class="NLM_lpage">649</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=9694915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK1cXlsVWiur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1998&pages=643-649&author=T.+Hoshinoauthor=R.+Yamauchiauthor=K.+Kikkawaauthor=H.+Yabanaauthor=S.+Murata&title=Pharmacological+Profile+of+T-0201%2C+a+Highly+Potent+and+Orally+Active+Endothelin+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist</span></div><div class="casAuthors">Hoshino, Tomoko; Yamauchi, Rikako; Kikkawa, Kohei; Yabana, Hideo; Murata, Sakae</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">643-649</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The pharmacol. properties of N-(6-(2-(5-bromopyrimidin-4-yl)-4-(2-hydroxy-1,1-dimethylethyl)benzensulfonamide sodium salt sesquihydrate (T-0201) was studied , a new nonpeptide endothelin (ET) receptor antagonist, in vitro and in vivo.  In binding studies, T-0201 competitively antagonized the specific binding of [125I]-ET-1 to human cloned ETA receptors (the Ki value was 0.015 nM).  T-0201 weakly inhibited [125I]-ET-1-binding to human cloned ETB receptors; the Ki value was 41 nM.  T-0201 shifted the concn.-response curve of ET-1-induced contraction of the isolated rat aorta (ETA receptors) to the right (pA2 = 9.0).  In the isolated rat trachea, a selective ETB agonist sarafotoxin S6c-induced contraction was inhibited by T-0201 (pA2 = 6.8).  T-0201 also caused the inhibition of ET-1-induced contraction of the isolated rabbit pulmonary artery (pA2 = 5.7).  In anesthetized rats, T-0201 (0.01-1 mg/kg) inhibited the pressor response to exogenous big ET-1 (1 nmol/kg i.v.), after both i.v. and p.o. administration, in a dose-dependent manner.  The significant inhibitory effect of orally administered T-0201 on big ET-1-induced pressor response lasted for 4 h at 0.1 mg/kg and for 8 h at 1 mg/kg.  Thus the present study demonstrates that T-0201 is a highly potent, long-lasting, orally active active and selective ETA receptor antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfn4EJzzFBcrVg90H21EOLACvtfcHk0lg8JpCvwGwGWg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlsVWiur8%253D&md5=b73aa3c5da3b7bd6e0673bfc151ddcb9</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoshino%26aufirst%3DT.%26aulast%3DYamauchi%26aufirst%3DR.%26aulast%3DKikkawa%26aufirst%3DK.%26aulast%3DYabana%26aufirst%3DH.%26aulast%3DMurata%26aufirst%3DS.%26atitle%3DPharmacological%2520Profile%2520of%2520T-0201%252C%2520a%2520Highly%2520Potent%2520and%2520Orally%2520Active%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D286%26spage%3D643%26epage%3D649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Ohlstein, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douglas, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lago, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leber, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cousins, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peishoff, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bean, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggleston, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elshourbagy, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feuerstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poste, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruffolo, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleason, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. D.</span><span> </span><span class="NLM_article-title">SB 209670, a Rationally Designed Potent Nonpeptide Endothelin Receptor Antagonist</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">8052</span><span class="NLM_x">â</span> <span class="NLM_lpage">8056</span><span class="refDoi">Â DOI: 10.1073/pnas.91.17.8052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1073%2Fpnas.91.17.8052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=8052-8056&author=E.+H.+Ohlsteinauthor=P.+Nambiauthor=S.+A.+Douglasauthor=R.+M.+Edwardsauthor=M.+Gellaiauthor=A.+Lagoauthor=J.+D.+Leberauthor=R.+D.+Cousinsauthor=A.+Gaoauthor=J.+S.+Frazeeauthor=C.+E.+Peishoffauthor=J.+W.+Beanauthor=D.+S.+Egglestonauthor=N.+A.+Elshourbagyauthor=C.+Kumarauthor=J.+A.+Leeauthor=T.+L.+Yueauthor=C.+Loudenauthor=D.+P.+Brooksauthor=J.+Weinstockauthor=G.+Feuersteinauthor=G.+Posteauthor=R.+R.+Ruffoloauthor=J.+G.+Gleasonauthor=J.+D.+Elliott&title=SB+209670%2C+a+Rationally+Designed+Potent+Nonpeptide+Endothelin+Receptor+Antagonist&doi=10.1073%2Fpnas.91.17.8052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.17.8052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.17.8052%26sid%3Dliteratum%253Aachs%26aulast%3DOhlstein%26aufirst%3DE.%2BH.%26aulast%3DNambi%26aufirst%3DP.%26aulast%3DDouglas%26aufirst%3DS.%2BA.%26aulast%3DEdwards%26aufirst%3DR.%2BM.%26aulast%3DGellai%26aufirst%3DM.%26aulast%3DLago%26aufirst%3DA.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DCousins%26aufirst%3DR.%2BD.%26aulast%3DGao%26aufirst%3DA.%26aulast%3DFrazee%26aufirst%3DJ.%2BS.%26aulast%3DPeishoff%26aufirst%3DC.%2BE.%26aulast%3DBean%26aufirst%3DJ.%2BW.%26aulast%3DEggleston%26aufirst%3DD.%2BS.%26aulast%3DElshourbagy%26aufirst%3DN.%2BA.%26aulast%3DKumar%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DYue%26aufirst%3DT.%2BL.%26aulast%3DLouden%26aufirst%3DC.%26aulast%3DBrooks%26aufirst%3DD.%2BP.%26aulast%3DWeinstock%26aufirst%3DJ.%26aulast%3DFeuerstein%26aufirst%3DG.%26aulast%3DPoste%26aufirst%3DG.%26aulast%3DRuffolo%26aufirst%3DR.%2BR.%26aulast%3DGleason%26aufirst%3DJ.%2BG.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26atitle%3DSB%2520209670%252C%2520a%2520Rationally%2520Designed%2520Potent%2520Nonpeptide%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D8052%26epage%3D8056%26doi%3D10.1073%2Fpnas.91.17.8052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Ohlstein, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lago, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eddy, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. D.</span><span> </span><span class="NLM_article-title">Nonpeptide Endothelin Receptor Antagonists. VI: Pharmacological Characterization of SB 217242, a Potent and Highly Bioavailable Endothelin Receptor Antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">â</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=8632328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK28XhtFaktrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1996&pages=609-615&author=E.+H.+Ohlsteinauthor=P.+Nambiauthor=A.+Lagoauthor=D.+W.+Hayauthor=G.+Beckauthor=K.+L.+Fongauthor=E.+P.+Eddyauthor=P.+Smithauthor=H.+Ellensauthor=J.+D.+Elliott&title=Nonpeptide+Endothelin+Receptor+Antagonists.+VI%3A+Pharmacological+Characterization+of+SB+217242%2C+a+Potent+and+Highly+Bioavailable+Endothelin+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist</span></div><div class="casAuthors">Ohlstein, Eliot H.; Nambi, Ponnal; Largo, Amparo; Hay, Douglas W. P.; Beck, George; Fong, Kei-Lai; Eddy, E. Priya; Smith, Philip; Ellens, Harma; Elliott, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-15</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">This study describes the pharmacol. characterization of SB 217242, a highly potent orally bioavailable nonpeptide antagonist of both endothelin type A (ETA) and endothelin type B (ETB) receptors.  In human cloned ETA and ETB receptors, SB 217242 produced concn.-dependent displacement of [125]I-endothelin-1 (ET-1) in both receptor subtypes with Ki values of 1.1 and 111 nM, resp.  SB 217242 produced concn.-dependent, parallel rightward shifts in the ET-1 concn.-response curves in rat isolated aorta and human isolated pulmonary artery (ETA receptor-mediated vascular contraction) with Kb values of 4.4 and 5.0 nM, resp.  SB 217242 was 4-, 62- and 125-fold more potent as an ETA receptor antagonist than the previously reported compds. BQ-123, PD 142893 and Ro 46-2005, resp.  SB 217242 (10 Î¼M) did not produce significant effects against contraction produced by other vasoactive agents.  SB 21742 produced concn.-dependent antagonism of responses produced by ETB receptor activation as demonstrated by antagonism of sarafotoxin S6c-mediated contraction in the rabbit isolated pulmonary artery with a Kb value of 352 nM.  In vitro cell monolayers of Caco-2 cells had high permeability of SB 217242.  In vivo pharmacokinetics in the rat confirmed that SB 217242 was rapidly absorbed from the gastrointestinal tract with a bioavailability of 66%.  The Sb 217242 plasma half-life in rats after intraduodenal administration was 3.3 h, with a systemic clearance of 27.3 mL/min/kg.  Orally administered SB 217242 (0.3-30 mg/kg) produced dose-dependent inhibition of the pressor response to exogenous ET-1 in conscious rats; with a dose of 30 mg/kg p.o., inhibition was obsd. for at least 5.5 h.  The present study demonstrates that SB 217242 is a highly potent antagonist of both ETA and ETB receptors.  In addn., SB 217242 has high in vitro permeability and high oral bioavailability.  SB 217242 represents a new orally active pharmacol. tool that should assist in the elucidation of the chronic role of endothelin in pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2rt-NUxVpy7Vg90H21EOLACvtfcHk0lg8JpCvwGwGWg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtFaktrY%253D&md5=16ebb073ac6142f3ab7fc04c89b18422</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOhlstein%26aufirst%3DE.%2BH.%26aulast%3DNambi%26aufirst%3DP.%26aulast%3DLago%26aufirst%3DA.%26aulast%3DHay%26aufirst%3DD.%2BW.%26aulast%3DBeck%26aufirst%3DG.%26aulast%3DFong%26aufirst%3DK.%2BL.%26aulast%3DEddy%26aufirst%3DE.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DEllens%26aufirst%3DH.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26atitle%3DNonpeptide%2520Endothelin%2520Receptor%2520Antagonists.%2520VI%253A%2520Pharmacological%2520Characterization%2520of%2520SB%2520217242%252C%2520a%2520Potent%2520and%2520Highly%2520Bioavailable%2520Endothelin%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1996%26volume%3D276%26spage%3D609%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">von Geldern, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorensen, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczepankiewicz, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wessale, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opgenorth, T. J.</span><span> </span><span class="NLM_article-title">Pyrrolidine-3-Carboxylic Acids as Endothelin Antagonists. 4. Side Chain Conformational Restriction Leads to ET<sub>B</sub> selectivity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3668</span><span class="NLM_x">â</span> <span class="NLM_lpage">3678</span><span class="refDoi">Â DOI: 10.1021/jm990170q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990170q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3668-3678&author=T.+W.+von+Geldernauthor=A.+S.+Taskerauthor=B.+K.+Sorensenauthor=M.+Winnauthor=B.+G.+Szczepankiewiczauthor=D.+B.+Dixonauthor=W.+J.+Chiouauthor=L.+Wangauthor=J.+L.+Wessaleauthor=A.+Adlerauthor=K.+C.+Marshauthor=B.+Nguyenauthor=T.+J.+Opgenorth&title=Pyrrolidine-3-Carboxylic+Acids+as+Endothelin+Antagonists.+4.+Side+Chain+Conformational+Restriction+Leads+to+ETB+selectivity&doi=10.1021%2Fjm990170q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm990170q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990170q%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BGeldern%26aufirst%3DT.%2BW.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DSorensen%26aufirst%3DB.%2BK.%26aulast%3DWinn%26aufirst%3DM.%26aulast%3DSzczepankiewicz%26aufirst%3DB.%2BG.%26aulast%3DDixon%26aufirst%3DD.%2BB.%26aulast%3DChiou%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWessale%26aufirst%3DJ.%2BL.%26aulast%3DAdler%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DOpgenorth%26aufirst%3DT.%2BJ.%26atitle%3DPyrrolidine-3-Carboxylic%2520Acids%2520as%2520Endothelin%2520Antagonists.%25204.%2520Side%2520Chain%2520Conformational%2520Restriction%2520Leads%2520to%2520ETB%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D3668%26epage%3D3678%26doi%3D10.1021%2Fjm990170q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Balwierczak, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruseo, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DelGrande, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shetty, S. S.</span><span> </span><span class="NLM_article-title">Characterization of a Potent and Selective Endothelin-B Receptor Antagonist, IRL 2500</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S393</span><span class="NLM_x">â</span> <span class="NLM_lpage">S396</span><span class="refDoi">Â DOI: 10.1097/00005344-199526003-00116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2F00005344-199526003-00116" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1995&pages=S393-S396&issue=Suppl.+3&author=J.+L.+Balwierczakauthor=C.+W.+Bruseoauthor=D.+DelGrandeauthor=A.+Y.+Jengauthor=P.+Savageauthor=S.+S.+Shetty&title=Characterization+of+a+Potent+and+Selective+Endothelin-B+Receptor+Antagonist%2C+IRL+2500&doi=10.1097%2F00005344-199526003-00116"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1097%2F00005344-199526003-00116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199526003-00116%26sid%3Dliteratum%253Aachs%26aulast%3DBalwierczak%26aufirst%3DJ.%2BL.%26aulast%3DBruseo%26aufirst%3DC.%2BW.%26aulast%3DDelGrande%26aufirst%3DD.%26aulast%3DJeng%26aufirst%3DA.%2BY.%26aulast%3DSavage%26aufirst%3DP.%26aulast%3DShetty%26aufirst%3DS.%2BS.%26atitle%3DCharacterization%2520of%2520a%2520Potent%2520and%2520Selective%2520Endothelin-B%2520Receptor%2520Antagonist%252C%2520IRL%25202500%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1995%26volume%3D26%26issue%3DSuppl.%25203%26spage%3DS393%26epage%3DS396%26doi%3D10.1097%2F00005344-199526003-00116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Ikemura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohmori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, S.</span><span> </span><span class="NLM_article-title">Effects of Endothelin B Antagonist RES-701-1 on Endothelin-induced Contractile Responses In-vivo and In-vitro in Guinea-pigs</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">â</span> <span class="NLM_lpage">105</span><span class="refDoi">Â DOI: 10.1111/j.2042-7158.1996.tb05886.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fj.2042-7158.1996.tb05886.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=8722505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADyaK28XisFCrtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1996&pages=100-105&author=T.+Ikemuraauthor=K.+Ohmoriauthor=T.+Tanakaauthor=Y.+Matsudaauthor=S.+Kitamura&title=Effects+of+Endothelin+B+Antagonist+RES-701-1+on+Endothelin-induced+Contractile+Responses+In-vivo+and+In-vitro+in+Guinea-pigs&doi=10.1111%2Fj.2042-7158.1996.tb05886.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of endothelin B antagonist RES-701-1 on endothelin-induced contractile responses in vivo and in vitro in guinea pigs</span></div><div class="casAuthors">Ikemura, Toshihide; Ohmori, Kenji; Tanaka, Takeo; Matsuda, Yuzuru; Kitamura, Shigeto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-5</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Royal Pharmaceutical Society of Great Britain</span>)
        </div><div class="casAbstract">The effects of an endothelin (ET)-receptor B-specific antagonist, RES-701-1, on ET-induced contraction of guinea pig trachea and on ET-induced bronchoconstriction in anesthetized guinea pigs were investigated.  In the epithelium-removed tracheal prepn., 1 Ã 10-5 M RES-701-1 inhibited contractions induced by the ETB-specific agonist sarafotoxin S6c (pKB = 6.10).  In the epithelium-intact tracheal prepn., RES-701-1 (1 Ã 10-5 M) inhibited the ET-3-induced contraction (pKB = 5.27), but enhanced the ET-1-induced contraction significantly and shifted the concn. response curve to the left.  The maximal responses to ET-1 and ET-3-induced contraction were augmented by epithelium removal by 1.5 and 1.8-fold, resp.  Against ET-3-induced contraction in the tracheal prepn. without epithelium, RES-701-1 (0.3-10 Ã 10-6 M) antagonized the contraction in a concn.-dependent manner (pA2 = 5.9).  On the other hand, RES-701-1 (1 Ã 10-5 M) did not affect ET-1-evoked responses in the trachea without epithelium.  The i.v. administration of ET-1 (1.5 nmol/kg) or ET-3 (1.5 nmol/kg) evoked a biphasic, fast and sustained bronchoconstriction in anesthetized guinea pigs pretreated with propranolol (1.0 mg/kg).  When administered i.v., RES-701-1 (0.3 or 1.0 mg/kg) showed significant redn. in both phases of bronchoconstriction induced by ET-3.  As in the case of ET-1-induced bronchoconstriction, RES-701-1 augmented the sustained phase although a significant redn. of the fast phase was obsd.  These results indicate that RES-701-1 can inhibit the ET-3-induced airway responses not only in vitro but also in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmMmYjQZZCSbVg90H21EOLACvtfcHk0liKwhlqG9hpbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XisFCrtL4%253D&md5=a294a9cd7fe603941647ac574b3d6d3a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.1996.tb05886.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.1996.tb05886.x%26sid%3Dliteratum%253Aachs%26aulast%3DIkemura%26aufirst%3DT.%26aulast%3DOhmori%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DMatsuda%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DS.%26atitle%3DEffects%2520of%2520Endothelin%2520B%2520Antagonist%2520RES-701-1%2520on%2520Endothelin-induced%2520Contractile%2520Responses%2520In-vivo%2520and%2520In-vitro%2520in%2520Guinea-pigs%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D1996%26volume%3D48%26spage%3D100%26epage%3D105%26doi%3D10.1111%2Fj.2042-7158.1996.tb05886.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Breu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidhart, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramuz, H.</span><span> </span><span class="NLM_article-title">In-vitro Characterisation of Ro 46-8443, the First Non-peptide Antagonist Selective for the Endothelin ET<sub>B</sub> Receptor</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">383</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">â</span> <span class="NLM_lpage">41</span><span class="refDoi">Â DOI: 10.1016/0014-5793(96)00213-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2F0014-5793%2896%2900213-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=1996&pages=37-41&author=V.+Breuauthor=M.+Clozelauthor=K.+Burriauthor=G.+Hirthauthor=W.+Neidhartauthor=H.+Ramuz&title=In-vitro+Characterisation+of+Ro+46-8443%2C+the+First+Non-peptide+Antagonist+Selective+for+the+Endothelin+ETB+Receptor&doi=10.1016%2F0014-5793%2896%2900213-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2896%2900213-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252896%252900213-X%26sid%3Dliteratum%253Aachs%26aulast%3DBreu%26aufirst%3DV.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DBurri%26aufirst%3DK.%26aulast%3DHirth%26aufirst%3DG.%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DRamuz%26aufirst%3DH.%26atitle%3DIn-vitro%2520Characterisation%2520of%2520Ro%252046-8443%252C%2520the%2520First%2520Non-peptide%2520Antagonist%2520Selective%2520for%2520the%2520Endothelin%2520ETB%2520Receptor%26jtitle%3DFEBS%2520Lett.%26date%3D1996%26volume%3D383%26spage%3D37%26epage%3D41%26doi%3D10.1016%2F0014-5793%2896%2900213-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marfurt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grisostomi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binkert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramuz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span> </span><span class="NLM_article-title">Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2776</span><span class="NLM_x">â</span> <span class="NLM_lpage">2795</span><span class="refDoi">Â DOI: 10.1021/jm031115r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031115r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2776-2795&author=M.+H.+Bolliauthor=J.+Marfurtauthor=C.+Grisostomiauthor=C.+Bossauthor=C.+Binkertauthor=P.+Hessauthor=A.+Treiberauthor=E.+Thorinauthor=K.+Morrisonauthor=S.+Buchmannauthor=D.+Burauthor=H.+Ramuzauthor=M.+Clozelauthor=W.+Fischliauthor=T.+Weller&title=Novel+Benzo%5B1%2C4%5Ddiazepin-2-one+Derivatives+as+Endothelin+Receptor+Antagonists&doi=10.1021%2Fjm031115r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm031115r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031115r%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DMarfurt%26aufirst%3DJ.%26aulast%3DGrisostomi%26aufirst%3DC.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DThorin%26aufirst%3DE.%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DRamuz%26aufirst%3DH.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DNovel%2520Benzo%255B1%252C4%255Ddiazepin-2-one%2520Derivatives%2520as%2520Endothelin%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2776%26epage%3D2795%26doi%3D10.1021%2Fjm031115r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Ishizuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamori, T.</span><span> </span><span class="NLM_article-title">Structure-Activity Relationships of a Novel Class of Endothelin-A Receptor Antagonists and Discovery of Potent and Selective Receptor Antagonist, 2-(Benzo[1,3]Dioxol-5-yl)-6-isopropyloxy-4-(4-Methoxyphenyl)-2<i>H</i>-chromene-3-carboxylic Acid (S-1255). 1. Study on Structure-activity Relationships and Basic Structure Crucial for ET<sub>A</sub> Antagonism</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2041</span><span class="NLM_x">â</span> <span class="NLM_lpage">2055</span><span class="refDoi">Â DOI: 10.1021/jm010382z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010382z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2041-2055&author=N.+Ishizukaauthor=K.+Matsumuraauthor=K.+Sakaiauthor=M.+Fujimotoauthor=S.+Miharaauthor=T.+Yamamori&title=Structure-Activity+Relationships+of+a+Novel+Class+of+Endothelin-A+Receptor+Antagonists+and+Discovery+of+Potent+and+Selective+Receptor+Antagonist%2C+2-%28Benzo%5B1%2C3%5DDioxol-5-yl%29-6-isopropyloxy-4-%284-Methoxyphenyl%29-2H-chromene-3-carboxylic+Acid+%28S-1255%29.+1.+Study+on+Structure-activity+Relationships+and+Basic+Structure+Crucial+for+ETA+Antagonism&doi=10.1021%2Fjm010382z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm010382z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010382z%26sid%3Dliteratum%253Aachs%26aulast%3DIshizuka%26aufirst%3DN.%26aulast%3DMatsumura%26aufirst%3DK.%26aulast%3DSakai%26aufirst%3DK.%26aulast%3DFujimoto%26aufirst%3DM.%26aulast%3DMihara%26aufirst%3DS.%26aulast%3DYamamori%26aufirst%3DT.%26atitle%3DStructure-Activity%2520Relationships%2520of%2520a%2520Novel%2520Class%2520of%2520Endothelin-A%2520Receptor%2520Antagonists%2520and%2520Discovery%2520of%2520Potent%2520and%2520Selective%2520Receptor%2520Antagonist%252C%25202-%2528Benzo%255B1%252C3%255DDioxol-5-yl%2529-6-isopropyloxy-4-%25284-Methoxyphenyl%2529-2H-chromene-3-carboxylic%2520Acid%2520%2528S-1255%2529.%25201.%2520Study%2520on%2520Structure-activity%2520Relationships%2520and%2520Basic%2520Structure%2520Crucial%2520for%2520ETA%2520Antagonism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2041%26epage%3D2055%26doi%3D10.1021%2Fjm010382z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Amberg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">HergenrÃ¶der, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettschau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschack, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riechers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, L.</span><span> </span><span class="NLM_article-title">Discovery and Synthesis of (<i>S</i>)-3-[2-(3,4-Dimethoxyphenyl)Ethoxy]-2-(4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic Acid (LU 302872), a Novel Orally Active Mixed ET<sub>A</sub>/ET<sub>B</sub> Receptor Antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3026</span><span class="NLM_x">â</span> <span class="NLM_lpage">3032</span><span class="refDoi">Â DOI: 10.1021/jm9910425</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9910425" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3026-3032&author=W.+Ambergauthor=S.+Hergenr%C3%B6derauthor=H.+Hillenauthor=R.+Jansenauthor=G.+Kettschauauthor=A.+Klingauthor=D.+Klingeauthor=M.+Raschackauthor=H.+Riechersauthor=L.+Unger&title=Discovery+and+Synthesis+of+%28S%29-3-%5B2-%283%2C4-Dimethoxyphenyl%29Ethoxy%5D-2-%284%2C6-dimethylpyrimidin-2-yloxy%29-3%2C3-diphenylpropionic+Acid+%28LU+302872%29%2C+a+Novel+Orally+Active+Mixed+ETA%2FETB+Receptor+Antagonist&doi=10.1021%2Fjm9910425"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm9910425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9910425%26sid%3Dliteratum%253Aachs%26aulast%3DAmberg%26aufirst%3DW.%26aulast%3DHergenr%25C3%25B6der%26aufirst%3DS.%26aulast%3DHillen%26aufirst%3DH.%26aulast%3DJansen%26aufirst%3DR.%26aulast%3DKettschau%26aufirst%3DG.%26aulast%3DKling%26aufirst%3DA.%26aulast%3DKlinge%26aufirst%3DD.%26aulast%3DRaschack%26aufirst%3DM.%26aulast%3DRiechers%26aufirst%3DH.%26aulast%3DUnger%26aufirst%3DL.%26atitle%3DDiscovery%2520and%2520Synthesis%2520of%2520%2528S%2529-3-%255B2-%25283%252C4-Dimethoxyphenyl%2529Ethoxy%255D-2-%25284%252C6-dimethylpyrimidin-2-yloxy%2529-3%252C3-diphenylpropionic%2520Acid%2520%2528LU%2520302872%2529%252C%2520a%2520Novel%2520Orally%2520Active%2520Mixed%2520ETA%252FETB%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D3026%26epage%3D3032%26doi%3D10.1021%2Fjm9910425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Patel, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olgun, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengyel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reznik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephani, R. A.</span><span> </span><span class="NLM_article-title">Synthesis and Pharmacological Activity of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic Acids as Selective ET<sub>A</sub> Antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6840</span><span class="NLM_x">â</span> <span class="NLM_lpage">6844</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2010.08.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.bmcl.2010.08.074" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=6840-6844&author=H.+J.+Patelauthor=N.+Olgunauthor=I.+Lengyelauthor=S.+Reznikauthor=R.+A.+Stephani&title=Synthesis+and+Pharmacological+Activity+of+1%2C3%2C6-trisubstituted-4-oxo-1%2C4-dihydroquinoline-2-carboxylic+Acids+as+Selective+ETA+Antagonists&doi=10.1016%2Fj.bmcl.2010.08.074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.08.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.08.074%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BJ.%26aulast%3DOlgun%26aufirst%3DN.%26aulast%3DLengyel%26aufirst%3DI.%26aulast%3DReznik%26aufirst%3DS.%26aulast%3DStephani%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Activity%2520of%25201%252C3%252C6-trisubstituted-4-oxo-1%252C4-dihydroquinoline-2-carboxylic%2520Acids%2520as%2520Selective%2520ETA%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D6840%26epage%3D6844%26doi%3D10.1016%2Fj.bmcl.2010.08.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Xia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span> </span><span class="NLM_article-title">Synthesis and In-vitro Evaluation of Ambrisentan Analogues as Potential Endothelin Receptor Antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3894</span><span class="NLM_x">â</span> <span class="NLM_lpage">3897</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.05.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.bmcl.2011.05.034" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3894-3897&author=J.+Xiaauthor=J.+Songauthor=L.+Zhenauthor=X.+Zhangauthor=X.+Leiauthor=L.+Zhengauthor=Q.+Wangauthor=H.+Sun&title=Synthesis+and+In-vitro+Evaluation+of+Ambrisentan+Analogues+as+Potential+Endothelin+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2011.05.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.05.034%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DZhen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLei%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520In-vitro%2520Evaluation%2520of%2520Ambrisentan%2520Analogues%2520as%2520Potential%2520Endothelin%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3894%26epage%3D3897%26doi%3D10.1016%2Fj.bmcl.2011.05.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Allard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijkhuisen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrull, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshayes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamourette, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducancel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boquet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couraud, J. Y.</span><span> </span><span class="NLM_article-title">Generation and Characterization of Rendomab-B1, a Monoclonal Antibody Displaying Potent and Specific Antagonism of the Human Endothelin B Receptor</span> <span class="citation_source-journal">MAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">â</span> <span class="NLM_lpage">69</span><span class="refDoi">Â DOI: 10.4161/mabs.22696</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.4161%2Fmabs.22696" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=56-69&author=B.+Allardauthor=A.+Wijkhuisenauthor=A.+Borrullauthor=F.+Deshayesauthor=F.+Priamauthor=P.+Lamouretteauthor=F.+Ducancelauthor=D.+Boquetauthor=J.+Y.+Couraud&title=Generation+and+Characterization+of+Rendomab-B1%2C+a+Monoclonal+Antibody+Displaying+Potent+and+Specific+Antagonism+of+the+Human+Endothelin+B+Receptor&doi=10.4161%2Fmabs.22696"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.4161%2Fmabs.22696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fmabs.22696%26sid%3Dliteratum%253Aachs%26aulast%3DAllard%26aufirst%3DB.%26aulast%3DWijkhuisen%26aufirst%3DA.%26aulast%3DBorrull%26aufirst%3DA.%26aulast%3DDeshayes%26aufirst%3DF.%26aulast%3DPriam%26aufirst%3DF.%26aulast%3DLamourette%26aufirst%3DP.%26aulast%3DDucancel%26aufirst%3DF.%26aulast%3DBoquet%26aufirst%3DD.%26aulast%3DCouraud%26aufirst%3DJ.%2BY.%26atitle%3DGeneration%2520and%2520Characterization%2520of%2520Rendomab-B1%252C%2520a%2520Monoclonal%2520Antibody%2520Displaying%2520Potent%2520and%2520Specific%2520Antagonism%2520of%2520the%2520Human%2520Endothelin%2520B%2520Receptor%26jtitle%3DMAbs%26date%3D2013%26volume%3D5%26spage%3D56%26epage%3D69%26doi%3D10.4161%2Fmabs.22696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Aubert, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Therapeutic Potential of Endothelin Receptor Modulators: Lessons from Human Clinical Trials</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1069</span><span class="NLM_x">â</span> <span class="NLM_lpage">1084</span><span class="refDoi">Â DOI: 10.1517/14728220903074570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1517%2F14728220903074570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=19659448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFaltL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=1069-1084&author=J.+D.+Aubertauthor=L.+Juillerat-Jeanneret&title=Therapeutic+Potential+of+Endothelin+Receptor+Modulators%3A+Lessons+from+Human+Clinical+Trials&doi=10.1517%2F14728220903074570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials</span></div><div class="casAuthors">Aubert, John-David; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1069-1084</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The endothelin system, and in particular endothelin receptors, are targets for therapeutic intervention in human diseases.  Endothelin receptor antagonists have reached clin. use for treating pulmonary arterial hypertension, and are under clin. investigation for several other diseases, such as cancer, vasospasm or fibrogenic diseases.  We review the mols. that have been evaluated in the main clin. trials, from the point of view of receptor selectivity and of their chem. characteristics which were important for efficacy in pulmonary hypertension.  We will also discuss future use of antagonists to endothelin receptor(s) in several human diseases and what should be the necessary properties of the future mols. for efficacy in diseases where the presently tested mols. displayed suboptimal efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAwp9dwjsEbbVg90H21EOLACvtfcHk0lgIjJGtj3jRoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFaltL8%253D&md5=81343b0ba9cb9b9d4640ddecc4e0d22d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1517%2F14728220903074570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728220903074570%26sid%3Dliteratum%253Aachs%26aulast%3DAubert%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DTherapeutic%2520Potential%2520of%2520Endothelin%2520Receptor%2520Modulators%253A%2520Lessons%2520from%2520Human%2520Clinical%2520Trials%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2009%26volume%3D13%26spage%3D1069%26epage%3D1084%26doi%3D10.1517%2F14728220903074570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Kiowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¼scher, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linder, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BÃ¼hler, F. R.</span><span> </span><span class="NLM_article-title">Endothelin-1-induced Vasoconstriction in Humans. Reversal by Calcium Channel Blockade but Not by Nitrovasodilators or Endothelium-derived Relaxing Factor</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">â</span> <span class="NLM_lpage">475</span><span class="refDoi">Â DOI: 10.1161/01.CIR.83.2.469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1161%2F01.CIR.83.2.469" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1991&pages=469-475&author=W.+Kiowskiauthor=T.+F.+L%C3%BCscherauthor=L.+Linderauthor=F.+R.+B%C3%BChler&title=Endothelin-1-induced+Vasoconstriction+in+Humans.+Reversal+by+Calcium+Channel+Blockade+but+Not+by+Nitrovasodilators+or+Endothelium-derived+Relaxing+Factor&doi=10.1161%2F01.CIR.83.2.469"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.83.2.469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.83.2.469%26sid%3Dliteratum%253Aachs%26aulast%3DKiowski%26aufirst%3DW.%26aulast%3DL%25C3%25BCscher%26aufirst%3DT.%2BF.%26aulast%3DLinder%26aufirst%3DL.%26aulast%3DB%25C3%25BChler%26aufirst%3DF.%2BR.%26atitle%3DEndothelin-1-induced%2520Vasoconstriction%2520in%2520Humans.%2520Reversal%2520by%2520Calcium%2520Channel%2520Blockade%2520but%2520Not%2520by%2520Nitrovasodilators%2520or%2520Endothelium-derived%2520Relaxing%2520Factor%26jtitle%3DCirculation%26date%3D1991%26volume%3D83%26spage%3D469%26epage%3D475%26doi%3D10.1161%2F01.CIR.83.2.469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Haynes, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. J.</span><span> </span><span class="NLM_article-title">Contribution of Endogenous Generation of Endothelin-1 to Basal Vascular Tone</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">â</span> <span class="NLM_lpage">854</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(94)92827-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0140-6736%2894%2992827-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=1994&pages=852-854&author=W.+G.+Haynesauthor=D.+J.+Webb&title=Contribution+of+Endogenous+Generation+of+Endothelin-1+to+Basal+Vascular+Tone&doi=10.1016%2FS0140-6736%2894%2992827-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2894%2992827-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252894%252992827-4%26sid%3Dliteratum%253Aachs%26aulast%3DHaynes%26aufirst%3DW.%2BG.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26atitle%3DContribution%2520of%2520Endogenous%2520Generation%2520of%2520Endothelin-1%2520to%2520Basal%2520Vascular%2520Tone%26jtitle%3DLancet%26date%3D1994%26volume%3D344%26spage%3D852%26epage%3D854%26doi%3D10.1016%2FS0140-6736%2894%2992827-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Ertl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauersachs, J.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists in Heart Failure: Current Status and Future Directions</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">â</span> <span class="NLM_lpage">1040</span><span class="refDoi">Â DOI: 10.2165/00003495-200464100-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2165%2F00003495-200464100-00001" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=1029-1040&author=G.+Ertlauthor=J.+Bauersachs&title=Endothelin+Receptor+Antagonists+in+Heart+Failure%3A+Current+Status+and+Future+Directions&doi=10.2165%2F00003495-200464100-00001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2165%2F00003495-200464100-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200464100-00001%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DG.%26aulast%3DBauersachs%26aufirst%3DJ.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%2520in%2520Heart%2520Failure%253A%2520Current%2520Status%2520and%2520Future%2520Directions%26jtitle%3DDrugs%26date%3D2004%26volume%3D64%26spage%3D1029%26epage%3D1040%26doi%3D10.2165%2F00003495-200464100-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Morrell, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLean, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurtry, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenmark, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thistlethwaite, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissmann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, E. K.</span><span> </span><span class="NLM_article-title">Cellular and Molecular Basis of Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">S20</span><span class="NLM_x">â</span> <span class="NLM_lpage">S31</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2009.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.jacc.2009.04.018" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=S20-S31&author=N.+W.+Morrellauthor=S.+Adnotauthor=S.+L.+Archerauthor=J.+Dupuisauthor=P.+L.+Jonesauthor=M.+R.+MacLeanauthor=I.+F.+McMurtryauthor=K.+R.+Stenmarkauthor=P.+A.+Thistlethwaiteauthor=N.+Weissmannauthor=J.+X.+Yuanauthor=E.+K.+Weir&title=Cellular+and+Molecular+Basis+of+Pulmonary+Arterial+Hypertension&doi=10.1016%2Fj.jacc.2009.04.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2009.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2009.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DMorrell%26aufirst%3DN.%2BW.%26aulast%3DAdnot%26aufirst%3DS.%26aulast%3DArcher%26aufirst%3DS.%2BL.%26aulast%3DDupuis%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DP.%2BL.%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26aulast%3DMcMurtry%26aufirst%3DI.%2BF.%26aulast%3DStenmark%26aufirst%3DK.%2BR.%26aulast%3DThistlethwaite%26aufirst%3DP.%2BA.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DYuan%26aufirst%3DJ.%2BX.%26aulast%3DWeir%26aufirst%3DE.%2BK.%26atitle%3DCellular%2520and%2520Molecular%2520Basis%2520of%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2009%26volume%3D54%26spage%3DS20%26epage%3DS31%26doi%3D10.1016%2Fj.jacc.2009.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Tuder, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DorfmÃ¼ller, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erzurum, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guignabert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michelakis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovitch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schermuly, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenmark, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrell, N. W.</span><span> </span><span class="NLM_article-title">Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">D4</span><span class="NLM_x">â</span> <span class="NLM_lpage">D12</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2013.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.jacc.2013.10.025" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=D4-D12&author=R.+M.+Tuderauthor=S.+L.+Archerauthor=P.+Dorfm%C3%BCllerauthor=S.+C.+Erzurumauthor=C.+Guignabertauthor=E.+Michelakisauthor=M.+Rabinovitchauthor=R.+Schermulyauthor=K.+R.+Stenmarkauthor=N.+W.+Morrell&title=Relevant+Issues+in+the+Pathology+and+Pathobiology+of+Pulmonary+Hypertension&doi=10.1016%2Fj.jacc.2013.10.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2013.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2013.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DTuder%26aufirst%3DR.%2BM.%26aulast%3DArcher%26aufirst%3DS.%2BL.%26aulast%3DDorfm%25C3%25BCller%26aufirst%3DP.%26aulast%3DErzurum%26aufirst%3DS.%2BC.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DMichelakis%26aufirst%3DE.%26aulast%3DRabinovitch%26aufirst%3DM.%26aulast%3DSchermuly%26aufirst%3DR.%26aulast%3DStenmark%26aufirst%3DK.%2BR.%26aulast%3DMorrell%26aufirst%3DN.%2BW.%26atitle%3DRelevant%2520Issues%2520in%2520the%2520Pathology%2520and%2520Pathobiology%2520of%2520Pulmonary%2520Hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2013%26volume%3D62%26spage%3DD4%26epage%3DD12%26doi%3D10.1016%2Fj.jacc.2013.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Macchia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchioli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tognoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marfisi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavazzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, S.</span><span> </span><span class="NLM_article-title">Systematic Review of Trials Using Vasodilators in Pulmonary Arterial Hypertension: Why a New Approach is Needed</span> <span class="citation_source-journal">Am. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">159</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">â</span> <span class="NLM_lpage">257</span><span class="refDoi">Â DOI: 10.1016/j.ahj.2009.11.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.ahj.2009.11.028" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2010&pages=245-257&author=A.+Macchiaauthor=R.+Marchioliauthor=G.+Tognoniauthor=M.+Scaranoauthor=R.+Marfisiauthor=L.+Tavazziauthor=S.+Rich&title=Systematic+Review+of+Trials+Using+Vasodilators+in+Pulmonary+Arterial+Hypertension%3A+Why+a+New+Approach+is+Needed&doi=10.1016%2Fj.ahj.2009.11.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2009.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2009.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DMacchia%26aufirst%3DA.%26aulast%3DMarchioli%26aufirst%3DR.%26aulast%3DTognoni%26aufirst%3DG.%26aulast%3DScarano%26aufirst%3DM.%26aulast%3DMarfisi%26aufirst%3DR.%26aulast%3DTavazzi%26aufirst%3DL.%26aulast%3DRich%26aufirst%3DS.%26atitle%3DSystematic%2520Review%2520of%2520Trials%2520Using%2520Vasodilators%2520in%2520Pulmonary%2520Arterial%2520Hypertension%253A%2520Why%2520a%2520New%2520Approach%2520is%2520Needed%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2010%26volume%3D159%26spage%3D245%26epage%3D257%26doi%3D10.1016%2Fj.ahj.2009.11.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Sauvageau, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupuis, J.</span><span> </span><span class="NLM_article-title">Endothelin-1-induced Pulmonary Vasoreactivity is Regulated by ET(A) and ET(B) Receptor Interactions</span> <span class="citation_source-journal">J. Vasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">â</span> <span class="NLM_lpage">381</span><span class="refDoi">Â DOI: 10.1159/000102534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1159%2F000102534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=17495482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsVaqt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2007&pages=375-381&author=S.+Sauvageauauthor=E.+Thorinauthor=A.+Caronauthor=J.+Dupuis&title=Endothelin-1-induced+Pulmonary+Vasoreactivity+is+Regulated+by+ET%28A%29+and+ET%28B%29+Receptor+Interactions&doi=10.1159%2F000102534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1-Induced Pulmonary Vasoreactivity Is Regulated by ETA and ETB Receptor Interactions</span></div><div class="casAuthors">Sauvageau, Stephanie; Thorin, Eric; Caron, Alexandre; Dupuis, Jocelyn</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Vascular Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">375-381</span>CODEN:
                <span class="NLM_cas:coden">JVREE9</span>;
        ISSN:<span class="NLM_cas:issn">1018-1172</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Roles of endothelin (ET) receptors (R) and of the endothelium on ET-1-induced pulmonary vasoreactivity are subjects of debate.  This stems from endothelial ETB-R that can release both vasodilators and vasoconstrictors.  The aim of this study was to evaluate the roles of the endothelium and of ET-Rs on ET-1-induced pulmonary vasoreactivity.  Methods: Pharmacol. expts. were performed in isolated rat lungs and in pulmonary resistance arteries.  Results: In isolated lungs, ET-1 and the selective ETB-R agonist sarafotoxin 6c (S6c) induced a similar vasoconstriction.  ET-1 constriction was reduced by a selective ETA-R antagonist; however, the selective ETB-R antagonist had no significant effect.  In preconstricted lungs, ETB-R stimulation caused mild vasodilation at low concns. but severe vasoconstriction at higher concns.  In isolated arteries, responses to ET-1 and S6c were not different and unaffected by removal of endothelium.  Interestingly, concns. of ETA-R and ETB-R antagonists that only mildly reduced ET-1 vasoconstriction when used alone, prevented maximal constriction and greatly reduced vascular sensitivity to ET-1 when used in combination.  Conclusion: In rat lungs, both ETA-R and ETB-R contribute to ET-1-induced pulmonary vasoconstriction with evidence of interaction between receptors.  A mild vasodilator role of the endothelial ETB-R is evident only at low agonist concn. and when baseline vascular tone is increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqwehQuhFm_LVg90H21EOLACvtfcHk0lhiz8PVDb9lgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsVaqt7c%253D&md5=d569b0f014a406d1e75a842f58cfbc2a</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1159%2F000102534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000102534%26sid%3Dliteratum%253Aachs%26aulast%3DSauvageau%26aufirst%3DS.%26aulast%3DThorin%26aufirst%3DE.%26aulast%3DCaron%26aufirst%3DA.%26aulast%3DDupuis%26aufirst%3DJ.%26atitle%3DEndothelin-1-induced%2520Pulmonary%2520Vasoreactivity%2520is%2520Regulated%2520by%2520ET%2528A%2529%2520and%2520ET%2528B%2529%2520Receptor%2520Interactions%26jtitle%3DJ.%2520Vasc.%2520Res.%26date%3D2007%26volume%3D44%26spage%3D375%26epage%3D381%26doi%3D10.1159%2F000102534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Porter, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riches, K.</span><span> </span><span class="NLM_article-title">Vascular Smooth Muscle as a Target for Novel Therapeutics</span> <span class="citation_source-journal">Curr. Diabetes Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="refDoi">Â DOI: 10.1007/s11892-015-0647-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs11892-015-0647-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=26277484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC287jsVeiuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=72&author=K.+E.+Porterauthor=K.+Riches&title=Vascular+Smooth+Muscle+as+a+Target+for+Novel+Therapeutics&doi=10.1007%2Fs11892-015-0647-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Smooth Muscle as a Target for Novel Therapeutics</span></div><div class="casAuthors">Porter Karen E; Riches Kirsten</div><div class="citationInfo"><span class="NLM_cas:title">Current diabetes reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cardiovascular disease is the principal cause of death in patients with type 2 diabetes (T2DM).  Exposure of the vasculature to metabolic disturbances leaves a persistent imprint on vascular walls, and specifically on smooth muscle cells (SMC) that favours their dysfunction and potentially underlies macrovascular complications of T2DM.  Current diabetes therapies and continued development of newer treatments has led to the ability to achieve more efficient glycaemic control.  There is also some evidence to suggest that some of these treatments may exert favourable pleiotropic effects, some of which may be at the level of SMC.  However, emerging interest in epigenetic markers as determinants of vascular disease, and a putative link with diabetes, opens the possibility for new avenues to develop robust and specific new therapies.  These will likely need to target cell-specific epigenetic changes such as effectors of DNA histone modifications that promote or inhibit gene transcription, and/or microRNAs capable of regulating entire cellular pathways through target gene repression.  The growing epidemic of T2DM worldwide, and its attendant cardiovascular mortality, dictates a need for novel therapies and personalised approaches to ameliorate vascular complications in this vulnerable population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0Eyf06DQ28EPI-fCgwosgfW6udTcc2ebv9afKGd_iqbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287jsVeiuw%253D%253D&md5=d96ce55a7399c10c9bf591a6a84f255d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1007%2Fs11892-015-0647-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11892-015-0647-9%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DK.%2BE.%26aulast%3DRiches%26aufirst%3DK.%26atitle%3DVascular%2520Smooth%2520Muscle%2520as%2520a%2520Target%2520for%2520Novel%2520Therapeutics%26jtitle%3DCurr.%2520Diabetes%2520Rep.%26date%3D2015%26volume%3D15%26spage%3D72%26doi%3D10.1007%2Fs11892-015-0647-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Tonelli, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ioannidis, J. P.</span><span> </span><span class="NLM_article-title">Geometry of the Randomized Evidence for Treatments of Pulmonary Hypertension</span> <span class="citation_source-journal">Cardiovasc. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">e138</span><span class="NLM_x">â</span> <span class="NLM_lpage">e146</span><span class="refDoi">Â DOI: 10.1111/1755-5922.12050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2F1755-5922.12050" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=e138-e146&author=A.+R.+Tonelliauthor=J.+Zeinauthor=J.+P.+Ioannidis&title=Geometry+of+the+Randomized+Evidence+for+Treatments+of+Pulmonary+Hypertension&doi=10.1111%2F1755-5922.12050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1111%2F1755-5922.12050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1755-5922.12050%26sid%3Dliteratum%253Aachs%26aulast%3DTonelli%26aufirst%3DA.%2BR.%26aulast%3DZein%26aufirst%3DJ.%26aulast%3DIoannidis%26aufirst%3DJ.%2BP.%26atitle%3DGeometry%2520of%2520the%2520Randomized%2520Evidence%2520for%2520Treatments%2520of%2520Pulmonary%2520Hypertension%26jtitle%3DCardiovasc.%2520Ther.%26date%3D2013%26volume%3D31%26spage%3De138%26epage%3De146%26doi%3D10.1111%2F1755-5922.12050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Montani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaumais, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guignabert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GÃ¼nther, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girerd, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">JaÃ¯s, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Algalarrondo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savale, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitbon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbert, M.</span><span> </span><span class="NLM_article-title">Targeted Therapies in Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">â</span> <span class="NLM_lpage">191</span><span class="refDoi">Â DOI: 10.1016/j.pharmthera.2013.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.pharmthera.2013.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24134901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsleru7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2014&pages=172-191&author=D.+Montaniauthor=M.+C.+Chaumaisauthor=C.+Guignabertauthor=S.+G%C3%BCntherauthor=B.+Girerdauthor=X.+Ja%C3%AFsauthor=V.+Algalarrondoauthor=L.+C.+Priceauthor=L.+Savaleauthor=O.+Sitbonauthor=G.+Simonneauauthor=M.+Humbert&title=Targeted+Therapies+in+Pulmonary+Arterial+Hypertension&doi=10.1016%2Fj.pharmthera.2013.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapies in pulmonary arterial hypertension</span></div><div class="casAuthors">Montani, David; Chaumais, Marie-Camille; Guignabert, Christophe; Gunther, Sven; Girerd, Barbara; Jais, Xavier; Algalarrondo, Vincent; Price, Laura C.; Savale, Laurent; Sitbon, Olivier; Simonneau, Gerald; Humbert, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-191</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Pulmonary arterial hypertension (PAH) is a rare disorder characterized by progressive obliteration of small pulmonary arteries that leads to elevated pulmonary arterial pressure and right heart failure.  During the last decades, an improved understanding of the pathophysiol. of the disease has resulted in the development of effective therapies targeting endothelial dysfunction (epoprostenol and derivs., endothelin receptor antagonists and phosphodiesterase type 5 inhibitors).  These drugs allow clin., functional and hemodynamic improvement.  Even though, no cure exists for PAH and prognosis remains poor.  Recently, several addnl. pathways have been suggested to be involved in the pathogenesis of PAH, and may represent innovative therapies.  In this summary, we review conventional therapy, pharmacol. agents currently available for the treatment of PAH and the benefit/risk ratio of potential future therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRWQUrsAAiHbVg90H21EOLACvtfcHk0li1MrERY_STLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsleru7zO&md5=ac19ee640f860eda78ed2e09caa083dc</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2013.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2013.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DChaumais%26aufirst%3DM.%2BC.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DG%25C3%25BCnther%26aufirst%3DS.%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DJa%25C3%25AFs%26aufirst%3DX.%26aulast%3DAlgalarrondo%26aufirst%3DV.%26aulast%3DPrice%26aufirst%3DL.%2BC.%26aulast%3DSavale%26aufirst%3DL.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DHumbert%26aufirst%3DM.%26atitle%3DTargeted%2520Therapies%2520in%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DPharmacol.%2520Ther.%26date%3D2014%26volume%3D141%26spage%3D172%26epage%3D191%26doi%3D10.1016%2Fj.pharmthera.2013.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Humbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span> </span><span class="NLM_article-title">The Molecular Targets of Approved Treatments for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">â</span> <span class="NLM_lpage">83</span><span class="refDoi">Â DOI: 10.1136/thoraxjnl-2015-207170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1136%2Fthoraxjnl-2015-207170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=26219978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FnsFyntA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2016&pages=73-83&author=M.+Humbertauthor=H.+A.+Ghofrani&title=The+Molecular+Targets+of+Approved+Treatments+for+Pulmonary+Arterial+Hypertension&doi=10.1136%2Fthoraxjnl-2015-207170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular targets of approved treatments for pulmonary arterial hypertension</span></div><div class="casAuthors">Humbert Marc; Ghofrani Hossein-Ardeschir</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)--prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors.  With the approval of the soluble guanylate cyclase stimulator riociguat, an additional drug class has become available targeting a distinct molecular target in the same pathway as PDE5 inhibitors.  Treatment recommendations currently include the use of all four drug classes to treat PAH, but there is a lack of comparative data for these therapies.  Therefore, an understanding of the mechanistic differences between these agents is critical when making treatment decisions.  Combination therapy is often used to treat PAH and it is therefore important that physicians understand how the modes of action of these drugs may interact to work as complementary partners, or potentially with unwanted consequences.  Furthermore, different patient phenotypes mean that patients respond differently to treatment; while a certain monotherapy may be adequate for some patients, for others it will be important to consider alternating or combining compounds with different molecular targets.  This review describes how the four currently approved drug classes target the complex pathobiology of PAH and will consider the distinct target molecules of each drug class, their modes of action, and review the pivotal clinical trial data supporting their use.  It will also discuss the rationale for combining drugs (or not) from the different classes, and review the clinical data from studies on combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJNcbGvIMVpe2mnZh2OgS0fW6udTcc2ebz8xCOEE8gZrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FnsFyntA%253D%253D&md5=a03f21a28cd4481cf38ddbb1cc6e636a</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2015-207170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2015-207170%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26atitle%3DThe%2520Molecular%2520Targets%2520of%2520Approved%2520Treatments%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DThorax%26date%3D2016%26volume%3D71%26spage%3D73%26epage%3D83%26doi%3D10.1136%2Fthoraxjnl-2015-207170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">68</span><span class="refDoi">Â DOI: 10.1002/14651858.CD004434.pub5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2F14651858.CD004434.pub5" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=1-68&author=C.+Liuauthor=J.+Chenauthor=Y.+Gaoauthor=B.+Dengauthor=K.+Liu&title=Endothelin+Receptor+Antagonists+for+Pulmonary+Arterial+Hypertension&doi=10.1002%2F14651858.CD004434.pub5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD004434.pub5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD004434.pub5%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%2520for%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2013%26volume%3D2%26spage%3D1%26epage%3D68%26doi%3D10.1002%2F14651858.CD004434.pub5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Langleben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brock, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">STRIDE-1 Study Group.</span><span> </span><span class="NLM_article-title">Stride 1: Effects of the Selective ET(A) Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension That Meets Traditional Inclusion Criteria of Previous Pulmonary Arterial Hypertension Trials</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S80</span><span class="NLM_x">â</span> <span class="NLM_lpage">S84</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=S80-S84&issue=Suppl.+1&author=D.+Langlebenauthor=T.+Brockauthor=R.+Dixonauthor=R.+Barstauthor=STRIDE-1+Study+Group.&title=Stride+1%3A+Effects+of+the+Selective+ET%28A%29+Receptor+Antagonist%2C+Sitaxsentan+Sodium%2C+in+a+Patient+Population+with+Pulmonary+Arterial+Hypertension+That+Meets+Traditional+Inclusion+Criteria+of+Previous+Pulmonary+Arterial+Hypertension+Trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DBrock%26aufirst%3DT.%26aulast%3DDixon%26aufirst%3DR.%26aulast%3DBarst%26aufirst%3DR.%26aulast%3D%26atitle%3DStride%25201%253A%2520Effects%2520of%2520the%2520Selective%2520ET%2528A%2529%2520Receptor%2520Antagonist%252C%2520Sitaxsentan%2520Sodium%252C%2520in%2520a%2520Patient%2520Population%2520with%2520Pulmonary%2520Arterial%2520Hypertension%2520That%2520Meets%2520Traditional%2520Inclusion%2520Criteria%2520of%2520Previous%2520Pulmonary%2520Arterial%2520Hypertension%2520Trials%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2004%26volume%3D44%26issue%3DSuppl.%25201%26spage%3DS80%26epage%3DS84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langleben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeije, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galie, N.</span><span> </span><span class="NLM_article-title">Treatment of Pulmonary Arterial Hypertension with the Selective Endothelin-A Receptor Antagonist Sitaxsentan</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2049</span><span class="NLM_x">â</span> <span class="NLM_lpage">2056</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2006.01.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.jacc.2006.01.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=16697324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFalsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=2049-2056&author=R.+J.+Barstauthor=D.+Langlebenauthor=D.+Badeschauthor=A.+Frostauthor=E.+C.+Lawrenceauthor=S.+Shapiroauthor=R.+Naeijeauthor=N.+Galie&title=Treatment+of+Pulmonary+Arterial+Hypertension+with+the+Selective+Endothelin-A+Receptor+Antagonist+Sitaxsentan&doi=10.1016%2Fj.jacc.2006.01.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan</span></div><div class="casAuthors">Barst, Robyn J.; Langleben, David; Badesch, David; Frost, Adaani; Lawrence, E. Clinton; Shapiro, Shelley; Naeije, Robert; Galie, Nazzareno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2049-2056</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We sought to det. the optimal dose of the selective endothelin A (ETA) receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for observation only, an open-label (OL) bosentan arm was included.  Endothelin is a mediator of PAH.  In a preliminary PAH study, the selective ETA receptor antagonist sitaxsentan improved six-min walk (6MW) distance, World Health Organization (WHO) functional class (FC), and hemodynamics.  In this double-blind, placebo-controlled 18-wk study, 247 PAH patients (idiopathic, or assocd. with connective tissue disease or congenital heart disease) were randomized; 245 patients were treated: placebo (n = 62), sitaxsentan 50 mg (n = 62) or 100 mg (n = 61), or OL (6MW tests, Borg dyspnea scores, and WHO FC assessments third-party blind) bosentan (n = 60).  The primary end point was change in 6MW distance from baseline to week 18.  Secondary end points included change in WHO FC, time to clin. worsening, and change in Borg dyspnea score.  At week 18, patients treated with sitaxsentan 100 mg had an increased 6MW distance compared with the placebo group (31.4 m, p = 0.03), and an improved WHO FC (p = 0.04).  The placebo-subtracted treatment effect for sitaxsentan 50 mg was 24.2 m (p = 0.07) and for OL bosentan, 29.5 m (p = 0.05).  The incidence of elevated hepatic transaminases (>3Ã the upper limit of normal) was 6% for placebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100 mg, and 11% for bosentan.  Treatment with the selective ETA receptor antagonist sitaxsentan, orally once daily at a dose of 100 mg, improves exercise capacity and WHO FC in PAH patients, with a low incidence of hepatic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ8rFM0c55NLVg90H21EOLACvtfcHk0lge6iEfedlQUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFalsbs%253D&md5=b68081ed4dccf86d36293b82f765a9b6</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2006.01.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2006.01.057%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DLawrence%26aufirst%3DE.%2BC.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DGalie%26aufirst%3DN.%26atitle%3DTreatment%2520of%2520Pulmonary%2520Arterial%2520Hypertension%2520with%2520the%2520Selective%2520Endothelin-A%2520Receptor%2520Antagonist%2520Sitaxsentan%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2006%26volume%3D47%26spage%3D2049%26epage%3D2056%26doi%3D10.1016%2Fj.jacc.2006.01.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Sandoval, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torbicki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzyna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jardim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerjes-Sanchez Diaz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teal, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulido, T.</span><span> </span><span class="NLM_article-title">Safety and Efficacy of Sitaxsentan 50 and 100 mg in Patients with Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">â</span> <span class="NLM_lpage">39</span><span class="refDoi">Â DOI: 10.1016/j.pupt.2011.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.pupt.2011.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22079088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFOktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=33-39&author=J.+Sandovalauthor=A.+Torbickiauthor=R.+Souzaauthor=A.+Ramirezauthor=M.+Kurzynaauthor=C.+Jardimauthor=C.+Jerjes-Sanchez+Diazauthor=S.+A.+Tealauthor=L.+J.+Hwangauthor=T.+Pulido&title=Safety+and+Efficacy+of+Sitaxsentan+50+and+100+mg+in+Patients+with+Pulmonary+Arterial+Hypertension&doi=10.1016%2Fj.pupt.2011.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension</span></div><div class="casAuthors">Sandoval, Julio; Torbicki, Adam; Souza, Rogerio; Ramirez, Alicia; Kurzyna, Marcin; Jardim, Carlos; Jerjes-Sanchez Diaz, Carlos; Teal, Simon A.; Hwang, Lie-Ju; Pulido, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-39</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To assess safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension (PAH).  Sitaxsentan is a highly selective endothelin-A receptor antagonist that was recently withdrawn by the manufacturer because of a pattern of idiosyncratic liver injury.  Before sitaxsentan withdrawal, this 18-wk double-blind, placebo-controlled study randomized patients with PAH to receive placebo or sitaxsentan 50 or 100 mg once daily.  The primary efficacy endpoint was change from baseline in 6-min walk distance (6MWD) at week 18.  Changes in World Health Organization (WHO) functional class and time to clin. worsening (TTCW) were secondary endpoints.  The primary efficacy anal. was powered for sitaxsentan 100 mg vs. placebo.  Of 98 randomized patients, 61% were WHO functional class II at baseline.  Improvement from baseline to week 18 in 6MWD occurred with sitaxsentan 100 but not 50 mg; a strong placebo effect was obsd.  At week 18, WHO functional class was improved or maintained in more patients receiving sitaxsentan 100 mg than placebo (P = 0.038); 0% vs. 12% of patients deteriorated, resp.  TTCW was not significantly different for 100-mg sitaxsentan patients than placebo (P = 0.090).  Adverse events (AEs) occurring more frequently with sitaxsentan (50 or 100 mg) included headache, peripheral edema, dizziness, nausea, extremity pain, and fatigue; most AEs were of mild or moderate severity.  Sitaxsentan 100 mg improved functional class but not 6MWD in PAH patients who were mostly WHO functional class II at baseline.  No patient receiving sitaxsentan 100 mg experienced clin. worsening; sitaxsentan was well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ZyDN7nwdbbVg90H21EOLACvtfcHk0lge6iEfedlQUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFOktLg%253D&md5=2d9aaf20d6ebdad24b9ba841a02cfc44</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2011.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2011.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DSandoval%26aufirst%3DJ.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DSouza%26aufirst%3DR.%26aulast%3DRamirez%26aufirst%3DA.%26aulast%3DKurzyna%26aufirst%3DM.%26aulast%3DJardim%26aufirst%3DC.%26aulast%3DJerjes-Sanchez%2BDiaz%26aufirst%3DC.%26aulast%3DTeal%26aufirst%3DS.%2BA.%26aulast%3DHwang%26aufirst%3DL.%2BJ.%26aulast%3DPulido%26aufirst%3DT.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Sitaxsentan%252050%2520and%2520100%2520mg%2520in%2520Patients%2520with%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D25%26spage%3D33%26epage%3D39%26doi%3D10.1016%2Fj.pupt.2011.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mubarak, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machado, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ataga, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benza, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeije, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sood, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swerdlow, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hildesheim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gladwin, M. T.</span><span> </span><span class="NLM_article-title">Exercise Capacity and Haemodynamics in Patients with Sickle Cell Disease with Pulmonary Hypertension Treated with Bosentan: Results of the ASSET Studies</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">â</span> <span class="NLM_lpage">435</span><span class="refDoi">Â DOI: 10.1111/j.1365-2141.2010.08097.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fj.1365-2141.2010.08097.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=20175775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3cXms1yjs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2010&pages=426-435&author=R.+J.+Barstauthor=K.+K.+Mubarakauthor=R.+F.+Machadoauthor=K.+I.+Atagaauthor=R.+L.+Benzaauthor=O.+Castroauthor=R.+Naeijeauthor=N.+Soodauthor=P.+S.+Swerdlowauthor=M.+Hildesheimauthor=M.+T.+Gladwin&title=Exercise+Capacity+and+Haemodynamics+in+Patients+with+Sickle+Cell+Disease+with+Pulmonary+Hypertension+Treated+with+Bosentan%3A+Results+of+the+ASSET+Studies&doi=10.1111%2Fj.1365-2141.2010.08097.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies</span></div><div class="casAuthors">Barst, Robyn J.; Mubarak, Kamal K.; Machado, Roberto F.; Ataga, Kenneth I.; Benza, Raymond L.; Castro, Oswaldo; Naeije, Robert; Sood, Namita; Swerdlow, Paul S.; Hildesheim, Mariana; Gladwin, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">426-435</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Doppler-defined pulmonary hypertension (PH) in sickle cell disease (SCD) is assocd. with 40% mortality at 40 mo.  To assess the effect of bosentan in SCD-PH, two randomized, double-blind, placebo-controlled, 16-wk studies were initiated.  Safety concerns are particularly relevant in SCD due to comorbid conditions.  ASSET-1 and -2 enrolled patients with pulmonary arterial hypertension (PAH) and pulmonary venous hypertension (PH), resp.  Haemodynamics and 6-min walk distance (6MWD) were obtained at baseline and week 16.  The studies were terminated due to slow site initiation and patient enrollment (n = 26).  Bosentan appeared to be well tolerated.  Although sample sizes were limited, in ASSET-1 at baseline, 6MWD correlated with cardiac output (CO; P = 0.006) with non-significant inverse correlations between 6MWD and pulmonary vascular resistance (PVR; P = 0.07) and between 6MWD and right atrial pressure (P = 0.08).  In ASSET-2 at baseline, there was a non-significant correlation between 6MWD and CO (P = 0.06).  Due to limited sample sizes, efficacy endpoints were not analyzed.  However, in both studies, non-significant increases in CO were obsd. with bosentan compared to placebo.  Similarly, non-significant decreases in PVR were obsd. with bosentan.  Limited data in SCD-PH suggest that a low 6MWD predicts a low CO.  Std.-dose bosentan appears to be well tolerated.  Further investigation is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeA982uMAHvbVg90H21EOLACvtfcHk0lge6iEfedlQUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXms1yjs7Y%253D&md5=3308ec2b88bc8224ef71ac372b960335</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08097.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08097.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DMubarak%26aufirst%3DK.%2BK.%26aulast%3DMachado%26aufirst%3DR.%2BF.%26aulast%3DAtaga%26aufirst%3DK.%2BI.%26aulast%3DBenza%26aufirst%3DR.%2BL.%26aulast%3DCastro%26aufirst%3DO.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DSood%26aufirst%3DN.%26aulast%3DSwerdlow%26aufirst%3DP.%2BS.%26aulast%3DHildesheim%26aufirst%3DM.%26aulast%3DGladwin%26aufirst%3DM.%2BT.%26atitle%3DExercise%2520Capacity%2520and%2520Haemodynamics%2520in%2520Patients%2520with%2520Sickle%2520Cell%2520Disease%2520with%2520Pulmonary%2520Hypertension%2520Treated%2520with%2520Bosentan%253A%2520Results%2520of%2520the%2520ASSET%2520Studies%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2010%26volume%3D149%26spage%3D426%26epage%3D435%26doi%3D10.1111%2Fj.1365-2141.2010.08097.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Channick, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitbon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapson, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainisio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">Effects of the Dual Endothelin-receptor Antagonist Bosentan in Patients with Pulmonary Hypertension: A Randomized Placebo-controlled Study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">â</span> <span class="NLM_lpage">1123</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(01)06250-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0140-6736%2801%2906250-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2001&pages=1119-1123&author=R.+N.+Channickauthor=G.+Simonneauauthor=O.+Sitbonauthor=I.+M.+Robbinsauthor=A.+Frostauthor=V.+F.+Tapsonauthor=D.+B.+Badeschauthor=S.+Rouxauthor=M.+Rainisioauthor=F.+Bodinauthor=L.+J.+Rubin&title=Effects+of+the+Dual+Endothelin-receptor+Antagonist+Bosentan+in+Patients+with+Pulmonary+Hypertension%3A+A+Randomized+Placebo-controlled+Study&doi=10.1016%2FS0140-6736%2801%2906250-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2801%2906250-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252801%252906250-X%26sid%3Dliteratum%253Aachs%26aulast%3DChannick%26aufirst%3DR.%2BN.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DTapson%26aufirst%3DV.%2BF.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DRoux%26aufirst%3DS.%26aulast%3DRainisio%26aufirst%3DM.%26aulast%3DBodin%26aufirst%3DF.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DEffects%2520of%2520the%2520Dual%2520Endothelin-receptor%2520Antagonist%2520Bosentan%2520in%2520Patients%2520with%2520Pulmonary%2520Hypertension%253A%2520A%2520Randomized%2520Placebo-controlled%2520Study%26jtitle%3DLancet%26date%3D2001%26volume%3D358%26spage%3D1119%26epage%3D1123%26doi%3D10.1016%2FS0140-6736%2801%2906250-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Humbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Channick, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boonstra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span> </span><span class="NLM_article-title">Combination of Bosentan with Epoprostenol in Pulmonary Arterial Hypertension: BREATHE-2</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">â</span> <span class="NLM_lpage">359</span><span class="refDoi">Â DOI: 10.1183/09031936.04.00028404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1183%2F09031936.04.00028404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15358690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotlyrtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=353-359&author=M.+Humbertauthor=R.+J.+Barstauthor=I.+M.+Robbinsauthor=R.+N.+Channickauthor=N.+Gali%C3%A8author=A.+Boonstraauthor=L.+J.+Rubinauthor=E.+M.+Hornauthor=A.+Manesauthor=G.+Simonneau&title=Combination+of+Bosentan+with+Epoprostenol+in+Pulmonary+Arterial+Hypertension%3A+BREATHE-2&doi=10.1183%2F09031936.04.00028404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2</span></div><div class="casAuthors">Humbert, M.; Barst, R. J.; Robbins, I. M.; Channick, R. N.; Galie, N.; Boonstra, A.; Rubin, L. J.; Horn, E. M.; Manes, A.; Simonneau, G.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of pulmonary arterial hypertension (PAH) was investigated.  In this double-blind, placebo-controlled prospective study, 33 patients with PAH started epoprostenol treatment (2 ngÂ·kg-1min-1 starting dose, up to 14Â±2 ngÂ·kg-1min-1 at week 16) and were randomized for 16 wk in a 2:1 ratio to bosentan (62.5 mg b.i.d for 4 wk then 125 mg b.i.d) or placebo.  Hemodynamics, exercise capacity and functional class improved in both groups at week 16.  In the combination treatment group, there was a trend for a greater (although nonsignificant) improvement in all measured hemodynamic parameters.  There were four withdrawals in the bosentan/epoprostenol group (two deaths due to cardio-pulmonary failure, one clin. worsening, and one adverse event) and one withdrawal in the placebo/epoprostenol group (adverse event).  This study showed a trend but no statistical significance towards hemodynamics or clin. improvement due to the combination of bosentan and epoprostenol therapy in patients with pulmonary arterial hypertension.  Several cases of early and late major complications were reported.  Addnl. information is needed to evaluate the risk/benefit ratio of combined bosentan-epoprostenol therapy in pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh63MpV9Xg-7Vg90H21EOLACvtfcHk0lg4C8QL44d6Ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotlyrtL4%253D&md5=5865cd016496c94d27463210bda238f4</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1183%2F09031936.04.00028404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.04.00028404%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DChannick%26aufirst%3DR.%2BN.%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DBoonstra%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DHorn%26aufirst%3DE.%2BM.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DCombination%2520of%2520Bosentan%2520with%2520Epoprostenol%2520in%2520Pulmonary%2520Arterial%2520Hypertension%253A%2520BREATHE-2%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2004%26volume%3D24%26spage%3D353%26epage%3D359%26doi%3D10.1183%2F09031936.04.00028404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beghetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatzoulis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiossi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landzberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators.</span><span> </span><span class="NLM_article-title">Bosentan Therapy in Patients with Eisenmenger Syndrome: A Multicenter, Double-blind, Randomized, Placebo-controlled Study</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">â</span> <span class="NLM_lpage">54</span><span class="refDoi">Â DOI: 10.1161/CIRCULATIONAHA.106.630715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1161%2FCIRCULATIONAHA.106.630715" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2006&pages=48-54&author=N.+Gali%C3%A8author=M.+Beghettiauthor=M.+A.+Gatzoulisauthor=J.+Grantonauthor=R.+M.+Bergerauthor=A.+Lauerauthor=E.+Chiossiauthor=M.+Landzbergauthor=Bosentan+Randomized+Trial+of+Endothelin+Antagonist+Therapy-5+%28BREATHE-5%29+Investigators.&title=Bosentan+Therapy+in+Patients+with+Eisenmenger+Syndrome%3A+A+Multicenter%2C+Double-blind%2C+Randomized%2C+Placebo-controlled+Study&doi=10.1161%2FCIRCULATIONAHA.106.630715"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.106.630715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.106.630715%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DBeghetti%26aufirst%3DM.%26aulast%3DGatzoulis%26aufirst%3DM.%2BA.%26aulast%3DGranton%26aufirst%3DJ.%26aulast%3DBerger%26aufirst%3DR.%2BM.%26aulast%3DLauer%26aufirst%3DA.%26aulast%3DChiossi%26aufirst%3DE.%26aulast%3DLandzberg%26aufirst%3DM.%26aulast%3D%26atitle%3DBosentan%2520Therapy%2520in%2520Patients%2520with%2520Eisenmenger%2520Syndrome%253A%2520A%2520Multicenter%252C%2520Double-blind%252C%2520Randomized%252C%2520Placebo-controlled%2520Study%26jtitle%3DCirculation%26date%3D2006%26volume%3D114%26spage%3D48%26epage%3D54%26doi%3D10.1161%2FCIRCULATIONAHA.106.630715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">McLaughlin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Channick, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LemariÃ©, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naeije, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Souza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapson, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al Hiti, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M. M.</span><span> </span><span class="NLM_article-title">Bosentan Added to Sildenafil Therapy in Patients with Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">â</span> <span class="NLM_lpage">413</span><span class="refDoi">Â DOI: 10.1183/13993003.02044-2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1183%2F13993003.02044-2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=26113687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbnt1Onsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=405-413&author=V.+McLaughlinauthor=R.+N.+Channickauthor=H.+A.+Ghofraniauthor=J.+C.+Lemari%C3%A9author=R.+Naeijeauthor=M.+Packerauthor=R.+Souzaauthor=V.+F.+Tapsonauthor=J.+Tolsonauthor=H.+Al+Hitiauthor=G.+Meyerauthor=M.+M.+Hoeper&title=Bosentan+Added+to+Sildenafil+Therapy+in+Patients+with+Pulmonary+Arterial+Hypertension&doi=10.1183%2F13993003.02044-2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension</span></div><div class="casAuthors">McLaughlin Vallerie; Channick Richard N; Ghofrani Hossein-Ardeschir; Lemarie Jean-Christophe; Naeije Robert; Packer Milton; Souza Rogerio; Tapson Victor F; Tolson Jonathan; Al Hiti Hikmet; Meyer Gisela; Hoeper Marius M</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">405-13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated.In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (â¥20 mg three times daily) for â¥3 months were randomised (1:1) to placebo or bosentan (125 mg twice daily).  The composite primary end-point was the time to the first morbidity/mortality event, defined as all-cause death, hospitalisation for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or PAH worsening.  Secondary/exploratory end-points included change in 6-min walk distance and World Health Organization functional class at 16 weeks, change in N-terminal pro-brain natriuretic peptide (NT-proBNP) over time, and all-cause death.Overall, 334 PAH patients were randomised to placebo (n=175) or bosentan (n=159).  A primary end-point event occurred in 51.4% of patients randomised to placebo and 42.8% to bosentan (hazard ratio 0.83, 97.31% CI 0.58-1.19; p=0.2508).  The mean between-treatment difference in 6-min walk distance at 16 weeks was +21.8 m (95% CI +5.9-37.8 m; p=0.0106).  Except for NT-proBNP, no difference was observed for any other end-point.  The safety profile of bosentan added to sildenafil was consistent with the known bosentan safety profile.In COMPASS-2, adding bosentan to stable sildenafil therapy was not superior to sildenafil monotherapy in delaying the time to the first morbidity/mortality event.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBDudtqhw_bmlSCSgBhwJFfW6udTcc2eblsjpag0fyF7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbnt1Onsg%253D%253D&md5=b576a2cd4e1d3d8104e4af9a4eaf3d0d</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1183%2F13993003.02044-2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02044-2014%26sid%3Dliteratum%253Aachs%26aulast%3DMcLaughlin%26aufirst%3DV.%26aulast%3DChannick%26aufirst%3DR.%2BN.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DLemari%25C3%25A9%26aufirst%3DJ.%2BC.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DSouza%26aufirst%3DR.%26aulast%3DTapson%26aufirst%3DV.%2BF.%26aulast%3DTolson%26aufirst%3DJ.%26aulast%3DAl%2BHiti%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DG.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26atitle%3DBosentan%2520Added%2520to%2520Sildenafil%2520Therapy%2520in%2520Patients%2520with%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3D405%26epage%3D413%26doi%3D10.1183%2F13993003.02044-2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Hiti, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusic-Pajic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LemariÃ©, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">Long-term Results from the EARLY Study of Bosentan in WHO Functional Class II Pulmonary Arterial Hypertension Patients</span> <span class="citation_source-journal">Int. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">â</span> <span class="NLM_lpage">339</span><span class="refDoi">Â DOI: 10.1016/j.ijcard.2013.12.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.ijcard.2013.12.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24525158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC2cvkvFSmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2014&pages=332-339&author=G.+Simonneauauthor=N.+Gali%C3%A8author=P.+Jansaauthor=G.+M.+Meyerauthor=H.+Al-Hitiauthor=A.+Kusic-Pajicauthor=J.+C.+Lemari%C3%A9author=M.+M.+Hoeperauthor=L.+J.+Rubin&title=Long-term+Results+from+the+EARLY+Study+of+Bosentan+in+WHO+Functional+Class+II+Pulmonary+Arterial+Hypertension+Patients&doi=10.1016%2Fj.ijcard.2013.12.179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients</span></div><div class="casAuthors">Simonneau Gerald; Galie Nazzareno; Jansa Pavel; Meyer Gisela Martina Bohns; Al-Hiti Hikmet; Kusic-Pajic Andjela; Lemarie Jean-Christophe; Hoeper Marius M; Rubin Lewis J</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The double-blind phase of the EARLY study of bosentan remains the only randomized controlled trial of a PAH-targeted therapy in World Health Organization functional class (FC) II patients.  We report on the efficacy, safety, disease worsening, survival and prognostic factors in mildly symptomatic pulmonary arterial hypertension (PAH) patients treated with bosentan in the open-label extension phase of the EARLY study.  METHODS:  Exploratory efficacy outcomes included 6-minute walk distance (6 MWD) and WHO FC.  Adverse events were recorded.  Kaplan-Meier analysis was used to estimate time to first PAH worsening event (death, initiation of intravenous or subcutaneous prostanoids, atrial septostomy or lung transplantation) and survival.  Cox regression analysis determined factors prognostic of survival.  RESULTS:  Median exposure to bosentan (n=173) was 51 months.  At the end of the bosentan-treatment assessment period, 77.8% of patients were in WHO FC I/II.  Adverse events led to discontinuation of bosentan in 20.2% of patients.  Aminotransferase elevations>3Ã upper limit of normal occurred in 16.8%.  Four-year PAH-event-free survival and survival were 79.5% (95% confidence intervals [95% CI] 73.4, 85.6) and 84.8% [95% CI 79.4, 90.2], respectively.  Low 6 MWD, low mixed venous oxygenation, high N-terminal pro hormone of brain natriuretic peptide levels and PAH associated with connective tissue disease were associated with a higher risk of death.  CONCLUSIONS:  The majority of patients exposed to long-term bosentan maintained or improved their functional class.  Approximately 20% of the patients discontinued treatment because of adverse events, which were most commonly PAH worsening and elevated liver enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcl2qhPMOxQ1VwdslNBF-tfW6udTcc2eblsjpag0fyF7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvkvFSmsg%253D%253D&md5=fea3d9d24dec6f2fdd110117de4f7cb2</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2013.12.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2013.12.179%26sid%3Dliteratum%253Aachs%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DMeyer%26aufirst%3DG.%2BM.%26aulast%3DAl-Hiti%26aufirst%3DH.%26aulast%3DKusic-Pajic%26aufirst%3DA.%26aulast%3DLemari%25C3%25A9%26aufirst%3DJ.%2BC.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DLong-term%2520Results%2520from%2520the%2520EARLY%2520Study%2520of%2520Bosentan%2520in%2520WHO%2520Functional%2520Class%2520II%2520Pulmonary%2520Arterial%2520Hypertension%2520Patients%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2014%26volume%3D172%26spage%3D332%26epage%3D339%26doi%3D10.1016%2Fj.ijcard.2013.12.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Wilkins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strange, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunariu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gin-Sing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banya, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanidis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennell, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohiaddin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nihoyannopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, J. S.</span><span> </span><span class="NLM_article-title">Sildenafil Versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">1292</span><span class="NLM_x">â</span> <span class="NLM_lpage">1297</span><span class="refDoi">Â DOI: 10.1164/rccm.200410-1411OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1164%2Frccm.200410-1411OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15750042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2005&pages=1292-1297&author=M.+R.+Wilkinsauthor=G.+A.+Paulauthor=J.+W.+Strangeauthor=N.+Tunariuauthor=W.+Gin-Singauthor=W.+A.+Banyaauthor=M.+A.+Westwoodauthor=A.+Stefanidisauthor=L.+L.+Ngauthor=D.+J.+Pennellauthor=R.+H.+Mohiaddinauthor=P.+Nihoyannopoulosauthor=J.+S.+Gibbs&title=Sildenafil+Versus+Endothelin+Receptor+Antagonist+for+Pulmonary+Hypertension+%28SERAPH%29+Study&doi=10.1164%2Frccm.200410-1411OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study</span></div><div class="casAuthors">Wilkins Martin R; Paul Gideon A; Strange Julian W; Tunariu Nina; Gin-Sing Wendy; Banya Winston A; Westwood Mark A; Stefanidis Alexander; Ng Leong L; Pennell Dudley J; Mohiaddin Raad H; Nihoyannopoulos Petros; Gibbs J Simon R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1292-7</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">RATIONALE:  Phosphodiesterase type 5 (PDE5) inhibition has been proposed for the treatment for pulmonary arterial hypertension (PAH).  OBJECTIVE:  This study compared adding sildenafil, a PDE5 inhibitor, to conventional treatment with the current practice of adding bosentan, an endothelin receptor antagonist.  METHODS:  Twenty-six patients with PAH, idiopathic or associated with connective tissue disease, World Health Organization (WHO) functional class III, were randomized in a double-blind fashion to receive sildenafil (50 mg twice daily for 4 weeks, then 50 mg three times daily) or bosentan (62.5 mg twice daily for 4 weeks, then 125 mg twice daily) over 16 weeks.  MEASUREMENTS:  Changes in right ventricular (RV) mass (using cardiovascular magnetic resonance), 6-minute walk distance, cardiac function, brain natriuretic peptide, and Borg dyspnea index.  MAIN RESULTS:  When analyzed by intention to treat, there were no significant differences between the two treatment groups.  One patient on sildenafil died suddenly.  Patients on sildenafil who completed the protocol showed significant changes from baseline, namely, reductions in RV mass (-8.8 g; 95% confidence interval [CI], -2, -16; n = 13, p = 0.015) and plasma brain natriuretic peptide levels (-19.4 fmol x ml(-1); 95% CI, -5, -34; p = 0.014) and improvements in 6-minute walk distance (114 m; 95% CI, 67, 160; p = 0.0002), cardiac index (0.3 L x min(-1) x m(-2); 95% CI, 0.1, 0.4; p = 0.008), and systolic left ventricular eccentricity index (-0.2; 95% CI, -0.02, -0.37; p = 0.031).  Bosentan improved 6-minute walk distance (59 m; 95% CI, 29, 89; n = 12, p = 0.001) and cardiac index (0.3; 95% CI, 0.1, 0.4; p = 0.008).  CONCLUSIONS:  Sildenafil added to conventional treatment reduces RV mass and improves cardiac function and exercise capacity in patients with PAH, WHO functional class III.  Safety monitoring is important until more experience is obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6Hl7Y7MSGme2qxNLjzXe8fW6udTcc2eblsjpag0fyF7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtQ%253D%253D&md5=537fa548c4a1006d15fae4289b3f5875</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1164%2Frccm.200410-1411OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200410-1411OC%26sid%3Dliteratum%253Aachs%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DPaul%26aufirst%3DG.%2BA.%26aulast%3DStrange%26aufirst%3DJ.%2BW.%26aulast%3DTunariu%26aufirst%3DN.%26aulast%3DGin-Sing%26aufirst%3DW.%26aulast%3DBanya%26aufirst%3DW.%2BA.%26aulast%3DWestwood%26aufirst%3DM.%2BA.%26aulast%3DStefanidis%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DL.%2BL.%26aulast%3DPennell%26aufirst%3DD.%2BJ.%26aulast%3DMohiaddin%26aufirst%3DR.%2BH.%26aulast%3DNihoyannopoulos%26aufirst%3DP.%26aulast%3DGibbs%26aufirst%3DJ.%2BS.%26atitle%3DSildenafil%2520Versus%2520Endothelin%2520Receptor%2520Antagonist%2520for%2520Pulmonary%2520Hypertension%2520%2528SERAPH%2529%2520Study%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2005%26volume%3D171%26spage%3D1292%26epage%3D1297%26doi%3D10.1164%2Frccm.200410-1411OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olschewski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudiz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGoon, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roecker, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiens, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy (ARIES) Study 1 and 2</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">3010</span><span class="NLM_x">â</span> <span class="NLM_lpage">3019</span><span class="refDoi">Â DOI: 10.1161/CIRCULATIONAHA.107.742510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1161%2FCIRCULATIONAHA.107.742510" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2008&pages=3010-3019&author=N.+Gali%C3%A8author=H.+Olschewskiauthor=R.+J.+Oudizauthor=F.+Torresauthor=A.+Frostauthor=H.+A.+Ghofraniauthor=D.+B.+Badeschauthor=M.+D.+McGoonauthor=V.+V.+McLaughlinauthor=E.+B.+Roeckerauthor=M.+J.+Gerberauthor=C.+Duftonauthor=B.+L.+Wiensauthor=L.+J.+Rubin&title=Ambrisentan+in+Pulmonary+Arterial+Hypertension%2C+Randomized%2C+Double-blind%2C+Placebo-controlled%2C+Multicenter%2C+Efficacy+Studies+%28ARIES%29+Group.+Ambrisentan+for+the+Treatment+of+Pulmonary+Arterial+Hypertension%3A+Results+of+the+Ambrisentan+in+Pulmonary+Arterial+Hypertension%2C+Randomized%2C+Double-blind%2C+Placebo-controlled%2C+Multicenter%2C+Efficacy+%28ARIES%29+Study+1+and+2&doi=10.1161%2FCIRCULATIONAHA.107.742510"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.107.742510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.107.742510%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DRoecker%26aufirst%3DE.%2BB.%26aulast%3DGerber%26aufirst%3DM.%2BJ.%26aulast%3DDufton%26aufirst%3DC.%26aulast%3DWiens%26aufirst%3DB.%2BL.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DAmbrisentan%2520in%2520Pulmonary%2520Arterial%2520Hypertension%252C%2520Randomized%252C%2520Double-blind%252C%2520Placebo-controlled%252C%2520Multicenter%252C%2520Efficacy%2520Studies%2520%2528ARIES%2529%2520Group.%2520Ambrisentan%2520for%2520the%2520Treatment%2520of%2520Pulmonary%2520Arterial%2520Hypertension%253A%2520Results%2520of%2520the%2520Ambrisentan%2520in%2520Pulmonary%2520Arterial%2520Hypertension%252C%2520Randomized%252C%2520Double-blind%252C%2520Placebo-controlled%252C%2520Multicenter%252C%2520Efficacy%2520%2528ARIES%2529%2520Study%25201%2520and%25202%26jtitle%3DCirculation%26date%3D2008%26volume%3D117%26spage%3D3010%26epage%3D3019%26doi%3D10.1161%2FCIRCULATIONAHA.107.742510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">GaliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BarberÃ , J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peacock, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vachiery, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GrÃ¼nig, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudiz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonk-Noordegraaf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">â</span> <span class="NLM_lpage">844</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1413687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1056%2FNEJMoa1413687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=26308684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFGisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=834-844&author=N.+Gali%C3%A8author=J.+A.+Barber%C3%A0author=A.+E.+Frostauthor=H.+A.+Ghofraniauthor=M.+M.+Hoeperauthor=V.+V.+McLaughlinauthor=A.+J.+Peacockauthor=G.+Simonneauauthor=J.+L.+Vachieryauthor=E.+Gr%C3%BCnigauthor=R.+J.+Oudizauthor=A.+Vonk-Noordegraafauthor=R.+J.+Whiteauthor=C.+Blairauthor=H.+Gilliesauthor=K.+L.+Millerauthor=J.+H.+Harrisauthor=J.+Langleyauthor=L.+J.+Rubin&title=AMBITION+Investigators.+Initial+Use+of+Ambrisentan+plus+Tadalafil+in+Pulmonary+Arterial+Hypertension&doi=10.1056%2FNEJMoa1413687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, N.; Barbera, J. A.; Frost, A. E.; Ghofrani, H.-A.; Hoeper, M. M.; McLaughlin, V. V.; Peacock, A. J.; Simonneau, G.; Vachiery, J.-L.; Grunig, E.; Oudiz, R. J.; Vonk-Noordegraaf, A.; White, R. J.; Blair, C.; Gillies, H.; Miller, K. L.; Harris, J. H. N.; Langley, J.; Rubin, L. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">834-844</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.  Methods: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil (combination-therapy group), 10 mg of ambrisentan plus placebo (ambrisentanmonotherapy group), or 40 mg of tadalafil plus placebo (tadalafil-monotherapy group), all administered once daily.  The primary end point in a time-to-event anal. was the first event of clin. failure, which was defined as the first occurrence of a composite of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or unsatisfactory long-term clin. response.  Results: The primary anal. included 500 participants; 253 were assigned to the combination- therapy group, 126 to the ambrisentan-monotherapy group, and 121 to the tadalafil-monotherapy group.  A primary end-point event occurred in 18%, 34%, and 28% of the participants in these groups, resp., and in 31% of the pooledmonotherapy group (the two monotherapy groups combined).  The hazard ratio for the primary end point in the combination-therapy group vs. the pooled-monotherapy group was 0.50 (95% confidence interval [CI], 0.35 to 0.72; P<0.001).  At week 24, the combination-therapy group had greater redns. from baseline in N-terminal pro-brain natriuretic peptide levels than did the pooled-monotherapy group (mean change, -67.2% vs. -50.4%; P<0.001), as well as a higher percentage of patients with a satisfactory clin. response (39% vs. 29%; odds ratio, 1.56 [95% CI, 1.05 to 2.32]; P = 0.03) and a greater improvement in the 6-min walk distance (median change from baseline, 48.98 m vs. 23.80 m; P<0.001).  The adverse events that occurred more frequently in the combination-therapy group than in either monotherapy group included peripheral edema, headache, nasal congestion, and anemia.  Conclusions: Among participants with pulmonary arterial hypertension who had not received previous treatment, initial combination therapy with ambrisentan and tadalafil resulted in a significantly lower risk of clin.-failure events than the risk with ambrisentan or tadalafil monotherapy. (Funded by Gilead Sciences and GlaxoSmithKline; AMBITION ClinicalTrials.gov no., NCT01178073).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe4zQLE95kVbVg90H21EOLACvtfcHk0li4lHn6stBEdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFGisA%253D%253D&md5=018dd6202fa784e3570c7dd6395218e4</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413687%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DBarber%25C3%25A0%26aufirst%3DJ.%2BA.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DPeacock%26aufirst%3DA.%2BJ.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DVachiery%26aufirst%3DJ.%2BL.%26aulast%3DGr%25C3%25BCnig%26aufirst%3DE.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DVonk-Noordegraaf%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DR.%2BJ.%26aulast%3DBlair%26aufirst%3DC.%26aulast%3DGillies%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DK.%2BL.%26aulast%3DHarris%26aufirst%3DJ.%2BH.%26aulast%3DLangley%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DAMBITION%2520Investigators.%2520Initial%2520Use%2520of%2520Ambrisentan%2520plus%2520Tadalafil%2520in%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D834%26epage%3D844%26doi%3D10.1056%2FNEJMoa1413687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Miyamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyotani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyatake, K.</span><span> </span><span class="NLM_article-title">Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension. Comparison with Cardiopulmonary Exercise Testing</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">â</span> <span class="NLM_lpage">492</span><span class="refDoi">Â DOI: 10.1164/ajrccm.161.2.9906015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1164%2Fajrccm.161.2.9906015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10673190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BD3c7otVamuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2000&pages=487-492&author=S.+Miyamotoauthor=N.+Nagayaauthor=T.+Satohauthor=S.+Kyotaniauthor=F.+Sakamakiauthor=M.+Fujitaauthor=N.+Nakanishiauthor=K.+Miyatake&title=Clinical+Correlates+and+Prognostic+Significance+of+Six-minute+Walk+Test+in+Patients+with+Primary+Pulmonary+Hypertension.+Comparison+with+Cardiopulmonary+Exercise+Testing&doi=10.1164%2Fajrccm.161.2.9906015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing</span></div><div class="casAuthors">Miyamoto S; Nagaya N; Satoh T; Kyotani S; Sakamaki F; Fujita M; Nakanishi N; Miyatake K</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2 Pt 1</span>),
    <span class="NLM_cas:pages">487-92</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">The six-minute walk test is a submaximal exercise test that can be performed even by a patient with heart failure not tolerating maximal exercise testing.  To elucidate the clinical significance and prognostic value of the six-minute walk test in patients with primary pulmonary hypertension (PPH), we sought (1) to assess the relation between distance walked during the six-minute walk test and exercise capacity determined by maximal cardiopulmonary exercise testing, and (2) to investigate the prognostic value of the six-minute walk test in comparison with other noninvasive parameters.  The six-minute walk test was performed in 43 patients with PPH, together with echocardiography, right heart catheterization, and measurement of plasma epinephrine and norepinephrine.  Symptom-limited cardiopulmonary exercise testing was performed in a subsample of patients (n = 27).  Distance walked in 6 min was significantly shorter in patients with PPH than in age- and sex-matched healthy subjects (297 +/- 188 versus 655 +/- 91 m, p < 0. 001).  The distance significantly decreased in proportion to the severity of New York Heart Association functional class.  The distance walked correlated modestly with baseline cardiac output (r = 0.48, p < 0.05) and total pulmonary resistance (r = -0.49, p < 0. 05), but not significantly with mean pulmonary arterial pressure.  In contrast, the distance walked correlated strongly with peak V O(2) (r = 0.70, p < 0.001), oxygen pulse (r = 0.57, p < 0.01), and V E-VCO(2) slope (r = -0.66, p < 0.001) determined by cardiopulmonary exercise testing.  During a mean follow-up period of 21 +/- 16 mo, 12 patients died of cardiopulmonary causes.  Among noninvasive parameters including clinical, echocardiographic, and neurohumoral parameters, only the distance walked in 6 min was independently related to mortality in PPH by multivariate analysis.  Patients walking < 332 m had a significantly lower survival rate than those walking farther, assessed by Kaplan-Meier survival curves (log-rank test, p < 0.01).  These results suggest that the six-minute walk test, a submaximal exercise test, reflects exercise capacity determined by maximal cardiopulmonary exercise testing in patients with PPH, and it is the distance walked in 6 min that has a strong, independent association with mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3Cxch47IYMG52AMpI4GK2fW6udTcc2eYGUt0eQM9uwLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7otVamuw%253D%253D&md5=5febc88f23ce32c2e17108eab9b65078</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.161.2.9906015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.161.2.9906015%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DNagaya%26aufirst%3DN.%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DKyotani%26aufirst%3DS.%26aulast%3DSakamaki%26aufirst%3DF.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DNakanishi%26aufirst%3DN.%26aulast%3DMiyatake%26aufirst%3DK.%26atitle%3DClinical%2520Correlates%2520and%2520Prognostic%2520Significance%2520of%2520Six-minute%2520Walk%2520Test%2520in%2520Patients%2520with%2520Primary%2520Pulmonary%2520Hypertension.%2520Comparison%2520with%2520Cardiopulmonary%2520Exercise%2520Testing%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2000%26volume%3D161%26spage%3D487%26epage%3D492%26doi%3D10.1164%2Fajrccm.161.2.9906015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Hoeper, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarze, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehlerding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler-Schuermeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiekerkoetter, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedermeyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabel, H.</span><span> </span><span class="NLM_article-title">Long-term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">1866</span><span class="NLM_x">â</span> <span class="NLM_lpage">1870</span><span class="refDoi">Â DOI: 10.1056/NEJM200006223422503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1056%2FNEJM200006223422503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10861321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVCntL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2000&pages=1866-1870&author=M.+M.+Hoeperauthor=M.+Schwarzeauthor=S.+Ehlerdingauthor=A.+Adler-Schuermeyerauthor=E.+Spiekerkoetterauthor=J.+Niedermeyerauthor=M.+Hammauthor=H.+Fabel&title=Long-term+Treatment+of+Primary+Pulmonary+Hypertension+with+Aerosolized+Iloprost%2C+a+Prostacyclin+Analogue&doi=10.1056%2FNEJM200006223422503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue</span></div><div class="casAuthors">Hoeper, Marius M.; Schwarze, Michael; Ehlerding, Stefan; Adler-Schuermeyer, Angelika; Spiekerkoetter, Edda; Niedermeyer, Jost; Hamm, Michael; Fabel, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1866-1870</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Continuous i.v. infusion of epoprostenol (prostacyclin) is an effective treatment for primary pulmonary hypertension.  This approach requires the insertion of a permanent central venous catheter, with the assocd. risk of serious complications.  Recently, aerosolized iloprost, a stable prostacyclin analog, has been introduced as an alternative therapy for severe pulmonary hypertension.  Methods We evaluated the effects of aerosolized iloprost on exercise capacity and hemodynamic variables over a one-year period in patients with primary pulmonary hypertension.  Results Twenty-four patients with primary pulmonary hypertension received aerosolized iloprost at a daily dose of 100 or 150 Î¼g for at least one year.  The mean (Â±SD) distance covered in the six-minute walk test increased from 278Â±96 m at base line to 363Â±135 m after 12 mo (P<0.001).  During the same period, the mean pulmonary arterial pressure before the inhalation of iloprost declined from 59Â±10 mm Hg to 52Â±15 mm Hg (P=0.006), cardiac output increased from 3.8Â±1.4 L per min to 4.4Â±1.3 L per min (P=0.02), and pulmonary vascular resistance declined from 1205Â±467 dynÂ·secÂ·cm-5 to 925Â±469 dynÂ·secÂ·cm-5 (P<0.001).  The treatment was generally well tolerated, except for mild coughing, minor headache, and jaw pain in some patients.  Conclusions Long-term treatment with aerosolized iloprost is safe and has sustained effects on exercise capacity and pulmonary hemodynamics in patients with primary pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsJkw0ZmBShLVg90H21EOLACvtfcHk0lgwTrYEAPw76Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVCntL4%253D&md5=8c4a05a65346764c958a0234bc47c6b0</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1056%2FNEJM200006223422503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200006223422503%26sid%3Dliteratum%253Aachs%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DSchwarze%26aufirst%3DM.%26aulast%3DEhlerding%26aufirst%3DS.%26aulast%3DAdler-Schuermeyer%26aufirst%3DA.%26aulast%3DSpiekerkoetter%26aufirst%3DE.%26aulast%3DNiedermeyer%26aufirst%3DJ.%26aulast%3DHamm%26aufirst%3DM.%26aulast%3DFabel%26aufirst%3DH.%26atitle%3DLong-term%2520Treatment%2520of%2520Primary%2520Pulmonary%2520Hypertension%2520with%2520Aerosolized%2520Iloprost%252C%2520a%2520Prostacyclin%2520Analogue%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D342%26spage%3D1866%26epage%3D1870%26doi%3D10.1056%2FNEJM200006223422503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Gomberg-Maitland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saggar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barst, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elgazayerly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimminger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainisio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockbridge, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ventura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">D82</span><span class="NLM_x">â</span> <span class="NLM_lpage">D91</span><span class="refDoi">Â DOI: 10.1016/j.jacc.2013.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.jacc.2013.10.026" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=D82-D91&author=M.+Gomberg-Maitlandauthor=T.+M.+Bullauthor=R.+Saggarauthor=R.+J.+Barstauthor=A.+Elgazayerlyauthor=T.+R.+Flemingauthor=F.+Grimmingerauthor=M.+Rainisioauthor=D.+J.+Stewartauthor=N.+Stockbridgeauthor=C.+Venturaauthor=A.+H.+Ghofraniauthor=L.+J.+Rubin&title=New+Trial+Designs+and+Potential+Therapies+for+Pulmonary+Artery+Hypertension&doi=10.1016%2Fj.jacc.2013.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2013.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2013.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DGomberg-Maitland%26aufirst%3DM.%26aulast%3DBull%26aufirst%3DT.%2BM.%26aulast%3DSaggar%26aufirst%3DR.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DElgazayerly%26aufirst%3DA.%26aulast%3DFleming%26aufirst%3DT.%2BR.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DRainisio%26aufirst%3DM.%26aulast%3DStewart%26aufirst%3DD.%2BJ.%26aulast%3DStockbridge%26aufirst%3DN.%26aulast%3DVentura%26aufirst%3DC.%26aulast%3DGhofrani%26aufirst%3DA.%2BH.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DNew%2520Trial%2520Designs%2520and%2520Potential%2520Therapies%2520for%2520Pulmonary%2520Artery%2520Hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2013%26volume%3D62%26spage%3DD82%26epage%3DD91%26doi%3D10.1016%2Fj.jacc.2013.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Benza, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomberg-Maitland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frantz, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foreman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badesch, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGoon, M. D.</span><span> </span><span class="NLM_article-title">The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed with Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">â</span> <span class="NLM_lpage">362</span><span class="refDoi">Â DOI: 10.1378/chest.11-0676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1378%2Fchest.11-0676" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2012&pages=354-362&author=R.+L.+Benzaauthor=M.+Gomberg-Maitlandauthor=D.+P.+Millerauthor=A.+Frostauthor=R.+P.+Frantzauthor=A.+J.+Foremanauthor=D.+B.+Badeschauthor=M.+D.+McGoon&title=The+REVEAL+Registry+Risk+Score+Calculator+in+Patients+Newly+Diagnosed+with+Pulmonary+Arterial+Hypertension&doi=10.1378%2Fchest.11-0676"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1378%2Fchest.11-0676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.11-0676%26sid%3Dliteratum%253Aachs%26aulast%3DBenza%26aufirst%3DR.%2BL.%26aulast%3DGomberg-Maitland%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DD.%2BP.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DFrantz%26aufirst%3DR.%2BP.%26aulast%3DForeman%26aufirst%3DA.%2BJ.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26atitle%3DThe%2520REVEAL%2520Registry%2520Risk%2520Score%2520Calculator%2520in%2520Patients%2520Newly%2520Diagnosed%2520with%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DChest%26date%3D2012%26volume%3D141%26spage%3D354%26epage%3D362%26doi%3D10.1378%2Fchest.11-0676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">GalliÃ¨, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vachiery, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torbicki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peacock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonk Noordegraaf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beghetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez Sanchez, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klepetko, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancellotti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matucci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonagh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierard, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trindade, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zompatori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M.</span><span> </span><span class="NLM_article-title">2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). International Society for Heart and Lung Transplantation (ISHLT)</span> <span class="citation_source-journal">Eur. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">â</span> <span class="NLM_lpage">119</span><span class="refDoi">Â DOI: 10.1093/eurheartj/ehv317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1093%2Feurheartj%2Fehv317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=26320113" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=67-119&author=N.+Galli%C3%A8author=M.+Humbertauthor=J.+L.+Vachieryauthor=S.+Gibbsauthor=I.+Langauthor=A.+Torbickiauthor=G.+Simonneauauthor=A.+Peacockauthor=A.+Vonk+Noordegraafauthor=M.+Beghettiauthor=A.+Ghofraniauthor=M.+A.+Gomez+Sanchezauthor=G.+Hansmannauthor=W.+Klepetkoauthor=P.+Lancellottiauthor=M.+Matucciauthor=T.+McDonaghauthor=L.+A.+Pierardauthor=P.+T.+Trindadeauthor=M.+Zompatoriauthor=M.+Hoeper&title=2015+ESC%2FERS+Guidelines+for+the+Diagnosis+and+Treatment+of+Pulmonary+Hypertension%3A+The+Joint+Task+Force+for+the+Diagnosis+and+Treatment+of+Pulmonary+Hypertension+of+the+European+Society+of+Cardiology+%28ESC%29+and+the+European+Respiratory+Society+%28ERS%29%3A+Endorsed+by%3A+Association+for+European+Paediatric+and+Congenital+Cardiology+%28AEPC%29.+International+Society+for+Heart+and+Lung+Transplantation+%28ISHLT%29&doi=10.1093%2Feurheartj%2Fehv317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehv317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehv317%26sid%3Dliteratum%253Aachs%26aulast%3DGalli%25C3%25A8%26aufirst%3DN.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DVachiery%26aufirst%3DJ.%2BL.%26aulast%3DGibbs%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DI.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DPeacock%26aufirst%3DA.%26aulast%3DVonk%2BNoordegraaf%26aufirst%3DA.%26aulast%3DBeghetti%26aufirst%3DM.%26aulast%3DGhofrani%26aufirst%3DA.%26aulast%3DGomez%2BSanchez%26aufirst%3DM.%2BA.%26aulast%3DHansmann%26aufirst%3DG.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DLancellotti%26aufirst%3DP.%26aulast%3DMatucci%26aufirst%3DM.%26aulast%3DMcDonagh%26aufirst%3DT.%26aulast%3DPierard%26aufirst%3DL.%2BA.%26aulast%3DTrindade%26aufirst%3DP.%2BT.%26aulast%3DZompatori%26aufirst%3DM.%26aulast%3DHoeper%26aufirst%3DM.%26atitle%3D2015%2520ESC%252FERS%2520Guidelines%2520for%2520the%2520Diagnosis%2520and%2520Treatment%2520of%2520Pulmonary%2520Hypertension%253A%2520The%2520Joint%2520Task%2520Force%2520for%2520the%2520Diagnosis%2520and%2520Treatment%2520of%2520Pulmonary%2520Hypertension%2520of%2520the%2520European%2520Society%2520of%2520Cardiology%2520%2528ESC%2529%2520and%2520the%2520European%2520Respiratory%2520Society%2520%2528ERS%2529%253A%2520Endorsed%2520by%253A%2520Association%2520for%2520European%2520Paediatric%2520and%2520Congenital%2520Cardiology%2520%2528AEPC%2529.%2520International%2520Society%2520for%2520Heart%2520and%2520Lung%2520Transplantation%2520%2528ISHLT%2529%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2016%26volume%3D37%26spage%3D67%26epage%3D119%26doi%3D10.1093%2Feurheartj%2Fehv317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâArmini, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimminger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span> </span><span class="NLM_article-title">Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">â</span> <span class="NLM_lpage">329</span><span class="refDoi">Â DOI: 10.1056/NEJMoa1209657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1056%2FNEJMoa1209657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23883377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=319-329&author=H.+A.+Ghofraniauthor=A.+M.+D%E2%80%99Arminiauthor=F.+Grimmingerauthor=M.+M.+Hoeperauthor=P.+Jansaauthor=N.+H.+Kimauthor=E.+Mayerauthor=G.+Simonneauauthor=M.+R.+Wilkinsauthor=A.+Fritschauthor=D.+Neuserauthor=G.+Weimannauthor=C.+Wang&title=Riociguat+for+the+Treatment+of+Chronic+Thromboembolic+Pulmonary+Hypertension&doi=10.1056%2FNEJMoa1209657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Riociguat for the treatment of chronic thromboembolic pulmonary hypertension</span></div><div class="casAuthors">Ghofrani, Hossein-Ardeschir; D'Armini, Andrea M.; Grimminger, Friedrich; Hoeper, Marius M.; Jansa, Pavel; Kim, Nick H.; Mayer, Eckhard; Simonneau, Gerald; Wilkins, Martin R.; Fritsch, Arno; Neuser, Dieter; Weimann, Gerrit; Wang, Chen</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-329</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Riociguat, a member of a new class of compds. (sol. guanylate cyclase stimulators), has been shown in previous clin. studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension.  METHODS In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat.  The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 min.  Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clin. worsening, Borg dyspnea score, quality-of-life variables, and safety.  RESULTS By week 16, the 6-min walk distance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m in the placebo group (least-squares mean difference, 46 m; 95% confidence interval [CI], 25 to 67; P<0.001).  Pulmonary vascular resistance decreased by 226 dynÂ·secÂ·cm-5 in the riociguat group and increased by 23 dynÂ·secÂ·cm-5 in the placebo group (least-squares mean difference, -246 dynÂ·secÂ·cm-5; 95% CI, -303 to -190; P<0.001).  Riociguat was also assocd. with significant improvements in the NT-proBNP level (P<0.001) and WHO functional class (P = 0.003).  The most common serious adverse events were right ventricular failure (in 3% of patients in each group) and syncope (in 2% of the riociguat group and in 3% of the placebo group).  CONCLUSIONS Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2KTSYf5k0YLVg90H21EOLACvtfcHk0lhAMSoRNlyo-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7J&md5=4b274ffd0efef3d69383bd7d4d1c9275</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209657%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DD%25E2%2580%2599Armini%26aufirst%3DA.%2BM.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DN.%2BH.%26aulast%3DMayer%26aufirst%3DE.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DNeuser%26aufirst%3DD.%26aulast%3DWeimann%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DRiociguat%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Thromboembolic%2520Pulmonary%2520Hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D319%26epage%3D329%26doi%3D10.1056%2FNEJMoa1209657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Egidy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeannin, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosman, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinet, F.</span><span> </span><span class="NLM_article-title">Modulation of Human Colon Tumor-stromal Interactions by the Endothelin System</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">157</span><span class="NLM_x">, </span> <span class="NLM_fpage">1863</span><span class="NLM_x">â</span> <span class="NLM_lpage">1874</span><span class="refDoi">Â DOI: 10.1016/S0002-9440(10)64825-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0002-9440%2810%2964825-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=11106559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsVKrtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2000&pages=1863-1874&author=G.+Egidyauthor=L.+Juillerat-Jeanneretauthor=J.-F.+Jeanninauthor=P.+Korthauthor=F.+T.+Bosmanauthor=F.+Pinet&title=Modulation+of+Human+Colon+Tumor-stromal+Interactions+by+the+Endothelin+System&doi=10.1016%2FS0002-9440%2810%2964825-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of human colon tumor-stromal interactions by the endothelin system</span></div><div class="casAuthors">Egidy, Giorgia; Juillerat-Jeanneret, Lucienne; Jeannin, Jean-Francois; Korth, Petra; Bosman, Fred T.; Pinet, Florence</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1863-1874</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Tumor neovascularization is considered to be a crit. step in the development of a malignant tumor.  Endothelin (ET)-1 is a powerful vasoconstrictor and mitogenic peptide that is produced by many cancer cell lines.  The cellular distribution of the ET components was evaluated in human colon tumors and compared to normal colon.  There was more of the ET components (prepro-ET-1, endothelin-converting enzyme-1, and ETA and ETB receptors) in adenomas and adenocarcinomas than in the normal colon.  There was overprodn. of preproET-1 and endothelin-converting enzyme-1 in carcinoma cells and stromal vessels, suggesting that they are a local source of ET-1.  ETA receptors were present in stromal myofibroblasts of neoplastic tissue, and there were large amts. of ETB receptors in the endothelium and myofibroblasts.  There was also a redistribution of Î±-smooth muscle actin-pos. cells in the vascular structures of tumors.  An exptl. rat model of induced colon cancer treated for 30 days with bosentan, a mixed antagonist of both ET receptors, confirmed the morphol. changes obsd. during the tumor vascularization.  Our data suggest that ET-1 and its receptor play a role in colon cancer progression, with ET-1 functioning as a neg. modulator of the stromal response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppPtXX2Ad-MLVg90H21EOLACvtfcHk0lhAMSoRNlyo-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsVKrtg%253D%253D&md5=7a4dfadc4b03105642fc2389353ffdde</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2964825-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252964825-0%26sid%3Dliteratum%253Aachs%26aulast%3DEgidy%26aufirst%3DG.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DJeannin%26aufirst%3DJ.-F.%26aulast%3DKorth%26aufirst%3DP.%26aulast%3DBosman%26aufirst%3DF.%2BT.%26aulast%3DPinet%26aufirst%3DF.%26atitle%3DModulation%2520of%2520Human%2520Colon%2520Tumor-stromal%2520Interactions%2520by%2520the%2520Endothelin%2520System%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2000%26volume%3D157%26spage%3D1863%26epage%3D1874%26doi%3D10.1016%2FS0002-9440%2810%2964825-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Egidy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberl, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdenaire, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irmler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majdi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diserens, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzer, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">The Endothelin System in Human Glioblastoma</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">1681</span><span class="NLM_x">â</span> <span class="NLM_lpage">1689</span><span class="refDoi">Â DOI: 10.1038/labinvest.3780178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Flabinvest.3780178" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2000&pages=1681-1689&author=G.+Egidyauthor=L.+P.+Eberlauthor=O.+Valdenaireauthor=M.+Irmlerauthor=R.+Majdiauthor=A.+C.+Diserensauthor=A.+Fontanaauthor=R.+C.+Janzerauthor=F.+Pinetauthor=L.+Juillerat-Jeanneret&title=The+Endothelin+System+in+Human+Glioblastoma&doi=10.1038%2Flabinvest.3780178"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.3780178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.3780178%26sid%3Dliteratum%253Aachs%26aulast%3DEgidy%26aufirst%3DG.%26aulast%3DEberl%26aufirst%3DL.%2BP.%26aulast%3DValdenaire%26aufirst%3DO.%26aulast%3DIrmler%26aufirst%3DM.%26aulast%3DMajdi%26aufirst%3DR.%26aulast%3DDiserens%26aufirst%3DA.%2BC.%26aulast%3DFontana%26aufirst%3DA.%26aulast%3DJanzer%26aufirst%3DR.%2BC.%26aulast%3DPinet%26aufirst%3DF.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DThe%2520Endothelin%2520System%2520in%2520Human%2520Glioblastoma%26jtitle%3DLab.%2520Invest.%26date%3D2000%26volume%3D80%26spage%3D1681%26epage%3D1689%26doi%3D10.1038%2Flabinvest.3780178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Douglas, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicol, D. L.</span><span> </span><span class="NLM_article-title">Endothelin Axis Expression Is Markedly Different in the Two Main Subtypes of Renal Cell Carcinoma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">2118</span><span class="NLM_x">â</span> <span class="NLM_lpage">2124</span><span class="refDoi">Â DOI: 10.1002/cncr.20222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fcncr.20222" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2004&pages=2118-2124&author=M.+L.+Douglasauthor=M.+M.+Richardsonauthor=D.+L.+Nicol&title=Endothelin+Axis+Expression+Is+Markedly+Different+in+the+Two+Main+Subtypes+of+Renal+Cell+Carcinoma&doi=10.1002%2Fcncr.20222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fcncr.20222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.20222%26sid%3Dliteratum%253Aachs%26aulast%3DDouglas%26aufirst%3DM.%2BL.%26aulast%3DRichardson%26aufirst%3DM.%2BM.%26aulast%3DNicol%26aufirst%3DD.%2BL.%26atitle%3DEndothelin%2520Axis%2520Expression%2520Is%2520Markedly%2520Different%2520in%2520the%2520Two%2520Main%2520Subtypes%2520of%2520Renal%2520Cell%2520Carcinoma%26jtitle%3DCancer%26date%3D2004%26volume%3D100%26spage%3D2118%26epage%3D2124%26doi%3D10.1002%2Fcncr.20222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Grant, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span> </span><span class="NLM_article-title">Endothelin-1: A Multifunctional Molecule in Cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">â</span> <span class="NLM_lpage">166</span><span class="refDoi">Â DOI: 10.1038/sj.bjc.6700750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fsj.bjc.6700750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=12610497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsV2rtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=163-166&author=K.+Grantauthor=M.+Loizidouauthor=I.+Taylor&title=Endothelin-1%3A+A+Multifunctional+Molecule+in+Cancer&doi=10.1038%2Fsj.bjc.6700750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1: a multifunctional molecule in cancer</span></div><div class="casAuthors">Grant, K.; Loizidou, M.; Taylor, I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-166</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Endothelin-1 is a small vasoconstrictor peptide that was first identified in 1988.  Here the authors review the evidence implicating ET-1 in tumorigenesis.  In particular, the authors conc. on the role of ET-1 in mitogenesis, apoptosis, angiogenesis, tumor invasion and metastasis, and discuss the potential for endothelin-system modulation as an adjuvant therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9uaGOlyxOr7Vg90H21EOLACvtfcHk0ljd1MiUUR9szA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsV2rtbo%253D&md5=2d42889b82f426e56665460b6dbb7922</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6700750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6700750%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DK.%26aulast%3DLoizidou%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DI.%26atitle%3DEndothelin-1%253A%2520A%2520Multifunctional%2520Molecule%2520in%2520Cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D88%26spage%3D163%26epage%3D166%26doi%3D10.1038%2Fsj.bjc.6700750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Grimshaw, M. J.</span><span> </span><span class="NLM_article-title">Endothelins in Breast Tumour Cell Invasion</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">222</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">â</span> <span class="NLM_lpage">138</span><span class="refDoi">Â DOI: 10.1016/j.canlet.2004.08.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.canlet.2004.08.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15863261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Ghs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2005&pages=129-138&author=M.+J.+Grimshaw&title=Endothelins+in+Breast+Tumour+Cell+Invasion&doi=10.1016%2Fj.canlet.2004.08.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelins in breast tumour cell invasion</span></div><div class="casAuthors">Grimshaw, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-138</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Endothelins are a family of small, structurally related, vasoactive peptides that have a great no. of physiol. roles in many tissues.  The endothelin axis' consists of three 21 amino acid peptides (ET-1, ET-2 and ET-3), two G-protein-coupled receptors (ET-RA and ET-RB), and two activating peptidases or endothelin-converting enzymes (ECE-1 and ECE-2).  There is increased expression of the endothelin axis in invasive breast cancer compared to the normal breast or non-invasive neoplastic tissue.  Endothelin expression is assocd. with invading regions of tumors in patient biopsies and is more common in tumors with high histol. grade and lymphovascular invasion, and there is increased systemic endothelin in patients with lymph node metastases compared to those without lymph node involvement.  Stimulation of breast tumor cell lines with endothelins leads to an invasive phenotype in vitro.  Over-expression of the endothelins and their receptors is insufficient to induce an invasive phenotype in benign cells, yet expression by tumor cells leads to markedly increased invasive ability indicating that endothelins act in concert with other factors-both autocrine and paracrine-including cytokines, matrix metalloproteinases and the activation of tumor-assocd. macrophages.  The assocn. between endothelins, poor prognosis and invasion may mean that the endothelin axis is a valid therapeutic target for the treatment of invasive breast cancer.  This review summarizes the authors' current knowledge of endothelins in breast cancer invasion and discusses the potential further directions of such research as well as the possibility of anti-endothelin-based therapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkaSckEJMuwLVg90H21EOLACvtfcHk0ljd1MiUUR9szA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Ghs78%253D&md5=8dcf1ca6ac8ac525d21c749b61137114</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.08.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.08.029%26sid%3Dliteratum%253Aachs%26aulast%3DGrimshaw%26aufirst%3DM.%2BJ.%26atitle%3DEndothelins%2520in%2520Breast%2520Tumour%2520Cell%2520Invasion%26jtitle%3DCancer%2520Lett.%26date%3D2005%26volume%3D222%26spage%3D129%26epage%3D138%26doi%3D10.1016%2Fj.canlet.2004.08.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Kusuhara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, K.</span><span> </span><span class="NLM_article-title">Production of Endothelin in Human Cancer Cell Lines</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">3257</span><span class="NLM_x">â</span> <span class="NLM_lpage">3261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1990&pages=3257-3261&author=M.+Kusuharaauthor=K.+Yamaguchiauthor=K.+Nagasakiauthor=C.+Hayashiauthor=A.+Suzakiauthor=S.+Horiauthor=S.+Handaauthor=Y.+Nakamuraauthor=K.+Abe&title=Production+of+Endothelin+in+Human+Cancer+Cell+Lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKusuhara%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DNagasaki%26aufirst%3DK.%26aulast%3DHayashi%26aufirst%3DC.%26aulast%3DSuzaki%26aufirst%3DA.%26aulast%3DHori%26aufirst%3DS.%26aulast%3DHanda%26aufirst%3DS.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DK.%26atitle%3DProduction%2520of%2520Endothelin%2520in%2520Human%2520Cancer%2520Cell%2520Lines%26jtitle%3DCancer%2520Res.%26date%3D1990%26volume%3D50%26spage%3D3257%26epage%3D3261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Nelson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battistini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nisen, P.</span><span> </span><span class="NLM_article-title">The Endothelin Axis: Emerging Role in Cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">â</span> <span class="NLM_lpage">116</span><span class="refDoi">Â DOI: 10.1038/nrc990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fnrc990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=12563310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVCqsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=110-116&author=J.+Nelsonauthor=A.+Bagnatoauthor=B.+Battistiniauthor=P.+Nisen&title=The+Endothelin+Axis%3A+Emerging+Role+in+Cancer&doi=10.1038%2Fnrc990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The endothelin axis: emerging role in cancer</span></div><div class="casAuthors">Nelson, Joel; Bagnato, Anna; Battistini, Bruno; Nisen, Perry</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">110-116</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Collectively, the endothelins and their receptors - referred to as the endothelin (ET) axis - have key physiol. functions in normal tissue, acting as modulators of vasomotor tone, tissue, differentiation, development, cell proliferation and hormone prodn.  Based on new data, the ET axis also functions in the growth and progression of various tumors.  Preliminary results from clin. trials, such as those with atrasentan - an ETA-receptor antagonist-in prostate cancer are encouraging.  The place of ET-receptor antagonists in cancer therapy for a range of malignancies merits further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiRW-JWyEHbbVg90H21EOLACvtfcHk0ljK_JlA5IWmCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVCqsr4%253D&md5=d405432e9766b126391159b8ef60e858</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fnrc990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc990%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DJ.%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DBattistini%26aufirst%3DB.%26aulast%3DNisen%26aufirst%3DP.%26atitle%3DThe%2520Endothelin%2520Axis%253A%2520Emerging%2520Role%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D110%26epage%3D116%26doi%3D10.1038%2Fnrc990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Nelson, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Love, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulman, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleep, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M.</span><span> </span><span class="NLM_article-title">Atrasentan Phase 3 Study Group. Phase 3, Randomized, Controlled Trial of Atrasentan in Patients with Nonmetaststic Hormone-refractory Prostate Cancer</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">2478</span><span class="NLM_x">â</span> <span class="NLM_lpage">2487</span><span class="refDoi">Â DOI: 10.1002/cncr.23864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fcncr.23864" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2008&pages=2478-2487&author=J.+B.+Nelsonauthor=W.+Loveauthor=J.+L.+Chinauthor=F.+Saadauthor=C.+C.+Schulmanauthor=D.+J.+Sleepauthor=J.+Qianauthor=J.+Steinbergauthor=M.+Carducci&title=Atrasentan+Phase+3+Study+Group.+Phase+3%2C+Randomized%2C+Controlled+Trial+of+Atrasentan+in+Patients+with+Nonmetaststic+Hormone-refractory+Prostate+Cancer&doi=10.1002%2Fcncr.23864"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2Fcncr.23864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.23864%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DJ.%2BB.%26aulast%3DLove%26aufirst%3DW.%26aulast%3DChin%26aufirst%3DJ.%2BL.%26aulast%3DSaad%26aufirst%3DF.%26aulast%3DSchulman%26aufirst%3DC.%2BC.%26aulast%3DSleep%26aufirst%3DD.%2BJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DSteinberg%26aufirst%3DJ.%26aulast%3DCarducci%26aufirst%3DM.%26atitle%3DAtrasentan%2520Phase%25203%2520Study%2520Group.%2520Phase%25203%252C%2520Randomized%252C%2520Controlled%2520Trial%2520of%2520Atrasentan%2520in%2520Patients%2520with%2520Nonmetaststic%2520Hormone-refractory%2520Prostate%2520Cancer%26jtitle%3DCancer%26date%3D2008%26volume%3D113%26spage%3D2478%26epage%3D2487%26doi%3D10.1002%2Fcncr.23864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">RosanÃ², L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span> </span><span class="NLM_article-title">Endothelin 1 in Cancer: Biological Implications and Therapeutic Opportunities</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">â</span> <span class="NLM_lpage">651</span><span class="refDoi">Â DOI: 10.1038/nrc3546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fnrc3546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23884378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKnurjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=637-651&author=L.+Rosan%C3%B2author=F.+Spinellaauthor=A.+Bagnato&title=Endothelin+1+in+Cancer%3A+Biological+Implications+and+Therapeutic+Opportunities&doi=10.1038%2Fnrc3546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin 1 in cancer: biological implications and therapeutic opportunities</span></div><div class="casAuthors">Rosano, Laura; Spinella, Francesca; Bagnato, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">637-651</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Activation of autocrine and paracrine signalling by endothelin 1 (ET1) binding to its receptors elicits pleiotropic effects on tumor cells and on the host microenvironment.  This activation modulates cell proliferation, apoptosis, migration, epithelial-to-mesenchymal transition, chemoresistance and neovascularization, thus providing a strong rationale for targeting ET1 receptors in cancer.  In this Review, we discuss the advances in our understanding of the diverse biol. roles of ET1 in cancer and describe the latest preclin. and clin. progress that has been made using small-mol. antagonists of ET1 receptors that inhibit ET1-driven signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxNs394LN35bVg90H21EOLACvtfcHk0ljK_JlA5IWmCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKnurjF&md5=3951fcbc98bf24c955d56f004164ec4e</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnrc3546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3546%26sid%3Dliteratum%253Aachs%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3DEndothelin%25201%2520in%2520Cancer%253A%2520Biological%2520Implications%2520and%2520Therapeutic%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D637%26epage%3D651%26doi%3D10.1038%2Fnrc3546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Bagnato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">RosanÃ², L.</span><span> </span><span class="NLM_article-title">Understanding and Overcoming Chemoresistance in Ovarian Cancer: Emerging Role of the Endothelin Axis</span> <span class="citation_source-journal">Curr. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">â</span> <span class="NLM_lpage">38</span><span class="refDoi">Â DOI: 10.3747/co.19.895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.3747%2Fco.19.895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22328840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC383is1ahtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=36-38&author=A.+Bagnatoauthor=L.+Rosan%C3%B2&title=Understanding+and+Overcoming+Chemoresistance+in+Ovarian+Cancer%3A+Emerging+Role+of+the+Endothelin+Axis&doi=10.3747%2Fco.19.895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis</span></div><div class="casAuthors">Bagnato A; Rosano L</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology (Toronto, Ont.)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTnlReWd_6rDEwO064Z95rfW6udTcc2eZ9SkxRm46zb7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383is1ahtw%253D%253D&md5=416dfde251ce5c5497fa45faaa1ddd5e</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.3747%2Fco.19.895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3747%252Fco.19.895%26sid%3Dliteratum%253Aachs%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26atitle%3DUnderstanding%2520and%2520Overcoming%2520Chemoresistance%2520in%2520Ovarian%2520Cancer%253A%2520Emerging%2520Role%2520of%2520the%2520Endothelin%2520Axis%26jtitle%3DCurr.%2520Oncol.%26date%3D2012%26volume%3D19%26spage%3D36%26epage%3D38%26doi%3D10.3747%2Fco.19.895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Bagnato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflug, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curwen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Growcott, J.</span><span> </span><span class="NLM_article-title">Role of the Endothelin Axis and Its Antagonists in the Treatment of Cancer</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">â</span> <span class="NLM_lpage">233</span><span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01217.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fj.1476-5381.2011.01217.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21232046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Git7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=220-233&author=A.+Bagnatoauthor=M.+Loizidouauthor=B.+R.+Pflugauthor=J.+Curwenauthor=J.+Growcott&title=Role+of+the+Endothelin+Axis+and+Its+Antagonists+in+the+Treatment+of+Cancer&doi=10.1111%2Fj.1476-5381.2011.01217.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the endothelin axis and its antagonists in the treatment of cancer</span></div><div class="casAuthors">Bagnato, A.; Loizidou, M.; Pflug, B. R.; Curwen, J.; Growcott, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">220-233</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The endothelins (ET) are a group of proteins that act through G-protein coupled receptors.  Endothelin-1 (ET-1) was initially identified as a potent vasoconstrictor and dysregulation of the ET axis contributes to pathol. processes responsible for cardiovascular disease states.  More recently, the ET axis, in particular ET-1 acting through the endothelin A receptor (ETA), was implicated in the development of several cancers through activation of pathways involved in cell proliferation, migration, invasion, epithelial-mesenchymal transition, osteogenesis and angiogenesis.  The endothelin B receptor (ETB) may counter tumor progression by promoting apoptosis and clearing ET-1; however, it has recently been implicated in the development of some tumor types including melanomas and oligodendrogliomas.  Here, we review emerging preclin. and clin. data outlining the role of the ET axis in cancer, and its antagonism as an attractive and challenging approach to improve clin. cancer management.  Clin. data of ETA antagonists in patients with prostate cancer are encouraging and provide promise for new ETA antagonist-based treatment strategies.  Given the unexpected opportunities to affect pleiotrophic tumorigenic signals by targeting ETA-mediated pathways in a no. of cancers, the evaluation of ET-targeted therapy in cancer warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvXY6CHI2Fc7Vg90H21EOLACvtfcHk0lh3Yba633YL3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Git7w%253D&md5=3dd34f827a5218ee031a461e7c36b770</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01217.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01217.x%26sid%3Dliteratum%253Aachs%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DLoizidou%26aufirst%3DM.%26aulast%3DPflug%26aufirst%3DB.%2BR.%26aulast%3DCurwen%26aufirst%3DJ.%26aulast%3DGrowcott%26aufirst%3DJ.%26atitle%3DRole%2520of%2520the%2520Endothelin%2520Axis%2520and%2520Its%2520Antagonists%2520in%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D220%26epage%3D233%26doi%3D10.1111%2Fj.1476-5381.2011.01217.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Bagnato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natali, P. G.</span><span> </span><span class="NLM_article-title">Endothelin Receptors as Novel Targets in Tumor Therapy</span> <span class="citation_source-journal">J. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="refDoi">Â DOI: 10.1186/1479-5876-2-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1186%2F1479-5876-2-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15165288" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=16&author=A.+Bagnatoauthor=P.+G.+Natali&title=Endothelin+Receptors+as+Novel+Targets+in+Tumor+Therapy&doi=10.1186%2F1479-5876-2-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1186%2F1479-5876-2-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1479-5876-2-16%26sid%3Dliteratum%253Aachs%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26atitle%3DEndothelin%2520Receptors%2520as%2520Novel%2520Targets%2520in%2520Tumor%2520Therapy%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2004%26volume%3D2%26spage%3D16%26doi%3D10.1186%2F1479-5876-2-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Bagnato, A.</span><span> </span><span class="NLM_article-title">The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2720</span><span class="NLM_x">â</span> <span class="NLM_lpage">2733</span><span class="refDoi">Â DOI: 10.2174/138161212800626157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2174%2F138161212800626157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22390759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslCrs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2720-2733&author=A.+Bagnato&title=The+Endothelin+Axis+as+Therapeutic+Target+in+Human+Malignancies%3A+Present+and+Future&doi=10.2174%2F138161212800626157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The endothelin axis as therapeutic target in human malignancies: present and future</span></div><div class="casAuthors">Bagnato, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2720-2733</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  To assure their growth advantage cancer cells require the appropriation of key pathways, such as those controlled by G-protein coupled receptor (GPCR), that influence cell growth, migration, and death, as well as the expansion of vascular networks.  Accumulating mol. and in vivo evidences demonstrate that the activation of the endothelin-1 (ET-1) axis elicites pleiotropic effects on tumor cells and on the tumor microenvironment as well, modulating epithelial to mesenchymal transition, chemoresistance, and other tumor-assocd. processes.  As ET-1 axis blockade has been shown to reduce tumor growth in preclin. models, several small mol. antagonists of ET-1 receptors are currently undergoing clin. trial as novel agents in cancer therapy.  To fully appreciate the potential hegemony of the ET-1 axis in cancer, here we review emerging preclin. and clin. data outlining the spectrum of cellular activities triggered by ET-1 signaling and the challenges facing mol. targeted therapy.  Because scaffold proteins, such as Î²-arrestin, create signalling platforms that drive cellular transformation upon GPCR activation, mechanisms mediated by Î²-arrestin in ET-1 signalling are discussed.  Deeper understanding of mol. mechanisms activated by ET-1 receptor, as well as of how pathway crosstalk can influence ET-1 signalling outcome in cancer, is of paramount translational relevance in the study of ET-1 receptor-targeted therapy.  The improved knowledge of the interconnected mol. mechanism promoted by ET-1 axis in cancer will certainly result in more effective and durable mechanism-guided combinations of ET-1 receptor antagonists with cytotoxic drugs or other targeted agents in the clin. management of ET-1 axis-dependent malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDUZofHp1_57Vg90H21EOLACvtfcHk0lh3Yba633YL3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslCrs70%253D&md5=cbfdef8f8b701415c9472326ee9968e9</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.2174%2F138161212800626157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800626157%26sid%3Dliteratum%253Aachs%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3DThe%2520Endothelin%2520Axis%2520as%2520Therapeutic%2520Target%2520in%2520Human%2520Malignancies%253A%2520Present%2520and%2520Future%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2720%26epage%3D2733%26doi%3D10.2174%2F138161212800626157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Peduto Eberl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bovey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Endothelin-receptor Antagonists Are Pro-apoptotic and Anti-proliferative in Human Colon Cancer Cells</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">â</span> <span class="NLM_lpage">795</span><span class="refDoi">Â DOI: 10.1038/sj.bjc.6600810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fsj.bjc.6600810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=12618891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1CrsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=788-795&author=L.+Peduto+Eberlauthor=R.+Boveyauthor=L.+Juillerat-Jeanneret&title=Endothelin-receptor+Antagonists+Are+Pro-apoptotic+and+Anti-proliferative+in+Human+Colon+Cancer+Cells&doi=10.1038%2Fsj.bjc.6600810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells</span></div><div class="casAuthors">Peduto Eberl, L.; Bovey, R.; Juillerat-Jeanneret, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">788-795</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Endothelin (ET)-1 can act as an autocrine/paracrine growth factor or an antiapoptotic factor in human cancers.  To study the role of ET-1 in human colon cancer, proliferation and apoptosis of colon carcinoma cells was investigated using human HT-29 and SW480 colon carcinoma cells.  ET-1 was secreted by these cells.  Treatment of cells with bosentan, a dual ETA/B-receptor antagonist, decreased cell no.  Inhibition of DNA synthesis by bosentan was obsd. only in the presence of serum.  Exogenously added ET-1 did not increase DNA synthesis in serum-deprived cells.  SW480 cells were sensitive and HT-29 cells were resistant to FasL-induced apoptosis.  Bosentan sensitized resistant HT-29 cells to FasL-induced, caspase-mediated apoptosis, but not to TNF-Î±-induced apoptosis.  Bosentan and/or FasLigand (FasL) did not modulate the expression of caspase-8 or FLIP.  Bosentan sensitization to apoptosis was reversed by low concns. (10-13-10-10 M), but not by high concns. (10-9-10-7 M) of ET-1.  These results suggest that the binding of ET-1 to high-affinity sites inhibits FasL-induced apoptosis, while the binding of either ET-1 or receptor antagonists to low-affinity sites promotes FasL-induced apoptosis.  In conclusion, endothelin signalling pathways do not induce human colon cancer cell proliferation, but are survival signals controlling resistance to apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZXqLlBmWYirVg90H21EOLACvtfcHk0lh3Yba633YL3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1CrsLo%253D&md5=3558e16edc9356773e58cfff54ea912d</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600810%26sid%3Dliteratum%253Aachs%26aulast%3DPeduto%2BEberl%26aufirst%3DL.%26aulast%3DBovey%26aufirst%3DR.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin-receptor%2520Antagonists%2520Are%2520Pro-apoptotic%2520and%2520Anti-proliferative%2520in%2520Human%2520Colon%2520Cancer%2520Cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D88%26spage%3D788%26epage%3D795%26doi%3D10.1038%2Fsj.bjc.6600810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Peduto Eberl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egidy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Blockade Potentiates FasL-induced Apoptosis in Colon Carcinoma Cells via the Protein Kinase C-pathway</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">S354</span><span class="NLM_x">â</span> <span class="NLM_lpage">S356</span><span class="refDoi">Â DOI: 10.1097/00005344-200036001-00103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2F00005344-200036001-00103" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=S354-S356&author=L.+Peduto+Eberlauthor=G.+Egidyauthor=F.+Pinetauthor=L.+Juillerat-Jeanneret&title=Endothelin+Receptor+Blockade+Potentiates+FasL-induced+Apoptosis+in+Colon+Carcinoma+Cells+via+the+Protein+Kinase+C-pathway&doi=10.1097%2F00005344-200036001-00103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1097%2F00005344-200036001-00103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-200036001-00103%26sid%3Dliteratum%253Aachs%26aulast%3DPeduto%2BEberl%26aufirst%3DL.%26aulast%3DEgidy%26aufirst%3DG.%26aulast%3DPinet%26aufirst%3DF.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin%2520Receptor%2520Blockade%2520Potentiates%2520FasL-induced%2520Apoptosis%2520in%2520Colon%2520Carcinoma%2520Cells%2520via%2520the%2520Protein%2520Kinase%2520C-pathway%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2000%26volume%3D35%26spage%3DS354%26epage%3DS356%26doi%3D10.1097%2F00005344-200036001-00103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Said, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theodorescu, D.</span><span> </span><span class="NLM_article-title">Permissive Role of Endothelin Receptors in Tumor Metastasis</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">522</span><span class="NLM_x">â</span> <span class="NLM_lpage">527</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2012.03.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.lfs.2012.03.040" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=522-527&author=N.+Saidauthor=D.+Theodorescu&title=Permissive+Role+of+Endothelin+Receptors+in+Tumor+Metastasis&doi=10.1016%2Fj.lfs.2012.03.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.03.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.03.040%26sid%3Dliteratum%253Aachs%26aulast%3DSaid%26aufirst%3DN.%26aulast%3DTheodorescu%26aufirst%3DD.%26atitle%3DPermissive%2520Role%2520of%2520Endothelin%2520Receptors%2520in%2520Tumor%2520Metastasis%26jtitle%3DLife%2520Sci.%26date%3D2012%26volume%3D91%26spage%3D522%26epage%3D527%26doi%3D10.1016%2Fj.lfs.2012.03.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Irani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salajegheh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. K.</span><span> </span><span class="NLM_article-title">A Review of the Profile of Endothelin Axis in Cancer and Its Management</span> <span class="citation_source-journal">Crit. Review Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">â</span> <span class="NLM_lpage">321</span><span class="refDoi">Â DOI: 10.1016/j.critrevonc.2013.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.critrevonc.2013.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24035584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC3sbotVylsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2014&pages=314-321&author=S.+Iraniauthor=A.+Salajeghehauthor=R.+A.+Smithauthor=A.+K.+Lam&title=A+Review+of+the+Profile+of+Endothelin+Axis+in+Cancer+and+Its+Management&doi=10.1016%2Fj.critrevonc.2013.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the profile of endothelin axis in cancer and its management</span></div><div class="casAuthors">Irani Soussan; Salajegheh Ali; Smith Robert Anthony; Lam Alfred King-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">314-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The endothelins and their associated receptors are important controllers of vascular growth, inflammation and vascular tone.  In cancer, they have roles in the control of numerous factors in cancer development and progression, including angiogenesis, stromal reaction, epithelial mesenchymal transitions, apoptosis, invasion, metastases and drug resistance.  Also, we consider current information on the role of this signalling system in cancer and examine the state of the current cell, animal and clinical trials utilizing endothelin targeted drugs for cancer management.  Although targeting the endothelin axis in cell lines and xenografts show some promise in retarding cellular growth, results from limited clinical trials in prostatic cancer are less encouraging and did not offer significant survival benefit.  The ability to target both cancer cells and vasculature via endothelin is an important consideration that necessitates the further refining of therapeutic strategies as we continue to explore the possibilities of the endothelin axis in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTizkEGuZWmMcScOqQTSkOffW6udTcc2eYsAjKPPe1aw7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbotVylsw%253D%253D&md5=5f198ffa631e4b313b3bbcc063ec434f</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2013.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2013.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DIrani%26aufirst%3DS.%26aulast%3DSalajegheh%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DLam%26aufirst%3DA.%2BK.%26atitle%3DA%2520Review%2520of%2520the%2520Profile%2520of%2520Endothelin%2520Axis%2520in%2520Cancer%2520and%2520Its%2520Management%26jtitle%3DCrit.%2520Review%2520Oncol.%2520Hematol.%26date%3D2014%26volume%3D89%26spage%3D314%26epage%3D321%26doi%3D10.1016%2Fj.critrevonc.2013.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Knowles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span> </span><span class="NLM_article-title">Endothelin-1 and Angiogenesis in Cancer</span> <span class="citation_source-journal">Curr. Vasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">â</span> <span class="NLM_lpage">314</span><span class="refDoi">Â DOI: 10.2174/157016105774329462</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.2174%2F157016105774329462" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=16248773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVaht7jP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=309-314&author=J.+Knowlesauthor=M.+Loizidouauthor=I.+Taylor&title=Endothelin-1+and+Angiogenesis+in+Cancer&doi=10.2174%2F157016105774329462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1 and angiogenesis in cancer</span></div><div class="casAuthors">Knowles, Jonathan; Loizidou, Marilena; Taylor, Irving</div><div class="citationInfo"><span class="NLM_cas:title">Current Vascular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-314</span>CODEN:
                <span class="NLM_cas:coden">CVPUAY</span>;
        ISSN:<span class="NLM_cas:issn">1570-1611</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tumors require oxygenation, nutrition and a route for dissemination.  This necessitates the development of new vessels or angiogenesis.  High levels of new vessel development are indicators of poor prognosis in cancer; they also provide new avenues of anti-tumor therapy.  Angiogenesis in cancer produces structurally different vessels from angiogenesis in wound healing and inflammation.  This article reviews the differences between vessels in tumor angiogenesis and 'normal angiogenesis.  The main focus of the article is the role of the vasoactive peptide endothelin-1 (ET-1) in tumor angiogenesis.  The role of ET-1 in tumor development is reviewed, before the direct and indirect effects of ET-1 in angiogenesis are examd.  ET-1 has a direct angiogenic effect on endothelial and peri-vascular cells.  It also has an indirect action through the increased release of the potent pro-angiogenic substance vascular endothelial growth factor (VEGF), via hypoxia inducible factor-1.  ET-1 also indirectly stimulates angiogenesis by stimulating fibroblasts and cancer cells to produce pro-angiogenic proteases.  ET-1 is a novel stimulator of tumor angiogenesis and warrants further examn. as an anti-angiogenic treatment target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqePqs90AAhebVg90H21EOLACvtfcHk0liIR1YWxDC_Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVaht7jP&md5=521d02e0d22fe7c9c22992b7d2898fe6</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.2174%2F157016105774329462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157016105774329462%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DJ.%26aulast%3DLoizidou%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DI.%26atitle%3DEndothelin-1%2520and%2520Angiogenesis%2520in%2520Cancer%26jtitle%3DCurr.%2520Vasc.%2520Pharmacol.%26date%3D2005%26volume%3D3%26spage%3D309%26epage%3D314%26doi%3D10.2174%2F157016105774329462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Knowles, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi-Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haque, S. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winslet, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span> </span><span class="NLM_article-title">Endothelin-1 Stimulates Colon Cancer Adjacent Fibroblasts</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">â</span> <span class="NLM_lpage">1272</span><span class="refDoi">Â DOI: 10.1002/ijc.26090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fijc.26090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21445967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVSjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2012&pages=1264-1272&author=J.+P.+Knowlesauthor=X.+Shi-Wenauthor=S.+U.+Haqueauthor=A.+Bhallaauthor=M.+R.+Dashwoodauthor=S.+Yangauthor=I.+Taylorauthor=M.+C.+Winsletauthor=D.+J.+Abrahamauthor=M.+Loizidou&title=Endothelin-1+Stimulates+Colon+Cancer+Adjacent+Fibroblasts&doi=10.1002%2Fijc.26090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1 stimulates colon cancer adjacent fibroblasts</span></div><div class="casAuthors">Knowles, Jonathan P.; Xu, Shi-Wen; Haque, Samer-ul; Bhalla, Ashish; Dashwood, Michael R.; Yang, Shiyu; Taylor, Irving; Winslet, Marc C.; Abraham, David J.; Loizidou, Marilena</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1264-1272</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Endothelin-1 (ET-1) is produced by and stimulates colorectal cancer cells.  Fibroblasts produce tumor stroma required for cancer development.  We investigated whether ET-1 stimulated processes involved in tumor stroma prodn. by colonic fibroblasts.  Primary human fibroblasts, isolated from normal tissues adjacent to colon cancers, were cultured with or without ET-1 and its antagonists.  Cellular proliferation, migration and contraction were measured.  Expression of enzymes involved in tumor stroma development and alterations in gene transcription were detd. by Western blotting and genome microarrays.  ET-1 stimulated proliferation, contraction and migration (p < 0.01 v control) and the expression of matrix degrading enzymes TIMP-1 and MMP-2, but not MMP-3.  ET-1 upregulated genes for profibrotic growth factors and receptors, signalling mols., actin modulators and extracellular matrix components.  ET-1 stimulated colonic fibroblast cellular processes in vitro that are involved in developing tumor stroma.  Upregulated genes were consistent with these processes.  By acting as a strong stimulus for tumor stroma creation, ET-1 is proposed as a target for adjuvant cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk2uwuS_fnnrVg90H21EOLACvtfcHk0lgI403uRbEVHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVSjsA%253D%253D&md5=f2970124a0c36abfbfd90058f52b4960</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1002%2Fijc.26090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.26090%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DJ.%2BP.%26aulast%3DShi-Wen%26aufirst%3DX.%26aulast%3DHaque%26aufirst%3DS.%2BU.%26aulast%3DBhalla%26aufirst%3DA.%26aulast%3DDashwood%26aufirst%3DM.%2BR.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DWinslet%26aufirst%3DM.%2BC.%26aulast%3DAbraham%26aufirst%3DD.%2BJ.%26aulast%3DLoizidou%26aufirst%3DM.%26atitle%3DEndothelin-1%2520Stimulates%2520Colon%2520Cancer%2520Adjacent%2520Fibroblasts%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D130%26spage%3D1264%26epage%3D1272%26doi%3D10.1002%2Fijc.26090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Nelson, J. B.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists</span> <span class="citation_source-journal">World J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">â</span> <span class="NLM_lpage">27</span><span class="refDoi">Â DOI: 10.1007/s00345-004-0478-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00345-004-0478-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15654644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Ols7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=19-27&author=J.+B.+Nelson&title=Endothelin+Receptor+Antagonists&doi=10.1007%2Fs00345-004-0478-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin receptor antagonists</span></div><div class="casAuthors">Nelson, Joel B.</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Urology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-27</span>CODEN:
                <span class="NLM_cas:coden">WJURDJ</span>;
        ISSN:<span class="NLM_cas:issn">0724-4983</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Hormone refractory prostate cancer remains true to its middle name: it is largely refractory to attempts to delay its progression.  New targets and new therapies are demanded.  Through a review of the available literature on endothelin and several preclin. observations, the endothelin axis has emerged as one such target.  In phase II and III clin. trials of atrasentan, a potent and selective endothelin receptor A subtype (ETA) antagonist, disease progression was delayed in some men.  This well tolerated, oral agent may help convert advanced prostate cancer to a more chronic disease.  This review will discuss the endothelin axis, preclin. rationale and some of the available clin. trial data on this promising new approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5DvdTmNzgc7Vg90H21EOLACvtfcHk0lgI403uRbEVHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Ols7k%253D&md5=40aacd331807c5d4c02f85e5c95b84de</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1007%2Fs00345-004-0478-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00345-004-0478-9%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DJ.%2BB.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%26jtitle%3DWorld%2520J.%2520Urol.%26date%3D2005%26volume%3D23%26spage%3D19%26epage%3D27%26doi%3D10.1007%2Fs00345-004-0478-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">RosanÃ², L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Castro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicotra, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dedhar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Herreros, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span> </span><span class="NLM_article-title">Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">11649</span><span class="NLM_x">â</span> <span class="NLM_lpage">11657</span><span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-05-2123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F0008-5472.CAN-05-2123" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=11649-11657&author=L.+Rosan%C3%B2author=F.+Spinellaauthor=V.+Di+Castroauthor=M.+R.+Nicotraauthor=S.+Dedharauthor=A.+G.+de+Herrerosauthor=P.+G.+Nataliauthor=A.+Bagnato&title=Endothelin-1+Promotes+Epithelial-to-Mesenchymal+Transition+in+Human+Ovarian+Cancer+Cells&doi=10.1158%2F0008-5472.CAN-05-2123"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2123%26sid%3Dliteratum%253Aachs%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DNicotra%26aufirst%3DM.%2BR.%26aulast%3DDedhar%26aufirst%3DS.%26aulast%3Dde%2BHerreros%26aufirst%3DA.%2BG.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3DEndothelin-1%2520Promotes%2520Epithelial-to-Mesenchymal%2520Transition%2520in%2520Human%2520Ovarian%2520Cancer%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D11649%26epage%3D11657%26doi%3D10.1158%2F0008-5472.CAN-05-2123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">RosanÃ², L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianfrocca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Castro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicotra, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucidi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrandina, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span> </span><span class="NLM_article-title">Acquisition of Chemoresistance and EMT Phenotype is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2350</span><span class="NLM_x">â</span> <span class="NLM_lpage">2360</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-10-2325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1078-0432.CCR-10-2325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=21220476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2350-2360&author=L.+Rosan%C3%B2author=R.+Cianfroccaauthor=F.+Spinellaauthor=V.+Di+Castroauthor=M.+R.+Nicotraauthor=A.+Lucidiauthor=G.+Ferrandinaauthor=P.+G.+Nataliauthor=A.+Bagnato&title=Acquisition+of+Chemoresistance+and+EMT+Phenotype+is+Linked+with+Activation+of+the+Endothelin+A+Receptor+Pathway+in+Ovarian+Carcinoma+Cells&doi=10.1158%2F1078-0432.CCR-10-2325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells</span></div><div class="casAuthors">Rosano, Laura; Cianfrocca, Roberta; Spinella, Francesca; Di Castro, Valeriana; Nicotra, Maria Rita; Lucidi, Alessandro; Ferrandina, Gabriella; Natali, Pier Giorgio; Bagnato, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2350-2360</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Emerging evidence suggests mol. and phenotypic assocn. between chemoresistance and epithelial-mesenchymal transition (EMT) in cancer.  Endothelin-1 (ET-1)/endothelin A receptor (ETAR) axis is implicated in the pathobiol. of epithelial ovarian cancer (EOC) by driving tumor-promoting effects, including EMT.  Here, we analyzed how ETAR regulates chemoresistance and EMT in EOC.  Exptl. Design: The effects of ET-1 axis on cell proliferation, drug-induced apoptosis, invasiveness, and EMT were analyzed in cultured EOC cells sensitive and resistant to cisplatinum and taxol.  Tumor growth in response to ETAR antagonist was examd. in EOC xenografts.  ETAR expression was examd. in 60 human EOC tumors by immunohistochem. and correlated with chemoresistance and EMT.  RESULTS: In resistant EOC cells ET-1 and ETAR are upregulated, paralleled by enhanced mitogen activated protein kinase (MAPK) and Akt phosphorylation and cell proliferation.  Moreover, in these cells the expression of E-cadherin transcriptional repressors, including Snail, Slug, and Twist, as well as of mesenchymal markers, such as vimentin and N-cadherin, were upregulated and linked with enhanced invasive behavior.  Interestingly, ETAR blockade with zibotentan, a specific ETAR antagonist, or its silencing, downregulated Snail activity, restored drug sensitivity to cytotoxic-induced apoptosis, and inhibited the invasiveness of resistant cells.  In vivo, zibotentan inhibited tumor growth of sensitive and resistant EOC xenografts, and sensitized to chemotherapy.  Anal. of EOC human tissues revealed that ETAR is overexpressed in resistant tumors and is assocd. with EMT phenotype.  CONCLUSIONS: Our data provide the first evidence that blockade of ETAR-driven EMT can overcome chemoresistance and inhibit tumor progression, improving the outcome of EOC patients' treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9X_Qbp2vGw7Vg90H21EOLACvtfcHk0lgI403uRbEVHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgtrw%253D&md5=293bd24befd83097b960bb87626f1c20</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2325%26sid%3Dliteratum%253Aachs%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DNicotra%26aufirst%3DM.%2BR.%26aulast%3DLucidi%26aufirst%3DA.%26aulast%3DFerrandina%26aufirst%3DG.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3DAcquisition%2520of%2520Chemoresistance%2520and%2520EMT%2520Phenotype%2520is%2520Linked%2520with%2520Activation%2520of%2520the%2520Endothelin%2520A%2520Receptor%2520Pathway%2520in%2520Ovarian%2520Carcinoma%2520Cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2350%26epage%3D2360%26doi%3D10.1158%2F1078-0432.CCR-10-2325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">RosanÃ², L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianfrocca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tocci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Castro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spadaro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biroccio, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span> </span><span class="NLM_article-title">Beta-arrestin-1 is a Nuclear Transcriptional Regulator of Endothelin-1-induced Beta-catenin Signaling</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">5066</span><span class="NLM_x">â</span> <span class="NLM_lpage">5077</span><span class="refDoi">Â DOI: 10.1038/onc.2012.527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fonc.2012.527" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=5066-5077&author=L.+Rosan%C3%B2author=R.+Cianfroccaauthor=P.+Tocciauthor=F.+Spinellaauthor=V.+Di+Castroauthor=F.+Spadaroauthor=E.+Salvatiauthor=A.+M.+Biroccioauthor=P.+G.+Nataliauthor=A.+Bagnato&title=Beta-arrestin-1+is+a+Nuclear+Transcriptional+Regulator+of+Endothelin-1-induced+Beta-catenin+Signaling&doi=10.1038%2Fonc.2012.527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.527%26sid%3Dliteratum%253Aachs%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DTocci%26aufirst%3DP.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DSpadaro%26aufirst%3DF.%26aulast%3DSalvati%26aufirst%3DE.%26aulast%3DBiroccio%26aufirst%3DA.%2BM.%26aulast%3DNatali%26aufirst%3DP.%2BG.%26aulast%3DBagnato%26aufirst%3DA.%26atitle%3DBeta-arrestin-1%2520is%2520a%2520Nuclear%2520Transcriptional%2520Regulator%2520of%2520Endothelin-1-induced%2520Beta-catenin%2520Signaling%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D5066%26epage%3D5077%26doi%3D10.1038%2Fonc.2012.527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Cianfrocca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tocci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Castro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">RosanÃ², L.</span><span> </span><span class="NLM_article-title">The Endothelin A Receptor and Epidermal Growth Factor Receptor Signaling Converge on Beta-catenin to Promote Ovarian Cancer Metastasis</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">â</span> <span class="NLM_lpage">556</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2012.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.lfs.2012.03.023" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=550-556&author=R.+Cianfroccaauthor=P.+Tocciauthor=F.+Spinellaauthor=V.+Di+Castroauthor=A.+Bagnatoauthor=L.+Rosan%C3%B2&title=The+Endothelin+A+Receptor+and+Epidermal+Growth+Factor+Receptor+Signaling+Converge+on+Beta-catenin+to+Promote+Ovarian+Cancer+Metastasis&doi=10.1016%2Fj.lfs.2012.03.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DCianfrocca%26aufirst%3DR.%26aulast%3DTocci%26aufirst%3DP.%26aulast%3DSpinella%26aufirst%3DF.%26aulast%3DDi%2BCastro%26aufirst%3DV.%26aulast%3DBagnato%26aufirst%3DA.%26aulast%3DRosan%25C3%25B2%26aufirst%3DL.%26atitle%3DThe%2520Endothelin%2520A%2520Receptor%2520and%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Signaling%2520Converge%2520on%2520Beta-catenin%2520to%2520Promote%2520Ovarian%2520Cancer%2520Metastasis%26jtitle%3DLife%2520Sci.%26date%3D2012%26volume%3D91%26spage%3D550%26epage%3D556%26doi%3D10.1016%2Fj.lfs.2012.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Coffman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckanovich, R. J.</span><span> </span><span class="NLM_article-title">Endothelin Receptor-A is Required for the Recruitment of Antitumor T Cells and Modulates Chemotherapy Induction of Cancer Stem Cells</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">â</span> <span class="NLM_lpage">192</span><span class="refDoi">Â DOI: 10.4161/cbt.22959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.4161%2Fcbt.22959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23192269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFOmurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=184-192&author=L.+Coffmanauthor=C.+Mooneyauthor=J.+Limauthor=S.+Baiauthor=I.+Silvaauthor=Y.+Gongauthor=K.+Yangauthor=R.+J.+Buckanovich&title=Endothelin+Receptor-A+is+Required+for+the+Recruitment+of+Antitumor+T+Cells+and+Modulates+Chemotherapy+Induction+of+Cancer+Stem+Cells&doi=10.4161%2Fcbt.22959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells</span></div><div class="casAuthors">Coffman, Lan; Mooney, Collin; Lim, Jaeyoung; Bai, Shoumei; Silva, Ines; Gong, Yusong; Yang, Kun; Buckanovich, Ronald J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-192</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Background: The endothelin receptor-A (ETRA) plays an important role in tumor cell migration, metastasis, and proliferation.  The endothelin receptor B (ETRB) plays a crit. role in angiogenesis and the inhibition of antitumor immune cell recruitment.  Thus dual blockade of ETRA and ETRB could have significant antitumor effects.  Results: Dual ETRA/ETRB blockade with macitentan (or the combination of the ETRA and ETRB antagonists BQ123 and BQ788) did not enhance antitumor immune cell recruitment.  In vitro studies demonstrate that ETRA inhibition prevents the induction of ICAM1 necessary for immune cell recruitment.  When used as a single agent against human tumor xenografts, macitentan demonstrated non-significant antitumor activity.  However, when used in combination with chemotherapy, macitentan specifically reduced tumor growth in cell lines with CD133+ cancer stem cells.  We found that ETRA is primarily expressed on CD133+ CSC in both cell lines and primary human tumor cells.  ETRA inhibition of CSC prevented chemotherapy induced increases in tumor stem cells.  Furthermore, ETRA inhibition in combination with chemotherapy reduced the formation of tumor spheres.  Methods: We tested the dual ETRA/ETRB antagonist macitentan in conjunction with (1) an antitumor vaccine and (2) chemotherapy, in order to assess the impact of dual ETRA/ETRB blockade on antitumor immune cell infiltration and ovarian tumor growth.  In vitro murine and human cell line, tumor sphere assays and tumor xenograft models were utilized to evaluate the effect of ETRA/ETRB blockade on cell proliferation, immune cell infiltration and cancer stem cell populations.  Conclusions: These studies indicate a crit. role for ETRA in the regulation of immune cell recruitment and in the CSC resistance to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg_ZsXglJa8bVg90H21EOLACvtfcHk0ljavrFmZ6-xsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFOmurw%253D&md5=faa3e849b7607a8c6316f615c4dd5089</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.4161%2Fcbt.22959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.22959%26sid%3Dliteratum%253Aachs%26aulast%3DCoffman%26aufirst%3DL.%26aulast%3DMooney%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DS.%26aulast%3DSilva%26aufirst%3DI.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DBuckanovich%26aufirst%3DR.%2BJ.%26atitle%3DEndothelin%2520Receptor-A%2520is%2520Required%2520for%2520the%2520Recruitment%2520of%2520Antitumor%2520T%2520Cells%2520and%2520Modulates%2520Chemotherapy%2520Induction%2520of%2520Cancer%2520Stem%2520Cells%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2013%26volume%3D14%26spage%3D184%26epage%3D192%26doi%3D10.4161%2Fcbt.22959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Lahav, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffner, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, P. H.</span><span> </span><span class="NLM_article-title">An Endothelin Receptor B Antagonist Inhibits Growth and Induces Cell Death in Human Melanoma Cells In Vitro and In Vivo</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">11496</span><span class="NLM_x">â</span> <span class="NLM_lpage">11500</span><span class="refDoi">Â DOI: 10.1073/pnas.96.20.11496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1073%2Fpnas.96.20.11496" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=11496-11500&author=R.+Lahavauthor=G.+Heffnerauthor=P.+H.+Patterson&title=An+Endothelin+Receptor+B+Antagonist+Inhibits+Growth+and+Induces+Cell+Death+in+Human+Melanoma+Cells+In+Vitro+and+In+Vivo&doi=10.1073%2Fpnas.96.20.11496"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.20.11496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.20.11496%26sid%3Dliteratum%253Aachs%26aulast%3DLahav%26aufirst%3DR.%26aulast%3DHeffner%26aufirst%3DG.%26aulast%3DPatterson%26aufirst%3DP.%2BH.%26atitle%3DAn%2520Endothelin%2520Receptor%2520B%2520Antagonist%2520Inhibits%2520Growth%2520and%2520Induces%2520Cell%2520Death%2520in%2520Human%2520Melanoma%2520Cells%2520In%2520Vitro%2520and%2520In%2520Vivo%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D11496%26epage%3D11500%26doi%3D10.1073%2Fpnas.96.20.11496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Hsieh, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, D. Y.</span><span> </span><span class="NLM_article-title">Exogenous Endothelin-1 Induces Cell Migration and Matrix Metalloproteinase Expression in U251 Human Glioblastoma Multiforme</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">â</span> <span class="NLM_lpage">269</span><span class="refDoi">Â DOI: 10.1007/s11060-014-1442-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs11060-014-1442-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24756349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFOltLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=257-269&author=W.+T.+Hsiehauthor=W.+L.+Yehauthor=R.+Y.+Chengauthor=C.+Linauthor=C.+F.+Tsaiauthor=B.+R.+Huangauthor=C.+Y.+Wuauthor=H.+Y.+Linauthor=S.+S.+Huangauthor=D.+Y.+Lu&title=Exogenous+Endothelin-1+Induces+Cell+Migration+and+Matrix+Metalloproteinase+Expression+in+U251+Human+Glioblastoma+Multiforme&doi=10.1007%2Fs11060-014-1442-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Exogenous endothelin-1 induces cell migration and matrix metalloproteinase expression in U251 human glioblastoma multiforme</span></div><div class="casAuthors">Hsieh, Wen-Tsong; Yeh, Wei-Lan; Cheng, Ruo-Yuo; Lin, Chingju; Tsai, Cheng-Fang; Huang, Bor-Ren; Wu, Caren Yu-Ju; Lin, Hsiao-Yun; Huang, Shiang-Suo; Lu, Dah-Yuu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-269</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most common and lethal type of primary brain tumor characterized by its rapid infiltration to surrounding tissues during the early stages.  The fast spreading of GBM obscures the initiation of the tumor mass making the treatment outcome undesirable.  Endothelin-1 is known as a secretory protein presented in various types of brain cells, which has been indicated as a factor for cancer pathol.  The aim of the present study was to investigate the mol. mechanism of cell migration in GBM.  We found that various malignant glioma cells expressed higher amts. of endothelin-1, ETA, and ETB receptors than nonmalignant human astrocytes.  The application of endothelin-1 enhanced the migratory activity in human U251 glioma cells corresponding to increased expression of matrix metalloproteinase (MMP)-9 and MMP-13.  The endothelin-1-induced cell migration was attenuated by MMP-9 and MMP-13 inhibitors and inhibitors of mitogen-activated protein (MAP) kinase and PI3 kinase/Akt.  Furthermore, the elevated levels of phosphate c-Jun accumulation in the nucleus and activator protein-1 (AP-1)-DNA binding activity were also found in endothelin-1 treated glioma cells.  In migration-prone sublines, cells with greater migration ability showed higher endothelin-1, ETB receptor, and MMP expressions.  These results indicate that endothelin-1 activates MAP kinase and AP-1 signaling, resulting in enhanced MMP-9 and MMP-13 expressions and cell migration in GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq93zpEIigF1bVg90H21EOLACvtfcHk0liX2JwBiGaNOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFOltLw%253D&md5=4fb0854d27a7a5dd029a0f2b703b3f3c</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1007%2Fs11060-014-1442-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-014-1442-1%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DW.%2BT.%26aulast%3DYeh%26aufirst%3DW.%2BL.%26aulast%3DCheng%26aufirst%3DR.%2BY.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DTsai%26aufirst%3DC.%2BF.%26aulast%3DHuang%26aufirst%3DB.%2BR.%26aulast%3DWu%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DHuang%26aufirst%3DS.%2BS.%26aulast%3DLu%26aufirst%3DD.%2BY.%26atitle%3DExogenous%2520Endothelin-1%2520Induces%2520Cell%2520Migration%2520and%2520Matrix%2520Metalloproteinase%2520Expression%2520in%2520U251%2520Human%2520Glioblastoma%2520Multiforme%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2014%26volume%3D118%26spage%3D257%26epage%3D269%26doi%3D10.1007%2Fs11060-014-1442-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tso, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dembo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eskin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischel, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornblum, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tso, C. L.</span><span> </span><span class="NLM_article-title">Autocrine endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1668</span><span class="NLM_x">â</span> <span class="NLM_lpage">1685</span><span class="refDoi">Â DOI: 10.1158/1541-7786.MCR-10-0563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1541-7786.MCR-10-0563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22013079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1elt7bP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=1668-1685&author=Y.+Liuauthor=F.+Yeauthor=K.+Yamadaauthor=J.+L.+Tsoauthor=Y.+Zhangauthor=D.+H.+Nguyenauthor=Q.+Dongauthor=H.+Sotoauthor=J.+Choeauthor=A.+Demboauthor=H.+Wheelerauthor=A.+Eskinauthor=I.+Schmidauthor=W.+H.+Yongauthor=P.+S.+Mischelauthor=T.+F.+Cloughesyauthor=H.+I.+Kornblumauthor=S.+F.+Nelsonauthor=L.+M.+Liauauthor=C.+L.+Tso&title=Autocrine+endothelin-3%2FEndothelin+Receptor+B+Signaling+Maintains+Cellular+and+Molecular+Properties+of+Glioblastoma+Stem+Cells&doi=10.1158%2F1541-7786.MCR-10-0563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine Endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells</span></div><div class="casAuthors">Liu, Yue; Ye, Fei; Yamada, Kazunari; Tso, Jonathan L.; Zhang, Yibei; Nguyen, David H.; Dong, Qinghua; Soto, Horacio; Choe, Jinny; Dembo, Anna; Wheeler, Hayley; Eskin, Ascia; Schmid, Ingrid; Yong, William H.; Mischel, Paul S.; Cloughesy, Timothy F.; Kornblum, Harley I.; Nelson, Stanley F.; Liau, Linda M.; Tso, Cho-Lea</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1668-1685</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Glioblastoma stem cells (GSC) express both radial glial cell and neural crest cell (NCC)-assocd. genes.  We report that endothelin 3 (EDN3), an essential mitogen for NCC development and migration, is highly produced by GSCs.  Serum-induced proliferative differentiation rapidly decreased EDN3 prodn. and downregulated the expression of stemness-assocd. genes, and reciprocally, two glioblastoma markers, EDN1 and YKL-40 transcripts, were induced.  Correspondingly, patient glioblastoma tissues express low levels of EDN3 mRNA and high levels of EDN1 and YKL-40 mRNA.  Blocking EDN3/EDN receptor B (EDNRB) signaling by an EDNRB antagonist (BQ788), or EDN3 RNA interference (siRNA), leads to cell apoptosis and functional impairment of tumor sphere formation and cell spreading/migration in culture and loss of tumorigenic capacity in animals.  Using exogenous EDN3 as the sole mitogen in culture does not support GSC propagation, but it can rescue GSCs from undergoing cell apoptosis.  Mol. anal. by gene expression profiling revealed that most genes downregulated by EDN3/EDNRB blockade were those involved in cytoskeleton organization, pause of growth and differentiation, and DNA damage response, implicating the involvement of EDN3/EDNRB signaling in maintaining GSC migration, undifferentiation, and survival.  These data suggest that autocrine EDN3/EDNRB signaling is essential for maintaining GSCs.  Incorporating END3/EDNRB-targeted therapies into conventional cancer treatments may have clin. implication for the prevention of tumor recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3alOjINGaqbVg90H21EOLACvtfcHk0liX2JwBiGaNOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1elt7bP&md5=46cf7164714e61c7d872319e40b20d69</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-10-0563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-10-0563%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DTso%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DNguyen%26aufirst%3DD.%2BH.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DSoto%26aufirst%3DH.%26aulast%3DChoe%26aufirst%3DJ.%26aulast%3DDembo%26aufirst%3DA.%26aulast%3DWheeler%26aufirst%3DH.%26aulast%3DEskin%26aufirst%3DA.%26aulast%3DSchmid%26aufirst%3DI.%26aulast%3DYong%26aufirst%3DW.%2BH.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DKornblum%26aufirst%3DH.%2BI.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DLiau%26aufirst%3DL.%2BM.%26aulast%3DTso%26aufirst%3DC.%2BL.%26atitle%3DAutocrine%2520endothelin-3%252FEndothelin%2520Receptor%2520B%2520Signaling%2520Maintains%2520Cellular%2520and%2520Molecular%2520Properties%2520of%2520Glioblastoma%2520Stem%2520Cells%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2011%26volume%3D9%26spage%3D1668%26epage%3D1685%26doi%3D10.1158%2F1541-7786.MCR-10-0563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Paolillo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russo, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinelli, S.</span><span> </span><span class="NLM_article-title">Endothelin B Receptor Antagonists Block Proliferation and Induce Apoptosis in Glioma Cells</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">306</span><span class="NLM_x">â</span> <span class="NLM_lpage">315</span><span class="refDoi">Â DOI: 10.1016/j.phrs.2009.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.phrs.2009.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=19931393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1WjtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2010&pages=306-315&author=M.+Paolilloauthor=M.+A.+Russoauthor=D.+Curtiauthor=C.+Lanniauthor=S.+Schinelli&title=Endothelin+B+Receptor+Antagonists+Block+Proliferation+and+Induce+Apoptosis+in+Glioma+Cells&doi=10.1016%2Fj.phrs.2009.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin B receptor antagonists block proliferation and induce apoptosis in glioma cells</span></div><div class="casAuthors">Paolillo, Mayra; Russo, Marika A.; Curti, Daniela; Lanni, Cristina; Schinelli, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">306-315</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The proliferative and antiapoptotic actions of endothelin (ET)-1 in cancer cells have been documented and ET receptor antagonists have been exploited as potential anticancer drugs.  Glioblastoma cell lines express both ETA and ETB receptors and previous works have shown that ETB receptors are involved in the proliferation of different cancer cell types.  In this study we have investigated the effects of two structurally unrelated ETB receptor antagonists, BQ788 and A192621, on cell survival, proliferation and apoptosis in 1321-N1, U87 and IPDDCA2 glioma cell lines.  BQ788 and A192621 reduced glioma cells viability and proliferation assessed by BrdU incorporation and cell cycle anal. by flow cytometry, while in contrast the ETA receptor antagonist BQ123 had no effect on cell survival.  TUNEL assay and immunocytochem. expts. showed that BQ788 and A192621 trigger apoptotic processes mainly via activation of the intrinsic mitochondrial pathway involving caspase-9 activation, AIF release and cytochrome c translocation.  Furthermore, treatment with ETB antagonists downregulates ERK- and p38MAPK-dependent pathways but does not affect VEGF mRNA levels.  Our findings support the hypothesis that ETB antagonists represent a new promising therapeutic strategy for the treatment of high grade gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYIfmnQIogP7Vg90H21EOLACvtfcHk0liX2JwBiGaNOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1WjtL8%253D&md5=52116b8f4e6f2e4a08ac77123cad0ebf</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2009.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2009.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DPaolillo%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DM.%2BA.%26aulast%3DCurti%26aufirst%3DD.%26aulast%3DLanni%26aufirst%3DC.%26aulast%3DSchinelli%26aufirst%3DS.%26atitle%3DEndothelin%2520B%2520Receptor%2520Antagonists%2520Block%2520Proliferation%2520and%2520Induce%2520Apoptosis%2520in%2520Glioma%2520Cells%26jtitle%3DPharmacol.%2520Res.%26date%3D2010%26volume%3D61%26spage%3D306%26epage%3D315%26doi%3D10.1016%2Fj.phrs.2009.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Anguelova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuvon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaverot, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varlet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couraud, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daumas-Duport, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cazaubon, S.</span><span> </span><span class="NLM_article-title">Functional Endothelin ET B Receptors Are Selectively Expressed in Human Oligodendrogliomas</span> <span class="citation_source-journal">Mol. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">88</span><span class="refDoi">Â DOI: 10.1016/j.molbrainres.2005.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.molbrainres.2005.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15950764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFarsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2005&pages=77-88&author=E.+Anguelovaauthor=F.+Beuvonauthor=N.+Leonardauthor=N.+Chaverotauthor=P.+Varletauthor=P.+O.+Couraudauthor=C.+Daumas-Duportauthor=S.+Cazaubon&title=Functional+Endothelin+ET+B+Receptors+Are+Selectively+Expressed+in+Human+Oligodendrogliomas&doi=10.1016%2Fj.molbrainres.2005.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Functional endothelin ETB receptors are selectively expressed in human oligodendrogliomas</span></div><div class="casAuthors">Anguelova, E.; Beuvon, F.; Leonard, N.; Chaverot, N.; Varlet, P.; Couraud, P.-O.; Daumas-Duport, C.; Cazaubon, S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">77-88</span>CODEN:
                <span class="NLM_cas:coden">MBREE4</span>;
        ISSN:<span class="NLM_cas:issn">0169-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Endothelin-1 (ET-1), a vasoactive and mitogenic peptide mainly produced by vascular endothelial cells, may be involved in the progression of several human tumors.  Here, the authors present an immunohistochem. anal. of the expression pattern of ET-1 receptor subtypes (ETA-R and ETB-R) and a functional study of their potential role in human oligodendrogliomas and oligoastrocytomas.  By comparison, the authors assessed the corresponding expression patterns of glioblastomas.  Interestingly, a nuclear localization of ET-1 receptor subtypes (assocd. or not with a cytoplasmic labeling) was constantly obsd. in tumor cells from all 3 glioma types.  Moreover, the authors noted a distinct receptor distribution in the different gliomas: a nuclear expression of ETB-R by tumor cells was found to be restricted to oligodendrogliomas and oligoastrocytomas, while a nuclear expression of ETA-R was only detected in tumor cells from some glioblastomas.  Using primary cultures of oligodendroglial tumor cells, the authors confirmed the selective expression of nuclear ETB-R, together with a plasma membrane expression, and further demonstrated that this receptor was functionally coupled to intracellular signaling pathways known to be involved in cell survival and/or proliferation: extracellular signal-regulated kinase and focal adhesion kinase activation, actin cytoskeleton reorganization.  In addn., impairment of ETB-R activation in these cells by in vitro treatment with an ETB-R-specific antagonist induced cell death.  These data point to ET-1 as a possible survival factor for oligodendrogliomas via ETB-R activation and suggest that ETB-R-specific antagonists might constitute a potential therapeutic alternative for oligodendrogliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreg8FMxCm2ubVg90H21EOLACvtfcHk0lgZgbeUezCNhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFarsb0%253D&md5=e0556c4c0c6fa92488465cadc6fcad95</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.molbrainres.2005.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molbrainres.2005.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DAnguelova%26aufirst%3DE.%26aulast%3DBeuvon%26aufirst%3DF.%26aulast%3DLeonard%26aufirst%3DN.%26aulast%3DChaverot%26aufirst%3DN.%26aulast%3DVarlet%26aufirst%3DP.%26aulast%3DCouraud%26aufirst%3DP.%2BO.%26aulast%3DDaumas-Duport%26aufirst%3DC.%26aulast%3DCazaubon%26aufirst%3DS.%26atitle%3DFunctional%2520Endothelin%2520ET%2520B%2520Receptors%2520Are%2520Selectively%2520Expressed%2520in%2520Human%2520Oligodendrogliomas%26jtitle%3DMol.%2520Brain%2520Res.%26date%3D2005%26volume%3D137%26spage%3D77%26epage%3D88%26doi%3D10.1016%2Fj.molbrainres.2005.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Chen, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T. S.</span><span> </span><span class="NLM_article-title">The Endothelin-integrin Axis is Involved in Macrophage-induced Breast Cancer Cell Chemotactic Interactions with Endothelial Cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">10029</span><span class="NLM_x">â</span> <span class="NLM_lpage">10044</span><span class="refDoi">Â DOI: 10.1074/jbc.M113.528406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1074%2Fjbc.M113.528406" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=10029-10044&author=C.+C.+Chenauthor=L.+L.+Chenauthor=Y.+T.+Hsuauthor=K.+J.+Liuauthor=C.+S.+Fanauthor=T.+S.+Huang&title=The+Endothelin-integrin+Axis+is+Involved+in+Macrophage-induced+Breast+Cancer+Cell+Chemotactic+Interactions+with+Endothelial+Cells&doi=10.1074%2Fjbc.M113.528406"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.528406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.528406%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BC.%26aulast%3DChen%26aufirst%3DL.%2BL.%26aulast%3DHsu%26aufirst%3DY.%2BT.%26aulast%3DLiu%26aufirst%3DK.%2BJ.%26aulast%3DFan%26aufirst%3DC.%2BS.%26aulast%3DHuang%26aufirst%3DT.%2BS.%26atitle%3DThe%2520Endothelin-integrin%2520Axis%2520is%2520Involved%2520in%2520Macrophage-induced%2520Breast%2520Cancer%2520Cell%2520Chemotactic%2520Interactions%2520with%2520Endothelial%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D10029%26epage%3D10044%26doi%3D10.1074%2Fjbc.M113.528406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Moraitis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langdon, S. P.</span><span> </span><span class="NLM_article-title">Paracrine Regulation of Ovarian Cancer by Endothelin</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1381</span><span class="NLM_x">â</span> <span class="NLM_lpage">1387</span><span class="refDoi">Â DOI: 10.1016/S0959-8049(99)00131-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2FS0959-8049%2899%2900131-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1999&pages=1381-1387&author=S.+Moraitisauthor=W.+R.+Millerauthor=J.+F.+Smythauthor=S.+P.+Langdon&title=Paracrine+Regulation+of+Ovarian+Cancer+by+Endothelin&doi=10.1016%2FS0959-8049%2899%2900131-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2899%2900131-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252899%252900131-8%26sid%3Dliteratum%253Aachs%26aulast%3DMoraitis%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DW.%2BR.%26aulast%3DSmyth%26aufirst%3DJ.%2BF.%26aulast%3DLangdon%26aufirst%3DS.%2BP.%26atitle%3DParacrine%2520Regulation%2520of%2520Ovarian%2520Cancer%2520by%2520Endothelin%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1999%26volume%3D35%26spage%3D1381%26epage%3D1387%26doi%3D10.1016%2FS0959-8049%2899%2900131-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Haque, S. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heetun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiwen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farooqui, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramesh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogunbiyi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span> </span><span class="NLM_article-title">Efficacy of the Specific Endothelin A Receptor Antagonist Zibotentan (ZD4054) in Colorectal Cancer: A Preclinical Study</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1556</span><span class="NLM_x">â</span> <span class="NLM_lpage">1567</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-12-0975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1535-7163.MCT-12-0975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23723122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ChurjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1556-1567&author=S.+U.+Haqueauthor=M.+R.+Dashwoodauthor=M.+Heetunauthor=X.+Shiwenauthor=N.+Farooquiauthor=B.+Rameshauthor=H.+Welchauthor=F.+J.+Savageauthor=O.+Ogunbiyiauthor=D.+J.+Abrahamauthor=M.+Loizidou&title=Efficacy+of+the+Specific+Endothelin+A+Receptor+Antagonist+Zibotentan+%28ZD4054%29+in+Colorectal+Cancer%3A+A+Preclinical+Study&doi=10.1158%2F1535-7163.MCT-12-0975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of the Specific Endothelin A Receptor Antagonist Zibotentan (ZD4054) in Colorectal Cancer: A Preclinical Study</span></div><div class="casAuthors">Haque, Samer-ul; Dashwood, Michael R.; Heetun, Mohammed; Shiwen, Xu; Farooqui, Noreen; Ramesh, Bala; Welch, Hazel; Savage, Felicity J.; Ogunbiyi, Olagunju; Abraham, David J.; Loizidou, Marilena</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1556-1567</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Endothelin 1 (ET-1) is overexpressed in cancer, contributing to disease progression.  We previously showed that ET-1 stimulated proliferative, migratory, and contractile tumorigenic effects via the ETA receptor.  Here, for the first time, we evaluate zibotentan, a specific ETA receptor antagonist, in the setting of colorectal cancer, in cellular models.  Pharmacol. characteristics were further detd. in patient tissues.  Colorectal cancer lines (n = 4) and fibroblast strains (n = 6), isolated from uninvolved areas of colorectal cancer specimens, were exposed to ET-1 and/or ETA/B receptor antagonists.  Proliferation (methylene blue), migration (scratch wounds), and contraction (gel lattices) were assessed.  Receptor distribution and binding characteristics (Kd, Bmax) were detd. using autoradiog. on tissue sections and homogenates and cytospun cells, supported by immunohistochem.  Proliferation was inhibited by ETA (zibotentan > BQ123; P < 0.05), migration by ETB > ETA, and contraction by combined ETA and ETB antagonism.  Intense ET-1 stromal binding correlated with fibroblasts and endothelial cells.  Colorectal cancer lines and fibroblasts revealed high d. and affinity ET-1 binding (Bmax = 2.435 fmol/1 Ã 106 cells, Kd = 367.7 pmol/L; Bmax = 3.03 fmol/1 Ã 106 cells, Kd = 213.6 pmol/L).  In cancer tissues, ETA receptor antagonists (zibotentan; BQ123) reduced ET-1 binding more effectively (IC50: 0.1-10 Î¼mol/L) than ETB receptor antagonist BQ788 (â¼IC50, 1 mmol/L).  ET-1 stimulated cancer-contributory processes.  Its localization to tumor stroma, with greatest binding/affinity to fibroblasts, implicates these cells in tumor progression.  ETA receptor upregulation in cancer tissues and its role in tumorigenic processes show the receptor's importance in therapeutic targeting.  Zibotentan, the most specific ETA receptor antagonist available, showed the greatest inhibition of ET-1 binding.  With its known safety profile, we provide evidence for zibotentan's potential role as adjuvant therapy in colorectal cancer.  Mol Cancer Ther; 12(8); 1556-67. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfY8AQYsQIWLVg90H21EOLACvtfcHk0lgZgbeUezCNhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ChurjO&md5=ffa3075c122338c86fd1c93214cba9aa</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0975%26sid%3Dliteratum%253Aachs%26aulast%3DHaque%26aufirst%3DS.%2BU.%26aulast%3DDashwood%26aufirst%3DM.%2BR.%26aulast%3DHeetun%26aufirst%3DM.%26aulast%3DShiwen%26aufirst%3DX.%26aulast%3DFarooqui%26aufirst%3DN.%26aulast%3DRamesh%26aufirst%3DB.%26aulast%3DWelch%26aufirst%3DH.%26aulast%3DSavage%26aufirst%3DF.%2BJ.%26aulast%3DOgunbiyi%26aufirst%3DO.%26aulast%3DAbraham%26aufirst%3DD.%2BJ.%26aulast%3DLoizidou%26aufirst%3DM.%26atitle%3DEfficacy%2520of%2520the%2520Specific%2520Endothelin%2520A%2520Receptor%2520Antagonist%2520Zibotentan%2520%2528ZD4054%2529%2520in%2520Colorectal%2520Cancer%253A%2520A%2520Preclinical%2520Study%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1556%26epage%3D1567%26doi%3D10.1158%2F1535-7163.MCT-12-0975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Hoosein, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dashwood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loizidou, M.</span><span> </span><span class="NLM_article-title">Altered Endothelin Receptor Subtypes in Colorectal Cancer</span> <span class="citation_source-journal">Eur. J. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">â</span> <span class="NLM_lpage">782</span><span class="refDoi">Â DOI: 10.1097/MEG.0b013e3282c563de</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2FMEG.0b013e3282c563de" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=17700263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGmu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=775-782&author=M.+M.+Hooseinauthor=M.+R.+Dashwoodauthor=K.+Dawasauthor=H.+M.+Aliauthor=K.+Grantauthor=F.+Savageauthor=I.+Taylorauthor=M.+Loizidou&title=Altered+Endothelin+Receptor+Subtypes+in+Colorectal+Cancer&doi=10.1097%2FMEG.0b013e3282c563de"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Altered endothelin receptor subtypes in colorectal cancer</span></div><div class="casAuthors">Hoosein, Moinuddin M.; Dashwood, Michael R.; Dawas, Khaled; Ali, Haythem; Grant, Katherine; Savage, Felicity; Taylor, Irving; Loizidou, Marilena</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">775-782</span>CODEN:
                <span class="NLM_cas:coden">EJGHES</span>;
        ISSN:<span class="NLM_cas:issn">0954-691X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: The vasoactive peptide endothelin-1 (ET-1) acts via two endothelin receptor subtypes, ETA (ETAR) and ETB (ETBR).  ET-1 and ETAR are overexpressed in colorectal cancer tissues.  In vitro, ET-1 acting via ETAR, is a mitogen for colorectal cancer cells.  To identify other potential stimulatory loops, we investigated the distribution and cell-specific localization of both ETAR and ETBR in tissue sections from patients with colorectal cancer.  Methods: Frozen sections from specimens of colorectal cancer (n = 9) and normal colon (n = 9) were cut and subjected to either (i) autoradiog. or (ii) a combination of cell type-specific immunohistochem., using antibodies against fibroblasts (AS02), endothelial cells (CD31) or nerve fibers (NF200) and in-vitro receptor microautoradiog., using ETAR-specific and ETBR-specific radioligands.  Results: ETARs were upregulated in all cell types, apart from nerve, in cancer compared with normal colon (1 : 1.59 normal to cancer).  Specifically, ETAR binding was highest in cancer-assocd. blood vessels and fibroblasts and to a lesser extent in epithelial cancer cells.  In contrast, ETBRs were the predominant receptors in normal colon (1 : 0.59 normal to cancer) and were markedly down-regulated in cancer-assocd. blood vessels, fibroblasts and to a lesser extent in epithelial cells.  Nerve colocalization was demonstrated, but remained unchanged for all tissues.  Conclusion: The shift in ET receptor binding obsd. in epithelial cancer cells and cancer-assocd. fibroblasts and endothelial cells may favor ET-1 signals contributing to colorectal cancer growth and neovascularization via ETAR.  This may provide the basis for therapeutic use of specific ETAR antagonists as adjuvant treatment of colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1mTMXFLBxK7Vg90H21EOLACvtfcHk0lj4KIuFkjDLgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGmu78%253D&md5=24d35f467c529eb52720a3e577f5e2ca</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1097%2FMEG.0b013e3282c563de&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMEG.0b013e3282c563de%26sid%3Dliteratum%253Aachs%26aulast%3DHoosein%26aufirst%3DM.%2BM.%26aulast%3DDashwood%26aufirst%3DM.%2BR.%26aulast%3DDawas%26aufirst%3DK.%26aulast%3DAli%26aufirst%3DH.%2BM.%26aulast%3DGrant%26aufirst%3DK.%26aulast%3DSavage%26aufirst%3DF.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLoizidou%26aufirst%3DM.%26atitle%3DAltered%2520Endothelin%2520Receptor%2520Subtypes%2520in%2520Colorectal%2520Cancer%26jtitle%3DEur.%2520J.%2520Gastroenterol.%2520Hepatol.%26date%3D2007%26volume%3D19%26spage%3D775%26epage%3D782%26doi%3D10.1097%2FMEG.0b013e3282c563de" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Harland, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuc, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickard, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title">Expression of Endothelin A Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707</span> <span class="citation_source-journal">Neurosurgery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">890</span><span class="NLM_x">â</span> <span class="NLM_lpage">898</span><span class="refDoi">Â DOI: 10.1097/00006123-199810000-00097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1097%2F00006123-199810000-00097" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1998&pages=890-898&author=S.+P.+Harlandauthor=R.+E.+Kucauthor=J.+D.+Pickardauthor=A.+P.+Davenport&title=Expression+of+Endothelin+A+Receptors+in+Human+Gliomas+and+Meningiomas%2C+with+High+Affinity+for+the+Selective+Antagonist+PD156707&doi=10.1097%2F00006123-199810000-00097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1097%2F00006123-199810000-00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00006123-199810000-00097%26sid%3Dliteratum%253Aachs%26aulast%3DHarland%26aufirst%3DS.%2BP.%26aulast%3DKuc%26aufirst%3DR.%2BE.%26aulast%3DPickard%26aufirst%3DJ.%2BD.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DExpression%2520of%2520Endothelin%2520A%2520Receptors%2520in%2520Human%2520Gliomas%2520and%2520Meningiomas%252C%2520with%2520High%2520Affinity%2520for%2520the%2520Selective%2520Antagonist%2520PD156707%26jtitle%3DNeurosurgery%26date%3D1998%26volume%3D43%26spage%3D890%26epage%3D898%26doi%3D10.1097%2F00006123-199810000-00097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Hartz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fricker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. S.</span><span> </span><span class="NLM_article-title">Rapid Regulation of P-glycoprotein at the Blood-Brain Barrier by Endothelin-1</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">â</span> <span class="NLM_lpage">394</span><span class="refDoi">Â DOI: 10.1124/mol.104.001503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1124%2Fmol.104.001503" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2004&pages=387-394&author=A.+M.+Hartzauthor=B.+Bauerauthor=G.+Frickerauthor=D.+S.+Miller&title=Rapid+Regulation+of+P-glycoprotein+at+the+Blood-Brain+Barrier+by+Endothelin-1&doi=10.1124%2Fmol.104.001503"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1124%2Fmol.104.001503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.104.001503%26sid%3Dliteratum%253Aachs%26aulast%3DHartz%26aufirst%3DA.%2BM.%26aulast%3DBauer%26aufirst%3DB.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DD.%2BS.%26atitle%3DRapid%2520Regulation%2520of%2520P-glycoprotein%2520at%2520the%2520Blood-Brain%2520Barrier%2520by%2520Endothelin-1%26jtitle%3DMol.%2520Pharmacol.%26date%3D2004%26volume%3D66%26spage%3D387%26epage%3D394%26doi%3D10.1124%2Fmol.104.001503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Binder, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pukrop, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimshaw, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrenreich, H.</span><span> </span><span class="NLM_article-title">Stromal Endothelin B Receptor-deficiency Inhibits Breast Cancer Growth and Metastasis</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2452</span><span class="NLM_x">â</span> <span class="NLM_lpage">2460</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-09-0032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1535-7163.MCT-09-0032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=19671740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCms7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2452-2460&author=C.+Binderauthor=T.+Hagemannauthor=S.+Sperlingauthor=M.+Schulzauthor=T.+Pukropauthor=M.+J.+Grimshawauthor=H.+Ehrenreich&title=Stromal+Endothelin+B+Receptor-deficiency+Inhibits+Breast+Cancer+Growth+and+Metastasis&doi=10.1158%2F1535-7163.MCT-09-0032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis</span></div><div class="casAuthors">Binder, Claudia; Hagemann, Thorsten; Sperling, Swetlana; Schulz, Matthias; Pukrop, Tobias; Grimshaw, Matthew J.; Ehrenreich, Hannelore</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2452-2460</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The endothelin (ET) axis, often deregulated in cancers, is a promising target for anticancer strategies.  Whereas previous investigations have focused mostly on ET action in malignant cells, we chose a model allowing sep. assessment of the effects of ETs and their receptors ETAR and ETBR in the tumor cells and the stromal compartment, which is increasingly recognized as a key player in cancer progression.  In homozygous spotting lethal rats (sl/sl), a model of constitutive ETBR deficiency, we showed significant redn. of growth and metastasis of MAT B III rat mammary adenocarcinoma cells overexpressing ETAR and ET-1 but neg. for ETBR.  Lack of stromal ETBR expression did not influence angiogenesis.  However, it was correlated with diminished infiltration by tumor-assocd. macrophages and with reduced prodn. of tumor necrosis factor-Î±, both known as powerful promoters of tumor progression.  These effects were almost completely abolished in transgenic sl/sl rats, wherein ETBR function is restored by expression of an intact ETBR transgene.  This shows that tumor growth and metastasis are critically dependent on ETBR function in cells of the microenvironment and suggests that successful ETR antagonist therapy should also target the stromal component of ET signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlWtc62CcX5bVg90H21EOLACvtfcHk0lj4KIuFkjDLgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCms7c%253D&md5=27e49405f97a0faaa4497abdfb1542f7</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0032%26sid%3Dliteratum%253Aachs%26aulast%3DBinder%26aufirst%3DC.%26aulast%3DHagemann%26aufirst%3DT.%26aulast%3DSperling%26aufirst%3DS.%26aulast%3DSchulz%26aufirst%3DM.%26aulast%3DPukrop%26aufirst%3DT.%26aulast%3DGrimshaw%26aufirst%3DM.%2BJ.%26aulast%3DEhrenreich%26aufirst%3DH.%26atitle%3DStromal%2520Endothelin%2520B%2520Receptor-deficiency%2520Inhibits%2520Breast%2520Cancer%2520Growth%2520and%2520Metastasis%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2452%26epage%3D2460%26doi%3D10.1158%2F1535-7163.MCT-09-0032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurosumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, Y.</span><span> </span><span class="NLM_article-title">High-incidence Spontaneous Tumors in JF1/Ms Mice: Relevance of Hypomorphic Germline Mutation and Subsequent Promoter Methylation of <i>Ednrb</i></span> <span class="citation_source-journal">J. Cancer Res. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">â</span> <span class="NLM_lpage">107</span><span class="refDoi">Â DOI: 10.1007/s00432-013-1546-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00432-013-1546-6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2014&pages=99-107&author=J.+Watanabeauthor=Y.+Kanekoauthor=M.+Kurosumiauthor=Y.+Kobayashiauthor=M.+Sakamotoauthor=M.+A.+Yoshidaauthor=M.+Akiyamaauthor=Y.+Matsushima&title=High-incidence+Spontaneous+Tumors+in+JF1%2FMs+Mice%3A+Relevance+of+Hypomorphic+Germline+Mutation+and+Subsequent+Promoter+Methylation+of+Ednrb&doi=10.1007%2Fs00432-013-1546-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1007%2Fs00432-013-1546-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-013-1546-6%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DKaneko%26aufirst%3DY.%26aulast%3DKurosumi%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DSakamoto%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DM.%2BA.%26aulast%3DAkiyama%26aufirst%3DM.%26aulast%3DMatsushima%26aufirst%3DY.%26atitle%3DHigh-incidence%2520Spontaneous%2520Tumors%2520in%2520JF1%252FMs%2520Mice%253A%2520Relevance%2520of%2520Hypomorphic%2520Germline%2520Mutation%2520and%2520Subsequent%2520Promoter%2520Methylation%2520of%2520Ednrb%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D140%26spage%3D99%26epage%3D107%26doi%3D10.1007%2Fs00432-013-1546-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">De Freitas Cordeiro-Silva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agostini, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de PodestÃ¡, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Oliveira, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soares, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MendonÃ§a, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouvea, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Zeidler, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louro, D.</span><span> </span><span class="NLM_article-title">Promoter Hypermethylation in Primary Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: A Study of a Brazilian Cohort, I</span> <span class="citation_source-journal">Mol. Biol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">10111</span><span class="NLM_x">â</span> <span class="NLM_lpage">10119</span><span class="refDoi">Â DOI: 10.1007/s11033-012-1885-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs11033-012-1885-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22936053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC38bivVyktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=10111-10119&author=M.+De+Freitas+Cordeiro-Silvaauthor=E.+Sturauthor=L.+P.+Agostiniauthor=J.+R.+de+Podest%C3%A1author=J.+C.+de+Oliveiraauthor=M.+S.+Soaresauthor=E.+F.+Mendon%C3%A7aauthor=S.+A.+Gouveaauthor=S.+V.+Von+Zeidlerauthor=D.+Louro&title=Promoter+Hypermethylation+in+Primary+Squamous+Cell+Carcinoma+of+the+Oral+Cavity+and+Oropharynx%3A+A+Study+of+a+Brazilian+Cohort%2C+I&doi=10.1007%2Fs11033-012-1885-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Promoter hypermethylation in primary squamous cell carcinoma of the oral cavity and oropharynx: a study of a Brazilian cohort</span></div><div class="casAuthors">de Freitas Cordeiro-Silva Melissa; Stur Elaine; Agostini Lidiane Pignaton; de Podesta Jose Roberto Vasconcelos; de Oliveira Jose Carlos; Soares Mariana Silveira; Mendonca Elismauro Francisco; Gouvea Sonia Alves; Von Zeidler Sandra Ventorin; Louro Iuri Drumond</div><div class="citationInfo"><span class="NLM_cas:title">Molecular biology reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">10111-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epigenetic silencing of cancer-related genes plays an important role in oral/oropharyngeal squamous cell carcinoma (OSCC).  We evaluated promoter hypermethylation of 4 cancer-related genes in OSCCs of a Brazilian cohort and determined its relationship with exposure to alcohol, tobacco, HPV infection and clinicopathological parameters.  CDKN2A (cyclin-dependent kinase inhibitor 2A or p16), SFN (stratifin or 14-3-3 Ï), EDNRB (endothelin receptor B) and RUNX3 (runt-related transcript factor-3) had their methylation patterns evaluated by MSP analysis in OSCC tumors (n = 45).  HPV detection was carried out by PCR/RFLP.  Aberrant methylation was detected in 44/45 (97.8 %) OSCC; 24.4 % at CDKN2A, 77.8 % at EDNRB, 17.8 % at RUNX3 and 97.8 % at SFN gene.  There was no significant association between methylation patterns and clinical parameters.  HPV (subtype 16) was detected in 3 out of 45 patients (6 %).  Our findings indicate that HPV infection is uncommon and methylation is frequent in Brazilian OSCCs, however, EDNRB and SFN gene methylation are not suitable OSCC biomarkers due to indistinct methylation in tumoral and normal samples.  In contrast, CDKN2A and RUNX3 genes could be considered differentially methylated genes and potential tumor markers in OSCCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMYgBxJM9PvSsZ1x6zOs0vfW6udTcc2ebtEgtLWszX6rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bivVyktQ%253D%253D&md5=aad70a9a56ba3d5d137da0c8ebe6962a</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1007%2Fs11033-012-1885-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11033-012-1885-4%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFreitas%2BCordeiro-Silva%26aufirst%3DM.%26aulast%3DStur%26aufirst%3DE.%26aulast%3DAgostini%26aufirst%3DL.%2BP.%26aulast%3Dde%2BPodest%25C3%25A1%26aufirst%3DJ.%2BR.%26aulast%3Dde%2BOliveira%26aufirst%3DJ.%2BC.%26aulast%3DSoares%26aufirst%3DM.%2BS.%26aulast%3DMendon%25C3%25A7a%26aufirst%3DE.%2BF.%26aulast%3DGouvea%26aufirst%3DS.%2BA.%26aulast%3DVon%2BZeidler%26aufirst%3DS.%2BV.%26aulast%3DLouro%26aufirst%3DD.%26atitle%3DPromoter%2520Hypermethylation%2520in%2520Primary%2520Squamous%2520Cell%2520Carcinoma%2520of%2520the%2520Oral%2520Cavity%2520and%2520Oropharynx%253A%2520A%2520Study%2520of%2520a%2520Brazilian%2520Cohort%252C%2520I%26jtitle%3DMol.%2520Biol.%2520Rep.%26date%3D2012%26volume%3D39%26spage%3D10111%26epage%3D10119%26doi%3D10.1007%2Fs11033-012-1885-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Jimeno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carducci, M.</span><span> </span><span class="NLM_article-title">Atrasentan: a Novel and Rationally Designed Therapeutic Alternative in the Management of Cancer</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">â</span> <span class="NLM_lpage">427</span><span class="refDoi">Â DOI: 10.1586/14737140.5.3.419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1586%2F14737140.5.3.419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=16001950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtF2it7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=419-427&author=A.+Jimenoauthor=M.+Carducci&title=Atrasentan%3A+a+Novel+and+Rationally+Designed+Therapeutic+Alternative+in+the+Management+of+Cancer&doi=10.1586%2F14737140.5.3.419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Atrasentan: A novel and rationally designed therapeutic alternative in the management of cancer</span></div><div class="casAuthors">Jimeno, Antonio; Carducci, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">419-427</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli.  Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/or reverse several of those events.  Biol. and clin. activity in patients with prostate cancer has been demonstrated in a Phase III, placebo-controlled setting by the suppression of markers of biochem. prostate cancer progression and a delay in time to disease progression.  Atrasentan represents a new therapeutic option in the management of prostate cancer, esp. in those patients with bone metastases.  However, its precise role in other diseases such as ovrian cancer is yet to be defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH4xDWXjpNn7Vg90H21EOLACvtfcHk0ljPKgl-dHsmZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtF2it7g%253D&md5=794db9428a3d0cfc4023414e594838c8</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1586%2F14737140.5.3.419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.5.3.419%26sid%3Dliteratum%253Aachs%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DCarducci%26aufirst%3DM.%26atitle%3DAtrasentan%253A%2520a%2520Novel%2520and%2520Rationally%2520Designed%2520Therapeutic%2520Alternative%2520in%2520the%2520Management%2520of%2520Cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2005%26volume%3D5%26spage%3D419%26epage%3D427%26doi%3D10.1586%2F14737140.5.3.419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Nelson, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fizazi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moul, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akaza, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleave, M.</span><span> </span><span class="NLM_article-title">Phase 3, Randomized, Placebo-controlled Study of zibotentan (ZD4054) in Patients with Castration-resistant Prostate Cancer Metastatic to Bone</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">5709</span><span class="NLM_x">â</span> <span class="NLM_lpage">5718</span><span class="refDoi">Â DOI: 10.1002/cncr.27674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fcncr.27674" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=5709-5718&author=J.+B.+Nelsonauthor=K.+Fizaziauthor=K.+Millerauthor=C.+Higanoauthor=J.+W.+Moulauthor=H.+Akazaauthor=T.+Morrisauthor=S.+McIntoshauthor=K.+Pembertonauthor=M.+Gleave&title=Phase+3%2C+Randomized%2C+Placebo-controlled+Study+of+zibotentan+%28ZD4054%29+in+Patients+with+Castration-resistant+Prostate+Cancer+Metastatic+to+Bone&doi=10.1002%2Fcncr.27674"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fcncr.27674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.27674%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DJ.%2BB.%26aulast%3DFizazi%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DHigano%26aufirst%3DC.%26aulast%3DMoul%26aufirst%3DJ.%2BW.%26aulast%3DAkaza%26aufirst%3DH.%26aulast%3DMorris%26aufirst%3DT.%26aulast%3DMcIntosh%26aufirst%3DS.%26aulast%3DPemberton%26aufirst%3DK.%26aulast%3DGleave%26aufirst%3DM.%26atitle%3DPhase%25203%252C%2520Randomized%252C%2520Placebo-controlled%2520Study%2520of%2520zibotentan%2520%2528ZD4054%2529%2520in%2520Patients%2520with%2520Castration-resistant%2520Prostate%2520Cancer%2520Metastatic%2520to%2520Bone%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26spage%3D5709%26epage%3D5718%26doi%3D10.1002%2Fcncr.27674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Kohan, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleland, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theodorescu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, M.</span><span> </span><span class="NLM_article-title">Clinical Trials with Endothelin Receptor Antagonists: What Went Wrong and Where Can We Improve?</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">528</span><span class="NLM_x">â</span> <span class="NLM_lpage">539</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2012.07.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.lfs.2012.07.034" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=528-539&author=D.+E.+Kohanauthor=J.+G.+Clelandauthor=L.+J.+Rubinauthor=D.+Theodorescuauthor=M.+Barton&title=Clinical+Trials+with+Endothelin+Receptor+Antagonists%3A+What+Went+Wrong+and+Where+Can+We+Improve%3F&doi=10.1016%2Fj.lfs.2012.07.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.07.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.07.034%26sid%3Dliteratum%253Aachs%26aulast%3DKohan%26aufirst%3DD.%2BE.%26aulast%3DCleland%26aufirst%3DJ.%2BG.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DTheodorescu%26aufirst%3DD.%26aulast%3DBarton%26aufirst%3DM.%26atitle%3DClinical%2520Trials%2520with%2520Endothelin%2520Receptor%2520Antagonists%253A%2520What%2520Went%2520Wrong%2520and%2520Where%2520Can%2520We%2520Improve%253F%26jtitle%3DLife%2520Sci.%26date%3D2012%26volume%3D91%26spage%3D528%26epage%3D539%26doi%3D10.1016%2Fj.lfs.2012.07.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Lalich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeel, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists in Cancer Therapy</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">785</span><span class="NLM_x">â</span> <span class="NLM_lpage">794</span><span class="refDoi">Â DOI: 10.1080/07357900701522588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1080%2F07357900701522588" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=785-794&author=M.+Lalichauthor=D.+G.+McNeelauthor=G.+Wildingauthor=G.+Liu&title=Endothelin+Receptor+Antagonists+in+Cancer+Therapy&doi=10.1080%2F07357900701522588"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1080%2F07357900701522588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07357900701522588%26sid%3Dliteratum%253Aachs%26aulast%3DLalich%26aufirst%3DM.%26aulast%3DMcNeel%26aufirst%3DD.%2BG.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DG.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%2520in%2520Cancer%2520Therapy%26jtitle%3DCancer%2520Invest.%26date%3D2007%26volume%3D25%26spage%3D785%26epage%3D794%26doi%3D10.1080%2F07357900701522588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Armstrong, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turnbull, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yenser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gockerman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleep, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurwitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, D. J.</span><span> </span><span class="NLM_article-title">A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-resistant Metastatic Prostate Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6270</span><span class="NLM_x">â</span> <span class="NLM_lpage">6276</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-08-1085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1158%2F1078-0432.CCR-08-1085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=18829508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2nurnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=6270-6276&author=A.+J.+Armstrongauthor=P.+Creelauthor=J.+Turnbullauthor=C.+Mooreauthor=T.+A.+Jaffeauthor=S.+Haleyauthor=W.+Petrosauthor=S.+Yenserauthor=J.+P.+Gockermanauthor=D.+Sleepauthor=H.+Hurwitzauthor=D.+J.+George&title=A+Phase+I-II+Study+of+Docetaxel+and+Atrasentan+in+Men+with+Castration-resistant+Metastatic+Prostate+Cancer&doi=10.1158%2F1078-0432.CCR-08-1085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer</span></div><div class="casAuthors">Armstrong, Andrew J.; Creel, Patricia; Turnbull, James; Moore, Cassandra; Jaffe, Tracy A.; Haley, Sherri; Petros, William; Yenser, Sarah; Gockerman, Jon P.; Sleep, Darryl; Hurwitz, Herbert; George, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6270-6276</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The primary aims of this phase I-II study were to det. the max. tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary efficacy of the combination of docetaxel and the endothelin A receptor antagonist atrasentan as first-line treatment for men with metastatic castration-resistant prostate cancer.  Patients were treated with docetaxel at doses ranging from 60 to 75 mg/m2 every 21 days, with daily oral atrasentan 10 mg starting on day 3.  Patients were treated until evidence of disease progression or unacceptable toxicity.  Thirty-one patients were enrolled over three docetaxel dose levels (8 at 60 mg/m2, 19 at 70 mg/m2, and 4 at 75 mg/m2) including dose expansion at 70 mg/m2.  The max. tolerated dose of docetaxel was 70 to 75 mg/m2.  Drug-related grade 3-4 toxicities included neutropenia (50-63%) and febrile neutropenia (16-25%); other grade 1-2 toxicities included fatigue, peripheral edema, diarrhea, headache, rhinitis, anorexia, and nausea.  Confirmed prostate-specific antigen (PSA) responses were obsd. in 23% [95% confidence interval (95% CI), 10-41%]; the rate of >30% declines in PSA was 35% (95% CI, 19-55%).  Median overall survival was 17.6 mo (95% CI, 13.0-23.2) and median progression-free survival was 4.2 mo (95% CI, 2.3-5.8).  Significant declines in bone alk. phosphatase and serum N-telopeptides were obsd. with therapy.  The max. tolerated dose of every-3-wk docetaxel with 10 mg atrasentan is 70 to 75 mg/m2.  Overall survival and progression-free survival are comparable to that seen with docetaxel and prednisone, whereas the rates of PSA decline are slightly lower than expected.  A phase III study of this combination with prednisone has been initiated and is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov_UkRZorX97Vg90H21EOLACvtfcHk0lgkQg1m1tQRHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2nurnN&md5=cee90dcf963940bb53328daa6454a659</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1085%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DA.%2BJ.%26aulast%3DCreel%26aufirst%3DP.%26aulast%3DTurnbull%26aufirst%3DJ.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DJaffe%26aufirst%3DT.%2BA.%26aulast%3DHaley%26aufirst%3DS.%26aulast%3DPetros%26aufirst%3DW.%26aulast%3DYenser%26aufirst%3DS.%26aulast%3DGockerman%26aufirst%3DJ.%2BP.%26aulast%3DSleep%26aufirst%3DD.%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DGeorge%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Phase%2520I-II%2520Study%2520of%2520Docetaxel%2520and%2520Atrasentan%2520in%2520Men%2520with%2520Castration-resistant%2520Metastatic%2520Prostate%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D6270%26epage%3D6276%26doi%3D10.1158%2F1078-0432.CCR-08-1085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Pinto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamora, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redondo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinosa, E.</span><span> </span><span class="NLM_article-title">Targeting the Endothelin Axis in Prostate Carcinoma</span> <span class="citation_source-journal">Tumor Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">â</span> <span class="NLM_lpage">426</span><span class="refDoi">Â DOI: 10.1007/s13277-011-0299-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs13277-011-0299-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22203496" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=421-426&author=A.+Pintoauthor=M.+Merinoauthor=P.+Zamoraauthor=A.+Redondoauthor=B.+Casteloauthor=E.+Espinosa&title=Targeting+the+Endothelin+Axis+in+Prostate+Carcinoma&doi=10.1007%2Fs13277-011-0299-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1007%2Fs13277-011-0299-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-011-0299-6%26sid%3Dliteratum%253Aachs%26aulast%3DPinto%26aufirst%3DA.%26aulast%3DMerino%26aufirst%3DM.%26aulast%3DZamora%26aufirst%3DP.%26aulast%3DRedondo%26aufirst%3DA.%26aulast%3DCastelo%26aufirst%3DB.%26aulast%3DEspinosa%26aufirst%3DE.%26atitle%3DTargeting%2520the%2520Endothelin%2520Axis%2520in%2520Prostate%2520Carcinoma%26jtitle%3DTumor%2520Biol.%26date%3D2012%26volume%3D33%26spage%3D421%26epage%3D426%26doi%3D10.1007%2Fs13277-011-0299-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Witteveen, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Mijn, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kronemeijer, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groenewegen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span> </span><span class="NLM_article-title">Phase 1/2 Study of Atrasentan Combined with Peggylated Liposomal Doxorubicin in Platinum-resistant Recurrent Ovarian Cancer</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">â</span> <span class="NLM_lpage">945</span><span class="refDoi">Â DOI: 10.1593/neo.10582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1593%2Fneo.10582" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=941-945&author=P.+O.+Witteveenauthor=K.+J.+van+der+Mijnauthor=M.+Losauthor=R.+H.+Kronemeijerauthor=G.+Groenewegenauthor=E.+E.+Voest&title=Phase+1%2F2+Study+of+Atrasentan+Combined+with+Peggylated+Liposomal+Doxorubicin+in+Platinum-resistant+Recurrent+Ovarian+Cancer&doi=10.1593%2Fneo.10582"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1593%2Fneo.10582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.10582%26sid%3Dliteratum%253Aachs%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3Dvan%2Bder%2BMijn%26aufirst%3DK.%2BJ.%26aulast%3DLos%26aufirst%3DM.%26aulast%3DKronemeijer%26aufirst%3DR.%2BH.%26aulast%3DGroenewegen%26aufirst%3DG.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26atitle%3DPhase%25201%252F2%2520Study%2520of%2520Atrasentan%2520Combined%2520with%2520Peggylated%2520Liposomal%2520Doxorubicin%2520in%2520Platinum-resistant%2520Recurrent%2520Ovarian%2520Cancer%26jtitle%3DNeoplasia%26date%3D2010%26volume%3D12%26spage%3D941%26epage%3D945%26doi%3D10.1593%2Fneo.10582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Fizazi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higano, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleave, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pemberton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moul, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moul, J. W.</span><span> </span><span class="NLM_article-title">Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination with Zibotentan in Patients with Metastatic Castration-resistant Prostate Cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1740</span><span class="NLM_x">â</span> <span class="NLM_lpage">1747</span><span class="refDoi">Â DOI: 10.1200/JCO.2012.46.4149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1200%2FJCO.2012.46.4149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23569308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOrt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1740-1747&author=K.+Fizaziauthor=J.+B.+Higanoauthor=J.+B.+Nelsonauthor=M.+Gleaveauthor=K.+Millerauthor=T.+Morrisauthor=F.+E.+Nathanauthor=S.+McIntoshauthor=K.+Pembertonauthor=J.+W.+Moulauthor=J.+W.+Moul&title=Phase+III%2C+Randomized%2C+Placebo-Controlled+Study+of+Docetaxel+in+Combination+with+Zibotentan+in+Patients+with+Metastatic+Castration-resistant+Prostate+Cancer&doi=10.1200%2FJCO.2012.46.4149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer</span></div><div class="casAuthors">Fizazi, Karim; Higano, Celestia S.; Nelson, Joel B.; Gleave, Martin; Miller, Kurt; Morris, Thomas; Nathan, Faith E.; McIntosh, Stuart; Pemberton, Kristine; Moul, Judd W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1740-1747</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">As part of the ENTHUSE (Endothelin A Use) program, the efficacy and safety of zibotentan (ZD4054), an oral specific endothelin A receptor antagonist, has been investigated in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (CRPC).  In this randomized, double-blind, placebo-controlled, phase III study, patients received i.v. docetaxel 75 mg/m2 on day 1 of 21-day cycles plus oral zibotentan 10 mg or placebo once daily.  The primary end point was overall survival (OS).  Secondary end points included time to pain and prostate-specific antigen (PSA) progression, pain and PSA response, progression-free survival, health-related quality of life, and safety.  A total of 1,052 patients received study treatment (docetaxel-zibotentan, n = 524; docetaxel-placebo, n = 528).  At the time of data cutoff, there had been 277 and 280 deaths, resp.  There was no difference in OS for patients receiving docetaxel-zibotentan compared with those receiving docetaxel-placebo (hazard ratio, 1.00; 95% CI, 0.84 to 1.18; P = .963).  No significant differences were obsd. on secondary end points, including time to pain progression (median 9.3 v 10.0 mo, resp.) or pain response (odds ratio, 0.84; 95% CI, 0.61 to 1.16; P = .283).  The median time to death was 20.0 and 19.2 mo for the zibotentan and placebo groups, resp.  The most commonly reported adverse events in zibotentan-treated patients were peripheral edema (52.7%), diarrhea (35.4%), alopecia (33.9%), and nausea (33.3%).  Docetaxel plus zibotentan 10 mg/d did not result in a significant improvement in OS compared with docetaxel plus placebo in patients with metastatic CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-X6MNO3V11LVg90H21EOLACvtfcHk0lhoNHfNltXS0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOrt7o%253D&md5=a6ae86c349ec6829636a0d9b2aefbb36</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.46.4149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.46.4149%26sid%3Dliteratum%253Aachs%26aulast%3DFizazi%26aufirst%3DK.%26aulast%3DHigano%26aufirst%3DJ.%2BB.%26aulast%3DNelson%26aufirst%3DJ.%2BB.%26aulast%3DGleave%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DMorris%26aufirst%3DT.%26aulast%3DNathan%26aufirst%3DF.%2BE.%26aulast%3DMcIntosh%26aufirst%3DS.%26aulast%3DPemberton%26aufirst%3DK.%26aulast%3DMoul%26aufirst%3DJ.%2BW.%26aulast%3DMoul%26aufirst%3DJ.%2BW.%26atitle%3DPhase%2520III%252C%2520Randomized%252C%2520Placebo-Controlled%2520Study%2520of%2520Docetaxel%2520in%2520Combination%2520with%2520Zibotentan%2520in%2520Patients%2520with%2520Metastatic%2520Castration-resistant%2520Prostate%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1740%26epage%3D1747%26doi%3D10.1200%2FJCO.2012.46.4149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Phuphanich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesser, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikkelsen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desideri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, J. D.</span><span> </span><span class="NLM_article-title">New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium Phase I Safety Study of Escalating Doses of Atrasentan in Adults with Recurrent Malignant Glioma</span> <span class="citation_source-journal">Neuro-Oncology.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">â</span> <span class="NLM_lpage">623</span><span class="refDoi">Â DOI: 10.1215/15228517-2008-013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1215%2F15228517-2008-013" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=617-623&author=S.+Phuphanichauthor=K.+A.+Carsonauthor=S.+A.+Grossmanauthor=G.+Lesserauthor=J.+Olsonauthor=T.+Mikkelsenauthor=S.+Desideriauthor=J.+D.+Fisher&title=New+Approaches+to+Brain+Tumor+Therapy+%28NABTT%29+CNS+Consortium+Phase+I+Safety+Study+of+Escalating+Doses+of+Atrasentan+in+Adults+with+Recurrent+Malignant+Glioma&doi=10.1215%2F15228517-2008-013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1215%2F15228517-2008-013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1215%252F15228517-2008-013%26sid%3Dliteratum%253Aachs%26aulast%3DPhuphanich%26aufirst%3DS.%26aulast%3DCarson%26aufirst%3DK.%2BA.%26aulast%3DGrossman%26aufirst%3DS.%2BA.%26aulast%3DLesser%26aufirst%3DG.%26aulast%3DOlson%26aufirst%3DJ.%26aulast%3DMikkelsen%26aufirst%3DT.%26aulast%3DDesideri%26aufirst%3DS.%26aulast%3DFisher%26aufirst%3DJ.%2BD.%26atitle%3DNew%2520Approaches%2520to%2520Brain%2520Tumor%2520Therapy%2520%2528NABTT%2529%2520CNS%2520Consortium%2520Phase%2520I%2520Safety%2520Study%2520of%2520Escalating%2520Doses%2520of%2520Atrasentan%2520in%2520Adults%2520with%2520Recurrent%2520Malignant%2520Glioma%26jtitle%3DNeuro-Oncology.%26date%3D2008%26volume%3D10%26spage%3D617%26epage%3D623%26doi%3D10.1215%2F15228517-2008-013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Kefford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beith, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hazel, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trotter, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyld, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusic, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeniwas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morganti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span> </span><span class="NLM_article-title">A phase II Study of Bosentan, a Dual Endothelin Receptor Antagonist, as Monotherapy in Patients with Stage IV Metastatic Melanoma</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">â</span> <span class="NLM_lpage">252</span><span class="refDoi">Â DOI: 10.1007/s10637-006-9014-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs10637-006-9014-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=247-252&author=R.+Keffordauthor=J.+M.+Beithauthor=G.+A.+Van+Hazelauthor=M.+Millwardauthor=J.+M.+Trotterauthor=D.+K.+Wyldauthor=R.+Kusicauthor=R.+Shreeniwasauthor=A.+Morgantiauthor=A.+Ballmerauthor=E.+Segalauthor=O.+Naylerauthor=M.+Clozel&title=A+phase+II+Study+of+Bosentan%2C+a+Dual+Endothelin+Receptor+Antagonist%2C+as+Monotherapy+in+Patients+with+Stage+IV+Metastatic+Melanoma&doi=10.1007%2Fs10637-006-9014-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1007%2Fs10637-006-9014-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-006-9014-7%26sid%3Dliteratum%253Aachs%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DBeith%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BHazel%26aufirst%3DG.%2BA.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DTrotter%26aufirst%3DJ.%2BM.%26aulast%3DWyld%26aufirst%3DD.%2BK.%26aulast%3DKusic%26aufirst%3DR.%26aulast%3DShreeniwas%26aufirst%3DR.%26aulast%3DMorganti%26aufirst%3DA.%26aulast%3DBallmer%26aufirst%3DA.%26aulast%3DSegal%26aufirst%3DE.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DA%2520phase%2520II%2520Study%2520of%2520Bosentan%252C%2520a%2520Dual%2520Endothelin%2520Receptor%2520Antagonist%252C%2520as%2520Monotherapy%2520in%2520Patients%2520with%2520Stage%2520IV%2520Metastatic%2520Melanoma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2007%26volume%3D25%26spage%3D247%26epage%3D252%26doi%3D10.1007%2Fs10637-006-9014-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clingan, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morganti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, P.</span><span> </span><span class="NLM_article-title">A Randomized, Double-blind, Placebo-controlled Study of High-dose Bosentan in Patients with Stage IV Metastatic Melanoma Receiving First-line Dacarbazine Chemotherapy</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="refDoi">Â DOI: 10.1186/1476-4598-9-69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1186%2F1476-4598-9-69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=20350333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC3c3nt12ltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=69&author=R.+F.+Keffordauthor=P.+R.+Clinganauthor=B.+Bradyauthor=A.+Ballmerauthor=A.+Morgantiauthor=P.+Hersey&title=A+Randomized%2C+Double-blind%2C+Placebo-controlled+Study+of+High-dose+Bosentan+in+Patients+with+Stage+IV+Metastatic+Melanoma+Receiving+First-line+Dacarbazine+Chemotherapy&doi=10.1186%2F1476-4598-9-69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy</span></div><div class="casAuthors">Kefford Richard F; Clingan Philip R; Brady Benjamin; Ballmer Andrea; Morganti Adele; Hersey Peter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The endothelin system is implicated in the pathogenesis of melanoma.  We evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV metastatic cutaneous melanoma in a phase 2, proof-of-concept study.  RESULTS:  Eligible patients had metastatic cutaneous melanoma naive to chemotherapy or immunotherapy, no central nervous system involvement, and serum lactate dehydrogenase <1.5 x upper limit of normal.  Treatment comprised bosentan 500 mg twice daily or matching placebo, in addition to dacarbazine 1000 mg/m2 every three weeks.  Eighty patients were randomized (double-blind) and 38 in each group received study treatment.  Median time to tumor progression (primary endpoint) was not significantly different between the two groups (placebo, 2.8 months; bosentan, 1.6 months; bosentan/placebo hazard ratio, 1.144; 95% CI, 0.717-1.827; p = 0.5683).  Incidences of most adverse events and clinically relevant increases in hepatic transaminases were similar between treatment groups although hemoglobin decrease to >8 and < or = 10 g/dL and < or = 8 g/dL was more common in the bosentan group.  CONCLUSIONS:  In patients receiving dacarbazine as first-line chemotherapy for metastatic melanoma, the addition of high-dose bosentan had no effect on time to tumor progression or other efficacy parameters.  There were no unexpected safety findings.  TRIAL REGISTRATION:  This study is registered in ClinicalTrials.gov under the unique identifier NCT01009177.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnxCNyL99HbFw2ofyr07jXfW6udTcc2eZxeg9AdlPUT7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3nt12ltw%253D%253D&md5=4e9f2c9eceb1cbf04b419a2794458839</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-9-69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-9-69%26sid%3Dliteratum%253Aachs%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DClingan%26aufirst%3DP.%2BR.%26aulast%3DBrady%26aufirst%3DB.%26aulast%3DBallmer%26aufirst%3DA.%26aulast%3DMorganti%26aufirst%3DA.%26aulast%3DHersey%26aufirst%3DP.%26atitle%3DA%2520Randomized%252C%2520Double-blind%252C%2520Placebo-controlled%2520Study%2520of%2520High-dose%2520Bosentan%2520in%2520Patients%2520with%2520Stage%2520IV%2520Metastatic%2520Melanoma%2520Receiving%2520First-line%2520Dacarbazine%2520Chemotherapy%26jtitle%3DMol.%2520Cancer%26date%3D2010%26volume%3D9%26spage%3D69%26doi%3D10.1186%2F1476-4598-9-69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Shao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, N. H.</span><span> </span><span class="NLM_article-title">Immunotherapy and Endothelin Receptor Antagonists for Treatment of Castration-resistant Prostate Cancer</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">1743</span><span class="NLM_x">â</span> <span class="NLM_lpage">1750</span><span class="refDoi">Â DOI: 10.1002/ijc.28162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fijc.28162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23504603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltlOmtLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2013&pages=1743-1750&author=N.+Shaoauthor=Y.+Wangauthor=W.+Y.+Jiangauthor=D.+Qiaoauthor=S.+G.+Zhangauthor=Y.+Wuauthor=X.+X.+Zhangauthor=J.+L.+Wangauthor=Y.+Dingauthor=N.+H.+Feng&title=Immunotherapy+and+Endothelin+Receptor+Antagonists+for+Treatment+of+Castration-resistant+Prostate+Cancer&doi=10.1002%2Fijc.28162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer</span></div><div class="casAuthors">Shao, Ning; Wang, Yang; Jiang, Wen Yu; Qiao, Di; Zhang, Shi Ge; Wu, Ye; Zhang, Xiang Xiang; Wang, Jiu Ling; Ding, Yi; Feng, Ning Han</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1743-1750</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Recently, novel therapies of prostate cancer, such as immunotherapy, endothelin receptor antagonists, novel androgen receptor antagonist and novel taxanes, and others have been introduced into clin. practice.  This study was performed to summarize these results of immunotherapy and endothelin receptor antagonists in the treatment of castration-resistant prostate cancer (CRPC) and derive a more precise estn. of their effect on future treatment.  The PubMed database, refs. of published trials, and review articles were searched.  Two reviewers independently extd. data of these trials.  We used hazard ratios (HRs) to assess the effects on overall survival (OS), progression-free survival (PFS), or time to disease progression (TTP), and relative risk (RR) for the different types of toxicity.  In addn., 95% confidence intervals (CIs) give a sense of the precision of the est.  Nine randomized controlled trials were ultimately identified.  The pooled HR showed that immunotherapy could prolong OS significantly in patients with CRPC compared to placebo (HR = 0.70, 95% CI: 0.58-0.83, p < 0.001).  Endothelin receptor antagonists also had modest benefits (HR = 0.90, 95% CI: 0.82-1.00, p = 0.046).  Nevertheless, there were no significant benefits from both therapies on PFS or TTP.  In addn., immunotherapy led to more fatigue, pyrexia, chills, and endothelin receptor antagonists led to more peripheral edema, anemia, and dyspnea.  Our article suggested that the very acceptable toxicity and improving OS in patients with CRPC made immunotherapy an attractive option for such patients.  However, future studies with thoughtful clin. trial designs are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkvX7EAY3w8rVg90H21EOLACvtfcHk0ljrwIIzMWUARQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltlOmtLc%253D&md5=0694d3d0f0cde4b379b69d6d0f6dcb74</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1002%2Fijc.28162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.28162%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DW.%2BY.%26aulast%3DQiao%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%2BG.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%2BX.%26aulast%3DWang%26aufirst%3DJ.%2BL.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DN.%2BH.%26atitle%3DImmunotherapy%2520and%2520Endothelin%2520Receptor%2520Antagonists%2520for%2520Treatment%2520of%2520Castration-resistant%2520Prostate%2520Cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2013%26volume%3D133%26spage%3D1743%26epage%3D1750%26doi%3D10.1002%2Fijc.28162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Wynn, T. A.</span><span> </span><span class="NLM_article-title">Cellular and Molecular Mechanisms of Fibrosis</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">214</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">â</span> <span class="NLM_lpage">210</span><span class="refDoi">Â DOI: 10.1002/path.2277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1002%2Fpath.2277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=18161745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvFCkt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2008&pages=199-210&author=T.+A.+Wynn&title=Cellular+and+Molecular+Mechanisms+of+Fibrosis&doi=10.1002%2Fpath.2277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular and molecular mechanisms of fibrosis</span></div><div class="casAuthors">Wynn, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-210</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibrosis is defined by the overgrowth, hardening, and/or scarring of various tissues and is attributed to excess deposition of extracellular matrix components including collagen.  Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli including persistent infections, autoimmune reactions, allergic responses, chem. insults, radiation, and tissue injury.  Although current treatments for fibrotic diseases such as idiopathic pulmonary fibrosis, liver cirrhosis, systemic sclerosis, progressive kidney disease, and cardiovascular fibrosis typically target the inflammatory response, there is accumulating evidence that the mechanisms driving fibrogenesis are distinct from those regulating inflammation.  In fact, some studies have suggested that ongoing inflammation is needed to reverse established and progressive fibrosis.  The key cellular mediator of fibrosis is the myofibroblast, which when activated serves as the primary collagen-producing cell.  Myofibroblasts are generated from a variety of sources including resident mesenchymal cells, epithelial and endothelial cells in processes termed epithelial/endothelial-mesenchymal (EMT/EndMT) transition, as well as from circulating fibroblast-like cells called fibrocytes that are derived from bone-marrow stem cells.  Myofibroblasts are activated by a variety of mechanisms, including paracrine signals derived from lymphocytes and macrophages, autocrine factors secreted by myofibroblasts, and pathogen-assocd. mol. patterns (PAMPS) produced by pathogenic organisms that interact with pattern recognition receptors (i.e. TLRs) on fibroblasts.  Cytokines (IL-13, IL-21, TGF-Î²1), chemokines (MCP-1, MIP-1Î²), angiogenic factors (VEGF), growth factors (PDGF), peroxisome proliferator-activated receptors (PPARs), acute phase proteins (SAP), caspases, and components of the renin-angiotensin-aldosterone system (ANG II) have been identified as important regulators of fibrosis and are being investigated as potential targets of antifibrotic drugs.  This review explores our current understanding of the cellular and mol. mechanisms of fibrogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0w_vXtFhJmrVg90H21EOLACvtfcHk0ljrwIIzMWUARQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvFCkt7w%253D&md5=a6b143a20d478d96bc60b816f23370f1</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1002%2Fpath.2277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2277%26sid%3Dliteratum%253Aachs%26aulast%3DWynn%26aufirst%3DT.%2BA.%26atitle%3DCellular%2520and%2520Molecular%2520Mechanisms%2520of%2520Fibrosis%26jtitle%3DJ.%2520Pathol.%26date%3D2008%26volume%3D214%26spage%3D199%26epage%3D210%26doi%3D10.1002%2Fpath.2277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salloukh, H.</span><span> </span><span class="NLM_article-title">Role of Endothelin in Fibrosis and Anti-fibrotic Potential of Bosentan</span> <span class="citation_source-journal">Ann. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">â</span> <span class="NLM_lpage">12</span><span class="refDoi">Â DOI: 10.1080/07853890410018925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1080%2F07853890410018925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15902842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslenurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2005&pages=2-12&author=M.+Clozelauthor=H.+Salloukh&title=Role+of+Endothelin+in+Fibrosis+and+Anti-fibrotic+Potential+of+Bosentan&doi=10.1080%2F07853890410018925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Role of endothelin in fibrosis and anti-fibrotic potential of bosentan</span></div><div class="casAuthors">Clozel, Martine; Salloukh, Hashem</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Medicine (Basingstoke, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">ANMDEU</span>;
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent data demonstrate the fundamental role of endothelin in the pathogenesis of fibrosis, and the anti-fibrotic potential of dual endothelin receptor antagonists such as bosentan.  Although transforming growth factor-beta, aldosterone and connective tissue growth factor, have already been established as contributors to the process of fibrosis, endothelin now emerges as a key player, which may have a role both in the initiation and in maintenance of fibrosis, and may mediate the pro-fibrotic effects of the other agents.  Bosentan is an orally active, dual endothelin receptor antagonist, which competitively antagonizes the binding of endothelin to both endothelin receptors ETA and ETB.  Bosentan prevents endothelin-induced fibroblast proliferation and extracellular matrix deposition and contraction, and reduces cardiac, hepatic, pulmonary and renal fibrosis in different disease models characterized by the activation of the endothelin system.  Bosentan even reverses existing fibrosis, possibly by its effect of stimulating matrix metalloproteinase type 1 (collagenase) expression.  The anti-fibrotic effects of bosentan extend to fibrosis induced by mediators other than endothelin such as transforming growth factor-beta, angiotensin II and aldosterone, indicating a central role of endothelin and endothelin receptors in fibrotic processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOmwjYBPr9mbVg90H21EOLACvtfcHk0li34fz5C5TvLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslenurk%253D&md5=76966435b0243748c07b0cc8fd77960c</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1080%2F07853890410018925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07853890410018925%26sid%3Dliteratum%253Aachs%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DSalloukh%26aufirst%3DH.%26atitle%3DRole%2520of%2520Endothelin%2520in%2520Fibrosis%2520and%2520Anti-fibrotic%2520Potential%2520of%2520Bosentan%26jtitle%3DAnn.%2520Med.%26date%3D2005%26volume%3D37%26spage%3D2%26epage%3D12%26doi%3D10.1080%2F07853890410018925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Poncet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span> </span><span class="NLM_article-title">The Expression and Function of the Endothelin System in Contractile Properties of Vaginal Myofibroblasts of Women with Uterovaginal Prolapse</span> <span class="citation_source-journal">Am. J. Obstet. Gynecol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">â</span> <span class="NLM_lpage">432</span><span class="refDoi">Â DOI: 10.1016/j.ajog.2004.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.ajog.2004.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=15695982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKhs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2005&pages=426-432&author=S.+Poncetauthor=S.+Meyerauthor=C.+Richardauthor=J.+Aubertauthor=L.+Juillerat-Jeanneret&title=The+Expression+and+Function+of+the+Endothelin+System+in+Contractile+Properties+of+Vaginal+Myofibroblasts+of+Women+with+Uterovaginal+Prolapse&doi=10.1016%2Fj.ajog.2004.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">The expression and function of the endothelin system in contractile properties of vaginal myofibroblasts of women with uterovaginal prolapse</span></div><div class="casAuthors">Poncet, Sebastien; Meyer, Sylvain; Richard, Christelle; Aubert, John-David; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Obstetrics and Gynecology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">426-432</span>CODEN:
                <span class="NLM_cas:coden">AJOGAH</span>;
        ISSN:<span class="NLM_cas:issn">0002-9378</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Objective: The endothelin-1 system regulates (myo)fibroblast contraction in wound healing.  Our aim was to det. endothelin-1 system expression and function in contractile properties of vaginal myofibroblasts of women with uterovaginal prolapse.  Study Design: Cultures of Î±-smooth muscle actin-pos. myofibroblasts that were established at the time of repair surgery for prolapse (n = 30; mean age, 56 Â± 14 years) were analyzed and compared for their expression of the endothelin-1 system and contractile properties to myofibroblasts from primiparous women.  Results: Myofibroblasts expressed the complete endothelin system but did not secrete endothelin-1.  Endothelin-1 binding was mediated exclusively by the endothelin B-receptor.  In 3-dimensional collagen gels, spontaneous contraction of myofibroblasts from estrogen-treated women with prolapse was statistically significantly lower than from young primiparous women.  Exogenous addn. of endothelin-1 decreased the spontaneous contraction of myofibroblasts.  Conclusion: Genital myofibroblasts of women with uterovaginal prolapse are poorly contractile, and endothelin-1 further decreases vaginal myofibroblast contraction, which is opposite to observations in skin myofibroblasts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkVqtu6jAV17Vg90H21EOLACvtfcHk0li34fz5C5TvLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKhs7g%253D&md5=fcfdcb942eb21c939aa699ec32f57032</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.ajog.2004.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajog.2004.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DPoncet%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DRichard%26aufirst%3DC.%26aulast%3DAubert%26aufirst%3DJ.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DThe%2520Expression%2520and%2520Function%2520of%2520the%2520Endothelin%2520System%2520in%2520Contractile%2520Properties%2520of%2520Vaginal%2520Myofibroblasts%2520of%2520Women%2520with%2520Uterovaginal%2520Prolapse%26jtitle%3DAm.%2520J.%2520Obstet.%2520Gynecol.%26date%3D2005%26volume%3D192%26spage%3D426%26epage%3D432%26doi%3D10.1016%2Fj.ajog.2004.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Weng, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. H.</span><span> </span><span class="NLM_article-title">Endothelin-1 Induces Connective Tissue Growth Factor Expression in Human Lung Fibroblasts by ETAR-dependent JNK/AP-1 Pathway</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">â</span> <span class="NLM_lpage">411</span><span class="refDoi">Â DOI: 10.1016/j.bcp.2014.01.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.bcp.2014.01.030" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=402-411&author=C.+M.+Wengauthor=C.+C.+Yuauthor=M.+L.+Kuoauthor=B.+C.+Chenauthor=C.+H.+Lin&title=Endothelin-1+Induces+Connective+Tissue+Growth+Factor+Expression+in+Human+Lung+Fibroblasts+by+ETAR-dependent+JNK%2FAP-1+Pathway&doi=10.1016%2Fj.bcp.2014.01.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.01.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.01.030%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DC.%2BM.%26aulast%3DYu%26aufirst%3DC.%2BC.%26aulast%3DKuo%26aufirst%3DM.%2BL.%26aulast%3DChen%26aufirst%3DB.%2BC.%26aulast%3DLin%26aufirst%3DC.%2BH.%26atitle%3DEndothelin-1%2520Induces%2520Connective%2520Tissue%2520Growth%2520Factor%2520Expression%2520in%2520Human%2520Lung%2520Fibroblasts%2520by%2520ETAR-dependent%2520JNK%252FAP-1%2520Pathway%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D88%26spage%3D402%26epage%3D411%26doi%3D10.1016%2Fj.bcp.2014.01.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Antoniu, S. A.</span><span> </span><span class="NLM_article-title">Targeting the Endothelin Pathway in the Idiopathic Pulmonary Fibrosis: The Role of Bosentan</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1077</span><span class="NLM_x">â</span> <span class="NLM_lpage">1084</span><span class="refDoi">Â DOI: 10.1517/14728222.12.9.1077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1517%2F14728222.12.9.1077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=18694375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslaltrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=1077-1084&author=S.+A.+Antoniu&title=Targeting+the+Endothelin+Pathway+in+the+Idiopathic+Pulmonary+Fibrosis%3A+The+Role+of+Bosentan&doi=10.1517%2F14728222.12.9.1077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan</span></div><div class="casAuthors">Antoniu, Sabina A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1077-1084</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Idiopathic pulmonary fibrosis (IPF) is a rapidly lethal disease characterized by anarchic, progressive fibrosis.  Pulmonary fibrosis is the result of interactions between many effector cells and cytokines and better understanding of this can help with identification of novel therapeutic targets.  To evaluate the role of the endothelin-1 (ET-1) pathway in IPF pathogenesis and the effects of therapeutic targeting with bosentan, an ET-1 antagonist.  Data on ET-1's pathogenic involvement in IPF and the preclin. and clin. data on bosentan in this context are discussed and analyzed.  A parallel overview of existing and upcoming therapies for IPF is presented.  Bosentan is a promising antifibrotic therapy for IPF and clin. data on its long-term efficacy support its use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMCqTyzHxsq7Vg90H21EOLACvtfcHk0liAPLPll2CRBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslaltrY%253D&md5=d89da7ab5e42f12fb8f4dc4eb8061cf7</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.9.1077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.9.1077%26sid%3Dliteratum%253Aachs%26aulast%3DAntoniu%26aufirst%3DS.%2BA.%26atitle%3DTargeting%2520the%2520Endothelin%2520Pathway%2520in%2520the%2520Idiopathic%2520Pulmonary%2520Fibrosis%253A%2520The%2520Role%2520of%2520Bosentan%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2008%26volume%3D12%26spage%3D1077%26epage%3D1084%26doi%3D10.1517%2F14728222.12.9.1077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">King, T. E.</span><span> </span><span class="NLM_article-title">Bosentan for Idiopathic Pulmonary Fibrosis</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">â</span> <span class="NLM_lpage">1179</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=1171-1179&author=T.+E.+King&title=Bosentan+for+Idiopathic+Pulmonary+Fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DT.%2BE.%26atitle%3DBosentan%2520for%2520Idiopathic%2520Pulmonary%2520Fibrosis%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs.%26date%3D2008%26volume%3D9%26spage%3D1171%26epage%3D1179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Million-Rousseau, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morganti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perchenet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MUSIC Study Group.</span><span> </span><span class="NLM_article-title">Macitentan for the Treatment of Idiopathic Pulmonary Fibrosis: The Randomized Controlled MUSIC Trial</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1622</span><span class="NLM_x">â</span> <span class="NLM_lpage">1632</span><span class="refDoi">Â DOI: 10.1183/09031936.00104612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1183%2F09031936.00104612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=23682110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlagtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=1622-1632&author=G.+Raghuauthor=R.+Million-Rousseauauthor=A.+Morgantiauthor=L.+Perchenetauthor=J.+Behrauthor=MUSIC+Study+Group.&title=Macitentan+for+the+Treatment+of+Idiopathic+Pulmonary+Fibrosis%3A+The+Randomized+Controlled+MUSIC+Trial&doi=10.1183%2F09031936.00104612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomized controlled MUSIC trial</span></div><div class="casAuthors">Raghu, Ganesh; Million-Rousseau, Rachel; Morganti, Adele; Perchenet, Loic; Behr, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1622-1632</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive, fatal disease.  This prospective, randomized, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis.  Eligible subjects were adults with idiopathic pulmonary fibrosis of <3 years duration and a histol. pattern of usual interstitial pneumonia on surgical lung biopsy.  The primary objective was to demonstrate that macitentan (10 mg once daily) pos. affected forced vital capacity vs. placebo.  Using a centralized system, 178 subjects were randomized (2:1) to macitentan (n = 119) or placebo (n = 59).  The median change from baseline up to month 12 in forced vital capacity was -0.20 L in the macitentan arm and -0.20 L in the placebo arm.  Overall, no differences between treatments were obsd. in pulmonary function tests or time to disease worsening or death.  Median exposures to macitentan and placebo were 14.5 mo and 15.0 mo, resp.  Alanine and/or aspartate aminotransferase elevations over three times upper limit of normal arose in 3.4% of macitentan-treated subjects and 5.1% of placebo recipients.  In conclusion, the primary objective was not met.  Long-term exposure to macitentan was well tolerated with a similar, low incidence of elevated hepatic aminotransferases in each treatment group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEeb0nFAw0JLVg90H21EOLACvtfcHk0liAPLPll2CRBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlagtQ%253D%253D&md5=4d3495bc6413416a511a50a447acee62</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1183%2F09031936.00104612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00104612%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DMillion-Rousseau%26aufirst%3DR.%26aulast%3DMorganti%26aufirst%3DA.%26aulast%3DPerchenet%26aufirst%3DL.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3D%26atitle%3DMacitentan%2520for%2520the%2520Treatment%2520of%2520Idiopathic%2520Pulmonary%2520Fibrosis%253A%2520The%2520Randomized%2520Controlled%2520MUSIC%2520Trial%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D42%26spage%3D1622%26epage%3D1632%26doi%3D10.1183%2F09031936.00104612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Yuan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, P.</span><span> </span><span class="NLM_article-title">Endothelin-receptor Antagonists for Diabetic Nephropathy: A Meta-Analysis</span> <span class="citation_source-journal">Nephrology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">â</span> <span class="NLM_lpage">466</span><span class="refDoi">Â DOI: 10.1111/nep.12442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fnep.12442" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=459-466&author=W.+Yuanauthor=Y.+Liauthor=J.+Wangauthor=J.+Liauthor=S.+Gouauthor=P.+Fu&title=Endothelin-receptor+Antagonists+for+Diabetic+Nephropathy%3A+A+Meta-Analysis&doi=10.1111%2Fnep.12442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1111%2Fnep.12442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnep.12442%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DFu%26aufirst%3DP.%26atitle%3DEndothelin-receptor%2520Antagonists%2520for%2520Diabetic%2520Nephropathy%253A%2520A%2520Meta-Analysis%26jtitle%3DNephrology%26date%3D2015%26volume%3D20%26spage%3D459%26epage%3D466%26doi%3D10.1111%2Fnep.12442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Kohan, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, M.</span><span> </span><span class="NLM_article-title">Endothelin and Endothelin Antagonists in Chronic Kidney Disease</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">â</span> <span class="NLM_lpage">904</span><span class="refDoi">Â DOI: 10.1038/ki.2014.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fki.2014.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24805108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsl2nsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=896-904&author=D.+E.+Kohanauthor=M.+Barton&title=Endothelin+and+Endothelin+Antagonists+in+Chronic+Kidney+Disease&doi=10.1038%2Fki.2014.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin and endothelin antagonists in chronic kidney disease</span></div><div class="casAuthors">Kohan, Donald E.; Barton, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">896-904</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension accounting for the majority of cases, is on the rise, with up to 160 million individuals worldwide predicted to be affected by 2020.  Given that current treatment options, primarily targeted at the renin-angiotensin system, only modestly slow down progression to end-stage renal disease, the urgent need for addnl. effective therapeutics is evident.  Endothelin-1 (ET-1), largely through activation of endothelin A receptors, has been strongly implicated in renal cell injury, proteinuria, inflammation, and fibrosis leading to CKD.  Endothelin receptor antagonists (ERAs) have been demonstrated to ameliorate or even reverse renal injury and/or fibrosis in exptl. models of CKD, whereas clin. trials indicate a substantial antiproteinuric effect of ERAs in diabetic and nondiabetic CKD patients even on top of maximal renin-angiotensin system blockade.  This review summarizes the role of ET in CKD pathogenesis and discusses the potential therapeutic benefit of targeting the ET system in CKD, with attention to the risks and benefits of such an approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_WvqbVbFpLbVg90H21EOLACvtfcHk0liAPLPll2CRBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsl2nsro%253D&md5=b839dd0254aa519bc4707fbe784e464c</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fki.2014.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fki.2014.143%26sid%3Dliteratum%253Aachs%26aulast%3DKohan%26aufirst%3DD.%2BE.%26aulast%3DBarton%26aufirst%3DM.%26atitle%3DEndothelin%2520and%2520Endothelin%2520Antagonists%2520in%2520Chronic%2520Kidney%2520Disease%26jtitle%3DKidney%2520Int.%26date%3D2014%26volume%3D86%26spage%3D896%26epage%3D904%26doi%3D10.1038%2Fki.2014.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Murugesan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadnis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tellew, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baska, R. A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monshizadegan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowala, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macor, J. E.</span><span> </span><span class="NLM_article-title">Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2<i>â²</i>-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">â</span> <span class="NLM_lpage">179</span><span class="refDoi">Â DOI: 10.1021/jm049548x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049548x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=171-179&author=N.+Murugesanauthor=Z.+Guauthor=L.+Fadnisauthor=J.+E.+Tellewauthor=R.+A.+F.+Baskaauthor=Y.+Yangauthor=S.+M.+Beyerauthor=H.+Monshizadeganauthor=K.+E.+Dickinsonauthor=M.+T.+Valentineauthor=W.+G.+Humphreysauthor=S.+J.+Lanauthor=W.+R.+Ewingauthor=K.+E.+Carlsonauthor=M.+C.+Kowalaauthor=R.+Zahlerauthor=J.+E.+Macor&title=Dual+Angiotensin+II+and+Endothelin+A+Receptor+Antagonists%3A+Synthesis+of+2%E2%80%B2-Substituted+N-3-Isoxazolyl+Biphenylsulfonamides+with+Improved+Potency+and+Pharmacokinetics&doi=10.1021%2Fjm049548x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2'-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics</span></div><div class="casAuthors">Murugesan, Natesan; Gu, Zhengxiang; Fadnis, Leena; Tellew, John E.; Baska, Rose Ann F.; Yang, Yifan; Beyer, Sophie M.; Monshizadegan, Hossain; Dickinson, Kenneth E.; Valentine, Maria T.; Humphreys, W. Griffith; Lan, Shih-Jung; Ewing, William R.; Carlson, Kenneth E.; Kowala, Mark C.; Zahler, Robert; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previous report its was demonstrated that merging together key structural elements present in an AT1 receptor antagonist (irbesartan) with key structural elements in a biphenylsulfonamide ETA receptor antagonist followed by addnl. optimization provided a product which is a dual-action receptor antagonist (DARA), which potently blocked both AT1 and ETA receptors.  Described herein are our efforts directed toward improving both the pharmacokinetic profile as well as the AT1 and ETA receptor potency of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-2-sulfonamide (I).  Efforts centered on modifying the 2'-side chain of I and examg. the (isoxazolyl)sulfonamide moiety in I.  This effort resulted in the discovery of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)[1,1'-biphenyl]-2-sulfonamide (II) as a highly potent second-generation DARA.  This compd. also showed substantially improved pharmacokinetic properties compared to I.  In rats, DARA II reduced blood pressure elevations caused by i.v. infusion of Ang II or big ET-1 to a greater extent and with longer duration than DARA I or AT1 or ETA receptor antagonists alone.  II clearly demonstrated superiority over irbesartan (an AT1 receptor antagonist) in the normal SHR model of hypertension in a dose-dependent manner, demonstrating the synergy of AT1 and ETA receptor blockade in a single mol.  The crystal and mol. structures of II were reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2G8_AfjEVOrVg90H21EOLACvtfcHk0lgCgHeqbauWtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO&md5=d4e66dc82cd65970cde8ca8f3094c8c6</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fjm049548x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049548x%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DFadnis%26aufirst%3DL.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DBaska%26aufirst%3DR.%2BA.%2BF.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBeyer%26aufirst%3DS.%2BM.%26aulast%3DMonshizadegan%26aufirst%3DH.%26aulast%3DDickinson%26aufirst%3DK.%2BE.%26aulast%3DValentine%26aufirst%3DM.%2BT.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DLan%26aufirst%3DS.%2BJ.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DKowala%26aufirst%3DM.%2BC.%26aulast%3DZahler%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DDual%2520Angiotensin%2520II%2520and%2520Endothelin%2520A%2520Receptor%2520Antagonists%253A%2520Synthesis%2520of%25202%25E2%2580%25B2-Substituted%2520N-3-Isoxazolyl%2520Biphenylsulfonamides%2520with%2520Improved%2520Potency%2520and%2520Pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D171%26epage%3D179%26doi%3D10.1021%2Fjm049548x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Bai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of 4<i>â²</i>-(Benzimidazole-1-yl)methylbiphenyl-2-sulfonamide Derivatives as Dual Angiotensin II/Endothelin a Receptor Antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4661</span><span class="NLM_x">â</span> <span class="NLM_lpage">4667</span><span class="refDoi">Â DOI: 10.1016/j.bmc.2012.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.bmc.2012.06.011" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4661-4667&author=R.+Baiauthor=Z.+Weiauthor=J.+Liuauthor=W.+Xieauthor=H.+Yaoauthor=X.+Wuauthor=J.+Jiangauthor=Q.+Wangauthor=J.+Xu&title=Synthesis+and+Biological+Evaluation+of+4%E2%80%B2-%28Benzimidazole-1-yl%29methylbiphenyl-2-sulfonamide+Derivatives+as+Dual+Angiotensin+II%2FEndothelin+a+Receptor+Antagonists&doi=10.1016%2Fj.bmc.2012.06.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%25204%25E2%2580%25B2-%2528Benzimidazole-1-yl%2529methylbiphenyl-2-sulfonamide%2520Derivatives%2520as%2520Dual%2520Angiotensin%2520II%252FEndothelin%2520a%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D4661%26epage%3D4667%26doi%3D10.1016%2Fj.bmc.2012.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Macdonald, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashida, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molyneux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raabe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vajkoczy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanke, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowbakht, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassell, N.</span><span> </span><span class="NLM_article-title">Randomized Trial of Clazosentan in Patients with Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling</span> <span class="citation_source-journal">Stroke</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1463</span><span class="NLM_x">â</span> <span class="NLM_lpage">1469</span><span class="refDoi">Â DOI: 10.1161/STROKEAHA.111.648980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1161%2FSTROKEAHA.111.648980" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2012&pages=1463-1469&author=R.+L.+Macdonaldauthor=R.+T.+Higashidaauthor=E.+Kellerauthor=S.+A.+Mayerauthor=A.+Molyneuxauthor=A.+Raabeauthor=P.+Vajkoczyauthor=I.+Wankeauthor=D.+Bachauthor=A.+Freyauthor=P.+Nowbakhtauthor=S.+Rouxauthor=N.+Kassell&title=Randomized+Trial+of+Clazosentan+in+Patients+with+Aneurysmal+Subarachnoid+Hemorrhage+Undergoing+Endovascular+Coiling&doi=10.1161%2FSTROKEAHA.111.648980"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1161%2FSTROKEAHA.111.648980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FSTROKEAHA.111.648980%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DR.%2BL.%26aulast%3DHigashida%26aufirst%3DR.%2BT.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DMayer%26aufirst%3DS.%2BA.%26aulast%3DMolyneux%26aufirst%3DA.%26aulast%3DRaabe%26aufirst%3DA.%26aulast%3DVajkoczy%26aufirst%3DP.%26aulast%3DWanke%26aufirst%3DI.%26aulast%3DBach%26aufirst%3DD.%26aulast%3DFrey%26aufirst%3DA.%26aulast%3DNowbakht%26aufirst%3DP.%26aulast%3DRoux%26aufirst%3DS.%26aulast%3DKassell%26aufirst%3DN.%26atitle%3DRandomized%2520Trial%2520of%2520Clazosentan%2520in%2520Patients%2520with%2520Aneurysmal%2520Subarachnoid%2520Hemorrhage%2520Undergoing%2520Endovascular%2520Coiling%26jtitle%3DStroke%26date%3D2012%26volume%3D43%26spage%3D1463%26epage%3D1469%26doi%3D10.1161%2FSTROKEAHA.111.648980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Donate, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verri, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junta, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lima, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peres, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bombonato-Prado, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louzada, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donadi, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passos, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, F. Q.</span><span> </span><span class="NLM_article-title">Bosentan, an Endothelin Receptor Antagonist, Ameliorates Collagen-induced Arthritis: The Role of TNF-Î± in the Induction of Endothelin System Genes</span> <span class="citation_source-journal">Inflammation Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">â</span> <span class="NLM_lpage">348</span><span class="refDoi">Â DOI: 10.1007/s00011-011-0415-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00011-011-0415-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=22249931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1eks74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=337-348&author=P.+B.+Donateauthor=T.+M.+Cunhaauthor=W.+A.+Verriauthor=C.+M.+Juntaauthor=F.+O.+Limaauthor=S.+M.+Vieiraauthor=R.+S.+Peresauthor=K.+F.+Bombonato-Pradoauthor=P.+Louzadaauthor=S.+H.+Ferreiraauthor=E.+A.+Donadiauthor=G.+A.+Passosauthor=F.+Q.+Cunha&title=Bosentan%2C+an+Endothelin+Receptor+Antagonist%2C+Ameliorates+Collagen-induced+Arthritis%3A+The+Role+of+TNF-%CE%B1+in+the+Induction+of+Endothelin+System+Genes&doi=10.1007%2Fs00011-011-0415-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Bosentan, an endothelin receptor antagonist, ameliorates collagen-induced arthritis: the role of TNF-Î± in the induction of endothelin system genes</span></div><div class="casAuthors">Donate, Paula B.; Cunha, Thiago M.; Verri, Waldiceu A., Jr.; Junta, Cristina M.; Lima, Flavia O.; Vieira, Silvio M.; Peres, Rafael S.; Bombonato-Prado, Karina F.; Louzada, Paulo, Jr.; Ferreira, Sergio H.; Donadi, Eduardo A.; Passos, Geraldo A. S.; Cunha, Fernando Q.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-348</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Endothelins (ETs) are involved in several inflammatory events.  The present study investigated the efficacy of bosentan, a dual ETA/ETB receptor antagonist, in collagen-induced arthritis (CIA) in mice.  Treatment CIA was induced in DBA/1J mice.  Arthritic mice were treated with bosentan (100 mg/kg) once a day, starting from the day when arthritis was clin. detectable.  CIA progression was assessed by measurements of visual clin. score, paw swelling and hypernociception.  Histol. changes, neutrophil infiltration and pro-inflammatory cytokines were evaluated in the joints.  Gene expression in the lymph nodes of arthritic mice was evaluated by microarray technol.  PreproET-1 mRNA expression in the lymph nodes of mice and in peripheral blood mononuclear cells (PBMCs) was evaluated by real-time PCR.  The differences were evaluated by one-way ANOVA or Student's t test.  Oral treatment with bosentan markedly ameliorated the clin. aspects of CIA (visual clin. score, paw swelling and hyperalgesia).  Bosentan treatment also reduced joint damage, leukocyte infiltration and pro-inflammatory cytokine levels (IL-1Î², TNFÎ± and IL-17) in the joint tissues.  Changes in gene expression in the lymph nodes of arthritic mice returned to the levels of the control mice after bosentan treatment.  PreproET mRNA expression increased in PBMCs from rheumatoid arthritis (RA) patients but returned to basal level in PBMCs from patients under anti-TNF therapy.  In-vitro treatment of PBMCs with TNFÎ± upregulated ET system genes.  These findings indicate that ET receptor antagonists, such as bosentan, might be useful in controlling RA.  Moreover, it seems that ET mediation of arthritis is triggered by TNFÎ±.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYw3uModkXmrVg90H21EOLACvtfcHk0lgJgUzhL_J5Jg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1eks74%253D&md5=633fb63a37acb2d0fa40aea74a85dfc0</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1007%2Fs00011-011-0415-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00011-011-0415-5%26sid%3Dliteratum%253Aachs%26aulast%3DDonate%26aufirst%3DP.%2BB.%26aulast%3DCunha%26aufirst%3DT.%2BM.%26aulast%3DVerri%26aufirst%3DW.%2BA.%26aulast%3DJunta%26aufirst%3DC.%2BM.%26aulast%3DLima%26aufirst%3DF.%2BO.%26aulast%3DVieira%26aufirst%3DS.%2BM.%26aulast%3DPeres%26aufirst%3DR.%2BS.%26aulast%3DBombonato-Prado%26aufirst%3DK.%2BF.%26aulast%3DLouzada%26aufirst%3DP.%26aulast%3DFerreira%26aufirst%3DS.%2BH.%26aulast%3DDonadi%26aufirst%3DE.%2BA.%26aulast%3DPassos%26aufirst%3DG.%2BA.%26aulast%3DCunha%26aufirst%3DF.%2BQ.%26atitle%3DBosentan%252C%2520an%2520Endothelin%2520Receptor%2520Antagonist%252C%2520Ameliorates%2520Collagen-induced%2520Arthritis%253A%2520The%2520Role%2520of%2520TNF-%25CE%25B1%2520in%2520the%2520Induction%2520of%2520Endothelin%2520System%2520Genes%26jtitle%3DInflammation%2520Res.%26date%3D2012%26volume%3D61%26spage%3D337%26epage%3D348%26doi%3D10.1007%2Fs00011-011-0415-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Freeman, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machado, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanowitz, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desruisseaux, M. S.</span><span> </span><span class="NLM_article-title">Endothelin-1 and Its Role in the Pathogenesis of Infectious Diseases</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">â</span> <span class="NLM_lpage">119</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2014.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.lfs.2014.04.021" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=110-119&author=B.+D.+Freemanauthor=F.+S.+Machadoauthor=H.+B.+Tanowitzauthor=M.+S.+Desruisseaux&title=Endothelin-1+and+Its+Role+in+the+Pathogenesis+of+Infectious+Diseases&doi=10.1016%2Fj.lfs.2014.04.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2014.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2014.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DB.%2BD.%26aulast%3DMachado%26aufirst%3DF.%2BS.%26aulast%3DTanowitz%26aufirst%3DH.%2BB.%26aulast%3DDesruisseaux%26aufirst%3DM.%2BS.%26atitle%3DEndothelin-1%2520and%2520Its%2520Role%2520in%2520the%2520Pathogenesis%2520of%2520Infectious%2520Diseases%26jtitle%3DLife%2520Sci.%26date%3D2014%26volume%3D118%26spage%3D110%26epage%3D119%26doi%3D10.1016%2Fj.lfs.2014.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Suekane, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitabayashi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naruko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oshitani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanzawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirakawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, M.</span><span> </span><span class="NLM_article-title">Enhanced Expression of Endothelin-converting Enzyme and Endothelin Receptors in Human Colonic Tissues of Crohnâs Disease</span> <span class="citation_source-journal">J. Clin. Biochem. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">126</span><span class="NLM_x">â</span> <span class="NLM_lpage">132</span><span class="refDoi">Â DOI: 10.3164/jcbn.2008018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.3164%2Fjcbn.2008018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=18385829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BD1c3is1Kluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2008&pages=126-132&author=T.+Suekaneauthor=Y.+Ikuraauthor=J.+Arimotoauthor=M.+Nakagawaauthor=C.+Kitabayashiauthor=T.+Narukoauthor=T.+Watanabeauthor=Y.+Fujiwaraauthor=N.+Oshitaniauthor=K.+Maedaauthor=K.+Tanzawaauthor=K.+Hirakawaauthor=T.+Arakawaauthor=M.+Ueda&title=Enhanced+Expression+of+Endothelin-converting+Enzyme+and+Endothelin+Receptors+in+Human+Colonic+Tissues+of+Crohn%E2%80%99s+Disease&doi=10.3164%2Fjcbn.2008018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced expressions of endothelin-converting enzyme and endothelin receptors in human colonic tissues of Crohn's disease</span></div><div class="casAuthors">Suekane Takehisa; Ikura Yoshihiro; Arimoto Junko; Nakagawa Masashi; Kitabayashi Chizuko; Naruko Takahiko; Watanabe Toshio; Fujiwara Yasuhiro; Oshitani Nobuhide; Maeda Kiyoshi; Tanzawa Kazuhiko; Hirakawa Kosei; Arakawa Tetsuo; Ueda Makiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical biochemistry and nutrition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-32</span>
        ISSN:<span class="NLM_cas:issn">0912-0009</span>.
    </div><div class="casAbstract">Endothelin-1, a powerful vasoconstrictor, forms the endothelin system together with endothelin-converting enzyme and endothelin type A and type B receptors.  These endothelin system components are considered to participate in inflammatory and wound healing responses.  Previous reports have suggested a role for the endothelin-1 in the pathology of Crohn's disease.  In the present study, we immunohistochemically investigated the expressions of the endothelin system components in affected human intestinal tissues of Crohn's disease.  Eighteen surgical specimens of colonic tissue obtained from patients with Crohn's disease and 12 normal colonic tissues as controls were examined.  Frozen tissue sections cut from the samples were subjected to the immunohistochemical single and double staining.  The endothelin system components were expressed mainly in the muscular layers and blood vessels.  In diseased colonic tissues, inflammatory infiltration and fibrotic tissue reactions with marked smooth muscle cell proliferation were frequently seen, and were closely associated with increased expressions of the endothelin system components.  These results strongly suggest that endothelin-converting enzyme and endothelin type A and type B receptors collectively play a role in the inflammatory and fibrogenic processes of Crohn's disease.  Especially, submucosal smooth muscle proliferation, a histological hallmark of strictures, may be attributable to the upregulated endothelin system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkpeTSiwkiwCsZ1x6zOs0vfW6udTcc2eYKXudONWVL8Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3is1Kluw%253D%253D&md5=1778d3bb28fcebf735237b0c47302436</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.3164%2Fjcbn.2008018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3164%252Fjcbn.2008018%26sid%3Dliteratum%253Aachs%26aulast%3DSuekane%26aufirst%3DT.%26aulast%3DIkura%26aufirst%3DY.%26aulast%3DArimoto%26aufirst%3DJ.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DKitabayashi%26aufirst%3DC.%26aulast%3DNaruko%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DOshitani%26aufirst%3DN.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DTanzawa%26aufirst%3DK.%26aulast%3DHirakawa%26aufirst%3DK.%26aulast%3DArakawa%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DM.%26atitle%3DEnhanced%2520Expression%2520of%2520Endothelin-converting%2520Enzyme%2520and%2520Endothelin%2520Receptors%2520in%2520Human%2520Colonic%2520Tissues%2520of%2520Crohn%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Clin.%2520Biochem.%2520Nutr.%26date%3D2008%26volume%3D42%26spage%3D126%26epage%3D132%26doi%3D10.3164%2Fjcbn.2008018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Kowalczyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleniewska, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolodziejczyk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skibska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goraca, A.</span><span> </span><span class="NLM_article-title">The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis</span> <span class="citation_source-journal">Arch. Immunol. Ther. Exp.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">â</span> <span class="NLM_lpage">52</span><span class="refDoi">Â DOI: 10.1007/s00005-014-0310-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1007%2Fs00005-014-0310-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=25288367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslCis7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=41-52&author=A.+Kowalczykauthor=P.+Kleniewskaauthor=M.+Kolodziejczykauthor=B.+Skibskaauthor=A.+Goraca&title=The+Role+of+Endothelin-1+and+Endothelin+Receptor+Antagonists+in+Inflammatory+Response+and+Sepsis&doi=10.1007%2Fs00005-014-0310-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis</span></div><div class="casAuthors">Kowalczyk, Agata; Kleniewska, Paulina; Kolodziejczyk, Michal; Skibska, Beata; Goraca, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Archivum Immunologiae et Therapiae Experimentalis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-52</span>CODEN:
                <span class="NLM_cas:coden">AITEAT</span>;
        ISSN:<span class="NLM_cas:issn">0004-069X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor, mainly secreted by endothelial cells.  It acts through two types of receptors: ETA and ETB.  Apart from a vasoconstrictive action, ET-1 causes fibrosis of the vascular cells and stimulates prodn. of reactive oxygen species.  It is claimed that ET-1 induces proinflammatory mechanisms, increasing superoxide anion prodn. and cytokine secretion.  A recent study has shown that ET-1 is involved in the activation of transcription factors such as NF-ÎºB and expression of proinflammatory cytokines including TNF-Î±, IL-1, and IL-6.  It has been also indicated that during endotoxemia, the plasma level of ET-1 is increased in various animal species.  Some authors indicate a clear correlation between endothelin plasma level and morbidity/mortality rate in septic patients.  These pathol. effects of ET-1 may be abrogated at least partly by endothelin receptor blockade.  ET-1 receptor antagonists may be useful for prevention of various vascular diseases.  This review summarizes the current knowledge regarding endothelin receptor antagonists and the role of ET-1 in sepsis and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp42UEJnkObarVg90H21EOLACvtfcHk0lgJgUzhL_J5Jg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslCis7%252FM&md5=3ebd9c077169c1b10d1fa095a762e671</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1007%2Fs00005-014-0310-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00005-014-0310-1%26sid%3Dliteratum%253Aachs%26aulast%3DKowalczyk%26aufirst%3DA.%26aulast%3DKleniewska%26aufirst%3DP.%26aulast%3DKolodziejczyk%26aufirst%3DM.%26aulast%3DSkibska%26aufirst%3DB.%26aulast%3DGoraca%26aufirst%3DA.%26atitle%3DThe%2520Role%2520of%2520Endothelin-1%2520and%2520Endothelin%2520Receptor%2520Antagonists%2520in%2520Inflammatory%2520Response%2520and%2520Sepsis%26jtitle%3DArch.%2520Immunol.%2520Ther.%2520Exp.%26date%3D2015%26volume%3D63%26spage%3D41%26epage%3D52%26doi%3D10.1007%2Fs00005-014-0310-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span> </span><span class="NLM_article-title">Targeting Endothelin Receptors A and B Attenuates the Inflammatory Response and Improves Locomotor Function Following Spinal Cord Injury in Mice</span> <span class="citation_source-journal">Int. J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">74</span><span class="NLM_x">â</span> <span class="NLM_lpage">82</span><span class="refDoi">Â DOI: 10.3892/ijmm.2014.1751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.3892%2Fijmm.2014.1751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=24756152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlyktbvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=74-82&author=J.+Guoauthor=Y.+Liauthor=Z.+Heauthor=B.+Zhangauthor=Y.+Liauthor=J.+Huauthor=M.+Hanauthor=Y.+Xuauthor=Y.+Liauthor=J.+Guauthor=B.+Daiauthor=Z.+Chen&title=Targeting+Endothelin+Receptors+A+and+B+Attenuates+the+Inflammatory+Response+and+Improves+Locomotor+Function+Following+Spinal+Cord+Injury+in+Mice&doi=10.3892%2Fijmm.2014.1751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting endothelin receptors A and B attenuates the inflammatory response and improves locomotor function following spinal cord injury in mice</span></div><div class="casAuthors">Guo, Jian; Li, Yiqiao; He, Zhennian; Zhang, Bin; Li, Yonghuan; Hu, Jianghua; Han, Mingyuan; Xu, Yuanlin; Li, Yongfu; Gu, Jie; Dai, Bo; Chen, Zhong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-82</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">After spinal cord injury (SCI), the disruption of blood-spinal cord barrier by activation of the endothelin (ET) system is a crit. event leading to leukocyte infiltration, inflammatory response and oxidative stress, contributing to neurol. disability.  In the present study, we showed that blockade of ET receptor A (ETAR) and/or ET receptor B (ETBR) prevented early inflammatory responses directly via the inhibition of neutrophil and monocyte diapedesis and inflammatory mediator prodn. following traumatic SCI in mice.  Long-term neurol. improvement, based on a series of tests of locomotor performance, occurred only in the spinal cord-injured mice following blockade of ETAR and ETBR.  We also examd. the post-traumatic changes of the microenvironment within the injured spinal cord of mice following blockade of ET receptors.  Oxidative stress reflects an imbalance between malondialdehyde and superoxide dismutase in spinal cord-injured mice treated with vehicle, whereas blockade of ETAR and ETBR reversed the oxidn. state imbalance.  In addn., hemeoxygenase-1, a protective protease involved in early SCI, was increased in spinal cord-injured mice following the blockade of ETAR and ETBR, or only ETBR.  Matrix metalloproteinase-9, a tissue-destructive protease involved in early damage, was decreased in the injured spinal cord of mice following blockade of ETAR, ETBR or a combination thereof.  The findings of the present study therefore suggested an assocn. between ETAR and ETBR in regulating early pathogenesis of SCI and detg. the outcomes of long-term neurol. recovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqi9-6bl8Kt7Vg90H21EOLACvtfcHk0lhTHZHmT3Zg9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlyktbvF&md5=a392f903b924d80f21846c3c7c26ae26</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.3892%2Fijmm.2014.1751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijmm.2014.1751%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DTargeting%2520Endothelin%2520Receptors%2520A%2520and%2520B%2520Attenuates%2520the%2520Inflammatory%2520Response%2520and%2520Improves%2520Locomotor%2520Function%2520Following%2520Spinal%2520Cord%2520Injury%2520in%2520Mice%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2014%26volume%3D34%26spage%3D74%26epage%3D82%26doi%3D10.3892%2Fijmm.2014.1751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group">Reichetzeder, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuprykov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocher, B.</span><span> </span><span class="NLM_article-title">Endothelin Receptor Antagonists in Clinical Research-lessons Learned from Preclinical and Clinical Kidney Studies</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">â</span> <span class="NLM_lpage">148</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2014.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.lfs.2014.02.025" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=141-148&author=C.+Reichetzederauthor=O.+Tsuprykovauthor=B.+Hocher&title=Endothelin+Receptor+Antagonists+in+Clinical+Research-lessons+Learned+from+Preclinical+and+Clinical+Kidney+Studies&doi=10.1016%2Fj.lfs.2014.02.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2014.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2014.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DReichetzeder%26aufirst%3DC.%26aulast%3DTsuprykov%26aufirst%3DO.%26aulast%3DHocher%26aufirst%3DB.%26atitle%3DEndothelin%2520Receptor%2520Antagonists%2520in%2520Clinical%2520Research-lessons%2520Learned%2520from%2520Preclinical%2520and%2520Clinical%2520Kidney%2520Studies%26jtitle%3DLife%2520Sci.%26date%3D2014%26volume%3D118%26spage%3D141%26epage%3D148%26doi%3D10.1016%2Fj.lfs.2014.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group">Remuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perico, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benigni, A.</span><span> </span><span class="NLM_article-title">New Therapeutics that Antagonize Endothelin: Promises and Frustrations</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">986</span><span class="NLM_x">â</span> <span class="NLM_lpage">1001</span><span class="refDoi">Â DOI: 10.1038/nrd962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1038%2Fnrd962" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=986-1001&author=G.+Remuzziauthor=N.+Pericoauthor=A.+Benigni&title=New+Therapeutics+that+Antagonize+Endothelin%3A+Promises+and+Frustrations&doi=10.1038%2Fnrd962"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1038%2Fnrd962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd962%26sid%3Dliteratum%253Aachs%26aulast%3DRemuzzi%26aufirst%3DG.%26aulast%3DPerico%26aufirst%3DN.%26aulast%3DBenigni%26aufirst%3DA.%26atitle%3DNew%2520Therapeutics%2520that%2520Antagonize%2520Endothelin%253A%2520Promises%2520and%2520Frustrations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D986%26epage%3D1001%26doi%3D10.1038%2Fnrd962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Gagliardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoja, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benigni, A.</span><span> </span><span class="NLM_article-title">ET and Diabetic Nephropathy: Preclinical and Clinical Studies</span> <span class="citation_source-journal">Semin. Nephrol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">â</span> <span class="NLM_lpage">196</span><span class="refDoi">Â DOI: 10.1016/j.semnephrol.2015.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1016%2Fj.semnephrol.2015.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=25966350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhslOrsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=188-196&author=E.+Gagliardiniauthor=C.+Zojaauthor=A.+Benigni&title=ET+and+Diabetic+Nephropathy%3A+Preclinical+and+Clinical+Studies&doi=10.1016%2Fj.semnephrol.2015.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Et and diabetic nephropathy: preclinical and clinical studies</span></div><div class="casAuthors">Gagliardini Elena; Zoja Carlamaria; Benigni Ariela</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in nephrology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The incidence of progressive kidney disease associated with diabetes continues to increase worldwide.  Only partial renoprotection is achieved by current standard therapy with angiotensin-converting enzyme inhibitors and/or angiotensin-receptor blockers, increasing the need for novel therapeutic approaches.  Experimental studies have provided evidence of a pathogenic role for endothelin-1 (ET-1) and its cognate receptors in the development and progression of diabetic nephropathy.  ET-1, mainly through the activation of ETA receptor, contributes to renal cell injury, inflammation, and fibrosis.  In animal models of type 1 and type 2 diabetes, ETA-selective antagonists have been shown to provide renoprotective effects, supplying the rationale for clinical trials in patients with diabetic nephropathy with ETA-receptor antagonists administered in addition to renin-angiotensin system blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnSdLVzfLCnbesJRIHUP1ofW6udTcc2easv9sdOw1ZIbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhslOrsg%253D%253D&md5=cbea1b55345cf9294a9616d55331211a</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.semnephrol.2015.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semnephrol.2015.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DGagliardini%26aufirst%3DE.%26aulast%3DZoja%26aufirst%3DC.%26aulast%3DBenigni%26aufirst%3DA.%26atitle%3DET%2520and%2520Diabetic%2520Nephropathy%253A%2520Preclinical%2520and%2520Clinical%2520Studies%26jtitle%3DSemin.%2520Nephrol.%26date%3D2015%26volume%3D35%26spage%3D188%26epage%3D196%26doi%3D10.1016%2Fj.semnephrol.2015.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">Maguire, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, A. P.</span><span> </span><span class="NLM_article-title"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="bcf9d2d8d3c8d4d9d0d5d2fc8e89">[emailÂ protected]</a> - New Agonists, Antagonists, Inhibitors and Emerging Research Frontiers: IUPHAR Review 12</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">5555</span><span class="NLM_x">â</span> <span class="NLM_lpage">5572</span><span class="refDoi">Â DOI: 10.1111/bph.12874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=10.1111%2Fbph.12874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=25131455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVamtLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=5555-5572&author=J.+J.+Maguireauthor=A.+P.+Davenport&title=Endothelin%4025+-+New+Agonists%2C+Antagonists%2C+Inhibitors+and+Emerging+Research+Frontiers%3A+IUPHAR+Review+12&doi=10.1111%2Fbph.12874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="94d1faf0fbe0fcf1f8fdfad4a6a1">[emailÂ protected]</a> - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12</span></div><div class="casAuthors">Maguire, J. J.; Davenport, A. P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5555-5572</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Since the discovery of endothelin (ET)-1 in 1988, the main components of the signalling pathway have become established, comprising three structurally similar endogenous 21-amino acid peptides, ET-1, ET-2 and ET-3, that activate two GPCRs, ETA and ETB.  Our aim in this review is to highlight the recent progress in ET research.  The ET-like domain peptide, corresponding to prepro-ET-193-166, has been proposed to be co-synthesized and released with ET-1, to modulate the actions of the peptide.  ET-1 remains the most potent vasoconstrictor in the human cardiovascular system with a particularly long-lasting action.  To date, the major therapeutic strategy to block the unwanted actions of ET in disease, principally in pulmonary arterial hypertension, has been to use antagonists that are selective for the ETA receptor (ambrisentan) or that block both receptor subtypes (bosentan).  Macitentan represents the next generation of antagonists, being more potent than bosentan, with longer receptor occupancy and it is converted to an active metabolite; properties contributing to greater pharmacodynamic and pharmacokinetic efficacy.  A second strategy is now being more widely tested in clin. trials and uses combined inhibitors of ET-converting enzyme and neutral endopeptidase such as SLV306 (daglutril).  A third strategy based on activating the ETB receptor, has led to the renaissance of the modified peptide agonist IRL1620 as a clin. candidate in delivering anti-tumor drugs and as a pharmacol. tool to investigate exptl. pathophysiol. conditions.  Finally, we discuss biased signalling, epigenetic regulation and targeting with monoclonal antibodies as prospective new areas for ET research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0sVvlUszqFrVg90H21EOLACvtfcHk0lhaFRZfbYTRTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVamtLjE&md5=fa0c85b807532f68e298675218239332</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1111%2Fbph.12874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12874%26sid%3Dliteratum%253Aachs%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26atitle%3DEndothelin%254025%2520-%2520New%2520Agonists%252C%2520Antagonists%252C%2520Inhibitors%2520and%2520Emerging%2520Research%2520Frontiers%253A%2520IUPHAR%2520Review%252012%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D5555%26epage%3D5572%26doi%3D10.1111%2Fbph.12874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01781%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-18" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01781" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677aca4b1fde3da6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
